column_name,broad_id,dose,screen_id,compound_plate,name,moa,target,disease.area,indication,smiles,phase
BRD-A25234499-001-19-1::0.00061::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,0.00061,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::0.00244::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,0.00244,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::0.00977::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,0.00977,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::0.0391::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,0.0391,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::0.15625::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,0.15625,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::0.625::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,0.625,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::10::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,10.0,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-19-1::2.5::MTS010::PROS003_PR500,BRD-A25234499-001-19-1,2.5,MTS010,PROS003_PR500,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A70858459-001-01-7::0.00061::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,0.00061,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.00244::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,0.00244,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.00977::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,0.00977,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.0391::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,0.0391,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.15625::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,0.15625,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.625::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,0.625,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::10::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,10.0,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::2.5::MTS010::PROS003_PR500,BRD-A70858459-001-01-7,2.5,MTS010,PROS003_PR500,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A74914197-001-02-9::0.000153::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.000153,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.00061::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.00061,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.00244::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.00244,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.00977::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.00977,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.0391::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.0391,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.15625::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.15625,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.625::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,0.625,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::3.81e-05::MTS010::PROS005_PR500,BRD-A74914197-001-02-9,3.81e-05,MTS010,PROS005_PR500,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-K02113016-001-19-6::0.00061::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,0.00061,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::0.00244::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,0.00244,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::0.00977::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,0.00977,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::0.0391::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,0.0391,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::0.15625::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,0.15625,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::0.625::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,0.625,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::10::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,10.0,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-19-6::2.5::MTS010::PROS004_PR500,BRD-K02113016-001-19-6,2.5,MTS010,PROS004_PR500,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02130563-001-11-4::0.00061::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,0.00061,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.00244::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,0.00244,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.00977::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,0.00977,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.0391::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,0.0391,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.15625::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,0.15625,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.625::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,0.625,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::10::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,10.0,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::2.5::MTS010::PROS002_PR500,BRD-K02130563-001-11-4,2.5,MTS010,PROS002_PR500,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K03390685-001-01-7::0.00061::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,0.00061,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.00244::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,0.00244,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.00977::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,0.00977,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.0391::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,0.0391,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.15625::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,0.15625,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.625::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,0.625,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::10::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,10.0,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::2.5::MTS010::PROS001_PR500,BRD-K03390685-001-01-7,2.5,MTS010,PROS001_PR500,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03406345-001-21-1::0.00061::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,0.00061,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::0.00244::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,0.00244,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::0.00977::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,0.00977,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::0.0391::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,0.0391,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::0.15625::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,0.15625,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::0.625::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,0.625,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::10::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,10.0,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-21-1::2.5::MTS010::PROS001_PR500,BRD-K03406345-001-21-1,2.5,MTS010,PROS001_PR500,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03449891-001-08-6::0.00061::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,0.00061,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.00244::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,0.00244,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.00977::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,0.00977,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.0391::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,0.0391,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.15625::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,0.15625,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.625::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,0.625,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::10::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,10.0,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::2.5::MTS010::PROS004_PR500,BRD-K03449891-001-08-6,2.5,MTS010,PROS004_PR500,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03765900-001-01-9::0.00061::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,0.00061,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.00244::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,0.00244,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.00977::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,0.00977,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.0391::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,0.0391,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.156249::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,0.156249,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.624997::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,0.624997,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::2.49999::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,2.49999,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::9.99995::MTS010::PROS002_PR500,BRD-K03765900-001-01-9,9.99995,MTS010,PROS002_PR500,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K05804044-001-18-5::0.00061::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,0.00061,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00061::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,0.00061,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00061::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,0.00061,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00061::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,0.00061,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00061::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,0.00061,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00244::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,0.00244,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00244::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,0.00244,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00244::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,0.00244,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00244::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,0.00244,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00244::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,0.00244,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00977::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,0.00977,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00977::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,0.00977,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00977::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,0.00977,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00977::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,0.00977,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.00977::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,0.00977,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.0391::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,0.0391,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.0391::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,0.0391,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.0391::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,0.0391,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.0391::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,0.0391,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.0391::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,0.0391,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.15625::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,0.15625,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.15625::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,0.15625,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.15625::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,0.15625,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.15625::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,0.15625,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.15625::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,0.15625,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.625::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,0.625,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.625::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,0.625,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.625::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,0.625,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.625::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,0.625,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::0.625::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,0.625,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::10::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,10.0,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::10::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,10.0,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::10::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,10.0,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::10::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,10.0,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::10::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,10.0,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::2.5::MTS010::PROS001_PR500,BRD-K05804044-001-18-5,2.5,MTS010,PROS001_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::2.5::MTS010::PROS002_PR500,BRD-K05804044-001-18-5,2.5,MTS010,PROS002_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::2.5::MTS010::PROS003_PR500,BRD-K05804044-001-18-5,2.5,MTS010,PROS003_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::2.5::MTS010::PROS004_PR500,BRD-K05804044-001-18-5,2.5,MTS010,PROS004_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-18-5::2.5::MTS010::PROS005_PR500,BRD-K05804044-001-18-5,2.5,MTS010,PROS005_PR500,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K06814349-304-02-7::0.00061::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,0.00061,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::0.00244::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,0.00244,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::0.00977::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,0.00977,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::0.0391::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,0.0391,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::0.15625::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,0.15625,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::0.625::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,0.625,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::10::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,10.0,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-02-7::2.5::MTS010::PROS002_PR500,BRD-K06814349-304-02-7,2.5,MTS010,PROS002_PR500,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K08109215-001-06-4::0.00061::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,0.00061,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.00244::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,0.00244,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.00977::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,0.00977,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.0391::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,0.0391,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.15625::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,0.15625,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.625::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,0.625,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::10::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,10.0,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::2.5::MTS010::PROS002_PR500,BRD-K08109215-001-06-4,2.5,MTS010,PROS002_PR500,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08542803-001-02-3::0.00061::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,0.00061,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::0.00244::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,0.00244,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::0.00977::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,0.00977,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::0.0391::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,0.0391,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::0.15625::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,0.15625,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::0.625::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,0.625,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::10::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,10.0,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-02-3::2.5::MTS010::PROS005_PR500,BRD-K08542803-001-02-3,2.5,MTS010,PROS005_PR500,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08547377-001-04-4::0.00061::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,0.00061,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::0.00244::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,0.00244,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::0.00977::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,0.00977,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::0.0391::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,0.0391,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::0.15625::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,0.15625,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::0.625::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,0.625,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::10::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,10.0,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-001-04-4::2.5::MTS010::PROS001_PR500,BRD-K08547377-001-04-4,2.5,MTS010,PROS001_PR500,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08703257-001-13-9::0.00061::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,0.00061,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::0.00244::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,0.00244,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::0.00977::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,0.00977,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::0.0391::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,0.0391,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::0.15625::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,0.15625,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::0.625::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,0.625,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::10::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,10.0,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-13-9::2.5::MTS010::PROS001_PR500,BRD-K08703257-001-13-9,2.5,MTS010,PROS001_PR500,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08799216-001-05-3::0.00061::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,0.00061,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.00244::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,0.00244,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.00977::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,0.00977,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.0391::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,0.0391,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.15625::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,0.15625,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.625::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,0.625,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::10::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,10.0,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::2.5::MTS010::PROS002_PR500,BRD-K08799216-001-05-3,2.5,MTS010,PROS002_PR500,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K09951645-001-11-8::0.00061::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,0.00061,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::0.00244::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,0.00244,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::0.00977::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,0.00977,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::0.0391::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,0.0391,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::0.15625::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,0.15625,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::0.625::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,0.625,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::10::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,10.0,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-11-8::2.5::MTS010::PROS001_PR500,BRD-K09951645-001-11-8,2.5,MTS010,PROS001_PR500,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K11267252-001-05-1::0.00061::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,0.00061,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::0.00244::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,0.00244,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::0.00977::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,0.00977,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::0.0391::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,0.0391,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::0.15625::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,0.15625,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::0.625::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,0.625,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::10::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,10.0,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-05-1::2.5::MTS010::PROS003_PR500,BRD-K11267252-001-05-1,2.5,MTS010,PROS003_PR500,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11630072-001-13-2::0.00061::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,0.00061,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.00244::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,0.00244,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.00977::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,0.00977,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.0391::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,0.0391,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.15625::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,0.15625,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.625::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,0.625,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::10::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,10.0,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::2.5::MTS010::PROS004_PR500,BRD-K11630072-001-13-2,2.5,MTS010,PROS004_PR500,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K12184916-001-19-6::0.000594::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,0.000594,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::0.00238::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,0.00238,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::0.0095::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,0.0095,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::0.038::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,0.038,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::0.152073::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,0.152073,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::0.608294::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,0.608294,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::2.43317::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,2.43317,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-19-6::9.7327::MTS010::PROS004_PR500,BRD-K12184916-001-19-6,9.7327,MTS010,PROS004_PR500,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12343256-001-14-7::0.00061::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,0.00061,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::0.00244::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,0.00244,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::0.00977::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,0.00977,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::0.0391::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,0.0391,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::0.15625::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,0.15625,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::0.625::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,0.625,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::10::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,10.0,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-14-7::2.5::MTS010::PROS003_PR500,BRD-K12343256-001-14-7,2.5,MTS010,PROS003_PR500,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K13049116-001-04-0::0.00061::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,0.00061,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::0.00244::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,0.00244,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::0.00977::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,0.00977,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::0.0391::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,0.0391,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::0.156251::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,0.156251,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::0.625006::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,0.625006,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::10.0001::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,10.0001,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-04-0::2.50002::MTS010::PROS002_PR500,BRD-K13049116-001-04-0,2.50002,MTS010,PROS002_PR500,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13390322-001-06-3::0.00061::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,0.00061,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.00244::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,0.00244,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.00977::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,0.00977,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.0391::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,0.0391,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.15625::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,0.15625,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.625::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,0.625,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::10::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,10.0,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::2.5::MTS010::PROS004_PR500,BRD-K13390322-001-06-3,2.5,MTS010,PROS004_PR500,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13514097-001-04-6::0.00061::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,0.00061,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::0.00244::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,0.00244,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::0.00977::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,0.00977,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::0.0391::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,0.0391,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::0.15625::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,0.15625,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::0.625::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,0.625,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::10::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,10.0,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-04-6::2.5::MTS010::PROS003_PR500,BRD-K13514097-001-04-6,2.5,MTS010,PROS003_PR500,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13662825-001-07-5::0.000153::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.000153,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.00061::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.00061,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.00244::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.00244,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.00977::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.00977,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.0391::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.0391,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.15625::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.15625,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.625::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,0.625,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::2.5::MTS010::PROS005_PR500,BRD-K13662825-001-07-5,2.5,MTS010,PROS005_PR500,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K14109347-001-03-4::0.00061::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,0.00061,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.00244::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,0.00244,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.00977::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,0.00977,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.0391::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,0.0391,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.15625::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,0.15625,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.625::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,0.625,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::10::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,10.0,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::2.5::MTS010::PROS004_PR500,BRD-K14109347-001-03-4,2.5,MTS010,PROS004_PR500,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K15179879-001-03-2::0.00061::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,0.00061,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.00244::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,0.00244,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.00977::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,0.00977,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.0391::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,0.0391,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.15625::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,0.15625,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.625::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,0.625,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::10::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,10.0,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::2.5::MTS010::PROS003_PR500,BRD-K15179879-001-03-2,2.5,MTS010,PROS003_PR500,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15600710-066-05-8::0.000599::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,0.000599,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::0.0024::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,0.0024,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::0.00959::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,0.00959,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::0.0384::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,0.0384,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::0.153406::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,0.153406,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::0.613626::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,0.613626,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::2.4545::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,2.4545,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-05-8::9.81801::MTS010::PROS004_PR500,BRD-K15600710-066-05-8,9.81801,MTS010,PROS004_PR500,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K16730910-001-10-7::0.00061::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,0.00061,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::0.00244::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,0.00244,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::0.00977::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,0.00977,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::0.0391::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,0.0391,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::0.15625::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,0.15625,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::0.625::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,0.625,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::10::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,10.0,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-10-7::2.5::MTS010::PROS004_PR500,BRD-K16730910-001-10-7,2.5,MTS010,PROS004_PR500,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K17555800-003-02-3::0.00061::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,0.00061,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::0.00244::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,0.00244,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::0.00977::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,0.00977,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::0.0391::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,0.0391,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::0.15625::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,0.15625,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::0.625::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,0.625,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::10::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,10.0,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-02-3::2.5::MTS010::PROS002_PR500,BRD-K17555800-003-02-3,2.5,MTS010,PROS002_PR500,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17610631-001-03-3::0.000591::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,0.000591,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.00236::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,0.00236,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.00946::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,0.00946,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.0378::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,0.0378,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.151324::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,0.151324,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.605298::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,0.605298,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::2.42119::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,2.42119,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::9.68476::MTS010::PROS001_PR500,BRD-K17610631-001-03-3,9.68476,MTS010,PROS001_PR500,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17743125-001-08-4::0.00061::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,0.00061,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.00244::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,0.00244,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.00977::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,0.00977,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.0391::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,0.0391,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.15625::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,0.15625,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.625::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,0.625,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::10::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,10.0,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::2.5::MTS010::PROS003_PR500,BRD-K17743125-001-08-4,2.5,MTS010,PROS003_PR500,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17894950-001-14-3::0.00061::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,0.00061,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.00244::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,0.00244,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.00977::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,0.00977,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.0391::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,0.0391,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.15625::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,0.15625,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.625::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,0.625,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::10::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,10.0,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::2.5::MTS010::PROS002_PR500,BRD-K17894950-001-14-3,2.5,MTS010,PROS002_PR500,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K18961567-001-01-1::0.00061::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,0.00061,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.00244::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,0.00244,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.00977::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,0.00977,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.0391::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,0.0391,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.15625::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,0.15625,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.625::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,0.625,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::10::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,10.0,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::2.5::MTS010::PROS002_PR500,BRD-K18961567-001-01-1,2.5,MTS010,PROS002_PR500,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K19540840-001-09-4::0.00061::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,0.00061,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.00244::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,0.00244,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.00977::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,0.00977,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.0391::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,0.0391,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.15625::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,0.15625,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.625::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,0.625,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::10::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,10.0,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::2.5::MTS010::PROS004_PR500,BRD-K19540840-001-09-4,2.5,MTS010,PROS004_PR500,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19687926-001-04-1::0.00061::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,0.00061,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::0.00244::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,0.00244,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::0.00977::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,0.00977,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::0.0391::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,0.0391,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::0.15625::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,0.15625,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::0.625::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,0.625,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::10::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,10.0,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-001-04-1::2.5::MTS010::PROS004_PR500,BRD-K19687926-001-04-1,2.5,MTS010,PROS004_PR500,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19796430-001-05-6::0.00061::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,0.00061,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.00244::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,0.00244,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.00977::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,0.00977,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.0391::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,0.0391,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.15625::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,0.15625,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.625::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,0.625,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::10::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,10.0,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::2.5::MTS010::PROS004_PR500,BRD-K19796430-001-05-6,2.5,MTS010,PROS004_PR500,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K22064724-001-01-8::0.00061::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,0.00061,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.00244::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,0.00244,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.00977::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,0.00977,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.0391::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,0.0391,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.156249::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,0.156249,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.624997::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,0.624997,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::2.49999::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,2.49999,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::9.99996::MTS010::PROS004_PR500,BRD-K22064724-001-01-8,9.99996,MTS010,PROS004_PR500,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22822991-001-02-3::0.00061::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,0.00061,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.00244::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,0.00244,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.00977::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,0.00977,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.0391::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,0.0391,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.15625::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,0.15625,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.625::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,0.625,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::10::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,10.0,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::2.5::MTS010::PROS001_PR500,BRD-K22822991-001-02-3,2.5,MTS010,PROS001_PR500,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K23228615-001-02-8::0.00061::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,0.00061,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.00244::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,0.00244,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.00977::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,0.00977,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.0391::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,0.0391,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.15625::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,0.15625,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.625::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,0.625,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::10::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,10.0,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::2.5::MTS010::PROS004_PR500,BRD-K23228615-001-02-8,2.5,MTS010,PROS004_PR500,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23984367-001-07-5::0.00061::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,0.00061,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::0.00244::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,0.00244,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::0.00977::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,0.00977,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::0.0391::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,0.0391,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::0.15625::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,0.15625,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::0.625::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,0.625,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::10::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,10.0,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-001-07-5::2.5::MTS010::PROS001_PR500,BRD-K23984367-001-07-5,2.5,MTS010,PROS001_PR500,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K26026438-001-01-0::0.00061::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,0.00061,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.00244::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,0.00244,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.00977::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,0.00977,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.0391::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,0.0391,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.156249::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,0.156249,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.624995::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,0.624995,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::2.49998::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,2.49998,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::9.99992::MTS010::PROS004_PR500,BRD-K26026438-001-01-0,9.99992,MTS010,PROS004_PR500,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26657438-001-15-2::0.00061::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,0.00061,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.00244::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,0.00244,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.00977::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,0.00977,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.0391::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,0.0391,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.15625::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,0.15625,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.625::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,0.625,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::10::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,10.0,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::2.5::MTS010::PROS003_PR500,BRD-K26657438-001-15-2,2.5,MTS010,PROS003_PR500,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K28822270-001-03-7::0.000639::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,0.000639,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::0.00255::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,0.00255,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::0.0102::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,0.0102,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::0.0409::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,0.0409,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::0.163478::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,0.163478,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::0.653912::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,0.653912,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::10.4626::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,10.4626,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-03-7::2.61565::MTS010::PROS002_PR500,BRD-K28822270-001-03-7,2.61565,MTS010,PROS002_PR500,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K29905972-001-06-3::0.00061::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,0.00061,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.00244::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,0.00244,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.00977::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,0.00977,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.0391::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,0.0391,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.15625::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,0.15625,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.625::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,0.625,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::10::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,10.0,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::2.5::MTS010::PROS001_PR500,BRD-K29905972-001-06-3,2.5,MTS010,PROS001_PR500,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K30577245-001-05-0::0.000153::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.000153,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::0.00061::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.00061,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::0.00244::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.00244,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::0.00977::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.00977,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::0.0391::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.0391,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::0.15625::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.15625,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::0.625::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,0.625,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-001-05-0::3.81e-05::MTS010::PROS005_PR500,BRD-K30577245-001-05-0,3.81e-05,MTS010,PROS005_PR500,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K31698212-001-02-9::0.00061::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,0.00061,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.00244::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,0.00244,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.00977::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,0.00977,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.0391::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,0.0391,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.15625::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,0.15625,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.625::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,0.625,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::10::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,10.0,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::2.5::MTS010::PROS003_PR500,BRD-K31698212-001-02-9,2.5,MTS010,PROS003_PR500,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31928526-001-02-1::0.00061::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,0.00061,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.00244::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,0.00244,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.00977::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,0.00977,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.0391::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,0.0391,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.15625::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,0.15625,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.625::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,0.625,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::10::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,10.0,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::2.5::MTS010::PROS001_PR500,BRD-K31928526-001-02-1,2.5,MTS010,PROS001_PR500,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K33379087-001-07-5::0.00061::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,0.00061,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.00244::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,0.00244,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.00977::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,0.00977,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.0391::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,0.0391,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.15625::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,0.15625,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.625::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,0.625,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::10::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,10.0,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::2.5::MTS010::PROS004_PR500,BRD-K33379087-001-07-5,2.5,MTS010,PROS004_PR500,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33610132-001-02-9::0.00061::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,0.00061,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.00244::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,0.00244,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.00977::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,0.00977,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.0391::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,0.0391,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.15625::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,0.15625,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.625::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,0.625,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::10::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,10.0,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::2.5::MTS010::PROS002_PR500,BRD-K33610132-001-02-9,2.5,MTS010,PROS002_PR500,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33622447-066-01-9::0.00061::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,0.00061,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.00244::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,0.00244,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.00977::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,0.00977,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.0391::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,0.0391,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.15625::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,0.15625,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.625::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,0.625,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::10::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,10.0,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::2.5::MTS010::PROS003_PR500,BRD-K33622447-066-01-9,2.5,MTS010,PROS003_PR500,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K35520305-001-16-9::0.00061::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,0.00061,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::0.00244::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,0.00244,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::0.00977::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,0.00977,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::0.0391::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,0.0391,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::0.15625::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,0.15625,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::0.625::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,0.625,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::10::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,10.0,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-16-9::2.5::MTS010::PROS002_PR500,BRD-K35520305-001-16-9,2.5,MTS010,PROS002_PR500,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K36627727-001-05-4::0.00061::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,0.00061,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.00244::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,0.00244,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.00977::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,0.00977,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.0391::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,0.0391,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.15625::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,0.15625,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.625::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,0.625,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::10::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,10.0,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::2.5::MTS010::PROS005_PR500,BRD-K36627727-001-05-4,2.5,MTS010,PROS005_PR500,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36788280-001-01-2::0.00061::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,0.00061,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.00244::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,0.00244,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.00977::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,0.00977,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.0391::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,0.0391,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.15625::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,0.15625,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.625::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,0.625,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::10::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,10.0,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::2.5::MTS010::PROS001_PR500,BRD-K36788280-001-01-2,2.5,MTS010,PROS001_PR500,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K37379014-001-02-0::0.000152::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,0.000152,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::0.000609::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,0.000609,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::0.00244::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,0.00244,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::0.00975::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,0.00975,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::0.039::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,0.039,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::0.156::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,0.156,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::3.81e-05::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,3.81e-05,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-02-0::9.52e-06::MTS010::PROS005_PR500,BRD-K37379014-001-02-0,9.52e-06,MTS010,PROS005_PR500,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K38332599-001-01-3::0.00061::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,0.00061,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.00244::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,0.00244,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.00977::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,0.00977,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.0391::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,0.0391,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.15625::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,0.15625,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.625::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,0.625,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::10::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,10.0,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::2.5::MTS010::PROS002_PR500,BRD-K38332599-001-01-3,2.5,MTS010,PROS002_PR500,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38527262-300-01-0::0.000562::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,0.000562,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.00225::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,0.00225,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.00899::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,0.00899,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.036::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,0.036,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.143812::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,0.143812,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.575247::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,0.575247,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::2.30099::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,2.30099,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::9.20395::MTS010::PROS001_PR500,BRD-K38527262-300-01-0,9.20395,MTS010,PROS001_PR500,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38852836-001-02-1::0.000153::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.000153,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.00061::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.00061,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.00244::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.00244,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.00977::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.00977,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.0391::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.0391,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.15625::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.15625,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.625::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,0.625,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::2.5::MTS010::PROS005_PR500,BRD-K38852836-001-02-1,2.5,MTS010,PROS005_PR500,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K39974922-001-04-3::0.00061::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,0.00061,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.00244::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,0.00244,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.00977::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,0.00977,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.0391::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,0.0391,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.15625::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,0.15625,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.625::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,0.625,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::10::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,10.0,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::2.5::MTS010::PROS003_PR500,BRD-K39974922-001-04-3,2.5,MTS010,PROS003_PR500,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K41859756-001-06-8::0.000153::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.000153,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.00061::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.00061,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.00244::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.00244,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.00977::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.00977,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.0391::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.0391,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.15625::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.15625,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.625::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,0.625,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::2.5::MTS010::PROS005_PR500,BRD-K41859756-001-06-8,2.5,MTS010,PROS005_PR500,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K42495768-001-01-7::0.00061::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,0.00061,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.00244::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,0.00244,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.00977::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,0.00977,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.0391::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,0.0391,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.15625::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,0.15625,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.625::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,0.625,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::10::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,10.0,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::2.5::MTS010::PROS001_PR500,BRD-K42495768-001-01-7,2.5,MTS010,PROS001_PR500,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42805893-001-04-9::0.00061::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,0.00061,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.00244::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,0.00244,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.00977::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,0.00977,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.0391::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,0.0391,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.15625::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,0.15625,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.625::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,0.625,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::10::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,10.0,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::2.5::MTS010::PROS003_PR500,BRD-K42805893-001-04-9,2.5,MTS010,PROS003_PR500,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42828737-001-03-3::0.00061::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,0.00061,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::0.00244::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,0.00244,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::0.00977::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,0.00977,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::0.0391::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,0.0391,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::0.15625::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,0.15625,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::0.625001::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,0.625001,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::10::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,10.0,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-001-03-3::2.5::MTS010::PROS001_PR500,BRD-K42828737-001-03-3,2.5,MTS010,PROS001_PR500,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42898655-001-01-8::0.000153::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.000153,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.00061::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.00061,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.00244::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.00244,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.00977::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.00977,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.0391::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.0391,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.15625::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.15625,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.625::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,0.625,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::3.81e-05::MTS010::PROS005_PR500,BRD-K42898655-001-01-8,3.81e-05,MTS010,PROS005_PR500,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K43389675-001-02-1::0.00061::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,0.00061,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::0.00244::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,0.00244,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::0.00977::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,0.00977,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::0.0391::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,0.0391,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::0.15625::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,0.15625,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::0.625::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,0.625,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::10::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,10.0,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-001-02-1::2.5::MTS010::PROS001_PR500,BRD-K43389675-001-02-1,2.5,MTS010,PROS001_PR500,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K44227013-001-06-4::0.00061::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,0.00061,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.00244::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,0.00244,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.00977::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,0.00977,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.0391::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,0.0391,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.15625::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,0.15625,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.625::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,0.625,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::10::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,10.0,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::2.5::MTS010::PROS003_PR500,BRD-K44227013-001-06-4,2.5,MTS010,PROS003_PR500,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44408410-001-17-6::0.00061::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,0.00061,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.00244::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,0.00244,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.00977::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,0.00977,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.0391::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,0.0391,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.15625::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,0.15625,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.625::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,0.625,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::10::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,10.0,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::2.5::MTS010::PROS001_PR500,BRD-K44408410-001-17-6,2.5,MTS010,PROS001_PR500,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44827188-001-06-0::0.00061::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,0.00061,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.00244::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,0.00244,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.00977::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,0.00977,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.0391::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,0.0391,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.15625::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,0.15625,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.625::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,0.625,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::10::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,10.0,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::2.5::MTS010::PROS003_PR500,BRD-K44827188-001-06-0,2.5,MTS010,PROS003_PR500,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K46386702-001-02-1::0.00061::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,0.00061,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.00244::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,0.00244,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.00977::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,0.00977,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.0391::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,0.0391,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.15625::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,0.15625,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.625::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,0.625,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::10::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,10.0,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::2.5::MTS010::PROS001_PR500,BRD-K46386702-001-02-1,2.5,MTS010,PROS001_PR500,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K49328571-001-15-0::0.00061::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,0.00061,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.00244::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,0.00244,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.00977::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,0.00977,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.0391::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,0.0391,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.15625::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,0.15625,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.625::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,0.625,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::10::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,10.0,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::2.5::MTS010::PROS005_PR500,BRD-K49328571-001-15-0,2.5,MTS010,PROS005_PR500,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49350383-001-14-5::0.00061::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,0.00061,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::0.00244::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,0.00244,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::0.00977::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,0.00977,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::0.0391::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,0.0391,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::0.15625::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,0.15625,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::0.625::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,0.625,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::10::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,10.0,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-14-5::2.5::MTS010::PROS002_PR500,BRD-K49350383-001-14-5,2.5,MTS010,PROS002_PR500,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K50010139-001-01-5::0.00061::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,0.00061,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::0.00244::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,0.00244,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::0.00977::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,0.00977,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::0.0391::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,0.0391,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::0.15625::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,0.15625,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::0.625::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,0.625,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::10::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,10.0,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-01-5::2.5::MTS010::PROS003_PR500,BRD-K50010139-001-01-5,2.5,MTS010,PROS003_PR500,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50168500-001-07-9::0.00061::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,0.00061,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.00244::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,0.00244,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.00977::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,0.00977,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.0391::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,0.0391,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.15625::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,0.15625,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.625::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,0.625,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::10::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,10.0,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::2.5::MTS010::PROS001_PR500,BRD-K50168500-001-07-9,2.5,MTS010,PROS001_PR500,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K51313569-001-07-8::0.00061::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,0.00061,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::0.00244::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,0.00244,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::0.00977::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,0.00977,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::0.0391::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,0.0391,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::0.15625::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,0.15625,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::0.625::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,0.625,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::10::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,10.0,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-001-07-8::2.5::MTS010::PROS003_PR500,BRD-K51313569-001-07-8,2.5,MTS010,PROS003_PR500,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51791723-003-01-7::0.00061::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,0.00061,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.00244::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,0.00244,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.00977::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,0.00977,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.0391::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,0.0391,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.15625::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,0.15625,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.625::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,0.625,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::10::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,10.0,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::2.5::MTS010::PROS004_PR500,BRD-K51791723-003-01-7,2.5,MTS010,PROS004_PR500,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51967704-001-03-6::0.00061::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,0.00061,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.00244::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,0.00244,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.00977::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,0.00977,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.0391::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,0.0391,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.15625::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,0.15625,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.625::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,0.625,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::10::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,10.0,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::2.5::MTS010::PROS004_PR500,BRD-K51967704-001-03-6,2.5,MTS010,PROS004_PR500,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K52313696-001-12-3::0.00061::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,0.00061,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.00244::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,0.00244,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.00977::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,0.00977,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.0391::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,0.0391,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.15625::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,0.15625,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.625::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,0.625,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::10::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,10.0,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::2.5::MTS010::PROS004_PR500,BRD-K52313696-001-12-3,2.5,MTS010,PROS004_PR500,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K53414658-001-08-2::0.00061::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,0.00061,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.00244::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,0.00244,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.00977::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,0.00977,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.0391::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,0.0391,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.15625::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,0.15625,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.625::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,0.625,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::10::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,10.0,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::2.5::MTS010::PROS001_PR500,BRD-K53414658-001-08-2,2.5,MTS010,PROS001_PR500,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53972329-001-07-0::0.00061::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,0.00061,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.00244::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,0.00244,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.00977::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,0.00977,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.0391::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,0.0391,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.15625::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,0.15625,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.625::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,0.625,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::10::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,10.0,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::2.5::MTS010::PROS003_PR500,BRD-K53972329-001-07-0,2.5,MTS010,PROS003_PR500,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K54256913-001-08-7::0.00061::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,0.00061,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.00244::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,0.00244,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.00977::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,0.00977,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.0391::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,0.0391,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.15625::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,0.15625,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.625::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,0.625,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::10::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,10.0,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::2.5::MTS010::PROS004_PR500,BRD-K54256913-001-08-7,2.5,MTS010,PROS004_PR500,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54955827-001-02-2::0.00061::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,0.00061,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.00244::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,0.00244,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.00977::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,0.00977,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.0391::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,0.0391,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.156249::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,0.156249,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.624995::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,0.624995,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::2.49998::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,2.49998,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::9.99992::MTS010::PROS001_PR500,BRD-K54955827-001-02-2,9.99992,MTS010,PROS001_PR500,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54997624-001-06-0::0.00061::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,0.00061,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.00244::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,0.00244,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.00977::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,0.00977,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.0391::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,0.0391,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.15625::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,0.15625,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.625::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,0.625,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::10::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,10.0,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::2.5::MTS010::PROS002_PR500,BRD-K54997624-001-06-0,2.5,MTS010,PROS002_PR500,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K55187425-236-05-2::0.00061::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,0.00061,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.00244::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,0.00244,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.00977::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,0.00977,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.0391::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,0.0391,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.15625::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,0.15625,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.625::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,0.625,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::10::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,10.0,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::2.5::MTS010::PROS004_PR500,BRD-K55187425-236-05-2,2.5,MTS010,PROS004_PR500,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K56343971-001-14-8::0.00061::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,0.00061,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::0.00244::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,0.00244,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::0.00977::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,0.00977,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::0.0391::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,0.0391,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::0.15625::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,0.15625,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::0.625::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,0.625,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::10::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,10.0,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-14-8::2.5::MTS010::PROS004_PR500,BRD-K56343971-001-14-8,2.5,MTS010,PROS004_PR500,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56981171-001-02-8::0.00061::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,0.00061,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::0.00244::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,0.00244,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::0.00977::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,0.00977,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::0.0391::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,0.0391,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::0.15625::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,0.15625,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::0.625::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,0.625,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::10::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,10.0,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-02-8::2.5::MTS010::PROS001_PR500,BRD-K56981171-001-02-8,2.5,MTS010,PROS001_PR500,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K57080016-001-15-9::0.00061::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,0.00061,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.00244::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,0.00244,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.00977::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,0.00977,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.0391::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,0.0391,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.15625::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,0.15625,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.625::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,0.625,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::10::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,10.0,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::2.5::MTS010::PROS002_PR500,BRD-K57080016-001-15-9,2.5,MTS010,PROS002_PR500,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57169635-001-04-5::0.00061::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,0.00061,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.00244::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,0.00244,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.00977::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,0.00977,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.0391::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,0.0391,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.15625::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,0.15625,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.625::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,0.625,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::10::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,10.0,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::2.5::MTS010::PROS002_PR500,BRD-K57169635-001-04-5,2.5,MTS010,PROS002_PR500,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K58435339-001-03-0::0.00061::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,0.00061,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.00244::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,0.00244,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.00977::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,0.00977,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.0391::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,0.0391,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.15625::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,0.15625,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.625::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,0.625,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::10::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,10.0,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::2.5::MTS010::PROS002_PR500,BRD-K58435339-001-03-0,2.5,MTS010,PROS002_PR500,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58529924-001-01-5::0.000647::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,0.000647,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.00259::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,0.00259,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.0103::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,0.0103,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.0414::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,0.0414,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.165536::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,0.165536,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.662144::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,0.662144,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::10.5943::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,10.5943,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::2.64858::MTS010::PROS001_PR500,BRD-K58529924-001-01-5,2.64858,MTS010,PROS001_PR500,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58550667-001-08-7::0.000153::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.000153,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.00061::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.00061,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.00244::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.00244,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.00977::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.00977,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.0391::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.0391,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.15625::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.15625,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.625::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,0.625,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::3.81e-05::MTS010::PROS005_PR500,BRD-K58550667-001-08-7,3.81e-05,MTS010,PROS005_PR500,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K59317601-001-05-5::0.00061::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,0.00061,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.00244::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,0.00244,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.00977::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,0.00977,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.0391::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,0.0391,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.15625::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,0.15625,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.625::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,0.625,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::10::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,10.0,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::2.5::MTS010::PROS004_PR500,BRD-K59317601-001-05-5,2.5,MTS010,PROS004_PR500,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59369769-001-22-9::0.00061::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,0.00061,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::0.00244::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,0.00244,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::0.00977::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,0.00977,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::0.0391::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,0.0391,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::0.15625::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,0.15625,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::0.625::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,0.625,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::10::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,10.0,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-22-9::2.5::MTS010::PROS003_PR500,BRD-K59369769-001-22-9,2.5,MTS010,PROS003_PR500,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K60866521-001-07-1::0.00061::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,0.00061,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.00244::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,0.00244,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.00977::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,0.00977,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.0391::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,0.0391,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.15625::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,0.15625,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.625::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,0.625,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::10::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,10.0,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::2.5::MTS010::PROS003_PR500,BRD-K60866521-001-07-1,2.5,MTS010,PROS003_PR500,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60997853-001-02-3::0.00061::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,0.00061,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.00244::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,0.00244,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.00977::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,0.00977,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.0391::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,0.0391,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.15625::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,0.15625,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.625::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,0.625,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::10::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,10.0,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::2.5::MTS010::PROS004_PR500,BRD-K60997853-001-02-3,2.5,MTS010,PROS004_PR500,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K61192372-001-08-9::0.00061::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,0.00061,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.00244::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,0.00244,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.00977::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,0.00977,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.0391::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,0.0391,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.15625::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,0.15625,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.625::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,0.625,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::10::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,10.0,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::2.5::MTS010::PROS003_PR500,BRD-K61192372-001-08-9,2.5,MTS010,PROS003_PR500,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K62008436-001-23-9::0.000153::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.000153,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::0.00061::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.00061,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::0.00244::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.00244,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::0.00977::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.00977,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::0.0391::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.0391,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::0.15625::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.15625,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::0.625::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,0.625,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-23-9::3.81e-05::MTS010::PROS005_PR500,BRD-K62008436-001-23-9,3.81e-05,MTS010,PROS005_PR500,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62196610-001-01-6::0.00061::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,0.00061,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.00244::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,0.00244,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.00977::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,0.00977,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.0391::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,0.0391,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.15625::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,0.15625,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.625::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,0.625,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::10::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,10.0,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::2.5::MTS010::PROS004_PR500,BRD-K62196610-001-01-6,2.5,MTS010,PROS004_PR500,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62200014-003-10-5::0.00061::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,0.00061,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.00244::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,0.00244,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.00977::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,0.00977,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.0391::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,0.0391,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.15625::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,0.15625,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.625::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,0.625,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::10::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,10.0,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::2.5::MTS010::PROS001_PR500,BRD-K62200014-003-10-5,2.5,MTS010,PROS001_PR500,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62391742-001-09-7::0.00061::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,0.00061,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::0.00244::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,0.00244,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::0.00977::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,0.00977,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::0.0391::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,0.0391,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::0.15625::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,0.15625,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::0.625::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,0.625,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::10::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,10.0,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-09-7::2.5::MTS010::PROS001_PR500,BRD-K62391742-001-09-7,2.5,MTS010,PROS001_PR500,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62627508-001-01-5::0.00061::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,0.00061,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.00244::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,0.00244,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.00977::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,0.00977,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.0391::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,0.0391,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.15625::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,0.15625,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.625::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,0.625,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::10::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,10.0,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::2.5::MTS010::PROS003_PR500,BRD-K62627508-001-01-5,2.5,MTS010,PROS003_PR500,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K63504947-001-14-7::0.00061::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,0.00061,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::0.00244::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,0.00244,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::0.00977::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,0.00977,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::0.0391::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,0.0391,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::0.15625::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,0.15625,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::0.625::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,0.625,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::10::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,10.0,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-14-7::2.5::MTS010::PROS002_PR500,BRD-K63504947-001-14-7,2.5,MTS010,PROS002_PR500,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63712959-001-01-8::0.00061::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,0.00061,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.00244::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,0.00244,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.00977::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,0.00977,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.0391::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,0.0391,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.15625::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,0.15625,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.625::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,0.625,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::10::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,10.0,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::2.5::MTS010::PROS005_PR500,BRD-K63712959-001-01-8,2.5,MTS010,PROS005_PR500,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K64052750-001-22-5::0.00061::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,0.00061,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::0.00244::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,0.00244,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::0.00977::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,0.00977,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::0.0391::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,0.0391,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::0.15625::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,0.15625,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::0.625::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,0.625,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::10::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,10.0,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-22-5::2.5::MTS010::PROS002_PR500,BRD-K64052750-001-22-5,2.5,MTS010,PROS002_PR500,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64881305-001-03-7::0.00061::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,0.00061,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.00244::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,0.00244,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.00977::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,0.00977,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.0391::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,0.0391,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.15625::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,0.15625,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.625::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,0.625,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::10::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,10.0,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::2.5::MTS010::PROS001_PR500,BRD-K64881305-001-03-7,2.5,MTS010,PROS001_PR500,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K66175015-001-12-4::0.00061::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,0.00061,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::0.00244::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,0.00244,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::0.00977::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,0.00977,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::0.0391::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,0.0391,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::0.15625::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,0.15625,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::0.625::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,0.625,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::10::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,10.0,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-12-4::2.5::MTS010::PROS003_PR500,BRD-K66175015-001-12-4,2.5,MTS010,PROS003_PR500,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K67844266-003-01-9::0.00061::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,0.00061,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.00244::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,0.00244,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.00977::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,0.00977,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.0391::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,0.0391,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.15625::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,0.15625,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.625::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,0.625,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::10::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,10.0,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::2.5::MTS010::PROS003_PR500,BRD-K67844266-003-01-9,2.5,MTS010,PROS003_PR500,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K69001009-001-02-8::0.00061::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,0.00061,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.00244::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,0.00244,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.00977::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,0.00977,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.0391::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,0.0391,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.15625::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,0.15625,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.625::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,0.625,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::10::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,10.0,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::2.5::MTS010::PROS001_PR500,BRD-K69001009-001-02-8,2.5,MTS010,PROS001_PR500,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69694239-001-02-2::0.00061::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,0.00061,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.00244::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,0.00244,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.00977::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,0.00977,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.0391::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,0.0391,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.15625::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,0.15625,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.625::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,0.625,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::10::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,10.0,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::2.5::MTS010::PROS002_PR500,BRD-K69694239-001-02-2,2.5,MTS010,PROS002_PR500,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69776681-001-03-8::0.00061::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,0.00061,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.00244::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,0.00244,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.00977::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,0.00977,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.0391::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,0.0391,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.15625::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,0.15625,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.625::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,0.625,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::10::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,10.0,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::2.5::MTS010::PROS003_PR500,BRD-K69776681-001-03-8,2.5,MTS010,PROS003_PR500,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K70301465-001-05-9::0.00061::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,0.00061,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::0.00244::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,0.00244,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::0.00977::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,0.00977,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::0.0391::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,0.0391,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::0.15625::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,0.15625,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::0.625::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,0.625,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::10::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,10.0,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-05-9::2.5::MTS010::PROS003_PR500,BRD-K70301465-001-05-9,2.5,MTS010,PROS003_PR500,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70401845-001-15-7::0.00061::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,0.00061,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::0.00244::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,0.00244,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::0.00977::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,0.00977,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::0.0391::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,0.0391,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::0.15625::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,0.15625,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::0.625::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,0.625,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::10::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,10.0,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-001-15-7::2.5::MTS010::PROS003_PR500,BRD-K70401845-001-15-7,2.5,MTS010,PROS003_PR500,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K73838513-003-05-5::0.00061::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,0.00061,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.00244::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,0.00244,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.00977::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,0.00977,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.0391::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,0.0391,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.15625::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,0.15625,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.625::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,0.625,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::10::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,10.0,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::2.5::MTS010::PROS003_PR500,BRD-K73838513-003-05-5,2.5,MTS010,PROS003_PR500,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K74514084-003-09-2::0.00061::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,0.00061,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::0.00244::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,0.00244,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::0.00977::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,0.00977,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::0.0391::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,0.0391,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::0.15625::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,0.15625,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::0.625::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,0.625,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::10::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,10.0,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-003-09-2::2.5::MTS010::PROS004_PR500,BRD-K74514084-003-09-2,2.5,MTS010,PROS004_PR500,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K75009076-001-02-1::0.00061::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,0.00061,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.00244::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,0.00244,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.00977::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,0.00977,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.0391::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,0.0391,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.15625::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,0.15625,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.625::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,0.625,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::10::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,10.0,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::2.5::MTS010::PROS004_PR500,BRD-K75009076-001-02-1,2.5,MTS010,PROS004_PR500,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K76210423-001-01-6::0.00061::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,0.00061,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.00244::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,0.00244,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.00977::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,0.00977,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.0391::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,0.0391,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.15625::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,0.15625,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.625::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,0.625,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::10::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,10.0,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::2.5::MTS010::PROS001_PR500,BRD-K76210423-001-01-6,2.5,MTS010,PROS001_PR500,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76239644-001-02-6::0.00061::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,0.00061,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::0.00244::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,0.00244,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::0.00977::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,0.00977,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::0.0391::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,0.0391,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::0.15625::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,0.15625,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::0.624999::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,0.624999,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::2.5::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,2.5,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-02-6::9.99999::MTS010::PROS001_PR500,BRD-K76239644-001-02-6,9.99999,MTS010,PROS001_PR500,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76674262-001-03-3::0.00061::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,0.00061,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.00244::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,0.00244,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.00977::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,0.00977,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.0391::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,0.0391,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.15625::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,0.15625,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.625::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,0.625,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::10::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,10.0,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::2.5::MTS010::PROS003_PR500,BRD-K76674262-001-03-3,2.5,MTS010,PROS003_PR500,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76908866-001-07-6::0.00061::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,0.00061,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.00244::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,0.00244,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.00977::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,0.00977,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.0391::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,0.0391,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.15625::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,0.15625,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.625::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,0.625,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::10::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,10.0,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::2.5::MTS010::PROS002_PR500,BRD-K76908866-001-07-6,2.5,MTS010,PROS002_PR500,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K77625799-001-07-7::0.00061::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,0.00061,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.00244::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,0.00244,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.00977::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,0.00977,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.0391::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,0.0391,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.15625::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,0.15625,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.625::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,0.625,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::10::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,10.0,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::2.5::MTS010::PROS002_PR500,BRD-K77625799-001-07-7,2.5,MTS010,PROS002_PR500,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K78431006-001-15-1::0.00061::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,0.00061,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::0.00244::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,0.00244,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::0.00977::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,0.00977,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::0.0391::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,0.0391,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::0.15625::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,0.15625,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::0.625::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,0.625,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::10::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,10.0,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-15-1::2.5::MTS010::PROS004_PR500,BRD-K78431006-001-15-1,2.5,MTS010,PROS004_PR500,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K79254416-001-21-8::0.00061::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,0.00061,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::0.00244::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,0.00244,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::0.00977::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,0.00977,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::0.0391::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,0.0391,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::0.15625::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,0.15625,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::0.625::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,0.625,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::10::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,10.0,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-21-8::2.5::MTS010::PROS004_PR500,BRD-K79254416-001-21-8,2.5,MTS010,PROS004_PR500,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K81016934-001-02-0::0.00061::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,0.00061,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.00244::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,0.00244,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.00977::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,0.00977,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.0391::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,0.0391,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.15625::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,0.15625,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.625::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,0.625,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::10::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,10.0,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::2.5::MTS010::PROS004_PR500,BRD-K81016934-001-02-0,2.5,MTS010,PROS004_PR500,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81418486-001-44-2::0.00061::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,0.00061,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::0.00244::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,0.00244,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::0.00977::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,0.00977,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::0.0391::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,0.0391,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::0.15625::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,0.15625,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::0.625::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,0.625,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::10::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,10.0,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-44-2::2.5::MTS010::PROS001_PR500,BRD-K81418486-001-44-2,2.5,MTS010,PROS001_PR500,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81473043-001-19-5::0.000153::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.000153,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::0.00061::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.00061,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::0.00244::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.00244,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::0.00977::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.00977,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::0.0391::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.0391,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::0.15625::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.15625,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::0.625::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,0.625,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-19-5::3.81e-05::MTS010::PROS005_PR500,BRD-K81473043-001-19-5,3.81e-05,MTS010,PROS005_PR500,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K82135108-001-04-3::0.00061::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,0.00061,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.00244::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,0.00244,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.00977::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,0.00977,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.0391::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,0.0391,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.15625::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,0.15625,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.625::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,0.625,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::10::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,10.0,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::2.5::MTS010::PROS001_PR500,BRD-K82135108-001-04-3,2.5,MTS010,PROS001_PR500,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82746043-001-19-3::0.00061::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,0.00061,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::0.00244::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,0.00244,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::0.00977::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,0.00977,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::0.0391::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,0.0391,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::0.15625::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,0.15625,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::0.625::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,0.625,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::10::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,10.0,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-19-3::2.5::MTS010::PROS002_PR500,BRD-K82746043-001-19-3,2.5,MTS010,PROS002_PR500,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82818427-001-04-8::0.00061::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,0.00061,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::0.00244::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,0.00244,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::0.00977::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,0.00977,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::0.0391::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,0.0391,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::0.15625::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,0.15625,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::0.625::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,0.625,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::10::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,10.0,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-04-8::2.5::MTS010::PROS003_PR500,BRD-K82818427-001-04-8,2.5,MTS010,PROS003_PR500,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K83029223-001-01-3::0.000153::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.000153,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.00061::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.00061,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.00244::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.00244,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.00977::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.00977,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.0391::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.0391,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.15625::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.15625,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.625::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,0.625,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::3.81e-05::MTS010::PROS005_PR500,BRD-K83029223-001-01-3,3.81e-05,MTS010,PROS005_PR500,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83988098-001-02-0::0.000152::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,0.000152,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::0.000609::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,0.000609,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::0.00244::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,0.00244,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::0.00975::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,0.00975,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::0.039::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,0.039,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::0.156::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,0.156,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::3.81e-05::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,3.81e-05,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-001-02-0::9.52e-06::MTS010::PROS005_PR500,BRD-K83988098-001-02-0,9.52e-06,MTS010,PROS005_PR500,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K85402309-043-01-9::0.00061::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,0.00061,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::0.00244::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,0.00244,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::0.00977::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,0.00977,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::0.0391::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,0.0391,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::0.15625::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,0.15625,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::0.625::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,0.625,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::10::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,10.0,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-043-01-9::2.5::MTS010::PROS001_PR500,BRD-K85402309-043-01-9,2.5,MTS010,PROS001_PR500,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85606544-001-09-1::0.00061::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,0.00061,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.00244::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,0.00244,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.00977::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,0.00977,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.0391::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,0.0391,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.15625::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,0.15625,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.625::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,0.625,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::10::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,10.0,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::2.5::MTS010::PROS004_PR500,BRD-K85606544-001-09-1,2.5,MTS010,PROS004_PR500,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K86118762-001-01-8::0.00061::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,0.00061,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.00244::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,0.00244,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.00977::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,0.00977,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.0391::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,0.0391,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.15625::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,0.15625,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.625::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,0.625,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::10::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,10.0,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::2.5::MTS010::PROS002_PR500,BRD-K86118762-001-01-8,2.5,MTS010,PROS002_PR500,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86972824-001-01-4::0.00061::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,0.00061,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.00244::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,0.00244,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.00977::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,0.00977,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.0391::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,0.0391,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.15625::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,0.15625,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.625::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,0.625,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::10::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,10.0,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::2.5::MTS010::PROS005_PR500,BRD-K86972824-001-01-4,2.5,MTS010,PROS005_PR500,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K87737963-001-06-0::0.00061::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,0.00061,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.00244::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,0.00244,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.00977::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,0.00977,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.0391::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,0.0391,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.15625::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,0.15625,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.625::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,0.625,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::10::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,10.0,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::2.5::MTS010::PROS002_PR500,BRD-K87737963-001-06-0,2.5,MTS010,PROS002_PR500,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87782578-001-01-4::0.00061::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,0.00061,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.00244::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,0.00244,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.00977::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,0.00977,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.0391::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,0.0391,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.15625::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,0.15625,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.625::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,0.625,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::10::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,10.0,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::2.5::MTS010::PROS001_PR500,BRD-K87782578-001-01-4,2.5,MTS010,PROS001_PR500,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87909389-003-03-4::0.00061::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,0.00061,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.00244::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,0.00244,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.00977::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,0.00977,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.0391::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,0.0391,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.15625::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,0.15625,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.625::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,0.625,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::10::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,10.0,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::2.5::MTS010::PROS002_PR500,BRD-K87909389-003-03-4,2.5,MTS010,PROS002_PR500,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K88510285-001-17-8::0.000153::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.000153,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::0.00061::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.00061,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::0.00244::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.00244,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::0.00977::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.00977,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::0.0391::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.0391,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::0.15625::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.15625,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::0.625::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,0.625,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-17-8::2.5::MTS010::PROS005_PR500,BRD-K88510285-001-17-8,2.5,MTS010,PROS005_PR500,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K89014967-001-04-3::0.00061::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,0.00061,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.00244::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,0.00244,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.00977::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,0.00977,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.0391::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,0.0391,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.15625::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,0.15625,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.625::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,0.625,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::10::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,10.0,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::2.5::MTS010::PROS004_PR500,BRD-K89014967-001-04-3,2.5,MTS010,PROS004_PR500,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K92441787-001-04-1::0.00061::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,0.00061,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.00244::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,0.00244,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.00977::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,0.00977,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.0391::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,0.0391,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.15625::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,0.15625,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.625::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,0.625,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::10::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,10.0,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::2.5::MTS010::PROS003_PR500,BRD-K92441787-001-04-1,2.5,MTS010,PROS003_PR500,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92723993-001-17-4::0.00061::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,0.00061,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00061::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,0.00061,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00061::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,0.00061,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00061::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,0.00061,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00061::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,0.00061,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00244::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,0.00244,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00244::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,0.00244,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00244::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,0.00244,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00244::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,0.00244,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00244::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,0.00244,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00977::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,0.00977,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00977::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,0.00977,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00977::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,0.00977,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00977::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,0.00977,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.00977::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,0.00977,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.0391::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,0.0391,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.0391::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,0.0391,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.0391::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,0.0391,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.0391::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,0.0391,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.0391::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,0.0391,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.15625::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,0.15625,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.15625::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,0.15625,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.15625::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,0.15625,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.15625::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,0.15625,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.15625::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,0.15625,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.625::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,0.625,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.625::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,0.625,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.625::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,0.625,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.625::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,0.625,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::0.625::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,0.625,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::10::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,10.0,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::10::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,10.0,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::10::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,10.0,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::10::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,10.0,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::10::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,10.0,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::2.5::MTS010::PROS001_PR500,BRD-K92723993-001-17-4,2.5,MTS010,PROS001_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::2.5::MTS010::PROS002_PR500,BRD-K92723993-001-17-4,2.5,MTS010,PROS002_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::2.5::MTS010::PROS003_PR500,BRD-K92723993-001-17-4,2.5,MTS010,PROS003_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::2.5::MTS010::PROS004_PR500,BRD-K92723993-001-17-4,2.5,MTS010,PROS004_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-17-4::2.5::MTS010::PROS005_PR500,BRD-K92723993-001-17-4,2.5,MTS010,PROS005_PR500,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K95142244-001-01-5::0.00061::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,0.00061,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.00244::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,0.00244,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.00977::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,0.00977,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.0391::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,0.0391,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.15625::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,0.15625,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.625::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,0.625,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::10::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,10.0,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::2.5::MTS010::PROS003_PR500,BRD-K95142244-001-01-5,2.5,MTS010,PROS003_PR500,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K96123349-236-02-8::0.00061::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,0.00061,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.00244::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,0.00244,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.00977::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,0.00977,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.0391::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,0.0391,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.15625::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,0.15625,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.625::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,0.625,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::10::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,10.0,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::2.5::MTS010::PROS002_PR500,BRD-K96123349-236-02-8,2.5,MTS010,PROS002_PR500,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K98572433-001-02-9::0.00061::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,0.00061,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.00244::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,0.00244,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.00977::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,0.00977,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.0391::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,0.0391,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.15625::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,0.15625,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.625::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,0.625,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::10::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,10.0,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::2.5::MTS010::PROS002_PR500,BRD-K98572433-001-02-9,2.5,MTS010,PROS002_PR500,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K99113996-001-02-0::0.00061::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,0.00061,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.00244::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,0.00244,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.00977::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,0.00977,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.0391::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,0.0391,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.15625::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,0.15625,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.625::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,0.625,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::10::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,10.0,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::2.5::MTS010::PROS001_PR500,BRD-K99113996-001-02-0,2.5,MTS010,PROS001_PR500,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99616396-001-05-1::0.00061::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,0.00061,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.00244::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,0.00244,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.00977::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,0.00977,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.0391::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,0.0391,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.156249::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,0.156249,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.624998::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,0.624998,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::2.49999::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,2.49999,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::9.99997::MTS010::PROS005_PR500,BRD-K99616396-001-05-1,9.99997,MTS010,PROS005_PR500,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99749624-001-07-0::0.00061::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,0.00061,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.00244::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,0.00244,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.00977::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,0.00977,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.0391::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,0.0391,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.15625::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,0.15625,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.625::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,0.625,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::10::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,10.0,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::2.5::MTS010::PROS001_PR500,BRD-K99749624-001-07-0,2.5,MTS010,PROS001_PR500,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-M97302542-001-04-4::0.00061::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,0.00061,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::0.00244::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,0.00244,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::0.00977::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,0.00977,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::0.0391::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,0.0391,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::0.15625::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,0.15625,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::0.625::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,0.625,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::10::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,10.0,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-04-4::2.5::MTS010::PROS001_PR500,BRD-M97302542-001-04-4,2.5,MTS010,PROS001_PR500,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-U25960968-000-01-9::0.000610351569230769::HTS002,BRD-U25960968-000-01-9,0.0006103515692307692,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::0.00244140624615385::HTS002,BRD-U25960968-000-01-9,0.002441406246153846,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::0.009765625::HTS002,BRD-U25960968-000-01-9,0.009765625,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::0.0390625::HTS002,BRD-U25960968-000-01-9,0.0390625,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::0.15625::HTS002,BRD-U25960968-000-01-9,0.15625,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::0.625::HTS002,BRD-U25960968-000-01-9,0.625,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::2.5::HTS002,BRD-U25960968-000-01-9,2.5,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U25960968-000-01-9::10::HTS002,BRD-U25960968-000-01-9,10.0,HTS002,PREP022,tyloxapol,NFkB pathway inhibitor,"LPL, NFKB2",NA,NA,"C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , , C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1",Launched
BRD-U45393375-000-01-6::0.000610351569230769::HTS002,BRD-U45393375-000-01-6,0.0006103515692307692,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::0.00244140624615385::HTS002,BRD-U45393375-000-01-6,0.002441406246153846,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::0.009765625::HTS002,BRD-U45393375-000-01-6,0.009765625,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::0.0390625::HTS002,BRD-U45393375-000-01-6,0.0390625,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::0.15625::HTS002,BRD-U45393375-000-01-6,0.15625,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::0.625::HTS002,BRD-U45393375-000-01-6,0.625,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::2.5::HTS002,BRD-U45393375-000-01-6,2.5,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-U45393375-000-01-6::10::HTS002,BRD-U45393375-000-01-6,10.0,HTS002,PREP016,sevelamer,phosphate antagonist,NA,nephrology,chronic kidney disease (CKD),", NCC=C.ClCC1CO1",Launched
BRD-A00077618-236-07-6::0.00061034::HTS002,BRD-A00077618-236-07-6,0.00061034,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::0.0024414::HTS002,BRD-A00077618-236-07-6,0.0024414,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::0.00976562::HTS002,BRD-A00077618-236-07-6,0.00976562,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::0.0390625::HTS002,BRD-A00077618-236-07-6,0.0390625,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::0.15625::HTS002,BRD-A00077618-236-07-6,0.15625,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::0.625::HTS002,BRD-A00077618-236-07-6,0.625,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::2.5::HTS002,BRD-A00077618-236-07-6,2.5,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00077618-236-07-6::10::HTS002,BRD-A00077618-236-07-6,10.0,HTS002,PREP036,8-bromo-cGMP,PKA activator,PRKG1,NA,NA,Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1,Preclinical
BRD-A00758722-001-04-9::0.00061034::HTS002,BRD-A00758722-001-04-9,0.00061034,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::0.0024414::HTS002,BRD-A00758722-001-04-9,0.0024414,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::0.00976562::HTS002,BRD-A00758722-001-04-9,0.00976562,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::0.0390625::HTS002,BRD-A00758722-001-04-9,0.0390625,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::0.15625::HTS002,BRD-A00758722-001-04-9,0.15625,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::0.625::HTS002,BRD-A00758722-001-04-9,0.625,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::2.5::HTS002,BRD-A00758722-001-04-9,2.5,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-A00758722-001-04-9::10::HTS002,BRD-A00758722-001-04-9,10.0,HTS002,PREP021,noretynodrel,progestogen hormone,PGR,endocrinology,contraceptive,C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C#C,Launched
BRD-K61496577-001-20-2::0.00061034::HTS002,BRD-K61496577-001-20-2,0.00061034,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::0.0024414::HTS002,BRD-K61496577-001-20-2,0.0024414,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::0.00976562::HTS002,BRD-K61496577-001-20-2,0.00976562,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::0.0390625::HTS002,BRD-K61496577-001-20-2,0.0390625,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::0.15625::HTS002,BRD-K61496577-001-20-2,0.15625,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::0.625::HTS002,BRD-K61496577-001-20-2,0.625,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::2.5::HTS002,BRD-K61496577-001-20-2,2.5,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-K61496577-001-20-2::10::HTS002,BRD-K61496577-001-20-2,10.0,HTS002,PREP035,flumethasone,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",Launched
BRD-A01643550-001-04-9::0.00061034::HTS002,BRD-A01643550-001-04-9,0.00061034,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::0.0024414::HTS002,BRD-A01643550-001-04-9,0.0024414,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::0.00976562::HTS002,BRD-A01643550-001-04-9,0.00976562,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::0.0390625::HTS002,BRD-A01643550-001-04-9,0.0390625,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::0.15625::HTS002,BRD-A01643550-001-04-9,0.15625,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::0.625::HTS002,BRD-A01643550-001-04-9,0.625,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::2.5::HTS002,BRD-A01643550-001-04-9,2.5,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A01643550-001-04-9::10::HTS002,BRD-A01643550-001-04-9,10.0,HTS002,PREP020,prednisolone-acetate,glucocorticoid receptor agonist,NR3C1,"ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C",Launched
BRD-A02180903-001-04-5::0.00061034::HTS002,BRD-A02180903-001-04-5,0.00061034,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::0.0024414::HTS002,BRD-A02180903-001-04-5,0.0024414,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::0.00976562::HTS002,BRD-A02180903-001-04-5,0.00976562,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::0.0390625::HTS002,BRD-A02180903-001-04-5,0.0390625,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::0.15625::HTS002,BRD-A02180903-001-04-5,0.15625,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::0.625::HTS002,BRD-A02180903-001-04-5,0.625,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::2.5::HTS002,BRD-A02180903-001-04-5,2.5,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-A02180903-001-04-5::10::HTS002,BRD-A02180903-001-04-5,10.0,HTS002,PREP021,betamethasone,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",Launched
BRD-K48195008-001-19-9::0.00061034::HTS002,BRD-K48195008-001-19-9,0.00061034,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::0.0024414::HTS002,BRD-K48195008-001-19-9,0.0024414,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::0.00976562::HTS002,BRD-K48195008-001-19-9,0.00976562,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::0.0390625::HTS002,BRD-K48195008-001-19-9,0.0390625,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::0.15625::HTS002,BRD-K48195008-001-19-9,0.15625,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::0.625::HTS002,BRD-K48195008-001-19-9,0.625,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::2.5::HTS002,BRD-K48195008-001-19-9,2.5,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K48195008-001-19-9::10::HTS002,BRD-K48195008-001-19-9,10.0,HTS002,PREP021,ethinyl-estradiol,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-A03216249-003-24-3::0.00061034::HTS002,BRD-A03216249-003-24-3,0.00061034,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::0.0024414::HTS002,BRD-A03216249-003-24-3,0.0024414,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::0.00976562::HTS002,BRD-A03216249-003-24-3,0.00976562,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::0.0390625::HTS002,BRD-A03216249-003-24-3,0.0390625,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::0.15625::HTS002,BRD-A03216249-003-24-3,0.15625,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::0.625::HTS002,BRD-A03216249-003-24-3,0.625,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::2.5::HTS002,BRD-A03216249-003-24-3,2.5,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A03216249-003-24-3::10::HTS002,BRD-A03216249-003-24-3,10.0,HTS002,PREP016,mepivacaine,"potassium channel blocker, sodium channel blocker",SCN10A,neurology/psychiatry,local anesthetic,"CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C",Launched
BRD-A85667082-001-12-7::0.00061034::HTS002,BRD-A85667082-001-12-7,0.00061034,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::0.0024414::HTS002,BRD-A85667082-001-12-7,0.0024414,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::0.00976562::HTS002,BRD-A85667082-001-12-7,0.00976562,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::0.0390625::HTS002,BRD-A85667082-001-12-7,0.0390625,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::0.15625::HTS002,BRD-A85667082-001-12-7,0.15625,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::0.625::HTS002,BRD-A85667082-001-12-7,0.625,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::2.5::HTS002,BRD-A85667082-001-12-7,2.5,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A85667082-001-12-7::10::HTS002,BRD-A85667082-001-12-7,10.0,HTS002,PREP014,fulvestrant,estrogen receptor antagonist,"ESR1, ESR2, GPER1",oncology,breast cancer,"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31",Launched
BRD-A03506276-001-01-5::0.00061034::HTS002,BRD-A03506276-001-01-5,0.00061034,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::0.0024414::HTS002,BRD-A03506276-001-01-5,0.0024414,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::0.00976562::HTS002,BRD-A03506276-001-01-5,0.00976562,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::0.0390625::HTS002,BRD-A03506276-001-01-5,0.0390625,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::0.15625::HTS002,BRD-A03506276-001-01-5,0.15625,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::0.625::HTS002,BRD-A03506276-001-01-5,0.625,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::2.5::HTS002,BRD-A03506276-001-01-5,2.5,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03506276-001-01-5::10::HTS002,BRD-A03506276-001-01-5,10.0,HTS002,PREP026,XL888,HSP inhibitor,NA,NA,NA,CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O,Phase 1
BRD-A03623303-045-09-5::0.00061034::HTS002,BRD-A03623303-045-09-5,0.00061034,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::0.0024414::HTS002,BRD-A03623303-045-09-5,0.0024414,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::0.00976562::HTS002,BRD-A03623303-045-09-5,0.00976562,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::0.0390625::HTS002,BRD-A03623303-045-09-5,0.0390625,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::0.15625::HTS002,BRD-A03623303-045-09-5,0.15625,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::0.625::HTS002,BRD-A03623303-045-09-5,0.625,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::2.5::HTS002,BRD-A03623303-045-09-5,2.5,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03623303-045-09-5::10::HTS002,BRD-A03623303-045-09-5,10.0,HTS002,PREP017,metoprolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris, myocardial infarction","COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1",Launched
BRD-A03932035-004-04-3::0.00061034::HTS002,BRD-A03932035-004-04-3,0.00061034,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::0.0024414::HTS002,BRD-A03932035-004-04-3,0.0024414,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::0.00976562::HTS002,BRD-A03932035-004-04-3,0.00976562,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::0.0390625::HTS002,BRD-A03932035-004-04-3,0.0390625,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::0.15625::HTS002,BRD-A03932035-004-04-3,0.15625,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::0.625::HTS002,BRD-A03932035-004-04-3,0.625,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::2.5::HTS002,BRD-A03932035-004-04-3,2.5,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A03932035-004-04-3::10::HTS002,BRD-A03932035-004-04-3,10.0,HTS002,PREP029,methscopolamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),"C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K30577245-341-01-9::0.00061034::HTS002,BRD-K30577245-341-01-9,0.00061034,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::0.0024414::HTS002,BRD-K30577245-341-01-9,0.0024414,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::0.00976562::HTS002,BRD-K30577245-341-01-9,0.00976562,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::0.0390625::HTS002,BRD-K30577245-341-01-9,0.0390625,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::0.15625::HTS002,BRD-K30577245-341-01-9,0.15625,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::0.625::HTS002,BRD-K30577245-341-01-9,0.625,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::2.5::HTS002,BRD-K30577245-341-01-9,2.5,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-K30577245-341-01-9::10::HTS002,BRD-K30577245-341-01-9,10.0,HTS002,PREP017,docetaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C",Launched
BRD-A05906449-004-01-1::0.00061034::HTS002,BRD-A05906449-004-01-1,0.00061034,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::0.0024414::HTS002,BRD-A05906449-004-01-1,0.0024414,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::0.00976562::HTS002,BRD-A05906449-004-01-1,0.00976562,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::0.0390625::HTS002,BRD-A05906449-004-01-1,0.0390625,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::0.15625::HTS002,BRD-A05906449-004-01-1,0.15625,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::0.625::HTS002,BRD-A05906449-004-01-1,0.625,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::2.5::HTS002,BRD-A05906449-004-01-1,2.5,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A05906449-004-01-1::10::HTS002,BRD-A05906449-004-01-1,10.0,HTS002,PREP039,lappaconite,sodium channel blocker,NA,NA,NA,CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O,Phase 2
BRD-A06352418-001-25-9::0.00061034::HTS002,BRD-A06352418-001-25-9,0.00061034,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::0.0024414::HTS002,BRD-A06352418-001-25-9,0.0024414,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::0.00976562::HTS002,BRD-A06352418-001-25-9,0.00976562,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::0.0390625::HTS002,BRD-A06352418-001-25-9,0.0390625,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::0.15625::HTS002,BRD-A06352418-001-25-9,0.15625,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::0.625::HTS002,BRD-A06352418-001-25-9,0.625,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::2.5::HTS002,BRD-A06352418-001-25-9,2.5,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352418-001-25-9::10::HTS002,BRD-A06352418-001-25-9,10.0,HTS002,PREP021,terfenadine,histamine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2",NA,NA,"CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1",Withdrawn
BRD-A06352508-001-03-7::0.00061034::HTS002,BRD-A06352508-001-03-7,0.00061034,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::0.0024414::HTS002,BRD-A06352508-001-03-7,0.0024414,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::0.00976562::HTS002,BRD-A06352508-001-03-7,0.00976562,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::0.0390625::HTS002,BRD-A06352508-001-03-7,0.0390625,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::0.15625::HTS002,BRD-A06352508-001-03-7,0.15625,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::0.625::HTS002,BRD-A06352508-001-03-7,0.625,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::2.5::HTS002,BRD-A06352508-001-03-7,2.5,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06352508-001-03-7::10::HTS002,BRD-A06352508-001-03-7,10.0,HTS002,PREP043,SB-218078,CHK inhibitor,CHEK1,NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13",Preclinical
BRD-A06426627-001-03-5::0.00061034::HTS002,BRD-A06426627-001-03-5,0.00061034,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::0.0024414::HTS002,BRD-A06426627-001-03-5,0.0024414,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::0.00976562::HTS002,BRD-A06426627-001-03-5,0.00976562,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::0.0390625::HTS002,BRD-A06426627-001-03-5,0.0390625,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::0.15625::HTS002,BRD-A06426627-001-03-5,0.15625,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::0.625::HTS002,BRD-A06426627-001-03-5,0.625,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::2.5::HTS002,BRD-A06426627-001-03-5,2.5,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A06426627-001-03-5::10::HTS002,BRD-A06426627-001-03-5,10.0,HTS002,PREP028,diclazuril,antiprotozoal agent,NA,infectious disease,equine protozoal myeloencephalitis (EPM),"Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O, Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O",Launched
BRD-A07704283-001-01-3::0.000610352::HTS002,BRD-A07704283-001-01-3,0.000610352,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::0.00244141::HTS002,BRD-A07704283-001-01-3,0.00244141,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::0.00976562::HTS002,BRD-A07704283-001-01-3,0.00976562,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::0.0390625::HTS002,BRD-A07704283-001-01-3,0.0390625,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::0.15625::HTS002,BRD-A07704283-001-01-3,0.15625,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::0.625::HTS002,BRD-A07704283-001-01-3,0.625,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::2.5::HTS002,BRD-A07704283-001-01-3,2.5,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07704283-001-01-3::10::HTS002,BRD-A07704283-001-01-3,10.0,HTS002,PREP027,isofloxythepin,dopamine receptor antagonist,NA,NA,NA,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,Phase 2
BRD-A07986123-001-02-8::0.00061034::HTS002,BRD-A07986123-001-02-8,0.00061034,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::0.0024414::HTS002,BRD-A07986123-001-02-8,0.0024414,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::0.00976562::HTS002,BRD-A07986123-001-02-8,0.00976562,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::0.0390625::HTS002,BRD-A07986123-001-02-8,0.0390625,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::0.15625::HTS002,BRD-A07986123-001-02-8,0.15625,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::0.625::HTS002,BRD-A07986123-001-02-8,0.625,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::2.5::HTS002,BRD-A07986123-001-02-8,2.5,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A07986123-001-02-8::10::HTS002,BRD-A07986123-001-02-8,10.0,HTS002,PREP046,galeterone,androgen receptor modulator,"AR, CYP17A1",NA,NA,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12,Phase 3
BRD-A08187463-001-12-9::0.00061034::HTS002,BRD-A08187463-001-12-9,0.00061034,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::0.0024414::HTS002,BRD-A08187463-001-12-9,0.0024414,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::0.00976562::HTS002,BRD-A08187463-001-12-9,0.00976562,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::0.0390625::HTS002,BRD-A08187463-001-12-9,0.0390625,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::0.15625::HTS002,BRD-A08187463-001-12-9,0.15625,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::0.625::HTS002,BRD-A08187463-001-12-9,0.625,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::2.5::HTS002,BRD-A08187463-001-12-9,2.5,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08187463-001-12-9::10::HTS002,BRD-A08187463-001-12-9,10.0,HTS002,PREP028,racecadotril,enkephalinase inhibitor,MME,gastroenterology,diarrhea,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1",Launched
BRD-A08545410-003-07-8::0.000580005::HTS002,BRD-A08545410-003-07-8,0.000580005,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::0.00232002::HTS002,BRD-A08545410-003-07-8,0.00232002,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::0.00928008::HTS002,BRD-A08545410-003-07-8,0.00928008,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::0.0371203::HTS002,BRD-A08545410-003-07-8,0.0371203,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::0.148481::HTS002,BRD-A08545410-003-07-8,0.148481,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::0.593925::HTS002,BRD-A08545410-003-07-8,0.593925,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::2.3757::HTS002,BRD-A08545410-003-07-8,2.3757,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-003-07-8::9.5028::HTS002,BRD-A08545410-003-07-8,9.5028,HTS002,PREP031,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::0.000610352::HTS002,BRD-A08545410-311-03-4,0.000610352,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::0.00244141::HTS002,BRD-A08545410-311-03-4,0.00244141,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::0.00976562::HTS002,BRD-A08545410-311-03-4,0.00976562,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::0.0390625::HTS002,BRD-A08545410-311-03-4,0.0390625,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::0.15625::HTS002,BRD-A08545410-311-03-4,0.15625,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::0.625::HTS002,BRD-A08545410-311-03-4,0.625,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::2.5::HTS002,BRD-A08545410-311-03-4,2.5,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08545410-311-03-4::10::HTS002,BRD-A08545410-311-03-4,10.0,HTS002,PREP034,doxycycline,metalloproteinase inhibitor,MMP8,dental,periodontitis,"C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12",Launched
BRD-A08840375-001-01-3::0.000610352::HTS002,BRD-A08840375-001-01-3,0.000610352,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::0.00244141::HTS002,BRD-A08840375-001-01-3,0.00244141,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::0.00976562::HTS002,BRD-A08840375-001-01-3,0.00976562,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::0.0390625::HTS002,BRD-A08840375-001-01-3,0.0390625,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::0.15625::HTS002,BRD-A08840375-001-01-3,0.15625,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::0.625::HTS002,BRD-A08840375-001-01-3,0.625,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::2.5::HTS002,BRD-A08840375-001-01-3,2.5,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A08840375-001-01-3::10::HTS002,BRD-A08840375-001-01-3,10.0,HTS002,PREP043,CID-5458317,MAP kinase phosphatase inhibitor,MAPK3,NA,NA,O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1,Preclinical
BRD-A09349126-001-10-7::0.00061034::HTS002,BRD-A09349126-001-10-7,0.00061034,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::0.0024414::HTS002,BRD-A09349126-001-10-7,0.0024414,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::0.00976562::HTS002,BRD-A09349126-001-10-7,0.00976562,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::0.0390625::HTS002,BRD-A09349126-001-10-7,0.0390625,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::0.15625::HTS002,BRD-A09349126-001-10-7,0.15625,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::0.625::HTS002,BRD-A09349126-001-10-7,0.625,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::2.5::HTS002,BRD-A09349126-001-10-7,2.5,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09349126-001-10-7::10::HTS002,BRD-A09349126-001-10-7,10.0,HTS002,PREP028,norethindrone-acetate,progesterone receptor agonist,NA,"endocrinology, orthopedics, obstetrics/gynecology","menopause, osteoporosis, vaginal atrophy",CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,Launched
BRD-A09722536-002-18-0::0.00061034::HTS002,BRD-A09722536-002-18-0,0.00061034,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::0.0024414::HTS002,BRD-A09722536-002-18-0,0.0024414,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::0.00976562::HTS002,BRD-A09722536-002-18-0,0.00976562,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::0.0390625::HTS002,BRD-A09722536-002-18-0,0.0390625,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::0.15625::HTS002,BRD-A09722536-002-18-0,0.15625,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::0.625::HTS002,BRD-A09722536-002-18-0,0.625,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::2.5::HTS002,BRD-A09722536-002-18-0,2.5,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-A09722536-002-18-0::10::HTS002,BRD-A09722536-002-18-0,10.0,HTS002,PREP023,cyclophosphamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7","hematologic malignancy, oncology","Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer","ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1",Launched
BRD-K23925186-001-02-8::0.000612254::HTS002,BRD-K23925186-001-02-8,0.000612254,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::0.00244901::HTS002,BRD-K23925186-001-02-8,0.00244901,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::0.00979606::HTS002,BRD-K23925186-001-02-8,0.00979606,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::0.0391842::HTS002,BRD-K23925186-001-02-8,0.0391842,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::0.156737::HTS002,BRD-K23925186-001-02-8,0.156737,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::0.626948::HTS002,BRD-K23925186-001-02-8,0.626948,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::2.50779::HTS002,BRD-K23925186-001-02-8,2.50779,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-K23925186-001-02-8::10.0312::HTS002,BRD-K23925186-001-02-8,10.0312,HTS002,PREP035,oridonin,BCL inhibitor,BCL2,NA,NA,"O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C, O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",Preclinical
BRD-A06627858-236-03-0::0.00061034::HTS002,BRD-A06627858-236-03-0,0.00061034,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.0024414::HTS002,BRD-A06627858-236-03-0,0.0024414,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.00976562::HTS002,BRD-A06627858-236-03-0,0.00976562,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.0390625::HTS002,BRD-A06627858-236-03-0,0.0390625,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.15625::HTS002,BRD-A06627858-236-03-0,0.15625,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.625::HTS002,BRD-A06627858-236-03-0,0.625,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::2.5::HTS002,BRD-A06627858-236-03-0,2.5,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::10::HTS002,BRD-A06627858-236-03-0,10.0,HTS002,PREP023,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A10039652-001-01-2::0.00061034::HTS002,BRD-A10039652-001-01-2,0.00061034,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::0.0024414::HTS002,BRD-A10039652-001-01-2,0.0024414,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::0.00976562::HTS002,BRD-A10039652-001-01-2,0.00976562,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::0.0390625::HTS002,BRD-A10039652-001-01-2,0.0390625,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::0.15625::HTS002,BRD-A10039652-001-01-2,0.15625,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::0.625::HTS002,BRD-A10039652-001-01-2,0.625,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::2.5::HTS002,BRD-A10039652-001-01-2,2.5,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10039652-001-01-2::10::HTS002,BRD-A10039652-001-01-2,10.0,HTS002,PREP044,tipranavir,HIV protease inhibitor,NA,infectious disease,human immunodeficiency virus (HIV-1),"CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1, CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1",Launched
BRD-A10070317-003-28-3::0.00061034::HTS002,BRD-A10070317-003-28-3,0.00061034,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::0.0024414::HTS002,BRD-A10070317-003-28-3,0.0024414,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::0.00976562::HTS002,BRD-A10070317-003-28-3,0.00976562,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::0.0390625::HTS002,BRD-A10070317-003-28-3,0.0390625,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::0.15625::HTS002,BRD-A10070317-003-28-3,0.15625,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::0.625::HTS002,BRD-A10070317-003-28-3,0.625,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::2.5::HTS002,BRD-A10070317-003-28-3,2.5,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10070317-003-28-3::10::HTS002,BRD-A10070317-003-28-3,10.0,HTS002,PREP021,propranolol,adrenergic receptor antagonist,NA,"cardiology, neurology/psychiatry","hypertension, angina pectoris, migraine headache","CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12",Launched
BRD-A10523515-001-07-9::0.00061034::HTS002,BRD-A10523515-001-07-9,0.00061034,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::0.0024414::HTS002,BRD-A10523515-001-07-9,0.0024414,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::0.00976562::HTS002,BRD-A10523515-001-07-9,0.00976562,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::0.0390625::HTS002,BRD-A10523515-001-07-9,0.0390625,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::0.15625::HTS002,BRD-A10523515-001-07-9,0.15625,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::0.625::HTS002,BRD-A10523515-001-07-9,0.625,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::2.5::HTS002,BRD-A10523515-001-07-9,2.5,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10523515-001-07-9::10::HTS002,BRD-A10523515-001-07-9,10.0,HTS002,PREP037,GSK429286A,rho associated kinase inhibitor,ROCK1,NA,NA,"CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F",Preclinical
BRD-A10903566-003-07-7::0.00061034::HTS002,BRD-A10903566-003-07-7,0.00061034,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::0.0024414::HTS002,BRD-A10903566-003-07-7,0.0024414,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::0.00976562::HTS002,BRD-A10903566-003-07-7,0.00976562,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::0.0390625::HTS002,BRD-A10903566-003-07-7,0.0390625,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::0.15625::HTS002,BRD-A10903566-003-07-7,0.15625,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::0.625::HTS002,BRD-A10903566-003-07-7,0.625,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::2.5::HTS002,BRD-A10903566-003-07-7,2.5,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10903566-003-07-7::10::HTS002,BRD-A10903566-003-07-7,10.0,HTS002,PREP025,imiloxan,adrenergic receptor antagonist,"ADRA2A, ADRA2B",NA,NA,CCn1ccnc1CC1COc2ccccc2O1,Phase 1
BRD-A10977446-001-12-1::0.00061034::HTS002,BRD-A10977446-001-12-1,0.00061034,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::0.0024414::HTS002,BRD-A10977446-001-12-1,0.0024414,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::0.00976562::HTS002,BRD-A10977446-001-12-1,0.00976562,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::0.0390625::HTS002,BRD-A10977446-001-12-1,0.0390625,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::0.15625::HTS002,BRD-A10977446-001-12-1,0.15625,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::0.625::HTS002,BRD-A10977446-001-12-1,0.625,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::2.5::HTS002,BRD-A10977446-001-12-1,2.5,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A10977446-001-12-1::10::HTS002,BRD-A10977446-001-12-1,10.0,HTS002,PREP028,carvedilol,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA",cardiology,"myocardial infarction, hypertension","COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12",Launched
BRD-A11132253-001-08-2::0.00061034::HTS002,BRD-A11132253-001-08-2,0.00061034,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::0.0024414::HTS002,BRD-A11132253-001-08-2,0.0024414,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::0.00976562::HTS002,BRD-A11132253-001-08-2,0.00976562,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::0.0390625::HTS002,BRD-A11132253-001-08-2,0.0390625,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::0.15625::HTS002,BRD-A11132253-001-08-2,0.15625,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::0.625::HTS002,BRD-A11132253-001-08-2,0.625,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::2.5::HTS002,BRD-A11132253-001-08-2,2.5,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-A11132253-001-08-2::10::HTS002,BRD-A11132253-001-08-2,10.0,HTS002,PREP021,nadide,electron acceptor,"AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2",NA,NA,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,Launched
BRD-K97810537-001-13-6::0.00061034::HTS002,BRD-K97810537-001-13-6,0.00061034,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::0.0024414::HTS002,BRD-K97810537-001-13-6,0.0024414,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::0.00976562::HTS002,BRD-K97810537-001-13-6,0.00976562,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::0.0390625::HTS002,BRD-K97810537-001-13-6,0.0390625,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::0.15625::HTS002,BRD-K97810537-001-13-6,0.15625,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::0.625::HTS002,BRD-K97810537-001-13-6,0.625,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::2.5::HTS002,BRD-K97810537-001-13-6,2.5,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-K97810537-001-13-6::10::HTS002,BRD-K97810537-001-13-6,10.0,HTS002,PREP021,beclomethasone-dipropionate,glucocorticoid receptor agonist,"GPR97, NR3C1",allergy,allergic rhinitis,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C",Launched
BRD-A11551002-001-04-6::0.00061034::HTS002,BRD-A11551002-001-04-6,0.00061034,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::0.0024414::HTS002,BRD-A11551002-001-04-6,0.0024414,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::0.00976562::HTS002,BRD-A11551002-001-04-6,0.00976562,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::0.0390625::HTS002,BRD-A11551002-001-04-6,0.0390625,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::0.15625::HTS002,BRD-A11551002-001-04-6,0.15625,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::0.625::HTS002,BRD-A11551002-001-04-6,0.625,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::2.5::HTS002,BRD-A11551002-001-04-6,2.5,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11551002-001-04-6::10::HTS002,BRD-A11551002-001-04-6,10.0,HTS002,PREP015,dehydrocholate-acid,NA,NA,NA,NA,CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,Preclinical
BRD-A11815689-001-01-1::0.00061034::HTS002,BRD-A11815689-001-01-1,0.00061034,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::0.0024414::HTS002,BRD-A11815689-001-01-1,0.0024414,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::0.00976562::HTS002,BRD-A11815689-001-01-1,0.00976562,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::0.0390625::HTS002,BRD-A11815689-001-01-1,0.0390625,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::0.15625::HTS002,BRD-A11815689-001-01-1,0.15625,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::0.625::HTS002,BRD-A11815689-001-01-1,0.625,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::2.5::HTS002,BRD-A11815689-001-01-1,2.5,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11815689-001-01-1::10::HTS002,BRD-A11815689-001-01-1,10.0,HTS002,PREP023,proscillaridin-a,NA,NA,cardiology,"congestive heart failure, cardiac arrythmia",C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O,Launched
BRD-A11990600-001-03-4::0.00061034::HTS002,BRD-A11990600-001-03-4,0.00061034,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::0.0024414::HTS002,BRD-A11990600-001-03-4,0.0024414,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::0.00976562::HTS002,BRD-A11990600-001-03-4,0.00976562,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::0.0390625::HTS002,BRD-A11990600-001-03-4,0.0390625,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::0.15625::HTS002,BRD-A11990600-001-03-4,0.15625,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::0.625::HTS002,BRD-A11990600-001-03-4,0.625,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::2.5::HTS002,BRD-A11990600-001-03-4,2.5,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A11990600-001-03-4::10::HTS002,BRD-A11990600-001-03-4,10.0,HTS002,PREP034,lorazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,status epilepticus,OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O,Launched
BRD-A12230535-001-06-7::0.00061034::HTS002,BRD-A12230535-001-06-7,0.00061034,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::0.0024414::HTS002,BRD-A12230535-001-06-7,0.0024414,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::0.00976562::HTS002,BRD-A12230535-001-06-7,0.00976562,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::0.0390625::HTS002,BRD-A12230535-001-06-7,0.0390625,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::0.15625::HTS002,BRD-A12230535-001-06-7,0.15625,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::0.625::HTS002,BRD-A12230535-001-06-7,0.625,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::2.5::HTS002,BRD-A12230535-001-06-7,2.5,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12230535-001-06-7::10::HTS002,BRD-A12230535-001-06-7,10.0,HTS002,PREP015,nutlin-3,MDM inhibitor,"MDM2, TP53",NA,NA,"COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=N[C@@H]([C@@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1",Preclinical
BRD-A12417644-001-07-6::0.000564918::HTS002,BRD-A12417644-001-07-6,0.000564918,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::0.00225967::HTS002,BRD-A12417644-001-07-6,0.00225967,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::0.00903869::HTS002,BRD-A12417644-001-07-6,0.00903869,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::0.0361548::HTS002,BRD-A12417644-001-07-6,0.0361548,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::0.144619::HTS002,BRD-A12417644-001-07-6,0.144619,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::0.578476::HTS002,BRD-A12417644-001-07-6,0.578476,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::2.3139::HTS002,BRD-A12417644-001-07-6,2.3139,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12417644-001-07-6::9.25562::HTS002,BRD-A12417644-001-07-6,9.25562,HTS002,PREP048,usniacin-(+),MAP kinase activator,PTPN1,NA,NA,"CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O",Preclinical
BRD-A12994259-001-02-1::0.00061034::HTS002,BRD-A12994259-001-02-1,0.00061034,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::0.0024414::HTS002,BRD-A12994259-001-02-1,0.0024414,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::0.00976562::HTS002,BRD-A12994259-001-02-1,0.00976562,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::0.0390625::HTS002,BRD-A12994259-001-02-1,0.0390625,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::0.15625::HTS002,BRD-A12994259-001-02-1,0.15625,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::0.625::HTS002,BRD-A12994259-001-02-1,0.625,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::2.5::HTS002,BRD-A12994259-001-02-1,2.5,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A12994259-001-02-1::10::HTS002,BRD-A12994259-001-02-1,10.0,HTS002,PREP034,pomalidomide,"angiogenesis inhibitor, tumor necrosis factor production inhibitor","CRBN, PTGS2, TNF",hematologic malignancy,multiple myeloma,Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12,Launched
BRD-A13133631-001-04-0::0.00061034::HTS002,BRD-A13133631-001-04-0,0.00061034,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::0.0024414::HTS002,BRD-A13133631-001-04-0,0.0024414,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::0.00976562::HTS002,BRD-A13133631-001-04-0,0.00976562,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::0.0390625::HTS002,BRD-A13133631-001-04-0,0.0390625,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::0.15625::HTS002,BRD-A13133631-001-04-0,0.15625,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::0.625::HTS002,BRD-A13133631-001-04-0,0.625,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::2.5::HTS002,BRD-A13133631-001-04-0,2.5,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13133631-001-04-0::10::HTS002,BRD-A13133631-001-04-0,10.0,HTS002,PREP028,fluorometholone,glucocorticoid receptor agonist,NR3C1,ophthalmology,eye inflammation,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,Launched
BRD-A13561534-003-02-0::0.00061034::HTS002,BRD-A13561534-003-02-0,0.00061034,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::0.0024414::HTS002,BRD-A13561534-003-02-0,0.0024414,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::0.00976562::HTS002,BRD-A13561534-003-02-0,0.00976562,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::0.0390625::HTS002,BRD-A13561534-003-02-0,0.0390625,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::0.15625::HTS002,BRD-A13561534-003-02-0,0.15625,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::0.625::HTS002,BRD-A13561534-003-02-0,0.625,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::2.5::HTS002,BRD-A13561534-003-02-0,2.5,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13561534-003-02-0::10::HTS002,BRD-A13561534-003-02-0,10.0,HTS002,PREP048,ornithine,NFkB pathway modulator,"ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4",NA,NA,NCCCC(N)C(O)=O,Launched
BRD-A13964793-001-02-6::0.00061034::HTS002,BRD-A13964793-001-02-6,0.00061034,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::0.0024414::HTS002,BRD-A13964793-001-02-6,0.0024414,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::0.00976562::HTS002,BRD-A13964793-001-02-6,0.00976562,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::0.0390625::HTS002,BRD-A13964793-001-02-6,0.0390625,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::0.15625::HTS002,BRD-A13964793-001-02-6,0.15625,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::0.625::HTS002,BRD-A13964793-001-02-6,0.625,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::2.5::HTS002,BRD-A13964793-001-02-6,2.5,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A13964793-001-02-6::10::HTS002,BRD-A13964793-001-02-6,10.0,HTS002,PREP032,TC1,beta-secretase inhibitor,BACE1,NA,NA,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,Preclinical
BRD-A14240607-003-26-1::0.00061034::HTS002,BRD-A14240607-003-26-1,0.00061034,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::0.0024414::HTS002,BRD-A14240607-003-26-1,0.0024414,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::0.00976562::HTS002,BRD-A14240607-003-26-1,0.00976562,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::0.0390625::HTS002,BRD-A14240607-003-26-1,0.0390625,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::0.15625::HTS002,BRD-A14240607-003-26-1,0.15625,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::0.625::HTS002,BRD-A14240607-003-26-1,0.625,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::2.5::HTS002,BRD-A14240607-003-26-1,2.5,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14240607-003-26-1::10::HTS002,BRD-A14240607-003-26-1,10.0,HTS002,PREP014,octopamine,trace amine associated receptor agonist,"F10, TAAR1",NA,NA,"NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",Preclinical
BRD-A14344385-001-03-2::0.00061034::HTS002,BRD-A14344385-001-03-2,0.00061034,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::0.0024414::HTS002,BRD-A14344385-001-03-2,0.0024414,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::0.00976562::HTS002,BRD-A14344385-001-03-2,0.00976562,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::0.0390625::HTS002,BRD-A14344385-001-03-2,0.0390625,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::0.15625::HTS002,BRD-A14344385-001-03-2,0.15625,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::0.625::HTS002,BRD-A14344385-001-03-2,0.625,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::2.5::HTS002,BRD-A14344385-001-03-2,2.5,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14344385-001-03-2::10::HTS002,BRD-A14344385-001-03-2,10.0,HTS002,PREP024,IDRA-21,glutamate receptor positive allosteric modulator,"GRIA1, GRIA2, GRIA3, GRIA4",NA,NA,"CC1Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1Nc2ccc(Cl)cc2S(=O)(=O)N1",Preclinical
BRD-A14395271-074-17-8::0.00061034::HTS002,BRD-A14395271-074-17-8,0.00061034,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::0.0024414::HTS002,BRD-A14395271-074-17-8,0.0024414,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::0.00976562::HTS002,BRD-A14395271-074-17-8,0.00976562,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::0.0390625::HTS002,BRD-A14395271-074-17-8,0.0390625,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::0.15625::HTS002,BRD-A14395271-074-17-8,0.15625,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::0.625::HTS002,BRD-A14395271-074-17-8,0.625,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::2.5::HTS002,BRD-A14395271-074-17-8,2.5,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14395271-074-17-8::10::HTS002,BRD-A14395271-074-17-8,10.0,HTS002,PREP016,mesoridazine,dopamine receptor antagonist,"DRD2, HTR2A",neurology/psychiatry,schizophrenia,"CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O",Launched
BRD-A14886633-001-01-6::0.00061034::HTS002,BRD-A14886633-001-01-6,0.00061034,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::0.0024414::HTS002,BRD-A14886633-001-01-6,0.0024414,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::0.00976562::HTS002,BRD-A14886633-001-01-6,0.00976562,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::0.0390625::HTS002,BRD-A14886633-001-01-6,0.0390625,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::0.15625::HTS002,BRD-A14886633-001-01-6,0.15625,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::0.625::HTS002,BRD-A14886633-001-01-6,0.625,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::2.5::HTS002,BRD-A14886633-001-01-6,2.5,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A14886633-001-01-6::10::HTS002,BRD-A14886633-001-01-6,10.0,HTS002,PREP029,norgestrel,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-A16700644-003-04-4::0.00061034::HTS002,BRD-A16700644-003-04-4,0.00061034,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::0.0024414::HTS002,BRD-A16700644-003-04-4,0.0024414,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::0.00976562::HTS002,BRD-A16700644-003-04-4,0.00976562,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::0.0390625::HTS002,BRD-A16700644-003-04-4,0.0390625,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::0.15625::HTS002,BRD-A16700644-003-04-4,0.15625,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::0.625::HTS002,BRD-A16700644-003-04-4,0.625,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::2.5::HTS002,BRD-A16700644-003-04-4,2.5,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16700644-003-04-4::10::HTS002,BRD-A16700644-003-04-4,10.0,HTS002,PREP022,isoxsuprine,adrenergic receptor agonist,ADRB2,"rheumatology, cardiology","Raynaud's disease, arteriosclerosis, Buerger's disease",CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,Launched
BRD-A16997652-001-02-3::0.00061034::HTS002,BRD-A16997652-001-02-3,0.00061034,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::0.0024414::HTS002,BRD-A16997652-001-02-3,0.0024414,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::0.00976562::HTS002,BRD-A16997652-001-02-3,0.00976562,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::0.0390625::HTS002,BRD-A16997652-001-02-3,0.0390625,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::0.15625::HTS002,BRD-A16997652-001-02-3,0.15625,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::0.625::HTS002,BRD-A16997652-001-02-3,0.625,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::2.5::HTS002,BRD-A16997652-001-02-3,2.5,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A16997652-001-02-3::10::HTS002,BRD-A16997652-001-02-3,10.0,HTS002,PREP016,protirelin,thyrotropin releasing hormone receptor agonist,TRHR,radiology,thyroid function diagnostic,NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1,Launched
BRD-A17846016-001-13-9::0.00061034::HTS002,BRD-A17846016-001-13-9,0.00061034,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::0.0024414::HTS002,BRD-A17846016-001-13-9,0.0024414,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::0.00976562::HTS002,BRD-A17846016-001-13-9,0.00976562,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::0.0390625::HTS002,BRD-A17846016-001-13-9,0.0390625,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::0.15625::HTS002,BRD-A17846016-001-13-9,0.15625,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::0.625::HTS002,BRD-A17846016-001-13-9,0.625,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::2.5::HTS002,BRD-A17846016-001-13-9,2.5,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17846016-001-13-9::10::HTS002,BRD-A17846016-001-13-9,10.0,HTS002,PREP029,trolox,antioxidant,NA,NA,NA,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O,Launched
BRD-A17883755-001-06-1::0.00061034::HTS002,BRD-A17883755-001-06-1,0.00061034,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::0.0024414::HTS002,BRD-A17883755-001-06-1,0.0024414,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::0.00976562::HTS002,BRD-A17883755-001-06-1,0.00976562,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::0.0390625::HTS002,BRD-A17883755-001-06-1,0.0390625,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::0.15625::HTS002,BRD-A17883755-001-06-1,0.15625,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::0.625::HTS002,BRD-A17883755-001-06-1,0.625,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::2.5::HTS002,BRD-A17883755-001-06-1,2.5,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A17883755-001-06-1::10::HTS002,BRD-A17883755-001-06-1,10.0,HTS002,PREP030,lenalidomide,anticancer agent,"CDH5, CRBN, PTGS2, TNF, TNFSF11",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)",Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O,Launched
BRD-A18696154-003-22-6::0.00061034::HTS002,BRD-A18696154-003-22-6,0.00061034,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::0.0024414::HTS002,BRD-A18696154-003-22-6,0.0024414,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::0.00976562::HTS002,BRD-A18696154-003-22-6,0.00976562,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::0.0390625::HTS002,BRD-A18696154-003-22-6,0.0390625,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::0.15625::HTS002,BRD-A18696154-003-22-6,0.15625,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::0.625::HTS002,BRD-A18696154-003-22-6,0.625,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::2.5::HTS002,BRD-A18696154-003-22-6,2.5,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A18696154-003-22-6::10::HTS002,BRD-A18696154-003-22-6,10.0,HTS002,PREP045,idazoxan,adrenergic receptor antagonist,ADRA2A,NA,NA,"C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1",Phase 3
BRD-A19585813-003-03-3::0.00061034::HTS002,BRD-A19585813-003-03-3,0.00061034,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::0.0024414::HTS002,BRD-A19585813-003-03-3,0.0024414,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::0.00976562::HTS002,BRD-A19585813-003-03-3,0.00976562,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::0.0390625::HTS002,BRD-A19585813-003-03-3,0.0390625,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::0.15625::HTS002,BRD-A19585813-003-03-3,0.15625,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::0.625::HTS002,BRD-A19585813-003-03-3,0.625,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::2.5::HTS002,BRD-A19585813-003-03-3,2.5,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A19585813-003-03-3::10::HTS002,BRD-A19585813-003-03-3,10.0,HTS002,PREP014,methylphenidate,dopamine-norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,"attention-deficit/hyperactivity disorder (ADHD), narcolepsy",COC(=O)C(C1CCCCN1)c1ccccc1,Launched
BRD-A20239487-001-24-9::0.00061034::HTS002,BRD-A20239487-001-24-9,0.00061034,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::0.0024414::HTS002,BRD-A20239487-001-24-9,0.0024414,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::0.00976562::HTS002,BRD-A20239487-001-24-9,0.00976562,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::0.0390625::HTS002,BRD-A20239487-001-24-9,0.0390625,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::0.15625::HTS002,BRD-A20239487-001-24-9,0.15625,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::0.625::HTS002,BRD-A20239487-001-24-9,0.625,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::2.5::HTS002,BRD-A20239487-001-24-9,2.5,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20239487-001-24-9::10::HTS002,BRD-A20239487-001-24-9,10.0,HTS002,PREP028,atenolol-(+/-),adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"hypertension, angina pectoris","CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1",Launched
BRD-A20644369-001-08-6::0.00061034::HTS002,BRD-A20644369-001-08-6,0.00061034,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::0.0024414::HTS002,BRD-A20644369-001-08-6,0.0024414,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::0.00976562::HTS002,BRD-A20644369-001-08-6,0.00976562,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::0.0390625::HTS002,BRD-A20644369-001-08-6,0.0390625,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::0.15625::HTS002,BRD-A20644369-001-08-6,0.15625,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::0.625::HTS002,BRD-A20644369-001-08-6,0.625,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::2.5::HTS002,BRD-A20644369-001-08-6,2.5,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A20644369-001-08-6::10::HTS002,BRD-A20644369-001-08-6,10.0,HTS002,PREP034,canrenone,mineralocorticoid receptor antagonist,NR3C2,NA,NA,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,Withdrawn
BRD-A22081593-001-11-1::0.00061034::HTS002,BRD-A22081593-001-11-1,0.00061034,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::0.0024414::HTS002,BRD-A22081593-001-11-1,0.0024414,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::0.00976562::HTS002,BRD-A22081593-001-11-1,0.00976562,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::0.0390625::HTS002,BRD-A22081593-001-11-1,0.0390625,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::0.15625::HTS002,BRD-A22081593-001-11-1,0.15625,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::0.625::HTS002,BRD-A22081593-001-11-1,0.625,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::2.5::HTS002,BRD-A22081593-001-11-1,2.5,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22081593-001-11-1::10::HTS002,BRD-A22081593-001-11-1,10.0,HTS002,PREP038,sulmazole,adenosine receptor antagonist,NA,NA,NA,COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O,Phase 1
BRD-A22707317-001-10-8::0.00061034::HTS002,BRD-A22707317-001-10-8,0.00061034,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::0.0024414::HTS002,BRD-A22707317-001-10-8,0.0024414,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::0.00976562::HTS002,BRD-A22707317-001-10-8,0.00976562,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::0.0390625::HTS002,BRD-A22707317-001-10-8,0.0390625,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::0.15625::HTS002,BRD-A22707317-001-10-8,0.15625,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::0.625::HTS002,BRD-A22707317-001-10-8,0.625,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::2.5::HTS002,BRD-A22707317-001-10-8,2.5,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A22707317-001-10-8::10::HTS002,BRD-A22707317-001-10-8,10.0,HTS002,PREP037,SB-205384,GABA receptor modulator,"GABRA3, GABRA5, GABRA6",NA,NA,"CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N, CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N",Preclinical
BRD-A23067620-300-01-3::0.00061034::HTS002,BRD-A23067620-300-01-3,0.00061034,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::0.0024414::HTS002,BRD-A23067620-300-01-3,0.0024414,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::0.00976562::HTS002,BRD-A23067620-300-01-3,0.00976562,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::0.0390625::HTS002,BRD-A23067620-300-01-3,0.0390625,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::0.15625::HTS002,BRD-A23067620-300-01-3,0.15625,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::0.625::HTS002,BRD-A23067620-300-01-3,0.625,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::2.5::HTS002,BRD-A23067620-300-01-3,2.5,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23067620-300-01-3::10::HTS002,BRD-A23067620-300-01-3,10.0,HTS002,PREP020,itraconazole,cytochrome P450 inhibitor,CYP51A1,infectious disease,"onychomycosis, histoplasmosis, blastomycosis, aspergillosis","CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O",Launched
BRD-A23072235-050-18-5::0.00061034::HTS002,BRD-A23072235-050-18-5,0.00061034,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::0.0024414::HTS002,BRD-A23072235-050-18-5,0.0024414,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::0.00976562::HTS002,BRD-A23072235-050-18-5,0.00976562,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::0.0390625::HTS002,BRD-A23072235-050-18-5,0.0390625,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::0.15625::HTS002,BRD-A23072235-050-18-5,0.15625,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::0.625::HTS002,BRD-A23072235-050-18-5,0.625,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::2.5::HTS002,BRD-A23072235-050-18-5,2.5,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23072235-050-18-5::10::HTS002,BRD-A23072235-050-18-5,10.0,HTS002,PREP048,pheniramine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria","CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1",Launched
BRD-A23127772-001-02-3::0.00061034::HTS002,BRD-A23127772-001-02-3,0.00061034,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::0.0024414::HTS002,BRD-A23127772-001-02-3,0.0024414,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::0.00976562::HTS002,BRD-A23127772-001-02-3,0.00976562,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::0.0390625::HTS002,BRD-A23127772-001-02-3,0.0390625,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::0.15625::HTS002,BRD-A23127772-001-02-3,0.15625,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::0.625::HTS002,BRD-A23127772-001-02-3,0.625,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::2.5::HTS002,BRD-A23127772-001-02-3,2.5,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-A23127772-001-02-3::10::HTS002,BRD-A23127772-001-02-3,10.0,HTS002,PREP033,sclareol,NA,NA,NA,NA,CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C,Preclinical
BRD-K67511046-001-02-3::0.00061034::HTS002,BRD-K67511046-001-02-3,0.00061034,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::0.0024414::HTS002,BRD-K67511046-001-02-3,0.0024414,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::0.00976562::HTS002,BRD-K67511046-001-02-3,0.00976562,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::0.0390625::HTS002,BRD-K67511046-001-02-3,0.0390625,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::0.15625::HTS002,BRD-K67511046-001-02-3,0.15625,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::0.625::HTS002,BRD-K67511046-001-02-3,0.625,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::2.5::HTS002,BRD-K67511046-001-02-3,2.5,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K67511046-001-02-3::10::HTS002,BRD-K67511046-001-02-3,10.0,HTS002,PREP021,naloxone,opioid receptor antagonist,"CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4",pulmonary,respiratory depression,"Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-A24397426-001-10-4::0.00061034::HTS002,BRD-A24397426-001-10-4,0.00061034,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::0.0024414::HTS002,BRD-A24397426-001-10-4,0.0024414,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::0.00976562::HTS002,BRD-A24397426-001-10-4,0.00976562,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::0.0390625::HTS002,BRD-A24397426-001-10-4,0.0390625,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::0.15625::HTS002,BRD-A24397426-001-10-4,0.15625,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::0.625::HTS002,BRD-A24397426-001-10-4,0.625,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::2.5::HTS002,BRD-A24397426-001-10-4,2.5,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24397426-001-10-4::10::HTS002,BRD-A24397426-001-10-4,10.0,HTS002,PREP022,nadifloxacin,bacterial DNA gyrase inhibitor,NA,"dermatology, infectious disease","acne vulgaris (AV), skin infections","CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O",Launched
BRD-A24514565-001-09-7::0.00061034::HTS002,BRD-A24514565-001-09-7,0.00061034,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::0.0024414::HTS002,BRD-A24514565-001-09-7,0.0024414,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::0.00976562::HTS002,BRD-A24514565-001-09-7,0.00976562,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::0.0390625::HTS002,BRD-A24514565-001-09-7,0.0390625,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::0.15625::HTS002,BRD-A24514565-001-09-7,0.15625,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::0.625::HTS002,BRD-A24514565-001-09-7,0.625,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::2.5::HTS002,BRD-A24514565-001-09-7,2.5,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24514565-001-09-7::10::HTS002,BRD-A24514565-001-09-7,10.0,HTS002,PREP028,warfarin,vitamin K antagonist,VKORC1,"hematology, cardiology","deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction",CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,Launched
BRD-A24587114-066-22-5::0.00061034::HTS002,BRD-A24587114-066-22-5,0.00061034,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::0.0024414::HTS002,BRD-A24587114-066-22-5,0.0024414,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::0.00976562::HTS002,BRD-A24587114-066-22-5,0.00976562,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::0.0390625::HTS002,BRD-A24587114-066-22-5,0.0390625,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::0.15625::HTS002,BRD-A24587114-066-22-5,0.15625,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::0.625::HTS002,BRD-A24587114-066-22-5,0.625,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::2.5::HTS002,BRD-A24587114-066-22-5,2.5,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A24587114-066-22-5::10::HTS002,BRD-A24587114-066-22-5,10.0,HTS002,PREP024,isoetharine,adrenergic receptor agonist,"ADRB1, ADRB2",pulmonary,"bronchospasm, asthma","CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1",Launched
BRD-A25004090-001-08-4::0.00061034::HTS002,BRD-A25004090-001-08-4,0.00061034,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::0.0024414::HTS002,BRD-A25004090-001-08-4,0.0024414,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::0.00976562::HTS002,BRD-A25004090-001-08-4,0.00976562,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::0.0390625::HTS002,BRD-A25004090-001-08-4,0.0390625,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::0.15625::HTS002,BRD-A25004090-001-08-4,0.15625,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::0.625::HTS002,BRD-A25004090-001-08-4,0.625,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::2.5::HTS002,BRD-A25004090-001-08-4,2.5,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25004090-001-08-4::10::HTS002,BRD-A25004090-001-08-4,10.0,HTS002,PREP044,erastin,ion channel antagonist,VDAC2,NA,NA,"CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1",Preclinical
BRD-A25234499-001-18-3::0.00061034::HTS002,BRD-A25234499-001-18-3,0.00061034,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::0.0024414::HTS002,BRD-A25234499-001-18-3,0.0024414,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::0.00976562::HTS002,BRD-A25234499-001-18-3,0.00976562,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::0.0390625::HTS002,BRD-A25234499-001-18-3,0.0390625,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::0.15625::HTS002,BRD-A25234499-001-18-3,0.15625,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::0.625::HTS002,BRD-A25234499-001-18-3,0.625,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::2.5::HTS002,BRD-A25234499-001-18-3,2.5,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25234499-001-18-3::10::HTS002,BRD-A25234499-001-18-3,10.0,HTS002,PREP017,aminoglutethimide,glucocorticoid receptor antagonist,"CYP11A1, CYP19A1","endocrinology, oncology","Cushing's syndrome, breast cancer","CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1",Launched
BRD-A25569250-001-03-3::0.00061034::HTS002,BRD-A25569250-001-03-3,0.00061034,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::0.0024414::HTS002,BRD-A25569250-001-03-3,0.0024414,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::0.00976562::HTS002,BRD-A25569250-001-03-3,0.00976562,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::0.0390625::HTS002,BRD-A25569250-001-03-3,0.0390625,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::0.15625::HTS002,BRD-A25569250-001-03-3,0.15625,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::0.625::HTS002,BRD-A25569250-001-03-3,0.625,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::2.5::HTS002,BRD-A25569250-001-03-3,2.5,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25569250-001-03-3::10::HTS002,BRD-A25569250-001-03-3,10.0,HTS002,PREP043,KI-16425,lysophosphatidic acid receptor antagonist,"LPAR1, LPAR3",NA,NA,CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl,Preclinical
BRD-A25608658-001-01-1::0.00061034::HTS002,BRD-A25608658-001-01-1,0.00061034,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.0024414::HTS002,BRD-A25608658-001-01-1,0.0024414,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.00976562::HTS002,BRD-A25608658-001-01-1,0.00976562,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.0390625::HTS002,BRD-A25608658-001-01-1,0.0390625,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.15625::HTS002,BRD-A25608658-001-01-1,0.15625,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.625::HTS002,BRD-A25608658-001-01-1,0.625,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::2.5::HTS002,BRD-A25608658-001-01-1,2.5,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::10::HTS002,BRD-A25608658-001-01-1,10.0,HTS002,PREP016,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25687296-300-04-3::0.00061034::HTS002,BRD-A25687296-300-04-3,0.00061034,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::0.0024414::HTS002,BRD-A25687296-300-04-3,0.0024414,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::0.00976562::HTS002,BRD-A25687296-300-04-3,0.00976562,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::0.0390625::HTS002,BRD-A25687296-300-04-3,0.0390625,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::0.15625::HTS002,BRD-A25687296-300-04-3,0.15625,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::0.625::HTS002,BRD-A25687296-300-04-3,0.625,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::2.5::HTS002,BRD-A25687296-300-04-3,2.5,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A25687296-300-04-3::10::HTS002,BRD-A25687296-300-04-3,10.0,HTS002,PREP019,emetine,protein synthesis inhibitor,RPS2,NA,NA,"CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",Phase 2
BRD-A26032986-050-02-1::0.00061034::HTS002,BRD-A26032986-050-02-1,0.00061034,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::0.0024414::HTS002,BRD-A26032986-050-02-1,0.0024414,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::0.00976562::HTS002,BRD-A26032986-050-02-1,0.00976562,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::0.0390625::HTS002,BRD-A26032986-050-02-1,0.0390625,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::0.15625::HTS002,BRD-A26032986-050-02-1,0.15625,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::0.625::HTS002,BRD-A26032986-050-02-1,0.625,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::2.5::HTS002,BRD-A26032986-050-02-1,2.5,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-A26032986-050-02-1::10::HTS002,BRD-A26032986-050-02-1,10.0,HTS002,PREP027,zaldaride,calmodulin antagonist,CALM1,NA,NA,"CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12, CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12",Phase 3
BRD-K10799896-001-26-2::0.00061034::HTS002,BRD-K10799896-001-26-2,0.00061034,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::0.0024414::HTS002,BRD-K10799896-001-26-2,0.0024414,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::0.00976562::HTS002,BRD-K10799896-001-26-2,0.00976562,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::0.0390625::HTS002,BRD-K10799896-001-26-2,0.0390625,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::0.15625::HTS002,BRD-K10799896-001-26-2,0.15625,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::0.625::HTS002,BRD-K10799896-001-26-2,0.625,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::2.5::HTS002,BRD-K10799896-001-26-2,2.5,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-K10799896-001-26-2::10::HTS002,BRD-K10799896-001-26-2,10.0,HTS002,PREP017,clobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl",Launched
BRD-A26503646-001-16-6::0.00061034::HTS002,BRD-A26503646-001-16-6,0.00061034,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::0.0024414::HTS002,BRD-A26503646-001-16-6,0.0024414,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::0.00976562::HTS002,BRD-A26503646-001-16-6,0.00976562,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::0.0390625::HTS002,BRD-A26503646-001-16-6,0.0390625,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::0.15625::HTS002,BRD-A26503646-001-16-6,0.15625,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::0.625::HTS002,BRD-A26503646-001-16-6,0.625,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::2.5::HTS002,BRD-A26503646-001-16-6,2.5,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A26503646-001-16-6::10::HTS002,BRD-A26503646-001-16-6,10.0,HTS002,PREP030,formestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A27376179-001-01-3::0.000610352::HTS002,BRD-A27376179-001-01-3,0.000610352,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::0.00244141::HTS002,BRD-A27376179-001-01-3,0.00244141,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::0.00976562::HTS002,BRD-A27376179-001-01-3,0.00976562,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::0.0390625::HTS002,BRD-A27376179-001-01-3,0.0390625,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::0.15625::HTS002,BRD-A27376179-001-01-3,0.15625,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::0.625::HTS002,BRD-A27376179-001-01-3,0.625,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::2.5::HTS002,BRD-A27376179-001-01-3,2.5,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27376179-001-01-3::10::HTS002,BRD-A27376179-001-01-3,10.0,HTS002,PREP044,lestaurtinib,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1",NA,NA,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,Phase 3
BRD-A27883417-300-01-6::0.00061034::HTS002,BRD-A27883417-300-01-6,0.00061034,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::0.0024414::HTS002,BRD-A27883417-300-01-6,0.0024414,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::0.00976562::HTS002,BRD-A27883417-300-01-6,0.00976562,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::0.0390625::HTS002,BRD-A27883417-300-01-6,0.0390625,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::0.15625::HTS002,BRD-A27883417-300-01-6,0.15625,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::0.625::HTS002,BRD-A27883417-300-01-6,0.625,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::2.5::HTS002,BRD-A27883417-300-01-6,2.5,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27883417-300-01-6::10::HTS002,BRD-A27883417-300-01-6,10.0,HTS002,PREP043,alexidine,phosphatidylglycerophosphatase inhibitor,PTPMT1,NA,NA,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,Preclinical
BRD-A27887842-001-04-0::0.00061034::HTS002,BRD-A27887842-001-04-0,0.00061034,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::0.0024414::HTS002,BRD-A27887842-001-04-0,0.0024414,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::0.00976562::HTS002,BRD-A27887842-001-04-0,0.00976562,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::0.0390625::HTS002,BRD-A27887842-001-04-0,0.0390625,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::0.15625::HTS002,BRD-A27887842-001-04-0,0.15625,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::0.625::HTS002,BRD-A27887842-001-04-0,0.625,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::2.5::HTS002,BRD-A27887842-001-04-0,2.5,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A27887842-001-04-0::10::HTS002,BRD-A27887842-001-04-0,10.0,HTS002,PREP021,prednisolone,glucocorticoid receptor agonist,"NR3C1, NR3C2, SERPINA6","ophthalmology, dermatology, infectious disease","conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO",Launched
BRD-A28329383-001-02-1::0.00061034::HTS002,BRD-A28329383-001-02-1,0.00061034,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::0.0024414::HTS002,BRD-A28329383-001-02-1,0.0024414,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::0.00976562::HTS002,BRD-A28329383-001-02-1,0.00976562,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::0.0390625::HTS002,BRD-A28329383-001-02-1,0.0390625,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::0.15625::HTS002,BRD-A28329383-001-02-1,0.15625,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::0.625::HTS002,BRD-A28329383-001-02-1,0.625,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::2.5::HTS002,BRD-A28329383-001-02-1,2.5,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28329383-001-02-1::10::HTS002,BRD-A28329383-001-02-1,10.0,HTS002,PREP043,MTPG,glutamate receptor antagonist,"GRM2, GRM3",NA,NA,CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1,Preclinical
BRD-A28467416-002-01-0::0.000610352::HTS002,BRD-A28467416-002-01-0,0.000610352,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::0.00244141::HTS002,BRD-A28467416-002-01-0,0.00244141,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::0.00976562::HTS002,BRD-A28467416-002-01-0,0.00976562,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::0.0390625::HTS002,BRD-A28467416-002-01-0,0.0390625,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::0.15625::HTS002,BRD-A28467416-002-01-0,0.15625,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::0.625::HTS002,BRD-A28467416-002-01-0,0.625,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::2.5::HTS002,BRD-A28467416-002-01-0,2.5,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-A28467416-002-01-0::10::HTS002,BRD-A28467416-002-01-0,10.0,HTS002,PREP045,PKI-179,"mTOR inhibitor, PI3K inhibitor",MTOR,NA,NA,O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2,Phase 1
BRD-K62008436-001-22-1::0.00061034::HTS002,BRD-K62008436-001-22-1,0.00061034,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::0.0024414::HTS002,BRD-K62008436-001-22-1,0.0024414,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::0.00976562::HTS002,BRD-K62008436-001-22-1,0.00976562,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::0.0390625::HTS002,BRD-K62008436-001-22-1,0.0390625,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::0.15625::HTS002,BRD-K62008436-001-22-1,0.15625,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::0.625::HTS002,BRD-K62008436-001-22-1,0.625,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::2.5::HTS002,BRD-K62008436-001-22-1,2.5,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-K62008436-001-22-1::10::HTS002,BRD-K62008436-001-22-1,10.0,HTS002,PREP017,paclitaxel,tubulin polymerization inhibitor,"BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)","CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1",Launched
BRD-A28970875-300-04-9::0.00061034::HTS002,BRD-A28970875-300-04-9,0.00061034,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::0.0024414::HTS002,BRD-A28970875-300-04-9,0.0024414,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::0.00976562::HTS002,BRD-A28970875-300-04-9,0.00976562,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::0.0390625::HTS002,BRD-A28970875-300-04-9,0.0390625,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::0.15625::HTS002,BRD-A28970875-300-04-9,0.15625,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::0.625::HTS002,BRD-A28970875-300-04-9,0.625,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::2.5::HTS002,BRD-A28970875-300-04-9,2.5,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A28970875-300-04-9::10::HTS002,BRD-A28970875-300-04-9,10.0,HTS002,PREP014,puromycin,protein synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,Preclinical
BRD-A29485665-001-12-8::0.00061034::HTS002,BRD-A29485665-001-12-8,0.00061034,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::0.0024414::HTS002,BRD-A29485665-001-12-8,0.0024414,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::0.00976562::HTS002,BRD-A29485665-001-12-8,0.00976562,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::0.0390625::HTS002,BRD-A29485665-001-12-8,0.0390625,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::0.15625::HTS002,BRD-A29485665-001-12-8,0.15625,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::0.625::HTS002,BRD-A29485665-001-12-8,0.625,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::2.5::HTS002,BRD-A29485665-001-12-8,2.5,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A29485665-001-12-8::10::HTS002,BRD-A29485665-001-12-8,10.0,HTS002,PREP016,bicalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",Launched
BRD-A30582499-003-05-1::0.00061034::HTS002,BRD-A30582499-003-05-1,0.00061034,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::0.0024414::HTS002,BRD-A30582499-003-05-1,0.0024414,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::0.00976562::HTS002,BRD-A30582499-003-05-1,0.00976562,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::0.0390625::HTS002,BRD-A30582499-003-05-1,0.0390625,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::0.15625::HTS002,BRD-A30582499-003-05-1,0.15625,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::0.625::HTS002,BRD-A30582499-003-05-1,0.625,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::2.5::HTS002,BRD-A30582499-003-05-1,2.5,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30582499-003-05-1::10::HTS002,BRD-A30582499-003-05-1,10.0,HTS002,PREP021,tiletamine,glutamate receptor antagonist,NA,neurology/psychiatry,anesthetic,CCNC1(CCCCC1=O)c1cccs1,Launched
BRD-A30886737-001-02-9::0.00061034::HTS002,BRD-A30886737-001-02-9,0.00061034,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::0.0024414::HTS002,BRD-A30886737-001-02-9,0.0024414,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::0.00976562::HTS002,BRD-A30886737-001-02-9,0.00976562,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::0.0390625::HTS002,BRD-A30886737-001-02-9,0.0390625,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::0.15625::HTS002,BRD-A30886737-001-02-9,0.15625,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::0.625::HTS002,BRD-A30886737-001-02-9,0.625,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::2.5::HTS002,BRD-A30886737-001-02-9,2.5,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A30886737-001-02-9::10::HTS002,BRD-A30886737-001-02-9,10.0,HTS002,PREP029,florfenicol,protein synthesis inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl",Launched
BRD-A31095847-001-02-3::0.00061034::HTS002,BRD-A31095847-001-02-3,0.00061034,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.0024414::HTS002,BRD-A31095847-001-02-3,0.0024414,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.00976562::HTS002,BRD-A31095847-001-02-3,0.00976562,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.0390625::HTS002,BRD-A31095847-001-02-3,0.0390625,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.15625::HTS002,BRD-A31095847-001-02-3,0.15625,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.625::HTS002,BRD-A31095847-001-02-3,0.625,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::2.5::HTS002,BRD-A31095847-001-02-3,2.5,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::10::HTS002,BRD-A31095847-001-02-3,10.0,HTS002,PREP017,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31521121-001-26-4::0.00061034::HTS002,BRD-A31521121-001-26-4,0.00061034,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::0.0024414::HTS002,BRD-A31521121-001-26-4,0.0024414,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::0.00976562::HTS002,BRD-A31521121-001-26-4,0.00976562,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::0.0390625::HTS002,BRD-A31521121-001-26-4,0.0390625,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::0.15625::HTS002,BRD-A31521121-001-26-4,0.15625,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::0.625::HTS002,BRD-A31521121-001-26-4,0.625,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::2.5::HTS002,BRD-A31521121-001-26-4,2.5,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-A31521121-001-26-4::10::HTS002,BRD-A31521121-001-26-4,10.0,HTS002,PREP023,methocarbamol,muscle relaxant,CA1,neurology/psychiatry,muscle relaxant,"COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O",Launched
BRD-K37798499-001-27-2::0.00061034::HTS002,BRD-K37798499-001-27-2,0.00061034,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::0.0024414::HTS002,BRD-K37798499-001-27-2,0.0024414,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::0.00976562::HTS002,BRD-K37798499-001-27-2,0.00976562,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::0.0390625::HTS002,BRD-K37798499-001-27-2,0.0390625,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::0.15625::HTS002,BRD-K37798499-001-27-2,0.15625,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::0.625::HTS002,BRD-K37798499-001-27-2,0.625,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::2.5::HTS002,BRD-K37798499-001-27-2,2.5,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K37798499-001-27-2::10::HTS002,BRD-K37798499-001-27-2,10.0,HTS002,PREP017,etoposide,topoisomerase inhibitor,"TOP2A, TOP2B",oncology,non-small cell lung cancer (NSCLC),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12",Launched
BRD-K40787673-001-02-1::0.00061034::HTS002,BRD-K40787673-001-02-1,0.00061034,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::0.0024414::HTS002,BRD-K40787673-001-02-1,0.0024414,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::0.00976562::HTS002,BRD-K40787673-001-02-1,0.00976562,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::0.0390625::HTS002,BRD-K40787673-001-02-1,0.0390625,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::0.15625::HTS002,BRD-K40787673-001-02-1,0.15625,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::0.625::HTS002,BRD-K40787673-001-02-1,0.625,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::2.5::HTS002,BRD-K40787673-001-02-1,2.5,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-K40787673-001-02-1::10::HTS002,BRD-K40787673-001-02-1,10.0,HTS002,PREP022,lacitol,osmosis stimulant,NA,gastroenterology,constipation,"OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO",Launched
BRD-A34751532-001-06-9::0.00061034::HTS002,BRD-A34751532-001-06-9,0.00061034,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::0.0024414::HTS002,BRD-A34751532-001-06-9,0.0024414,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::0.00976562::HTS002,BRD-A34751532-001-06-9,0.00976562,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::0.0390625::HTS002,BRD-A34751532-001-06-9,0.0390625,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::0.15625::HTS002,BRD-A34751532-001-06-9,0.15625,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::0.625::HTS002,BRD-A34751532-001-06-9,0.625,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::2.5::HTS002,BRD-A34751532-001-06-9,2.5,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A34751532-001-06-9::10::HTS002,BRD-A34751532-001-06-9,10.0,HTS002,PREP024,homosalate,HSP inducer,NA,NA,NA,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,Preclinical
BRD-A35588707-001-05-5::0.00061034::HTS002,BRD-A35588707-001-05-5,0.00061034,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::0.0024414::HTS002,BRD-A35588707-001-05-5,0.0024414,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::0.00976562::HTS002,BRD-A35588707-001-05-5,0.00976562,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::0.0390625::HTS002,BRD-A35588707-001-05-5,0.0390625,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::0.15625::HTS002,BRD-A35588707-001-05-5,0.15625,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::0.625::HTS002,BRD-A35588707-001-05-5,0.625,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::2.5::HTS002,BRD-A35588707-001-05-5,2.5,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A35588707-001-05-5::10::HTS002,BRD-A35588707-001-05-5,10.0,HTS002,PREP016,teniposide,topoisomerase inhibitor,"TOP2A, TOP2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12",Launched
BRD-A36057565-001-01-0::0.00061034::HTS002,BRD-A36057565-001-01-0,0.00061034,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::0.0024414::HTS002,BRD-A36057565-001-01-0,0.0024414,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::0.00976562::HTS002,BRD-A36057565-001-01-0,0.00976562,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::0.0390625::HTS002,BRD-A36057565-001-01-0,0.0390625,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::0.15625::HTS002,BRD-A36057565-001-01-0,0.15625,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::0.625::HTS002,BRD-A36057565-001-01-0,0.625,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::2.5::HTS002,BRD-A36057565-001-01-0,2.5,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36057565-001-01-0::10::HTS002,BRD-A36057565-001-01-0,10.0,HTS002,PREP033,bruceantin,protein synthesis inhibitor,NA,NA,NA,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,Phase 2
BRD-A36267905-003-18-4::0.00061034::HTS002,BRD-A36267905-003-18-4,0.00061034,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::0.0024414::HTS002,BRD-A36267905-003-18-4,0.0024414,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::0.00976562::HTS002,BRD-A36267905-003-18-4,0.00976562,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::0.0390625::HTS002,BRD-A36267905-003-18-4,0.0390625,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::0.15625::HTS002,BRD-A36267905-003-18-4,0.15625,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::0.625::HTS002,BRD-A36267905-003-18-4,0.625,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::2.5::HTS002,BRD-A36267905-003-18-4,2.5,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36267905-003-18-4::10::HTS002,BRD-A36267905-003-18-4,10.0,HTS002,PREP021,buphenine,adrenergic receptor agonist,ADRB2,rheumatology,Raynaud's disease,"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1",Launched
BRD-A36331462-001-02-1::0.00061034::HTS002,BRD-A36331462-001-02-1,0.00061034,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::0.0024414::HTS002,BRD-A36331462-001-02-1,0.0024414,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::0.00976562::HTS002,BRD-A36331462-001-02-1,0.00976562,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::0.0390625::HTS002,BRD-A36331462-001-02-1,0.0390625,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::0.15625::HTS002,BRD-A36331462-001-02-1,0.15625,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::0.625::HTS002,BRD-A36331462-001-02-1,0.625,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::2.5::HTS002,BRD-A36331462-001-02-1,2.5,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36331462-001-02-1::10::HTS002,BRD-A36331462-001-02-1,10.0,HTS002,PREP044,oprozomib,proteasome inhibitor,NA,NA,NA,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,Phase 1/Phase 2
BRD-A36456202-001-01-3::0.000610352::HTS002,BRD-A36456202-001-01-3,0.000610352,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::0.00244141::HTS002,BRD-A36456202-001-01-3,0.00244141,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::0.00976562::HTS002,BRD-A36456202-001-01-3,0.00976562,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::0.0390625::HTS002,BRD-A36456202-001-01-3,0.0390625,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::0.15625::HTS002,BRD-A36456202-001-01-3,0.15625,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::0.625::HTS002,BRD-A36456202-001-01-3,0.625,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::2.5::HTS002,BRD-A36456202-001-01-3,2.5,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-A36456202-001-01-3::10::HTS002,BRD-A36456202-001-01-3,10.0,HTS002,PREP021,colistin-b-sulfate,bacterial permeability inducer,NA,infectious disease,gram-negative bacterial infections,CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O,Launched
BRD-K81839095-001-30-1::0.00061034::HTS002,BRD-K81839095-001-30-1,0.00061034,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::0.0024414::HTS002,BRD-K81839095-001-30-1,0.0024414,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::0.00976562::HTS002,BRD-K81839095-001-30-1,0.00976562,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::0.0390625::HTS002,BRD-K81839095-001-30-1,0.0390625,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::0.15625::HTS002,BRD-K81839095-001-30-1,0.15625,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::0.625::HTS002,BRD-K81839095-001-30-1,0.625,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::2.5::HTS002,BRD-K81839095-001-30-1,2.5,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-K81839095-001-30-1::10::HTS002,BRD-K81839095-001-30-1,10.0,HTS002,PREP016,estrone,"estrogen receptor agonist, estrogenic hormone","ESR1, ESR2",NA,NA,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O",Launched
BRD-A38350138-001-04-9::0.00061034::HTS002,BRD-A38350138-001-04-9,0.00061034,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::0.0024414::HTS002,BRD-A38350138-001-04-9,0.0024414,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::0.00976562::HTS002,BRD-A38350138-001-04-9,0.00976562,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::0.0390625::HTS002,BRD-A38350138-001-04-9,0.0390625,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::0.15625::HTS002,BRD-A38350138-001-04-9,0.15625,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::0.625::HTS002,BRD-A38350138-001-04-9,0.625,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::2.5::HTS002,BRD-A38350138-001-04-9,2.5,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A38350138-001-04-9::10::HTS002,BRD-A38350138-001-04-9,10.0,HTS002,PREP023,ketoconazole,sterol demethylase inhibitor,"AR, CYP19A1, CYP21A2, KCNA10",dermatology,seborrheic dermatitis,"CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A39390670-236-10-7::0.00061034::HTS002,BRD-A39390670-236-10-7,0.00061034,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::0.0024414::HTS002,BRD-A39390670-236-10-7,0.0024414,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::0.00976562::HTS002,BRD-A39390670-236-10-7,0.00976562,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::0.0390625::HTS002,BRD-A39390670-236-10-7,0.0390625,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::0.15625::HTS002,BRD-A39390670-236-10-7,0.15625,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::0.625::HTS002,BRD-A39390670-236-10-7,0.625,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::2.5::HTS002,BRD-A39390670-236-10-7,2.5,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-A39390670-236-10-7::10::HTS002,BRD-A39390670-236-10-7,10.0,HTS002,PREP023,rabeprazole,"ATPase inhibitor, gastrin inhibitor",ATP4A,gastroenterology,"gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome","COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C",Launched
BRD-K92073408-001-16-5::0.00061034::HTS002,BRD-K92073408-001-16-5,0.00061034,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::0.0024414::HTS002,BRD-K92073408-001-16-5,0.0024414,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::0.00976562::HTS002,BRD-K92073408-001-16-5,0.00976562,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::0.0390625::HTS002,BRD-K92073408-001-16-5,0.0390625,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::0.15625::HTS002,BRD-K92073408-001-16-5,0.15625,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::0.625::HTS002,BRD-K92073408-001-16-5,0.625,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::2.5::HTS002,BRD-K92073408-001-16-5,2.5,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-16-5::10::HTS002,BRD-K92073408-001-16-5,10.0,HTS002,PREP023,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-M92675308-003-07-1::0.00061034::HTS002,BRD-M92675308-003-07-1,0.00061034,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::0.0024414::HTS002,BRD-M92675308-003-07-1,0.0024414,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::0.00976562::HTS002,BRD-M92675308-003-07-1,0.00976562,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::0.0390625::HTS002,BRD-M92675308-003-07-1,0.0390625,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::0.15625::HTS002,BRD-M92675308-003-07-1,0.15625,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::0.625::HTS002,BRD-M92675308-003-07-1,0.625,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::2.5::HTS002,BRD-M92675308-003-07-1,2.5,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-M92675308-003-07-1::10::HTS002,BRD-M92675308-003-07-1,10.0,HTS002,PREP039,efonidipine-monoethanolate,"L-type calcium channel blocker, T-type calcium channel blocker","CACNA1C, CACNA1G",NA,NA,"CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1, CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",Launched
BRD-A39935389-001-05-9::0.000610352::HTS002,BRD-A39935389-001-05-9,0.000610352,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::0.00244141::HTS002,BRD-A39935389-001-05-9,0.00244141,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::0.00976562::HTS002,BRD-A39935389-001-05-9,0.00976562,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::0.0390625::HTS002,BRD-A39935389-001-05-9,0.0390625,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::0.15625::HTS002,BRD-A39935389-001-05-9,0.15625,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::0.625::HTS002,BRD-A39935389-001-05-9,0.625,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::2.5::HTS002,BRD-A39935389-001-05-9,2.5,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-A39935389-001-05-9::10::HTS002,BRD-A39935389-001-05-9,10.0,HTS002,PREP027,teroxirone,DNA inhibitor,NA,NA,NA,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,Phase 1
BRD-K92872987-001-02-9::0.00061034::HTS002,BRD-K92872987-001-02-9,0.00061034,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::0.0024414::HTS002,BRD-K92872987-001-02-9,0.0024414,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::0.00976562::HTS002,BRD-K92872987-001-02-9,0.00976562,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::0.0390625::HTS002,BRD-K92872987-001-02-9,0.0390625,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::0.15625::HTS002,BRD-K92872987-001-02-9,0.15625,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::0.625::HTS002,BRD-K92872987-001-02-9,0.625,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::2.5::HTS002,BRD-K92872987-001-02-9,2.5,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K92872987-001-02-9::10::HTS002,BRD-K92872987-001-02-9,10.0,HTS002,PREP021,cefpiramide,bacterial cell wall synthesis inhibitor,NA,infectious disease,gram-negative bacterial infections,"Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1",Launched
BRD-K54187111-001-09-2::0.00061034::HTS002,BRD-K54187111-001-09-2,0.00061034,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::0.0024414::HTS002,BRD-K54187111-001-09-2,0.0024414,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::0.00976562::HTS002,BRD-K54187111-001-09-2,0.00976562,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::0.0390625::HTS002,BRD-K54187111-001-09-2,0.0390625,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::0.15625::HTS002,BRD-K54187111-001-09-2,0.15625,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::0.625::HTS002,BRD-K54187111-001-09-2,0.625,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::2.5::HTS002,BRD-K54187111-001-09-2,2.5,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-K54187111-001-09-2::10::HTS002,BRD-K54187111-001-09-2,10.0,HTS002,PREP044,dichlorisone-acetate,NA,NA,NA,NA,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C",Phase 2
BRD-A41304429-001-14-8::0.00061034::HTS002,BRD-A41304429-001-14-8,0.00061034,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::0.0024414::HTS002,BRD-A41304429-001-14-8,0.0024414,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::0.00976562::HTS002,BRD-A41304429-001-14-8,0.00976562,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::0.0390625::HTS002,BRD-A41304429-001-14-8,0.0390625,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::0.15625::HTS002,BRD-A41304429-001-14-8,0.15625,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::0.625::HTS002,BRD-A41304429-001-14-8,0.625,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::2.5::HTS002,BRD-A41304429-001-14-8,2.5,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A41304429-001-14-8::10::HTS002,BRD-A41304429-001-14-8,10.0,HTS002,PREP023,practolol,adrenergic receptor antagonist,ADRB1,NA,NA,"CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1",Withdrawn
BRD-A42699921-001-03-6::0.000635154::HTS002,BRD-A42699921-001-03-6,0.000635154,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::0.00254061::HTS002,BRD-A42699921-001-03-6,0.00254061,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::0.0101625::HTS002,BRD-A42699921-001-03-6,0.0101625,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::0.0406498::HTS002,BRD-A42699921-001-03-6,0.0406498,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::0.162599::HTS002,BRD-A42699921-001-03-6,0.162599,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::0.650397::HTS002,BRD-A42699921-001-03-6,0.650397,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::2.60159::HTS002,BRD-A42699921-001-03-6,2.60159,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42699921-001-03-6::10.4064::HTS002,BRD-A42699921-001-03-6,10.4064,HTS002,PREP035,teriflunomide,dihydroorotate dehydrogenase inhibitor,DHODH,neurology/psychiatry,multiple sclerosis,"CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F, CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F",Launched
BRD-A42746051-001-02-9::0.00061034::HTS002,BRD-A42746051-001-02-9,0.00061034,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::0.0024414::HTS002,BRD-A42746051-001-02-9,0.0024414,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::0.00976562::HTS002,BRD-A42746051-001-02-9,0.00976562,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::0.0390625::HTS002,BRD-A42746051-001-02-9,0.0390625,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::0.15625::HTS002,BRD-A42746051-001-02-9,0.15625,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::0.625::HTS002,BRD-A42746051-001-02-9,0.625,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::2.5::HTS002,BRD-A42746051-001-02-9,2.5,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A42746051-001-02-9::10::HTS002,BRD-A42746051-001-02-9,10.0,HTS002,PREP033,melengestrol-acetate,progesterone receptor agonist,NA,NA,NA,CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C,Preclinical
BRD-A43082461-001-06-3::0.000610352::HTS002,BRD-A43082461-001-06-3,0.000610352,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::0.00244141::HTS002,BRD-A43082461-001-06-3,0.00244141,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::0.00976562::HTS002,BRD-A43082461-001-06-3,0.00976562,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::0.0390625::HTS002,BRD-A43082461-001-06-3,0.0390625,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::0.15625::HTS002,BRD-A43082461-001-06-3,0.15625,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::0.625::HTS002,BRD-A43082461-001-06-3,0.625,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::2.5::HTS002,BRD-A43082461-001-06-3,2.5,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43082461-001-06-3::10::HTS002,BRD-A43082461-001-06-3,10.0,HTS002,PREP048,linalool,anticonvulsant,NA,NA,NA,CC(C)=CCCC(C)(O)C=C,Phase 1
BRD-A43671941-003-11-9::0.00061034::HTS002,BRD-A43671941-003-11-9,0.00061034,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::0.0024414::HTS002,BRD-A43671941-003-11-9,0.0024414,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::0.00976562::HTS002,BRD-A43671941-003-11-9,0.00976562,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::0.0390625::HTS002,BRD-A43671941-003-11-9,0.0390625,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::0.15625::HTS002,BRD-A43671941-003-11-9,0.15625,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::0.625::HTS002,BRD-A43671941-003-11-9,0.625,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::2.5::HTS002,BRD-A43671941-003-11-9,2.5,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43671941-003-11-9::10::HTS002,BRD-A43671941-003-11-9,10.0,HTS002,PREP016,oxprenolol,adrenergic receptor antagonist,"ADRB1, ADRB2",cardiology,"angina pectoris, hypertension, cardiac arrythmia",CC(C)NCC(O)COc1ccccc1OCC=C,Launched
BRD-A43809092-003-02-1::0.00061034::HTS002,BRD-A43809092-003-02-1,0.00061034,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::0.0024414::HTS002,BRD-A43809092-003-02-1,0.0024414,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::0.00976562::HTS002,BRD-A43809092-003-02-1,0.00976562,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::0.0390625::HTS002,BRD-A43809092-003-02-1,0.0390625,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::0.15625::HTS002,BRD-A43809092-003-02-1,0.15625,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::0.625::HTS002,BRD-A43809092-003-02-1,0.625,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::2.5::HTS002,BRD-A43809092-003-02-1,2.5,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43809092-003-02-1::10::HTS002,BRD-A43809092-003-02-1,10.0,HTS002,PREP025,clobutinol,antitussive,NA,NA,NA,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,Withdrawn
BRD-A43885598-001-08-1::0.00061034::HTS002,BRD-A43885598-001-08-1,0.00061034,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::0.0024414::HTS002,BRD-A43885598-001-08-1,0.0024414,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::0.00976562::HTS002,BRD-A43885598-001-08-1,0.00976562,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::0.0390625::HTS002,BRD-A43885598-001-08-1,0.0390625,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::0.15625::HTS002,BRD-A43885598-001-08-1,0.15625,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::0.625::HTS002,BRD-A43885598-001-08-1,0.625,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::2.5::HTS002,BRD-A43885598-001-08-1,2.5,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A43885598-001-08-1::10::HTS002,BRD-A43885598-001-08-1,10.0,HTS002,PREP042,SID-7969543,steroidogenic factor antagonist,NR5A1,NA,NA,"CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O, CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O",Preclinical
BRD-A44090213-001-25-6::0.00061034::HTS002,BRD-A44090213-001-25-6,0.00061034,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::0.0024414::HTS002,BRD-A44090213-001-25-6,0.0024414,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::0.00976562::HTS002,BRD-A44090213-001-25-6,0.00976562,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::0.0390625::HTS002,BRD-A44090213-001-25-6,0.0390625,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::0.15625::HTS002,BRD-A44090213-001-25-6,0.15625,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::0.625::HTS002,BRD-A44090213-001-25-6,0.625,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::2.5::HTS002,BRD-A44090213-001-25-6,2.5,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44090213-001-25-6::10::HTS002,BRD-A44090213-001-25-6,10.0,HTS002,PREP035,indoprofen,"cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2",NA,NA,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,Withdrawn
BRD-A44500574-001-01-8::0.00061034::HTS002,BRD-A44500574-001-01-8,0.00061034,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::0.0024414::HTS002,BRD-A44500574-001-01-8,0.0024414,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::0.00976562::HTS002,BRD-A44500574-001-01-8,0.00976562,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::0.0390625::HTS002,BRD-A44500574-001-01-8,0.0390625,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::0.15625::HTS002,BRD-A44500574-001-01-8,0.15625,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::0.625::HTS002,BRD-A44500574-001-01-8,0.625,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::2.5::HTS002,BRD-A44500574-001-01-8,2.5,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A44500574-001-01-8::10::HTS002,BRD-A44500574-001-01-8,10.0,HTS002,PREP015,FLI-06,notch signaling inhibitor,NA,NA,NA,"CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1",Preclinical
BRD-A45498368-001-07-1::0.00061034::HTS002,BRD-A45498368-001-07-1,0.00061034,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::0.0024414::HTS002,BRD-A45498368-001-07-1,0.0024414,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::0.00976562::HTS002,BRD-A45498368-001-07-1,0.00976562,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::0.0390625::HTS002,BRD-A45498368-001-07-1,0.0390625,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::0.15625::HTS002,BRD-A45498368-001-07-1,0.15625,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::0.625::HTS002,BRD-A45498368-001-07-1,0.625,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::2.5::HTS002,BRD-A45498368-001-07-1,2.5,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A45498368-001-07-1::10::HTS002,BRD-A45498368-001-07-1,10.0,HTS002,PREP041,WYE-125132,mTOR inhibitor,MTOR,NA,NA,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,Preclinical
BRD-A46813902-001-01-6::0.00061034::HTS002,BRD-A46813902-001-01-6,0.00061034,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::0.0024414::HTS002,BRD-A46813902-001-01-6,0.0024414,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::0.00976562::HTS002,BRD-A46813902-001-01-6,0.00976562,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::0.0390625::HTS002,BRD-A46813902-001-01-6,0.0390625,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::0.15625::HTS002,BRD-A46813902-001-01-6,0.15625,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::0.625::HTS002,BRD-A46813902-001-01-6,0.625,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::2.5::HTS002,BRD-A46813902-001-01-6,2.5,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A46813902-001-01-6::10::HTS002,BRD-A46813902-001-01-6,10.0,HTS002,PREP019,iododexetimide,acetylcholine receptor antagonist,NA,NA,NA,Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1,Phase 2
BRD-A47706533-001-02-6::0.00061034::HTS002,BRD-A47706533-001-02-6,0.00061034,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::0.0024414::HTS002,BRD-A47706533-001-02-6,0.0024414,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::0.00976562::HTS002,BRD-A47706533-001-02-6,0.00976562,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::0.0390625::HTS002,BRD-A47706533-001-02-6,0.0390625,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::0.15625::HTS002,BRD-A47706533-001-02-6,0.15625,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::0.625::HTS002,BRD-A47706533-001-02-6,0.625,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::2.5::HTS002,BRD-A47706533-001-02-6,2.5,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47706533-001-02-6::10::HTS002,BRD-A47706533-001-02-6,10.0,HTS002,PREP019,buthionine-sulfoximine,glutathione transferase inhibitor,GCLM,NA,NA,CCCCS(=N)(=O)CC[C@H](N)C(O)=O,Phase 1
BRD-A47953250-001-01-7::0.00061034::HTS002,BRD-A47953250-001-01-7,0.00061034,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::0.0024414::HTS002,BRD-A47953250-001-01-7,0.0024414,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::0.00976562::HTS002,BRD-A47953250-001-01-7,0.00976562,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::0.0390625::HTS002,BRD-A47953250-001-01-7,0.0390625,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::0.15625::HTS002,BRD-A47953250-001-01-7,0.15625,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::0.625::HTS002,BRD-A47953250-001-01-7,0.625,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::2.5::HTS002,BRD-A47953250-001-01-7,2.5,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A47953250-001-01-7::10::HTS002,BRD-A47953250-001-01-7,10.0,HTS002,PREP020,ecamsule-triethanolamine,NA,NA,dermatology,"skin protectant, sunscreen lotion",CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C,Launched
BRD-A48237631-001-04-8::0.00061034::HTS002,BRD-A48237631-001-04-8,0.00061034,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::0.0024414::HTS002,BRD-A48237631-001-04-8,0.0024414,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::0.00976562::HTS002,BRD-A48237631-001-04-8,0.00976562,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::0.0390625::HTS002,BRD-A48237631-001-04-8,0.0390625,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::0.15625::HTS002,BRD-A48237631-001-04-8,0.15625,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::0.625::HTS002,BRD-A48237631-001-04-8,0.625,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::2.5::HTS002,BRD-A48237631-001-04-8,2.5,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48237631-001-04-8::10::HTS002,BRD-A48237631-001-04-8,10.0,HTS002,PREP029,mitomycin-c,"DNA alkylating agent, DNA synthesis inhibitor",NA,oncology,"pancreatic cancer, gastric adenocarcinoma",CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O,Launched
BRD-A48300215-001-04-8::0.00061034::HTS002,BRD-A48300215-001-04-8,0.00061034,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::0.0024414::HTS002,BRD-A48300215-001-04-8,0.0024414,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::0.00976562::HTS002,BRD-A48300215-001-04-8,0.00976562,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::0.0390625::HTS002,BRD-A48300215-001-04-8,0.0390625,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::0.15625::HTS002,BRD-A48300215-001-04-8,0.15625,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::0.625::HTS002,BRD-A48300215-001-04-8,0.625,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::2.5::HTS002,BRD-A48300215-001-04-8,2.5,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A48300215-001-04-8::10::HTS002,BRD-A48300215-001-04-8,10.0,HTS002,PREP021,ajmaline,sodium channel blocker,SCN5A,cardiology,Wolff-Parkinson-White Syndrome (WPW),CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,Launched
BRD-A49035384-003-28-9::0.000582446::HTS002,BRD-A49035384-003-28-9,0.000582446,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::0.00232979::HTS002,BRD-A49035384-003-28-9,0.00232979,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::0.00931914::HTS002,BRD-A49035384-003-28-9,0.00931914,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::0.0372766::HTS002,BRD-A49035384-003-28-9,0.0372766,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::0.149106::HTS002,BRD-A49035384-003-28-9,0.149106,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::0.596425::HTS002,BRD-A49035384-003-28-9,0.596425,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::2.3857::HTS002,BRD-A49035384-003-28-9,2.3857,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49035384-003-28-9::9.5428::HTS002,BRD-A49035384-003-28-9,9.5428,HTS002,PREP031,methacycline,protein synthesis inhibitor,NA,pulmonary,bronchitis,"CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",Launched
BRD-A49358627-001-14-6::0.00061034::HTS002,BRD-A49358627-001-14-6,0.00061034,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::0.0024414::HTS002,BRD-A49358627-001-14-6,0.0024414,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::0.00976562::HTS002,BRD-A49358627-001-14-6,0.00976562,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::0.0390625::HTS002,BRD-A49358627-001-14-6,0.0390625,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::0.15625::HTS002,BRD-A49358627-001-14-6,0.15625,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::0.625::HTS002,BRD-A49358627-001-14-6,0.625,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::2.5::HTS002,BRD-A49358627-001-14-6,2.5,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49358627-001-14-6::10::HTS002,BRD-A49358627-001-14-6,10.0,HTS002,PREP021,ciprofibrate,PPAR receptor agonist,PPARA,endocrinology,hyperlipidemia,"CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O",Launched
BRD-A49765801-001-04-1::0.00061034::HTS002,BRD-A49765801-001-04-1,0.00061034,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::0.0024414::HTS002,BRD-A49765801-001-04-1,0.0024414,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::0.00976562::HTS002,BRD-A49765801-001-04-1,0.00976562,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::0.0390625::HTS002,BRD-A49765801-001-04-1,0.0390625,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::0.15625::HTS002,BRD-A49765801-001-04-1,0.15625,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::0.625::HTS002,BRD-A49765801-001-04-1,0.625,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::2.5::HTS002,BRD-A49765801-001-04-1,2.5,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A49765801-001-04-1::10::HTS002,BRD-A49765801-001-04-1,10.0,HTS002,PREP029,fludroxycortide,glucocorticoid receptor agonist,"NR3C1, SERPINA6","infectious disease, dermatology","skin infections, psoriasis",CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Launched
BRD-A50049929-001-01-9::0.00061034::HTS002,BRD-A50049929-001-01-9,0.00061034,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::0.0024414::HTS002,BRD-A50049929-001-01-9,0.0024414,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::0.00976562::HTS002,BRD-A50049929-001-01-9,0.00976562,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::0.0390625::HTS002,BRD-A50049929-001-01-9,0.0390625,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::0.15625::HTS002,BRD-A50049929-001-01-9,0.15625,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::0.625::HTS002,BRD-A50049929-001-01-9,0.625,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::2.5::HTS002,BRD-A50049929-001-01-9,2.5,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50049929-001-01-9::10::HTS002,BRD-A50049929-001-01-9,10.0,HTS002,PREP020,oxazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3",neurology/psychiatry,anxiety,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,Launched
BRD-A50064262-001-04-7::0.00061034::HTS002,BRD-A50064262-001-04-7,0.00061034,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::0.0024414::HTS002,BRD-A50064262-001-04-7,0.0024414,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::0.00976562::HTS002,BRD-A50064262-001-04-7,0.00976562,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::0.0390625::HTS002,BRD-A50064262-001-04-7,0.0390625,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::0.15625::HTS002,BRD-A50064262-001-04-7,0.15625,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::0.625::HTS002,BRD-A50064262-001-04-7,0.625,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::2.5::HTS002,BRD-A50064262-001-04-7,2.5,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50064262-001-04-7::10::HTS002,BRD-A50064262-001-04-7,10.0,HTS002,PREP046,flumethasone-pivalate,glucocorticoid receptor agonist,"NR3C1, SERPINA6",NA,NA,C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,Launched
BRD-A50157456-065-20-6::0.00061034::HTS002,BRD-A50157456-065-20-6,0.00061034,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::0.0024414::HTS002,BRD-A50157456-065-20-6,0.0024414,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::0.00976562::HTS002,BRD-A50157456-065-20-6,0.00976562,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::0.0390625::HTS002,BRD-A50157456-065-20-6,0.0390625,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::0.15625::HTS002,BRD-A50157456-065-20-6,0.15625,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::0.625::HTS002,BRD-A50157456-065-20-6,0.625,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::2.5::HTS002,BRD-A50157456-065-20-6,2.5,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50157456-065-20-6::10::HTS002,BRD-A50157456-065-20-6,10.0,HTS002,PREP028,terbutaline,adrenergic receptor agonist,ADRB2,pulmonary,"bronchospasm, bronchitis, emphysema","CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1",Launched
BRD-A50311610-300-10-4::0.00061034::HTS002,BRD-A50311610-300-10-4,0.00061034,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::0.0024414::HTS002,BRD-A50311610-300-10-4,0.0024414,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::0.00976562::HTS002,BRD-A50311610-300-10-4,0.00976562,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::0.0390625::HTS002,BRD-A50311610-300-10-4,0.0390625,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::0.15625::HTS002,BRD-A50311610-300-10-4,0.15625,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::0.625::HTS002,BRD-A50311610-300-10-4,0.625,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::2.5::HTS002,BRD-A50311610-300-10-4,2.5,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50311610-300-10-4::10::HTS002,BRD-A50311610-300-10-4,10.0,HTS002,PREP021,meclizine,constitutive androstane receptor (CAR) agonist,"HRH1, NR1I3","gastroenterology, neurology/psychiatry","nausea, vomiting, motion sickness","Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1",Launched
BRD-A50998626-001-02-1::0.00061034::HTS002,BRD-A50998626-001-02-1,0.00061034,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::0.0024414::HTS002,BRD-A50998626-001-02-1,0.0024414,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::0.00976562::HTS002,BRD-A50998626-001-02-1,0.00976562,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::0.0390625::HTS002,BRD-A50998626-001-02-1,0.0390625,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::0.15625::HTS002,BRD-A50998626-001-02-1,0.15625,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::0.625::HTS002,BRD-A50998626-001-02-1,0.625,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::2.5::HTS002,BRD-A50998626-001-02-1,2.5,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A50998626-001-02-1::10::HTS002,BRD-A50998626-001-02-1,10.0,HTS002,PREP018,palomid-529,"AKT inhibitor, mTOR inhibitor",MTOR,NA,NA,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,Phase 1
BRD-A51571244-001-01-9::0.000610352::HTS002,BRD-A51571244-001-01-9,0.000610352,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::0.00244141::HTS002,BRD-A51571244-001-01-9,0.00244141,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::0.00976562::HTS002,BRD-A51571244-001-01-9,0.00976562,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::0.0390625::HTS002,BRD-A51571244-001-01-9,0.0390625,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::0.15625::HTS002,BRD-A51571244-001-01-9,0.15625,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::0.625::HTS002,BRD-A51571244-001-01-9,0.625,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::2.5::HTS002,BRD-A51571244-001-01-9,2.5,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-A51571244-001-01-9::10::HTS002,BRD-A51571244-001-01-9,10.0,HTS002,PREP025,hypoestoxide,IKK inhibitor,"IKBKB, IL1B, TNF",NA,NA,CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C,Phase 1
BRD-K58049875-001-04-7::0.00061034::HTS002,BRD-K58049875-001-04-7,0.00061034,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::0.0024414::HTS002,BRD-K58049875-001-04-7,0.0024414,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::0.00976562::HTS002,BRD-K58049875-001-04-7,0.00976562,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::0.0390625::HTS002,BRD-K58049875-001-04-7,0.0390625,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::0.15625::HTS002,BRD-K58049875-001-04-7,0.15625,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::0.625::HTS002,BRD-K58049875-001-04-7,0.625,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::2.5::HTS002,BRD-K58049875-001-04-7,2.5,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-K58049875-001-04-7::10::HTS002,BRD-K58049875-001-04-7,10.0,HTS002,PREP024,thiostrepton,"FOXM1 inhibitor, protein synthesis inhibitor",FOXM1,obstetrics/gynecology,mastitis,"CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O",Launched
BRD-A51964809-003-12-6::0.00061034::HTS002,BRD-A51964809-003-12-6,0.00061034,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::0.0024414::HTS002,BRD-A51964809-003-12-6,0.0024414,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::0.00976562::HTS002,BRD-A51964809-003-12-6,0.00976562,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::0.0390625::HTS002,BRD-A51964809-003-12-6,0.0390625,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::0.15625::HTS002,BRD-A51964809-003-12-6,0.15625,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::0.625::HTS002,BRD-A51964809-003-12-6,0.625,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::2.5::HTS002,BRD-A51964809-003-12-6,2.5,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A51964809-003-12-6::10::HTS002,BRD-A51964809-003-12-6,10.0,HTS002,PREP031,halofantrine,antimalarial agent,"KCNH2, KCNN4",infectious disease,malaria,CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F,Launched
BRD-A53134341-001-03-2::0.00061034::HTS002,BRD-A53134341-001-03-2,0.00061034,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::0.0024414::HTS002,BRD-A53134341-001-03-2,0.0024414,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::0.00976562::HTS002,BRD-A53134341-001-03-2,0.00976562,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::0.0390625::HTS002,BRD-A53134341-001-03-2,0.0390625,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::0.15625::HTS002,BRD-A53134341-001-03-2,0.15625,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::0.625::HTS002,BRD-A53134341-001-03-2,0.625,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::2.5::HTS002,BRD-A53134341-001-03-2,2.5,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53134341-001-03-2::10::HTS002,BRD-A53134341-001-03-2,10.0,HTS002,PREP040,Ro-106-9920,NFkB pathway inhibitor,NA,NA,NA,"O=S(c1ccccc1)c1ccc2nnnn2n1, O=S(c1ccccc1)c1ccc2nnnn2n1",Preclinical
BRD-A53151380-001-01-2::0.00061034::HTS002,BRD-A53151380-001-01-2,0.00061034,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::0.0024414::HTS002,BRD-A53151380-001-01-2,0.0024414,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::0.00976562::HTS002,BRD-A53151380-001-01-2,0.00976562,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::0.0390625::HTS002,BRD-A53151380-001-01-2,0.0390625,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::0.15625::HTS002,BRD-A53151380-001-01-2,0.15625,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::0.625::HTS002,BRD-A53151380-001-01-2,0.625,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::2.5::HTS002,BRD-A53151380-001-01-2,2.5,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-A53151380-001-01-2::10::HTS002,BRD-A53151380-001-01-2,10.0,HTS002,PREP023,prednisolone-tebutate,anti-inflammatory agent,NA,NA,NA,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C,Launched
BRD-K35240538-001-26-2::0.00061034::HTS002,BRD-K35240538-001-26-2,0.00061034,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::0.0024414::HTS002,BRD-K35240538-001-26-2,0.0024414,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::0.00976562::HTS002,BRD-K35240538-001-26-2,0.00976562,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::0.0390625::HTS002,BRD-K35240538-001-26-2,0.0390625,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::0.15625::HTS002,BRD-K35240538-001-26-2,0.15625,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::0.625::HTS002,BRD-K35240538-001-26-2,0.625,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::2.5::HTS002,BRD-K35240538-001-26-2,2.5,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-K35240538-001-26-2::10::HTS002,BRD-K35240538-001-26-2,10.0,HTS002,PREP021,methylprednisolone,glucocorticoid receptor agonist,NR3C1,"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12",Launched
BRD-A57886255-001-01-1::0.00061034::HTS002,BRD-A57886255-001-01-1,0.00061034,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::0.0024414::HTS002,BRD-A57886255-001-01-1,0.0024414,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::0.00976562::HTS002,BRD-A57886255-001-01-1,0.00976562,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::0.0390625::HTS002,BRD-A57886255-001-01-1,0.0390625,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::0.15625::HTS002,BRD-A57886255-001-01-1,0.15625,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::0.625::HTS002,BRD-A57886255-001-01-1,0.625,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::2.5::HTS002,BRD-A57886255-001-01-1,2.5,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A57886255-001-01-1::10::HTS002,BRD-A57886255-001-01-1,10.0,HTS002,PREP047,golgicide-a,ARF inhibitor,GBF1,NA,NA,Fc1cc(F)c2NC([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1,Preclinical
BRD-A53951045-004-01-6::0.00061034::HTS002,BRD-A53951045-004-01-6,0.00061034,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::0.0024414::HTS002,BRD-A53951045-004-01-6,0.0024414,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::0.00976562::HTS002,BRD-A53951045-004-01-6,0.00976562,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::0.0390625::HTS002,BRD-A53951045-004-01-6,0.0390625,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::0.15625::HTS002,BRD-A53951045-004-01-6,0.15625,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::0.625::HTS002,BRD-A53951045-004-01-6,0.625,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::2.5::HTS002,BRD-A53951045-004-01-6,2.5,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A53951045-004-01-6::10::HTS002,BRD-A53951045-004-01-6,10.0,HTS002,PREP028,butylscopolamine-bromide,cholinergic receptor antagonist,NA,gastroenterology,abdominal pain,CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1,Launched
BRD-A54275602-001-01-0::0.000610352::HTS002,BRD-A54275602-001-01-0,0.000610352,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::0.00244141::HTS002,BRD-A54275602-001-01-0,0.00244141,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::0.00976562::HTS002,BRD-A54275602-001-01-0,0.00976562,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::0.0390625::HTS002,BRD-A54275602-001-01-0,0.0390625,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::0.15625::HTS002,BRD-A54275602-001-01-0,0.15625,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::0.625::HTS002,BRD-A54275602-001-01-0,0.625,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::2.5::HTS002,BRD-A54275602-001-01-0,2.5,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54275602-001-01-0::10::HTS002,BRD-A54275602-001-01-0,10.0,HTS002,PREP023,lanoconazole,sterol demethylase inhibitor,NA,infectious disease,fungal infection,Clc1ccccc1C1CS\C(S1)=C(\C#N)n1ccnc1,Launched
BRD-A54927599-001-16-9::0.00061034::HTS002,BRD-A54927599-001-16-9,0.00061034,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::0.0024414::HTS002,BRD-A54927599-001-16-9,0.0024414,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::0.00976562::HTS002,BRD-A54927599-001-16-9,0.00976562,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::0.0390625::HTS002,BRD-A54927599-001-16-9,0.0390625,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::0.15625::HTS002,BRD-A54927599-001-16-9,0.15625,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::0.625::HTS002,BRD-A54927599-001-16-9,0.625,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::2.5::HTS002,BRD-A54927599-001-16-9,2.5,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A54927599-001-16-9::10::HTS002,BRD-A54927599-001-16-9,10.0,HTS002,PREP047,KF-38789,P selectin inhibitor,SELP,NA,NA,"COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1, COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1",Preclinical
BRD-A55312468-001-04-7::0.000301783::HTS002,BRD-A55312468-001-04-7,0.000301783,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::0.00120713::HTS002,BRD-A55312468-001-04-7,0.00120713,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::0.00482853::HTS002,BRD-A55312468-001-04-7,0.00482853,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::0.0193141::HTS002,BRD-A55312468-001-04-7,0.0193141,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::0.0772565::HTS002,BRD-A55312468-001-04-7,0.0772565,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::0.309026::HTS002,BRD-A55312468-001-04-7,0.309026,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::1.2361::HTS002,BRD-A55312468-001-04-7,1.2361,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55312468-001-04-7::4.94442::HTS002,BRD-A55312468-001-04-7,4.94442,HTS002,PREP025,k-strophanthidin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,Phase 2
BRD-A55424491-001-19-9::0.00061034::HTS002,BRD-A55424491-001-19-9,0.00061034,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::0.0024414::HTS002,BRD-A55424491-001-19-9,0.0024414,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::0.00976562::HTS002,BRD-A55424491-001-19-9,0.00976562,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::0.0390625::HTS002,BRD-A55424491-001-19-9,0.0390625,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::0.15625::HTS002,BRD-A55424491-001-19-9,0.15625,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::0.625::HTS002,BRD-A55424491-001-19-9,0.625,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::2.5::HTS002,BRD-A55424491-001-19-9,2.5,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55424491-001-19-9::10::HTS002,BRD-A55424491-001-19-9,10.0,HTS002,PREP023,methotrexate,dihydrofolate reductase inhibitor,DHFR,"oncology, hematologic malignancy, dermatology, rheumatology","gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",Launched
BRD-A55484088-050-02-5::0.00061034::HTS002,BRD-A55484088-050-02-5,0.00061034,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::0.0024414::HTS002,BRD-A55484088-050-02-5,0.0024414,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::0.00976562::HTS002,BRD-A55484088-050-02-5,0.00976562,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::0.0390625::HTS002,BRD-A55484088-050-02-5,0.0390625,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::0.15625::HTS002,BRD-A55484088-050-02-5,0.15625,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::0.625::HTS002,BRD-A55484088-050-02-5,0.625,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::2.5::HTS002,BRD-A55484088-050-02-5,2.5,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55484088-050-02-5::10::HTS002,BRD-A55484088-050-02-5,10.0,HTS002,PREP041,BNTX,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1",NA,NA,"Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1, Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1",Preclinical
BRD-A55913614-316-09-6::0.00061034::HTS002,BRD-A55913614-316-09-6,0.00061034,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::0.0024414::HTS002,BRD-A55913614-316-09-6,0.0024414,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::0.00976562::HTS002,BRD-A55913614-316-09-6,0.00976562,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::0.0390625::HTS002,BRD-A55913614-316-09-6,0.0390625,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::0.15625::HTS002,BRD-A55913614-316-09-6,0.15625,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::0.625::HTS002,BRD-A55913614-316-09-6,0.625,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::2.5::HTS002,BRD-A55913614-316-09-6,2.5,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55913614-316-09-6::10::HTS002,BRD-A55913614-316-09-6,10.0,HTS002,PREP015,primaquine,"antimalarial agent, DNA inhibitor","KRT7, NQO2",infectious disease,malaria,"COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1",Launched
BRD-A55962179-001-22-1::0.00061034::HTS002,BRD-A55962179-001-22-1,0.00061034,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::0.0024414::HTS002,BRD-A55962179-001-22-1,0.0024414,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::0.00976562::HTS002,BRD-A55962179-001-22-1,0.00976562,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::0.0390625::HTS002,BRD-A55962179-001-22-1,0.0390625,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::0.15625::HTS002,BRD-A55962179-001-22-1,0.15625,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::0.625::HTS002,BRD-A55962179-001-22-1,0.625,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::2.5::HTS002,BRD-A55962179-001-22-1,2.5,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A55962179-001-22-1::10::HTS002,BRD-A55962179-001-22-1,10.0,HTS002,PREP022,omeprazole,ATPase inhibitor,"ATP4A, CLCN2",gastroenterology,heartburn,"COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C",Launched
BRD-A56085258-001-01-8::0.00061034::HTS002,BRD-A56085258-001-01-8,0.00061034,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::0.0024414::HTS002,BRD-A56085258-001-01-8,0.0024414,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::0.00976562::HTS002,BRD-A56085258-001-01-8,0.00976562,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::0.0390625::HTS002,BRD-A56085258-001-01-8,0.0390625,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::0.15625::HTS002,BRD-A56085258-001-01-8,0.15625,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::0.625::HTS002,BRD-A56085258-001-01-8,0.625,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::2.5::HTS002,BRD-A56085258-001-01-8,2.5,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A56085258-001-01-8::10::HTS002,BRD-A56085258-001-01-8,10.0,HTS002,PREP027,LGX818,RAF inhibitor,BRAF,NA,NA,COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C,Phase 3
BRD-A57382968-001-29-0::0.00061034::HTS002,BRD-A57382968-001-29-0,0.00061034,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::0.0024414::HTS002,BRD-A57382968-001-29-0,0.0024414,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::0.00976562::HTS002,BRD-A57382968-001-29-0,0.00976562,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::0.0390625::HTS002,BRD-A57382968-001-29-0,0.0390625,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::0.15625::HTS002,BRD-A57382968-001-29-0,0.15625,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::0.625::HTS002,BRD-A57382968-001-29-0,0.625,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::2.5::HTS002,BRD-A57382968-001-29-0,2.5,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57382968-001-29-0::10::HTS002,BRD-A57382968-001-29-0,10.0,HTS002,PREP015,piroxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A57798112-001-03-7::0.00061034::HTS002,BRD-A57798112-001-03-7,0.00061034,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::0.0024414::HTS002,BRD-A57798112-001-03-7,0.0024414,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::0.00976562::HTS002,BRD-A57798112-001-03-7,0.00976562,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::0.0390625::HTS002,BRD-A57798112-001-03-7,0.0390625,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::0.15625::HTS002,BRD-A57798112-001-03-7,0.15625,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::0.625::HTS002,BRD-A57798112-001-03-7,0.625,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::2.5::HTS002,BRD-A57798112-001-03-7,2.5,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57798112-001-03-7::10::HTS002,BRD-A57798112-001-03-7,10.0,HTS002,PREP033,PD-318088,MEK inhibitor,MAP2K1,NA,NA,OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F,Preclinical
BRD-A57833392-001-01-7::0.00061034::HTS002,BRD-A57833392-001-01-7,0.00061034,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::0.0024414::HTS002,BRD-A57833392-001-01-7,0.0024414,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::0.00976562::HTS002,BRD-A57833392-001-01-7,0.00976562,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::0.0390625::HTS002,BRD-A57833392-001-01-7,0.0390625,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::0.15625::HTS002,BRD-A57833392-001-01-7,0.15625,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::0.625::HTS002,BRD-A57833392-001-01-7,0.625,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::2.5::HTS002,BRD-A57833392-001-01-7,2.5,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A57833392-001-01-7::10::HTS002,BRD-A57833392-001-01-7,10.0,HTS002,PREP015,oxymatrine,NA,NA,NA,NA,[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23,Launched
BRD-A58193911-003-18-7::0.00061034::HTS002,BRD-A58193911-003-18-7,0.00061034,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::0.0024414::HTS002,BRD-A58193911-003-18-7,0.0024414,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::0.00976562::HTS002,BRD-A58193911-003-18-7,0.00976562,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::0.0390625::HTS002,BRD-A58193911-003-18-7,0.0390625,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::0.15625::HTS002,BRD-A58193911-003-18-7,0.15625,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::0.625::HTS002,BRD-A58193911-003-18-7,0.625,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::2.5::HTS002,BRD-A58193911-003-18-7,2.5,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58193911-003-18-7::10::HTS002,BRD-A58193911-003-18-7,10.0,HTS002,PREP048,oxyphencyclimine,cholinergic receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,peptic ulcer disease (PUD),CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1,Launched
BRD-A58564983-001-04-6::0.00061034::HTS002,BRD-A58564983-001-04-6,0.00061034,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::0.0024414::HTS002,BRD-A58564983-001-04-6,0.0024414,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::0.00976562::HTS002,BRD-A58564983-001-04-6,0.00976562,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::0.0390625::HTS002,BRD-A58564983-001-04-6,0.0390625,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::0.15625::HTS002,BRD-A58564983-001-04-6,0.15625,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::0.625::HTS002,BRD-A58564983-001-04-6,0.625,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::2.5::HTS002,BRD-A58564983-001-04-6,2.5,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A58564983-001-04-6::10::HTS002,BRD-A58564983-001-04-6,10.0,HTS002,PREP022,selamectin,nematocide,NA,infectious disease,flea control,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,Launched
BRD-A59303141-001-10-4::0.00061034::HTS002,BRD-A59303141-001-10-4,0.00061034,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::0.0024414::HTS002,BRD-A59303141-001-10-4,0.0024414,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::0.00976562::HTS002,BRD-A59303141-001-10-4,0.00976562,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::0.0390625::HTS002,BRD-A59303141-001-10-4,0.0390625,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::0.15625::HTS002,BRD-A59303141-001-10-4,0.15625,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::0.625::HTS002,BRD-A59303141-001-10-4,0.625,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::2.5::HTS002,BRD-A59303141-001-10-4,2.5,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A59303141-001-10-4::10::HTS002,BRD-A59303141-001-10-4,10.0,HTS002,PREP020,quinethazone,thiazide diuretic,"CA1, CA2, SLC12A1, SLC12A2, SLC12A3",cardiology,hypertension,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,Launched
BRD-A60197193-001-14-6::0.00061034::HTS002,BRD-A60197193-001-14-6,0.00061034,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::0.0024414::HTS002,BRD-A60197193-001-14-6,0.0024414,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::0.00976562::HTS002,BRD-A60197193-001-14-6,0.00976562,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::0.0390625::HTS002,BRD-A60197193-001-14-6,0.0390625,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::0.15625::HTS002,BRD-A60197193-001-14-6,0.15625,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::0.625::HTS002,BRD-A60197193-001-14-6,0.625,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::2.5::HTS002,BRD-A60197193-001-14-6,2.5,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60197193-001-14-6::10::HTS002,BRD-A60197193-001-14-6,10.0,HTS002,PREP028,amisulpride,dopamine receptor antagonist,"DRD2, DRD3, HTR2A, HTR7",neurology/psychiatry,"psychosis, bipolar disorder, schizophrenia","CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC",Launched
BRD-A60594020-034-01-1::0.00061034::HTS002,BRD-A60594020-034-01-1,0.00061034,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::0.0024414::HTS002,BRD-A60594020-034-01-1,0.0024414,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::0.00976562::HTS002,BRD-A60594020-034-01-1,0.00976562,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::0.0390625::HTS002,BRD-A60594020-034-01-1,0.0390625,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::0.15625::HTS002,BRD-A60594020-034-01-1,0.15625,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::0.625::HTS002,BRD-A60594020-034-01-1,0.625,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::2.5::HTS002,BRD-A60594020-034-01-1,2.5,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60594020-034-01-1::10::HTS002,BRD-A60594020-034-01-1,10.0,HTS002,PREP040,8-hydroxy-PIPAT,dopamine receptor ligand,"DRD2, DRD3",NA,NA,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,Preclinical
BRD-A60786380-412-01-5::0.00061034::HTS002,BRD-A60786380-412-01-5,0.00061034,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::0.0024414::HTS002,BRD-A60786380-412-01-5,0.0024414,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::0.00976562::HTS002,BRD-A60786380-412-01-5,0.00976562,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::0.0390625::HTS002,BRD-A60786380-412-01-5,0.0390625,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::0.15625::HTS002,BRD-A60786380-412-01-5,0.15625,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::0.625::HTS002,BRD-A60786380-412-01-5,0.625,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::2.5::HTS002,BRD-A60786380-412-01-5,2.5,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A60786380-412-01-5::10::HTS002,BRD-A60786380-412-01-5,10.0,HTS002,PREP048,sodium-stibogluconate,tyrosine phosphatase inhibitor,"PTPN6, TOP1",infectious disease,leishmaniasis,OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O,Launched
BRD-A63546914-003-02-0::0.00061034::HTS002,BRD-A63546914-003-02-0,0.00061034,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::0.0024414::HTS002,BRD-A63546914-003-02-0,0.0024414,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::0.00976562::HTS002,BRD-A63546914-003-02-0,0.00976562,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::0.0390625::HTS002,BRD-A63546914-003-02-0,0.0390625,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::0.15625::HTS002,BRD-A63546914-003-02-0,0.15625,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::0.625::HTS002,BRD-A63546914-003-02-0,0.625,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::2.5::HTS002,BRD-A63546914-003-02-0,2.5,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A63546914-003-02-0::10::HTS002,BRD-A63546914-003-02-0,10.0,HTS002,PREP041,Ro-04-5595,NA,GRIN2B,NA,NA,"COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O, COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O",Preclinical
BRD-A64064900-001-02-3::0.000610352::HTS002,BRD-A64064900-001-02-3,0.000610352,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::0.00244141::HTS002,BRD-A64064900-001-02-3,0.00244141,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::0.00976562::HTS002,BRD-A64064900-001-02-3,0.00976562,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::0.0390625::HTS002,BRD-A64064900-001-02-3,0.0390625,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::0.15625::HTS002,BRD-A64064900-001-02-3,0.15625,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::0.625::HTS002,BRD-A64064900-001-02-3,0.625,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::2.5::HTS002,BRD-A64064900-001-02-3,2.5,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64064900-001-02-3::10::HTS002,BRD-A64064900-001-02-3,10.0,HTS002,PREP025,sangivamycin,DNA inhibitor,NA,NA,NA,NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12,Phase 1
BRD-A64092382-003-18-3::0.00061034::HTS002,BRD-A64092382-003-18-3,0.00061034,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::0.0024414::HTS002,BRD-A64092382-003-18-3,0.0024414,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::0.00976562::HTS002,BRD-A64092382-003-18-3,0.00976562,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::0.0390625::HTS002,BRD-A64092382-003-18-3,0.0390625,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::0.15625::HTS002,BRD-A64092382-003-18-3,0.15625,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::0.625::HTS002,BRD-A64092382-003-18-3,0.625,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::2.5::HTS002,BRD-A64092382-003-18-3,2.5,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64092382-003-18-3::10::HTS002,BRD-A64092382-003-18-3,10.0,HTS002,PREP048,mexiletine,sodium channel blocker,"AHR, SCN4A, SCN5A",cardiology,"ventricular arrhythmias, ventricular tachycardia (VT)","CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C",Launched
BRD-A64242993-001-05-6::0.00061034::HTS002,BRD-A64242993-001-05-6,0.00061034,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::0.0024414::HTS002,BRD-A64242993-001-05-6,0.0024414,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::0.00976562::HTS002,BRD-A64242993-001-05-6,0.00976562,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::0.0390625::HTS002,BRD-A64242993-001-05-6,0.0390625,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::0.15625::HTS002,BRD-A64242993-001-05-6,0.15625,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::0.625::HTS002,BRD-A64242993-001-05-6,0.625,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::2.5::HTS002,BRD-A64242993-001-05-6,2.5,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64242993-001-05-6::10::HTS002,BRD-A64242993-001-05-6,10.0,HTS002,PREP015,lanatoside-c,cardiac glycoside,NA,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1,Preclinical
BRD-A64553394-001-04-4::0.000654078::HTS002,BRD-A64553394-001-04-4,0.000654078,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::0.00261631::HTS002,BRD-A64553394-001-04-4,0.00261631,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::0.0104652::HTS002,BRD-A64553394-001-04-4,0.0104652,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::0.041861::HTS002,BRD-A64553394-001-04-4,0.041861,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::0.167444::HTS002,BRD-A64553394-001-04-4,0.167444,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::0.669776::HTS002,BRD-A64553394-001-04-4,0.669776,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::2.6791::HTS002,BRD-A64553394-001-04-4,2.6791,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64553394-001-04-4::10.7164::HTS002,BRD-A64553394-001-04-4,10.7164,HTS002,PREP019,DPI-201106,sodium channel activator,ADRB2,NA,NA,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,Phase 2
BRD-A64743628-001-01-5::0.00061034::HTS002,BRD-A64743628-001-01-5,0.00061034,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::0.0024414::HTS002,BRD-A64743628-001-01-5,0.0024414,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::0.00976562::HTS002,BRD-A64743628-001-01-5,0.00976562,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::0.0390625::HTS002,BRD-A64743628-001-01-5,0.0390625,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::0.15625::HTS002,BRD-A64743628-001-01-5,0.15625,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::0.625::HTS002,BRD-A64743628-001-01-5,0.625,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::2.5::HTS002,BRD-A64743628-001-01-5,2.5,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A64743628-001-01-5::10::HTS002,BRD-A64743628-001-01-5,10.0,HTS002,PREP023,isometheptene-mucate,NA,"ADRA1A, SLC18A2",neurology/psychiatry,headache,CNC(C)CCC=C(C)C,Launched
BRD-A65248799-001-01-7::0.000610352::HTS002,BRD-A65248799-001-01-7,0.000610352,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::0.00244141::HTS002,BRD-A65248799-001-01-7,0.00244141,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::0.00976562::HTS002,BRD-A65248799-001-01-7,0.00976562,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::0.0390625::HTS002,BRD-A65248799-001-01-7,0.0390625,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::0.15625::HTS002,BRD-A65248799-001-01-7,0.15625,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::0.625::HTS002,BRD-A65248799-001-01-7,0.625,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::2.5::HTS002,BRD-A65248799-001-01-7,2.5,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A65248799-001-01-7::10::HTS002,BRD-A65248799-001-01-7,10.0,HTS002,PREP038,EMD-53998,phosphodiesterase inhibitor,TNNC1,NA,NA,COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C,Phase 1
BRD-A66419424-001-02-4::0.00061034::HTS002,BRD-A66419424-001-02-4,0.00061034,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::0.0024414::HTS002,BRD-A66419424-001-02-4,0.0024414,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::0.00976562::HTS002,BRD-A66419424-001-02-4,0.00976562,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::0.0390625::HTS002,BRD-A66419424-001-02-4,0.0390625,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::0.15625::HTS002,BRD-A66419424-001-02-4,0.15625,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::0.625::HTS002,BRD-A66419424-001-02-4,0.625,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::2.5::HTS002,BRD-A66419424-001-02-4,2.5,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-A66419424-001-02-4::10::HTS002,BRD-A66419424-001-02-4,10.0,HTS002,PREP046,ixazomib-citrate,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O,Launched
BRD-K58148589-001-03-6::0.00061034::HTS002,BRD-K58148589-001-03-6,0.00061034,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::0.0024414::HTS002,BRD-K58148589-001-03-6,0.0024414,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::0.00976562::HTS002,BRD-K58148589-001-03-6,0.00976562,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::0.0390625::HTS002,BRD-K58148589-001-03-6,0.0390625,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::0.15625::HTS002,BRD-K58148589-001-03-6,0.15625,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::0.625::HTS002,BRD-K58148589-001-03-6,0.625,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::2.5::HTS002,BRD-K58148589-001-03-6,2.5,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-K58148589-001-03-6::10::HTS002,BRD-K58148589-001-03-6,10.0,HTS002,PREP030,betamethasone-dipropionate,anti-inflammatory agent,NA,dermatology,corticosteroid-responsive dermatoses,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",Launched
BRD-A67097164-001-18-7::0.00061034::HTS002,BRD-A67097164-001-18-7,0.00061034,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::0.0024414::HTS002,BRD-A67097164-001-18-7,0.0024414,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::0.00976562::HTS002,BRD-A67097164-001-18-7,0.00976562,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::0.0390625::HTS002,BRD-A67097164-001-18-7,0.0390625,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::0.15625::HTS002,BRD-A67097164-001-18-7,0.15625,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::0.625::HTS002,BRD-A67097164-001-18-7,0.625,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::2.5::HTS002,BRD-A67097164-001-18-7,2.5,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67097164-001-18-7::10::HTS002,BRD-A67097164-001-18-7,10.0,HTS002,PREP029,ifosfamide,DNA alkylating agent,"CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1","oncology, urology","testicular carcinoma, hemorrhagic cystitis","ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl",Launched
BRD-A67516570-001-02-8::0.00061034::HTS002,BRD-A67516570-001-02-8,0.00061034,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::0.0024414::HTS002,BRD-A67516570-001-02-8,0.0024414,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::0.00976562::HTS002,BRD-A67516570-001-02-8,0.00976562,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::0.0390625::HTS002,BRD-A67516570-001-02-8,0.0390625,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::0.15625::HTS002,BRD-A67516570-001-02-8,0.15625,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::0.625::HTS002,BRD-A67516570-001-02-8,0.625,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::2.5::HTS002,BRD-A67516570-001-02-8,2.5,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67516570-001-02-8::10::HTS002,BRD-A67516570-001-02-8,10.0,HTS002,PREP030,lafutidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, peptic ulcer disease (PUD)",O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1,Launched
BRD-A67748489-001-10-0::0.00061034::HTS002,BRD-A67748489-001-10-0,0.00061034,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::0.0024414::HTS002,BRD-A67748489-001-10-0,0.0024414,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::0.00976562::HTS002,BRD-A67748489-001-10-0,0.00976562,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::0.0390625::HTS002,BRD-A67748489-001-10-0,0.0390625,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::0.15625::HTS002,BRD-A67748489-001-10-0,0.15625,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::0.625::HTS002,BRD-A67748489-001-10-0,0.625,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::2.5::HTS002,BRD-A67748489-001-10-0,2.5,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67748489-001-10-0::10::HTS002,BRD-A67748489-001-10-0,10.0,HTS002,PREP042,K-858,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1,Preclinical
BRD-A67862938-034-14-9::0.00061034::HTS002,BRD-A67862938-034-14-9,0.00061034,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::0.0024414::HTS002,BRD-A67862938-034-14-9,0.0024414,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::0.00976562::HTS002,BRD-A67862938-034-14-9,0.00976562,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::0.0390625::HTS002,BRD-A67862938-034-14-9,0.0390625,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::0.15625::HTS002,BRD-A67862938-034-14-9,0.15625,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::0.625::HTS002,BRD-A67862938-034-14-9,0.625,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::2.5::HTS002,BRD-A67862938-034-14-9,2.5,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-A67862938-034-14-9::10::HTS002,BRD-A67862938-034-14-9,10.0,HTS002,PREP023,naftidrofuryl,adrenergic receptor antagonist,NA,cardiology,claudication,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,Launched
BRD-K43389675-003-20-9::0.00061034::HTS002,BRD-K43389675-003-20-9,0.00061034,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::0.0024414::HTS002,BRD-K43389675-003-20-9,0.0024414,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::0.00976562::HTS002,BRD-K43389675-003-20-9,0.00976562,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::0.0390625::HTS002,BRD-K43389675-003-20-9,0.0390625,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::0.15625::HTS002,BRD-K43389675-003-20-9,0.15625,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::0.625::HTS002,BRD-K43389675-003-20-9,0.625,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::2.5::HTS002,BRD-K43389675-003-20-9,2.5,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-K43389675-003-20-9::10::HTS002,BRD-K43389675-003-20-9,10.0,HTS002,PREP020,daunorubicin,"RNA synthesis inhibitor, topoisomerase inhibitor","TOP2A, TOP2B",hematologic malignancy,"acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O",Launched
BRD-A68083442-001-01-6::0.000610352::HTS002,BRD-A68083442-001-01-6,0.000610352,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::0.00244141::HTS002,BRD-A68083442-001-01-6,0.00244141,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::0.00976562::HTS002,BRD-A68083442-001-01-6,0.00976562,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::0.0390625::HTS002,BRD-A68083442-001-01-6,0.0390625,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::0.15625::HTS002,BRD-A68083442-001-01-6,0.15625,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::0.625::HTS002,BRD-A68083442-001-01-6,0.625,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::2.5::HTS002,BRD-A68083442-001-01-6,2.5,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68083442-001-01-6::10::HTS002,BRD-A68083442-001-01-6,10.0,HTS002,PREP032,pranidipine,calcium channel blocker,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1,Phase 2
BRD-A68304895-003-02-2::0.00061034::HTS002,BRD-A68304895-003-02-2,0.00061034,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::0.0024414::HTS002,BRD-A68304895-003-02-2,0.0024414,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::0.00976562::HTS002,BRD-A68304895-003-02-2,0.00976562,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::0.0390625::HTS002,BRD-A68304895-003-02-2,0.0390625,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::0.15625::HTS002,BRD-A68304895-003-02-2,0.15625,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::0.625::HTS002,BRD-A68304895-003-02-2,0.625,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::2.5::HTS002,BRD-A68304895-003-02-2,2.5,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A68304895-003-02-2::10::HTS002,BRD-A68304895-003-02-2,10.0,HTS002,PREP023,BTS-54505,dopamine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,"CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1",Withdrawn
BRD-A73871920-236-03-6::0.00061034::HTS002,BRD-A73871920-236-03-6,0.00061034,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::0.0024414::HTS002,BRD-A73871920-236-03-6,0.0024414,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::0.00976562::HTS002,BRD-A73871920-236-03-6,0.00976562,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::0.0390625::HTS002,BRD-A73871920-236-03-6,0.0390625,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::0.15625::HTS002,BRD-A73871920-236-03-6,0.15625,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::0.625::HTS002,BRD-A73871920-236-03-6,0.625,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::2.5::HTS002,BRD-A73871920-236-03-6,2.5,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A73871920-236-03-6::10::HTS002,BRD-A73871920-236-03-6,10.0,HTS002,PREP032,nanchangmycin,other antibiotic,NA,NA,NA,CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C,Preclinical
BRD-A68631409-001-05-4::0.00061034::HTS002,BRD-A68631409-001-05-4,0.00061034,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::0.0024414::HTS002,BRD-A68631409-001-05-4,0.0024414,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::0.00976562::HTS002,BRD-A68631409-001-05-4,0.00976562,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::0.0390625::HTS002,BRD-A68631409-001-05-4,0.0390625,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::0.15625::HTS002,BRD-A68631409-001-05-4,0.15625,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::0.625::HTS002,BRD-A68631409-001-05-4,0.625,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::2.5::HTS002,BRD-A68631409-001-05-4,2.5,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-A68631409-001-05-4::10::HTS002,BRD-A68631409-001-05-4,10.0,HTS002,PREP032,evodiamine,"ATPase inhibitor, TRPV agonist",TRPV1,NA,NA,"CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12",Preclinical
BRD-K33277808-331-01-3::0.00061034::HTS002,BRD-K33277808-331-01-3,0.00061034,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::0.0024414::HTS002,BRD-K33277808-331-01-3,0.0024414,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::0.00976562::HTS002,BRD-K33277808-331-01-3,0.00976562,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::0.0390625::HTS002,BRD-K33277808-331-01-3,0.0390625,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::0.15625::HTS002,BRD-K33277808-331-01-3,0.15625,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::0.625::HTS002,BRD-K33277808-331-01-3,0.625,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::2.5::HTS002,BRD-K33277808-331-01-3,2.5,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K33277808-331-01-3::10::HTS002,BRD-K33277808-331-01-3,10.0,HTS002,PREP024,ouabain,ATPase inhibitor,ATP1A1,cardiology,"hypertension, cardiac arrythmia","C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-A68969091-001-12-7::0.000628134::HTS002,BRD-A68969091-001-12-7,0.000628134,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::0.00251254::HTS002,BRD-A68969091-001-12-7,0.00251254,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::0.0100501::HTS002,BRD-A68969091-001-12-7,0.0100501,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::0.0402006::HTS002,BRD-A68969091-001-12-7,0.0402006,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::0.160802::HTS002,BRD-A68969091-001-12-7,0.160802,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::0.643209::HTS002,BRD-A68969091-001-12-7,0.643209,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::2.57284::HTS002,BRD-A68969091-001-12-7,2.57284,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A68969091-001-12-7::10.2913::HTS002,BRD-A68969091-001-12-7,10.2913,HTS002,PREP045,echinomycin,DNA intercalating agent,NA,NA,NA,CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1,Phase 2
BRD-A69651145-003-07-2::0.00061034::HTS002,BRD-A69651145-003-07-2,0.00061034,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::0.0024414::HTS002,BRD-A69651145-003-07-2,0.0024414,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::0.00976562::HTS002,BRD-A69651145-003-07-2,0.00976562,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::0.0390625::HTS002,BRD-A69651145-003-07-2,0.0390625,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::0.15625::HTS002,BRD-A69651145-003-07-2,0.15625,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::0.625::HTS002,BRD-A69651145-003-07-2,0.625,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::2.5::HTS002,BRD-A69651145-003-07-2,2.5,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69651145-003-07-2::10::HTS002,BRD-A69651145-003-07-2,10.0,HTS002,PREP021,minocycline,bacterial 30S ribosomal subunit inhibitor,"ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA","endocrinology, infectious disease, ophthalmology, urology","fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis","CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C",Launched
BRD-A69815203-001-07-6::0.00061034::HTS002,BRD-A69815203-001-07-6,0.00061034,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::0.0024414::HTS002,BRD-A69815203-001-07-6,0.0024414,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::0.00976562::HTS002,BRD-A69815203-001-07-6,0.00976562,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::0.0390625::HTS002,BRD-A69815203-001-07-6,0.0390625,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::0.15625::HTS002,BRD-A69815203-001-07-6,0.15625,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::0.625::HTS002,BRD-A69815203-001-07-6,0.625,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::2.5::HTS002,BRD-A69815203-001-07-6,2.5,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A69815203-001-07-6::10::HTS002,BRD-A69815203-001-07-6,10.0,HTS002,PREP016,cyclosporin-a,calcineurin inhibitor,PPP3CA,"rheumatology, dermatology","rheumatoid arthritis, psoriasis","CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-A70083328-001-23-5::0.00061034::HTS002,BRD-A70083328-001-23-5,0.00061034,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::0.0024414::HTS002,BRD-A70083328-001-23-5,0.0024414,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::0.00976562::HTS002,BRD-A70083328-001-23-5,0.00976562,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::0.0390625::HTS002,BRD-A70083328-001-23-5,0.0390625,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::0.15625::HTS002,BRD-A70083328-001-23-5,0.15625,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::0.625::HTS002,BRD-A70083328-001-23-5,0.625,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::2.5::HTS002,BRD-A70083328-001-23-5,2.5,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70083328-001-23-5::10::HTS002,BRD-A70083328-001-23-5,10.0,HTS002,PREP017,secnidazole,"acetylcholinesterase inhibitor, microtubule inhibitor",NA,infectious disease,protozoan infection,"CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O",Launched
BRD-A70649075-008-30-8::0.00061034::HTS002,BRD-A70649075-008-30-8,0.00061034,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::0.0024414::HTS002,BRD-A70649075-008-30-8,0.0024414,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::0.00976562::HTS002,BRD-A70649075-008-30-8,0.00976562,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::0.0390625::HTS002,BRD-A70649075-008-30-8,0.0390625,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::0.15625::HTS002,BRD-A70649075-008-30-8,0.15625,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::0.625::HTS002,BRD-A70649075-008-30-8,0.625,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::2.5::HTS002,BRD-A70649075-008-30-8,2.5,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70649075-008-30-8::10::HTS002,BRD-A70649075-008-30-8,10.0,HTS002,PREP017,sulconazole,sterol demethylase inhibitor,NA,infectious disease,"tinea pedis, tinea cruris, tinea corporis","Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-A70858459-001-01-7::0.00061034::HTS002,BRD-A70858459-001-01-7,0.00061034,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.0024414::HTS002,BRD-A70858459-001-01-7,0.0024414,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.00976562::HTS002,BRD-A70858459-001-01-7,0.00976562,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.0390625::HTS002,BRD-A70858459-001-01-7,0.0390625,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.15625::HTS002,BRD-A70858459-001-01-7,0.15625,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::0.625::HTS002,BRD-A70858459-001-01-7,0.625,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::2.5::HTS002,BRD-A70858459-001-01-7,2.5,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A70858459-001-01-7::10::HTS002,BRD-A70858459-001-01-7,10.0,HTS002,PREP015,estramustine,DNA alkylating agent,"ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O,Launched
BRD-A71033472-003-23-9::0.00061034::HTS002,BRD-A71033472-003-23-9,0.00061034,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::0.0024414::HTS002,BRD-A71033472-003-23-9,0.0024414,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::0.00976562::HTS002,BRD-A71033472-003-23-9,0.00976562,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::0.0390625::HTS002,BRD-A71033472-003-23-9,0.0390625,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::0.15625::HTS002,BRD-A71033472-003-23-9,0.15625,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::0.625::HTS002,BRD-A71033472-003-23-9,0.625,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::2.5::HTS002,BRD-A71033472-003-23-9,2.5,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71033472-003-23-9::10::HTS002,BRD-A71033472-003-23-9,10.0,HTS002,PREP036,fendiline,calcium channel blocker,HTR2B,NA,NA,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,Preclinical
BRD-A71725768-001-01-3::0.000610352::HTS002,BRD-A71725768-001-01-3,0.000610352,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::0.00244141::HTS002,BRD-A71725768-001-01-3,0.00244141,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::0.00976562::HTS002,BRD-A71725768-001-01-3,0.00976562,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::0.0390625::HTS002,BRD-A71725768-001-01-3,0.0390625,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::0.15625::HTS002,BRD-A71725768-001-01-3,0.15625,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::0.625::HTS002,BRD-A71725768-001-01-3,0.625,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::2.5::HTS002,BRD-A71725768-001-01-3,2.5,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A71725768-001-01-3::10::HTS002,BRD-A71725768-001-01-3,10.0,HTS002,PREP014,metoxibutropate,cyclooxygenase inhibitor,"PTGS1, PTGS2",NA,NA,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,Launched
BRD-A72703248-003-04-9::0.00061034::HTS002,BRD-A72703248-003-04-9,0.00061034,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::0.0024414::HTS002,BRD-A72703248-003-04-9,0.0024414,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::0.00976562::HTS002,BRD-A72703248-003-04-9,0.00976562,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::0.0390625::HTS002,BRD-A72703248-003-04-9,0.0390625,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::0.15625::HTS002,BRD-A72703248-003-04-9,0.15625,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::0.625::HTS002,BRD-A72703248-003-04-9,0.625,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::2.5::HTS002,BRD-A72703248-003-04-9,2.5,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72703248-003-04-9::10::HTS002,BRD-A72703248-003-04-9,10.0,HTS002,PREP024,SKF-96365,calcium channel blocker,"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2",NA,NA,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,Preclinical
BRD-A72711497-236-03-8::0.00061034::HTS002,BRD-A72711497-236-03-8,0.00061034,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::0.0024414::HTS002,BRD-A72711497-236-03-8,0.0024414,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::0.00976562::HTS002,BRD-A72711497-236-03-8,0.00976562,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::0.0390625::HTS002,BRD-A72711497-236-03-8,0.0390625,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::0.15625::HTS002,BRD-A72711497-236-03-8,0.15625,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::0.625::HTS002,BRD-A72711497-236-03-8,0.625,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::2.5::HTS002,BRD-A72711497-236-03-8,2.5,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72711497-236-03-8::10::HTS002,BRD-A72711497-236-03-8,10.0,HTS002,PREP016,lasalocid,bacterial permeability inducer,NA,infectious disease,coccidiosis,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,Launched
BRD-A72716251-001-01-5::0.000222486::HTS002,BRD-A72716251-001-01-5,0.000222486,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::0.000889944::HTS002,BRD-A72716251-001-01-5,0.000889944,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::0.00355978::HTS002,BRD-A72716251-001-01-5,0.00355978,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::0.0142391::HTS002,BRD-A72716251-001-01-5,0.0142391,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::0.0569564::HTS002,BRD-A72716251-001-01-5,0.0569564,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::0.227826::HTS002,BRD-A72716251-001-01-5,0.227826,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::0.911303::HTS002,BRD-A72716251-001-01-5,0.911303,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A72716251-001-01-5::3.64521::HTS002,BRD-A72716251-001-01-5,3.64521,HTS002,PREP026,peruvoside,cardiac glycoside,NA,NA,NA,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,Phase 1
BRD-A73427433-240-01-3::0.000610352::HTS002,BRD-A73427433-240-01-3,0.000610352,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::0.00244141::HTS002,BRD-A73427433-240-01-3,0.00244141,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::0.00976562::HTS002,BRD-A73427433-240-01-3,0.00976562,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::0.0390625::HTS002,BRD-A73427433-240-01-3,0.0390625,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::0.15625::HTS002,BRD-A73427433-240-01-3,0.15625,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::0.625::HTS002,BRD-A73427433-240-01-3,0.625,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::2.5::HTS002,BRD-A73427433-240-01-3,2.5,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73427433-240-01-3::10::HTS002,BRD-A73427433-240-01-3,10.0,HTS002,PREP032,adaprev,TGF beta receptor inhibitor,"IGF2R, M6PR",NA,NA,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,Phase 3
BRD-A73556557-001-06-4::0.000610352::HTS002,BRD-A73556557-001-06-4,0.000610352,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::0.00244141::HTS002,BRD-A73556557-001-06-4,0.00244141,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::0.00976562::HTS002,BRD-A73556557-001-06-4,0.00976562,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::0.0390625::HTS002,BRD-A73556557-001-06-4,0.0390625,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::0.15625::HTS002,BRD-A73556557-001-06-4,0.15625,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::0.625::HTS002,BRD-A73556557-001-06-4,0.625,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::2.5::HTS002,BRD-A73556557-001-06-4,2.5,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-A73556557-001-06-4::10::HTS002,BRD-A73556557-001-06-4,10.0,HTS002,PREP039,tagatose,phosphorylase inhibitor,PYGL,NA,NA,"OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OCC(O)C(O)C(O)C(=O)CO, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO",Phase 3
BRD-K33425534-001-12-5::0.00061034::HTS002,BRD-K33425534-001-12-5,0.00061034,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::0.0024414::HTS002,BRD-K33425534-001-12-5,0.0024414,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::0.00976562::HTS002,BRD-K33425534-001-12-5,0.00976562,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::0.0390625::HTS002,BRD-K33425534-001-12-5,0.0390625,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::0.15625::HTS002,BRD-K33425534-001-12-5,0.15625,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::0.625::HTS002,BRD-K33425534-001-12-5,0.625,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::2.5::HTS002,BRD-K33425534-001-12-5,2.5,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-K33425534-001-12-5::10::HTS002,BRD-K33425534-001-12-5,10.0,HTS002,PREP023,exemestane,aromatase inhibitor,CYP19A1,oncology,breast cancer,"C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O",Launched
BRD-A74208568-003-01-5::0.00061034::HTS002,BRD-A74208568-003-01-5,0.00061034,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::0.0024414::HTS002,BRD-A74208568-003-01-5,0.0024414,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::0.00976562::HTS002,BRD-A74208568-003-01-5,0.00976562,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::0.0390625::HTS002,BRD-A74208568-003-01-5,0.0390625,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::0.15625::HTS002,BRD-A74208568-003-01-5,0.15625,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::0.625::HTS002,BRD-A74208568-003-01-5,0.625,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::2.5::HTS002,BRD-A74208568-003-01-5,2.5,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74208568-003-01-5::10::HTS002,BRD-A74208568-003-01-5,10.0,HTS002,PREP025,CGP-54626,GABA receptor antagonist,"GABBR1, GABBR2, KCTD12, KCTD16, KCTD8",NA,NA,"C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1",Preclinical
BRD-A74391928-051-01-3::0.00061034::HTS002,BRD-A74391928-051-01-3,0.00061034,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::0.0024414::HTS002,BRD-A74391928-051-01-3,0.0024414,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::0.00976562::HTS002,BRD-A74391928-051-01-3,0.00976562,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::0.0390625::HTS002,BRD-A74391928-051-01-3,0.0390625,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::0.15625::HTS002,BRD-A74391928-051-01-3,0.15625,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::0.625::HTS002,BRD-A74391928-051-01-3,0.625,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::2.5::HTS002,BRD-A74391928-051-01-3,2.5,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74391928-051-01-3::10::HTS002,BRD-A74391928-051-01-3,10.0,HTS002,PREP028,ibutilide,potassium channel blocker,"CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6",cardiology,atrial fibrillation (AF),"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1",Launched
BRD-A74765037-001-01-1::0.00061034::HTS002,BRD-A74765037-001-01-1,0.00061034,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::0.0024414::HTS002,BRD-A74765037-001-01-1,0.0024414,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::0.00976562::HTS002,BRD-A74765037-001-01-1,0.00976562,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::0.0390625::HTS002,BRD-A74765037-001-01-1,0.0390625,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::0.15625::HTS002,BRD-A74765037-001-01-1,0.15625,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::0.625::HTS002,BRD-A74765037-001-01-1,0.625,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::2.5::HTS002,BRD-A74765037-001-01-1,2.5,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74765037-001-01-1::10::HTS002,BRD-A74765037-001-01-1,10.0,HTS002,PREP015,estradiol-benzoate,contraceptive agent,ESR1,NA,NA,C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O,Preclinical
BRD-A74914197-001-02-9::0.00061034::HTS002,BRD-A74914197-001-02-9,0.00061034,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.0024414::HTS002,BRD-A74914197-001-02-9,0.0024414,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.00976562::HTS002,BRD-A74914197-001-02-9,0.00976562,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.0390625::HTS002,BRD-A74914197-001-02-9,0.0390625,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.15625::HTS002,BRD-A74914197-001-02-9,0.15625,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::0.625::HTS002,BRD-A74914197-001-02-9,0.625,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::2.5::HTS002,BRD-A74914197-001-02-9,2.5,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-A74914197-001-02-9::10::HTS002,BRD-A74914197-001-02-9,10.0,HTS002,PREP015,pralatrexate,dihydrofolate reductase inhibitor,"DHFR, TYMS",hematologic malignancy,peripheral T-cell lymphoma (PTCL),Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1,Launched
BRD-K93568044-001-32-0::0.00061034::HTS002,BRD-K93568044-001-32-0,0.00061034,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::0.0024414::HTS002,BRD-K93568044-001-32-0,0.0024414,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::0.00976562::HTS002,BRD-K93568044-001-32-0,0.00976562,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::0.0390625::HTS002,BRD-K93568044-001-32-0,0.0390625,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::0.15625::HTS002,BRD-K93568044-001-32-0,0.15625,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::0.625::HTS002,BRD-K93568044-001-32-0,0.625,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::2.5::HTS002,BRD-K93568044-001-32-0,2.5,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-K93568044-001-32-0::10::HTS002,BRD-K93568044-001-32-0,10.0,HTS002,PREP023,hydrocortisone,glucocorticoid receptor agonist,NA,"dermatology, neurology/psychiatry","eczema, psoriasis, seborrheic dermatitis, itching","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO",Launched
BRD-A75726477-003-21-3::0.00061034::HTS002,BRD-A75726477-003-21-3,0.00061034,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::0.0024414::HTS002,BRD-A75726477-003-21-3,0.0024414,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::0.00976562::HTS002,BRD-A75726477-003-21-3,0.00976562,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::0.0390625::HTS002,BRD-A75726477-003-21-3,0.0390625,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::0.15625::HTS002,BRD-A75726477-003-21-3,0.15625,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::0.625::HTS002,BRD-A75726477-003-21-3,0.625,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::2.5::HTS002,BRD-A75726477-003-21-3,2.5,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75726477-003-21-3::10::HTS002,BRD-A75726477-003-21-3,10.0,HTS002,PREP029,clenbuterol,adrenergic receptor agonist,"ADRB1, ADRB2, ADRB3, NGF, TNF",pulmonary,"chronic obstructive pulmonary disease (COPD), asthma",CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,Launched
BRD-A75850590-213-01-0::0.00061034::HTS002,BRD-A75850590-213-01-0,0.00061034,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::0.0024414::HTS002,BRD-A75850590-213-01-0,0.0024414,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::0.00976562::HTS002,BRD-A75850590-213-01-0,0.00976562,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::0.0390625::HTS002,BRD-A75850590-213-01-0,0.0390625,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::0.15625::HTS002,BRD-A75850590-213-01-0,0.15625,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::0.625::HTS002,BRD-A75850590-213-01-0,0.625,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::2.5::HTS002,BRD-A75850590-213-01-0,2.5,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75850590-213-01-0::10::HTS002,BRD-A75850590-213-01-0,10.0,HTS002,PREP025,lomefloxacin,bacterial DNA gyrase inhibitor,TOP2A,infectious disease,"respiratory tract infections, urinary tract infections","CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12",Launched
BRD-A75919782-399-02-6::0.00061034::HTS002,BRD-A75919782-399-02-6,0.00061034,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::0.0024414::HTS002,BRD-A75919782-399-02-6,0.0024414,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::0.00976562::HTS002,BRD-A75919782-399-02-6,0.00976562,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::0.0390625::HTS002,BRD-A75919782-399-02-6,0.0390625,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::0.15625::HTS002,BRD-A75919782-399-02-6,0.15625,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::0.625::HTS002,BRD-A75919782-399-02-6,0.625,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::2.5::HTS002,BRD-A75919782-399-02-6,2.5,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-A75919782-399-02-6::10::HTS002,BRD-A75919782-399-02-6,10.0,HTS002,PREP020,leucovorin,folate receptor ligand,TYMS,oncology,osteosarcoma,"Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",Launched
BRD-K08542803-001-03-1::0.000194147::HTS002,BRD-K08542803-001-03-1,0.000194147,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::0.000776589::HTS002,BRD-K08542803-001-03-1,0.000776589,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::0.00310636::HTS002,BRD-K08542803-001-03-1,0.00310636,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::0.0124254::HTS002,BRD-K08542803-001-03-1,0.0124254,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::0.0497017::HTS002,BRD-K08542803-001-03-1,0.0497017,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::0.198807::HTS002,BRD-K08542803-001-03-1,0.198807,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::0.795227::HTS002,BRD-K08542803-001-03-1,0.795227,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K08542803-001-03-1::3.18091::HTS002,BRD-K08542803-001-03-1,3.18091,HTS002,PREP018,gambogic-acid,caspase activator,BCL2,NA,NA,"CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C",Phase 2
BRD-K32007074-001-02-9::0.000772399::HTS002,BRD-K32007074-001-02-9,0.000772399,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::0.0030896::HTS002,BRD-K32007074-001-02-9,0.0030896,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::0.0123584::HTS002,BRD-K32007074-001-02-9,0.0123584,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::0.0494335::HTS002,BRD-K32007074-001-02-9,0.0494335,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::0.197734::HTS002,BRD-K32007074-001-02-9,0.197734,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::0.790937::HTS002,BRD-K32007074-001-02-9,0.790937,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::3.16375::HTS002,BRD-K32007074-001-02-9,3.16375,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K32007074-001-02-9::12.655::HTS002,BRD-K32007074-001-02-9,12.655,HTS002,PREP035,enocitabine,DNA synthesis inhibitor,"CMPK1, RRM1, TYMS",NA,NA,"CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1",Launched
BRD-K94353609-001-21-6::0.00061034::HTS002,BRD-K94353609-001-21-6,0.00061034,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::0.0024414::HTS002,BRD-K94353609-001-21-6,0.0024414,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::0.00976562::HTS002,BRD-K94353609-001-21-6,0.00976562,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::0.0390625::HTS002,BRD-K94353609-001-21-6,0.0390625,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::0.15625::HTS002,BRD-K94353609-001-21-6,0.15625,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::0.625::HTS002,BRD-K94353609-001-21-6,0.625,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::2.5::HTS002,BRD-K94353609-001-21-6,2.5,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K94353609-001-21-6::10::HTS002,BRD-K94353609-001-21-6,10.0,HTS002,PREP031,fluocinolone-acetonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,seborrheic dermatitis,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K40530731-001-11-6::0.00061034::HTS002,BRD-K40530731-001-11-6,0.00061034,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::0.0024414::HTS002,BRD-K40530731-001-11-6,0.0024414,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::0.00976562::HTS002,BRD-K40530731-001-11-6,0.00976562,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::0.0390625::HTS002,BRD-K40530731-001-11-6,0.0390625,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::0.15625::HTS002,BRD-K40530731-001-11-6,0.15625,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::0.625::HTS002,BRD-K40530731-001-11-6,0.625,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::2.5::HTS002,BRD-K40530731-001-11-6,2.5,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-K40530731-001-11-6::10::HTS002,BRD-K40530731-001-11-6,10.0,HTS002,PREP039,hyoscyamine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4","gastroenterology, urology, neurology/psychiatry, allergy","peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1",Launched
BRD-A78391468-001-02-8::0.00061034::HTS002,BRD-A78391468-001-02-8,0.00061034,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::0.0024414::HTS002,BRD-A78391468-001-02-8,0.0024414,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::0.00976562::HTS002,BRD-A78391468-001-02-8,0.00976562,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::0.0390625::HTS002,BRD-A78391468-001-02-8,0.0390625,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::0.15625::HTS002,BRD-A78391468-001-02-8,0.15625,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::0.625::HTS002,BRD-A78391468-001-02-8,0.625,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::2.5::HTS002,BRD-A78391468-001-02-8,2.5,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-A78391468-001-02-8::10::HTS002,BRD-A78391468-001-02-8,10.0,HTS002,PREP032,prednisolone-hemisuccinate,glucocorticoid receptor agonist,NR3C1,NA,NA,C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O,Preclinical
BRD-K50866992-003-10-3::0.00061034::HTS002,BRD-K50866992-003-10-3,0.00061034,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::0.0024414::HTS002,BRD-K50866992-003-10-3,0.0024414,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::0.00976562::HTS002,BRD-K50866992-003-10-3,0.00976562,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::0.0390625::HTS002,BRD-K50866992-003-10-3,0.0390625,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::0.15625::HTS002,BRD-K50866992-003-10-3,0.15625,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::0.625::HTS002,BRD-K50866992-003-10-3,0.625,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::2.5::HTS002,BRD-K50866992-003-10-3,2.5,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-K50866992-003-10-3::10::HTS002,BRD-K50866992-003-10-3,10.0,HTS002,PREP029,tropisetron,serotonin receptor antagonist,"GLRA1, GLRA2, GLRB, HTR3A, HTR4",gastroenterology,"nausea, vomiting, nausea, vomiting","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12",Launched
BRD-A79981887-003-16-4::0.00061034::HTS002,BRD-A79981887-003-16-4,0.00061034,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::0.0024414::HTS002,BRD-A79981887-003-16-4,0.0024414,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::0.00976562::HTS002,BRD-A79981887-003-16-4,0.00976562,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::0.0390625::HTS002,BRD-A79981887-003-16-4,0.0390625,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::0.15625::HTS002,BRD-A79981887-003-16-4,0.15625,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::0.625::HTS002,BRD-A79981887-003-16-4,0.625,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::2.5::HTS002,BRD-A79981887-003-16-4,2.5,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A79981887-003-16-4::10::HTS002,BRD-A79981887-003-16-4,10.0,HTS002,PREP029,midodrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D",cardiology,hypotension,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,Launched
BRD-A80017228-001-25-7::0.00061034::HTS002,BRD-A80017228-001-25-7,0.00061034,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::0.0024414::HTS002,BRD-A80017228-001-25-7,0.0024414,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::0.00976562::HTS002,BRD-A80017228-001-25-7,0.00976562,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::0.0390625::HTS002,BRD-A80017228-001-25-7,0.0390625,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::0.15625::HTS002,BRD-A80017228-001-25-7,0.15625,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::0.625::HTS002,BRD-A80017228-001-25-7,0.625,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::2.5::HTS002,BRD-A80017228-001-25-7,2.5,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80017228-001-25-7::10::HTS002,BRD-A80017228-001-25-7,10.0,HTS002,PREP029,bendroflumethiazide,sodium/potassium/chloride transporter inhibitor,"CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3",cardiology,hypertension,"NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F",Launched
BRD-A80213327-305-08-3::0.00061034::HTS002,BRD-A80213327-305-08-3,0.00061034,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::0.0024414::HTS002,BRD-A80213327-305-08-3,0.0024414,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::0.00976562::HTS002,BRD-A80213327-305-08-3,0.00976562,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::0.0390625::HTS002,BRD-A80213327-305-08-3,0.0390625,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::0.15625::HTS002,BRD-A80213327-305-08-3,0.15625,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::0.625::HTS002,BRD-A80213327-305-08-3,0.625,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::2.5::HTS002,BRD-A80213327-305-08-3,2.5,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A80213327-305-08-3::10::HTS002,BRD-A80213327-305-08-3,10.0,HTS002,PREP037,NSC-23766,Ras GTPase inhibitor,NA,NA,NA,"CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1",Preclinical
BRD-A81129465-001-03-8::0.00061034::HTS002,BRD-A81129465-001-03-8,0.00061034,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::0.0024414::HTS002,BRD-A81129465-001-03-8,0.0024414,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::0.00976562::HTS002,BRD-A81129465-001-03-8,0.00976562,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::0.0390625::HTS002,BRD-A81129465-001-03-8,0.0390625,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::0.15625::HTS002,BRD-A81129465-001-03-8,0.15625,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::0.625::HTS002,BRD-A81129465-001-03-8,0.625,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::2.5::HTS002,BRD-A81129465-001-03-8,2.5,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81129465-001-03-8::10::HTS002,BRD-A81129465-001-03-8,10.0,HTS002,PREP020,fenoprofen,prostaglandin inhibitor,"PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1",Launched
BRD-A81370665-001-03-6::0.00061034::HTS002,BRD-A81370665-001-03-6,0.00061034,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::0.0024414::HTS002,BRD-A81370665-001-03-6,0.0024414,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::0.00976562::HTS002,BRD-A81370665-001-03-6,0.00976562,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::0.0390625::HTS002,BRD-A81370665-001-03-6,0.0390625,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::0.15625::HTS002,BRD-A81370665-001-03-6,0.15625,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::0.625::HTS002,BRD-A81370665-001-03-6,0.625,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::2.5::HTS002,BRD-A81370665-001-03-6,2.5,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81370665-001-03-6::10::HTS002,BRD-A81370665-001-03-6,10.0,HTS002,PREP043,BI-D1870,ribosomal protein inhibitor,"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6",NA,NA,"CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12",Preclinical
BRD-A81513827-001-03-6::0.00061034::HTS002,BRD-A81513827-001-03-6,0.00061034,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::0.0024414::HTS002,BRD-A81513827-001-03-6,0.0024414,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::0.00976562::HTS002,BRD-A81513827-001-03-6,0.00976562,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::0.0390625::HTS002,BRD-A81513827-001-03-6,0.0390625,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::0.15625::HTS002,BRD-A81513827-001-03-6,0.15625,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::0.625::HTS002,BRD-A81513827-001-03-6,0.625,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::2.5::HTS002,BRD-A81513827-001-03-6,2.5,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A81513827-001-03-6::10::HTS002,BRD-A81513827-001-03-6,10.0,HTS002,PREP016,saxagliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2,Launched
BRD-A83650191-004-02-8::0.00061034::HTS002,BRD-A83650191-004-02-8,0.00061034,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::0.0024414::HTS002,BRD-A83650191-004-02-8,0.0024414,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::0.00976562::HTS002,BRD-A83650191-004-02-8,0.00976562,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::0.0390625::HTS002,BRD-A83650191-004-02-8,0.0390625,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::0.15625::HTS002,BRD-A83650191-004-02-8,0.15625,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::0.625::HTS002,BRD-A83650191-004-02-8,0.625,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::2.5::HTS002,BRD-A83650191-004-02-8,2.5,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83650191-004-02-8::10::HTS002,BRD-A83650191-004-02-8,10.0,HTS002,PREP042,A61603,adrenergic receptor agonist,ADRA1A,NA,NA,CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1,Preclinical
BRD-A83937277-001-10-5::0.00061034::HTS002,BRD-A83937277-001-10-5,0.00061034,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::0.0024414::HTS002,BRD-A83937277-001-10-5,0.0024414,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::0.00976562::HTS002,BRD-A83937277-001-10-5,0.00976562,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::0.0390625::HTS002,BRD-A83937277-001-10-5,0.0390625,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::0.15625::HTS002,BRD-A83937277-001-10-5,0.15625,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::0.625::HTS002,BRD-A83937277-001-10-5,0.625,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::2.5::HTS002,BRD-A83937277-001-10-5,2.5,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A83937277-001-10-5::10::HTS002,BRD-A83937277-001-10-5,10.0,HTS002,PREP020,mephenytoin,hydantoin antiepileptic,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,CCC1(NC(=O)N(C)C1=O)c1ccccc1,Launched
BRD-A84174393-236-07-1::0.00061034::HTS002,BRD-A84174393-236-07-1,0.00061034,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::0.0024414::HTS002,BRD-A84174393-236-07-1,0.0024414,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::0.00976562::HTS002,BRD-A84174393-236-07-1,0.00976562,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::0.0390625::HTS002,BRD-A84174393-236-07-1,0.0390625,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::0.15625::HTS002,BRD-A84174393-236-07-1,0.15625,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::0.625::HTS002,BRD-A84174393-236-07-1,0.625,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::2.5::HTS002,BRD-A84174393-236-07-1,2.5,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-A84174393-236-07-1::10::HTS002,BRD-A84174393-236-07-1,10.0,HTS002,PREP035,meloxicam,cyclooxygenase inhibitor,"PTGS1, PTGS2",rheumatology,"osteoarthritis, rheumatoid arthritis","CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O",Launched
BRD-K77841042-001-14-1::0.00061034::HTS002,BRD-K77841042-001-14-1,0.00061034,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::0.0024414::HTS002,BRD-K77841042-001-14-1,0.0024414,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::0.00976562::HTS002,BRD-K77841042-001-14-1,0.00976562,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::0.0390625::HTS002,BRD-K77841042-001-14-1,0.0390625,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::0.15625::HTS002,BRD-K77841042-001-14-1,0.15625,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::0.625::HTS002,BRD-K77841042-001-14-1,0.625,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::2.5::HTS002,BRD-K77841042-001-14-1,2.5,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K77841042-001-14-1::10::HTS002,BRD-K77841042-001-14-1,10.0,HTS002,PREP047,brefeldin-a,protein synthesis inhibitor,"ARF1, CYTH2",NA,NA,"C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1",Preclinical
BRD-K76634210-001-14-7::0.00061034::HTS002,BRD-K76634210-001-14-7,0.00061034,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::0.0024414::HTS002,BRD-K76634210-001-14-7,0.0024414,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::0.00976562::HTS002,BRD-K76634210-001-14-7,0.00976562,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::0.0390625::HTS002,BRD-K76634210-001-14-7,0.0390625,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::0.15625::HTS002,BRD-K76634210-001-14-7,0.15625,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::0.625::HTS002,BRD-K76634210-001-14-7,0.625,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::2.5::HTS002,BRD-K76634210-001-14-7,2.5,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-K76634210-001-14-7::10::HTS002,BRD-K76634210-001-14-7,10.0,HTS002,PREP035,idoxuridine,DNA directed DNA polymerase inhibitor,NA,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O",Launched
BRD-A85651701-001-19-7::0.00061034::HTS002,BRD-A85651701-001-19-7,0.00061034,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::0.0024414::HTS002,BRD-A85651701-001-19-7,0.0024414,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::0.00976562::HTS002,BRD-A85651701-001-19-7,0.00976562,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::0.0390625::HTS002,BRD-A85651701-001-19-7,0.0390625,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::0.15625::HTS002,BRD-A85651701-001-19-7,0.15625,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::0.625::HTS002,BRD-A85651701-001-19-7,0.625,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::2.5::HTS002,BRD-A85651701-001-19-7,2.5,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A85651701-001-19-7::10::HTS002,BRD-A85651701-001-19-7,10.0,HTS002,PREP034,clopamide,sodium/chloride cotransporter inhibitor,NA,cardiology,hypertension,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,Launched
BRD-A86248581-001-01-4::0.000610352::HTS002,BRD-A86248581-001-01-4,0.000610352,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::0.00244141::HTS002,BRD-A86248581-001-01-4,0.00244141,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::0.00976562::HTS002,BRD-A86248581-001-01-4,0.00976562,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::0.0390625::HTS002,BRD-A86248581-001-01-4,0.0390625,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::0.15625::HTS002,BRD-A86248581-001-01-4,0.15625,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::0.625::HTS002,BRD-A86248581-001-01-4,0.625,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::2.5::HTS002,BRD-A86248581-001-01-4,2.5,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A86248581-001-01-4::10::HTS002,BRD-A86248581-001-01-4,10.0,HTS002,PREP038,tetrahydrouridine,cytidine deaminase inhibitor,CDA,NA,NA,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O,Phase 2
BRD-A88138582-001-04-8::0.00061034::HTS002,BRD-A88138582-001-04-8,0.00061034,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::0.0024414::HTS002,BRD-A88138582-001-04-8,0.0024414,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::0.00976562::HTS002,BRD-A88138582-001-04-8,0.00976562,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::0.0390625::HTS002,BRD-A88138582-001-04-8,0.0390625,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::0.15625::HTS002,BRD-A88138582-001-04-8,0.15625,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::0.625::HTS002,BRD-A88138582-001-04-8,0.625,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::2.5::HTS002,BRD-A88138582-001-04-8,2.5,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A88138582-001-04-8::10::HTS002,BRD-A88138582-001-04-8,10.0,HTS002,PREP035,halcinonide,glucocorticoid receptor agonist,NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl",Launched
BRD-A90272038-001-01-7::0.000610352::HTS002,BRD-A90272038-001-01-7,0.000610352,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::0.00244141::HTS002,BRD-A90272038-001-01-7,0.00244141,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::0.00976562::HTS002,BRD-A90272038-001-01-7,0.00976562,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::0.0390625::HTS002,BRD-A90272038-001-01-7,0.0390625,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::0.15625::HTS002,BRD-A90272038-001-01-7,0.15625,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::0.625::HTS002,BRD-A90272038-001-01-7,0.625,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::2.5::HTS002,BRD-A90272038-001-01-7,2.5,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90272038-001-01-7::10::HTS002,BRD-A90272038-001-01-7,10.0,HTS002,PREP035,CGP-37849,glutamate receptor antagonist,"GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"C\C(CP(O)(O)=O)=C/C(N)C(O)=O, C\C(CP(O)(O)=O)=C/C(N)C(O)=O",Phase 1
BRD-A90547603-001-02-5::0.00061034::HTS002,BRD-A90547603-001-02-5,0.00061034,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::0.0024414::HTS002,BRD-A90547603-001-02-5,0.0024414,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::0.00976562::HTS002,BRD-A90547603-001-02-5,0.00976562,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::0.0390625::HTS002,BRD-A90547603-001-02-5,0.0390625,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::0.15625::HTS002,BRD-A90547603-001-02-5,0.15625,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::0.625::HTS002,BRD-A90547603-001-02-5,0.625,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::2.5::HTS002,BRD-A90547603-001-02-5,2.5,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A90547603-001-02-5::10::HTS002,BRD-A90547603-001-02-5,10.0,HTS002,PREP016,eptifibatide,platelet aggregation inhibitor,"ITGA2B, ITGB3",cardiology,"acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)",NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O,Launched
BRD-A91366704-001-01-9::0.00061034::HTS002,BRD-A91366704-001-01-9,0.00061034,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::0.0024414::HTS002,BRD-A91366704-001-01-9,0.0024414,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::0.00976562::HTS002,BRD-A91366704-001-01-9,0.00976562,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::0.0390625::HTS002,BRD-A91366704-001-01-9,0.0390625,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::0.15625::HTS002,BRD-A91366704-001-01-9,0.15625,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::0.625::HTS002,BRD-A91366704-001-01-9,0.625,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::2.5::HTS002,BRD-A91366704-001-01-9,2.5,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91366704-001-01-9::10::HTS002,BRD-A91366704-001-01-9,10.0,HTS002,PREP025,eprinomectin,benzodiazepine receptor agonist,NA,infectious disease,"gastrointestinal roundworms, lungworms",CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,Launched
BRD-A91452556-001-04-0::0.00061034::HTS002,BRD-A91452556-001-04-0,0.00061034,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::0.0024414::HTS002,BRD-A91452556-001-04-0,0.0024414,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::0.00976562::HTS002,BRD-A91452556-001-04-0,0.00976562,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::0.0390625::HTS002,BRD-A91452556-001-04-0,0.0390625,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::0.15625::HTS002,BRD-A91452556-001-04-0,0.15625,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::0.625::HTS002,BRD-A91452556-001-04-0,0.625,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::2.5::HTS002,BRD-A91452556-001-04-0,2.5,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91452556-001-04-0::10::HTS002,BRD-A91452556-001-04-0,10.0,HTS002,PREP017,estradiol-cypionate,estrogen receptor agonist,ESR1,endocrinology,"hypoestrogenism, menopause",C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1,Launched
BRD-A91733352-300-04-5::0.00061034::HTS002,BRD-A91733352-300-04-5,0.00061034,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::0.0024414::HTS002,BRD-A91733352-300-04-5,0.0024414,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::0.00976562::HTS002,BRD-A91733352-300-04-5,0.00976562,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::0.0390625::HTS002,BRD-A91733352-300-04-5,0.0390625,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::0.15625::HTS002,BRD-A91733352-300-04-5,0.15625,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::0.625::HTS002,BRD-A91733352-300-04-5,0.625,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::2.5::HTS002,BRD-A91733352-300-04-5,2.5,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91733352-300-04-5::10::HTS002,BRD-A91733352-300-04-5,10.0,HTS002,PREP016,camylofine-chlorhydrate,NA,NA,gastroenterology,abdominal pain,"CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1",Launched
BRD-A91831168-003-02-5::0.00061034::HTS002,BRD-A91831168-003-02-5,0.00061034,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::0.0024414::HTS002,BRD-A91831168-003-02-5,0.0024414,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::0.00976562::HTS002,BRD-A91831168-003-02-5,0.00976562,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::0.0390625::HTS002,BRD-A91831168-003-02-5,0.0390625,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::0.15625::HTS002,BRD-A91831168-003-02-5,0.15625,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::0.625::HTS002,BRD-A91831168-003-02-5,0.625,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::2.5::HTS002,BRD-A91831168-003-02-5,2.5,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-A91831168-003-02-5::10::HTS002,BRD-A91831168-003-02-5,10.0,HTS002,PREP037,tetrahydropapaverine,NA,NA,NA,NA,COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC,Preclinical
BRD-K61192372-001-08-9::0.00061034::HTS002,BRD-K61192372-001-08-9,0.00061034,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.0024414::HTS002,BRD-K61192372-001-08-9,0.0024414,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.00976562::HTS002,BRD-K61192372-001-08-9,0.00976562,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.0390625::HTS002,BRD-K61192372-001-08-9,0.0390625,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.15625::HTS002,BRD-K61192372-001-08-9,0.15625,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::0.625::HTS002,BRD-K61192372-001-08-9,0.625,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::2.5::HTS002,BRD-K61192372-001-08-9,2.5,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-K61192372-001-08-9::10::HTS002,BRD-K61192372-001-08-9,10.0,HTS002,PREP017,capecitabine,"DNA synthesis inhibitor, thymidylate synthase inhibitor",TYMS,oncology,"breast cancer, colorectal cancer","CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O",Launched
BRD-A92537424-001-04-7::0.00061034::HTS002,BRD-A92537424-001-04-7,0.00061034,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::0.0024414::HTS002,BRD-A92537424-001-04-7,0.0024414,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::0.00976562::HTS002,BRD-A92537424-001-04-7,0.00976562,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::0.0390625::HTS002,BRD-A92537424-001-04-7,0.0390625,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::0.15625::HTS002,BRD-A92537424-001-04-7,0.15625,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::0.625::HTS002,BRD-A92537424-001-04-7,0.625,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::2.5::HTS002,BRD-A92537424-001-04-7,2.5,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92537424-001-04-7::10::HTS002,BRD-A92537424-001-04-7,10.0,HTS002,PREP035,danazol,"estrogen receptor antagonist, progesterone receptor agonist","AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","obstetrics/gynecology, cardiology","endometriosis, angioedema",C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C#C,Launched
BRD-A92630576-050-24-1::0.00061034::HTS002,BRD-A92630576-050-24-1,0.00061034,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::0.0024414::HTS002,BRD-A92630576-050-24-1,0.0024414,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::0.00976562::HTS002,BRD-A92630576-050-24-1,0.00976562,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::0.0390625::HTS002,BRD-A92630576-050-24-1,0.0390625,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::0.15625::HTS002,BRD-A92630576-050-24-1,0.15625,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::0.625::HTS002,BRD-A92630576-050-24-1,0.625,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::2.5::HTS002,BRD-A92630576-050-24-1,2.5,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92630576-050-24-1::10::HTS002,BRD-A92630576-050-24-1,10.0,HTS002,PREP029,trimebutine,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",gastroenterology,irritable bowel syndrome,"CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1",Launched
BRD-A92872453-001-01-8::0.000610352::HTS002,BRD-A92872453-001-01-8,0.000610352,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::0.00244141::HTS002,BRD-A92872453-001-01-8,0.00244141,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::0.00976562::HTS002,BRD-A92872453-001-01-8,0.00976562,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::0.0390625::HTS002,BRD-A92872453-001-01-8,0.0390625,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::0.15625::HTS002,BRD-A92872453-001-01-8,0.15625,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::0.625::HTS002,BRD-A92872453-001-01-8,0.625,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::2.5::HTS002,BRD-A92872453-001-01-8,2.5,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A92872453-001-01-8::10::HTS002,BRD-A92872453-001-01-8,10.0,HTS002,PREP044,N-acetylmannosamine,NA,CHIT1,NA,NA,CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O,Phase 1
BRD-A93093700-001-02-9::0.00061034::HTS002,BRD-A93093700-001-02-9,0.00061034,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::0.0024414::HTS002,BRD-A93093700-001-02-9,0.0024414,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::0.00976562::HTS002,BRD-A93093700-001-02-9,0.00976562,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::0.0390625::HTS002,BRD-A93093700-001-02-9,0.0390625,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::0.15625::HTS002,BRD-A93093700-001-02-9,0.15625,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::0.625::HTS002,BRD-A93093700-001-02-9,0.625,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::2.5::HTS002,BRD-A93093700-001-02-9,2.5,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93093700-001-02-9::10::HTS002,BRD-A93093700-001-02-9,10.0,HTS002,PREP035,temazepam,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO",NA,NA,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,Withdrawn
BRD-A93236127-001-04-5::0.00061034::HTS002,BRD-A93236127-001-04-5,0.00061034,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::0.0024414::HTS002,BRD-A93236127-001-04-5,0.0024414,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::0.00976562::HTS002,BRD-A93236127-001-04-5,0.00976562,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::0.0390625::HTS002,BRD-A93236127-001-04-5,0.0390625,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::0.15625::HTS002,BRD-A93236127-001-04-5,0.15625,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::0.625::HTS002,BRD-A93236127-001-04-5,0.625,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::2.5::HTS002,BRD-A93236127-001-04-5,2.5,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A93236127-001-04-5::10::HTS002,BRD-A93236127-001-04-5,10.0,HTS002,PREP023,digitoxin,ATPase inhibitor,ATP1A1,NA,NA,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-K47635719-001-21-1::0.00061034::HTS002,BRD-K47635719-001-21-1,0.00061034,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::0.0024414::HTS002,BRD-K47635719-001-21-1,0.0024414,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::0.00976562::HTS002,BRD-K47635719-001-21-1,0.00976562,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::0.0390625::HTS002,BRD-K47635719-001-21-1,0.0390625,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::0.15625::HTS002,BRD-K47635719-001-21-1,0.15625,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::0.625::HTS002,BRD-K47635719-001-21-1,0.625,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::2.5::HTS002,BRD-K47635719-001-21-1,2.5,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-K47635719-001-21-1::10::HTS002,BRD-K47635719-001-21-1,10.0,HTS002,PREP022,dexamethasone-acetate,glucocorticoid receptor agonist,NA,"endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology","hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O",Launched
BRD-A93477898-001-04-2::0.00061034::HTS002,BRD-A93477898-001-04-2,0.00061034,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::0.0024414::HTS002,BRD-A93477898-001-04-2,0.0024414,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::0.00976562::HTS002,BRD-A93477898-001-04-2,0.00976562,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::0.0390625::HTS002,BRD-A93477898-001-04-2,0.0390625,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::0.15625::HTS002,BRD-A93477898-001-04-2,0.15625,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::0.625::HTS002,BRD-A93477898-001-04-2,0.625,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::2.5::HTS002,BRD-A93477898-001-04-2,2.5,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93477898-001-04-2::10::HTS002,BRD-A93477898-001-04-2,10.0,HTS002,PREP036,PETCM,caspase activator,CASP3,NA,NA,OC(Cc1ccncc1)C(Cl)(Cl)Cl,Preclinical
BRD-A93695607-322-02-5::0.000603198::HTS002,BRD-A93695607-322-02-5,0.000603198,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::0.00241279::HTS002,BRD-A93695607-322-02-5,0.00241279,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::0.00965117::HTS002,BRD-A93695607-322-02-5,0.00965117,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::0.0386047::HTS002,BRD-A93695607-322-02-5,0.0386047,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::0.154419::HTS002,BRD-A93695607-322-02-5,0.154419,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::0.617675::HTS002,BRD-A93695607-322-02-5,0.617675,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::2.4707::HTS002,BRD-A93695607-322-02-5,2.4707,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A93695607-322-02-5::9.8828::HTS002,BRD-A93695607-322-02-5,9.8828,HTS002,PREP028,nicotine,acetylcholine receptor agonist,"CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1",neurology/psychiatry,smoking cessation,"CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1",Launched
BRD-A94624445-236-17-0::0.00061034::HTS002,BRD-A94624445-236-17-0,0.00061034,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::0.0024414::HTS002,BRD-A94624445-236-17-0,0.0024414,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::0.00976562::HTS002,BRD-A94624445-236-17-0,0.00976562,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::0.0390625::HTS002,BRD-A94624445-236-17-0,0.0390625,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::0.15625::HTS002,BRD-A94624445-236-17-0,0.15625,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::0.625::HTS002,BRD-A94624445-236-17-0,0.625,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::2.5::HTS002,BRD-A94624445-236-17-0,2.5,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A94624445-236-17-0::10::HTS002,BRD-A94624445-236-17-0,10.0,HTS002,PREP025,bucladesine,"adenosine receptor agonist, cAMP stimulant",PRKACA,dermatology,skin ulcer,"CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC",Launched
BRD-A95121829-001-08-9::0.00061034::HTS002,BRD-A95121829-001-08-9,0.00061034,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::0.0024414::HTS002,BRD-A95121829-001-08-9,0.0024414,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::0.00976562::HTS002,BRD-A95121829-001-08-9,0.00976562,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::0.0390625::HTS002,BRD-A95121829-001-08-9,0.0390625,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::0.15625::HTS002,BRD-A95121829-001-08-9,0.15625,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::0.625::HTS002,BRD-A95121829-001-08-9,0.625,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::2.5::HTS002,BRD-A95121829-001-08-9,2.5,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A95121829-001-08-9::10::HTS002,BRD-A95121829-001-08-9,10.0,HTS002,PREP043,ginkgolide-a,GABA receptor antagonist,"GLRA1, GLRB",NA,NA,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O,Preclinical
BRD-A94756469-001-04-7::0.00061034::HTS002,BRD-A94756469-001-04-7,0.00061034,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::0.0024414::HTS002,BRD-A94756469-001-04-7,0.0024414,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::0.00976562::HTS002,BRD-A94756469-001-04-7,0.00976562,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::0.0390625::HTS002,BRD-A94756469-001-04-7,0.0390625,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::0.15625::HTS002,BRD-A94756469-001-04-7,0.15625,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::0.625::HTS002,BRD-A94756469-001-04-7,0.625,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::2.5::HTS002,BRD-A94756469-001-04-7,2.5,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A94756469-001-04-7::10::HTS002,BRD-A94756469-001-04-7,10.0,HTS002,PREP028,digoxin,ATPase inhibitor,ATP1A1,cardiology,"congestive heart failure, atrial fibrillation (AF)",C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,Launched
BRD-A95696066-003-13-8::0.00061034::HTS002,BRD-A95696066-003-13-8,0.00061034,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::0.0024414::HTS002,BRD-A95696066-003-13-8,0.0024414,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::0.00976562::HTS002,BRD-A95696066-003-13-8,0.00976562,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::0.0390625::HTS002,BRD-A95696066-003-13-8,0.0390625,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::0.15625::HTS002,BRD-A95696066-003-13-8,0.15625,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::0.625::HTS002,BRD-A95696066-003-13-8,0.625,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::2.5::HTS002,BRD-A95696066-003-13-8,2.5,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95696066-003-13-8::10::HTS002,BRD-A95696066-003-13-8,10.0,HTS002,PREP019,nisoxetine,norepinephrine reuptake inhibitor,"SLC6A2, SLC6A3, SLC6A4",NA,NA,CNCCC(Oc1ccccc1OC)c1ccccc1,Phase 1
BRD-A95886749-001-03-5::0.000610352::HTS002,BRD-A95886749-001-03-5,0.000610352,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::0.00244141::HTS002,BRD-A95886749-001-03-5,0.00244141,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::0.00976562::HTS002,BRD-A95886749-001-03-5,0.00976562,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::0.0390625::HTS002,BRD-A95886749-001-03-5,0.0390625,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::0.15625::HTS002,BRD-A95886749-001-03-5,0.15625,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::0.625::HTS002,BRD-A95886749-001-03-5,0.625,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::2.5::HTS002,BRD-A95886749-001-03-5,2.5,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-A95886749-001-03-5::10::HTS002,BRD-A95886749-001-03-5,10.0,HTS002,PREP035,colfosceril-palmitate,pulmonary surfactant,NA,pulmonary,respiratory distress syndrome (RDS),"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC",Launched
BRD-K69608737-001-10-2::0.00061034::HTS002,BRD-K69608737-001-10-2,0.00061034,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::0.0024414::HTS002,BRD-K69608737-001-10-2,0.0024414,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::0.00976562::HTS002,BRD-K69608737-001-10-2,0.00976562,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::0.0390625::HTS002,BRD-K69608737-001-10-2,0.0390625,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::0.15625::HTS002,BRD-K69608737-001-10-2,0.15625,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::0.625::HTS002,BRD-K69608737-001-10-2,0.625,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::2.5::HTS002,BRD-K69608737-001-10-2,2.5,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-K69608737-001-10-2::10::HTS002,BRD-K69608737-001-10-2,10.0,HTS002,PREP016,tacrolimus,calcineurin inhibitor,FKBP1A,transplant,organ rejection,"CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",Launched
BRD-A97701745-001-16-0::0.00061034::HTS002,BRD-A97701745-001-16-0,0.00061034,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::0.0024414::HTS002,BRD-A97701745-001-16-0,0.0024414,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::0.00976562::HTS002,BRD-A97701745-001-16-0,0.00976562,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::0.0390625::HTS002,BRD-A97701745-001-16-0,0.0390625,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::0.15625::HTS002,BRD-A97701745-001-16-0,0.15625,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::0.625::HTS002,BRD-A97701745-001-16-0,0.625,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::2.5::HTS002,BRD-A97701745-001-16-0,2.5,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97701745-001-16-0::10::HTS002,BRD-A97701745-001-16-0,10.0,HTS002,PREP029,pindolol,adrenergic receptor antagonist,"ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B",cardiology,hypertension,"CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12",Launched
BRD-A97739905-001-26-5::0.00061034::HTS002,BRD-A97739905-001-26-5,0.00061034,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::0.0024414::HTS002,BRD-A97739905-001-26-5,0.0024414,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::0.00976562::HTS002,BRD-A97739905-001-26-5,0.00976562,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::0.0390625::HTS002,BRD-A97739905-001-26-5,0.0390625,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::0.15625::HTS002,BRD-A97739905-001-26-5,0.15625,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::0.625::HTS002,BRD-A97739905-001-26-5,0.625,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::2.5::HTS002,BRD-A97739905-001-26-5,2.5,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A97739905-001-26-5::10::HTS002,BRD-A97739905-001-26-5,10.0,HTS002,PREP029,ketoprofen,cyclooxygenase inhibitor,"CXCR1, PTGS1, PTGS2, SLC5A8",rheumatology,"rheumatoid arthritis, osteoarthritis","CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1",Launched
BRD-A98299281-050-09-6::0.00061034::HTS002,BRD-A98299281-050-09-6,0.00061034,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::0.0024414::HTS002,BRD-A98299281-050-09-6,0.0024414,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::0.00976562::HTS002,BRD-A98299281-050-09-6,0.00976562,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::0.0390625::HTS002,BRD-A98299281-050-09-6,0.0390625,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::0.15625::HTS002,BRD-A98299281-050-09-6,0.15625,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::0.625::HTS002,BRD-A98299281-050-09-6,0.625,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::2.5::HTS002,BRD-A98299281-050-09-6,2.5,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A98299281-050-09-6::10::HTS002,BRD-A98299281-050-09-6,10.0,HTS002,PREP036,"hydroxytacrine-maleate-(r,s)",cholinesterase inhibitor,ACHE,NA,NA,Nc1c2C(O)CCCc2nc2ccccc12,Preclinical
BRD-A28301258-001-03-0::0.00061034::HTS002,BRD-A28301258-001-03-0,0.00061034,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::0.0024414::HTS002,BRD-A28301258-001-03-0,0.0024414,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::0.00976562::HTS002,BRD-A28301258-001-03-0,0.00976562,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::0.0390625::HTS002,BRD-A28301258-001-03-0,0.0390625,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::0.15625::HTS002,BRD-A28301258-001-03-0,0.15625,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::0.625::HTS002,BRD-A28301258-001-03-0,0.625,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::2.5::HTS002,BRD-A28301258-001-03-0,2.5,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A28301258-001-03-0::10::HTS002,BRD-A28301258-001-03-0,10.0,HTS002,PREP029,salinomycin,NA,NA,infectious disease,coccidiosis,"CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H](C1CC[C@H](C)C(O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)C1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O",Launched
BRD-A98990573-003-01-3::0.00061034::HTS002,BRD-A98990573-003-01-3,0.00061034,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::0.0024414::HTS002,BRD-A98990573-003-01-3,0.0024414,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::0.00976562::HTS002,BRD-A98990573-003-01-3,0.00976562,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::0.0390625::HTS002,BRD-A98990573-003-01-3,0.0390625,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::0.15625::HTS002,BRD-A98990573-003-01-3,0.15625,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::0.625::HTS002,BRD-A98990573-003-01-3,0.625,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::2.5::HTS002,BRD-A98990573-003-01-3,2.5,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A98990573-003-01-3::10::HTS002,BRD-A98990573-003-01-3,10.0,HTS002,PREP014,epinastine,histamine receptor antagonist,"ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7",ophthalmology,conjunctivitis,NC1=NCC2N1c1ccccc1Cc1ccccc21,Launched
BRD-A99888680-001-03-8::0.000580986::HTS002,BRD-A99888680-001-03-8,0.000580986,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::0.00232395::HTS002,BRD-A99888680-001-03-8,0.00232395,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::0.00929578::HTS002,BRD-A99888680-001-03-8,0.00929578,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::0.0371831::HTS002,BRD-A99888680-001-03-8,0.0371831,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::0.148732::HTS002,BRD-A99888680-001-03-8,0.148732,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::0.59493::HTS002,BRD-A99888680-001-03-8,0.59493,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::2.37972::HTS002,BRD-A99888680-001-03-8,2.37972,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-A99888680-001-03-8::9.51888::HTS002,BRD-A99888680-001-03-8,9.51888,HTS002,PREP030,paliperidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C",neurology/psychiatry,schizophrenia,"Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12",Launched
BRD-K00077635-304-01-2::0.00061034::HTS002,BRD-K00077635-304-01-2,0.00061034,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::0.0024414::HTS002,BRD-K00077635-304-01-2,0.0024414,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::0.00976562::HTS002,BRD-K00077635-304-01-2,0.00976562,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::0.0390625::HTS002,BRD-K00077635-304-01-2,0.0390625,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::0.15625::HTS002,BRD-K00077635-304-01-2,0.15625,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::0.625::HTS002,BRD-K00077635-304-01-2,0.625,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::2.5::HTS002,BRD-K00077635-304-01-2,2.5,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K00077635-304-01-2::10::HTS002,BRD-K00077635-304-01-2,10.0,HTS002,PREP014,estramustine-phosphate,"DNA synthesis inhibitor, microtubule inhibitor","ESR1, ESR2, MAP1A, MAP2",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O,Launched
BRD-K50071428-001-03-3::0.00061034::HTS002,BRD-K50071428-001-03-3,0.00061034,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::0.0024414::HTS002,BRD-K50071428-001-03-3,0.0024414,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::0.00976562::HTS002,BRD-K50071428-001-03-3,0.00976562,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::0.0390625::HTS002,BRD-K50071428-001-03-3,0.0390625,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::0.15625::HTS002,BRD-K50071428-001-03-3,0.15625,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::0.625::HTS002,BRD-K50071428-001-03-3,0.625,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::2.5::HTS002,BRD-K50071428-001-03-3,2.5,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K50071428-001-03-3::10::HTS002,BRD-K50071428-001-03-3,10.0,HTS002,PREP031,abiraterone,androgen biosynthesis inhibitor,"CYP11B1, CYP17A1",oncology,prostate cancer,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1,Launched
BRD-K00152668-001-01-5::0.00061034::HTS002,BRD-K00152668-001-01-5,0.00061034,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::0.0024414::HTS002,BRD-K00152668-001-01-5,0.0024414,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::0.00976562::HTS002,BRD-K00152668-001-01-5,0.00976562,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::0.0390625::HTS002,BRD-K00152668-001-01-5,0.0390625,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::0.15625::HTS002,BRD-K00152668-001-01-5,0.15625,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::0.625::HTS002,BRD-K00152668-001-01-5,0.625,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::2.5::HTS002,BRD-K00152668-001-01-5,2.5,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00152668-001-01-5::10::HTS002,BRD-K00152668-001-01-5,10.0,HTS002,PREP026,adarotene,retinoid receptor agonist,"RARB, RARG",NA,NA,OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,Phase 1
BRD-K00259736-001-16-4::0.00061034::HTS002,BRD-K00259736-001-16-4,0.00061034,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::0.0024414::HTS002,BRD-K00259736-001-16-4,0.0024414,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::0.00976562::HTS002,BRD-K00259736-001-16-4,0.00976562,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::0.0390625::HTS002,BRD-K00259736-001-16-4,0.0390625,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::0.15625::HTS002,BRD-K00259736-001-16-4,0.15625,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::0.625::HTS002,BRD-K00259736-001-16-4,0.625,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::2.5::HTS002,BRD-K00259736-001-16-4,2.5,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00259736-001-16-4::10::HTS002,BRD-K00259736-001-16-4,10.0,HTS002,PREP020,colchicine,microtubule inhibitor,"GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8","rheumatology, endocrinology","gout, fever","COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC",Launched
BRD-K00312224-001-09-5::0.00061034::HTS002,BRD-K00312224-001-09-5,0.00061034,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::0.0024414::HTS002,BRD-K00312224-001-09-5,0.0024414,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::0.00976562::HTS002,BRD-K00312224-001-09-5,0.00976562,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::0.0390625::HTS002,BRD-K00312224-001-09-5,0.0390625,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::0.15625::HTS002,BRD-K00312224-001-09-5,0.15625,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::0.625::HTS002,BRD-K00312224-001-09-5,0.625,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::2.5::HTS002,BRD-K00312224-001-09-5,2.5,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00312224-001-09-5::10::HTS002,BRD-K00312224-001-09-5,10.0,HTS002,PREP041,PPT,estrogen receptor agonist,ESR1,NA,NA,"CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",Preclinical
BRD-K00317371-001-06-1::0.000587001::HTS002,BRD-K00317371-001-06-1,0.000587001,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::0.002348::HTS002,BRD-K00317371-001-06-1,0.002348,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::0.00939201::HTS002,BRD-K00317371-001-06-1,0.00939201,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::0.037568::HTS002,BRD-K00317371-001-06-1,0.037568,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::0.150272::HTS002,BRD-K00317371-001-06-1,0.150272,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::0.601089::HTS002,BRD-K00317371-001-06-1,0.601089,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::2.40436::HTS002,BRD-K00317371-001-06-1,2.40436,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00317371-001-06-1::9.61742::HTS002,BRD-K00317371-001-06-1,9.61742,HTS002,PREP015,RITA,MDM inhibitor,MDM2,NA,NA,"OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",Preclinical
BRD-K00494077-066-01-9::0.00061034::HTS002,BRD-K00494077-066-01-9,0.00061034,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::0.0024414::HTS002,BRD-K00494077-066-01-9,0.0024414,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::0.00976562::HTS002,BRD-K00494077-066-01-9,0.00976562,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::0.0390625::HTS002,BRD-K00494077-066-01-9,0.0390625,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::0.15625::HTS002,BRD-K00494077-066-01-9,0.15625,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::0.625::HTS002,BRD-K00494077-066-01-9,0.625,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::2.5::HTS002,BRD-K00494077-066-01-9,2.5,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00494077-066-01-9::10::HTS002,BRD-K00494077-066-01-9,10.0,HTS002,PREP028,trovafloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",Withdrawn
BRD-K00535541-001-06-3::0.000610352::HTS002,BRD-K00535541-001-06-3,0.000610352,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::0.00244141::HTS002,BRD-K00535541-001-06-3,0.00244141,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::0.00976562::HTS002,BRD-K00535541-001-06-3,0.00976562,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::0.0390625::HTS002,BRD-K00535541-001-06-3,0.0390625,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::0.15625::HTS002,BRD-K00535541-001-06-3,0.15625,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::0.625::HTS002,BRD-K00535541-001-06-3,0.625,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::2.5::HTS002,BRD-K00535541-001-06-3,2.5,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00535541-001-06-3::10::HTS002,BRD-K00535541-001-06-3,10.0,HTS002,PREP014,9-aminoacridine,NA,NA,NA,NA,"Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",Preclinical
BRD-K00615600-001-12-9::0.00061034::HTS002,BRD-K00615600-001-12-9,0.00061034,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::0.0024414::HTS002,BRD-K00615600-001-12-9,0.0024414,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::0.00976562::HTS002,BRD-K00615600-001-12-9,0.00976562,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::0.0390625::HTS002,BRD-K00615600-001-12-9,0.0390625,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::0.15625::HTS002,BRD-K00615600-001-12-9,0.15625,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::0.625::HTS002,BRD-K00615600-001-12-9,0.625,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::2.5::HTS002,BRD-K00615600-001-12-9,2.5,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00615600-001-12-9::10::HTS002,BRD-K00615600-001-12-9,10.0,HTS002,PREP014,AG-14361,PARP inhibitor,PARP1,NA,NA,"CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",Preclinical
BRD-K00662280-001-09-4::0.00061034::HTS002,BRD-K00662280-001-09-4,0.00061034,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::0.0024414::HTS002,BRD-K00662280-001-09-4,0.0024414,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::0.00976562::HTS002,BRD-K00662280-001-09-4,0.00976562,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::0.0390625::HTS002,BRD-K00662280-001-09-4,0.0390625,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::0.15625::HTS002,BRD-K00662280-001-09-4,0.15625,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::0.625::HTS002,BRD-K00662280-001-09-4,0.625,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::2.5::HTS002,BRD-K00662280-001-09-4,2.5,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00662280-001-09-4::10::HTS002,BRD-K00662280-001-09-4,10.0,HTS002,PREP039,CL-218872,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",Phase 1
BRD-K00673382-001-18-9::0.00061034::HTS002,BRD-K00673382-001-18-9,0.00061034,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::0.0024414::HTS002,BRD-K00673382-001-18-9,0.0024414,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::0.00976562::HTS002,BRD-K00673382-001-18-9,0.00976562,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::0.0390625::HTS002,BRD-K00673382-001-18-9,0.0390625,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::0.15625::HTS002,BRD-K00673382-001-18-9,0.15625,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::0.625::HTS002,BRD-K00673382-001-18-9,0.625,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::2.5::HTS002,BRD-K00673382-001-18-9,2.5,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K00673382-001-18-9::10::HTS002,BRD-K00673382-001-18-9,10.0,HTS002,PREP020,famotidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1",Launched
BRD-K01029106-001-01-4::0.000614764::HTS002,BRD-K01029106-001-01-4,0.000614764,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::0.00245905::HTS002,BRD-K01029106-001-01-4,0.00245905,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::0.00983622::HTS002,BRD-K01029106-001-01-4,0.00983622,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::0.0393449::HTS002,BRD-K01029106-001-01-4,0.0393449,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::0.157379::HTS002,BRD-K01029106-001-01-4,0.157379,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::0.629518::HTS002,BRD-K01029106-001-01-4,0.629518,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::2.51807::HTS002,BRD-K01029106-001-01-4,2.51807,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01029106-001-01-4::10.0723::HTS002,BRD-K01029106-001-01-4,10.0723,HTS002,PREP026,picolinic-acid,chelating agent,NA,NA,NA,"O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1",Phase 2
BRD-K01109406-001-03-7::0.00061034::HTS002,BRD-K01109406-001-03-7,0.00061034,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::0.0024414::HTS002,BRD-K01109406-001-03-7,0.0024414,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::0.00976562::HTS002,BRD-K01109406-001-03-7,0.00976562,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::0.0390625::HTS002,BRD-K01109406-001-03-7,0.0390625,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::0.15625::HTS002,BRD-K01109406-001-03-7,0.15625,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::0.625::HTS002,BRD-K01109406-001-03-7,0.625,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::2.5::HTS002,BRD-K01109406-001-03-7,2.5,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K01109406-001-03-7::10::HTS002,BRD-K01109406-001-03-7,10.0,HTS002,PREP016,nitisinone,hydroxyphenylpyruvate dioxygenase inhibitor,HPD,metabolism,tyrosinemia,"[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F",Launched
BRD-K78809024-001-05-7::0.00061034::HTS002,BRD-K78809024-001-05-7,0.00061034,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::0.0024414::HTS002,BRD-K78809024-001-05-7,0.0024414,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::0.00976562::HTS002,BRD-K78809024-001-05-7,0.00976562,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::0.0390625::HTS002,BRD-K78809024-001-05-7,0.0390625,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::0.15625::HTS002,BRD-K78809024-001-05-7,0.15625,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::0.625::HTS002,BRD-K78809024-001-05-7,0.625,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::2.5::HTS002,BRD-K78809024-001-05-7,2.5,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K78809024-001-05-7::10::HTS002,BRD-K78809024-001-05-7,10.0,HTS002,PREP040,SB-590885,RAF inhibitor,BRAF,NA,NA,"CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1",Preclinical
BRD-K01295354-001-02-8::0.000610352::HTS002,BRD-K01295354-001-02-8,0.000610352,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::0.00244141::HTS002,BRD-K01295354-001-02-8,0.00244141,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::0.00976562::HTS002,BRD-K01295354-001-02-8,0.00976562,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::0.0390625::HTS002,BRD-K01295354-001-02-8,0.0390625,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::0.15625::HTS002,BRD-K01295354-001-02-8,0.15625,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::0.625::HTS002,BRD-K01295354-001-02-8,0.625,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::2.5::HTS002,BRD-K01295354-001-02-8,2.5,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01295354-001-02-8::10::HTS002,BRD-K01295354-001-02-8,10.0,HTS002,PREP045,uric-acid,NA,PYGL,NA,NA,O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1,Phase 3
BRD-K01614093-001-02-6::0.00061034::HTS002,BRD-K01614093-001-02-6,0.00061034,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::0.0024414::HTS002,BRD-K01614093-001-02-6,0.0024414,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::0.00976562::HTS002,BRD-K01614093-001-02-6,0.00976562,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::0.0390625::HTS002,BRD-K01614093-001-02-6,0.0390625,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::0.15625::HTS002,BRD-K01614093-001-02-6,0.15625,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::0.625::HTS002,BRD-K01614093-001-02-6,0.625,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::2.5::HTS002,BRD-K01614093-001-02-6,2.5,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01614093-001-02-6::10::HTS002,BRD-K01614093-001-02-6,10.0,HTS002,PREP036,dihydromyricetin,NA,NA,NA,NA,"O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",Preclinical
BRD-K01653460-001-01-1::0.00061034::HTS002,BRD-K01653460-001-01-1,0.00061034,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::0.0024414::HTS002,BRD-K01653460-001-01-1,0.0024414,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::0.00976562::HTS002,BRD-K01653460-001-01-1,0.00976562,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::0.0390625::HTS002,BRD-K01653460-001-01-1,0.0390625,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::0.15625::HTS002,BRD-K01653460-001-01-1,0.15625,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::0.625::HTS002,BRD-K01653460-001-01-1,0.625,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::2.5::HTS002,BRD-K01653460-001-01-1,2.5,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01653460-001-01-1::10::HTS002,BRD-K01653460-001-01-1,10.0,HTS002,PREP032,chlorindanol,NA,NA,NA,NA,Oc1ccc(Cl)c2CCCc12,Preclinical
BRD-K01669786-001-02-2::0.000610352::HTS002,BRD-K01669786-001-02-2,0.000610352,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::0.00244141::HTS002,BRD-K01669786-001-02-2,0.00244141,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::0.00976562::HTS002,BRD-K01669786-001-02-2,0.00976562,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::0.0390625::HTS002,BRD-K01669786-001-02-2,0.0390625,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::0.15625::HTS002,BRD-K01669786-001-02-2,0.15625,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::0.625::HTS002,BRD-K01669786-001-02-2,0.625,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::2.5::HTS002,BRD-K01669786-001-02-2,2.5,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01669786-001-02-2::10::HTS002,BRD-K01669786-001-02-2,10.0,HTS002,PREP035,triapine,ribonucleotide reductase inhibitor,"RRM1, RRM2",NA,NA,"NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",Phase 2
BRD-K01683783-001-02-6::0.00061034::HTS002,BRD-K01683783-001-02-6,0.00061034,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::0.0024414::HTS002,BRD-K01683783-001-02-6,0.0024414,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::0.00976562::HTS002,BRD-K01683783-001-02-6,0.00976562,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::0.0390625::HTS002,BRD-K01683783-001-02-6,0.0390625,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::0.15625::HTS002,BRD-K01683783-001-02-6,0.15625,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::0.625::HTS002,BRD-K01683783-001-02-6,0.625,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::2.5::HTS002,BRD-K01683783-001-02-6,2.5,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K01683783-001-02-6::10::HTS002,BRD-K01683783-001-02-6,10.0,HTS002,PREP039,TAK-901,Aurora kinase inhibitor,AURKB,NA,NA,CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12,Phase 1
BRD-K13112821-001-17-4::0.00061034::HTS002,BRD-K13112821-001-17-4,0.00061034,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::0.0024414::HTS002,BRD-K13112821-001-17-4,0.0024414,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::0.00976562::HTS002,BRD-K13112821-001-17-4,0.00976562,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::0.0390625::HTS002,BRD-K13112821-001-17-4,0.0390625,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::0.15625::HTS002,BRD-K13112821-001-17-4,0.15625,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::0.625::HTS002,BRD-K13112821-001-17-4,0.625,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::2.5::HTS002,BRD-K13112821-001-17-4,2.5,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K13112821-001-17-4::10::HTS002,BRD-K13112821-001-17-4,10.0,HTS002,PREP017,artemisinin,DNA synthesis inhibitor,CYP2B6,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K01773560-001-02-4::0.000633077::HTS002,BRD-K01773560-001-02-4,0.000633077,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::0.00253231::HTS002,BRD-K01773560-001-02-4,0.00253231,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::0.0101292::HTS002,BRD-K01773560-001-02-4,0.0101292,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::0.0405169::HTS002,BRD-K01773560-001-02-4,0.0405169,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::0.162068::HTS002,BRD-K01773560-001-02-4,0.162068,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::0.648271::HTS002,BRD-K01773560-001-02-4,0.648271,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::2.59308::HTS002,BRD-K01773560-001-02-4,2.59308,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K01773560-001-02-4::10.3723::HTS002,BRD-K01773560-001-02-4,10.3723,HTS002,PREP014,UNC2250,MER tyrosine kinase inhibitor,MERTK,NA,NA,"CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1",Preclinical
BRD-K02113016-001-15-4::0.00061034::HTS002,BRD-K02113016-001-15-4,0.00061034,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::0.0024414::HTS002,BRD-K02113016-001-15-4,0.0024414,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::0.00976562::HTS002,BRD-K02113016-001-15-4,0.00976562,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::0.0390625::HTS002,BRD-K02113016-001-15-4,0.0390625,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::0.15625::HTS002,BRD-K02113016-001-15-4,0.15625,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::0.625::HTS002,BRD-K02113016-001-15-4,0.625,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::2.5::HTS002,BRD-K02113016-001-15-4,2.5,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02113016-001-15-4::10::HTS002,BRD-K02113016-001-15-4,10.0,HTS002,PREP017,olaparib,PARP inhibitor,"PARP1, PARP2",oncology,ovarian cancer,"Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1",Launched
BRD-K02130563-001-11-4::0.00061034::HTS002,BRD-K02130563-001-11-4,0.00061034,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.0024414::HTS002,BRD-K02130563-001-11-4,0.0024414,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.00976562::HTS002,BRD-K02130563-001-11-4,0.00976562,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.0390625::HTS002,BRD-K02130563-001-11-4,0.0390625,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.15625::HTS002,BRD-K02130563-001-11-4,0.15625,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::0.625::HTS002,BRD-K02130563-001-11-4,0.625,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::2.5::HTS002,BRD-K02130563-001-11-4,2.5,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02130563-001-11-4::10::HTS002,BRD-K02130563-001-11-4,10.0,HTS002,PREP029,panobinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,multiple myeloma,"Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1",Launched
BRD-K02241333-001-02-7::0.00061034::HTS002,BRD-K02241333-001-02-7,0.00061034,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::0.0024414::HTS002,BRD-K02241333-001-02-7,0.0024414,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::0.00976562::HTS002,BRD-K02241333-001-02-7,0.00976562,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::0.0390625::HTS002,BRD-K02241333-001-02-7,0.0390625,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::0.15625::HTS002,BRD-K02241333-001-02-7,0.15625,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::0.625::HTS002,BRD-K02241333-001-02-7,0.625,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::2.5::HTS002,BRD-K02241333-001-02-7,2.5,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02241333-001-02-7::10::HTS002,BRD-K02241333-001-02-7,10.0,HTS002,PREP042,CHIR-124,CHK inhibitor,CHEK1,NA,NA,Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1,Preclinical
BRD-K02389548-001-02-5::0.00061034::HTS002,BRD-K02389548-001-02-5,0.00061034,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::0.0024414::HTS002,BRD-K02389548-001-02-5,0.0024414,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::0.00976562::HTS002,BRD-K02389548-001-02-5,0.00976562,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::0.0390625::HTS002,BRD-K02389548-001-02-5,0.0390625,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::0.15625::HTS002,BRD-K02389548-001-02-5,0.15625,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::0.625::HTS002,BRD-K02389548-001-02-5,0.625,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::2.5::HTS002,BRD-K02389548-001-02-5,2.5,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02389548-001-02-5::10::HTS002,BRD-K02389548-001-02-5,10.0,HTS002,PREP026,RG2833,HDAC inhibitor,"HDAC1, HDAC3",NA,NA,"Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",Phase 1
BRD-K02407574-001-09-7::0.00061034::HTS002,BRD-K02407574-001-09-7,0.00061034,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::0.0024414::HTS002,BRD-K02407574-001-09-7,0.0024414,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::0.00976562::HTS002,BRD-K02407574-001-09-7,0.00976562,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::0.0390625::HTS002,BRD-K02407574-001-09-7,0.0390625,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::0.15625::HTS002,BRD-K02407574-001-09-7,0.15625,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::0.625::HTS002,BRD-K02407574-001-09-7,0.625,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::2.5::HTS002,BRD-K02407574-001-09-7,2.5,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02407574-001-09-7::10::HTS002,BRD-K02407574-001-09-7,10.0,HTS002,PREP015,parbendazole,tubulin polymerization inhibitor,TUBB,NA,NA,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,Preclinical
BRD-K02594908-001-16-4::0.00061034::HTS002,BRD-K02594908-001-16-4,0.00061034,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::0.0024414::HTS002,BRD-K02594908-001-16-4,0.0024414,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::0.00976562::HTS002,BRD-K02594908-001-16-4,0.00976562,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::0.0390625::HTS002,BRD-K02594908-001-16-4,0.0390625,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::0.15625::HTS002,BRD-K02594908-001-16-4,0.15625,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::0.625::HTS002,BRD-K02594908-001-16-4,0.625,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::2.5::HTS002,BRD-K02594908-001-16-4,2.5,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02594908-001-16-4::10::HTS002,BRD-K02594908-001-16-4,10.0,HTS002,PREP020,sulfanilamide,carbonic anhydrase inhibitor,"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4",infectious disease,vulvovaginal candidiasis,"Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O",Launched
BRD-K02764365-001-13-6::0.00061034::HTS002,BRD-K02764365-001-13-6,0.00061034,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::0.0024414::HTS002,BRD-K02764365-001-13-6,0.0024414,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::0.00976562::HTS002,BRD-K02764365-001-13-6,0.00976562,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::0.0390625::HTS002,BRD-K02764365-001-13-6,0.0390625,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::0.15625::HTS002,BRD-K02764365-001-13-6,0.15625,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::0.625::HTS002,BRD-K02764365-001-13-6,0.625,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::2.5::HTS002,BRD-K02764365-001-13-6,2.5,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02764365-001-13-6::10::HTS002,BRD-K02764365-001-13-6,10.0,HTS002,PREP047,methiazole,anthelmintic agent,NA,NA,NA,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,Preclinical
BRD-K02898090-001-02-7::0.000610352::HTS002,BRD-K02898090-001-02-7,0.000610352,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::0.00244141::HTS002,BRD-K02898090-001-02-7,0.00244141,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::0.00976562::HTS002,BRD-K02898090-001-02-7,0.00976562,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::0.0390625::HTS002,BRD-K02898090-001-02-7,0.0390625,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::0.15625::HTS002,BRD-K02898090-001-02-7,0.15625,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::0.625::HTS002,BRD-K02898090-001-02-7,0.625,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::2.5::HTS002,BRD-K02898090-001-02-7,2.5,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02898090-001-02-7::10::HTS002,BRD-K02898090-001-02-7,10.0,HTS002,PREP045,kifunensine,mannosidase inhibitor,"MAN1B1, MAN2A1",NA,NA,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12,Phase 1
BRD-K02900412-001-11-3::0.00061034::HTS002,BRD-K02900412-001-11-3,0.00061034,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.0024414::HTS002,BRD-K02900412-001-11-3,0.0024414,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.00976562::HTS002,BRD-K02900412-001-11-3,0.00976562,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.0390625::HTS002,BRD-K02900412-001-11-3,0.0390625,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.15625::HTS002,BRD-K02900412-001-11-3,0.15625,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.625::HTS002,BRD-K02900412-001-11-3,0.625,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::2.5::HTS002,BRD-K02900412-001-11-3,2.5,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::10::HTS002,BRD-K02900412-001-11-3,10.0,HTS002,PREP021,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K03063480-001-06-6::0.000590687::HTS002,BRD-K03063480-001-06-6,0.000590687,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::0.00236275::HTS002,BRD-K03063480-001-06-6,0.00236275,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::0.009451::HTS002,BRD-K03063480-001-06-6,0.009451,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::0.037804::HTS002,BRD-K03063480-001-06-6,0.037804,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::0.151216::HTS002,BRD-K03063480-001-06-6,0.151216,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::0.604864::HTS002,BRD-K03063480-001-06-6,0.604864,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::2.41946::HTS002,BRD-K03063480-001-06-6,2.41946,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03063480-001-06-6::9.67782::HTS002,BRD-K03063480-001-06-6,9.67782,HTS002,PREP026,PF-477736,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",Phase 1
BRD-K03109492-001-02-2::0.00061034::HTS002,BRD-K03109492-001-02-2,0.00061034,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::0.0024414::HTS002,BRD-K03109492-001-02-2,0.0024414,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::0.00976562::HTS002,BRD-K03109492-001-02-2,0.00976562,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::0.0390625::HTS002,BRD-K03109492-001-02-2,0.0390625,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::0.15625::HTS002,BRD-K03109492-001-02-2,0.15625,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::0.625::HTS002,BRD-K03109492-001-02-2,0.625,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::2.5::HTS002,BRD-K03109492-001-02-2,2.5,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03109492-001-02-2::10::HTS002,BRD-K03109492-001-02-2,10.0,HTS002,PREP036,NSC-663284,CDC inhibitor,"CDC25A, CDC25B, CDC25C",NA,NA,"ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O",Preclinical
BRD-K03243820-001-23-8::0.000579417::HTS002,BRD-K03243820-001-23-8,0.000579417,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::0.00231767::HTS002,BRD-K03243820-001-23-8,0.00231767,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::0.00927067::HTS002,BRD-K03243820-001-23-8,0.00927067,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::0.0370827::HTS002,BRD-K03243820-001-23-8,0.0370827,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::0.148331::HTS002,BRD-K03243820-001-23-8,0.148331,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::0.593323::HTS002,BRD-K03243820-001-23-8,0.593323,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::2.37329::HTS002,BRD-K03243820-001-23-8,2.37329,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03243820-001-23-8::9.49316::HTS002,BRD-K03243820-001-23-8,9.49316,HTS002,PREP034,trifluridine,"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor",TYMS,infectious disease,virus herpes simplex (HSV),"OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F",Launched
BRD-K03273112-001-01-8::0.00061034::HTS002,BRD-K03273112-001-01-8,0.00061034,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::0.0024414::HTS002,BRD-K03273112-001-01-8,0.0024414,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::0.00976562::HTS002,BRD-K03273112-001-01-8,0.00976562,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::0.0390625::HTS002,BRD-K03273112-001-01-8,0.0390625,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::0.15625::HTS002,BRD-K03273112-001-01-8,0.15625,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::0.625::HTS002,BRD-K03273112-001-01-8,0.625,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::2.5::HTS002,BRD-K03273112-001-01-8,2.5,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03273112-001-01-8::10::HTS002,BRD-K03273112-001-01-8,10.0,HTS002,PREP037,1-azakenpaullone,glycogen synthase kinase inhibitor,"CCNB1, CDK1, CDK5, GSK3B",NA,NA,Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1,Preclinical
BRD-K03289018-001-02-7::0.00061034::HTS002,BRD-K03289018-001-02-7,0.00061034,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::0.0024414::HTS002,BRD-K03289018-001-02-7,0.0024414,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::0.00976562::HTS002,BRD-K03289018-001-02-7,0.00976562,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::0.0390625::HTS002,BRD-K03289018-001-02-7,0.0390625,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::0.15625::HTS002,BRD-K03289018-001-02-7,0.15625,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::0.625::HTS002,BRD-K03289018-001-02-7,0.625,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::2.5::HTS002,BRD-K03289018-001-02-7,2.5,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03289018-001-02-7::10::HTS002,BRD-K03289018-001-02-7,10.0,HTS002,PREP040,CCT137690,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1",Preclinical
BRD-K03294269-001-08-0::0.00061034::HTS002,BRD-K03294269-001-08-0,0.00061034,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::0.0024414::HTS002,BRD-K03294269-001-08-0,0.0024414,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::0.00976562::HTS002,BRD-K03294269-001-08-0,0.00976562,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::0.0390625::HTS002,BRD-K03294269-001-08-0,0.0390625,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::0.15625::HTS002,BRD-K03294269-001-08-0,0.15625,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::0.625::HTS002,BRD-K03294269-001-08-0,0.625,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::2.5::HTS002,BRD-K03294269-001-08-0,2.5,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03294269-001-08-0::10::HTS002,BRD-K03294269-001-08-0,10.0,HTS002,PREP047,NU6027,CDK inhibitor,"CCNA2, CDK2",NA,NA,Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1,Preclinical
BRD-K03384561-001-02-7::0.00061034::HTS002,BRD-K03384561-001-02-7,0.00061034,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::0.0024414::HTS002,BRD-K03384561-001-02-7,0.0024414,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::0.00976562::HTS002,BRD-K03384561-001-02-7,0.00976562,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::0.0390625::HTS002,BRD-K03384561-001-02-7,0.0390625,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::0.15625::HTS002,BRD-K03384561-001-02-7,0.15625,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::0.625::HTS002,BRD-K03384561-001-02-7,0.625,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::2.5::HTS002,BRD-K03384561-001-02-7,2.5,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03384561-001-02-7::10::HTS002,BRD-K03384561-001-02-7,10.0,HTS002,PREP019,roquinimex,"angiogenesis inhibitor, tumor necrosis factor production inhibitor",NA,NA,NA,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Phase 3
BRD-K03390685-001-01-7::0.00061034::HTS002,BRD-K03390685-001-01-7,0.00061034,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.0024414::HTS002,BRD-K03390685-001-01-7,0.0024414,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.00976562::HTS002,BRD-K03390685-001-01-7,0.00976562,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.0390625::HTS002,BRD-K03390685-001-01-7,0.0390625,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.15625::HTS002,BRD-K03390685-001-01-7,0.15625,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::0.625::HTS002,BRD-K03390685-001-01-7,0.625,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::2.5::HTS002,BRD-K03390685-001-01-7,2.5,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03390685-001-01-7::10::HTS002,BRD-K03390685-001-01-7,10.0,HTS002,PREP044,cobimetinib,MEK inhibitor,NA,oncology,melanoma,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,Launched
BRD-K03449891-001-08-6::0.00061034::HTS002,BRD-K03449891-001-08-6,0.00061034,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.0024414::HTS002,BRD-K03449891-001-08-6,0.0024414,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.00976562::HTS002,BRD-K03449891-001-08-6,0.00976562,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.0390625::HTS002,BRD-K03449891-001-08-6,0.0390625,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.15625::HTS002,BRD-K03449891-001-08-6,0.15625,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::0.625::HTS002,BRD-K03449891-001-08-6,0.625,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::2.5::HTS002,BRD-K03449891-001-08-6,2.5,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03449891-001-08-6::10::HTS002,BRD-K03449891-001-08-6,10.0,HTS002,PREP018,foretinib,VEGFR inhibitor,"FLT1, FLT4, KDR, MET",NA,NA,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,Phase 2
BRD-K03549949-001-01-0::0.00061034::HTS002,BRD-K03549949-001-01-0,0.00061034,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::0.0024414::HTS002,BRD-K03549949-001-01-0,0.0024414,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::0.00976562::HTS002,BRD-K03549949-001-01-0,0.00976562,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::0.0390625::HTS002,BRD-K03549949-001-01-0,0.0390625,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::0.15625::HTS002,BRD-K03549949-001-01-0,0.15625,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::0.625::HTS002,BRD-K03549949-001-01-0,0.625,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::2.5::HTS002,BRD-K03549949-001-01-0,2.5,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03549949-001-01-0::10::HTS002,BRD-K03549949-001-01-0,10.0,HTS002,PREP046,XL388,mTOR inhibitor,MTOR,NA,NA,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,Preclinical
BRD-K03601870-001-01-2::0.00061034::HTS002,BRD-K03601870-001-01-2,0.00061034,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::0.0024414::HTS002,BRD-K03601870-001-01-2,0.0024414,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::0.00976562::HTS002,BRD-K03601870-001-01-2,0.00976562,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::0.0390625::HTS002,BRD-K03601870-001-01-2,0.0390625,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::0.15625::HTS002,BRD-K03601870-001-01-2,0.15625,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::0.625::HTS002,BRD-K03601870-001-01-2,0.625,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::2.5::HTS002,BRD-K03601870-001-01-2,2.5,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K03601870-001-01-2::10::HTS002,BRD-K03601870-001-01-2,10.0,HTS002,PREP015,ixabepilone,microtubule stabilizing agent,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,breast cancer,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Launched
BRD-K04111260-001-10-0::0.00061034::HTS002,BRD-K04111260-001-10-0,0.00061034,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::0.0024414::HTS002,BRD-K04111260-001-10-0,0.0024414,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::0.00976562::HTS002,BRD-K04111260-001-10-0,0.00976562,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::0.0390625::HTS002,BRD-K04111260-001-10-0,0.0390625,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::0.15625::HTS002,BRD-K04111260-001-10-0,0.15625,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::0.625::HTS002,BRD-K04111260-001-10-0,0.625,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::2.5::HTS002,BRD-K04111260-001-10-0,2.5,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04111260-001-10-0::10::HTS002,BRD-K04111260-001-10-0,10.0,HTS002,PREP017,raclopride,dopamine receptor antagonist,"DRD2, DRD3, HTR1A",NA,NA,"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC",Launched
BRD-K04196797-001-24-4::0.00061034::HTS002,BRD-K04196797-001-24-4,0.00061034,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::0.0024414::HTS002,BRD-K04196797-001-24-4,0.0024414,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::0.00976562::HTS002,BRD-K04196797-001-24-4,0.00976562,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::0.0390625::HTS002,BRD-K04196797-001-24-4,0.0390625,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::0.15625::HTS002,BRD-K04196797-001-24-4,0.15625,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::0.625::HTS002,BRD-K04196797-001-24-4,0.625,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::2.5::HTS002,BRD-K04196797-001-24-4,2.5,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04196797-001-24-4::10::HTS002,BRD-K04196797-001-24-4,10.0,HTS002,PREP017,oxcarbazepine,sodium channel blocker,"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A",neurology/psychiatry,seizures,"NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12",Launched
BRD-K04264130-001-01-4::0.000610352::HTS002,BRD-K04264130-001-01-4,0.000610352,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::0.00244141::HTS002,BRD-K04264130-001-01-4,0.00244141,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::0.00976562::HTS002,BRD-K04264130-001-01-4,0.00976562,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::0.0390625::HTS002,BRD-K04264130-001-01-4,0.0390625,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::0.15625::HTS002,BRD-K04264130-001-01-4,0.15625,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::0.625::HTS002,BRD-K04264130-001-01-4,0.625,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::2.5::HTS002,BRD-K04264130-001-01-4,2.5,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04264130-001-01-4::10::HTS002,BRD-K04264130-001-01-4,10.0,HTS002,PREP018,favipiravir,RNA polymerase inhibitor,NA,NA,NA,NC(=O)c1nc(F)cnc1O,Phase 3
BRD-K04394237-001-03-7::0.000608811::HTS002,BRD-K04394237-001-03-7,0.000608811,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::0.00243525::HTS002,BRD-K04394237-001-03-7,0.00243525,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::0.00974098::HTS002,BRD-K04394237-001-03-7,0.00974098,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::0.0389639::HTS002,BRD-K04394237-001-03-7,0.0389639,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::0.155856::HTS002,BRD-K04394237-001-03-7,0.155856,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::0.623423::HTS002,BRD-K04394237-001-03-7,0.623423,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::2.49369::HTS002,BRD-K04394237-001-03-7,2.49369,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04394237-001-03-7::9.97476::HTS002,BRD-K04394237-001-03-7,9.97476,HTS002,PREP034,drospirenone,mineralocorticoid receptor antagonist,"AR, NR3C2, PGR",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1",Launched
BRD-K04430056-236-02-1::0.00061034::HTS002,BRD-K04430056-236-02-1,0.00061034,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::0.0024414::HTS002,BRD-K04430056-236-02-1,0.0024414,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::0.00976562::HTS002,BRD-K04430056-236-02-1,0.00976562,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::0.0390625::HTS002,BRD-K04430056-236-02-1,0.0390625,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::0.15625::HTS002,BRD-K04430056-236-02-1,0.15625,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::0.625::HTS002,BRD-K04430056-236-02-1,0.625,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::2.5::HTS002,BRD-K04430056-236-02-1,2.5,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04430056-236-02-1::10::HTS002,BRD-K04430056-236-02-1,10.0,HTS002,PREP015,7-nitroindazole,nitric oxide synthase inhibitor,"NOS1, NOS2, NOS3",NA,NA,"[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12",Preclinical
BRD-K04552268-001-02-4::0.000610352::HTS002,BRD-K04552268-001-02-4,0.000610352,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::0.00244141::HTS002,BRD-K04552268-001-02-4,0.00244141,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::0.00976562::HTS002,BRD-K04552268-001-02-4,0.00976562,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::0.0390625::HTS002,BRD-K04552268-001-02-4,0.0390625,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::0.15625::HTS002,BRD-K04552268-001-02-4,0.15625,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::0.625::HTS002,BRD-K04552268-001-02-4,0.625,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::2.5::HTS002,BRD-K04552268-001-02-4,2.5,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04552268-001-02-4::10::HTS002,BRD-K04552268-001-02-4,10.0,HTS002,PREP031,4-pyrimidinecarbonitrile,NA,NA,NA,NA,N#Cc1ccncn1,Preclinical
BRD-K04568635-300-01-4::0.000610352::HTS002,BRD-K04568635-300-01-4,0.000610352,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::0.00244141::HTS002,BRD-K04568635-300-01-4,0.00244141,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::0.00976562::HTS002,BRD-K04568635-300-01-4,0.00976562,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::0.0390625::HTS002,BRD-K04568635-300-01-4,0.0390625,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::0.15625::HTS002,BRD-K04568635-300-01-4,0.15625,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::0.625::HTS002,BRD-K04568635-300-01-4,0.625,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::2.5::HTS002,BRD-K04568635-300-01-4,2.5,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04568635-300-01-4::10::HTS002,BRD-K04568635-300-01-4,10.0,HTS002,PREP022,octenidine,membrane integrity inhibitor,NA,NA,NA,CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1,Launched
BRD-K04622161-001-02-3::0.00061034::HTS002,BRD-K04622161-001-02-3,0.00061034,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::0.0024414::HTS002,BRD-K04622161-001-02-3,0.0024414,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::0.00976562::HTS002,BRD-K04622161-001-02-3,0.00976562,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::0.0390625::HTS002,BRD-K04622161-001-02-3,0.0390625,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::0.15625::HTS002,BRD-K04622161-001-02-3,0.15625,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::0.625::HTS002,BRD-K04622161-001-02-3,0.625,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::2.5::HTS002,BRD-K04622161-001-02-3,2.5,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04622161-001-02-3::10::HTS002,BRD-K04622161-001-02-3,10.0,HTS002,PREP032,YO-01027,gamma secretase inhibitor,NA,NA,NA,"C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",Preclinical
BRD-K04623885-001-07-5::0.00061034::HTS002,BRD-K04623885-001-07-5,0.00061034,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::0.0024414::HTS002,BRD-K04623885-001-07-5,0.0024414,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::0.00976562::HTS002,BRD-K04623885-001-07-5,0.00976562,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::0.0390625::HTS002,BRD-K04623885-001-07-5,0.0390625,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::0.15625::HTS002,BRD-K04623885-001-07-5,0.15625,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::0.625::HTS002,BRD-K04623885-001-07-5,0.625,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::2.5::HTS002,BRD-K04623885-001-07-5,2.5,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04623885-001-07-5::10::HTS002,BRD-K04623885-001-07-5,10.0,HTS002,PREP037,BIBR-1532,telomerase inhibitor,TERT,NA,NA,"C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",Preclinical
BRD-K04833372-001-06-2::0.00061034::HTS002,BRD-K04833372-001-06-2,0.00061034,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::0.0024414::HTS002,BRD-K04833372-001-06-2,0.0024414,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::0.00976562::HTS002,BRD-K04833372-001-06-2,0.00976562,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::0.0390625::HTS002,BRD-K04833372-001-06-2,0.0390625,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::0.15625::HTS002,BRD-K04833372-001-06-2,0.15625,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::0.625::HTS002,BRD-K04833372-001-06-2,0.625,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::2.5::HTS002,BRD-K04833372-001-06-2,2.5,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04833372-001-06-2::10::HTS002,BRD-K04833372-001-06-2,10.0,HTS002,PREP042,GSK1904529A,"IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR",NA,NA,CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O,Preclinical
BRD-K04923131-001-15-4::0.00061034::HTS002,BRD-K04923131-001-15-4,0.00061034,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::0.0024414::HTS002,BRD-K04923131-001-15-4,0.0024414,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::0.00976562::HTS002,BRD-K04923131-001-15-4,0.00976562,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::0.0390625::HTS002,BRD-K04923131-001-15-4,0.0390625,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::0.15625::HTS002,BRD-K04923131-001-15-4,0.15625,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::0.625::HTS002,BRD-K04923131-001-15-4,0.625,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::2.5::HTS002,BRD-K04923131-001-15-4,2.5,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04923131-001-15-4::10::HTS002,BRD-K04923131-001-15-4,10.0,HTS002,PREP047,GSK-3-inhibitor-IX,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B",NA,NA,"O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12",Preclinical
BRD-K04993719-001-01-7::0.00061034::HTS002,BRD-K04993719-001-01-7,0.00061034,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::0.0024414::HTS002,BRD-K04993719-001-01-7,0.0024414,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::0.00976562::HTS002,BRD-K04993719-001-01-7,0.00976562,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::0.0390625::HTS002,BRD-K04993719-001-01-7,0.0390625,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::0.15625::HTS002,BRD-K04993719-001-01-7,0.15625,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::0.625::HTS002,BRD-K04993719-001-01-7,0.625,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::2.5::HTS002,BRD-K04993719-001-01-7,2.5,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K04993719-001-01-7::10::HTS002,BRD-K04993719-001-01-7,10.0,HTS002,PREP019,LY2334737,"antitumor agent, ribonucleotide reductase inhibitor",NA,NA,NA,CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Phase 1
BRD-K05104363-001-10-0::0.00061034::HTS002,BRD-K05104363-001-10-0,0.00061034,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::0.0024414::HTS002,BRD-K05104363-001-10-0,0.0024414,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::0.00976562::HTS002,BRD-K05104363-001-10-0,0.00976562,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::0.0390625::HTS002,BRD-K05104363-001-10-0,0.0390625,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::0.15625::HTS002,BRD-K05104363-001-10-0,0.15625,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::0.625::HTS002,BRD-K05104363-001-10-0,0.625,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::2.5::HTS002,BRD-K05104363-001-10-0,2.5,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05104363-001-10-0::10::HTS002,BRD-K05104363-001-10-0,10.0,HTS002,PREP045,PD-184352,MEK inhibitor,"MAP2K1, MAP3K1, MAP3K2",NA,NA,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,Phase 2
BRD-K05444225-001-01-7::0.00061034::HTS002,BRD-K05444225-001-01-7,0.00061034,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::0.0024414::HTS002,BRD-K05444225-001-01-7,0.0024414,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::0.00976562::HTS002,BRD-K05444225-001-01-7,0.00976562,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::0.0390625::HTS002,BRD-K05444225-001-01-7,0.0390625,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::0.15625::HTS002,BRD-K05444225-001-01-7,0.15625,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::0.625::HTS002,BRD-K05444225-001-01-7,0.625,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::2.5::HTS002,BRD-K05444225-001-01-7,2.5,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05444225-001-01-7::10::HTS002,BRD-K05444225-001-01-7,10.0,HTS002,PREP045,E7449,PARP inhibitor,"PARP1, PARP2, TNKS, TNKS2",NA,NA,"O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",Phase 1/Phase 2
BRD-K05445342-001-05-3::0.000626374::HTS002,BRD-K05445342-001-05-3,0.000626374,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::0.0025055::HTS002,BRD-K05445342-001-05-3,0.0025055,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::0.010022::HTS002,BRD-K05445342-001-05-3,0.010022,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::0.040088::HTS002,BRD-K05445342-001-05-3,0.040088,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::0.160352::HTS002,BRD-K05445342-001-05-3,0.160352,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::0.641407::HTS002,BRD-K05445342-001-05-3,0.641407,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::2.56563::HTS002,BRD-K05445342-001-05-3,2.56563,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05445342-001-05-3::10.2625::HTS002,BRD-K05445342-001-05-3,10.2625,HTS002,PREP027,WP1066,STAT inhibitor,STAT3,NA,NA,"C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Phase 1
BRD-K05524748-003-04-4::0.00061034::HTS002,BRD-K05524748-003-04-4,0.00061034,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::0.0024414::HTS002,BRD-K05524748-003-04-4,0.0024414,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::0.00976562::HTS002,BRD-K05524748-003-04-4,0.00976562,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::0.0390625::HTS002,BRD-K05524748-003-04-4,0.0390625,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::0.15625::HTS002,BRD-K05524748-003-04-4,0.15625,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::0.625::HTS002,BRD-K05524748-003-04-4,0.625,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::2.5::HTS002,BRD-K05524748-003-04-4,2.5,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05524748-003-04-4::10::HTS002,BRD-K05524748-003-04-4,10.0,HTS002,PREP028,dronedarone,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A",cardiology,atrial fibrillation (AF),CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,Launched
BRD-K05638300-001-01-2::0.000610352::HTS002,BRD-K05638300-001-01-2,0.000610352,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::0.00244141::HTS002,BRD-K05638300-001-01-2,0.00244141,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::0.00976562::HTS002,BRD-K05638300-001-01-2,0.00976562,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::0.0390625::HTS002,BRD-K05638300-001-01-2,0.0390625,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::0.15625::HTS002,BRD-K05638300-001-01-2,0.15625,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::0.625::HTS002,BRD-K05638300-001-01-2,0.625,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::2.5::HTS002,BRD-K05638300-001-01-2,2.5,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05638300-001-01-2::10::HTS002,BRD-K05638300-001-01-2,10.0,HTS002,PREP048,sevoflurane,membrane integrity inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1",neurology/psychiatry,anesthetic,"FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F",Launched
BRD-K05674516-001-01-7::0.00061034::HTS002,BRD-K05674516-001-01-7,0.00061034,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::0.0024414::HTS002,BRD-K05674516-001-01-7,0.0024414,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::0.00976562::HTS002,BRD-K05674516-001-01-7,0.00976562,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::0.0390625::HTS002,BRD-K05674516-001-01-7,0.0390625,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::0.15625::HTS002,BRD-K05674516-001-01-7,0.15625,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::0.625::HTS002,BRD-K05674516-001-01-7,0.625,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::2.5::HTS002,BRD-K05674516-001-01-7,2.5,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05674516-001-01-7::10::HTS002,BRD-K05674516-001-01-7,10.0,HTS002,PREP030,PSI-7976,HCV inhibitor,NA,NA,NA,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,Preclinical
BRD-K05804044-001-06-0::0.00061034::HTS002,BRD-K05804044-001-06-0,0.00061034,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::0.0024414::HTS002,BRD-K05804044-001-06-0,0.0024414,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::0.00976562::HTS002,BRD-K05804044-001-06-0,0.00976562,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::0.0390625::HTS002,BRD-K05804044-001-06-0,0.0390625,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::0.15625::HTS002,BRD-K05804044-001-06-0,0.15625,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::0.625::HTS002,BRD-K05804044-001-06-0,0.625,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::2.5::HTS002,BRD-K05804044-001-06-0,2.5,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K05804044-001-06-0::10::HTS002,BRD-K05804044-001-06-0,10.0,HTS002,PREP036,AZ-628,RAF inhibitor,"BRAF, RAF1",NA,NA,"Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",Preclinical
BRD-K06152156-001-01-8::0.000610352::HTS002,BRD-K06152156-001-01-8,0.000610352,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::0.00244141::HTS002,BRD-K06152156-001-01-8,0.00244141,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::0.00976562::HTS002,BRD-K06152156-001-01-8,0.00976562,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::0.0390625::HTS002,BRD-K06152156-001-01-8,0.0390625,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::0.15625::HTS002,BRD-K06152156-001-01-8,0.15625,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::0.625::HTS002,BRD-K06152156-001-01-8,0.625,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::2.5::HTS002,BRD-K06152156-001-01-8,2.5,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06152156-001-01-8::10::HTS002,BRD-K06152156-001-01-8,10.0,HTS002,PREP048,methoxyflurane,membrane permeability inhibitor,"ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1",neurology/psychiatry,general anaesthetic,"COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl",Launched
BRD-K06222852-001-03-2::0.00061034::HTS002,BRD-K06222852-001-03-2,0.00061034,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::0.0024414::HTS002,BRD-K06222852-001-03-2,0.0024414,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::0.00976562::HTS002,BRD-K06222852-001-03-2,0.00976562,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::0.0390625::HTS002,BRD-K06222852-001-03-2,0.0390625,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::0.15625::HTS002,BRD-K06222852-001-03-2,0.15625,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::0.625::HTS002,BRD-K06222852-001-03-2,0.625,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::2.5::HTS002,BRD-K06222852-001-03-2,2.5,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06222852-001-03-2::10::HTS002,BRD-K06222852-001-03-2,10.0,HTS002,PREP017,posaconazole,sterol demethylase inhibitor,CYP3A4,infectious disease,oropharyngeal candidiasis,"CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O",Launched
BRD-K06234293-001-04-2::0.00061034::HTS002,BRD-K06234293-001-04-2,0.00061034,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::0.0024414::HTS002,BRD-K06234293-001-04-2,0.0024414,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::0.00976562::HTS002,BRD-K06234293-001-04-2,0.00976562,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::0.0390625::HTS002,BRD-K06234293-001-04-2,0.0390625,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::0.15625::HTS002,BRD-K06234293-001-04-2,0.15625,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::0.625::HTS002,BRD-K06234293-001-04-2,0.625,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::2.5::HTS002,BRD-K06234293-001-04-2,2.5,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06234293-001-04-2::10::HTS002,BRD-K06234293-001-04-2,10.0,HTS002,PREP041,LY364947,"TGF beta receptor inhibitor, p38 MAPK inhibitor",TGFBR1,NA,NA,"c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",Preclinical
BRD-K06294530-001-01-5::0.00061034::HTS002,BRD-K06294530-001-01-5,0.00061034,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::0.0024414::HTS002,BRD-K06294530-001-01-5,0.0024414,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::0.00976562::HTS002,BRD-K06294530-001-01-5,0.00976562,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::0.0390625::HTS002,BRD-K06294530-001-01-5,0.0390625,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::0.15625::HTS002,BRD-K06294530-001-01-5,0.15625,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::0.625::HTS002,BRD-K06294530-001-01-5,0.625,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::2.5::HTS002,BRD-K06294530-001-01-5,2.5,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06294530-001-01-5::10::HTS002,BRD-K06294530-001-01-5,10.0,HTS002,PREP038,UK-383367,Procollagen C-Endopeptidase Inhibitors,BMP1,NA,NA,"NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",Phase 1
BRD-K06426971-001-02-7::0.00061034::HTS002,BRD-K06426971-001-02-7,0.00061034,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::0.0024414::HTS002,BRD-K06426971-001-02-7,0.0024414,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::0.00976562::HTS002,BRD-K06426971-001-02-7,0.00976562,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::0.0390625::HTS002,BRD-K06426971-001-02-7,0.0390625,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::0.15625::HTS002,BRD-K06426971-001-02-7,0.15625,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::0.625::HTS002,BRD-K06426971-001-02-7,0.625,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::2.5::HTS002,BRD-K06426971-001-02-7,2.5,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06426971-001-02-7::10::HTS002,BRD-K06426971-001-02-7,10.0,HTS002,PREP032,ryuvidine,histone lysine methyltransferase inhibitor,"CDK2, CDK4",NA,NA,"Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O",Preclinical
BRD-K06543683-066-02-1::0.00061034::HTS002,BRD-K06543683-066-02-1,0.00061034,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::0.0024414::HTS002,BRD-K06543683-066-02-1,0.0024414,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::0.00976562::HTS002,BRD-K06543683-066-02-1,0.00976562,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::0.0390625::HTS002,BRD-K06543683-066-02-1,0.0390625,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::0.15625::HTS002,BRD-K06543683-066-02-1,0.15625,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::0.625::HTS002,BRD-K06543683-066-02-1,0.625,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::2.5::HTS002,BRD-K06543683-066-02-1,2.5,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06543683-066-02-1::10::HTS002,BRD-K06543683-066-02-1,10.0,HTS002,PREP037,bisindolylmaleimide-ix,PKC inhibitor,"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1",NA,NA,"Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12",Preclinical
BRD-K06593056-001-04-8::0.00061034::HTS002,BRD-K06593056-001-04-8,0.00061034,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::0.0024414::HTS002,BRD-K06593056-001-04-8,0.0024414,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::0.00976562::HTS002,BRD-K06593056-001-04-8,0.00976562,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::0.0390625::HTS002,BRD-K06593056-001-04-8,0.0390625,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::0.15625::HTS002,BRD-K06593056-001-04-8,0.15625,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::0.625::HTS002,BRD-K06593056-001-04-8,0.625,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::2.5::HTS002,BRD-K06593056-001-04-8,2.5,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06593056-001-04-8::10::HTS002,BRD-K06593056-001-04-8,10.0,HTS002,PREP036,LE-135,retinoid receptor agonist,RARB,NA,NA,"CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C",Preclinical
BRD-K06749501-001-02-1::0.00061034::HTS002,BRD-K06749501-001-02-1,0.00061034,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::0.0024414::HTS002,BRD-K06749501-001-02-1,0.0024414,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::0.00976562::HTS002,BRD-K06749501-001-02-1,0.00976562,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::0.0390625::HTS002,BRD-K06749501-001-02-1,0.0390625,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::0.15625::HTS002,BRD-K06749501-001-02-1,0.15625,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::0.625::HTS002,BRD-K06749501-001-02-1,0.625,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::2.5::HTS002,BRD-K06749501-001-02-1,2.5,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06749501-001-02-1::10::HTS002,BRD-K06749501-001-02-1,10.0,HTS002,PREP042,GSK1838705A,insulin growth factor receptor inhibitor,"ALK, IGF1R, INSR, RPS6KA1",NA,NA,"CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",Preclinical
BRD-K06753942-001-14-5::0.00061034::HTS002,BRD-K06753942-001-14-5,0.00061034,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::0.0024414::HTS002,BRD-K06753942-001-14-5,0.0024414,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::0.00976562::HTS002,BRD-K06753942-001-14-5,0.00976562,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::0.0390625::HTS002,BRD-K06753942-001-14-5,0.0390625,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::0.15625::HTS002,BRD-K06753942-001-14-5,0.15625,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::0.625::HTS002,BRD-K06753942-001-14-5,0.625,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::2.5::HTS002,BRD-K06753942-001-14-5,2.5,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06753942-001-14-5::10::HTS002,BRD-K06753942-001-14-5,10.0,HTS002,PREP032,nobiletin,MEK inhibitor,MAP2K1,NA,NA,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,Preclinical
BRD-K06814349-304-01-9::0.00061034::HTS002,BRD-K06814349-304-01-9,0.00061034,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::0.0024414::HTS002,BRD-K06814349-304-01-9,0.0024414,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::0.00976562::HTS002,BRD-K06814349-304-01-9,0.00976562,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::0.0390625::HTS002,BRD-K06814349-304-01-9,0.0390625,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::0.15625::HTS002,BRD-K06814349-304-01-9,0.15625,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::0.625::HTS002,BRD-K06814349-304-01-9,0.625,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::2.5::HTS002,BRD-K06814349-304-01-9,2.5,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06814349-304-01-9::10::HTS002,BRD-K06814349-304-01-9,10.0,HTS002,PREP047,fosbretabulin,"tubulin polymerization inhibitor, VE-cadherin antagonist",CDH5,NA,NA,"COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",Phase 3
BRD-K06854232-001-19-9::0.00061034::HTS002,BRD-K06854232-001-19-9,0.00061034,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::0.0024414::HTS002,BRD-K06854232-001-19-9,0.0024414,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::0.00976562::HTS002,BRD-K06854232-001-19-9,0.00976562,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::0.0390625::HTS002,BRD-K06854232-001-19-9,0.0390625,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::0.15625::HTS002,BRD-K06854232-001-19-9,0.15625,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::0.625::HTS002,BRD-K06854232-001-19-9,0.625,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::2.5::HTS002,BRD-K06854232-001-19-9,2.5,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06854232-001-19-9::10::HTS002,BRD-K06854232-001-19-9,10.0,HTS002,PREP044,AM-580,retinoid receptor agonist,RARA,NA,NA,"CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",Preclinical
BRD-K06858286-001-01-3::0.00061034::HTS002,BRD-K06858286-001-01-3,0.00061034,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::0.0024414::HTS002,BRD-K06858286-001-01-3,0.0024414,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::0.00976562::HTS002,BRD-K06858286-001-01-3,0.00976562,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::0.0390625::HTS002,BRD-K06858286-001-01-3,0.0390625,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::0.15625::HTS002,BRD-K06858286-001-01-3,0.15625,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::0.625::HTS002,BRD-K06858286-001-01-3,0.625,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::2.5::HTS002,BRD-K06858286-001-01-3,2.5,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K06858286-001-01-3::10::HTS002,BRD-K06858286-001-01-3,10.0,HTS002,PREP017,cabazitaxel,microtubule inhibitor,"TUBA4A, TUBB, TUBB1",oncology,prostate cancer,CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,Launched
BRD-K07106112-003-03-8::0.00061034::HTS002,BRD-K07106112-003-03-8,0.00061034,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::0.0024414::HTS002,BRD-K07106112-003-03-8,0.0024414,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::0.00976562::HTS002,BRD-K07106112-003-03-8,0.00976562,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::0.0390625::HTS002,BRD-K07106112-003-03-8,0.0390625,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::0.15625::HTS002,BRD-K07106112-003-03-8,0.15625,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::0.625::HTS002,BRD-K07106112-003-03-8,0.625,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::2.5::HTS002,BRD-K07106112-003-03-8,2.5,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07106112-003-03-8::10::HTS002,BRD-K07106112-003-03-8,10.0,HTS002,PREP026,BMS-599626,"EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4",NA,NA,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",Phase 1
BRD-K07202345-001-19-4::0.00061034::HTS002,BRD-K07202345-001-19-4,0.00061034,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::0.0024414::HTS002,BRD-K07202345-001-19-4,0.0024414,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::0.00976562::HTS002,BRD-K07202345-001-19-4,0.00976562,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::0.0390625::HTS002,BRD-K07202345-001-19-4,0.0390625,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::0.15625::HTS002,BRD-K07202345-001-19-4,0.15625,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::0.625::HTS002,BRD-K07202345-001-19-4,0.625,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::2.5::HTS002,BRD-K07202345-001-19-4,2.5,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07202345-001-19-4::10::HTS002,BRD-K07202345-001-19-4,10.0,HTS002,PREP038,frentizole,immunosuppressant,NA,NA,NA,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,Phase 1
BRD-K07220430-001-18-4::0.000610352::HTS002,BRD-K07220430-001-18-4,0.000610352,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::0.00244141::HTS002,BRD-K07220430-001-18-4,0.00244141,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::0.00976562::HTS002,BRD-K07220430-001-18-4,0.00976562,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::0.0390625::HTS002,BRD-K07220430-001-18-4,0.0390625,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::0.15625::HTS002,BRD-K07220430-001-18-4,0.15625,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::0.625::HTS002,BRD-K07220430-001-18-4,0.625,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::2.5::HTS002,BRD-K07220430-001-18-4,2.5,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07220430-001-18-4::10::HTS002,BRD-K07220430-001-18-4,10.0,HTS002,PREP014,cinnarazine,calcium channel blocker,NA,"neurology/psychiatry, gastroenterology, ophthalmology","Meniere's disease, nausea, vomiting, Cogan's syndrome","C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",Launched
BRD-K07265709-003-05-6::0.000638303::HTS002,BRD-K07265709-003-05-6,0.000638303,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::0.00255321::HTS002,BRD-K07265709-003-05-6,0.00255321,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::0.0102128::HTS002,BRD-K07265709-003-05-6,0.0102128,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::0.0408514::HTS002,BRD-K07265709-003-05-6,0.0408514,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::0.163406::HTS002,BRD-K07265709-003-05-6,0.163406,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::0.653622::HTS002,BRD-K07265709-003-05-6,0.653622,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::2.61449::HTS002,BRD-K07265709-003-05-6,2.61449,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07265709-003-05-6::10.458::HTS002,BRD-K07265709-003-05-6,10.458,HTS002,PREP020,dexrazoxane,"chelating agent, topoisomerase inhibitor","TOP2A, TOP2B",cardiology,cardiomyopathy,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1",Launched
BRD-K07310275-001-02-5::0.00061034::HTS002,BRD-K07310275-001-02-5,0.00061034,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::0.0024414::HTS002,BRD-K07310275-001-02-5,0.0024414,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::0.00976562::HTS002,BRD-K07310275-001-02-5,0.00976562,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::0.0390625::HTS002,BRD-K07310275-001-02-5,0.0390625,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::0.15625::HTS002,BRD-K07310275-001-02-5,0.15625,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::0.625::HTS002,BRD-K07310275-001-02-5,0.625,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::2.5::HTS002,BRD-K07310275-001-02-5,2.5,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07310275-001-02-5::10::HTS002,BRD-K07310275-001-02-5,10.0,HTS002,PREP026,PF-04691502,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O,Phase 2
BRD-K07359318-001-03-9::0.00059797::HTS002,BRD-K07359318-001-03-9,0.00059797,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::0.00239188::HTS002,BRD-K07359318-001-03-9,0.00239188,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::0.00956752::HTS002,BRD-K07359318-001-03-9,0.00956752,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::0.0382701::HTS002,BRD-K07359318-001-03-9,0.0382701,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::0.15308::HTS002,BRD-K07359318-001-03-9,0.15308,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::0.612321::HTS002,BRD-K07359318-001-03-9,0.612321,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::2.44929::HTS002,BRD-K07359318-001-03-9,2.44929,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07359318-001-03-9::9.79714::HTS002,BRD-K07359318-001-03-9,9.79714,HTS002,PREP029,benfotiamine,antioxidant,AGER,rheumatology,lumbago,"C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1",Launched
BRD-K07442505-001-03-6::0.00061034::HTS002,BRD-K07442505-001-03-6,0.00061034,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::0.0024414::HTS002,BRD-K07442505-001-03-6,0.0024414,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::0.00976562::HTS002,BRD-K07442505-001-03-6,0.00976562,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::0.0390625::HTS002,BRD-K07442505-001-03-6,0.0390625,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::0.15625::HTS002,BRD-K07442505-001-03-6,0.15625,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::0.625::HTS002,BRD-K07442505-001-03-6,0.625,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::2.5::HTS002,BRD-K07442505-001-03-6,2.5,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07442505-001-03-6::10::HTS002,BRD-K07442505-001-03-6,10.0,HTS002,PREP041,BAM7,BAX activator,BAX,NA,NA,CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1,Preclinical
BRD-K07487750-001-03-3::0.00061034::HTS002,BRD-K07487750-001-03-3,0.00061034,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::0.0024414::HTS002,BRD-K07487750-001-03-3,0.0024414,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::0.00976562::HTS002,BRD-K07487750-001-03-3,0.00976562,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::0.0390625::HTS002,BRD-K07487750-001-03-3,0.0390625,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::0.15625::HTS002,BRD-K07487750-001-03-3,0.15625,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::0.625::HTS002,BRD-K07487750-001-03-3,0.625,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::2.5::HTS002,BRD-K07487750-001-03-3,2.5,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07487750-001-03-3::10::HTS002,BRD-K07487750-001-03-3,10.0,HTS002,PREP041,WHI-P154,JAK inhibitor,"EGFR, JAK1, JAK2, JAK3",NA,NA,"COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",Preclinical
BRD-K07572174-001-39-4::0.000605693::HTS002,BRD-K07572174-001-39-4,0.000605693,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::0.00242277::HTS002,BRD-K07572174-001-39-4,0.00242277,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::0.00969109::HTS002,BRD-K07572174-001-39-4,0.00969109,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::0.0387644::HTS002,BRD-K07572174-001-39-4,0.0387644,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::0.155057::HTS002,BRD-K07572174-001-39-4,0.155057,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::0.62023::HTS002,BRD-K07572174-001-39-4,0.62023,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::2.48092::HTS002,BRD-K07572174-001-39-4,2.48092,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07572174-001-39-4::9.92368::HTS002,BRD-K07572174-001-39-4,9.92368,HTS002,PREP035,curcumin,"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH",NA,NA,"COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1",Launched
BRD-K07612980-001-05-3::0.000631451::HTS002,BRD-K07612980-001-05-3,0.000631451,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::0.0025258::HTS002,BRD-K07612980-001-05-3,0.0025258,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::0.0101032::HTS002,BRD-K07612980-001-05-3,0.0101032,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::0.0404129::HTS002,BRD-K07612980-001-05-3,0.0404129,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::0.161651::HTS002,BRD-K07612980-001-05-3,0.161651,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::0.646606::HTS002,BRD-K07612980-001-05-3,0.646606,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::2.58642::HTS002,BRD-K07612980-001-05-3,2.58642,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07612980-001-05-3::10.3457::HTS002,BRD-K07612980-001-05-3,10.3457,HTS002,PREP034,sparfloxacin,bacterial DNA gyrase inhibitor,TOP2A,NA,NA,"C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",Withdrawn
BRD-K07736136-001-04-6::0.000612838::HTS002,BRD-K07736136-001-04-6,0.000612838,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::0.00245135::HTS002,BRD-K07736136-001-04-6,0.00245135,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::0.00980541::HTS002,BRD-K07736136-001-04-6,0.00980541,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::0.0392216::HTS002,BRD-K07736136-001-04-6,0.0392216,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::0.156887::HTS002,BRD-K07736136-001-04-6,0.156887,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::0.627546::HTS002,BRD-K07736136-001-04-6,0.627546,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::2.51018::HTS002,BRD-K07736136-001-04-6,2.51018,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07736136-001-04-6::10.0407::HTS002,BRD-K07736136-001-04-6,10.0407,HTS002,PREP019,VX-702,p38 MAPK inhibitor,"MAPK11, MAPK12, MAPK14",NA,NA,"NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",Phase 2
BRD-K07762753-001-04-4::0.00061034::HTS002,BRD-K07762753-001-04-4,0.00061034,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::0.0024414::HTS002,BRD-K07762753-001-04-4,0.0024414,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::0.00976562::HTS002,BRD-K07762753-001-04-4,0.00976562,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::0.0390625::HTS002,BRD-K07762753-001-04-4,0.0390625,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::0.15625::HTS002,BRD-K07762753-001-04-4,0.15625,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::0.625::HTS002,BRD-K07762753-001-04-4,0.625,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::2.5::HTS002,BRD-K07762753-001-04-4,2.5,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07762753-001-04-4::10::HTS002,BRD-K07762753-001-04-4,10.0,HTS002,PREP032,aminopurvalanol-a,"CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5, CDK6",NA,NA,"CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K07881437-001-04-6::0.000587755::HTS002,BRD-K07881437-001-04-6,0.000587755,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::0.00235102::HTS002,BRD-K07881437-001-04-6,0.00235102,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::0.00940408::HTS002,BRD-K07881437-001-04-6,0.00940408,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::0.0376163::HTS002,BRD-K07881437-001-04-6,0.0376163,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::0.150465::HTS002,BRD-K07881437-001-04-6,0.150465,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::0.601861::HTS002,BRD-K07881437-001-04-6,0.601861,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::2.40744::HTS002,BRD-K07881437-001-04-6,2.40744,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07881437-001-04-6::9.62978::HTS002,BRD-K07881437-001-04-6,9.62978,HTS002,PREP018,danusertib,"Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK",NA,NA,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",Phase 2
BRD-K07955840-001-02-3::0.00061034::HTS002,BRD-K07955840-001-02-3,0.00061034,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::0.0024414::HTS002,BRD-K07955840-001-02-3,0.0024414,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::0.00976562::HTS002,BRD-K07955840-001-02-3,0.00976562,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::0.0390625::HTS002,BRD-K07955840-001-02-3,0.0390625,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::0.15625::HTS002,BRD-K07955840-001-02-3,0.15625,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::0.625::HTS002,BRD-K07955840-001-02-3,0.625,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::2.5::HTS002,BRD-K07955840-001-02-3,2.5,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07955840-001-02-3::10::HTS002,BRD-K07955840-001-02-3,10.0,HTS002,PREP039,PF-05212384,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,"CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",Phase 2
BRD-K07972848-001-02-0::0.00061034::HTS002,BRD-K07972848-001-02-0,0.00061034,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::0.0024414::HTS002,BRD-K07972848-001-02-0,0.0024414,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::0.00976562::HTS002,BRD-K07972848-001-02-0,0.00976562,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::0.0390625::HTS002,BRD-K07972848-001-02-0,0.0390625,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::0.15625::HTS002,BRD-K07972848-001-02-0,0.15625,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::0.625::HTS002,BRD-K07972848-001-02-0,0.625,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::2.5::HTS002,BRD-K07972848-001-02-0,2.5,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K07972848-001-02-0::10::HTS002,BRD-K07972848-001-02-0,10.0,HTS002,PREP044,GSK2126458,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1,Phase 1
BRD-K08078237-001-19-8::0.000610352::HTS002,BRD-K08078237-001-19-8,0.000610352,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::0.00244141::HTS002,BRD-K08078237-001-19-8,0.00244141,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::0.00976562::HTS002,BRD-K08078237-001-19-8,0.00976562,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::0.0390625::HTS002,BRD-K08078237-001-19-8,0.0390625,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::0.15625::HTS002,BRD-K08078237-001-19-8,0.15625,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::0.625::HTS002,BRD-K08078237-001-19-8,0.625,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::2.5::HTS002,BRD-K08078237-001-19-8,2.5,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08078237-001-19-8::10::HTS002,BRD-K08078237-001-19-8,10.0,HTS002,PREP034,tetrandrine,calcium channel blocker,SLC6A3,NA,NA,"COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",Preclinical
BRD-K08109215-001-06-4::0.00061034::HTS002,BRD-K08109215-001-06-4,0.00061034,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.0024414::HTS002,BRD-K08109215-001-06-4,0.0024414,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.00976562::HTS002,BRD-K08109215-001-06-4,0.00976562,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.0390625::HTS002,BRD-K08109215-001-06-4,0.0390625,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.15625::HTS002,BRD-K08109215-001-06-4,0.15625,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::0.625::HTS002,BRD-K08109215-001-06-4,0.625,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::2.5::HTS002,BRD-K08109215-001-06-4,2.5,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08109215-001-06-4::10::HTS002,BRD-K08109215-001-06-4,10.0,HTS002,PREP046,I-BET-762,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12,Phase 2
BRD-K08248804-001-01-8::0.00061034::HTS002,BRD-K08248804-001-01-8,0.00061034,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::0.0024414::HTS002,BRD-K08248804-001-01-8,0.0024414,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::0.00976562::HTS002,BRD-K08248804-001-01-8,0.00976562,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::0.0390625::HTS002,BRD-K08248804-001-01-8,0.0390625,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::0.15625::HTS002,BRD-K08248804-001-01-8,0.15625,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::0.625::HTS002,BRD-K08248804-001-01-8,0.625,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::2.5::HTS002,BRD-K08248804-001-01-8,2.5,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08248804-001-01-8::10::HTS002,BRD-K08248804-001-01-8,10.0,HTS002,PREP046,LCL-161,XIAP inhibitor,"BIRC2, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,Phase 2
BRD-K08303368-001-10-0::0.00061034::HTS002,BRD-K08303368-001-10-0,0.00061034,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::0.0024414::HTS002,BRD-K08303368-001-10-0,0.0024414,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::0.00976562::HTS002,BRD-K08303368-001-10-0,0.00976562,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::0.0390625::HTS002,BRD-K08303368-001-10-0,0.0390625,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::0.15625::HTS002,BRD-K08303368-001-10-0,0.15625,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::0.625::HTS002,BRD-K08303368-001-10-0,0.625,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::2.5::HTS002,BRD-K08303368-001-10-0,2.5,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08303368-001-10-0::10::HTS002,BRD-K08303368-001-10-0,10.0,HTS002,PREP028,chlorpyrifos,acetylcholinesterase inhibitor,ACHE,NA,NA,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,Launched
BRD-K08525451-003-05-2::0.00061034::HTS002,BRD-K08525451-003-05-2,0.00061034,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::0.0024414::HTS002,BRD-K08525451-003-05-2,0.0024414,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::0.00976562::HTS002,BRD-K08525451-003-05-2,0.00976562,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::0.0390625::HTS002,BRD-K08525451-003-05-2,0.0390625,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::0.15625::HTS002,BRD-K08525451-003-05-2,0.15625,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::0.625::HTS002,BRD-K08525451-003-05-2,0.625,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::2.5::HTS002,BRD-K08525451-003-05-2,2.5,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08525451-003-05-2::10::HTS002,BRD-K08525451-003-05-2,10.0,HTS002,PREP028,sarafloxacin,bacterial DNA gyrase inhibitor,NA,NA,NA,"OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O",Launched
BRD-K08547377-394-03-5::0.00061034::HTS002,BRD-K08547377-394-03-5,0.00061034,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::0.0024414::HTS002,BRD-K08547377-394-03-5,0.0024414,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::0.00976562::HTS002,BRD-K08547377-394-03-5,0.00976562,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::0.0390625::HTS002,BRD-K08547377-394-03-5,0.0390625,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::0.15625::HTS002,BRD-K08547377-394-03-5,0.15625,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::0.625::HTS002,BRD-K08547377-394-03-5,0.625,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::2.5::HTS002,BRD-K08547377-394-03-5,2.5,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08547377-394-03-5::10::HTS002,BRD-K08547377-394-03-5,10.0,HTS002,PREP044,irinotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12",Launched
BRD-K08586861-001-01-1::0.00061034::HTS002,BRD-K08586861-001-01-1,0.00061034,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::0.0024414::HTS002,BRD-K08586861-001-01-1,0.0024414,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::0.00976562::HTS002,BRD-K08586861-001-01-1,0.00976562,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::0.0390625::HTS002,BRD-K08586861-001-01-1,0.0390625,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::0.15625::HTS002,BRD-K08586861-001-01-1,0.15625,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::0.625::HTS002,BRD-K08586861-001-01-1,0.625,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::2.5::HTS002,BRD-K08586861-001-01-1,2.5,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08586861-001-01-1::10::HTS002,BRD-K08586861-001-01-1,10.0,HTS002,PREP028,ramatroban,prostanoid receptor antagonist,"PTGDR2, TBXA2R","cardiology, pulmonary","coronary artery disease (CAD), asthma",OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,Launched
BRD-K08619574-334-05-4::0.00061034::HTS002,BRD-K08619574-334-05-4,0.00061034,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::0.0024414::HTS002,BRD-K08619574-334-05-4,0.0024414,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::0.00976562::HTS002,BRD-K08619574-334-05-4,0.00976562,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::0.0390625::HTS002,BRD-K08619574-334-05-4,0.0390625,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::0.15625::HTS002,BRD-K08619574-334-05-4,0.15625,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::0.625::HTS002,BRD-K08619574-334-05-4,0.625,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::2.5::HTS002,BRD-K08619574-334-05-4,2.5,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619574-334-05-4::10::HTS002,BRD-K08619574-334-05-4,10.0,HTS002,PREP023,thioproperazine,dopamine receptor antagonist,"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A",neurology/psychiatry,schizophrenia,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,Launched
BRD-K08619838-300-05-7::0.00061034::HTS002,BRD-K08619838-300-05-7,0.00061034,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::0.0024414::HTS002,BRD-K08619838-300-05-7,0.0024414,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::0.00976562::HTS002,BRD-K08619838-300-05-7,0.00976562,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::0.0390625::HTS002,BRD-K08619838-300-05-7,0.0390625,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::0.15625::HTS002,BRD-K08619838-300-05-7,0.15625,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::0.625::HTS002,BRD-K08619838-300-05-7,0.625,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::2.5::HTS002,BRD-K08619838-300-05-7,2.5,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08619838-300-05-7::10::HTS002,BRD-K08619838-300-05-7,10.0,HTS002,PREP046,tremorine,acetylcholine receptor agonist,NA,NA,NA,C(C#CCN1CCCC1)N1CCCC1,Preclinical
BRD-K08703257-001-12-1::0.00061034::HTS002,BRD-K08703257-001-12-1,0.00061034,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::0.0024414::HTS002,BRD-K08703257-001-12-1,0.0024414,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::0.00976562::HTS002,BRD-K08703257-001-12-1,0.00976562,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::0.0390625::HTS002,BRD-K08703257-001-12-1,0.0390625,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::0.15625::HTS002,BRD-K08703257-001-12-1,0.15625,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::0.625::HTS002,BRD-K08703257-001-12-1,0.625,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::2.5::HTS002,BRD-K08703257-001-12-1,2.5,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08703257-001-12-1::10::HTS002,BRD-K08703257-001-12-1,10.0,HTS002,PREP025,3-amino-benzamide,PARP inhibitor,PARP1,NA,NA,"NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",Phase 2
BRD-K08791496-001-01-0::0.00061034::HTS002,BRD-K08791496-001-01-0,0.00061034,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::0.0024414::HTS002,BRD-K08791496-001-01-0,0.0024414,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::0.00976562::HTS002,BRD-K08791496-001-01-0,0.00976562,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::0.0390625::HTS002,BRD-K08791496-001-01-0,0.0390625,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::0.15625::HTS002,BRD-K08791496-001-01-0,0.15625,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::0.625::HTS002,BRD-K08791496-001-01-0,0.625,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::2.5::HTS002,BRD-K08791496-001-01-0,2.5,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08791496-001-01-0::10::HTS002,BRD-K08791496-001-01-0,10.0,HTS002,PREP046,fenaclon,NA,NA,NA,NA,ClCCC(=O)NCCc1ccccc1,Preclinical
BRD-K08799216-001-05-3::0.00061034::HTS002,BRD-K08799216-001-05-3,0.00061034,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.0024414::HTS002,BRD-K08799216-001-05-3,0.0024414,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.00976562::HTS002,BRD-K08799216-001-05-3,0.00976562,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.0390625::HTS002,BRD-K08799216-001-05-3,0.0390625,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.15625::HTS002,BRD-K08799216-001-05-3,0.15625,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::0.625::HTS002,BRD-K08799216-001-05-3,0.625,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::2.5::HTS002,BRD-K08799216-001-05-3,2.5,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08799216-001-05-3::10::HTS002,BRD-K08799216-001-05-3,10.0,HTS002,PREP039,pelitinib,EGFR inhibitor,EGFR,NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 2
BRD-K08859203-001-01-9::0.00061034::HTS002,BRD-K08859203-001-01-9,0.00061034,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::0.0024414::HTS002,BRD-K08859203-001-01-9,0.0024414,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::0.00976562::HTS002,BRD-K08859203-001-01-9,0.00976562,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::0.0390625::HTS002,BRD-K08859203-001-01-9,0.0390625,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::0.15625::HTS002,BRD-K08859203-001-01-9,0.15625,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::0.625::HTS002,BRD-K08859203-001-01-9,0.625,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::2.5::HTS002,BRD-K08859203-001-01-9,2.5,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08859203-001-01-9::10::HTS002,BRD-K08859203-001-01-9,10.0,HTS002,PREP046,DU-728,structural glycoprotein antagonist,"ITGA2B, ITGB3",NA,NA,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,Phase 1
BRD-K08893438-001-04-9::0.000614857::HTS002,BRD-K08893438-001-04-9,0.000614857,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::0.00245943::HTS002,BRD-K08893438-001-04-9,0.00245943,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::0.00983771::HTS002,BRD-K08893438-001-04-9,0.00983771,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::0.0393509::HTS002,BRD-K08893438-001-04-9,0.0393509,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::0.157403::HTS002,BRD-K08893438-001-04-9,0.157403,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::0.629614::HTS002,BRD-K08893438-001-04-9,0.629614,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::2.51845::HTS002,BRD-K08893438-001-04-9,2.51845,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08893438-001-04-9::10.0738::HTS002,BRD-K08893438-001-04-9,10.0738,HTS002,PREP041,CCG-50014,G protein signaling inhibitor,"RGS4, RGS8",NA,NA,"Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",Preclinical
BRD-K08996725-332-01-7::0.00061034::HTS002,BRD-K08996725-332-01-7,0.00061034,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::0.0024414::HTS002,BRD-K08996725-332-01-7,0.0024414,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::0.00976562::HTS002,BRD-K08996725-332-01-7,0.00976562,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::0.0390625::HTS002,BRD-K08996725-332-01-7,0.0390625,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::0.15625::HTS002,BRD-K08996725-332-01-7,0.15625,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::0.625::HTS002,BRD-K08996725-332-01-7,0.625,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::2.5::HTS002,BRD-K08996725-332-01-7,2.5,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K08996725-332-01-7::10::HTS002,BRD-K08996725-332-01-7,10.0,HTS002,PREP025,zolantidine,histamine receptor antagonist,NA,NA,NA,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,Preclinical
BRD-K62304154-001-04-2::0.00061034::HTS002,BRD-K62304154-001-04-2,0.00061034,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::0.0024414::HTS002,BRD-K62304154-001-04-2,0.0024414,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::0.00976562::HTS002,BRD-K62304154-001-04-2,0.00976562,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::0.0390625::HTS002,BRD-K62304154-001-04-2,0.0390625,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::0.15625::HTS002,BRD-K62304154-001-04-2,0.15625,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::0.625::HTS002,BRD-K62304154-001-04-2,0.625,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::2.5::HTS002,BRD-K62304154-001-04-2,2.5,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K62304154-001-04-2::10::HTS002,BRD-K62304154-001-04-2,10.0,HTS002,PREP047,deforolimus,mTOR inhibitor,MTOR,NA,NA,"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O",Phase 3
BRD-K09090949-001-01-9::0.00061034::HTS002,BRD-K09090949-001-01-9,0.00061034,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::0.0024414::HTS002,BRD-K09090949-001-01-9,0.0024414,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::0.00976562::HTS002,BRD-K09090949-001-01-9,0.00976562,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::0.0390625::HTS002,BRD-K09090949-001-01-9,0.0390625,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::0.15625::HTS002,BRD-K09090949-001-01-9,0.15625,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::0.625::HTS002,BRD-K09090949-001-01-9,0.625,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::2.5::HTS002,BRD-K09090949-001-01-9,2.5,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09090949-001-01-9::10::HTS002,BRD-K09090949-001-01-9,10.0,HTS002,PREP047,"CP-945,598",cannabinoid receptor antagonist,CNR1,NA,NA,CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,Phase 3
BRD-K09132007-001-07-5::0.00061034::HTS002,BRD-K09132007-001-07-5,0.00061034,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::0.0024414::HTS002,BRD-K09132007-001-07-5,0.0024414,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::0.00976562::HTS002,BRD-K09132007-001-07-5,0.00976562,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::0.0390625::HTS002,BRD-K09132007-001-07-5,0.0390625,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::0.15625::HTS002,BRD-K09132007-001-07-5,0.15625,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::0.625::HTS002,BRD-K09132007-001-07-5,0.625,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::2.5::HTS002,BRD-K09132007-001-07-5,2.5,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09132007-001-07-5::10::HTS002,BRD-K09132007-001-07-5,10.0,HTS002,PREP015,D-4476,TGF beta receptor inhibitor,"CSNK1A1, CSNK1D, TGFB1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1",Preclinical
BRD-K09372874-001-01-0::0.00061034::HTS002,BRD-K09372874-001-01-0,0.00061034,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::0.0024414::HTS002,BRD-K09372874-001-01-0,0.0024414,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::0.00976562::HTS002,BRD-K09372874-001-01-0,0.00976562,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::0.0390625::HTS002,BRD-K09372874-001-01-0,0.0390625,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::0.15625::HTS002,BRD-K09372874-001-01-0,0.15625,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::0.625::HTS002,BRD-K09372874-001-01-0,0.625,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::2.5::HTS002,BRD-K09372874-001-01-0,2.5,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09372874-001-01-0::10::HTS002,BRD-K09372874-001-01-0,10.0,HTS002,PREP046,merimepodib,inosine monophosphate dehydrogenase inhibitor,IMPDH1,NA,NA,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,Phase 2
BRD-K09397065-003-06-1::0.00061034::HTS002,BRD-K09397065-003-06-1,0.00061034,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::0.0024414::HTS002,BRD-K09397065-003-06-1,0.0024414,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::0.00976562::HTS002,BRD-K09397065-003-06-1,0.00976562,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::0.0390625::HTS002,BRD-K09397065-003-06-1,0.0390625,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::0.15625::HTS002,BRD-K09397065-003-06-1,0.15625,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::0.625::HTS002,BRD-K09397065-003-06-1,0.625,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::2.5::HTS002,BRD-K09397065-003-06-1,2.5,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09397065-003-06-1::10::HTS002,BRD-K09397065-003-06-1,10.0,HTS002,PREP047,SR-57227A,serotonin receptor agonist,HTR3A,NA,NA,NC1CCN(CC1)c1cccc(Cl)n1,Phase 2
BRD-K09416995-001-39-9::0.00061034::HTS002,BRD-K09416995-001-39-9,0.00061034,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::0.0024414::HTS002,BRD-K09416995-001-39-9,0.0024414,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::0.00976562::HTS002,BRD-K09416995-001-39-9,0.00976562,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::0.0390625::HTS002,BRD-K09416995-001-39-9,0.0390625,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::0.15625::HTS002,BRD-K09416995-001-39-9,0.15625,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::0.625::HTS002,BRD-K09416995-001-39-9,0.625,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::2.5::HTS002,BRD-K09416995-001-39-9,2.5,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09416995-001-39-9::10::HTS002,BRD-K09416995-001-39-9,10.0,HTS002,PREP022,lovastatin,HMGCR inhibitor,"HDAC2, HMGCR, ITGAL, NR1I2","cardiology, endocrinology","coronary heart disease, myocardial infarction, hypercholesterolemia","CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K09426783-300-01-0::0.00061034::HTS002,BRD-K09426783-300-01-0,0.00061034,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::0.0024414::HTS002,BRD-K09426783-300-01-0,0.0024414,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::0.00976562::HTS002,BRD-K09426783-300-01-0,0.00976562,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::0.0390625::HTS002,BRD-K09426783-300-01-0,0.0390625,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::0.15625::HTS002,BRD-K09426783-300-01-0,0.15625,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::0.625::HTS002,BRD-K09426783-300-01-0,0.625,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::2.5::HTS002,BRD-K09426783-300-01-0,2.5,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09426783-300-01-0::10::HTS002,BRD-K09426783-300-01-0,10.0,HTS002,PREP046,TAS-103,topoisomerase inhibitor,TOP1,NA,NA,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,Phase 1
BRD-K09443272-001-03-3::0.00061034::HTS002,BRD-K09443272-001-03-3,0.00061034,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::0.0024414::HTS002,BRD-K09443272-001-03-3,0.0024414,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::0.00976562::HTS002,BRD-K09443272-001-03-3,0.00976562,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::0.0390625::HTS002,BRD-K09443272-001-03-3,0.0390625,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::0.15625::HTS002,BRD-K09443272-001-03-3,0.15625,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::0.625::HTS002,BRD-K09443272-001-03-3,0.625,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::2.5::HTS002,BRD-K09443272-001-03-3,2.5,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09443272-001-03-3::10::HTS002,BRD-K09443272-001-03-3,10.0,HTS002,PREP046,PHA-680632,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,Preclinical
BRD-K09549677-300-03-4::0.00061034::HTS002,BRD-K09549677-300-03-4,0.00061034,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::0.0024414::HTS002,BRD-K09549677-300-03-4,0.0024414,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::0.00976562::HTS002,BRD-K09549677-300-03-4,0.00976562,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::0.0390625::HTS002,BRD-K09549677-300-03-4,0.0390625,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::0.15625::HTS002,BRD-K09549677-300-03-4,0.15625,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::0.625::HTS002,BRD-K09549677-300-03-4,0.625,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::2.5::HTS002,BRD-K09549677-300-03-4,2.5,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09549677-300-03-4::10::HTS002,BRD-K09549677-300-03-4,10.0,HTS002,PREP028,mibefradil,T-type calcium channel blocker,"ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4",NA,NA,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",Withdrawn
BRD-K09602097-001-13-6::0.00061034::HTS002,BRD-K09602097-001-13-6,0.00061034,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::0.0024414::HTS002,BRD-K09602097-001-13-6,0.0024414,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::0.00976562::HTS002,BRD-K09602097-001-13-6,0.00976562,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::0.0390625::HTS002,BRD-K09602097-001-13-6,0.0390625,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::0.15625::HTS002,BRD-K09602097-001-13-6,0.15625,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::0.625::HTS002,BRD-K09602097-001-13-6,0.625,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::2.5::HTS002,BRD-K09602097-001-13-6,2.5,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09602097-001-13-6::10::HTS002,BRD-K09602097-001-13-6,10.0,HTS002,PREP024,forskolin,adenylyl cyclase activator,"ADCY2, ADCY5, GNAS",NA,NA,"CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C",Launched
BRD-K09877029-001-01-2::0.00061034::HTS002,BRD-K09877029-001-01-2,0.00061034,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::0.0024414::HTS002,BRD-K09877029-001-01-2,0.0024414,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::0.00976562::HTS002,BRD-K09877029-001-01-2,0.00976562,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::0.0390625::HTS002,BRD-K09877029-001-01-2,0.0390625,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::0.15625::HTS002,BRD-K09877029-001-01-2,0.15625,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::0.625::HTS002,BRD-K09877029-001-01-2,0.625,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::2.5::HTS002,BRD-K09877029-001-01-2,2.5,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09877029-001-01-2::10::HTS002,BRD-K09877029-001-01-2,10.0,HTS002,PREP041,VS-4718,focal adhesion kinase inhibitor,NA,NA,NA,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,Phase 1
BRD-K09900591-001-26-7::0.000610352::HTS002,BRD-K09900591-001-26-7,0.000610352,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::0.00244141::HTS002,BRD-K09900591-001-26-7,0.00244141,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::0.00976562::HTS002,BRD-K09900591-001-26-7,0.00976562,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::0.0390625::HTS002,BRD-K09900591-001-26-7,0.0390625,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::0.15625::HTS002,BRD-K09900591-001-26-7,0.15625,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::0.625::HTS002,BRD-K09900591-001-26-7,0.625,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::2.5::HTS002,BRD-K09900591-001-26-7,2.5,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09900591-001-26-7::10::HTS002,BRD-K09900591-001-26-7,10.0,HTS002,PREP015,caffeic-acid,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF",NA,NA,"OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",Preclinical
BRD-K09951645-001-06-8::0.00061034::HTS002,BRD-K09951645-001-06-8,0.00061034,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::0.0024414::HTS002,BRD-K09951645-001-06-8,0.0024414,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::0.00976562::HTS002,BRD-K09951645-001-06-8,0.00976562,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::0.0390625::HTS002,BRD-K09951645-001-06-8,0.0390625,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::0.15625::HTS002,BRD-K09951645-001-06-8,0.15625,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::0.625::HTS002,BRD-K09951645-001-06-8,0.625,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::2.5::HTS002,BRD-K09951645-001-06-8,2.5,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K09951645-001-06-8::10::HTS002,BRD-K09951645-001-06-8,10.0,HTS002,PREP020,dabrafenib,RAF inhibitor,"BRAF, LIMK1, NEK11, RAF1, SIK1",oncology,melanoma,"CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F",Launched
BRD-K10670311-001-15-5::0.00061034::HTS002,BRD-K10670311-001-15-5,0.00061034,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::0.0024414::HTS002,BRD-K10670311-001-15-5,0.0024414,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::0.00976562::HTS002,BRD-K10670311-001-15-5,0.00976562,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::0.0390625::HTS002,BRD-K10670311-001-15-5,0.0390625,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::0.15625::HTS002,BRD-K10670311-001-15-5,0.15625,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::0.625::HTS002,BRD-K10670311-001-15-5,0.625,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::2.5::HTS002,BRD-K10670311-001-15-5,2.5,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10670311-001-15-5::10::HTS002,BRD-K10670311-001-15-5,10.0,HTS002,PREP021,sulfasalazine,cyclooxygenase inhibitor,"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1",gastroenterology,ulcerative colitis,"OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1",Launched
BRD-K10705233-001-02-2::0.00061034::HTS002,BRD-K10705233-001-02-2,0.00061034,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::0.0024414::HTS002,BRD-K10705233-001-02-2,0.0024414,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::0.00976562::HTS002,BRD-K10705233-001-02-2,0.00976562,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::0.0390625::HTS002,BRD-K10705233-001-02-2,0.0390625,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::0.15625::HTS002,BRD-K10705233-001-02-2,0.15625,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::0.625::HTS002,BRD-K10705233-001-02-2,0.625,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::2.5::HTS002,BRD-K10705233-001-02-2,2.5,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10705233-001-02-2::10::HTS002,BRD-K10705233-001-02-2,10.0,HTS002,PREP036,GW-405833,cannabinoid receptor agonist,CNR2,NA,NA,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,Preclinical
BRD-K10784860-003-02-3::0.00061034::HTS002,BRD-K10784860-003-02-3,0.00061034,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::0.0024414::HTS002,BRD-K10784860-003-02-3,0.0024414,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::0.00976562::HTS002,BRD-K10784860-003-02-3,0.00976562,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::0.0390625::HTS002,BRD-K10784860-003-02-3,0.0390625,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::0.15625::HTS002,BRD-K10784860-003-02-3,0.15625,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::0.625::HTS002,BRD-K10784860-003-02-3,0.625,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::2.5::HTS002,BRD-K10784860-003-02-3,2.5,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10784860-003-02-3::10::HTS002,BRD-K10784860-003-02-3,10.0,HTS002,PREP038,temocapril,angiotensin converting enzyme inhibitor,ACE,"cardiology, nephrology","hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)",CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1,Launched
BRD-K10843433-001-22-7::0.00061034::HTS002,BRD-K10843433-001-22-7,0.00061034,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::0.0024414::HTS002,BRD-K10843433-001-22-7,0.0024414,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::0.00976562::HTS002,BRD-K10843433-001-22-7,0.00976562,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::0.0390625::HTS002,BRD-K10843433-001-22-7,0.0390625,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::0.15625::HTS002,BRD-K10843433-001-22-7,0.15625,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::0.625::HTS002,BRD-K10843433-001-22-7,0.625,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::2.5::HTS002,BRD-K10843433-001-22-7,2.5,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10843433-001-22-7::10::HTS002,BRD-K10843433-001-22-7,10.0,HTS002,PREP020,phenylbutazone,"cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2",NA,NA,"CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Withdrawn
BRD-K10845183-304-01-6::0.00061034::HTS002,BRD-K10845183-304-01-6,0.00061034,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::0.0024414::HTS002,BRD-K10845183-304-01-6,0.0024414,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::0.00976562::HTS002,BRD-K10845183-304-01-6,0.00976562,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::0.0390625::HTS002,BRD-K10845183-304-01-6,0.0390625,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::0.15625::HTS002,BRD-K10845183-304-01-6,0.15625,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::0.625::HTS002,BRD-K10845183-304-01-6,0.625,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::2.5::HTS002,BRD-K10845183-304-01-6,2.5,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10845183-304-01-6::10::HTS002,BRD-K10845183-304-01-6,10.0,HTS002,PREP020,tiludronate,"bone resorption inhibitor, osteoclast inhibitor","ATP6V1A, MMP2, PTPN1",orthopedics,navicular syndrome,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,Launched
BRD-K10961822-001-05-1::0.00061034::HTS002,BRD-K10961822-001-05-1,0.00061034,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::0.0024414::HTS002,BRD-K10961822-001-05-1,0.0024414,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::0.00976562::HTS002,BRD-K10961822-001-05-1,0.00976562,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::0.0390625::HTS002,BRD-K10961822-001-05-1,0.0390625,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::0.15625::HTS002,BRD-K10961822-001-05-1,0.15625,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::0.625::HTS002,BRD-K10961822-001-05-1,0.625,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::2.5::HTS002,BRD-K10961822-001-05-1,2.5,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K10961822-001-05-1::10::HTS002,BRD-K10961822-001-05-1,10.0,HTS002,PREP029,latanoprost,prostanoid receptor agonist,PTGFR,ophthalmology,"ocular hypertension, glaucoma",CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Launched
BRD-K11071038-001-01-7::0.00061034::HTS002,BRD-K11071038-001-01-7,0.00061034,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::0.0024414::HTS002,BRD-K11071038-001-01-7,0.0024414,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::0.00976562::HTS002,BRD-K11071038-001-01-7,0.00976562,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::0.0390625::HTS002,BRD-K11071038-001-01-7,0.0390625,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::0.15625::HTS002,BRD-K11071038-001-01-7,0.15625,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::0.625::HTS002,BRD-K11071038-001-01-7,0.625,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::2.5::HTS002,BRD-K11071038-001-01-7,2.5,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11071038-001-01-7::10::HTS002,BRD-K11071038-001-01-7,10.0,HTS002,PREP038,ICI-162846,histamine receptor antagonist,HRH2,NA,NA,NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F,Phase 1
BRD-K11073688-001-01-6::0.000610352::HTS002,BRD-K11073688-001-01-6,0.000610352,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::0.00244141::HTS002,BRD-K11073688-001-01-6,0.00244141,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::0.00976562::HTS002,BRD-K11073688-001-01-6,0.00976562,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::0.0390625::HTS002,BRD-K11073688-001-01-6,0.0390625,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::0.15625::HTS002,BRD-K11073688-001-01-6,0.15625,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::0.625::HTS002,BRD-K11073688-001-01-6,0.625,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::2.5::HTS002,BRD-K11073688-001-01-6,2.5,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11073688-001-01-6::10::HTS002,BRD-K11073688-001-01-6,10.0,HTS002,PREP039,CPI-1189,tumor necrosis factor release inhibitor,TNF,NA,NA,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,Phase 2
BRD-K11196887-001-22-0::0.000609118::HTS002,BRD-K11196887-001-22-0,0.000609118,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::0.00243647::HTS002,BRD-K11196887-001-22-0,0.00243647,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::0.00974588::HTS002,BRD-K11196887-001-22-0,0.00974588,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::0.0389835::HTS002,BRD-K11196887-001-22-0,0.0389835,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::0.155934::HTS002,BRD-K11196887-001-22-0,0.155934,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::0.623736::HTS002,BRD-K11196887-001-22-0,0.623736,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::2.49495::HTS002,BRD-K11196887-001-22-0,2.49495,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11196887-001-22-0::9.97978::HTS002,BRD-K11196887-001-22-0,9.97978,HTS002,PREP030,norfloxacin,bacterial DNA gyrase inhibitor,TOP2A,"infectious disease, urology","urinary tract infections, gonorrhea, prostatitis","CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1",Launched
BRD-K11215326-001-03-7::0.00056417::HTS002,BRD-K11215326-001-03-7,0.00056417,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::0.00225668::HTS002,BRD-K11215326-001-03-7,0.00225668,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::0.00902672::HTS002,BRD-K11215326-001-03-7,0.00902672,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::0.0361069::HTS002,BRD-K11215326-001-03-7,0.0361069,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::0.144427::HTS002,BRD-K11215326-001-03-7,0.144427,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::0.57771::HTS002,BRD-K11215326-001-03-7,0.57771,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::2.31084::HTS002,BRD-K11215326-001-03-7,2.31084,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11215326-001-03-7::9.24336::HTS002,BRD-K11215326-001-03-7,9.24336,HTS002,PREP019,tazemetostat,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1",Phase 2
BRD-K11244467-001-08-5::0.000610352::HTS002,BRD-K11244467-001-08-5,0.000610352,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::0.00244141::HTS002,BRD-K11244467-001-08-5,0.00244141,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::0.00976562::HTS002,BRD-K11244467-001-08-5,0.00976562,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::0.0390625::HTS002,BRD-K11244467-001-08-5,0.0390625,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::0.15625::HTS002,BRD-K11244467-001-08-5,0.15625,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::0.625::HTS002,BRD-K11244467-001-08-5,0.625,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::2.5::HTS002,BRD-K11244467-001-08-5,2.5,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11244467-001-08-5::10::HTS002,BRD-K11244467-001-08-5,10.0,HTS002,PREP046,ambazone,DNA damage inducer,NA,NA,NA,"NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1",Phase 1
BRD-K11267252-001-04-4::0.00061034::HTS002,BRD-K11267252-001-04-4,0.00061034,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::0.0024414::HTS002,BRD-K11267252-001-04-4,0.0024414,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::0.00976562::HTS002,BRD-K11267252-001-04-4,0.00976562,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::0.0390625::HTS002,BRD-K11267252-001-04-4,0.0390625,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::0.15625::HTS002,BRD-K11267252-001-04-4,0.15625,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::0.625::HTS002,BRD-K11267252-001-04-4,0.625,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::2.5::HTS002,BRD-K11267252-001-04-4,2.5,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K11267252-001-04-4::10::HTS002,BRD-K11267252-001-04-4,10.0,HTS002,PREP020,alectinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1",Launched
BRD-K62213621-001-01-6::0.00061034::HTS002,BRD-K62213621-001-01-6,0.00061034,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::0.0024414::HTS002,BRD-K62213621-001-01-6,0.0024414,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::0.00976562::HTS002,BRD-K62213621-001-01-6,0.00976562,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::0.0390625::HTS002,BRD-K62213621-001-01-6,0.0390625,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::0.15625::HTS002,BRD-K62213621-001-01-6,0.15625,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::0.625::HTS002,BRD-K62213621-001-01-6,0.625,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::2.5::HTS002,BRD-K62213621-001-01-6,2.5,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K62213621-001-01-6::10::HTS002,BRD-K62213621-001-01-6,10.0,HTS002,PREP014,dihydroartemisinin,antimalarial agent,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K11433652-001-17-0::0.00061034::HTS002,BRD-K11433652-001-17-0,0.00061034,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::0.0024414::HTS002,BRD-K11433652-001-17-0,0.0024414,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::0.00976562::HTS002,BRD-K11433652-001-17-0,0.00976562,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::0.0390625::HTS002,BRD-K11433652-001-17-0,0.0390625,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::0.15625::HTS002,BRD-K11433652-001-17-0,0.15625,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::0.625::HTS002,BRD-K11433652-001-17-0,0.625,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::2.5::HTS002,BRD-K11433652-001-17-0,2.5,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11433652-001-17-0::10::HTS002,BRD-K11433652-001-17-0,10.0,HTS002,PREP021,aspirin,cyclooxygenase inhibitor,"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","neurology/psychiatry, endocrinology, dental","headache, fever, toothache, muscle pain","CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O",Launched
BRD-K11510141-001-01-8::0.000610352::HTS002,BRD-K11510141-001-01-8,0.000610352,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::0.00244141::HTS002,BRD-K11510141-001-01-8,0.00244141,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::0.00976562::HTS002,BRD-K11510141-001-01-8,0.00976562,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::0.0390625::HTS002,BRD-K11510141-001-01-8,0.0390625,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::0.15625::HTS002,BRD-K11510141-001-01-8,0.15625,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::0.625::HTS002,BRD-K11510141-001-01-8,0.625,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::2.5::HTS002,BRD-K11510141-001-01-8,2.5,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11510141-001-01-8::10::HTS002,BRD-K11510141-001-01-8,10.0,HTS002,PREP029,teprenone,mucus protecting agent,NA,dermatology,cosmetic,"CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C",Launched
BRD-K11590034-002-03-4::0.000607367::HTS002,BRD-K11590034-002-03-4,0.000607367,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::0.00242947::HTS002,BRD-K11590034-002-03-4,0.00242947,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::0.00971788::HTS002,BRD-K11590034-002-03-4,0.00971788,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::0.0388715::HTS002,BRD-K11590034-002-03-4,0.0388715,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::0.155486::HTS002,BRD-K11590034-002-03-4,0.155486,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::0.621944::HTS002,BRD-K11590034-002-03-4,0.621944,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::2.48778::HTS002,BRD-K11590034-002-03-4,2.48778,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11590034-002-03-4::9.95111::HTS002,BRD-K11590034-002-03-4,9.95111,HTS002,PREP042,morin,cytochrome P450 inhibitor,"ADORA2A, ESR2, FASN, MCL1, SLC22A12",NA,NA,"Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",Preclinical
BRD-K11630072-001-13-2::0.000610352::HTS002,BRD-K11630072-001-13-2,0.000610352,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.00244141::HTS002,BRD-K11630072-001-13-2,0.00244141,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.00976562::HTS002,BRD-K11630072-001-13-2,0.00976562,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.0390625::HTS002,BRD-K11630072-001-13-2,0.0390625,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.15625::HTS002,BRD-K11630072-001-13-2,0.15625,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::0.625::HTS002,BRD-K11630072-001-13-2,0.625,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::2.5::HTS002,BRD-K11630072-001-13-2,2.5,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11630072-001-13-2::10::HTS002,BRD-K11630072-001-13-2,10.0,HTS002,PREP020,carmofur,thymidylate synthase inhibitor,TYMS,oncology,"breast cancer, colorectal cancer","CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K11636097-001-03-1::0.00061034::HTS002,BRD-K11636097-001-03-1,0.00061034,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::0.0024414::HTS002,BRD-K11636097-001-03-1,0.0024414,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::0.00976562::HTS002,BRD-K11636097-001-03-1,0.00976562,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::0.0390625::HTS002,BRD-K11636097-001-03-1,0.0390625,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::0.15625::HTS002,BRD-K11636097-001-03-1,0.15625,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::0.625::HTS002,BRD-K11636097-001-03-1,0.625,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::2.5::HTS002,BRD-K11636097-001-03-1,2.5,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11636097-001-03-1::10::HTS002,BRD-K11636097-001-03-1,10.0,HTS002,PREP042,JNJ-7706621,CDK inhibitor,"AURKA, AURKB, CDK1, CDK2",NA,NA,Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F,Preclinical
BRD-K11640013-236-10-1::0.00061034::HTS002,BRD-K11640013-236-10-1,0.00061034,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::0.0024414::HTS002,BRD-K11640013-236-10-1,0.0024414,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::0.00976562::HTS002,BRD-K11640013-236-10-1,0.00976562,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::0.0390625::HTS002,BRD-K11640013-236-10-1,0.0390625,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::0.15625::HTS002,BRD-K11640013-236-10-1,0.15625,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::0.625::HTS002,BRD-K11640013-236-10-1,0.625,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::2.5::HTS002,BRD-K11640013-236-10-1,2.5,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11640013-236-10-1::10::HTS002,BRD-K11640013-236-10-1,10.0,HTS002,PREP014,sulfamethazine,PABA antagonist,NA,gastroenterology,"enteritis, enteritis","Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1",Launched
BRD-K11663430-001-02-3::0.000610352::HTS002,BRD-K11663430-001-02-3,0.000610352,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::0.00244141::HTS002,BRD-K11663430-001-02-3,0.00244141,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::0.00976562::HTS002,BRD-K11663430-001-02-3,0.00976562,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::0.0390625::HTS002,BRD-K11663430-001-02-3,0.0390625,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::0.15625::HTS002,BRD-K11663430-001-02-3,0.15625,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::0.625::HTS002,BRD-K11663430-001-02-3,0.625,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::2.5::HTS002,BRD-K11663430-001-02-3,2.5,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11663430-001-02-3::10::HTS002,BRD-K11663430-001-02-3,10.0,HTS002,PREP046,pyroxamide,HDAC inhibitor,HDAC1,NA,NA,"ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",Phase 1
BRD-K11853856-001-01-7::0.00061034::HTS002,BRD-K11853856-001-01-7,0.00061034,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::0.0024414::HTS002,BRD-K11853856-001-01-7,0.0024414,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::0.00976562::HTS002,BRD-K11853856-001-01-7,0.00976562,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::0.0390625::HTS002,BRD-K11853856-001-01-7,0.0390625,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::0.15625::HTS002,BRD-K11853856-001-01-7,0.15625,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::0.625::HTS002,BRD-K11853856-001-01-7,0.625,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::2.5::HTS002,BRD-K11853856-001-01-7,2.5,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11853856-001-01-7::10::HTS002,BRD-K11853856-001-01-7,10.0,HTS002,PREP040,PJ-34,PARP inhibitor,"EEF2, PARP1, PARP15, PARP3",NA,NA,"CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",Preclinical
BRD-K11927976-050-02-9::0.00061034::HTS002,BRD-K11927976-050-02-9,0.00061034,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::0.0024414::HTS002,BRD-K11927976-050-02-9,0.0024414,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::0.00976562::HTS002,BRD-K11927976-050-02-9,0.00976562,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::0.0390625::HTS002,BRD-K11927976-050-02-9,0.0390625,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::0.15625::HTS002,BRD-K11927976-050-02-9,0.15625,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::0.625::HTS002,BRD-K11927976-050-02-9,0.625,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::2.5::HTS002,BRD-K11927976-050-02-9,2.5,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11927976-050-02-9::10::HTS002,BRD-K11927976-050-02-9,10.0,HTS002,PREP033,ER-27319,"mediator release inhibitor, SYK inhibitor",SYK,NA,NA,"Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",Preclinical
BRD-K11973162-003-01-8::0.00061034::HTS002,BRD-K11973162-003-01-8,0.00061034,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::0.0024414::HTS002,BRD-K11973162-003-01-8,0.0024414,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::0.00976562::HTS002,BRD-K11973162-003-01-8,0.00976562,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::0.0390625::HTS002,BRD-K11973162-003-01-8,0.0390625,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::0.15625::HTS002,BRD-K11973162-003-01-8,0.15625,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::0.625::HTS002,BRD-K11973162-003-01-8,0.625,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::2.5::HTS002,BRD-K11973162-003-01-8,2.5,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K11973162-003-01-8::10::HTS002,BRD-K11973162-003-01-8,10.0,HTS002,PREP035,tipiracil,thymidine phosphorylase inhibitor,TYMP,oncology,colorectal cancer,Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O,Launched
BRD-K12040459-001-06-0::0.00061034::HTS002,BRD-K12040459-001-06-0,0.00061034,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::0.0024414::HTS002,BRD-K12040459-001-06-0,0.0024414,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::0.00976562::HTS002,BRD-K12040459-001-06-0,0.00976562,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::0.0390625::HTS002,BRD-K12040459-001-06-0,0.0390625,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::0.15625::HTS002,BRD-K12040459-001-06-0,0.15625,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::0.625::HTS002,BRD-K12040459-001-06-0,0.625,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::2.5::HTS002,BRD-K12040459-001-06-0,2.5,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12040459-001-06-0::10::HTS002,BRD-K12040459-001-06-0,10.0,HTS002,PREP025,AT7867,AKT inhibitor,"AKT2, GSK3B, PKIA, PRKACA",NA,NA,"Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",Preclinical
BRD-K12068470-001-02-5::0.000577201::HTS002,BRD-K12068470-001-02-5,0.000577201,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::0.0023088::HTS002,BRD-K12068470-001-02-5,0.0023088,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::0.00923522::HTS002,BRD-K12068470-001-02-5,0.00923522,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::0.0369409::HTS002,BRD-K12068470-001-02-5,0.0369409,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::0.147764::HTS002,BRD-K12068470-001-02-5,0.147764,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::0.591054::HTS002,BRD-K12068470-001-02-5,0.591054,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::2.36422::HTS002,BRD-K12068470-001-02-5,2.36422,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12068470-001-02-5::9.45686::HTS002,BRD-K12068470-001-02-5,9.45686,HTS002,PREP033,LY2608204,glucokinase activator,GCK,NA,NA,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",Phase 2
BRD-K12184916-001-15-4::0.00061034::HTS002,BRD-K12184916-001-15-4,0.00061034,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::0.0024414::HTS002,BRD-K12184916-001-15-4,0.0024414,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::0.00976562::HTS002,BRD-K12184916-001-15-4,0.00976562,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::0.0390625::HTS002,BRD-K12184916-001-15-4,0.0390625,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::0.15625::HTS002,BRD-K12184916-001-15-4,0.15625,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::0.625::HTS002,BRD-K12184916-001-15-4,0.625,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::2.5::HTS002,BRD-K12184916-001-15-4,2.5,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12184916-001-15-4::10::HTS002,BRD-K12184916-001-15-4,10.0,HTS002,PREP025,NVP-BEZ235,"mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,"Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",Phase 2
BRD-K12244279-001-05-8::0.00061034::HTS002,BRD-K12244279-001-05-8,0.00061034,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::0.0024414::HTS002,BRD-K12244279-001-05-8,0.0024414,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::0.00976562::HTS002,BRD-K12244279-001-05-8,0.00976562,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::0.0390625::HTS002,BRD-K12244279-001-05-8,0.0390625,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::0.15625::HTS002,BRD-K12244279-001-05-8,0.15625,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::0.625::HTS002,BRD-K12244279-001-05-8,0.625,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::2.5::HTS002,BRD-K12244279-001-05-8,2.5,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12244279-001-05-8::10::HTS002,BRD-K12244279-001-05-8,10.0,HTS002,PREP040,MEK1-2-inhibitor,MEK inhibitor,MAP2K2,NA,NA,"N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F, N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F",Preclinical
BRD-K12343256-001-08-9::0.00061034::HTS002,BRD-K12343256-001-08-9,0.00061034,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::0.0024414::HTS002,BRD-K12343256-001-08-9,0.0024414,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::0.00976562::HTS002,BRD-K12343256-001-08-9,0.00976562,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::0.0390625::HTS002,BRD-K12343256-001-08-9,0.0390625,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::0.15625::HTS002,BRD-K12343256-001-08-9,0.15625,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::0.625::HTS002,BRD-K12343256-001-08-9,0.625,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::2.5::HTS002,BRD-K12343256-001-08-9,2.5,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12343256-001-08-9::10::HTS002,BRD-K12343256-001-08-9,10.0,HTS002,PREP035,trametinib,MEK inhibitor,"MAP2K1, MAP2K2",oncology,melanoma,"CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O",Launched
BRD-K12502280-001-08-0::0.00061034::HTS002,BRD-K12502280-001-08-0,0.00061034,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::0.0024414::HTS002,BRD-K12502280-001-08-0,0.0024414,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::0.00976562::HTS002,BRD-K12502280-001-08-0,0.00976562,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::0.0390625::HTS002,BRD-K12502280-001-08-0,0.0390625,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::0.15625::HTS002,BRD-K12502280-001-08-0,0.15625,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::0.625::HTS002,BRD-K12502280-001-08-0,0.625,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::2.5::HTS002,BRD-K12502280-001-08-0,2.5,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12502280-001-08-0::10::HTS002,BRD-K12502280-001-08-0,10.0,HTS002,PREP032,TG-101348,"FLT3 inhibitor, JAK inhibitor","BRD4, JAK1, JAK2, JAK3, TYK2",NA,NA,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C",Phase 3
BRD-K12539581-001-23-7::0.00061034::HTS002,BRD-K12539581-001-23-7,0.00061034,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::0.0024414::HTS002,BRD-K12539581-001-23-7,0.0024414,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::0.00976562::HTS002,BRD-K12539581-001-23-7,0.00976562,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::0.0390625::HTS002,BRD-K12539581-001-23-7,0.0390625,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::0.15625::HTS002,BRD-K12539581-001-23-7,0.15625,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::0.625::HTS002,BRD-K12539581-001-23-7,0.625,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::2.5::HTS002,BRD-K12539581-001-23-7,2.5,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12539581-001-23-7::10::HTS002,BRD-K12539581-001-23-7,10.0,HTS002,PREP040,nocodazole,tubulin polymerization inhibitor,HPGDS,NA,NA,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1",Preclinical
BRD-K12787259-001-04-3::0.00061034::HTS002,BRD-K12787259-001-04-3,0.00061034,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::0.0024414::HTS002,BRD-K12787259-001-04-3,0.0024414,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::0.00976562::HTS002,BRD-K12787259-001-04-3,0.00976562,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::0.0390625::HTS002,BRD-K12787259-001-04-3,0.0390625,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::0.15625::HTS002,BRD-K12787259-001-04-3,0.15625,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::0.625::HTS002,BRD-K12787259-001-04-3,0.625,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::2.5::HTS002,BRD-K12787259-001-04-3,2.5,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12787259-001-04-3::10::HTS002,BRD-K12787259-001-04-3,10.0,HTS002,PREP018,CX-5461,RNA polymerase inhibitor,NA,NA,NA,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,Phase 1
BRD-K12829205-003-02-8::0.00061034::HTS002,BRD-K12829205-003-02-8,0.00061034,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::0.0024414::HTS002,BRD-K12829205-003-02-8,0.0024414,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::0.00976562::HTS002,BRD-K12829205-003-02-8,0.00976562,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::0.0390625::HTS002,BRD-K12829205-003-02-8,0.0390625,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::0.15625::HTS002,BRD-K12829205-003-02-8,0.15625,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::0.625::HTS002,BRD-K12829205-003-02-8,0.625,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::2.5::HTS002,BRD-K12829205-003-02-8,2.5,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12829205-003-02-8::10::HTS002,BRD-K12829205-003-02-8,10.0,HTS002,PREP048,mechlorethamine,DNA inhibitor,NA,"hematologic malignancy, hematology, infectious disease, oncology","Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl",Launched
BRD-K12867552-001-04-7::0.00061034::HTS002,BRD-K12867552-001-04-7,0.00061034,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::0.0024414::HTS002,BRD-K12867552-001-04-7,0.0024414,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::0.00976562::HTS002,BRD-K12867552-001-04-7,0.00976562,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::0.0390625::HTS002,BRD-K12867552-001-04-7,0.0390625,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::0.15625::HTS002,BRD-K12867552-001-04-7,0.15625,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::0.625::HTS002,BRD-K12867552-001-04-7,0.625,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::2.5::HTS002,BRD-K12867552-001-04-7,2.5,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12867552-001-04-7::10::HTS002,BRD-K12867552-001-04-7,10.0,HTS002,PREP047,PCI-24781,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6",NA,NA,CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO,Phase 1/Phase 2
BRD-K12885236-001-02-7::0.00061034::HTS002,BRD-K12885236-001-02-7,0.00061034,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::0.0024414::HTS002,BRD-K12885236-001-02-7,0.0024414,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::0.00976562::HTS002,BRD-K12885236-001-02-7,0.00976562,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::0.0390625::HTS002,BRD-K12885236-001-02-7,0.0390625,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::0.15625::HTS002,BRD-K12885236-001-02-7,0.15625,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::0.625::HTS002,BRD-K12885236-001-02-7,0.625,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::2.5::HTS002,BRD-K12885236-001-02-7,2.5,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K12885236-001-02-7::10::HTS002,BRD-K12885236-001-02-7,10.0,HTS002,PREP018,dapivirine,non-nucleoside reverse transcriptase inhibitor,"CYP3A4, CYP3A5",NA,NA,Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1,Phase 3
BRD-K26634012-001-04-9::0.00061034::HTS002,BRD-K26634012-001-04-9,0.00061034,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::0.0024414::HTS002,BRD-K26634012-001-04-9,0.0024414,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::0.00976562::HTS002,BRD-K26634012-001-04-9,0.00976562,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::0.0390625::HTS002,BRD-K26634012-001-04-9,0.0390625,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::0.15625::HTS002,BRD-K26634012-001-04-9,0.15625,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::0.625::HTS002,BRD-K26634012-001-04-9,0.625,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::2.5::HTS002,BRD-K26634012-001-04-9,2.5,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K26634012-001-04-9::10::HTS002,BRD-K26634012-001-04-9,10.0,HTS002,PREP016,tilmicosin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bovine respiratory disease (BRD),"CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC",Launched
BRD-K12932420-001-02-3::0.00061034::HTS002,BRD-K12932420-001-02-3,0.00061034,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::0.0024414::HTS002,BRD-K12932420-001-02-3,0.0024414,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::0.00976562::HTS002,BRD-K12932420-001-02-3,0.00976562,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::0.0390625::HTS002,BRD-K12932420-001-02-3,0.0390625,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::0.15625::HTS002,BRD-K12932420-001-02-3,0.15625,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::0.625::HTS002,BRD-K12932420-001-02-3,0.625,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::2.5::HTS002,BRD-K12932420-001-02-3,2.5,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K12932420-001-02-3::10::HTS002,BRD-K12932420-001-02-3,10.0,HTS002,PREP047,YM-976,phosphodiesterase inhibitor,PDE4A,NA,NA,"CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",Phase 1
BRD-K13044802-213-20-7::0.00061034::HTS002,BRD-K13044802-213-20-7,0.00061034,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::0.0024414::HTS002,BRD-K13044802-213-20-7,0.0024414,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::0.00976562::HTS002,BRD-K13044802-213-20-7,0.00976562,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::0.0390625::HTS002,BRD-K13044802-213-20-7,0.0390625,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::0.15625::HTS002,BRD-K13044802-213-20-7,0.15625,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::0.625::HTS002,BRD-K13044802-213-20-7,0.625,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::2.5::HTS002,BRD-K13044802-213-20-7,2.5,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13044802-213-20-7::10::HTS002,BRD-K13044802-213-20-7,10.0,HTS002,PREP035,ciclopirox,membrane integrity inhibitor,ATP1A1,infectious disease,onychomycosis,"Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1",Launched
BRD-K13050303-001-17-3::0.000610352::HTS002,BRD-K13050303-001-17-3,0.000610352,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::0.00244141::HTS002,BRD-K13050303-001-17-3,0.00244141,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::0.00976562::HTS002,BRD-K13050303-001-17-3,0.00976562,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::0.0390625::HTS002,BRD-K13050303-001-17-3,0.0390625,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::0.15625::HTS002,BRD-K13050303-001-17-3,0.15625,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::0.625::HTS002,BRD-K13050303-001-17-3,0.625,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::2.5::HTS002,BRD-K13050303-001-17-3,2.5,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050303-001-17-3::10::HTS002,BRD-K13050303-001-17-3,10.0,HTS002,PREP034,uridine,dopamine receptor agonist,"LSM6, TYMP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",Phase 2
BRD-K13050541-001-01-9::0.000683584::HTS002,BRD-K13050541-001-01-9,0.000683584,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::0.00273434::HTS002,BRD-K13050541-001-01-9,0.00273434,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::0.0109373::HTS002,BRD-K13050541-001-01-9,0.0109373,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::0.0437494::HTS002,BRD-K13050541-001-01-9,0.0437494,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::0.174997::HTS002,BRD-K13050541-001-01-9,0.174997,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::0.69999::HTS002,BRD-K13050541-001-01-9,0.69999,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::2.79996::HTS002,BRD-K13050541-001-01-9,2.79996,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13050541-001-01-9::11.1998::HTS002,BRD-K13050541-001-01-9,11.1998,HTS002,PREP024,acivicin,gamma glutamyltransferase Inhibitors,CTPS1,NA,NA,N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O,Phase 2
BRD-K13087974-001-02-5::0.00061034::HTS002,BRD-K13087974-001-02-5,0.00061034,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::0.0024414::HTS002,BRD-K13087974-001-02-5,0.0024414,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::0.00976562::HTS002,BRD-K13087974-001-02-5,0.00976562,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::0.0390625::HTS002,BRD-K13087974-001-02-5,0.0390625,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::0.15625::HTS002,BRD-K13087974-001-02-5,0.15625,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::0.625::HTS002,BRD-K13087974-001-02-5,0.625,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::2.5::HTS002,BRD-K13087974-001-02-5,2.5,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13087974-001-02-5::10::HTS002,BRD-K13087974-001-02-5,10.0,HTS002,PREP041,CGP-52411,EGFR inhibitor,EGFR,NA,NA,"O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",Preclinical
BRD-K13094524-001-07-5::0.000642292::HTS002,BRD-K13094524-001-07-5,0.000642292,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::0.00256917::HTS002,BRD-K13094524-001-07-5,0.00256917,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::0.0102767::HTS002,BRD-K13094524-001-07-5,0.0102767,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::0.0411067::HTS002,BRD-K13094524-001-07-5,0.0411067,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::0.164427::HTS002,BRD-K13094524-001-07-5,0.164427,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::0.657707::HTS002,BRD-K13094524-001-07-5,0.657707,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::2.63083::HTS002,BRD-K13094524-001-07-5,2.63083,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13094524-001-07-5::10.5233::HTS002,BRD-K13094524-001-07-5,10.5233,HTS002,PREP037,PFI-1,bromodomain inhibitor,BRD4,NA,NA,"COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",Preclinical
BRD-K13514097-001-05-3::0.00061034::HTS002,BRD-K13514097-001-05-3,0.00061034,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::0.0024414::HTS002,BRD-K13514097-001-05-3,0.0024414,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::0.00976562::HTS002,BRD-K13514097-001-05-3,0.00976562,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::0.0390625::HTS002,BRD-K13514097-001-05-3,0.0390625,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::0.15625::HTS002,BRD-K13514097-001-05-3,0.15625,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::0.625::HTS002,BRD-K13514097-001-05-3,0.625,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::2.5::HTS002,BRD-K13514097-001-05-3,2.5,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13514097-001-05-3::10::HTS002,BRD-K13514097-001-05-3,10.0,HTS002,PREP020,everolimus,mTOR inhibitor,MTOR,"oncology, neurology/psychiatry, genetics, urology","breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO",Launched
BRD-K13167095-001-02-9::0.00061034::HTS002,BRD-K13167095-001-02-9,0.00061034,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::0.0024414::HTS002,BRD-K13167095-001-02-9,0.0024414,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::0.00976562::HTS002,BRD-K13167095-001-02-9,0.00976562,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::0.0390625::HTS002,BRD-K13167095-001-02-9,0.0390625,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::0.15625::HTS002,BRD-K13167095-001-02-9,0.15625,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::0.625::HTS002,BRD-K13167095-001-02-9,0.625,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::2.5::HTS002,BRD-K13167095-001-02-9,2.5,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13167095-001-02-9::10::HTS002,BRD-K13167095-001-02-9,10.0,HTS002,PREP047,AR-42,HDAC inhibitor,HDAC1,NA,NA,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,Phase 1
BRD-K13169950-001-14-4::0.00061034::HTS002,BRD-K13169950-001-14-4,0.00061034,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::0.0024414::HTS002,BRD-K13169950-001-14-4,0.0024414,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::0.00976562::HTS002,BRD-K13169950-001-14-4,0.00976562,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::0.0390625::HTS002,BRD-K13169950-001-14-4,0.0390625,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::0.15625::HTS002,BRD-K13169950-001-14-4,0.15625,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::0.625::HTS002,BRD-K13169950-001-14-4,0.625,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::2.5::HTS002,BRD-K13169950-001-14-4,2.5,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13169950-001-14-4::10::HTS002,BRD-K13169950-001-14-4,10.0,HTS002,PREP042,NSC-3852,HDAC inhibitor,HDAC1,NA,NA,Oc1ccc([N+][O-])c2cccnc12,Preclinical
BRD-K13183738-317-10-2::0.00061034::HTS002,BRD-K13183738-317-10-2,0.00061034,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::0.0024414::HTS002,BRD-K13183738-317-10-2,0.0024414,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::0.00976562::HTS002,BRD-K13183738-317-10-2,0.00976562,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::0.0390625::HTS002,BRD-K13183738-317-10-2,0.0390625,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::0.15625::HTS002,BRD-K13183738-317-10-2,0.15625,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::0.625::HTS002,BRD-K13183738-317-10-2,0.625,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::2.5::HTS002,BRD-K13183738-317-10-2,2.5,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13183738-317-10-2::10::HTS002,BRD-K13183738-317-10-2,10.0,HTS002,PREP020,pentamidine,anti-pneumocystis agent,TRDMT1,infectious disease,pneumonia,"NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1",Launched
BRD-K13249881-001-02-3::0.00061034::HTS002,BRD-K13249881-001-02-3,0.00061034,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::0.0024414::HTS002,BRD-K13249881-001-02-3,0.0024414,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::0.00976562::HTS002,BRD-K13249881-001-02-3,0.00976562,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::0.0390625::HTS002,BRD-K13249881-001-02-3,0.0390625,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::0.15625::HTS002,BRD-K13249881-001-02-3,0.15625,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::0.625::HTS002,BRD-K13249881-001-02-3,0.625,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::2.5::HTS002,BRD-K13249881-001-02-3,2.5,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13249881-001-02-3::10::HTS002,BRD-K13249881-001-02-3,10.0,HTS002,PREP021,piperazine,benzodiazepine receptor agonist,GABRB3,infectious disease,gastrointestinal roundworms,C1CNCCN1,Launched
BRD-K13302470-001-02-7::0.00061034::HTS002,BRD-K13302470-001-02-7,0.00061034,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::0.0024414::HTS002,BRD-K13302470-001-02-7,0.0024414,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::0.00976562::HTS002,BRD-K13302470-001-02-7,0.00976562,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::0.0390625::HTS002,BRD-K13302470-001-02-7,0.0390625,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::0.15625::HTS002,BRD-K13302470-001-02-7,0.15625,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::0.625::HTS002,BRD-K13302470-001-02-7,0.625,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::2.5::HTS002,BRD-K13302470-001-02-7,2.5,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13302470-001-02-7::10::HTS002,BRD-K13302470-001-02-7,10.0,HTS002,PREP041,KY02111,Wnt pathway inhibitor,DKK1,NA,NA,"COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",Preclinical
BRD-K13314656-001-01-0::0.00061034::HTS002,BRD-K13314656-001-01-0,0.00061034,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::0.0024414::HTS002,BRD-K13314656-001-01-0,0.0024414,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::0.00976562::HTS002,BRD-K13314656-001-01-0,0.00976562,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::0.0390625::HTS002,BRD-K13314656-001-01-0,0.0390625,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::0.15625::HTS002,BRD-K13314656-001-01-0,0.15625,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::0.625::HTS002,BRD-K13314656-001-01-0,0.625,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::2.5::HTS002,BRD-K13314656-001-01-0,2.5,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13314656-001-01-0::10::HTS002,BRD-K13314656-001-01-0,10.0,HTS002,PREP035,ebastine,histamine receptor antagonist,"CYP3A4, HRH1",allergy,"allergic rhinitis, urticaria",CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,Launched
BRD-K13387373-004-14-5::0.00061034::HTS002,BRD-K13387373-004-14-5,0.00061034,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::0.0024414::HTS002,BRD-K13387373-004-14-5,0.0024414,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::0.00976562::HTS002,BRD-K13387373-004-14-5,0.00976562,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::0.0390625::HTS002,BRD-K13387373-004-14-5,0.0390625,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::0.15625::HTS002,BRD-K13387373-004-14-5,0.15625,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::0.625::HTS002,BRD-K13387373-004-14-5,0.625,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::2.5::HTS002,BRD-K13387373-004-14-5,2.5,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13387373-004-14-5::10::HTS002,BRD-K13387373-004-14-5,10.0,HTS002,PREP028,thonzonium,ATPase inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1",Launched
BRD-K13390322-001-06-3::0.00061034::HTS002,BRD-K13390322-001-06-3,0.00061034,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.0024414::HTS002,BRD-K13390322-001-06-3,0.0024414,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.00976562::HTS002,BRD-K13390322-001-06-3,0.00976562,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.0390625::HTS002,BRD-K13390322-001-06-3,0.0390625,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.15625::HTS002,BRD-K13390322-001-06-3,0.15625,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::0.625::HTS002,BRD-K13390322-001-06-3,0.625,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::2.5::HTS002,BRD-K13390322-001-06-3,2.5,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13390322-001-06-3::10::HTS002,BRD-K13390322-001-06-3,10.0,HTS002,PREP024,AT-7519,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK9",NA,NA,Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1,Phase 2
BRD-K13409143-001-01-9::0.000610352::HTS002,BRD-K13409143-001-01-9,0.000610352,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::0.00244141::HTS002,BRD-K13409143-001-01-9,0.00244141,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::0.00976562::HTS002,BRD-K13409143-001-01-9,0.00976562,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::0.0390625::HTS002,BRD-K13409143-001-01-9,0.0390625,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::0.15625::HTS002,BRD-K13409143-001-01-9,0.15625,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::0.625::HTS002,BRD-K13409143-001-01-9,0.625,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::2.5::HTS002,BRD-K13409143-001-01-9,2.5,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13409143-001-01-9::10::HTS002,BRD-K13409143-001-01-9,10.0,HTS002,PREP048,isopropyl-myristate,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C",Launched
BRD-K13566078-001-02-3::0.00061034::HTS002,BRD-K13566078-001-02-3,0.00061034,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::0.0024414::HTS002,BRD-K13566078-001-02-3,0.0024414,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::0.00976562::HTS002,BRD-K13566078-001-02-3,0.00976562,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::0.0390625::HTS002,BRD-K13566078-001-02-3,0.0390625,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::0.15625::HTS002,BRD-K13566078-001-02-3,0.15625,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::0.625::HTS002,BRD-K13566078-001-02-3,0.625,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::2.5::HTS002,BRD-K13566078-001-02-3,2.5,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13566078-001-02-3::10::HTS002,BRD-K13566078-001-02-3,10.0,HTS002,PREP041,BMS-345541,IKK inhibitor,"CHUK, IKBKB",NA,NA,"Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",Preclinical
BRD-K13571841-001-14-4::0.00061034::HTS002,BRD-K13571841-001-14-4,0.00061034,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::0.0024414::HTS002,BRD-K13571841-001-14-4,0.0024414,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::0.00976562::HTS002,BRD-K13571841-001-14-4,0.00976562,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::0.0390625::HTS002,BRD-K13571841-001-14-4,0.0390625,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::0.15625::HTS002,BRD-K13571841-001-14-4,0.15625,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::0.625::HTS002,BRD-K13571841-001-14-4,0.625,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::2.5::HTS002,BRD-K13571841-001-14-4,2.5,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13571841-001-14-4::10::HTS002,BRD-K13571841-001-14-4,10.0,HTS002,PREP024,pepstatin,aspartic protease inhibitor,"CTSB, CTSD, CTSL, REN",NA,NA,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Preclinical
BRD-K13606314-001-01-3::0.00061034::HTS002,BRD-K13606314-001-01-3,0.00061034,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::0.0024414::HTS002,BRD-K13606314-001-01-3,0.0024414,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::0.00976562::HTS002,BRD-K13606314-001-01-3,0.00976562,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::0.0390625::HTS002,BRD-K13606314-001-01-3,0.0390625,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::0.15625::HTS002,BRD-K13606314-001-01-3,0.15625,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::0.625::HTS002,BRD-K13606314-001-01-3,0.625,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::2.5::HTS002,BRD-K13606314-001-01-3,2.5,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13606314-001-01-3::10::HTS002,BRD-K13606314-001-01-3,10.0,HTS002,PREP040,P5091,ubiquitin specific protease inhibitor,USP7,NA,NA,CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O,Preclinical
BRD-K13646352-001-03-8::0.00061034::HTS002,BRD-K13646352-001-03-8,0.00061034,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::0.0024414::HTS002,BRD-K13646352-001-03-8,0.0024414,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::0.00976562::HTS002,BRD-K13646352-001-03-8,0.00976562,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::0.0390625::HTS002,BRD-K13646352-001-03-8,0.0390625,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::0.15625::HTS002,BRD-K13646352-001-03-8,0.15625,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::0.625::HTS002,BRD-K13646352-001-03-8,0.625,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::2.5::HTS002,BRD-K13646352-001-03-8,2.5,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13646352-001-03-8::10::HTS002,BRD-K13646352-001-03-8,10.0,HTS002,PREP018,midostaurin,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","FLT3, PRKCG",hematologic malignancy,acute myeloid leukemia (AML),CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,Launched
BRD-K13662825-001-07-5::0.00061034::HTS002,BRD-K13662825-001-07-5,0.00061034,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.0024414::HTS002,BRD-K13662825-001-07-5,0.0024414,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.00976562::HTS002,BRD-K13662825-001-07-5,0.00976562,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.0390625::HTS002,BRD-K13662825-001-07-5,0.0390625,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.15625::HTS002,BRD-K13662825-001-07-5,0.15625,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::0.625::HTS002,BRD-K13662825-001-07-5,0.625,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::2.5::HTS002,BRD-K13662825-001-07-5,2.5,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13662825-001-07-5::10::HTS002,BRD-K13662825-001-07-5,10.0,HTS002,PREP032,dinaciclib,CDK inhibitor,"CDK1, CDK2, CDK5, CDK9",NA,NA,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO,Phase 3
BRD-K13756951-001-01-4::0.00061034::HTS002,BRD-K13756951-001-01-4,0.00061034,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::0.0024414::HTS002,BRD-K13756951-001-01-4,0.0024414,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::0.00976562::HTS002,BRD-K13756951-001-01-4,0.00976562,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::0.0390625::HTS002,BRD-K13756951-001-01-4,0.0390625,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::0.15625::HTS002,BRD-K13756951-001-01-4,0.15625,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::0.625::HTS002,BRD-K13756951-001-01-4,0.625,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::2.5::HTS002,BRD-K13756951-001-01-4,2.5,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13756951-001-01-4::10::HTS002,BRD-K13756951-001-01-4,10.0,HTS002,PREP027,bitopertin,"glycine transporter inhibitor, GlyT-1 inhibitor","SLC6A5, SLC6A9",NA,NA,C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F,Phase 3
BRD-K13810148-311-03-2::0.00061034::HTS002,BRD-K13810148-311-03-2,0.00061034,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::0.0024414::HTS002,BRD-K13810148-311-03-2,0.0024414,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::0.00976562::HTS002,BRD-K13810148-311-03-2,0.00976562,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::0.0390625::HTS002,BRD-K13810148-311-03-2,0.0390625,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::0.15625::HTS002,BRD-K13810148-311-03-2,0.15625,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::0.625::HTS002,BRD-K13810148-311-03-2,0.625,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::2.5::HTS002,BRD-K13810148-311-03-2,2.5,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13810148-311-03-2::10::HTS002,BRD-K13810148-311-03-2,10.0,HTS002,PREP046,givinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,Phase 2
BRD-K13949769-001-01-7::0.00061034::HTS002,BRD-K13949769-001-01-7,0.00061034,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::0.0024414::HTS002,BRD-K13949769-001-01-7,0.0024414,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::0.00976562::HTS002,BRD-K13949769-001-01-7,0.00976562,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::0.0390625::HTS002,BRD-K13949769-001-01-7,0.0390625,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::0.15625::HTS002,BRD-K13949769-001-01-7,0.15625,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::0.625::HTS002,BRD-K13949769-001-01-7,0.625,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::2.5::HTS002,BRD-K13949769-001-01-7,2.5,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K13949769-001-01-7::10::HTS002,BRD-K13949769-001-01-7,10.0,HTS002,PREP040,tenovin-6,SIRT inhibitor,"SIRT1, SIRT2, SIRT3",NA,NA,"CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",Preclinical
BRD-K14003026-003-09-0::0.000600684::HTS002,BRD-K14003026-003-09-0,0.000600684,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::0.00240274::HTS002,BRD-K14003026-003-09-0,0.00240274,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::0.00961095::HTS002,BRD-K14003026-003-09-0,0.00961095,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::0.0384438::HTS002,BRD-K14003026-003-09-0,0.0384438,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::0.153775::HTS002,BRD-K14003026-003-09-0,0.153775,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::0.615101::HTS002,BRD-K14003026-003-09-0,0.615101,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::2.4604::HTS002,BRD-K14003026-003-09-0,2.4604,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14003026-003-09-0::9.84161::HTS002,BRD-K14003026-003-09-0,9.84161,HTS002,PREP031,ritodrine,adrenergic receptor agonist,ADRB2,obstetrics/gynecology,premature labor,"C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",Launched
BRD-K14109347-001-03-4::0.00061034::HTS002,BRD-K14109347-001-03-4,0.00061034,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.0024414::HTS002,BRD-K14109347-001-03-4,0.0024414,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.00976562::HTS002,BRD-K14109347-001-03-4,0.00976562,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.0390625::HTS002,BRD-K14109347-001-03-4,0.0390625,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.15625::HTS002,BRD-K14109347-001-03-4,0.15625,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::0.625::HTS002,BRD-K14109347-001-03-4,0.625,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::2.5::HTS002,BRD-K14109347-001-03-4,2.5,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14109347-001-03-4::10::HTS002,BRD-K14109347-001-03-4,10.0,HTS002,PREP038,LY2603618,CHK inhibitor,CHEK1,NA,NA,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",Phase 2
BRD-K14175878-001-01-6::0.00061034::HTS002,BRD-K14175878-001-01-6,0.00061034,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::0.0024414::HTS002,BRD-K14175878-001-01-6,0.0024414,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::0.00976562::HTS002,BRD-K14175878-001-01-6,0.00976562,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::0.0390625::HTS002,BRD-K14175878-001-01-6,0.0390625,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::0.15625::HTS002,BRD-K14175878-001-01-6,0.15625,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::0.625::HTS002,BRD-K14175878-001-01-6,0.625,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::2.5::HTS002,BRD-K14175878-001-01-6,2.5,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14175878-001-01-6::10::HTS002,BRD-K14175878-001-01-6,10.0,HTS002,PREP038,MK-0812,CC chemokine receptor antagonist,CCR2,NA,NA,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F,Phase 2
BRD-K14329163-001-03-9::0.00061034::HTS002,BRD-K14329163-001-03-9,0.00061034,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::0.0024414::HTS002,BRD-K14329163-001-03-9,0.0024414,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::0.00976562::HTS002,BRD-K14329163-001-03-9,0.00976562,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::0.0390625::HTS002,BRD-K14329163-001-03-9,0.0390625,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::0.15625::HTS002,BRD-K14329163-001-03-9,0.15625,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::0.625::HTS002,BRD-K14329163-001-03-9,0.625,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::2.5::HTS002,BRD-K14329163-001-03-9,2.5,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14329163-001-03-9::10::HTS002,BRD-K14329163-001-03-9,10.0,HTS002,PREP014,BAY-K-8644-(s)-(-),L-type calcium channel activator,CACNA1C,NA,NA,COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O,Preclinical
BRD-K14385366-001-04-4::0.000633265::HTS002,BRD-K14385366-001-04-4,0.000633265,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::0.00253306::HTS002,BRD-K14385366-001-04-4,0.00253306,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::0.0101322::HTS002,BRD-K14385366-001-04-4,0.0101322,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::0.040529::HTS002,BRD-K14385366-001-04-4,0.040529,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::0.162116::HTS002,BRD-K14385366-001-04-4,0.162116,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::0.648464::HTS002,BRD-K14385366-001-04-4,0.648464,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::2.59386::HTS002,BRD-K14385366-001-04-4,2.59386,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14385366-001-04-4::10.3754::HTS002,BRD-K14385366-001-04-4,10.3754,HTS002,PREP026,FG-4592,hypoxia inducible factor prolyl hydroxylase inhibitor,EGLN2,NA,NA,"Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",Phase 3
BRD-K14560436-001-01-4::0.00061034::HTS002,BRD-K14560436-001-01-4,0.00061034,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::0.0024414::HTS002,BRD-K14560436-001-01-4,0.0024414,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::0.00976562::HTS002,BRD-K14560436-001-01-4,0.00976562,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::0.0390625::HTS002,BRD-K14560436-001-01-4,0.0390625,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::0.15625::HTS002,BRD-K14560436-001-01-4,0.15625,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::0.625::HTS002,BRD-K14560436-001-01-4,0.625,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::2.5::HTS002,BRD-K14560436-001-01-4,2.5,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14560436-001-01-4::10::HTS002,BRD-K14560436-001-01-4,10.0,HTS002,PREP037,TG-02,"CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2",NA,NA,CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2,Phase 1
BRD-K14618467-001-04-6::0.00061034::HTS002,BRD-K14618467-001-04-6,0.00061034,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::0.0024414::HTS002,BRD-K14618467-001-04-6,0.0024414,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::0.00976562::HTS002,BRD-K14618467-001-04-6,0.00976562,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::0.0390625::HTS002,BRD-K14618467-001-04-6,0.0390625,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::0.15625::HTS002,BRD-K14618467-001-04-6,0.15625,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::0.625::HTS002,BRD-K14618467-001-04-6,0.625,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::2.5::HTS002,BRD-K14618467-001-04-6,2.5,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14618467-001-04-6::10::HTS002,BRD-K14618467-001-04-6,10.0,HTS002,PREP040,IKK-16,IKK inhibitor,IKBKB,NA,NA,"O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",Preclinical
BRD-K14796088-003-26-8::0.00061034::HTS002,BRD-K14796088-003-26-8,0.00061034,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::0.0024414::HTS002,BRD-K14796088-003-26-8,0.0024414,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::0.00976562::HTS002,BRD-K14796088-003-26-8,0.00976562,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::0.0390625::HTS002,BRD-K14796088-003-26-8,0.0390625,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::0.15625::HTS002,BRD-K14796088-003-26-8,0.15625,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::0.625::HTS002,BRD-K14796088-003-26-8,0.625,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::2.5::HTS002,BRD-K14796088-003-26-8,2.5,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14796088-003-26-8::10::HTS002,BRD-K14796088-003-26-8,10.0,HTS002,PREP018,berberine,LDL receptor activator,LDLR,NA,NA,"COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC",Phase 2/Phase 3
BRD-K14880289-001-02-2::0.00061034::HTS002,BRD-K14880289-001-02-2,0.00061034,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::0.0024414::HTS002,BRD-K14880289-001-02-2,0.0024414,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::0.00976562::HTS002,BRD-K14880289-001-02-2,0.00976562,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::0.0390625::HTS002,BRD-K14880289-001-02-2,0.0390625,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::0.15625::HTS002,BRD-K14880289-001-02-2,0.15625,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::0.625::HTS002,BRD-K14880289-001-02-2,0.625,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::2.5::HTS002,BRD-K14880289-001-02-2,2.5,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14880289-001-02-2::10::HTS002,BRD-K14880289-001-02-2,10.0,HTS002,PREP026,GW-501516,PPAR receptor agonist,"PPARA, PPARD",NA,NA,"Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",Phase 2
BRD-K14991967-001-02-6::0.00061034::HTS002,BRD-K14991967-001-02-6,0.00061034,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::0.0024414::HTS002,BRD-K14991967-001-02-6,0.0024414,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::0.00976562::HTS002,BRD-K14991967-001-02-6,0.00976562,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::0.0390625::HTS002,BRD-K14991967-001-02-6,0.0390625,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::0.15625::HTS002,BRD-K14991967-001-02-6,0.15625,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::0.625::HTS002,BRD-K14991967-001-02-6,0.625,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::2.5::HTS002,BRD-K14991967-001-02-6,2.5,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K14991967-001-02-6::10::HTS002,BRD-K14991967-001-02-6,10.0,HTS002,PREP037,GSK650394,serum/glucocorticoid regulated kinase inhibitor,"SGK1, SGK2",NA,NA,"OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",Preclinical
BRD-K15025317-001-15-1::0.00061034::HTS002,BRD-K15025317-001-15-1,0.00061034,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::0.0024414::HTS002,BRD-K15025317-001-15-1,0.0024414,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::0.00976562::HTS002,BRD-K15025317-001-15-1,0.00976562,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::0.0390625::HTS002,BRD-K15025317-001-15-1,0.0390625,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::0.15625::HTS002,BRD-K15025317-001-15-1,0.15625,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::0.625::HTS002,BRD-K15025317-001-15-1,0.625,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::2.5::HTS002,BRD-K15025317-001-15-1,2.5,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15025317-001-15-1::10::HTS002,BRD-K15025317-001-15-1,10.0,HTS002,PREP041,BAY-11-7082,NFkB pathway inhibitor,RELA,NA,NA,"Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",Preclinical
BRD-K15071410-001-01-1::0.00061034::HTS002,BRD-K15071410-001-01-1,0.00061034,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::0.0024414::HTS002,BRD-K15071410-001-01-1,0.0024414,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::0.00976562::HTS002,BRD-K15071410-001-01-1,0.00976562,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::0.0390625::HTS002,BRD-K15071410-001-01-1,0.0390625,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::0.15625::HTS002,BRD-K15071410-001-01-1,0.15625,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::0.625::HTS002,BRD-K15071410-001-01-1,0.625,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::2.5::HTS002,BRD-K15071410-001-01-1,2.5,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15071410-001-01-1::10::HTS002,BRD-K15071410-001-01-1,10.0,HTS002,PREP038,tiotidine,histamine receptor antagonist,HRH2,NA,NA,"CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",Phase 2
BRD-K15108141-001-06-6::0.00061034::HTS002,BRD-K15108141-001-06-6,0.00061034,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::0.0024414::HTS002,BRD-K15108141-001-06-6,0.0024414,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::0.00976562::HTS002,BRD-K15108141-001-06-6,0.00976562,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::0.0390625::HTS002,BRD-K15108141-001-06-6,0.0390625,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::0.15625::HTS002,BRD-K15108141-001-06-6,0.15625,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::0.625::HTS002,BRD-K15108141-001-06-6,0.625,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::2.5::HTS002,BRD-K15108141-001-06-6,2.5,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15108141-001-06-6::10::HTS002,BRD-K15108141-001-06-6,10.0,HTS002,PREP034,gemcitabine,ribonucleotide reductase inhibitor,"CMPK1, RRM1, RRM2, TYMS",oncology,"ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",Launched
BRD-K15179879-001-03-2::0.00061034::HTS002,BRD-K15179879-001-03-2,0.00061034,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.0024414::HTS002,BRD-K15179879-001-03-2,0.0024414,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.00976562::HTS002,BRD-K15179879-001-03-2,0.00976562,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.0390625::HTS002,BRD-K15179879-001-03-2,0.0390625,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.15625::HTS002,BRD-K15179879-001-03-2,0.15625,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::0.625::HTS002,BRD-K15179879-001-03-2,0.625,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::2.5::HTS002,BRD-K15179879-001-03-2,2.5,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15179879-001-03-2::10::HTS002,BRD-K15179879-001-03-2,10.0,HTS002,PREP034,carfilzomib,proteasome inhibitor,"PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9",hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,Launched
BRD-K15409150-001-05-8::0.00061034::HTS002,BRD-K15409150-001-05-8,0.00061034,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::0.0024414::HTS002,BRD-K15409150-001-05-8,0.0024414,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::0.00976562::HTS002,BRD-K15409150-001-05-8,0.00976562,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::0.0390625::HTS002,BRD-K15409150-001-05-8,0.0390625,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::0.15625::HTS002,BRD-K15409150-001-05-8,0.15625,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::0.625::HTS002,BRD-K15409150-001-05-8,0.625,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::2.5::HTS002,BRD-K15409150-001-05-8,2.5,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15409150-001-05-8::10::HTS002,BRD-K15409150-001-05-8,10.0,HTS002,PREP034,penfluridol,T-type calcium channel blocker,CACNA1G,neurology/psychiatry,schizophrenia,"OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F",Launched
BRD-K15424032-001-03-6::0.00061034::HTS002,BRD-K15424032-001-03-6,0.00061034,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::0.0024414::HTS002,BRD-K15424032-001-03-6,0.0024414,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::0.00976562::HTS002,BRD-K15424032-001-03-6,0.00976562,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::0.0390625::HTS002,BRD-K15424032-001-03-6,0.0390625,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::0.15625::HTS002,BRD-K15424032-001-03-6,0.15625,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::0.625::HTS002,BRD-K15424032-001-03-6,0.625,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::2.5::HTS002,BRD-K15424032-001-03-6,2.5,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15424032-001-03-6::10::HTS002,BRD-K15424032-001-03-6,10.0,HTS002,PREP015,SB-228357,serotonin receptor antagonist,"HTR2A, HTR2B, HTR2C",NA,NA,"COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",Preclinical
BRD-K15519488-050-01-3::0.00061034::HTS002,BRD-K15519488-050-01-3,0.00061034,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::0.0024414::HTS002,BRD-K15519488-050-01-3,0.0024414,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::0.00976562::HTS002,BRD-K15519488-050-01-3,0.00976562,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::0.0390625::HTS002,BRD-K15519488-050-01-3,0.0390625,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::0.15625::HTS002,BRD-K15519488-050-01-3,0.15625,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::0.625::HTS002,BRD-K15519488-050-01-3,0.625,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::2.5::HTS002,BRD-K15519488-050-01-3,2.5,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15519488-050-01-3::10::HTS002,BRD-K15519488-050-01-3,10.0,HTS002,PREP045,CS-110266,dopamine receptor agonist,SLC6A3,NA,NA,"C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",Preclinical
BRD-K15567136-003-27-2::0.00061034::HTS002,BRD-K15567136-003-27-2,0.00061034,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::0.0024414::HTS002,BRD-K15567136-003-27-2,0.0024414,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::0.00976562::HTS002,BRD-K15567136-003-27-2,0.00976562,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::0.0390625::HTS002,BRD-K15567136-003-27-2,0.0390625,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::0.15625::HTS002,BRD-K15567136-003-27-2,0.15625,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::0.625::HTS002,BRD-K15567136-003-27-2,0.625,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::2.5::HTS002,BRD-K15567136-003-27-2,2.5,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15567136-003-27-2::10::HTS002,BRD-K15567136-003-27-2,10.0,HTS002,PREP020,papaverine,phosphodiesterase inhibitor,"PDE10A, PDE4B, PDE5A","cardiology, hematology, gastroenterology","myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm",COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Launched
BRD-K15600710-066-04-1::0.00061034::HTS002,BRD-K15600710-066-04-1,0.00061034,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::0.0024414::HTS002,BRD-K15600710-066-04-1,0.0024414,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::0.00976562::HTS002,BRD-K15600710-066-04-1,0.00976562,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::0.0390625::HTS002,BRD-K15600710-066-04-1,0.0390625,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::0.15625::HTS002,BRD-K15600710-066-04-1,0.15625,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::0.625::HTS002,BRD-K15600710-066-04-1,0.625,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::2.5::HTS002,BRD-K15600710-066-04-1,2.5,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15600710-066-04-1::10::HTS002,BRD-K15600710-066-04-1,10.0,HTS002,PREP025,obatoclax,BCL inhibitor,BCL2,NA,NA,"COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1",Phase 3
BRD-K15766189-001-09-8::0.00061034::HTS002,BRD-K15766189-001-09-8,0.00061034,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::0.0024414::HTS002,BRD-K15766189-001-09-8,0.0024414,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::0.00976562::HTS002,BRD-K15766189-001-09-8,0.00976562,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::0.0390625::HTS002,BRD-K15766189-001-09-8,0.0390625,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::0.15625::HTS002,BRD-K15766189-001-09-8,0.15625,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::0.625::HTS002,BRD-K15766189-001-09-8,0.625,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::2.5::HTS002,BRD-K15766189-001-09-8,2.5,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15766189-001-09-8::10::HTS002,BRD-K15766189-001-09-8,10.0,HTS002,PREP031,cefdinir,bacterial cell wall synthesis inhibitor,MPO,"infectious disease, otolaryngology, pulmonary","pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis","Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O",Launched
BRD-K15898725-001-01-7::0.00061034::HTS002,BRD-K15898725-001-01-7,0.00061034,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::0.0024414::HTS002,BRD-K15898725-001-01-7,0.0024414,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::0.00976562::HTS002,BRD-K15898725-001-01-7,0.00976562,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::0.0390625::HTS002,BRD-K15898725-001-01-7,0.0390625,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::0.15625::HTS002,BRD-K15898725-001-01-7,0.15625,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::0.625::HTS002,BRD-K15898725-001-01-7,0.625,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::2.5::HTS002,BRD-K15898725-001-01-7,2.5,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15898725-001-01-7::10::HTS002,BRD-K15898725-001-01-7,10.0,HTS002,PREP036,maytansinol-isobutyrate,NA,NA,NA,NA,CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2,Preclinical
BRD-K15916496-001-27-9::0.00061034::HTS002,BRD-K15916496-001-27-9,0.00061034,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::0.0024414::HTS002,BRD-K15916496-001-27-9,0.0024414,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::0.00976562::HTS002,BRD-K15916496-001-27-9,0.00976562,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::0.0390625::HTS002,BRD-K15916496-001-27-9,0.0390625,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::0.15625::HTS002,BRD-K15916496-001-27-9,0.15625,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::0.625::HTS002,BRD-K15916496-001-27-9,0.625,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::2.5::HTS002,BRD-K15916496-001-27-9,2.5,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K15916496-001-27-9::10::HTS002,BRD-K15916496-001-27-9,10.0,HTS002,PREP017,clotrimazole,"cytochrome P450 inhibitor, imidazoline receptor ligand","CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8",infectious disease,"vulvovaginal candidiasis, oropharyngeal candidiasis","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1",Launched
BRD-K24048528-001-02-5::0.00061034::HTS002,BRD-K24048528-001-02-5,0.00061034,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::0.0024414::HTS002,BRD-K24048528-001-02-5,0.0024414,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::0.00976562::HTS002,BRD-K24048528-001-02-5,0.00976562,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::0.0390625::HTS002,BRD-K24048528-001-02-5,0.0390625,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::0.15625::HTS002,BRD-K24048528-001-02-5,0.15625,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::0.625::HTS002,BRD-K24048528-001-02-5,0.625,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::2.5::HTS002,BRD-K24048528-001-02-5,2.5,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K24048528-001-02-5::10::HTS002,BRD-K24048528-001-02-5,10.0,HTS002,PREP020,abiraterone-acetate,androgen biosynthesis inhibitor,CYP17A1,oncology,prostate cancer,"CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1",Launched
BRD-K16136380-001-01-7::0.00061034::HTS002,BRD-K16136380-001-01-7,0.00061034,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::0.0024414::HTS002,BRD-K16136380-001-01-7,0.0024414,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::0.00976562::HTS002,BRD-K16136380-001-01-7,0.00976562,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::0.0390625::HTS002,BRD-K16136380-001-01-7,0.0390625,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::0.15625::HTS002,BRD-K16136380-001-01-7,0.15625,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::0.625::HTS002,BRD-K16136380-001-01-7,0.625,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::2.5::HTS002,BRD-K16136380-001-01-7,2.5,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16136380-001-01-7::10::HTS002,BRD-K16136380-001-01-7,10.0,HTS002,PREP048,pyrithione-zinc,ATP synthase inhibitor,"KCNQ1, KCNQ2, KCNQ4, KCNQ5",dermatology,dandruff,"O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1",Launched
BRD-K16189898-003-03-3::0.00061034::HTS002,BRD-K16189898-003-03-3,0.00061034,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::0.0024414::HTS002,BRD-K16189898-003-03-3,0.0024414,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::0.00976562::HTS002,BRD-K16189898-003-03-3,0.00976562,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::0.0390625::HTS002,BRD-K16189898-003-03-3,0.0390625,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::0.15625::HTS002,BRD-K16189898-003-03-3,0.15625,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::0.625::HTS002,BRD-K16189898-003-03-3,0.625,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::2.5::HTS002,BRD-K16189898-003-03-3,2.5,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16189898-003-03-3::10::HTS002,BRD-K16189898-003-03-3,10.0,HTS002,PREP041,CHIR-99021,glycogen synthase kinase inhibitor,"CDK1, GSK3A, GSK3B, MAPK1",NA,NA,"Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",Preclinical
BRD-K16195444-003-26-0::0.00061034::HTS002,BRD-K16195444-003-26-0,0.00061034,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::0.0024414::HTS002,BRD-K16195444-003-26-0,0.0024414,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::0.00976562::HTS002,BRD-K16195444-003-26-0,0.00976562,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::0.0390625::HTS002,BRD-K16195444-003-26-0,0.0390625,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::0.15625::HTS002,BRD-K16195444-003-26-0,0.15625,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::0.625::HTS002,BRD-K16195444-003-26-0,0.625,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::2.5::HTS002,BRD-K16195444-003-26-0,2.5,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16195444-003-26-0::10::HTS002,BRD-K16195444-003-26-0,10.0,HTS002,PREP030,oxymetazoline,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C",otolaryngology,nasal congestion,"Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C",Launched
BRD-K16277217-001-10-9::0.00061034::HTS002,BRD-K16277217-001-10-9,0.00061034,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::0.0024414::HTS002,BRD-K16277217-001-10-9,0.0024414,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::0.00976562::HTS002,BRD-K16277217-001-10-9,0.00976562,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::0.0390625::HTS002,BRD-K16277217-001-10-9,0.0390625,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::0.15625::HTS002,BRD-K16277217-001-10-9,0.15625,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::0.625::HTS002,BRD-K16277217-001-10-9,0.625,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::2.5::HTS002,BRD-K16277217-001-10-9,2.5,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16277217-001-10-9::10::HTS002,BRD-K16277217-001-10-9,10.0,HTS002,PREP020,piperacetazine,dopamine receptor antagonist,NA,neurology/psychiatry,schizophrenia,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1,Launched
BRD-K16478699-001-09-2::0.00061034::HTS002,BRD-K16478699-001-09-2,0.00061034,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::0.0024414::HTS002,BRD-K16478699-001-09-2,0.0024414,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::0.00976562::HTS002,BRD-K16478699-001-09-2,0.00976562,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::0.0390625::HTS002,BRD-K16478699-001-09-2,0.0390625,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::0.15625::HTS002,BRD-K16478699-001-09-2,0.15625,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::0.625::HTS002,BRD-K16478699-001-09-2,0.625,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::2.5::HTS002,BRD-K16478699-001-09-2,2.5,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16478699-001-09-2::10::HTS002,BRD-K16478699-001-09-2,10.0,HTS002,PREP037,PLX-4720,RAF inhibitor,"BRAF, KDR",NA,NA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F,Preclinical
BRD-K16485616-001-08-9::0.00061034::HTS002,BRD-K16485616-001-08-9,0.00061034,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::0.0024414::HTS002,BRD-K16485616-001-08-9,0.0024414,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::0.00976562::HTS002,BRD-K16485616-001-08-9,0.00976562,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::0.0390625::HTS002,BRD-K16485616-001-08-9,0.0390625,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::0.15625::HTS002,BRD-K16485616-001-08-9,0.15625,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::0.625::HTS002,BRD-K16485616-001-08-9,0.625,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::2.5::HTS002,BRD-K16485616-001-08-9,2.5,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16485616-001-08-9::10::HTS002,BRD-K16485616-001-08-9,10.0,HTS002,PREP025,mocetinostat,HDAC inhibitor,"HDAC1, HDAC11, HDAC2, HDAC3",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",Phase 2
BRD-K16551357-001-03-2::0.000610352::HTS002,BRD-K16551357-001-03-2,0.000610352,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::0.00244141::HTS002,BRD-K16551357-001-03-2,0.00244141,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::0.00976562::HTS002,BRD-K16551357-001-03-2,0.00976562,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::0.0390625::HTS002,BRD-K16551357-001-03-2,0.0390625,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::0.15625::HTS002,BRD-K16551357-001-03-2,0.15625,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::0.625::HTS002,BRD-K16551357-001-03-2,0.625,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::2.5::HTS002,BRD-K16551357-001-03-2,2.5,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16551357-001-03-2::10::HTS002,BRD-K16551357-001-03-2,10.0,HTS002,PREP019,evacetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",Phase 3
BRD-K16664969-001-03-3::0.00061034::HTS002,BRD-K16664969-001-03-3,0.00061034,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::0.0024414::HTS002,BRD-K16664969-001-03-3,0.0024414,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::0.00976562::HTS002,BRD-K16664969-001-03-3,0.00976562,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::0.0390625::HTS002,BRD-K16664969-001-03-3,0.0390625,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::0.15625::HTS002,BRD-K16664969-001-03-3,0.15625,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::0.625::HTS002,BRD-K16664969-001-03-3,0.625,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::2.5::HTS002,BRD-K16664969-001-03-3,2.5,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16664969-001-03-3::10::HTS002,BRD-K16664969-001-03-3,10.0,HTS002,PREP040,GTP-14564,"FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB",NA,NA,"c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21, c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21",Preclinical
BRD-K16730910-001-07-3::0.00061034::HTS002,BRD-K16730910-001-07-3,0.00061034,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::0.0024414::HTS002,BRD-K16730910-001-07-3,0.0024414,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::0.00976562::HTS002,BRD-K16730910-001-07-3,0.00976562,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::0.0390625::HTS002,BRD-K16730910-001-07-3,0.0390625,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::0.15625::HTS002,BRD-K16730910-001-07-3,0.15625,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::0.625::HTS002,BRD-K16730910-001-07-3,0.625,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::2.5::HTS002,BRD-K16730910-001-07-3,2.5,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16730910-001-07-3::10::HTS002,BRD-K16730910-001-07-3,10.0,HTS002,PREP016,regorafenib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK",oncology,"colorectal cancer, gastrointestinal stromal tumors (GIST)",CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,Launched
BRD-K16803204-001-01-6::0.00061034::HTS002,BRD-K16803204-001-01-6,0.00061034,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::0.0024414::HTS002,BRD-K16803204-001-01-6,0.0024414,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::0.00976562::HTS002,BRD-K16803204-001-01-6,0.00976562,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::0.0390625::HTS002,BRD-K16803204-001-01-6,0.0390625,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::0.15625::HTS002,BRD-K16803204-001-01-6,0.15625,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::0.625::HTS002,BRD-K16803204-001-01-6,0.625,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::2.5::HTS002,BRD-K16803204-001-01-6,2.5,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K16803204-001-01-6::10::HTS002,BRD-K16803204-001-01-6,10.0,HTS002,PREP044,filgotinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2",NA,NA,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,Phase 2
BRD-K17026858-001-01-2::0.00061034::HTS002,BRD-K17026858-001-01-2,0.00061034,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::0.0024414::HTS002,BRD-K17026858-001-01-2,0.0024414,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::0.00976562::HTS002,BRD-K17026858-001-01-2,0.00976562,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::0.0390625::HTS002,BRD-K17026858-001-01-2,0.0390625,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::0.15625::HTS002,BRD-K17026858-001-01-2,0.15625,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::0.625::HTS002,BRD-K17026858-001-01-2,0.625,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::2.5::HTS002,BRD-K17026858-001-01-2,2.5,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17026858-001-01-2::10::HTS002,BRD-K17026858-001-01-2,10.0,HTS002,PREP039,pibenzimol,DNA inhibitor,NA,NA,NA,"c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",Phase 2
BRD-K17061841-001-03-5::0.00061034::HTS002,BRD-K17061841-001-03-5,0.00061034,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::0.0024414::HTS002,BRD-K17061841-001-03-5,0.0024414,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::0.00976562::HTS002,BRD-K17061841-001-03-5,0.00976562,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::0.0390625::HTS002,BRD-K17061841-001-03-5,0.0390625,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::0.15625::HTS002,BRD-K17061841-001-03-5,0.15625,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::0.625::HTS002,BRD-K17061841-001-03-5,0.625,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::2.5::HTS002,BRD-K17061841-001-03-5,2.5,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17061841-001-03-5::10::HTS002,BRD-K17061841-001-03-5,10.0,HTS002,PREP046,stattic,NA,NA,NA,NA,[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1,Preclinical
BRD-K17068645-003-04-2::0.00061034::HTS002,BRD-K17068645-003-04-2,0.00061034,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::0.0024414::HTS002,BRD-K17068645-003-04-2,0.0024414,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::0.00976562::HTS002,BRD-K17068645-003-04-2,0.00976562,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::0.0390625::HTS002,BRD-K17068645-003-04-2,0.0390625,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::0.15625::HTS002,BRD-K17068645-003-04-2,0.15625,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::0.625::HTS002,BRD-K17068645-003-04-2,0.625,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::2.5::HTS002,BRD-K17068645-003-04-2,2.5,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17068645-003-04-2::10::HTS002,BRD-K17068645-003-04-2,10.0,HTS002,PREP030,bendamustine,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)","Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl",Launched
BRD-K17075857-001-18-4::0.000610352::HTS002,BRD-K17075857-001-18-4,0.000610352,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::0.00244141::HTS002,BRD-K17075857-001-18-4,0.00244141,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::0.00976562::HTS002,BRD-K17075857-001-18-4,0.00976562,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::0.0390625::HTS002,BRD-K17075857-001-18-4,0.0390625,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::0.15625::HTS002,BRD-K17075857-001-18-4,0.15625,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::0.625::HTS002,BRD-K17075857-001-18-4,0.625,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::2.5::HTS002,BRD-K17075857-001-18-4,2.5,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17075857-001-18-4::10::HTS002,BRD-K17075857-001-18-4,10.0,HTS002,PREP031,chloroxine,opioid receptor antagonist,OPRK1,"gastroenterology, infectious disease, dermatology","diarrhea, inflammatory bowel disease, giardiasis, dandruff","Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12",Launched
BRD-K17203476-001-01-9::0.00061034::HTS002,BRD-K17203476-001-01-9,0.00061034,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::0.0024414::HTS002,BRD-K17203476-001-01-9,0.0024414,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::0.00976562::HTS002,BRD-K17203476-001-01-9,0.00976562,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::0.0390625::HTS002,BRD-K17203476-001-01-9,0.0390625,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::0.15625::HTS002,BRD-K17203476-001-01-9,0.15625,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::0.625::HTS002,BRD-K17203476-001-01-9,0.625,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::2.5::HTS002,BRD-K17203476-001-01-9,2.5,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17203476-001-01-9::10::HTS002,BRD-K17203476-001-01-9,10.0,HTS002,PREP046,LY2874455,FGFR antagonist,"FGFR1, FGFR2, FGFR3, FGFR4, KDR",NA,NA,C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,Phase 1
BRD-K17294426-050-12-3::0.00061034::HTS002,BRD-K17294426-050-12-3,0.00061034,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::0.0024414::HTS002,BRD-K17294426-050-12-3,0.0024414,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::0.00976562::HTS002,BRD-K17294426-050-12-3,0.00976562,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::0.0390625::HTS002,BRD-K17294426-050-12-3,0.0390625,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::0.15625::HTS002,BRD-K17294426-050-12-3,0.15625,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::0.625::HTS002,BRD-K17294426-050-12-3,0.625,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::2.5::HTS002,BRD-K17294426-050-12-3,2.5,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17294426-050-12-3::10::HTS002,BRD-K17294426-050-12-3,10.0,HTS002,PREP023,clebopride,dopamine receptor antagonist,"ACHE, DRD2",gastroenterology,nausea,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,Launched
BRD-K17518951-001-03-0::0.00061034::HTS002,BRD-K17518951-001-03-0,0.00061034,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::0.0024414::HTS002,BRD-K17518951-001-03-0,0.0024414,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::0.00976562::HTS002,BRD-K17518951-001-03-0,0.00976562,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::0.0390625::HTS002,BRD-K17518951-001-03-0,0.0390625,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::0.15625::HTS002,BRD-K17518951-001-03-0,0.15625,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::0.625::HTS002,BRD-K17518951-001-03-0,0.625,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::2.5::HTS002,BRD-K17518951-001-03-0,2.5,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17518951-001-03-0::10::HTS002,BRD-K17518951-001-03-0,10.0,HTS002,PREP048,penicillamine-(D),chelating agent,NA,"metabolism, rheumatology, nephrology","Wilson's disease, rheumatoid arthritis, cystinuria","CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O",Launched
BRD-K17555800-003-01-5::0.00061034::HTS002,BRD-K17555800-003-01-5,0.00061034,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::0.0024414::HTS002,BRD-K17555800-003-01-5,0.0024414,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::0.00976562::HTS002,BRD-K17555800-003-01-5,0.00976562,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::0.0390625::HTS002,BRD-K17555800-003-01-5,0.0390625,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::0.15625::HTS002,BRD-K17555800-003-01-5,0.15625,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::0.625::HTS002,BRD-K17555800-003-01-5,0.625,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::2.5::HTS002,BRD-K17555800-003-01-5,2.5,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17555800-003-01-5::10::HTS002,BRD-K17555800-003-01-5,10.0,HTS002,PREP047,talmapimod,p38 MAPK inhibitor,"MAPK11, MAPK14",NA,NA,"C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",Phase 2
BRD-K17702546-001-03-2::0.00061034::HTS002,BRD-K17702546-001-03-2,0.00061034,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::0.0024414::HTS002,BRD-K17702546-001-03-2,0.0024414,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::0.00976562::HTS002,BRD-K17702546-001-03-2,0.00976562,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::0.0390625::HTS002,BRD-K17702546-001-03-2,0.0390625,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::0.15625::HTS002,BRD-K17702546-001-03-2,0.15625,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::0.625::HTS002,BRD-K17702546-001-03-2,0.625,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::2.5::HTS002,BRD-K17702546-001-03-2,2.5,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17702546-001-03-2::10::HTS002,BRD-K17702546-001-03-2,10.0,HTS002,PREP037,PD-168393,EGFR inhibitor,"EGFR, ERBB2, SRC",NA,NA,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,Preclinical
BRD-K17705806-003-04-4::0.00061034::HTS002,BRD-K17705806-003-04-4,0.00061034,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::0.0024414::HTS002,BRD-K17705806-003-04-4,0.0024414,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::0.00976562::HTS002,BRD-K17705806-003-04-4,0.00976562,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::0.0390625::HTS002,BRD-K17705806-003-04-4,0.0390625,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::0.15625::HTS002,BRD-K17705806-003-04-4,0.15625,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::0.625::HTS002,BRD-K17705806-003-04-4,0.625,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::2.5::HTS002,BRD-K17705806-003-04-4,2.5,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17705806-003-04-4::10::HTS002,BRD-K17705806-003-04-4,10.0,HTS002,PREP047,JTC-801,opioid receptor antagonist,OPRL1,NA,NA,"CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",Phase 2
BRD-K17743125-001-08-4::0.00061034::HTS002,BRD-K17743125-001-08-4,0.00061034,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.0024414::HTS002,BRD-K17743125-001-08-4,0.0024414,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.00976562::HTS002,BRD-K17743125-001-08-4,0.00976562,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.0390625::HTS002,BRD-K17743125-001-08-4,0.0390625,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.15625::HTS002,BRD-K17743125-001-08-4,0.15625,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::0.625::HTS002,BRD-K17743125-001-08-4,0.625,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::2.5::HTS002,BRD-K17743125-001-08-4,2.5,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17743125-001-08-4::10::HTS002,BRD-K17743125-001-08-4,10.0,HTS002,PREP014,belinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,peripheral T-cell lymphoma (PTCL),ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,Launched
BRD-K17849083-001-32-9::0.00059423::HTS002,BRD-K17849083-001-32-9,0.00059423,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::0.00237692::HTS002,BRD-K17849083-001-32-9,0.00237692,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::0.00950768::HTS002,BRD-K17849083-001-32-9,0.00950768,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::0.0380307::HTS002,BRD-K17849083-001-32-9,0.0380307,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::0.152123::HTS002,BRD-K17849083-001-32-9,0.152123,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::0.608491::HTS002,BRD-K17849083-001-32-9,0.608491,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::2.43397::HTS002,BRD-K17849083-001-32-9,2.43397,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17849083-001-32-9::9.73586::HTS002,BRD-K17849083-001-32-9,9.73586,HTS002,PREP030,tranilast,angiogenesis inhibitor,"HPGDS, HRH1",pulmonary,asthma,"COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC",Launched
BRD-K17894950-001-14-3::0.00061034::HTS002,BRD-K17894950-001-14-3,0.00061034,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.0024414::HTS002,BRD-K17894950-001-14-3,0.0024414,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.00976562::HTS002,BRD-K17894950-001-14-3,0.00976562,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.0390625::HTS002,BRD-K17894950-001-14-3,0.0390625,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.15625::HTS002,BRD-K17894950-001-14-3,0.15625,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::0.625::HTS002,BRD-K17894950-001-14-3,0.625,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::2.5::HTS002,BRD-K17894950-001-14-3,2.5,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K17894950-001-14-3::10::HTS002,BRD-K17894950-001-14-3,10.0,HTS002,PREP047,indirubin,"CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A",NA,NA,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,Phase 2/Phase 3
BRD-K54634444-001-05-9::0.00061034::HTS002,BRD-K54634444-001-05-9,0.00061034,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::0.0024414::HTS002,BRD-K54634444-001-05-9,0.0024414,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::0.00976562::HTS002,BRD-K54634444-001-05-9,0.00976562,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::0.0390625::HTS002,BRD-K54634444-001-05-9,0.0390625,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::0.15625::HTS002,BRD-K54634444-001-05-9,0.15625,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::0.625::HTS002,BRD-K54634444-001-05-9,0.625,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::2.5::HTS002,BRD-K54634444-001-05-9,2.5,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K54634444-001-05-9::10::HTS002,BRD-K54634444-001-05-9,10.0,HTS002,PREP031,artesunate,DNA synthesis inhibitor,NA,infectious disease,malaria,"C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4",Launched
BRD-K17979676-001-01-2::0.00061034::HTS002,BRD-K17979676-001-01-2,0.00061034,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::0.0024414::HTS002,BRD-K17979676-001-01-2,0.0024414,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::0.00976562::HTS002,BRD-K17979676-001-01-2,0.00976562,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::0.0390625::HTS002,BRD-K17979676-001-01-2,0.0390625,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::0.15625::HTS002,BRD-K17979676-001-01-2,0.15625,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::0.625::HTS002,BRD-K17979676-001-01-2,0.625,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::2.5::HTS002,BRD-K17979676-001-01-2,2.5,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K17979676-001-01-2::10::HTS002,BRD-K17979676-001-01-2,10.0,HTS002,PREP020,eprobemide,monoamine oxidase inhibitor,MAOA,neurology/psychiatry,depression,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,Launched
BRD-K18157228-001-01-7::0.000610352::HTS002,BRD-K18157228-001-01-7,0.000610352,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::0.00244141::HTS002,BRD-K18157228-001-01-7,0.00244141,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::0.00976562::HTS002,BRD-K18157228-001-01-7,0.00976562,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::0.0390625::HTS002,BRD-K18157228-001-01-7,0.0390625,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::0.15625::HTS002,BRD-K18157228-001-01-7,0.15625,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::0.625::HTS002,BRD-K18157228-001-01-7,0.625,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::2.5::HTS002,BRD-K18157228-001-01-7,2.5,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18157228-001-01-7::10::HTS002,BRD-K18157228-001-01-7,10.0,HTS002,PREP024,fdcyd,DNA methyltransferase inhibitor,NA,NA,NA,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,Phase 2
BRD-K18163608-001-05-6::0.00060548::HTS002,BRD-K18163608-001-05-6,0.00060548,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::0.00242192::HTS002,BRD-K18163608-001-05-6,0.00242192,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::0.00968768::HTS002,BRD-K18163608-001-05-6,0.00968768,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::0.0387507::HTS002,BRD-K18163608-001-05-6,0.0387507,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::0.155003::HTS002,BRD-K18163608-001-05-6,0.155003,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::0.620012::HTS002,BRD-K18163608-001-05-6,0.620012,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::2.48005::HTS002,BRD-K18163608-001-05-6,2.48005,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18163608-001-05-6::9.92019::HTS002,BRD-K18163608-001-05-6,9.92019,HTS002,PREP042,HA14-1,BCL inhibitor,BCL2,NA,NA,"CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC, CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",Preclinical
BRD-K18250272-003-11-0::0.00061034::HTS002,BRD-K18250272-003-11-0,0.00061034,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::0.0024414::HTS002,BRD-K18250272-003-11-0,0.0024414,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::0.00976562::HTS002,BRD-K18250272-003-11-0,0.00976562,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::0.0390625::HTS002,BRD-K18250272-003-11-0,0.0390625,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::0.15625::HTS002,BRD-K18250272-003-11-0,0.15625,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::0.625::HTS002,BRD-K18250272-003-11-0,0.625,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::2.5::HTS002,BRD-K18250272-003-11-0,2.5,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18250272-003-11-0::10::HTS002,BRD-K18250272-003-11-0,10.0,HTS002,PREP021,propoxycaine,local anesthetic,NA,neurology/psychiatry,anesthetic,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,Launched
BRD-K18375018-376-02-3::0.00061034::HTS002,BRD-K18375018-376-02-3,0.00061034,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::0.0024414::HTS002,BRD-K18375018-376-02-3,0.0024414,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::0.00976562::HTS002,BRD-K18375018-376-02-3,0.00976562,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::0.0390625::HTS002,BRD-K18375018-376-02-3,0.0390625,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::0.15625::HTS002,BRD-K18375018-376-02-3,0.15625,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::0.625::HTS002,BRD-K18375018-376-02-3,0.625,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::2.5::HTS002,BRD-K18375018-376-02-3,2.5,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18375018-376-02-3::10::HTS002,BRD-K18375018-376-02-3,10.0,HTS002,PREP033,spermine,NA,"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5",NA,NA,NCCCNCCCCNCCCN,Preclinical
BRD-K18424115-003-01-3::0.00061034::HTS002,BRD-K18424115-003-01-3,0.00061034,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::0.0024414::HTS002,BRD-K18424115-003-01-3,0.0024414,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::0.00976562::HTS002,BRD-K18424115-003-01-3,0.00976562,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::0.0390625::HTS002,BRD-K18424115-003-01-3,0.0390625,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::0.15625::HTS002,BRD-K18424115-003-01-3,0.15625,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::0.625::HTS002,BRD-K18424115-003-01-3,0.625,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::2.5::HTS002,BRD-K18424115-003-01-3,2.5,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18424115-003-01-3::10::HTS002,BRD-K18424115-003-01-3,10.0,HTS002,PREP037,TG-100572,"src inhibitor, VEGFR inhibitor","KDR, SRC",NA,NA,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl,Preclinical
BRD-K18518344-001-15-9::0.00061034::HTS002,BRD-K18518344-001-15-9,0.00061034,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::0.0024414::HTS002,BRD-K18518344-001-15-9,0.0024414,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::0.00976562::HTS002,BRD-K18518344-001-15-9,0.00976562,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::0.0390625::HTS002,BRD-K18518344-001-15-9,0.0390625,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::0.15625::HTS002,BRD-K18518344-001-15-9,0.15625,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::0.625::HTS002,BRD-K18518344-001-15-9,0.625,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::2.5::HTS002,BRD-K18518344-001-15-9,2.5,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18518344-001-15-9::10::HTS002,BRD-K18518344-001-15-9,10.0,HTS002,PREP037,digitoxigenin,ATPase inhibitor,ATP1A1,NA,NA,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,Preclinical
BRD-K18574842-236-17-7::0.00061034::HTS002,BRD-K18574842-236-17-7,0.00061034,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::0.0024414::HTS002,BRD-K18574842-236-17-7,0.0024414,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::0.00976562::HTS002,BRD-K18574842-236-17-7,0.00976562,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::0.0390625::HTS002,BRD-K18574842-236-17-7,0.0390625,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::0.15625::HTS002,BRD-K18574842-236-17-7,0.15625,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::0.625::HTS002,BRD-K18574842-236-17-7,0.625,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::2.5::HTS002,BRD-K18574842-236-17-7,2.5,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18574842-236-17-7::10::HTS002,BRD-K18574842-236-17-7,10.0,HTS002,PREP020,nafcillin,bacterial cell wall synthesis inhibitor,"CYP1A2, CYP3A4, SLC22A6",infectious disease,gram-positive bacterial infections,"CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O",Launched
BRD-K18613660-001-05-5::0.00061034::HTS002,BRD-K18613660-001-05-5,0.00061034,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::0.0024414::HTS002,BRD-K18613660-001-05-5,0.0024414,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::0.00976562::HTS002,BRD-K18613660-001-05-5,0.00976562,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::0.0390625::HTS002,BRD-K18613660-001-05-5,0.0390625,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::0.15625::HTS002,BRD-K18613660-001-05-5,0.15625,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::0.625::HTS002,BRD-K18613660-001-05-5,0.625,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::2.5::HTS002,BRD-K18613660-001-05-5,2.5,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18613660-001-05-5::10::HTS002,BRD-K18613660-001-05-5,10.0,HTS002,PREP036,mexeneone,NA,NA,NA,NA,COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1,Preclinical
BRD-K18619710-001-14-4::0.00061034::HTS002,BRD-K18619710-001-14-4,0.00061034,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::0.0024414::HTS002,BRD-K18619710-001-14-4,0.0024414,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::0.00976562::HTS002,BRD-K18619710-001-14-4,0.00976562,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::0.0390625::HTS002,BRD-K18619710-001-14-4,0.0390625,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::0.15625::HTS002,BRD-K18619710-001-14-4,0.15625,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::0.625::HTS002,BRD-K18619710-001-14-4,0.625,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::2.5::HTS002,BRD-K18619710-001-14-4,2.5,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18619710-001-14-4::10::HTS002,BRD-K18619710-001-14-4,10.0,HTS002,PREP037,digoxigenin,steroid,NA,NA,NA,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,Preclinical
BRD-K18779551-003-07-8::0.00061034::HTS002,BRD-K18779551-003-07-8,0.00061034,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::0.0024414::HTS002,BRD-K18779551-003-07-8,0.0024414,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::0.00976562::HTS002,BRD-K18779551-003-07-8,0.00976562,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::0.0390625::HTS002,BRD-K18779551-003-07-8,0.0390625,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::0.15625::HTS002,BRD-K18779551-003-07-8,0.15625,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::0.625::HTS002,BRD-K18779551-003-07-8,0.625,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::2.5::HTS002,BRD-K18779551-003-07-8,2.5,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18779551-003-07-8::10::HTS002,BRD-K18779551-003-07-8,10.0,HTS002,PREP030,bifemelane,acetylcholine release enhancer,"MAOA, MAOB","ophthalmology, neurology/psychiatry","glaucoma, senile dementia","CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1",Launched
BRD-K18787491-001-08-6::0.00061034::HTS002,BRD-K18787491-001-08-6,0.00061034,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::0.0024414::HTS002,BRD-K18787491-001-08-6,0.0024414,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::0.00976562::HTS002,BRD-K18787491-001-08-6,0.00976562,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::0.0390625::HTS002,BRD-K18787491-001-08-6,0.0390625,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::0.15625::HTS002,BRD-K18787491-001-08-6,0.15625,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::0.625::HTS002,BRD-K18787491-001-08-6,0.625,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::2.5::HTS002,BRD-K18787491-001-08-6,2.5,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18787491-001-08-6::10::HTS002,BRD-K18787491-001-08-6,10.0,HTS002,PREP037,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K18834913-001-01-1::0.00061034::HTS002,BRD-K18834913-001-01-1,0.00061034,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::0.0024414::HTS002,BRD-K18834913-001-01-1,0.0024414,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::0.00976562::HTS002,BRD-K18834913-001-01-1,0.00976562,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::0.0390625::HTS002,BRD-K18834913-001-01-1,0.0390625,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::0.15625::HTS002,BRD-K18834913-001-01-1,0.15625,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::0.625::HTS002,BRD-K18834913-001-01-1,0.625,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::2.5::HTS002,BRD-K18834913-001-01-1,2.5,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18834913-001-01-1::10::HTS002,BRD-K18834913-001-01-1,10.0,HTS002,PREP040,LB42708,farnesyltransferase inhibitor,NA,NA,NA,"Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",Preclinical
BRD-K18849474-001-04-4::0.000635997::HTS002,BRD-K18849474-001-04-4,0.000635997,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::0.00254399::HTS002,BRD-K18849474-001-04-4,0.00254399,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::0.010176::HTS002,BRD-K18849474-001-04-4,0.010176,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::0.0407038::HTS002,BRD-K18849474-001-04-4,0.0407038,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::0.162815::HTS002,BRD-K18849474-001-04-4,0.162815,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::0.651261::HTS002,BRD-K18849474-001-04-4,0.651261,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::2.60504::HTS002,BRD-K18849474-001-04-4,2.60504,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18849474-001-04-4::10.4202::HTS002,BRD-K18849474-001-04-4,10.4202,HTS002,PREP018,dalcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",Phase 3
BRD-K18910433-001-36-6::0.000630083::HTS002,BRD-K18910433-001-36-6,0.000630083,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::0.00252033::HTS002,BRD-K18910433-001-36-6,0.00252033,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::0.0100813::HTS002,BRD-K18910433-001-36-6,0.0100813,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::0.0403253::HTS002,BRD-K18910433-001-36-6,0.0403253,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::0.161301::HTS002,BRD-K18910433-001-36-6,0.161301,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::0.645205::HTS002,BRD-K18910433-001-36-6,0.645205,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::2.58082::HTS002,BRD-K18910433-001-36-6,2.58082,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18910433-001-36-6::10.3233::HTS002,BRD-K18910433-001-36-6,10.3233,HTS002,PREP028,estradiol,estrogen receptor agonist,"ESR1, ESR2, GPER1, KCNMA1, NR1I2",endocrinology,contraceptive,"C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O",Launched
BRD-K18961567-001-01-1::0.00061034::HTS002,BRD-K18961567-001-01-1,0.00061034,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.0024414::HTS002,BRD-K18961567-001-01-1,0.0024414,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.00976562::HTS002,BRD-K18961567-001-01-1,0.00976562,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.0390625::HTS002,BRD-K18961567-001-01-1,0.0390625,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.15625::HTS002,BRD-K18961567-001-01-1,0.15625,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::0.625::HTS002,BRD-K18961567-001-01-1,0.625,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::2.5::HTS002,BRD-K18961567-001-01-1,2.5,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K18961567-001-01-1::10::HTS002,BRD-K18961567-001-01-1,10.0,HTS002,PREP038,LY2801653,MET inhibitor,MET,NA,NA,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,Phase 2
BRD-K19034817-001-01-4::0.00061034::HTS002,BRD-K19034817-001-01-4,0.00061034,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::0.0024414::HTS002,BRD-K19034817-001-01-4,0.0024414,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::0.00976562::HTS002,BRD-K19034817-001-01-4,0.00976562,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::0.0390625::HTS002,BRD-K19034817-001-01-4,0.0390625,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::0.15625::HTS002,BRD-K19034817-001-01-4,0.15625,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::0.625::HTS002,BRD-K19034817-001-01-4,0.625,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::2.5::HTS002,BRD-K19034817-001-01-4,2.5,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19034817-001-01-4::10::HTS002,BRD-K19034817-001-01-4,10.0,HTS002,PREP018,pacritinib,"FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3",NA,NA,"C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3",Phase 3
BRD-K19061412-001-02-4::0.00061034::HTS002,BRD-K19061412-001-02-4,0.00061034,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::0.0024414::HTS002,BRD-K19061412-001-02-4,0.0024414,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::0.00976562::HTS002,BRD-K19061412-001-02-4,0.00976562,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::0.0390625::HTS002,BRD-K19061412-001-02-4,0.0390625,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::0.15625::HTS002,BRD-K19061412-001-02-4,0.15625,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::0.625::HTS002,BRD-K19061412-001-02-4,0.625,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::2.5::HTS002,BRD-K19061412-001-02-4,2.5,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19061412-001-02-4::10::HTS002,BRD-K19061412-001-02-4,10.0,HTS002,PREP025,mubritinib,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,"FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",Phase 1
BRD-K19085898-001-01-8::0.00061034::HTS002,BRD-K19085898-001-01-8,0.00061034,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::0.0024414::HTS002,BRD-K19085898-001-01-8,0.0024414,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::0.00976562::HTS002,BRD-K19085898-001-01-8,0.00976562,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::0.0390625::HTS002,BRD-K19085898-001-01-8,0.0390625,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::0.15625::HTS002,BRD-K19085898-001-01-8,0.15625,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::0.625::HTS002,BRD-K19085898-001-01-8,0.625,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::2.5::HTS002,BRD-K19085898-001-01-8,2.5,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19085898-001-01-8::10::HTS002,BRD-K19085898-001-01-8,10.0,HTS002,PREP045,darapladib,phospholipase inhibitor,PLA2G7,NA,NA,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,Phase 3
BRD-K19284129-001-02-6::0.00061034::HTS002,BRD-K19284129-001-02-6,0.00061034,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::0.0024414::HTS002,BRD-K19284129-001-02-6,0.0024414,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::0.00976562::HTS002,BRD-K19284129-001-02-6,0.00976562,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::0.0390625::HTS002,BRD-K19284129-001-02-6,0.0390625,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::0.15625::HTS002,BRD-K19284129-001-02-6,0.15625,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::0.625::HTS002,BRD-K19284129-001-02-6,0.625,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::2.5::HTS002,BRD-K19284129-001-02-6,2.5,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19284129-001-02-6::10::HTS002,BRD-K19284129-001-02-6,10.0,HTS002,PREP038,salvinorin-a,opioid receptor agonist,"OPRD1, OPRK1, OPRM1",NA,NA,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,Phase 1
BRD-K19295594-015-14-3::0.000558447::HTS002,BRD-K19295594-015-14-3,0.000558447,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::0.00223379::HTS002,BRD-K19295594-015-14-3,0.00223379,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::0.00893516::HTS002,BRD-K19295594-015-14-3,0.00893516,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::0.0357406::HTS002,BRD-K19295594-015-14-3,0.0357406,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::0.142963::HTS002,BRD-K19295594-015-14-3,0.142963,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::0.57185::HTS002,BRD-K19295594-015-14-3,0.57185,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::2.2874::HTS002,BRD-K19295594-015-14-3,2.2874,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19295594-015-14-3::9.1496::HTS002,BRD-K19295594-015-14-3,9.1496,HTS002,PREP019,gossypol,"BCL inhibitor, MCL1 inhibitor",BCL2,NA,NA,"CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",Phase 2
BRD-K19318328-001-01-3::0.00061034::HTS002,BRD-K19318328-001-01-3,0.00061034,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::0.0024414::HTS002,BRD-K19318328-001-01-3,0.0024414,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::0.00976562::HTS002,BRD-K19318328-001-01-3,0.00976562,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::0.0390625::HTS002,BRD-K19318328-001-01-3,0.0390625,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::0.15625::HTS002,BRD-K19318328-001-01-3,0.15625,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::0.625::HTS002,BRD-K19318328-001-01-3,0.625,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::2.5::HTS002,BRD-K19318328-001-01-3,2.5,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19318328-001-01-3::10::HTS002,BRD-K19318328-001-01-3,10.0,HTS002,PREP019,FR-139317,endothelin receptor antagonist,EDNRA,NA,NA,"CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",Phase 1
BRD-K19333160-001-01-3::0.00061034::HTS002,BRD-K19333160-001-01-3,0.00061034,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::0.0024414::HTS002,BRD-K19333160-001-01-3,0.0024414,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::0.00976562::HTS002,BRD-K19333160-001-01-3,0.00976562,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::0.0390625::HTS002,BRD-K19333160-001-01-3,0.0390625,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::0.15625::HTS002,BRD-K19333160-001-01-3,0.15625,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::0.625::HTS002,BRD-K19333160-001-01-3,0.625,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::2.5::HTS002,BRD-K19333160-001-01-3,2.5,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19333160-001-01-3::10::HTS002,BRD-K19333160-001-01-3,10.0,HTS002,PREP037,RKI-1447,rho associated kinase inhibitor,"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2",NA,NA,"Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",Preclinical
BRD-K19388745-003-01-7::0.000610352::HTS002,BRD-K19388745-003-01-7,0.000610352,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::0.00244141::HTS002,BRD-K19388745-003-01-7,0.00244141,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::0.00976562::HTS002,BRD-K19388745-003-01-7,0.00976562,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::0.0390625::HTS002,BRD-K19388745-003-01-7,0.0390625,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::0.15625::HTS002,BRD-K19388745-003-01-7,0.15625,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::0.625::HTS002,BRD-K19388745-003-01-7,0.625,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::2.5::HTS002,BRD-K19388745-003-01-7,2.5,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19388745-003-01-7::10::HTS002,BRD-K19388745-003-01-7,10.0,HTS002,PREP014,colforsin-daproate,adenylyl cyclase activator,NA,NA,NA,CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C,Launched
BRD-K19412355-001-01-0::0.00061034::HTS002,BRD-K19412355-001-01-0,0.00061034,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::0.0024414::HTS002,BRD-K19412355-001-01-0,0.0024414,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::0.00976562::HTS002,BRD-K19412355-001-01-0,0.00976562,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::0.0390625::HTS002,BRD-K19412355-001-01-0,0.0390625,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::0.15625::HTS002,BRD-K19412355-001-01-0,0.15625,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::0.625::HTS002,BRD-K19412355-001-01-0,0.625,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::2.5::HTS002,BRD-K19412355-001-01-0,2.5,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19412355-001-01-0::10::HTS002,BRD-K19412355-001-01-0,10.0,HTS002,PREP024,SB-242235,p38 MAPK inhibitor,"HSPB1, MAPK14",NA,NA,COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1,Phase 1
BRD-K19540840-001-09-4::0.00061034::HTS002,BRD-K19540840-001-09-4,0.00061034,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.0024414::HTS002,BRD-K19540840-001-09-4,0.0024414,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.00976562::HTS002,BRD-K19540840-001-09-4,0.00976562,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.0390625::HTS002,BRD-K19540840-001-09-4,0.0390625,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.15625::HTS002,BRD-K19540840-001-09-4,0.15625,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::0.625::HTS002,BRD-K19540840-001-09-4,0.625,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::2.5::HTS002,BRD-K19540840-001-09-4,2.5,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19540840-001-09-4::10::HTS002,BRD-K19540840-001-09-4,10.0,HTS002,PREP047,saracatinib,src inhibitor,"ABL1, LCK, SRC, YES1",NA,NA,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1,Phase 2/Phase 3
BRD-K19615002-001-02-3::0.000610352::HTS002,BRD-K19615002-001-02-3,0.000610352,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::0.00244141::HTS002,BRD-K19615002-001-02-3,0.00244141,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::0.00976562::HTS002,BRD-K19615002-001-02-3,0.00976562,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::0.0390625::HTS002,BRD-K19615002-001-02-3,0.0390625,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::0.15625::HTS002,BRD-K19615002-001-02-3,0.15625,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::0.625::HTS002,BRD-K19615002-001-02-3,0.625,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::2.5::HTS002,BRD-K19615002-001-02-3,2.5,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19615002-001-02-3::10::HTS002,BRD-K19615002-001-02-3,10.0,HTS002,PREP021,creatine,NA,"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8",NA,NA,CN(CC(O)=O)C(N)=N,Launched
BRD-K19669037-001-01-1::0.000305176::HTS002,BRD-K19669037-001-01-1,0.000305176,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::0.0012207::HTS002,BRD-K19669037-001-01-1,0.0012207,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::0.00488281::HTS002,BRD-K19669037-001-01-1,0.00488281,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::0.0195312::HTS002,BRD-K19669037-001-01-1,0.0195312,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::0.078125::HTS002,BRD-K19669037-001-01-1,0.078125,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::0.3125::HTS002,BRD-K19669037-001-01-1,0.3125,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::1.25::HTS002,BRD-K19669037-001-01-1,1.25,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19669037-001-01-1::5::HTS002,BRD-K19669037-001-01-1,5.0,HTS002,PREP043,GGTI-298,GGTase inhibitor,CDKN1A,NA,NA,COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12,Preclinical
BRD-K19687926-379-07-4::0.00061034::HTS002,BRD-K19687926-379-07-4,0.00061034,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::0.0024414::HTS002,BRD-K19687926-379-07-4,0.0024414,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::0.00976562::HTS002,BRD-K19687926-379-07-4,0.00976562,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::0.0390625::HTS002,BRD-K19687926-379-07-4,0.0390625,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::0.15625::HTS002,BRD-K19687926-379-07-4,0.15625,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::0.625::HTS002,BRD-K19687926-379-07-4,0.625,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::2.5::HTS002,BRD-K19687926-379-07-4,2.5,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19687926-379-07-4::10::HTS002,BRD-K19687926-379-07-4,10.0,HTS002,PREP030,lapatinib,EGFR inhibitor,"EGFR, ERBB2",oncology,breast cancer,"CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Launched
BRD-K19761926-001-03-6::0.000597796::HTS002,BRD-K19761926-001-03-6,0.000597796,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::0.00239118::HTS002,BRD-K19761926-001-03-6,0.00239118,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::0.00956474::HTS002,BRD-K19761926-001-03-6,0.00956474,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::0.0382589::HTS002,BRD-K19761926-001-03-6,0.0382589,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::0.153036::HTS002,BRD-K19761926-001-03-6,0.153036,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::0.612143::HTS002,BRD-K19761926-001-03-6,0.612143,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::2.44857::HTS002,BRD-K19761926-001-03-6,2.44857,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19761926-001-03-6::9.79429::HTS002,BRD-K19761926-001-03-6,9.79429,HTS002,PREP034,eplerenone,cytochrome P450 inhibitor,NR3C2,cardiology,"congestive heart failure, hypertension","COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13",Launched
BRD-K19796430-001-05-6::0.00061034::HTS002,BRD-K19796430-001-05-6,0.00061034,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.0024414::HTS002,BRD-K19796430-001-05-6,0.0024414,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.00976562::HTS002,BRD-K19796430-001-05-6,0.00976562,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.0390625::HTS002,BRD-K19796430-001-05-6,0.0390625,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.15625::HTS002,BRD-K19796430-001-05-6,0.15625,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::0.625::HTS002,BRD-K19796430-001-05-6,0.625,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::2.5::HTS002,BRD-K19796430-001-05-6,2.5,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K19796430-001-05-6::10::HTS002,BRD-K19796430-001-05-6,10.0,HTS002,PREP025,sonidegib,smoothened receptor antagonist,SMO,oncology,basal cell carcinoma (BCC),"C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1",Launched
BRD-K16338837-001-02-6::0.00061034::HTS002,BRD-K16338837-001-02-6,0.00061034,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::0.0024414::HTS002,BRD-K16338837-001-02-6,0.0024414,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::0.00976562::HTS002,BRD-K16338837-001-02-6,0.00976562,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::0.0390625::HTS002,BRD-K16338837-001-02-6,0.0390625,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::0.15625::HTS002,BRD-K16338837-001-02-6,0.15625,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::0.625::HTS002,BRD-K16338837-001-02-6,0.625,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::2.5::HTS002,BRD-K16338837-001-02-6,2.5,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K16338837-001-02-6::10::HTS002,BRD-K16338837-001-02-6,10.0,HTS002,PREP043,CCMI,acetylcholine receptor allosteric modulator,CHRNA7,NA,NA,"Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",Preclinical
BRD-K20285085-074-04-5::0.000610352::HTS002,BRD-K20285085-074-04-5,0.000610352,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::0.00244141::HTS002,BRD-K20285085-074-04-5,0.00244141,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::0.00976562::HTS002,BRD-K20285085-074-04-5,0.00976562,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::0.0390625::HTS002,BRD-K20285085-074-04-5,0.0390625,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::0.15625::HTS002,BRD-K20285085-074-04-5,0.15625,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::0.625::HTS002,BRD-K20285085-074-04-5,0.625,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::2.5::HTS002,BRD-K20285085-074-04-5,2.5,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20285085-074-04-5::10::HTS002,BRD-K20285085-074-04-5,10.0,HTS002,PREP018,R406,SYK inhibitor,"RET, SYK",NA,NA,"COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",Phase 1
BRD-K20290250-001-02-1::0.000600706::HTS002,BRD-K20290250-001-02-1,0.000600706,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::0.00240282::HTS002,BRD-K20290250-001-02-1,0.00240282,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::0.00961129::HTS002,BRD-K20290250-001-02-1,0.00961129,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::0.0384452::HTS002,BRD-K20290250-001-02-1,0.0384452,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::0.153781::HTS002,BRD-K20290250-001-02-1,0.153781,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::0.615123::HTS002,BRD-K20290250-001-02-1,0.615123,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::2.46049::HTS002,BRD-K20290250-001-02-1,2.46049,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20290250-001-02-1::9.84196::HTS002,BRD-K20290250-001-02-1,9.84196,HTS002,PREP048,BIX-02188,MEK inhibitor,MAP2K5,NA,NA,"CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1",Preclinical
BRD-K20482099-001-09-4::0.000610352::HTS002,BRD-K20482099-001-09-4,0.000610352,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::0.00244141::HTS002,BRD-K20482099-001-09-4,0.00244141,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::0.00976562::HTS002,BRD-K20482099-001-09-4,0.00976562,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::0.0390625::HTS002,BRD-K20482099-001-09-4,0.0390625,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::0.15625::HTS002,BRD-K20482099-001-09-4,0.15625,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::0.625::HTS002,BRD-K20482099-001-09-4,0.625,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::2.5::HTS002,BRD-K20482099-001-09-4,2.5,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20482099-001-09-4::10::HTS002,BRD-K20482099-001-09-4,10.0,HTS002,PREP031,rutin,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",AKR1C3,"rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy","joint pain, nasal congestion, constipation, irritability, allergic rhinitis","C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O",Launched
BRD-K20545304-001-01-6::0.00061034::HTS002,BRD-K20545304-001-01-6,0.00061034,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::0.0024414::HTS002,BRD-K20545304-001-01-6,0.0024414,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::0.00976562::HTS002,BRD-K20545304-001-01-6,0.00976562,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::0.0390625::HTS002,BRD-K20545304-001-01-6,0.0390625,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::0.15625::HTS002,BRD-K20545304-001-01-6,0.15625,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::0.625::HTS002,BRD-K20545304-001-01-6,0.625,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::2.5::HTS002,BRD-K20545304-001-01-6,2.5,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20545304-001-01-6::10::HTS002,BRD-K20545304-001-01-6,10.0,HTS002,PREP024,bardoxolone,"nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG",NA,NA,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,Phase 1
BRD-K20605374-001-05-4::0.00061034::HTS002,BRD-K20605374-001-05-4,0.00061034,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::0.0024414::HTS002,BRD-K20605374-001-05-4,0.0024414,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::0.00976562::HTS002,BRD-K20605374-001-05-4,0.00976562,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::0.0390625::HTS002,BRD-K20605374-001-05-4,0.0390625,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::0.15625::HTS002,BRD-K20605374-001-05-4,0.15625,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::0.625::HTS002,BRD-K20605374-001-05-4,0.625,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::2.5::HTS002,BRD-K20605374-001-05-4,2.5,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20605374-001-05-4::10::HTS002,BRD-K20605374-001-05-4,10.0,HTS002,PREP047,NSC-697923,ubiquitin-conjugating enzyme inhibitor,UBE2N,NA,NA,"Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",Preclinical
BRD-K20655524-003-12-0::0.00061034::HTS002,BRD-K20655524-003-12-0,0.00061034,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::0.0024414::HTS002,BRD-K20655524-003-12-0,0.0024414,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::0.00976562::HTS002,BRD-K20655524-003-12-0,0.00976562,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::0.0390625::HTS002,BRD-K20655524-003-12-0,0.0390625,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::0.15625::HTS002,BRD-K20655524-003-12-0,0.15625,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::0.625::HTS002,BRD-K20655524-003-12-0,0.625,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::2.5::HTS002,BRD-K20655524-003-12-0,2.5,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20655524-003-12-0::10::HTS002,BRD-K20655524-003-12-0,10.0,HTS002,PREP015,mefexamide,psychoactive drug,NA,NA,NA,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,Preclinical
BRD-K20722021-001-02-1::0.00061034::HTS002,BRD-K20722021-001-02-1,0.00061034,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::0.0024414::HTS002,BRD-K20722021-001-02-1,0.0024414,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::0.00976562::HTS002,BRD-K20722021-001-02-1,0.00976562,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::0.0390625::HTS002,BRD-K20722021-001-02-1,0.0390625,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::0.15625::HTS002,BRD-K20722021-001-02-1,0.15625,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::0.625::HTS002,BRD-K20722021-001-02-1,0.625,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::2.5::HTS002,BRD-K20722021-001-02-1,2.5,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20722021-001-02-1::10::HTS002,BRD-K20722021-001-02-1,10.0,HTS002,PREP046,CEP-32496,RAF inhibitor,"BRAF, RAF1",NA,NA,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC,Phase 1/Phase 2
BRD-K20755323-001-05-9::0.00061034::HTS002,BRD-K20755323-001-05-9,0.00061034,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::0.0024414::HTS002,BRD-K20755323-001-05-9,0.0024414,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::0.00976562::HTS002,BRD-K20755323-001-05-9,0.00976562,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::0.0390625::HTS002,BRD-K20755323-001-05-9,0.0390625,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::0.15625::HTS002,BRD-K20755323-001-05-9,0.15625,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::0.625::HTS002,BRD-K20755323-001-05-9,0.625,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::2.5::HTS002,BRD-K20755323-001-05-9,2.5,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20755323-001-05-9::10::HTS002,BRD-K20755323-001-05-9,10.0,HTS002,PREP043,SKI-II,sphingosine kinase inhibitor,SPHK1,NA,NA,"Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",Preclinical
BRD-K20958582-001-01-4::0.00061034::HTS002,BRD-K20958582-001-01-4,0.00061034,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::0.0024414::HTS002,BRD-K20958582-001-01-4,0.0024414,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::0.00976562::HTS002,BRD-K20958582-001-01-4,0.00976562,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::0.0390625::HTS002,BRD-K20958582-001-01-4,0.0390625,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::0.15625::HTS002,BRD-K20958582-001-01-4,0.15625,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::0.625::HTS002,BRD-K20958582-001-01-4,0.625,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::2.5::HTS002,BRD-K20958582-001-01-4,2.5,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K20958582-001-01-4::10::HTS002,BRD-K20958582-001-01-4,10.0,HTS002,PREP044,TH-302,DNA alkylating agent,NA,NA,NA,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,Phase 3
BRD-K21025364-001-05-6::0.000594798::HTS002,BRD-K21025364-001-05-6,0.000594798,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::0.00237919::HTS002,BRD-K21025364-001-05-6,0.00237919,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::0.00951676::HTS002,BRD-K21025364-001-05-6,0.00951676,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::0.038067::HTS002,BRD-K21025364-001-05-6,0.038067,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::0.152268::HTS002,BRD-K21025364-001-05-6,0.152268,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::0.609073::HTS002,BRD-K21025364-001-05-6,0.609073,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::2.43629::HTS002,BRD-K21025364-001-05-6,2.43629,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21025364-001-05-6::9.74516::HTS002,BRD-K21025364-001-05-6,9.74516,HTS002,PREP041,NVP-TAE226,protein tyrosine kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",Preclinical
BRD-K21164796-001-02-8::0.00061034::HTS002,BRD-K21164796-001-02-8,0.00061034,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::0.0024414::HTS002,BRD-K21164796-001-02-8,0.0024414,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::0.00976562::HTS002,BRD-K21164796-001-02-8,0.00976562,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::0.0390625::HTS002,BRD-K21164796-001-02-8,0.0390625,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::0.15625::HTS002,BRD-K21164796-001-02-8,0.15625,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::0.625::HTS002,BRD-K21164796-001-02-8,0.625,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::2.5::HTS002,BRD-K21164796-001-02-8,2.5,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21164796-001-02-8::10::HTS002,BRD-K21164796-001-02-8,10.0,HTS002,PREP047,beta-naphthol,NA,NA,NA,NA,Oc1ccc2ccccc2c1,Preclinical
BRD-K21283037-001-21-5::0.00061034::HTS002,BRD-K21283037-001-21-5,0.00061034,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::0.0024414::HTS002,BRD-K21283037-001-21-5,0.0024414,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::0.00976562::HTS002,BRD-K21283037-001-21-5,0.00976562,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::0.0390625::HTS002,BRD-K21283037-001-21-5,0.0390625,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::0.15625::HTS002,BRD-K21283037-001-21-5,0.15625,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::0.625::HTS002,BRD-K21283037-001-21-5,0.625,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::2.5::HTS002,BRD-K21283037-001-21-5,2.5,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21283037-001-21-5::10::HTS002,BRD-K21283037-001-21-5,10.0,HTS002,PREP020,riluzole,glutamate inhibitor,"KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11",neurology/psychiatry,amyotrophic lateral sclerosis (ALS),"Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1",Launched
BRD-K21361524-001-01-1::0.00061034::HTS002,BRD-K21361524-001-01-1,0.00061034,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.0024414::HTS002,BRD-K21361524-001-01-1,0.0024414,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.00976562::HTS002,BRD-K21361524-001-01-1,0.00976562,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.0390625::HTS002,BRD-K21361524-001-01-1,0.0390625,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.15625::HTS002,BRD-K21361524-001-01-1,0.15625,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.625::HTS002,BRD-K21361524-001-01-1,0.625,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::2.5::HTS002,BRD-K21361524-001-01-1,2.5,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::10::HTS002,BRD-K21361524-001-01-1,10.0,HTS002,PREP047,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21396683-001-04-8::0.00061034::HTS002,BRD-K21396683-001-04-8,0.00061034,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::0.0024414::HTS002,BRD-K21396683-001-04-8,0.0024414,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::0.00976562::HTS002,BRD-K21396683-001-04-8,0.00976562,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::0.0390625::HTS002,BRD-K21396683-001-04-8,0.0390625,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::0.15625::HTS002,BRD-K21396683-001-04-8,0.15625,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::0.625::HTS002,BRD-K21396683-001-04-8,0.625,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::2.5::HTS002,BRD-K21396683-001-04-8,2.5,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21396683-001-04-8::10::HTS002,BRD-K21396683-001-04-8,10.0,HTS002,PREP027,marimastat,matrix metalloprotease inhibitor,"MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9",NA,NA,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,Phase 3
BRD-K21528677-001-02-8::0.000594903::HTS002,BRD-K21528677-001-02-8,0.000594903,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::0.00237961::HTS002,BRD-K21528677-001-02-8,0.00237961,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::0.00951844::HTS002,BRD-K21528677-001-02-8,0.00951844,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::0.0380738::HTS002,BRD-K21528677-001-02-8,0.0380738,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::0.152295::HTS002,BRD-K21528677-001-02-8,0.152295,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::0.60918::HTS002,BRD-K21528677-001-02-8,0.60918,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::2.43672::HTS002,BRD-K21528677-001-02-8,2.43672,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21528677-001-02-8::9.74689::HTS002,BRD-K21528677-001-02-8,9.74689,HTS002,PREP031,desonide,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",gastroenterology,Crohn's disease,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K21547160-001-01-4::0.00061034::HTS002,BRD-K21547160-001-01-4,0.00061034,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::0.0024414::HTS002,BRD-K21547160-001-01-4,0.0024414,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::0.00976562::HTS002,BRD-K21547160-001-01-4,0.00976562,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::0.0390625::HTS002,BRD-K21547160-001-01-4,0.0390625,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::0.15625::HTS002,BRD-K21547160-001-01-4,0.15625,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::0.625::HTS002,BRD-K21547160-001-01-4,0.625,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::2.5::HTS002,BRD-K21547160-001-01-4,2.5,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21547160-001-01-4::10::HTS002,BRD-K21547160-001-01-4,10.0,HTS002,PREP029,sufentanil,opioid receptor modulator,"OPRD1, OPRK1, OPRM1",neurology/psychiatry,anesthetic,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Launched
BRD-K21565985-001-22-5::0.00061034::HTS002,BRD-K21565985-001-22-5,0.00061034,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::0.0024414::HTS002,BRD-K21565985-001-22-5,0.0024414,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::0.00976562::HTS002,BRD-K21565985-001-22-5,0.00976562,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::0.0390625::HTS002,BRD-K21565985-001-22-5,0.0390625,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::0.15625::HTS002,BRD-K21565985-001-22-5,0.15625,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::0.625::HTS002,BRD-K21565985-001-22-5,0.625,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::2.5::HTS002,BRD-K21565985-001-22-5,2.5,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21565985-001-22-5::10::HTS002,BRD-K21565985-001-22-5,10.0,HTS002,PREP017,xylazine,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C",neurology/psychiatry,anesthetic,"Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1",Launched
BRD-K21670884-001-01-9::0.000610352::HTS002,BRD-K21670884-001-01-9,0.000610352,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::0.00244141::HTS002,BRD-K21670884-001-01-9,0.00244141,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::0.00976562::HTS002,BRD-K21670884-001-01-9,0.00976562,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::0.0390625::HTS002,BRD-K21670884-001-01-9,0.0390625,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::0.15625::HTS002,BRD-K21670884-001-01-9,0.15625,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::0.625::HTS002,BRD-K21670884-001-01-9,0.625,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::2.5::HTS002,BRD-K21670884-001-01-9,2.5,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21670884-001-01-9::10::HTS002,BRD-K21670884-001-01-9,10.0,HTS002,PREP045,cariporide,sodium/hydrogen exchanger inhibitor,SLC9A1,NA,NA,CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N,Phase 3
BRD-K21673112-003-01-3::0.00061034::HTS002,BRD-K21673112-003-01-3,0.00061034,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::0.0024414::HTS002,BRD-K21673112-003-01-3,0.0024414,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::0.00976562::HTS002,BRD-K21673112-003-01-3,0.00976562,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::0.0390625::HTS002,BRD-K21673112-003-01-3,0.0390625,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::0.15625::HTS002,BRD-K21673112-003-01-3,0.15625,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::0.625::HTS002,BRD-K21673112-003-01-3,0.625,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::2.5::HTS002,BRD-K21673112-003-01-3,2.5,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21673112-003-01-3::10::HTS002,BRD-K21673112-003-01-3,10.0,HTS002,PREP038,BF2.649,histamine receptor antagonist,HRH3,NA,NA,"Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1",Phase 3
BRD-K21680192-300-14-4::0.00061034::HTS002,BRD-K21680192-300-14-4,0.00061034,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::0.0024414::HTS002,BRD-K21680192-300-14-4,0.0024414,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::0.00976562::HTS002,BRD-K21680192-300-14-4,0.00976562,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::0.0390625::HTS002,BRD-K21680192-300-14-4,0.0390625,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::0.15625::HTS002,BRD-K21680192-300-14-4,0.15625,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::0.625::HTS002,BRD-K21680192-300-14-4,0.625,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::2.5::HTS002,BRD-K21680192-300-14-4,2.5,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21680192-300-14-4::10::HTS002,BRD-K21680192-300-14-4,10.0,HTS002,PREP021,mitoxantrone,topoisomerase inhibitor,TOP2A,"neurology/psychiatry, oncology, hematologic malignancy","multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12",Launched
BRD-K21718444-001-06-8::0.00061034::HTS002,BRD-K21718444-001-06-8,0.00061034,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::0.0024414::HTS002,BRD-K21718444-001-06-8,0.0024414,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::0.00976562::HTS002,BRD-K21718444-001-06-8,0.00976562,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::0.0390625::HTS002,BRD-K21718444-001-06-8,0.0390625,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::0.15625::HTS002,BRD-K21718444-001-06-8,0.15625,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::0.625::HTS002,BRD-K21718444-001-06-8,0.625,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::2.5::HTS002,BRD-K21718444-001-06-8,2.5,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21718444-001-06-8::10::HTS002,BRD-K21718444-001-06-8,10.0,HTS002,PREP047,KW-2449,"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3",NA,NA,O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12,Phase 1
BRD-K21728777-001-02-3::0.00061034::HTS002,BRD-K21728777-001-02-3,0.00061034,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::0.0024414::HTS002,BRD-K21728777-001-02-3,0.0024414,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::0.00976562::HTS002,BRD-K21728777-001-02-3,0.00976562,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::0.0390625::HTS002,BRD-K21728777-001-02-3,0.0390625,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::0.15625::HTS002,BRD-K21728777-001-02-3,0.15625,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::0.625::HTS002,BRD-K21728777-001-02-3,0.625,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::2.5::HTS002,BRD-K21728777-001-02-3,2.5,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21728777-001-02-3::10::HTS002,BRD-K21728777-001-02-3,10.0,HTS002,PREP045,AMG900,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12,Phase 1
BRD-K21782625-001-02-4::0.00061034::HTS002,BRD-K21782625-001-02-4,0.00061034,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::0.0024414::HTS002,BRD-K21782625-001-02-4,0.0024414,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::0.00976562::HTS002,BRD-K21782625-001-02-4,0.00976562,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::0.0390625::HTS002,BRD-K21782625-001-02-4,0.0390625,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::0.15625::HTS002,BRD-K21782625-001-02-4,0.15625,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::0.625::HTS002,BRD-K21782625-001-02-4,0.625,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::2.5::HTS002,BRD-K21782625-001-02-4,2.5,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21782625-001-02-4::10::HTS002,BRD-K21782625-001-02-4,10.0,HTS002,PREP033,AMG458,MET inhibitor,MET,NA,NA,"COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",Preclinical
BRD-K21937671-001-09-2::0.000618715::HTS002,BRD-K21937671-001-09-2,0.000618715,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::0.00247486::HTS002,BRD-K21937671-001-09-2,0.00247486,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::0.00989944::HTS002,BRD-K21937671-001-09-2,0.00989944,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::0.0395978::HTS002,BRD-K21937671-001-09-2,0.0395978,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::0.158391::HTS002,BRD-K21937671-001-09-2,0.158391,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::0.633564::HTS002,BRD-K21937671-001-09-2,0.633564,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::2.53426::HTS002,BRD-K21937671-001-09-2,2.53426,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K21937671-001-09-2::10.137::HTS002,BRD-K21937671-001-09-2,10.137,HTS002,PREP029,loxistatin-acid,cysteine peptidase inhibitor,CTSB,NA,NA,"CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",Preclinical
BRD-K22025381-003-01-9::0.00061034::HTS002,BRD-K22025381-003-01-9,0.00061034,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::0.0024414::HTS002,BRD-K22025381-003-01-9,0.0024414,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::0.00976562::HTS002,BRD-K22025381-003-01-9,0.00976562,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::0.0390625::HTS002,BRD-K22025381-003-01-9,0.0390625,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::0.15625::HTS002,BRD-K22025381-003-01-9,0.15625,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::0.625::HTS002,BRD-K22025381-003-01-9,0.625,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::2.5::HTS002,BRD-K22025381-003-01-9,2.5,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22025381-003-01-9::10::HTS002,BRD-K22025381-003-01-9,10.0,HTS002,PREP045,U-18666A,oxidosqualene cyclase inhibitor,NA,NA,NA,CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,Preclinical
BRD-K22127577-001-03-7::0.000628853::HTS002,BRD-K22127577-001-03-7,0.000628853,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::0.00251541::HTS002,BRD-K22127577-001-03-7,0.00251541,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::0.0100616::HTS002,BRD-K22127577-001-03-7,0.0100616,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::0.0402466::HTS002,BRD-K22127577-001-03-7,0.0402466,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::0.160986::HTS002,BRD-K22127577-001-03-7,0.160986,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::0.643945::HTS002,BRD-K22127577-001-03-7,0.643945,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::2.57578::HTS002,BRD-K22127577-001-03-7,2.57578,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22127577-001-03-7::10.3031::HTS002,BRD-K22127577-001-03-7,10.3031,HTS002,PREP027,crenolanib,PDGFR tyrosine kinase receptor inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB",NA,NA,"CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",Phase 2
BRD-K22134346-001-24-9::0.000591976::HTS002,BRD-K22134346-001-24-9,0.000591976,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::0.00236791::HTS002,BRD-K22134346-001-24-9,0.00236791,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::0.00947162::HTS002,BRD-K22134346-001-24-9,0.00947162,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::0.0378865::HTS002,BRD-K22134346-001-24-9,0.0378865,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::0.151546::HTS002,BRD-K22134346-001-24-9,0.151546,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::0.606184::HTS002,BRD-K22134346-001-24-9,0.606184,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::2.42474::HTS002,BRD-K22134346-001-24-9,2.42474,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22134346-001-24-9::9.69894::HTS002,BRD-K22134346-001-24-9,9.69894,HTS002,PREP031,simvastatin,HMGCR inhibitor,"HMGCR, ITGB2","endocrinology, cardiology, neurology/psychiatry","hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Launched
BRD-K22385716-001-02-5::0.00061034::HTS002,BRD-K22385716-001-02-5,0.00061034,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::0.0024414::HTS002,BRD-K22385716-001-02-5,0.0024414,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::0.00976562::HTS002,BRD-K22385716-001-02-5,0.00976562,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::0.0390625::HTS002,BRD-K22385716-001-02-5,0.0390625,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::0.15625::HTS002,BRD-K22385716-001-02-5,0.15625,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::0.625::HTS002,BRD-K22385716-001-02-5,0.625,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::2.5::HTS002,BRD-K22385716-001-02-5,2.5,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22385716-001-02-5::10::HTS002,BRD-K22385716-001-02-5,10.0,HTS002,PREP036,LY303511,"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4",NA,NA,"O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",Preclinical
BRD-K22503835-001-11-0::0.00061034::HTS002,BRD-K22503835-001-11-0,0.00061034,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::0.0024414::HTS002,BRD-K22503835-001-11-0,0.0024414,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::0.00976562::HTS002,BRD-K22503835-001-11-0,0.00976562,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::0.0390625::HTS002,BRD-K22503835-001-11-0,0.0390625,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::0.15625::HTS002,BRD-K22503835-001-11-0,0.15625,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::0.625::HTS002,BRD-K22503835-001-11-0,0.625,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::2.5::HTS002,BRD-K22503835-001-11-0,2.5,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22503835-001-11-0::10::HTS002,BRD-K22503835-001-11-0,10.0,HTS002,PREP037,scriptaid,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",Preclinical
BRD-K22520627-001-01-7::0.00061034::HTS002,BRD-K22520627-001-01-7,0.00061034,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::0.0024414::HTS002,BRD-K22520627-001-01-7,0.0024414,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::0.00976562::HTS002,BRD-K22520627-001-01-7,0.00976562,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::0.0390625::HTS002,BRD-K22520627-001-01-7,0.0390625,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::0.15625::HTS002,BRD-K22520627-001-01-7,0.15625,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::0.625::HTS002,BRD-K22520627-001-01-7,0.625,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::2.5::HTS002,BRD-K22520627-001-01-7,2.5,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22520627-001-01-7::10::HTS002,BRD-K22520627-001-01-7,10.0,HTS002,PREP045,DVD-111,NA,NA,NA,NA,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,Phase 2
BRD-K22822991-001-02-3::0.00061034::HTS002,BRD-K22822991-001-02-3,0.00061034,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.0024414::HTS002,BRD-K22822991-001-02-3,0.0024414,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.00976562::HTS002,BRD-K22822991-001-02-3,0.00976562,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.0390625::HTS002,BRD-K22822991-001-02-3,0.0390625,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.15625::HTS002,BRD-K22822991-001-02-3,0.15625,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::0.625::HTS002,BRD-K22822991-001-02-3,0.625,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::2.5::HTS002,BRD-K22822991-001-02-3,2.5,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K22822991-001-02-3::10::HTS002,BRD-K22822991-001-02-3,10.0,HTS002,PREP024,odanacatib,cathepsin inhibitor,CTSK,NA,NA,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,Phase 3
BRD-K69694239-001-02-2::0.00061034::HTS002,BRD-K69694239-001-02-2,0.00061034,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.0024414::HTS002,BRD-K69694239-001-02-2,0.0024414,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.00976562::HTS002,BRD-K69694239-001-02-2,0.00976562,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.0390625::HTS002,BRD-K69694239-001-02-2,0.0390625,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.15625::HTS002,BRD-K69694239-001-02-2,0.15625,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::0.625::HTS002,BRD-K69694239-001-02-2,0.625,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::2.5::HTS002,BRD-K69694239-001-02-2,2.5,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K69694239-001-02-2::10::HTS002,BRD-K69694239-001-02-2,10.0,HTS002,PREP026,bardoxolone-methyl,"nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3",NA,NA,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,Phase 3
BRD-K23190681-001-01-1::0.00061034::HTS002,BRD-K23190681-001-01-1,0.00061034,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::0.0024414::HTS002,BRD-K23190681-001-01-1,0.0024414,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::0.00976562::HTS002,BRD-K23190681-001-01-1,0.00976562,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::0.0390625::HTS002,BRD-K23190681-001-01-1,0.0390625,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::0.15625::HTS002,BRD-K23190681-001-01-1,0.15625,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::0.625::HTS002,BRD-K23190681-001-01-1,0.625,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::2.5::HTS002,BRD-K23190681-001-01-1,2.5,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23190681-001-01-1::10::HTS002,BRD-K23190681-001-01-1,10.0,HTS002,PREP045,AV-412,protein tyrosine kinase inhibitor,"EGFR, ERBB2",NA,NA,CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C,Phase 1
BRD-K23204545-001-16-4::0.00061034::HTS002,BRD-K23204545-001-16-4,0.00061034,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::0.0024414::HTS002,BRD-K23204545-001-16-4,0.0024414,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::0.00976562::HTS002,BRD-K23204545-001-16-4,0.00976562,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::0.0390625::HTS002,BRD-K23204545-001-16-4,0.0390625,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::0.15625::HTS002,BRD-K23204545-001-16-4,0.15625,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::0.625::HTS002,BRD-K23204545-001-16-4,0.625,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::2.5::HTS002,BRD-K23204545-001-16-4,2.5,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23204545-001-16-4::10::HTS002,BRD-K23204545-001-16-4,10.0,HTS002,PREP020,busulfan,DNA inhibitor,NA,hematologic malignancy,chronic myeloid leukemia (CML),"CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O",Launched
BRD-K23228615-001-02-8::0.00061034::HTS002,BRD-K23228615-001-02-8,0.00061034,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.0024414::HTS002,BRD-K23228615-001-02-8,0.0024414,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.00976562::HTS002,BRD-K23228615-001-02-8,0.00976562,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.0390625::HTS002,BRD-K23228615-001-02-8,0.0390625,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.15625::HTS002,BRD-K23228615-001-02-8,0.15625,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::0.625::HTS002,BRD-K23228615-001-02-8,0.625,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::2.5::HTS002,BRD-K23228615-001-02-8,2.5,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23228615-001-02-8::10::HTS002,BRD-K23228615-001-02-8,10.0,HTS002,PREP025,GDC-0980,"mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK",NA,NA,"C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",Phase 2
BRD-K23301018-001-11-7::0.000642053::HTS002,BRD-K23301018-001-11-7,0.000642053,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::0.00256821::HTS002,BRD-K23301018-001-11-7,0.00256821,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::0.0102729::HTS002,BRD-K23301018-001-11-7,0.0102729,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::0.0410914::HTS002,BRD-K23301018-001-11-7,0.0410914,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::0.164366::HTS002,BRD-K23301018-001-11-7,0.164366,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::0.657463::HTS002,BRD-K23301018-001-11-7,0.657463,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::2.62985::HTS002,BRD-K23301018-001-11-7,2.62985,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23301018-001-11-7::10.5194::HTS002,BRD-K23301018-001-11-7,10.5194,HTS002,PREP019,broxyquinoline,antiprotozoal agent,NA,NA,NA,"Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",Phase 1
BRD-K23363278-001-02-1::0.000610352::HTS002,BRD-K23363278-001-02-1,0.000610352,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::0.00244141::HTS002,BRD-K23363278-001-02-1,0.00244141,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::0.00976562::HTS002,BRD-K23363278-001-02-1,0.00976562,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::0.0390625::HTS002,BRD-K23363278-001-02-1,0.0390625,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::0.15625::HTS002,BRD-K23363278-001-02-1,0.15625,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::0.625::HTS002,BRD-K23363278-001-02-1,0.625,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::2.5::HTS002,BRD-K23363278-001-02-1,2.5,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23363278-001-02-1::10::HTS002,BRD-K23363278-001-02-1,10.0,HTS002,PREP047,CYT-997,tubulin polymerization inhibitor,TUBB,NA,NA,CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1,Phase 2
BRD-K23403298-003-01-9::0.000610352::HTS002,BRD-K23403298-003-01-9,0.000610352,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::0.00244141::HTS002,BRD-K23403298-003-01-9,0.00244141,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::0.00976562::HTS002,BRD-K23403298-003-01-9,0.00976562,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::0.0390625::HTS002,BRD-K23403298-003-01-9,0.0390625,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::0.15625::HTS002,BRD-K23403298-003-01-9,0.15625,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::0.625::HTS002,BRD-K23403298-003-01-9,0.625,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::2.5::HTS002,BRD-K23403298-003-01-9,2.5,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23403298-003-01-9::10::HTS002,BRD-K23403298-003-01-9,10.0,HTS002,PREP032,benzyldimethylhexadecylammonium,cationic surfactant,NA,NA,NA,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,Preclinical
BRD-K23566484-001-15-1::0.00061034::HTS002,BRD-K23566484-001-15-1,0.00061034,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::0.0024414::HTS002,BRD-K23566484-001-15-1,0.0024414,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::0.00976562::HTS002,BRD-K23566484-001-15-1,0.00976562,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::0.0390625::HTS002,BRD-K23566484-001-15-1,0.0390625,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::0.15625::HTS002,BRD-K23566484-001-15-1,0.15625,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::0.625::HTS002,BRD-K23566484-001-15-1,0.625,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::2.5::HTS002,BRD-K23566484-001-15-1,2.5,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23566484-001-15-1::10::HTS002,BRD-K23566484-001-15-1,10.0,HTS002,PREP016,nilutamide,androgen receptor antagonist,AR,oncology,prostate cancer,"CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K23677682-003-01-2::0.00061034::HTS002,BRD-K23677682-003-01-2,0.00061034,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::0.0024414::HTS002,BRD-K23677682-003-01-2,0.0024414,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::0.00976562::HTS002,BRD-K23677682-003-01-2,0.00976562,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::0.0390625::HTS002,BRD-K23677682-003-01-2,0.0390625,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::0.15625::HTS002,BRD-K23677682-003-01-2,0.15625,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::0.625::HTS002,BRD-K23677682-003-01-2,0.625,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::2.5::HTS002,BRD-K23677682-003-01-2,2.5,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23677682-003-01-2::10::HTS002,BRD-K23677682-003-01-2,10.0,HTS002,PREP026,voreloxin,topoisomerase inhibitor,TOP2A,NA,NA,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1,Phase 3
BRD-K23779958-001-05-8::0.00061034::HTS002,BRD-K23779958-001-05-8,0.00061034,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::0.0024414::HTS002,BRD-K23779958-001-05-8,0.0024414,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::0.00976562::HTS002,BRD-K23779958-001-05-8,0.00976562,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::0.0390625::HTS002,BRD-K23779958-001-05-8,0.0390625,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::0.15625::HTS002,BRD-K23779958-001-05-8,0.15625,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::0.625::HTS002,BRD-K23779958-001-05-8,0.625,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::2.5::HTS002,BRD-K23779958-001-05-8,2.5,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23779958-001-05-8::10::HTS002,BRD-K23779958-001-05-8,10.0,HTS002,PREP048,dichlorvos,acetylcholinesterase inhibitor,NA,NA,NA,COP(=O)(OC)OC=C(Cl)Cl,Launched
BRD-K23952234-236-01-8::0.00061034::HTS002,BRD-K23952234-236-01-8,0.00061034,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::0.0024414::HTS002,BRD-K23952234-236-01-8,0.0024414,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::0.00976562::HTS002,BRD-K23952234-236-01-8,0.00976562,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::0.0390625::HTS002,BRD-K23952234-236-01-8,0.0390625,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::0.15625::HTS002,BRD-K23952234-236-01-8,0.15625,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::0.625::HTS002,BRD-K23952234-236-01-8,0.625,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::2.5::HTS002,BRD-K23952234-236-01-8,2.5,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23952234-236-01-8::10::HTS002,BRD-K23952234-236-01-8,10.0,HTS002,PREP038,BMS-986020,lysophosphatidic acid receptor antagonist,LPAR1,NA,NA,"C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",Phase 2
BRD-K23984367-075-15-2::0.00061034::HTS002,BRD-K23984367-075-15-2,0.00061034,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::0.0024414::HTS002,BRD-K23984367-075-15-2,0.0024414,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::0.00976562::HTS002,BRD-K23984367-075-15-2,0.00976562,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::0.0390625::HTS002,BRD-K23984367-075-15-2,0.0390625,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::0.15625::HTS002,BRD-K23984367-075-15-2,0.15625,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::0.625::HTS002,BRD-K23984367-075-15-2,0.625,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::2.5::HTS002,BRD-K23984367-075-15-2,2.5,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K23984367-075-15-2::10::HTS002,BRD-K23984367-075-15-2,10.0,HTS002,PREP029,sorafenib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET",oncology,"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1",Launched
BRD-K24187789-001-01-7::0.00061034::HTS002,BRD-K24187789-001-01-7,0.00061034,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::0.0024414::HTS002,BRD-K24187789-001-01-7,0.0024414,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::0.00976562::HTS002,BRD-K24187789-001-01-7,0.00976562,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::0.0390625::HTS002,BRD-K24187789-001-01-7,0.0390625,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::0.15625::HTS002,BRD-K24187789-001-01-7,0.15625,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::0.625::HTS002,BRD-K24187789-001-01-7,0.625,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::2.5::HTS002,BRD-K24187789-001-01-7,2.5,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24187789-001-01-7::10::HTS002,BRD-K24187789-001-01-7,10.0,HTS002,PREP036,VU0238429,acetylcholine receptor allosteric modulator,CHRM5,NA,NA,"COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",Preclinical
BRD-K24556098-001-16-7::0.000598997::HTS002,BRD-K24556098-001-16-7,0.000598997,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::0.00239599::HTS002,BRD-K24556098-001-16-7,0.00239599,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::0.00958396::HTS002,BRD-K24556098-001-16-7,0.00958396,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::0.0383358::HTS002,BRD-K24556098-001-16-7,0.0383358,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::0.153343::HTS002,BRD-K24556098-001-16-7,0.153343,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::0.613373::HTS002,BRD-K24556098-001-16-7,0.613373,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::2.45349::HTS002,BRD-K24556098-001-16-7,2.45349,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556098-001-16-7::9.81397::HTS002,BRD-K24556098-001-16-7,9.81397,HTS002,PREP017,deoxycorticosterone-acetate,progestogen hormone,NR3C2,NA,NA,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C",Preclinical
BRD-K24556407-001-02-3::0.00061034::HTS002,BRD-K24556407-001-02-3,0.00061034,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::0.0024414::HTS002,BRD-K24556407-001-02-3,0.0024414,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::0.00976562::HTS002,BRD-K24556407-001-02-3,0.00976562,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::0.0390625::HTS002,BRD-K24556407-001-02-3,0.0390625,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::0.15625::HTS002,BRD-K24556407-001-02-3,0.15625,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::0.625::HTS002,BRD-K24556407-001-02-3,0.625,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::2.5::HTS002,BRD-K24556407-001-02-3,2.5,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24556407-001-02-3::10::HTS002,BRD-K24556407-001-02-3,10.0,HTS002,PREP040,ETP-46464,ATR kinase inhibitor,NA,NA,NA,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,Preclinical
BRD-K24576554-001-04-8::0.00061034::HTS002,BRD-K24576554-001-04-8,0.00061034,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::0.0024414::HTS002,BRD-K24576554-001-04-8,0.0024414,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::0.00976562::HTS002,BRD-K24576554-001-04-8,0.00976562,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::0.0390625::HTS002,BRD-K24576554-001-04-8,0.0390625,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::0.15625::HTS002,BRD-K24576554-001-04-8,0.15625,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::0.625::HTS002,BRD-K24576554-001-04-8,0.625,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::2.5::HTS002,BRD-K24576554-001-04-8,2.5,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24576554-001-04-8::10::HTS002,BRD-K24576554-001-04-8,10.0,HTS002,PREP024,AT-9283,"Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A",NA,NA,O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1,Phase 2
BRD-K24593301-001-02-3::0.000621279::HTS002,BRD-K24593301-001-02-3,0.000621279,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::0.00248512::HTS002,BRD-K24593301-001-02-3,0.00248512,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::0.00994046::HTS002,BRD-K24593301-001-02-3,0.00994046,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::0.0397619::HTS002,BRD-K24593301-001-02-3,0.0397619,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::0.159047::HTS002,BRD-K24593301-001-02-3,0.159047,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::0.63619::HTS002,BRD-K24593301-001-02-3,0.63619,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::2.54476::HTS002,BRD-K24593301-001-02-3,2.54476,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24593301-001-02-3::10.179::HTS002,BRD-K24593301-001-02-3,10.179,HTS002,PREP014,AZD3463,"ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",Preclinical
BRD-K24601397-001-01-1::0.00061034::HTS002,BRD-K24601397-001-01-1,0.00061034,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::0.0024414::HTS002,BRD-K24601397-001-01-1,0.0024414,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::0.00976562::HTS002,BRD-K24601397-001-01-1,0.00976562,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::0.0390625::HTS002,BRD-K24601397-001-01-1,0.0390625,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::0.15625::HTS002,BRD-K24601397-001-01-1,0.15625,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::0.625::HTS002,BRD-K24601397-001-01-1,0.625,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::2.5::HTS002,BRD-K24601397-001-01-1,2.5,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24601397-001-01-1::10::HTS002,BRD-K24601397-001-01-1,10.0,HTS002,PREP033,phlorizin,sodium/glucose cotransporter inhibitor,"SLC5A1, SLC5A11, SLC5A2, SLC5A3",NA,NA,OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O,Preclinical
BRD-K24603946-001-02-1::0.00061034::HTS002,BRD-K24603946-001-02-1,0.00061034,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::0.0024414::HTS002,BRD-K24603946-001-02-1,0.0024414,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::0.00976562::HTS002,BRD-K24603946-001-02-1,0.00976562,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::0.0390625::HTS002,BRD-K24603946-001-02-1,0.0390625,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::0.15625::HTS002,BRD-K24603946-001-02-1,0.15625,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::0.625::HTS002,BRD-K24603946-001-02-1,0.625,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::2.5::HTS002,BRD-K24603946-001-02-1,2.5,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24603946-001-02-1::10::HTS002,BRD-K24603946-001-02-1,10.0,HTS002,PREP044,5-hydroxymethyl-tolterodine,acetylcholine receptor antagonist,CHRM3,NA,NA,"CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",Phase 1
BRD-K24696047-001-02-3::0.00061034::HTS002,BRD-K24696047-001-02-3,0.00061034,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::0.0024414::HTS002,BRD-K24696047-001-02-3,0.0024414,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::0.00976562::HTS002,BRD-K24696047-001-02-3,0.00976562,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::0.0390625::HTS002,BRD-K24696047-001-02-3,0.0390625,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::0.15625::HTS002,BRD-K24696047-001-02-3,0.15625,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::0.625::HTS002,BRD-K24696047-001-02-3,0.625,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::2.5::HTS002,BRD-K24696047-001-02-3,2.5,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24696047-001-02-3::10::HTS002,BRD-K24696047-001-02-3,10.0,HTS002,PREP036,NVP-AEW541,IGF-1 inhibitor,"IGF1R, INSR",NA,NA,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,Preclinical
BRD-K24715592-406-02-1::0.000617404::HTS002,BRD-K24715592-406-02-1,0.000617404,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::0.00246962::HTS002,BRD-K24715592-406-02-1,0.00246962,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::0.00987847::HTS002,BRD-K24715592-406-02-1,0.00987847,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::0.0395139::HTS002,BRD-K24715592-406-02-1,0.0395139,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::0.158056::HTS002,BRD-K24715592-406-02-1,0.158056,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::0.632222::HTS002,BRD-K24715592-406-02-1,0.632222,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::2.52889::HTS002,BRD-K24715592-406-02-1,2.52889,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24715592-406-02-1::10.1156::HTS002,BRD-K24715592-406-02-1,10.1156,HTS002,PREP041,ethacridine-lactate-monohydrate,DNA intercalating agent,NA,NA,NA,"CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",Preclinical
BRD-K24844714-001-24-5::0.00061034::HTS002,BRD-K24844714-001-24-5,0.00061034,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::0.0024414::HTS002,BRD-K24844714-001-24-5,0.0024414,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::0.00976562::HTS002,BRD-K24844714-001-24-5,0.00976562,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::0.0390625::HTS002,BRD-K24844714-001-24-5,0.0390625,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::0.15625::HTS002,BRD-K24844714-001-24-5,0.15625,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::0.625::HTS002,BRD-K24844714-001-24-5,0.625,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::2.5::HTS002,BRD-K24844714-001-24-5,2.5,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24844714-001-24-5::10::HTS002,BRD-K24844714-001-24-5,10.0,HTS002,PREP028,5-fluorouracil,thymidylate synthase inhibitor,"DPYD, TYMS",oncology,"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O",Launched
BRD-K24869513-001-02-1::0.00061034::HTS002,BRD-K24869513-001-02-1,0.00061034,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::0.0024414::HTS002,BRD-K24869513-001-02-1,0.0024414,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::0.00976562::HTS002,BRD-K24869513-001-02-1,0.00976562,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::0.0390625::HTS002,BRD-K24869513-001-02-1,0.0390625,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::0.15625::HTS002,BRD-K24869513-001-02-1,0.15625,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::0.625::HTS002,BRD-K24869513-001-02-1,0.625,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::2.5::HTS002,BRD-K24869513-001-02-1,2.5,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K24869513-001-02-1::10::HTS002,BRD-K24869513-001-02-1,10.0,HTS002,PREP046,CNX-2006,EGFR inhibitor,EGFR,NA,NA,COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F,Preclinical
BRD-K25224017-001-25-0::0.00061034::HTS002,BRD-K25224017-001-25-0,0.00061034,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::0.0024414::HTS002,BRD-K25224017-001-25-0,0.0024414,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::0.00976562::HTS002,BRD-K25224017-001-25-0,0.00976562,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::0.0390625::HTS002,BRD-K25224017-001-25-0,0.0390625,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::0.15625::HTS002,BRD-K25224017-001-25-0,0.15625,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::0.625::HTS002,BRD-K25224017-001-25-0,0.625,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::2.5::HTS002,BRD-K25224017-001-25-0,2.5,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25224017-001-25-0::10::HTS002,BRD-K25224017-001-25-0,10.0,HTS002,PREP037,pirenperone,serotonin receptor antagonist,"HTR2A, HTR7",NA,NA,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,Preclinical
BRD-K25244359-066-03-4::0.000654651::HTS002,BRD-K25244359-066-03-4,0.000654651,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::0.0026186::HTS002,BRD-K25244359-066-03-4,0.0026186,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::0.0104744::HTS002,BRD-K25244359-066-03-4,0.0104744,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::0.0418977::HTS002,BRD-K25244359-066-03-4,0.0418977,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::0.167591::HTS002,BRD-K25244359-066-03-4,0.167591,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::0.670363::HTS002,BRD-K25244359-066-03-4,0.670363,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::2.68145::HTS002,BRD-K25244359-066-03-4,2.68145,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25244359-066-03-4::10.7258::HTS002,BRD-K25244359-066-03-4,10.7258,HTS002,PREP018,apatinib,RET tyrosine kinase inhibitor,"CSK, KDR, KIT, RET",NA,NA,"O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",Phase 3
BRD-K25279140-001-01-5::0.00061034::HTS002,BRD-K25279140-001-01-5,0.00061034,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::0.0024414::HTS002,BRD-K25279140-001-01-5,0.0024414,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::0.00976562::HTS002,BRD-K25279140-001-01-5,0.00976562,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::0.0390625::HTS002,BRD-K25279140-001-01-5,0.0390625,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::0.15625::HTS002,BRD-K25279140-001-01-5,0.15625,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::0.625::HTS002,BRD-K25279140-001-01-5,0.625,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::2.5::HTS002,BRD-K25279140-001-01-5,2.5,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25279140-001-01-5::10::HTS002,BRD-K25279140-001-01-5,10.0,HTS002,PREP046,MK-8745,Aurora kinase inhibitor,AURKA,NA,NA,Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1,Preclinical
BRD-K25340465-001-11-1::0.000628993::HTS002,BRD-K25340465-001-11-1,0.000628993,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::0.00251597::HTS002,BRD-K25340465-001-11-1,0.00251597,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::0.0100639::HTS002,BRD-K25340465-001-11-1,0.0100639,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::0.0402556::HTS002,BRD-K25340465-001-11-1,0.0402556,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::0.161022::HTS002,BRD-K25340465-001-11-1,0.161022,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::0.644089::HTS002,BRD-K25340465-001-11-1,0.644089,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::2.57636::HTS002,BRD-K25340465-001-11-1,2.57636,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25340465-001-11-1::10.3054::HTS002,BRD-K25340465-001-11-1,10.3054,HTS002,PREP026,OSI-930,"KIT inhibitor, VEGFR inhibitor","KDR, KIT",NA,NA,"FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",Phase 1
BRD-K25412176-001-01-9::0.00061034::HTS002,BRD-K25412176-001-01-9,0.00061034,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.0024414::HTS002,BRD-K25412176-001-01-9,0.0024414,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.00976562::HTS002,BRD-K25412176-001-01-9,0.00976562,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.0390625::HTS002,BRD-K25412176-001-01-9,0.0390625,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.15625::HTS002,BRD-K25412176-001-01-9,0.15625,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.625::HTS002,BRD-K25412176-001-01-9,0.625,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::2.5::HTS002,BRD-K25412176-001-01-9,2.5,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::10::HTS002,BRD-K25412176-001-01-9,10.0,HTS002,PREP026,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25433859-003-25-4::0.00061034::HTS002,BRD-K25433859-003-25-4,0.00061034,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::0.0024414::HTS002,BRD-K25433859-003-25-4,0.0024414,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::0.00976562::HTS002,BRD-K25433859-003-25-4,0.00976562,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::0.0390625::HTS002,BRD-K25433859-003-25-4,0.0390625,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::0.15625::HTS002,BRD-K25433859-003-25-4,0.15625,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::0.625::HTS002,BRD-K25433859-003-25-4,0.625,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::2.5::HTS002,BRD-K25433859-003-25-4,2.5,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25433859-003-25-4::10::HTS002,BRD-K25433859-003-25-4,10.0,HTS002,PREP029,maprotiline,"norepinephrine reputake inhibitor, tricyclic antidepressant","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2",neurology/psychiatry,"depression, dysthymic disorder","CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21",Launched
BRD-K25596805-001-01-8::0.00061034::HTS002,BRD-K25596805-001-01-8,0.00061034,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::0.0024414::HTS002,BRD-K25596805-001-01-8,0.0024414,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::0.00976562::HTS002,BRD-K25596805-001-01-8,0.00976562,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::0.0390625::HTS002,BRD-K25596805-001-01-8,0.0390625,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::0.15625::HTS002,BRD-K25596805-001-01-8,0.15625,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::0.625::HTS002,BRD-K25596805-001-01-8,0.625,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::2.5::HTS002,BRD-K25596805-001-01-8,2.5,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25596805-001-01-8::10::HTS002,BRD-K25596805-001-01-8,10.0,HTS002,PREP042,JNJ-16259685,glutamate receptor antagonist,GRM1,NA,NA,"CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1",Preclinical
BRD-K25630527-001-03-8::0.00061034::HTS002,BRD-K25630527-001-03-8,0.00061034,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::0.0024414::HTS002,BRD-K25630527-001-03-8,0.0024414,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::0.00976562::HTS002,BRD-K25630527-001-03-8,0.00976562,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::0.0390625::HTS002,BRD-K25630527-001-03-8,0.0390625,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::0.15625::HTS002,BRD-K25630527-001-03-8,0.15625,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::0.625::HTS002,BRD-K25630527-001-03-8,0.625,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::2.5::HTS002,BRD-K25630527-001-03-8,2.5,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25630527-001-03-8::10::HTS002,BRD-K25630527-001-03-8,10.0,HTS002,PREP027,LY2784544,JAK inhibitor,"JAK2, JAK3",NA,NA,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1,Phase 2
BRD-K25690923-001-02-4::0.00061034::HTS002,BRD-K25690923-001-02-4,0.00061034,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::0.0024414::HTS002,BRD-K25690923-001-02-4,0.0024414,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::0.00976562::HTS002,BRD-K25690923-001-02-4,0.00976562,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::0.0390625::HTS002,BRD-K25690923-001-02-4,0.0390625,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::0.15625::HTS002,BRD-K25690923-001-02-4,0.15625,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::0.625::HTS002,BRD-K25690923-001-02-4,0.625,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::2.5::HTS002,BRD-K25690923-001-02-4,2.5,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25690923-001-02-4::10::HTS002,BRD-K25690923-001-02-4,10.0,HTS002,PREP036,4-iodo-6-phenylpyrimidine,macrophage migration inhibiting factor inhibitor,MIF,NA,NA,Ic1cc(ncn1)-c1ccccc1,Preclinical
BRD-K25835157-001-01-4::0.00061034::HTS002,BRD-K25835157-001-01-4,0.00061034,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::0.0024414::HTS002,BRD-K25835157-001-01-4,0.0024414,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::0.00976562::HTS002,BRD-K25835157-001-01-4,0.00976562,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::0.0390625::HTS002,BRD-K25835157-001-01-4,0.0390625,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::0.15625::HTS002,BRD-K25835157-001-01-4,0.15625,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::0.625::HTS002,BRD-K25835157-001-01-4,0.625,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::2.5::HTS002,BRD-K25835157-001-01-4,2.5,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25835157-001-01-4::10::HTS002,BRD-K25835157-001-01-4,10.0,HTS002,PREP032,PRT062070,"JAK inhibitor, syk inhibitor",SYK,NA,NA,"CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",Phase 1
BRD-K25837718-001-03-8::0.00061034::HTS002,BRD-K25837718-001-03-8,0.00061034,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::0.0024414::HTS002,BRD-K25837718-001-03-8,0.0024414,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::0.00976562::HTS002,BRD-K25837718-001-03-8,0.00976562,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::0.0390625::HTS002,BRD-K25837718-001-03-8,0.0390625,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::0.15625::HTS002,BRD-K25837718-001-03-8,0.15625,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::0.625::HTS002,BRD-K25837718-001-03-8,0.625,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::2.5::HTS002,BRD-K25837718-001-03-8,2.5,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K25837718-001-03-8::10::HTS002,BRD-K25837718-001-03-8,10.0,HTS002,PREP017,josamycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O,Launched
BRD-K26011976-001-01-0::0.00061034::HTS002,BRD-K26011976-001-01-0,0.00061034,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::0.0024414::HTS002,BRD-K26011976-001-01-0,0.0024414,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::0.00976562::HTS002,BRD-K26011976-001-01-0,0.00976562,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::0.0390625::HTS002,BRD-K26011976-001-01-0,0.0390625,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::0.15625::HTS002,BRD-K26011976-001-01-0,0.15625,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::0.625::HTS002,BRD-K26011976-001-01-0,0.625,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::2.5::HTS002,BRD-K26011976-001-01-0,2.5,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26011976-001-01-0::10::HTS002,BRD-K26011976-001-01-0,10.0,HTS002,PREP032,licochalcone-a,topoisomerase inhibitor,PTPN1,NA,NA,COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C,Phase 3
BRD-K26253904-001-01-5::0.00061034::HTS002,BRD-K26253904-001-01-5,0.00061034,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::0.0024414::HTS002,BRD-K26253904-001-01-5,0.0024414,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::0.00976562::HTS002,BRD-K26253904-001-01-5,0.00976562,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::0.0390625::HTS002,BRD-K26253904-001-01-5,0.0390625,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::0.15625::HTS002,BRD-K26253904-001-01-5,0.15625,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::0.625::HTS002,BRD-K26253904-001-01-5,0.625,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::2.5::HTS002,BRD-K26253904-001-01-5,2.5,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26253904-001-01-5::10::HTS002,BRD-K26253904-001-01-5,10.0,HTS002,PREP041,NMS-873,ATPase inhibitor,VCP,NA,NA,"Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",Preclinical
BRD-K26305185-001-02-1::0.000611294::HTS002,BRD-K26305185-001-02-1,0.000611294,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::0.00244518::HTS002,BRD-K26305185-001-02-1,0.00244518,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::0.0097807::HTS002,BRD-K26305185-001-02-1,0.0097807,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::0.0391228::HTS002,BRD-K26305185-001-02-1,0.0391228,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::0.156491::HTS002,BRD-K26305185-001-02-1,0.156491,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::0.625965::HTS002,BRD-K26305185-001-02-1,0.625965,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::2.50386::HTS002,BRD-K26305185-001-02-1,2.50386,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26305185-001-02-1::10.0154::HTS002,BRD-K26305185-001-02-1,10.0154,HTS002,PREP043,K-Ras(G12C)-inhibitor-6,K-ras inhibitor,NA,NA,NA,"SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",Preclinical
BRD-K26603252-003-04-9::0.00061034::HTS002,BRD-K26603252-003-04-9,0.00061034,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::0.0024414::HTS002,BRD-K26603252-003-04-9,0.0024414,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::0.00976562::HTS002,BRD-K26603252-003-04-9,0.00976562,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::0.0390625::HTS002,BRD-K26603252-003-04-9,0.0390625,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::0.15625::HTS002,BRD-K26603252-003-04-9,0.15625,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::0.625::HTS002,BRD-K26603252-003-04-9,0.625,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::2.5::HTS002,BRD-K26603252-003-04-9,2.5,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26603252-003-04-9::10::HTS002,BRD-K26603252-003-04-9,10.0,HTS002,PREP045,PD-153035,EGFR inhibitor,"EGFR, KDR",NA,NA,COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC,Phase 1
BRD-K26619122-001-02-1::0.00061034::HTS002,BRD-K26619122-001-02-1,0.00061034,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::0.0024414::HTS002,BRD-K26619122-001-02-1,0.0024414,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::0.00976562::HTS002,BRD-K26619122-001-02-1,0.00976562,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::0.0390625::HTS002,BRD-K26619122-001-02-1,0.0390625,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::0.15625::HTS002,BRD-K26619122-001-02-1,0.15625,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::0.625::HTS002,BRD-K26619122-001-02-1,0.625,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::2.5::HTS002,BRD-K26619122-001-02-1,2.5,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26619122-001-02-1::10::HTS002,BRD-K26619122-001-02-1,10.0,HTS002,PREP016,thiocolchicoside,GABA receptor antagonist,"GABRA1, GABRB2, GABRG2, GLRA1, GLRB",neurology/psychiatry,muscle relaxant,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,Launched
BRD-K26657438-001-15-2::0.00061034::HTS002,BRD-K26657438-001-15-2,0.00061034,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.0024414::HTS002,BRD-K26657438-001-15-2,0.0024414,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.00976562::HTS002,BRD-K26657438-001-15-2,0.00976562,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.0390625::HTS002,BRD-K26657438-001-15-2,0.0390625,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.15625::HTS002,BRD-K26657438-001-15-2,0.15625,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::0.625::HTS002,BRD-K26657438-001-15-2,0.625,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::2.5::HTS002,BRD-K26657438-001-15-2,2.5,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26657438-001-15-2::10::HTS002,BRD-K26657438-001-15-2,10.0,HTS002,PREP017,imiquimod,"interferon inducer, toll-like receptor agonist","TLR7, TLR8","dermatology, infectious disease, oncology","actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)","CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12",Launched
BRD-K26667523-001-02-5::0.00061034::HTS002,BRD-K26667523-001-02-5,0.00061034,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::0.0024414::HTS002,BRD-K26667523-001-02-5,0.0024414,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::0.00976562::HTS002,BRD-K26667523-001-02-5,0.00976562,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::0.0390625::HTS002,BRD-K26667523-001-02-5,0.0390625,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::0.15625::HTS002,BRD-K26667523-001-02-5,0.15625,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::0.625::HTS002,BRD-K26667523-001-02-5,0.625,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::2.5::HTS002,BRD-K26667523-001-02-5,2.5,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26667523-001-02-5::10::HTS002,BRD-K26667523-001-02-5,10.0,HTS002,PREP027,TAK-733,MEK inhibitor,MAP2K1,NA,NA,"Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",Phase 1
BRD-K26712974-001-01-5::0.00061034::HTS002,BRD-K26712974-001-01-5,0.00061034,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::0.0024414::HTS002,BRD-K26712974-001-01-5,0.0024414,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::0.00976562::HTS002,BRD-K26712974-001-01-5,0.00976562,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::0.0390625::HTS002,BRD-K26712974-001-01-5,0.0390625,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::0.15625::HTS002,BRD-K26712974-001-01-5,0.15625,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::0.625::HTS002,BRD-K26712974-001-01-5,0.625,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::2.5::HTS002,BRD-K26712974-001-01-5,2.5,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26712974-001-01-5::10::HTS002,BRD-K26712974-001-01-5,10.0,HTS002,PREP019,VX-765,caspase inhibitor,CASP1,NA,NA,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,Phase 2
BRD-K26756394-001-02-2::0.00061034::HTS002,BRD-K26756394-001-02-2,0.00061034,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::0.0024414::HTS002,BRD-K26756394-001-02-2,0.0024414,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::0.00976562::HTS002,BRD-K26756394-001-02-2,0.00976562,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::0.0390625::HTS002,BRD-K26756394-001-02-2,0.0390625,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::0.15625::HTS002,BRD-K26756394-001-02-2,0.15625,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::0.625::HTS002,BRD-K26756394-001-02-2,0.625,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::2.5::HTS002,BRD-K26756394-001-02-2,2.5,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26756394-001-02-2::10::HTS002,BRD-K26756394-001-02-2,10.0,HTS002,PREP037,VE-821,ATR kinase inhibitor,ATR,NA,NA,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,Preclinical
BRD-K26818574-305-04-3::0.00061034::HTS002,BRD-K26818574-305-04-3,0.00061034,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::0.0024414::HTS002,BRD-K26818574-305-04-3,0.0024414,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::0.00976562::HTS002,BRD-K26818574-305-04-3,0.00976562,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::0.0390625::HTS002,BRD-K26818574-305-04-3,0.0390625,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::0.15625::HTS002,BRD-K26818574-305-04-3,0.15625,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::0.625::HTS002,BRD-K26818574-305-04-3,0.625,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::2.5::HTS002,BRD-K26818574-305-04-3,2.5,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26818574-305-04-3::10::HTS002,BRD-K26818574-305-04-3,10.0,HTS002,PREP043,BIX-01294,histone lysine methyltransferase inhibitor,"EHMT1, EHMT2",NA,NA,"COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",Preclinical
BRD-K26823213-001-02-9::0.00061034::HTS002,BRD-K26823213-001-02-9,0.00061034,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::0.0024414::HTS002,BRD-K26823213-001-02-9,0.0024414,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::0.00976562::HTS002,BRD-K26823213-001-02-9,0.00976562,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::0.0390625::HTS002,BRD-K26823213-001-02-9,0.0390625,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::0.15625::HTS002,BRD-K26823213-001-02-9,0.15625,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::0.625::HTS002,BRD-K26823213-001-02-9,0.625,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::2.5::HTS002,BRD-K26823213-001-02-9,2.5,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26823213-001-02-9::10::HTS002,BRD-K26823213-001-02-9,10.0,HTS002,PREP027,GW-842166,cannabinoid receptor agonist,CNR2,NA,NA,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,Phase 2
BRD-K26824830-001-02-0::0.00061034::HTS002,BRD-K26824830-001-02-0,0.00061034,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::0.0024414::HTS002,BRD-K26824830-001-02-0,0.0024414,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::0.00976562::HTS002,BRD-K26824830-001-02-0,0.00976562,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::0.0390625::HTS002,BRD-K26824830-001-02-0,0.0390625,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::0.15625::HTS002,BRD-K26824830-001-02-0,0.15625,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::0.625::HTS002,BRD-K26824830-001-02-0,0.625,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::2.5::HTS002,BRD-K26824830-001-02-0,2.5,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26824830-001-02-0::10::HTS002,BRD-K26824830-001-02-0,10.0,HTS002,PREP014,azomycin-(2-nitroimidazole),protein synthesis inhibitor,NA,NA,NA,"[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",Preclinical
BRD-K26833429-001-02-8::0.00061034::HTS002,BRD-K26833429-001-02-8,0.00061034,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::0.0024414::HTS002,BRD-K26833429-001-02-8,0.0024414,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::0.00976562::HTS002,BRD-K26833429-001-02-8,0.00976562,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::0.0390625::HTS002,BRD-K26833429-001-02-8,0.0390625,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::0.15625::HTS002,BRD-K26833429-001-02-8,0.15625,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::0.625::HTS002,BRD-K26833429-001-02-8,0.625,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::2.5::HTS002,BRD-K26833429-001-02-8,2.5,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26833429-001-02-8::10::HTS002,BRD-K26833429-001-02-8,10.0,HTS002,PREP036,costunolide,telomerase inhibitor,NA,NA,NA,"C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1",Preclinical
BRD-K26838195-075-04-9::0.00061034::HTS002,BRD-K26838195-075-04-9,0.00061034,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::0.0024414::HTS002,BRD-K26838195-075-04-9,0.0024414,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::0.00976562::HTS002,BRD-K26838195-075-04-9,0.00976562,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::0.0390625::HTS002,BRD-K26838195-075-04-9,0.0390625,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::0.15625::HTS002,BRD-K26838195-075-04-9,0.15625,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::0.625::HTS002,BRD-K26838195-075-04-9,0.625,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::2.5::HTS002,BRD-K26838195-075-04-9,2.5,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26838195-075-04-9::10::HTS002,BRD-K26838195-075-04-9,10.0,HTS002,PREP024,AST-1306,EGFR inhibitor,"EGFR, ERBB2",NA,NA,Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1,Phase 1
BRD-K26997899-001-02-2::0.00061034::HTS002,BRD-K26997899-001-02-2,0.00061034,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::0.0024414::HTS002,BRD-K26997899-001-02-2,0.0024414,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::0.00976562::HTS002,BRD-K26997899-001-02-2,0.00976562,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::0.0390625::HTS002,BRD-K26997899-001-02-2,0.0390625,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::0.15625::HTS002,BRD-K26997899-001-02-2,0.15625,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::0.625::HTS002,BRD-K26997899-001-02-2,0.625,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::2.5::HTS002,BRD-K26997899-001-02-2,2.5,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K26997899-001-02-2::10::HTS002,BRD-K26997899-001-02-2,10.0,HTS002,PREP015,D-64131,microtubule inhibitor,TUBB,NA,NA,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,Preclinical
BRD-K27182532-001-02-3::0.00061034::HTS002,BRD-K27182532-001-02-3,0.00061034,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::0.0024414::HTS002,BRD-K27182532-001-02-3,0.0024414,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::0.00976562::HTS002,BRD-K27182532-001-02-3,0.00976562,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::0.0390625::HTS002,BRD-K27182532-001-02-3,0.0390625,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::0.15625::HTS002,BRD-K27182532-001-02-3,0.15625,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::0.625::HTS002,BRD-K27182532-001-02-3,0.625,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::2.5::HTS002,BRD-K27182532-001-02-3,2.5,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27182532-001-02-3::10::HTS002,BRD-K27182532-001-02-3,10.0,HTS002,PREP032,metatinib,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,Phase 1
BRD-K27184429-300-01-3::0.00061034::HTS002,BRD-K27184429-300-01-3,0.00061034,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::0.0024414::HTS002,BRD-K27184429-300-01-3,0.0024414,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::0.00976562::HTS002,BRD-K27184429-300-01-3,0.00976562,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::0.0390625::HTS002,BRD-K27184429-300-01-3,0.0390625,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::0.15625::HTS002,BRD-K27184429-300-01-3,0.15625,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::0.625::HTS002,BRD-K27184429-300-01-3,0.625,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::2.5::HTS002,BRD-K27184429-300-01-3,2.5,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27184429-300-01-3::10::HTS002,BRD-K27184429-300-01-3,10.0,HTS002,PREP030,levocetirizine,histamine receptor antagonist,HRH1,allergy,"allergic rhinitis, urticaria",OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1,Launched
BRD-K27217864-001-22-3::0.00061034::HTS002,BRD-K27217864-001-22-3,0.00061034,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::0.0024414::HTS002,BRD-K27217864-001-22-3,0.0024414,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::0.00976562::HTS002,BRD-K27217864-001-22-3,0.00976562,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::0.0390625::HTS002,BRD-K27217864-001-22-3,0.0390625,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::0.15625::HTS002,BRD-K27217864-001-22-3,0.15625,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::0.625::HTS002,BRD-K27217864-001-22-3,0.625,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::2.5::HTS002,BRD-K27217864-001-22-3,2.5,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27217864-001-22-3::10::HTS002,BRD-K27217864-001-22-3,10.0,HTS002,PREP028,butamben,sodium channel blocker,NA,NA,NA,CCCCOC(=O)c1ccc(N)cc1,Withdrawn
BRD-K27316855-001-13-3::0.000594718::HTS002,BRD-K27316855-001-13-3,0.000594718,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::0.00237887::HTS002,BRD-K27316855-001-13-3,0.00237887,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::0.00951549::HTS002,BRD-K27316855-001-13-3,0.00951549,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::0.038062::HTS002,BRD-K27316855-001-13-3,0.038062,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::0.152248::HTS002,BRD-K27316855-001-13-3,0.152248,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::0.608991::HTS002,BRD-K27316855-001-13-3,0.608991,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::2.43597::HTS002,BRD-K27316855-001-13-3,2.43597,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27316855-001-13-3::9.74386::HTS002,BRD-K27316855-001-13-3,9.74386,HTS002,PREP029,calcitriol,vitamin D receptor agonist,VDR,"endocrinology, orthopedics","hypocalcemia, hypoparathyroidism, osteoporosis","C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K27351809-001-09-5::0.00061034::HTS002,BRD-K27351809-001-09-5,0.00061034,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::0.0024414::HTS002,BRD-K27351809-001-09-5,0.0024414,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::0.00976562::HTS002,BRD-K27351809-001-09-5,0.00976562,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::0.0390625::HTS002,BRD-K27351809-001-09-5,0.0390625,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::0.15625::HTS002,BRD-K27351809-001-09-5,0.15625,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::0.625::HTS002,BRD-K27351809-001-09-5,0.625,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::2.5::HTS002,BRD-K27351809-001-09-5,2.5,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27351809-001-09-5::10::HTS002,BRD-K27351809-001-09-5,10.0,HTS002,PREP022,nomegestrol-acetate,progesterone receptor agonist,PGR,endocrinology,contraceptive,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,Launched
BRD-K27799744-001-02-8::0.000615367::HTS002,BRD-K27799744-001-02-8,0.000615367,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::0.00246147::HTS002,BRD-K27799744-001-02-8,0.00246147,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::0.00984587::HTS002,BRD-K27799744-001-02-8,0.00984587,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::0.0393835::HTS002,BRD-K27799744-001-02-8,0.0393835,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::0.157534::HTS002,BRD-K27799744-001-02-8,0.157534,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::0.630136::HTS002,BRD-K27799744-001-02-8,0.630136,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::2.52054::HTS002,BRD-K27799744-001-02-8,2.52054,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K27799744-001-02-8::10.0822::HTS002,BRD-K27799744-001-02-8,10.0822,HTS002,PREP030,cyclovirobuxin-d,calcium channel modulator,NA,NA,NA,"CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",Preclinical
BRD-K28143534-001-02-2::0.000610352::HTS002,BRD-K28143534-001-02-2,0.000610352,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::0.00244141::HTS002,BRD-K28143534-001-02-2,0.00244141,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::0.00976562::HTS002,BRD-K28143534-001-02-2,0.00976562,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::0.0390625::HTS002,BRD-K28143534-001-02-2,0.0390625,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::0.15625::HTS002,BRD-K28143534-001-02-2,0.15625,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::0.625::HTS002,BRD-K28143534-001-02-2,0.625,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::2.5::HTS002,BRD-K28143534-001-02-2,2.5,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28143534-001-02-2::10::HTS002,BRD-K28143534-001-02-2,10.0,HTS002,PREP032,cyproheptadine,histamine receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7","allergy, otolaryngology, ophthalmology, dermatology","allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism","CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12",Launched
BRD-K28192623-066-08-1::0.00061034::HTS002,BRD-K28192623-066-08-1,0.00061034,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::0.0024414::HTS002,BRD-K28192623-066-08-1,0.0024414,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::0.00976562::HTS002,BRD-K28192623-066-08-1,0.00976562,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::0.0390625::HTS002,BRD-K28192623-066-08-1,0.0390625,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::0.15625::HTS002,BRD-K28192623-066-08-1,0.15625,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::0.625::HTS002,BRD-K28192623-066-08-1,0.625,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::2.5::HTS002,BRD-K28192623-066-08-1,2.5,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28192623-066-08-1::10::HTS002,BRD-K28192623-066-08-1,10.0,HTS002,PREP018,spiradoline,opioid receptor agonist,OPRK1,NA,NA,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,Phase 2
BRD-K28307902-001-21-7::0.00061034::HTS002,BRD-K28307902-001-21-7,0.00061034,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::0.0024414::HTS002,BRD-K28307902-001-21-7,0.0024414,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::0.00976562::HTS002,BRD-K28307902-001-21-7,0.00976562,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::0.0390625::HTS002,BRD-K28307902-001-21-7,0.0390625,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::0.15625::HTS002,BRD-K28307902-001-21-7,0.15625,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::0.625::HTS002,BRD-K28307902-001-21-7,0.625,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::2.5::HTS002,BRD-K28307902-001-21-7,2.5,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28307902-001-21-7::10::HTS002,BRD-K28307902-001-21-7,10.0,HTS002,PREP017,flutamide,androgen receptor antagonist,"AHR, AR",oncology,prostate cancer,"CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",Launched
BRD-K28352084-001-02-3::0.00061034::HTS002,BRD-K28352084-001-02-3,0.00061034,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::0.0024414::HTS002,BRD-K28352084-001-02-3,0.0024414,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::0.00976562::HTS002,BRD-K28352084-001-02-3,0.00976562,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::0.0390625::HTS002,BRD-K28352084-001-02-3,0.0390625,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::0.15625::HTS002,BRD-K28352084-001-02-3,0.15625,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::0.625::HTS002,BRD-K28352084-001-02-3,0.625,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::2.5::HTS002,BRD-K28352084-001-02-3,2.5,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28352084-001-02-3::10::HTS002,BRD-K28352084-001-02-3,10.0,HTS002,PREP044,CH5132799,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",Phase 1
BRD-K28360340-001-08-3::0.000563224::HTS002,BRD-K28360340-001-08-3,0.000563224,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::0.0022529::HTS002,BRD-K28360340-001-08-3,0.0022529,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::0.00901159::HTS002,BRD-K28360340-001-08-3,0.00901159,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::0.0360464::HTS002,BRD-K28360340-001-08-3,0.0360464,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::0.144185::HTS002,BRD-K28360340-001-08-3,0.144185,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::0.576742::HTS002,BRD-K28360340-001-08-3,0.576742,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::2.30697::HTS002,BRD-K28360340-001-08-3,2.30697,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28360340-001-08-3::9.22787::HTS002,BRD-K28360340-001-08-3,9.22787,HTS002,PREP015,TW-37,BCL inhibitor,"BCL2, BCL2L1, MCL1",NA,NA,"CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",Preclinical
BRD-K28383148-001-01-4::0.00061034::HTS002,BRD-K28383148-001-01-4,0.00061034,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::0.0024414::HTS002,BRD-K28383148-001-01-4,0.0024414,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::0.00976562::HTS002,BRD-K28383148-001-01-4,0.00976562,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::0.0390625::HTS002,BRD-K28383148-001-01-4,0.0390625,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::0.15625::HTS002,BRD-K28383148-001-01-4,0.15625,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::0.625::HTS002,BRD-K28383148-001-01-4,0.625,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::2.5::HTS002,BRD-K28383148-001-01-4,2.5,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28383148-001-01-4::10::HTS002,BRD-K28383148-001-01-4,10.0,HTS002,PREP044,AP1903,NA,NA,NA,NA,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1,Phase 1/Phase 2
BRD-K28392481-001-05-1::0.00061034::HTS002,BRD-K28392481-001-05-1,0.00061034,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::0.0024414::HTS002,BRD-K28392481-001-05-1,0.0024414,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::0.00976562::HTS002,BRD-K28392481-001-05-1,0.00976562,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::0.0390625::HTS002,BRD-K28392481-001-05-1,0.0390625,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::0.15625::HTS002,BRD-K28392481-001-05-1,0.15625,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::0.625::HTS002,BRD-K28392481-001-05-1,0.625,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::2.5::HTS002,BRD-K28392481-001-05-1,2.5,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28392481-001-05-1::10::HTS002,BRD-K28392481-001-05-1,10.0,HTS002,PREP027,AZD4547,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR",NA,NA,COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1,Phase 2/Phase 3
BRD-K28453807-003-11-2::0.00061034::HTS002,BRD-K28453807-003-11-2,0.00061034,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::0.0024414::HTS002,BRD-K28453807-003-11-2,0.0024414,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::0.00976562::HTS002,BRD-K28453807-003-11-2,0.00976562,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::0.0390625::HTS002,BRD-K28453807-003-11-2,0.0390625,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::0.15625::HTS002,BRD-K28453807-003-11-2,0.15625,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::0.625::HTS002,BRD-K28453807-003-11-2,0.625,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::2.5::HTS002,BRD-K28453807-003-11-2,2.5,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28453807-003-11-2::10::HTS002,BRD-K28453807-003-11-2,10.0,HTS002,PREP014,nitrocaramiphen,cholinergic receptor antagonist,CHRM1,NA,NA,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K28542495-003-13-5::0.00061034::HTS002,BRD-K28542495-003-13-5,0.00061034,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::0.0024414::HTS002,BRD-K28542495-003-13-5,0.0024414,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::0.00976562::HTS002,BRD-K28542495-003-13-5,0.00976562,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::0.0390625::HTS002,BRD-K28542495-003-13-5,0.0390625,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::0.15625::HTS002,BRD-K28542495-003-13-5,0.15625,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::0.625::HTS002,BRD-K28542495-003-13-5,0.625,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::2.5::HTS002,BRD-K28542495-003-13-5,2.5,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28542495-003-13-5::10::HTS002,BRD-K28542495-003-13-5,10.0,HTS002,PREP035,benzydamine,prostanoid receptor antagonist,NA,"dental, otolaryngology","mouth inflammation, throat inflammation","CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12",Launched
BRD-K28570407-001-02-0::0.00061034::HTS002,BRD-K28570407-001-02-0,0.00061034,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::0.0024414::HTS002,BRD-K28570407-001-02-0,0.0024414,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::0.00976562::HTS002,BRD-K28570407-001-02-0,0.00976562,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::0.0390625::HTS002,BRD-K28570407-001-02-0,0.0390625,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::0.15625::HTS002,BRD-K28570407-001-02-0,0.15625,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::0.625::HTS002,BRD-K28570407-001-02-0,0.625,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::2.5::HTS002,BRD-K28570407-001-02-0,2.5,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28570407-001-02-0::10::HTS002,BRD-K28570407-001-02-0,10.0,HTS002,PREP014,A-803467,sodium channel blocker,SCN10A,NA,NA,"COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",Preclinical
BRD-K28578425-001-07-0::0.00061034::HTS002,BRD-K28578425-001-07-0,0.00061034,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::0.0024414::HTS002,BRD-K28578425-001-07-0,0.0024414,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::0.00976562::HTS002,BRD-K28578425-001-07-0,0.00976562,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::0.0390625::HTS002,BRD-K28578425-001-07-0,0.0390625,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::0.15625::HTS002,BRD-K28578425-001-07-0,0.15625,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::0.625::HTS002,BRD-K28578425-001-07-0,0.625,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::2.5::HTS002,BRD-K28578425-001-07-0,2.5,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28578425-001-07-0::10::HTS002,BRD-K28578425-001-07-0,10.0,HTS002,PREP041,cilostamide,phosphodiesterase inhibitor,"PDE3A, PDE3B",NA,NA,"CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",Preclinical
BRD-K28822270-001-01-1::0.00061034::HTS002,BRD-K28822270-001-01-1,0.00061034,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::0.0024414::HTS002,BRD-K28822270-001-01-1,0.0024414,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::0.00976562::HTS002,BRD-K28822270-001-01-1,0.00976562,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::0.0390625::HTS002,BRD-K28822270-001-01-1,0.0390625,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::0.15625::HTS002,BRD-K28822270-001-01-1,0.15625,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::0.625::HTS002,BRD-K28822270-001-01-1,0.625,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::2.5::HTS002,BRD-K28822270-001-01-1,2.5,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28822270-001-01-1::10::HTS002,BRD-K28822270-001-01-1,10.0,HTS002,PREP024,resminostat,HDAC inhibitor,"HDAC1, HDAC3, HDAC6, HDAC8",NA,NA,"CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO",Phase 2
BRD-K28824103-001-02-8::0.000610352::HTS002,BRD-K28824103-001-02-8,0.000610352,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::0.00244141::HTS002,BRD-K28824103-001-02-8,0.00244141,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::0.00976562::HTS002,BRD-K28824103-001-02-8,0.00976562,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::0.0390625::HTS002,BRD-K28824103-001-02-8,0.0390625,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::0.15625::HTS002,BRD-K28824103-001-02-8,0.15625,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::0.625::HTS002,BRD-K28824103-001-02-8,0.625,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::2.5::HTS002,BRD-K28824103-001-02-8,2.5,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28824103-001-02-8::10::HTS002,BRD-K28824103-001-02-8,10.0,HTS002,PREP030,genipin,choleretic agent,NA,NA,NA,"COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO",Preclinical
BRD-K28907958-001-04-3::0.00061034::HTS002,BRD-K28907958-001-04-3,0.00061034,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::0.0024414::HTS002,BRD-K28907958-001-04-3,0.0024414,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::0.00976562::HTS002,BRD-K28907958-001-04-3,0.00976562,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::0.0390625::HTS002,BRD-K28907958-001-04-3,0.0390625,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::0.15625::HTS002,BRD-K28907958-001-04-3,0.15625,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::0.625::HTS002,BRD-K28907958-001-04-3,0.625,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::2.5::HTS002,BRD-K28907958-001-04-3,2.5,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28907958-001-04-3::10::HTS002,BRD-K28907958-001-04-3,10.0,HTS002,PREP040,CD-437,retinoid receptor agonist,RARG,NA,NA,"OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K28965160-001-01-1::0.00061034::HTS002,BRD-K28965160-001-01-1,0.00061034,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::0.0024414::HTS002,BRD-K28965160-001-01-1,0.0024414,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::0.00976562::HTS002,BRD-K28965160-001-01-1,0.00976562,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::0.0390625::HTS002,BRD-K28965160-001-01-1,0.0390625,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::0.15625::HTS002,BRD-K28965160-001-01-1,0.15625,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::0.625::HTS002,BRD-K28965160-001-01-1,0.625,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::2.5::HTS002,BRD-K28965160-001-01-1,2.5,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K28965160-001-01-1::10::HTS002,BRD-K28965160-001-01-1,10.0,HTS002,PREP027,BVD-523,MAP kinase inhibitor,NA,NA,NA,CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1,Phase 1/Phase 2
BRD-K29173907-001-09-2::0.00061034::HTS002,BRD-K29173907-001-09-2,0.00061034,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::0.0024414::HTS002,BRD-K29173907-001-09-2,0.0024414,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::0.00976562::HTS002,BRD-K29173907-001-09-2,0.00976562,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::0.0390625::HTS002,BRD-K29173907-001-09-2,0.0390625,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::0.15625::HTS002,BRD-K29173907-001-09-2,0.15625,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::0.625::HTS002,BRD-K29173907-001-09-2,0.625,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::2.5::HTS002,BRD-K29173907-001-09-2,2.5,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29173907-001-09-2::10::HTS002,BRD-K29173907-001-09-2,10.0,HTS002,PREP014,isoflupredone-acetate,NA,NR3C1,NA,NA,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C,Preclinical
BRD-K29254801-001-14-7::0.00061034::HTS002,BRD-K29254801-001-14-7,0.00061034,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::0.0024414::HTS002,BRD-K29254801-001-14-7,0.0024414,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::0.00976562::HTS002,BRD-K29254801-001-14-7,0.00976562,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::0.0390625::HTS002,BRD-K29254801-001-14-7,0.0390625,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::0.15625::HTS002,BRD-K29254801-001-14-7,0.15625,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::0.625::HTS002,BRD-K29254801-001-14-7,0.625,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::2.5::HTS002,BRD-K29254801-001-14-7,2.5,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29254801-001-14-7::10::HTS002,BRD-K29254801-001-14-7,10.0,HTS002,PREP021,thiram,NA,JAK2,ophthalmology,contact dermatitis,CN(C)C(=S)SSC(=S)N(C)C,Launched
BRD-K29415052-050-04-8::0.00061034::HTS002,BRD-K29415052-050-04-8,0.00061034,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::0.0024414::HTS002,BRD-K29415052-050-04-8,0.0024414,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::0.00976562::HTS002,BRD-K29415052-050-04-8,0.00976562,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::0.0390625::HTS002,BRD-K29415052-050-04-8,0.0390625,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::0.15625::HTS002,BRD-K29415052-050-04-8,0.15625,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::0.625::HTS002,BRD-K29415052-050-04-8,0.625,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::2.5::HTS002,BRD-K29415052-050-04-8,2.5,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29415052-050-04-8::10::HTS002,BRD-K29415052-050-04-8,10.0,HTS002,PREP046,BGT226,PI3K inhibitor,"MTOR, PIK3CA, PIK3CB, PIK3CG",NA,NA,"COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",Phase 1/Phase 2
BRD-K29458283-001-29-9::0.00061034::HTS002,BRD-K29458283-001-29-9,0.00061034,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::0.0024414::HTS002,BRD-K29458283-001-29-9,0.0024414,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::0.00976562::HTS002,BRD-K29458283-001-29-9,0.00976562,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::0.0390625::HTS002,BRD-K29458283-001-29-9,0.0390625,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::0.15625::HTS002,BRD-K29458283-001-29-9,0.15625,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::0.625::HTS002,BRD-K29458283-001-29-9,0.625,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::2.5::HTS002,BRD-K29458283-001-29-9,2.5,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29458283-001-29-9::10::HTS002,BRD-K29458283-001-29-9,10.0,HTS002,PREP016,chlorambucil,DNA inhibitor,NA,hematologic malignancy,"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma",OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,Launched
BRD-K29542628-001-03-9::0.00061034::HTS002,BRD-K29542628-001-03-9,0.00061034,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::0.0024414::HTS002,BRD-K29542628-001-03-9,0.0024414,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::0.00976562::HTS002,BRD-K29542628-001-03-9,0.00976562,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::0.0390625::HTS002,BRD-K29542628-001-03-9,0.0390625,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::0.15625::HTS002,BRD-K29542628-001-03-9,0.15625,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::0.625::HTS002,BRD-K29542628-001-03-9,0.625,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::2.5::HTS002,BRD-K29542628-001-03-9,2.5,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29542628-001-03-9::10::HTS002,BRD-K29542628-001-03-9,10.0,HTS002,PREP042,1-naphthyl-PP1,src inhibitor,SRC,NA,NA,"CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",Preclinical
BRD-K29582115-066-01-2::0.00061034::HTS002,BRD-K29582115-066-01-2,0.00061034,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::0.0024414::HTS002,BRD-K29582115-066-01-2,0.0024414,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::0.00976562::HTS002,BRD-K29582115-066-01-2,0.00976562,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::0.0390625::HTS002,BRD-K29582115-066-01-2,0.0390625,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::0.15625::HTS002,BRD-K29582115-066-01-2,0.15625,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::0.625::HTS002,BRD-K29582115-066-01-2,0.625,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::2.5::HTS002,BRD-K29582115-066-01-2,2.5,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29582115-066-01-2::10::HTS002,BRD-K29582115-066-01-2,10.0,HTS002,PREP035,ziprasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4",neurology/psychiatry,"schizophrenia, bipolar disorder","Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12",Launched
BRD-K29656036-001-02-5::0.00061034::HTS002,BRD-K29656036-001-02-5,0.00061034,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::0.0024414::HTS002,BRD-K29656036-001-02-5,0.0024414,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::0.00976562::HTS002,BRD-K29656036-001-02-5,0.00976562,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::0.0390625::HTS002,BRD-K29656036-001-02-5,0.0390625,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::0.15625::HTS002,BRD-K29656036-001-02-5,0.15625,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::0.625::HTS002,BRD-K29656036-001-02-5,0.625,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::2.5::HTS002,BRD-K29656036-001-02-5,2.5,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29656036-001-02-5::10::HTS002,BRD-K29656036-001-02-5,10.0,HTS002,PREP032,MK-8245,stearoyl-CoA desaturase inhibitor,SCD,NA,NA,OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br,Phase 2
BRD-K29673530-001-05-4::0.00061034::HTS002,BRD-K29673530-001-05-4,0.00061034,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::0.0024414::HTS002,BRD-K29673530-001-05-4,0.0024414,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::0.00976562::HTS002,BRD-K29673530-001-05-4,0.00976562,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::0.0390625::HTS002,BRD-K29673530-001-05-4,0.0390625,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::0.15625::HTS002,BRD-K29673530-001-05-4,0.15625,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::0.625::HTS002,BRD-K29673530-001-05-4,0.625,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::2.5::HTS002,BRD-K29673530-001-05-4,2.5,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29673530-001-05-4::10::HTS002,BRD-K29673530-001-05-4,10.0,HTS002,PREP024,hypericin,tyrosine kinase inhibitor,NA,NA,NA,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,Phase 2
BRD-K29905972-001-06-3::0.00061034::HTS002,BRD-K29905972-001-06-3,0.00061034,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.0024414::HTS002,BRD-K29905972-001-06-3,0.0024414,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.00976562::HTS002,BRD-K29905972-001-06-3,0.00976562,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.0390625::HTS002,BRD-K29905972-001-06-3,0.0390625,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.15625::HTS002,BRD-K29905972-001-06-3,0.15625,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::0.625::HTS002,BRD-K29905972-001-06-3,0.625,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::2.5::HTS002,BRD-K29905972-001-06-3,2.5,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29905972-001-06-3::10::HTS002,BRD-K29905972-001-06-3,10.0,HTS002,PREP029,axitinib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, FLT1, FLT4, KDR, PLK4",oncology,renal cell carcinoma (RCC),"CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1",Launched
BRD-K29950728-048-17-4::0.00061034::HTS002,BRD-K29950728-048-17-4,0.00061034,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::0.0024414::HTS002,BRD-K29950728-048-17-4,0.0024414,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::0.00976562::HTS002,BRD-K29950728-048-17-4,0.00976562,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::0.0390625::HTS002,BRD-K29950728-048-17-4,0.0390625,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::0.15625::HTS002,BRD-K29950728-048-17-4,0.15625,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::0.625::HTS002,BRD-K29950728-048-17-4,0.625,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::2.5::HTS002,BRD-K29950728-048-17-4,2.5,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29950728-048-17-4::10::HTS002,BRD-K29950728-048-17-4,10.0,HTS002,PREP017,clomifene,estrogen receptor antagonist,ESR1,obstetrics/gynecology,infertility,"CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1",Launched
BRD-K29968218-001-03-2::0.00061034::HTS002,BRD-K29968218-001-03-2,0.00061034,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::0.0024414::HTS002,BRD-K29968218-001-03-2,0.0024414,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::0.00976562::HTS002,BRD-K29968218-001-03-2,0.00976562,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::0.0390625::HTS002,BRD-K29968218-001-03-2,0.0390625,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::0.15625::HTS002,BRD-K29968218-001-03-2,0.15625,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::0.625::HTS002,BRD-K29968218-001-03-2,0.625,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::2.5::HTS002,BRD-K29968218-001-03-2,2.5,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K29968218-001-03-2::10::HTS002,BRD-K29968218-001-03-2,10.0,HTS002,PREP026,KX2-391,"src inhibitor, tubulin polymerization inhibitor",SRC,NA,NA,O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1,Phase 2
BRD-K30431096-004-01-3::0.00061034::HTS002,BRD-K30431096-004-01-3,0.00061034,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::0.0024414::HTS002,BRD-K30431096-004-01-3,0.0024414,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::0.00976562::HTS002,BRD-K30431096-004-01-3,0.00976562,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::0.0390625::HTS002,BRD-K30431096-004-01-3,0.0390625,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::0.15625::HTS002,BRD-K30431096-004-01-3,0.15625,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::0.625::HTS002,BRD-K30431096-004-01-3,0.625,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::2.5::HTS002,BRD-K30431096-004-01-3,2.5,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30431096-004-01-3::10::HTS002,BRD-K30431096-004-01-3,10.0,HTS002,PREP042,domiphen,NA,NA,NA,NA,CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,Preclinical
BRD-K30480208-001-18-5::0.00061034::HTS002,BRD-K30480208-001-18-5,0.00061034,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::0.0024414::HTS002,BRD-K30480208-001-18-5,0.0024414,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::0.00976562::HTS002,BRD-K30480208-001-18-5,0.00976562,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::0.0390625::HTS002,BRD-K30480208-001-18-5,0.0390625,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::0.15625::HTS002,BRD-K30480208-001-18-5,0.15625,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::0.625::HTS002,BRD-K30480208-001-18-5,0.625,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::2.5::HTS002,BRD-K30480208-001-18-5,2.5,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30480208-001-18-5::10::HTS002,BRD-K30480208-001-18-5,10.0,HTS002,PREP028,torasemide,"electrolyte reabsorption inhibitor, thromboxane receptor antagonist",SLC12A1,cardiology,"edema, congestive heart failure, hypertension","CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1",Launched
BRD-K30519779-001-03-1::0.00061034::HTS002,BRD-K30519779-001-03-1,0.00061034,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::0.0024414::HTS002,BRD-K30519779-001-03-1,0.0024414,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::0.00976562::HTS002,BRD-K30519779-001-03-1,0.00976562,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::0.0390625::HTS002,BRD-K30519779-001-03-1,0.0390625,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::0.15625::HTS002,BRD-K30519779-001-03-1,0.15625,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::0.625::HTS002,BRD-K30519779-001-03-1,0.625,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::2.5::HTS002,BRD-K30519779-001-03-1,2.5,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30519779-001-03-1::10::HTS002,BRD-K30519779-001-03-1,10.0,HTS002,PREP042,homoquinolinic-acid,glutamate receptor agonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,OC(=O)Cc1cccnc1C(O)=O,Preclinical
BRD-K30867024-003-03-3::0.00061034::HTS002,BRD-K30867024-003-03-3,0.00061034,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::0.0024414::HTS002,BRD-K30867024-003-03-3,0.0024414,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::0.00976562::HTS002,BRD-K30867024-003-03-3,0.00976562,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::0.0390625::HTS002,BRD-K30867024-003-03-3,0.0390625,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::0.15625::HTS002,BRD-K30867024-003-03-3,0.15625,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::0.625::HTS002,BRD-K30867024-003-03-3,0.625,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::2.5::HTS002,BRD-K30867024-003-03-3,2.5,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30867024-003-03-3::10::HTS002,BRD-K30867024-003-03-3,10.0,HTS002,PREP040,SB-216641,serotonin receptor antagonist,"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C",NA,NA,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,Preclinical
BRD-K30933884-001-01-0::0.00061034::HTS002,BRD-K30933884-001-01-0,0.00061034,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::0.0024414::HTS002,BRD-K30933884-001-01-0,0.0024414,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::0.00976562::HTS002,BRD-K30933884-001-01-0,0.00976562,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::0.0390625::HTS002,BRD-K30933884-001-01-0,0.0390625,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::0.15625::HTS002,BRD-K30933884-001-01-0,0.15625,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::0.625::HTS002,BRD-K30933884-001-01-0,0.625,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::2.5::HTS002,BRD-K30933884-001-01-0,2.5,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30933884-001-01-0::10::HTS002,BRD-K30933884-001-01-0,10.0,HTS002,PREP018,UNBS-5162,CC chemokine receptor antagonist,NA,NA,NA,CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23,Phase 1
BRD-K30990140-003-02-4::0.00061034::HTS002,BRD-K30990140-003-02-4,0.00061034,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::0.0024414::HTS002,BRD-K30990140-003-02-4,0.0024414,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::0.00976562::HTS002,BRD-K30990140-003-02-4,0.00976562,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::0.0390625::HTS002,BRD-K30990140-003-02-4,0.0390625,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::0.15625::HTS002,BRD-K30990140-003-02-4,0.15625,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::0.625::HTS002,BRD-K30990140-003-02-4,0.625,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::2.5::HTS002,BRD-K30990140-003-02-4,2.5,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K30990140-003-02-4::10::HTS002,BRD-K30990140-003-02-4,10.0,HTS002,PREP015,FR-122047,cyclooxygenase inhibitor,NA,NA,NA,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,Preclinical
BRD-K31309378-001-01-5::0.00061034::HTS002,BRD-K31309378-001-01-5,0.00061034,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::0.0024414::HTS002,BRD-K31309378-001-01-5,0.0024414,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::0.00976562::HTS002,BRD-K31309378-001-01-5,0.00976562,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::0.0390625::HTS002,BRD-K31309378-001-01-5,0.0390625,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::0.15625::HTS002,BRD-K31309378-001-01-5,0.15625,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::0.625::HTS002,BRD-K31309378-001-01-5,0.625,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::2.5::HTS002,BRD-K31309378-001-01-5,2.5,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31309378-001-01-5::10::HTS002,BRD-K31309378-001-01-5,10.0,HTS002,PREP045,lucitanib,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,Phase 2
BRD-K31468676-237-01-8::0.000610352::HTS002,BRD-K31468676-237-01-8,0.000610352,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::0.00244141::HTS002,BRD-K31468676-237-01-8,0.00244141,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::0.00976562::HTS002,BRD-K31468676-237-01-8,0.00976562,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::0.0390625::HTS002,BRD-K31468676-237-01-8,0.0390625,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::0.15625::HTS002,BRD-K31468676-237-01-8,0.15625,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::0.625::HTS002,BRD-K31468676-237-01-8,0.625,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::2.5::HTS002,BRD-K31468676-237-01-8,2.5,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31468676-237-01-8::10::HTS002,BRD-K31468676-237-01-8,10.0,HTS002,PREP015,oxonic-acid,uricase inhibitor,NA,NA,NA,"OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",Preclinical
BRD-K31476763-001-01-5::0.00061034::HTS002,BRD-K31476763-001-01-5,0.00061034,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::0.0024414::HTS002,BRD-K31476763-001-01-5,0.0024414,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::0.00976562::HTS002,BRD-K31476763-001-01-5,0.00976562,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::0.0390625::HTS002,BRD-K31476763-001-01-5,0.0390625,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::0.15625::HTS002,BRD-K31476763-001-01-5,0.15625,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::0.625::HTS002,BRD-K31476763-001-01-5,0.625,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::2.5::HTS002,BRD-K31476763-001-01-5,2.5,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31476763-001-01-5::10::HTS002,BRD-K31476763-001-01-5,10.0,HTS002,PREP026,AZD9668,elastase inhibitor,ELANE,NA,NA,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,Phase 2
BRD-K31491153-003-05-9::0.00061034::HTS002,BRD-K31491153-003-05-9,0.00061034,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::0.0024414::HTS002,BRD-K31491153-003-05-9,0.0024414,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::0.00976562::HTS002,BRD-K31491153-003-05-9,0.00976562,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::0.0390625::HTS002,BRD-K31491153-003-05-9,0.0390625,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::0.15625::HTS002,BRD-K31491153-003-05-9,0.15625,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::0.625::HTS002,BRD-K31491153-003-05-9,0.625,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::2.5::HTS002,BRD-K31491153-003-05-9,2.5,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31491153-003-05-9::10::HTS002,BRD-K31491153-003-05-9,10.0,HTS002,PREP044,1-phenylbiguanide,serotonin receptor agonist,"HTR3A, HTR3B",NA,NA,NC(=N)NC(=N)Nc1ccccc1,Preclinical
BRD-K31627533-001-09-5::0.00061034::HTS002,BRD-K31627533-001-09-5,0.00061034,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::0.0024414::HTS002,BRD-K31627533-001-09-5,0.0024414,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::0.00976562::HTS002,BRD-K31627533-001-09-5,0.00976562,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::0.0390625::HTS002,BRD-K31627533-001-09-5,0.0390625,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::0.15625::HTS002,BRD-K31627533-001-09-5,0.15625,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::0.625::HTS002,BRD-K31627533-001-09-5,0.625,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::2.5::HTS002,BRD-K31627533-001-09-5,2.5,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31627533-001-09-5::10::HTS002,BRD-K31627533-001-09-5,10.0,HTS002,PREP015,rimexolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",ophthalmology,anterior uveitis,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Launched
BRD-K31698212-001-02-9::0.00061034::HTS002,BRD-K31698212-001-02-9,0.00061034,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.0024414::HTS002,BRD-K31698212-001-02-9,0.0024414,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.00976562::HTS002,BRD-K31698212-001-02-9,0.00976562,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.0390625::HTS002,BRD-K31698212-001-02-9,0.0390625,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.15625::HTS002,BRD-K31698212-001-02-9,0.15625,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::0.625::HTS002,BRD-K31698212-001-02-9,0.625,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::2.5::HTS002,BRD-K31698212-001-02-9,2.5,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31698212-001-02-9::10::HTS002,BRD-K31698212-001-02-9,10.0,HTS002,PREP035,icotinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1,Launched
BRD-K31812033-003-11-0::0.00061034::HTS002,BRD-K31812033-003-11-0,0.00061034,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::0.0024414::HTS002,BRD-K31812033-003-11-0,0.0024414,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::0.00976562::HTS002,BRD-K31812033-003-11-0,0.00976562,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::0.0390625::HTS002,BRD-K31812033-003-11-0,0.0390625,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::0.15625::HTS002,BRD-K31812033-003-11-0,0.15625,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::0.625::HTS002,BRD-K31812033-003-11-0,0.625,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::2.5::HTS002,BRD-K31812033-003-11-0,2.5,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31812033-003-11-0::10::HTS002,BRD-K31812033-003-11-0,10.0,HTS002,PREP028,levobunolol,adrenergic receptor antagonist,"ADRB1, ADRB2, ADRB3",ophthalmology,"glaucoma, ocular hypertension","CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12",Launched
BRD-K31866293-001-01-6::0.00061034::HTS002,BRD-K31866293-001-01-6,0.00061034,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::0.0024414::HTS002,BRD-K31866293-001-01-6,0.0024414,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::0.00976562::HTS002,BRD-K31866293-001-01-6,0.00976562,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::0.0390625::HTS002,BRD-K31866293-001-01-6,0.0390625,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::0.15625::HTS002,BRD-K31866293-001-01-6,0.15625,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::0.625::HTS002,BRD-K31866293-001-01-6,0.625,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::2.5::HTS002,BRD-K31866293-001-01-6,2.5,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31866293-001-01-6::10::HTS002,BRD-K31866293-001-01-6,10.0,HTS002,PREP046,TAK-632,RAF inhibitor,BRAF,NA,NA,Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F,Preclinical
BRD-K31928526-001-02-1::0.00061034::HTS002,BRD-K31928526-001-02-1,0.00061034,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.0024414::HTS002,BRD-K31928526-001-02-1,0.0024414,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.00976562::HTS002,BRD-K31928526-001-02-1,0.00976562,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.0390625::HTS002,BRD-K31928526-001-02-1,0.0390625,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.15625::HTS002,BRD-K31928526-001-02-1,0.15625,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::0.625::HTS002,BRD-K31928526-001-02-1,0.625,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::2.5::HTS002,BRD-K31928526-001-02-1,2.5,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K31928526-001-02-1::10::HTS002,BRD-K31928526-001-02-1,10.0,HTS002,PREP026,barasertib,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O,Phase 2/Phase 3
BRD-K32107296-001-16-9::0.00061034::HTS002,BRD-K32107296-001-16-9,0.00061034,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::0.0024414::HTS002,BRD-K32107296-001-16-9,0.0024414,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::0.00976562::HTS002,BRD-K32107296-001-16-9,0.00976562,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::0.0390625::HTS002,BRD-K32107296-001-16-9,0.0390625,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::0.15625::HTS002,BRD-K32107296-001-16-9,0.15625,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::0.625::HTS002,BRD-K32107296-001-16-9,0.625,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::2.5::HTS002,BRD-K32107296-001-16-9,2.5,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32107296-001-16-9::10::HTS002,BRD-K32107296-001-16-9,10.0,HTS002,PREP016,temozolomide,DNA alkylating agent,MGMT,oncology,"glioblastoma, astrocytoma","Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O",Launched
BRD-K32285926-001-02-1::0.00061034::HTS002,BRD-K32285926-001-02-1,0.00061034,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::0.0024414::HTS002,BRD-K32285926-001-02-1,0.0024414,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::0.00976562::HTS002,BRD-K32285926-001-02-1,0.00976562,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::0.0390625::HTS002,BRD-K32285926-001-02-1,0.0390625,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::0.15625::HTS002,BRD-K32285926-001-02-1,0.15625,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::0.625::HTS002,BRD-K32285926-001-02-1,0.625,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::2.5::HTS002,BRD-K32285926-001-02-1,2.5,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32285926-001-02-1::10::HTS002,BRD-K32285926-001-02-1,10.0,HTS002,PREP038,AMG-208,tyrosine kinase inhibitor,MET,NA,NA,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,Phase 1
BRD-K32372024-001-01-0::0.000610352::HTS002,BRD-K32372024-001-01-0,0.000610352,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::0.00244141::HTS002,BRD-K32372024-001-01-0,0.00244141,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::0.00976562::HTS002,BRD-K32372024-001-01-0,0.00976562,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::0.0390625::HTS002,BRD-K32372024-001-01-0,0.0390625,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::0.15625::HTS002,BRD-K32372024-001-01-0,0.15625,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::0.625::HTS002,BRD-K32372024-001-01-0,0.625,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::2.5::HTS002,BRD-K32372024-001-01-0,2.5,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32372024-001-01-0::10::HTS002,BRD-K32372024-001-01-0,10.0,HTS002,PREP048,D-7193,NA,NA,NA,NA,CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O,Phase 2
BRD-K32405725-001-02-8::0.00061034::HTS002,BRD-K32405725-001-02-8,0.00061034,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::0.0024414::HTS002,BRD-K32405725-001-02-8,0.0024414,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::0.00976562::HTS002,BRD-K32405725-001-02-8,0.00976562,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::0.0390625::HTS002,BRD-K32405725-001-02-8,0.0390625,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::0.15625::HTS002,BRD-K32405725-001-02-8,0.15625,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::0.625::HTS002,BRD-K32405725-001-02-8,0.625,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::2.5::HTS002,BRD-K32405725-001-02-8,2.5,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32405725-001-02-8::10::HTS002,BRD-K32405725-001-02-8,10.0,HTS002,PREP039,etomoxir,carnitine palmitoyltransferase inhibitor,CPT1A,NA,NA,CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1,Phase 2
BRD-K32501161-300-06-2::0.00061034::HTS002,BRD-K32501161-300-06-2,0.00061034,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::0.0024414::HTS002,BRD-K32501161-300-06-2,0.0024414,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::0.00976562::HTS002,BRD-K32501161-300-06-2,0.00976562,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::0.0390625::HTS002,BRD-K32501161-300-06-2,0.0390625,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::0.15625::HTS002,BRD-K32501161-300-06-2,0.15625,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::0.625::HTS002,BRD-K32501161-300-06-2,0.625,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::2.5::HTS002,BRD-K32501161-300-06-2,2.5,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32501161-300-06-2::10::HTS002,BRD-K32501161-300-06-2,10.0,HTS002,PREP038,vanoxerine,dopamine uptake inhibitor,SLC6A3,NA,NA,"Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",Phase 3
BRD-K32572029-001-04-4::0.00061034::HTS002,BRD-K32572029-001-04-4,0.00061034,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::0.0024414::HTS002,BRD-K32572029-001-04-4,0.0024414,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::0.00976562::HTS002,BRD-K32572029-001-04-4,0.00976562,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::0.0390625::HTS002,BRD-K32572029-001-04-4,0.0390625,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::0.15625::HTS002,BRD-K32572029-001-04-4,0.15625,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::0.625::HTS002,BRD-K32572029-001-04-4,0.625,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::2.5::HTS002,BRD-K32572029-001-04-4,2.5,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32572029-001-04-4::10::HTS002,BRD-K32572029-001-04-4,10.0,HTS002,PREP046,orotic-acid,NA,DHODH,NA,NA,"OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",Phase 2
BRD-K32730239-001-01-0::0.00061034::HTS002,BRD-K32730239-001-01-0,0.00061034,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::0.0024414::HTS002,BRD-K32730239-001-01-0,0.0024414,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::0.00976562::HTS002,BRD-K32730239-001-01-0,0.00976562,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::0.0390625::HTS002,BRD-K32730239-001-01-0,0.0390625,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::0.15625::HTS002,BRD-K32730239-001-01-0,0.15625,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::0.625::HTS002,BRD-K32730239-001-01-0,0.625,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::2.5::HTS002,BRD-K32730239-001-01-0,2.5,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32730239-001-01-0::10::HTS002,BRD-K32730239-001-01-0,10.0,HTS002,PREP037,SU3327,JNK inhibitor,MAPK8,NA,NA,"Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",Preclinical
BRD-K32744045-001-31-2::0.00061034::HTS002,BRD-K32744045-001-31-2,0.00061034,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.0024414::HTS002,BRD-K32744045-001-31-2,0.0024414,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.00976562::HTS002,BRD-K32744045-001-31-2,0.00976562,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.0390625::HTS002,BRD-K32744045-001-31-2,0.0390625,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.15625::HTS002,BRD-K32744045-001-31-2,0.15625,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.625::HTS002,BRD-K32744045-001-31-2,0.625,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::2.5::HTS002,BRD-K32744045-001-31-2,2.5,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::10::HTS002,BRD-K32744045-001-31-2,10.0,HTS002,PREP015,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32821942-001-21-3::0.00061034::HTS002,BRD-K32821942-001-21-3,0.00061034,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::0.0024414::HTS002,BRD-K32821942-001-21-3,0.0024414,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::0.00976562::HTS002,BRD-K32821942-001-21-3,0.00976562,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::0.0390625::HTS002,BRD-K32821942-001-21-3,0.0390625,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::0.15625::HTS002,BRD-K32821942-001-21-3,0.15625,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::0.625::HTS002,BRD-K32821942-001-21-3,0.625,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::2.5::HTS002,BRD-K32821942-001-21-3,2.5,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K32821942-001-21-3::10::HTS002,BRD-K32821942-001-21-3,10.0,HTS002,PREP015,azathioprine,dehydrogenase inhibitor,"HPRT1, IMPDH1, PPAT","transplant, rheumatology","renal homotransplantation, rheumatoid arthritis","Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O",Launched
BRD-K71847383-001-12-5::0.00061034::HTS002,BRD-K71847383-001-12-5,0.00061034,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::0.0024414::HTS002,BRD-K71847383-001-12-5,0.0024414,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::0.00976562::HTS002,BRD-K71847383-001-12-5,0.00976562,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::0.0390625::HTS002,BRD-K71847383-001-12-5,0.0390625,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::0.15625::HTS002,BRD-K71847383-001-12-5,0.15625,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::0.625::HTS002,BRD-K71847383-001-12-5,0.625,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::2.5::HTS002,BRD-K71847383-001-12-5,2.5,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K71847383-001-12-5::10::HTS002,BRD-K71847383-001-12-5,10.0,HTS002,PREP014,cytarabine,ribonucleotide reductase inhibitor,"POLA1, POLB, POLD1, POLE",hematologic malignancy,"acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K33127281-001-05-6::0.00061034::HTS002,BRD-K33127281-001-05-6,0.00061034,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.0024414::HTS002,BRD-K33127281-001-05-6,0.0024414,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.00976562::HTS002,BRD-K33127281-001-05-6,0.00976562,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.0390625::HTS002,BRD-K33127281-001-05-6,0.0390625,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.15625::HTS002,BRD-K33127281-001-05-6,0.15625,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.625::HTS002,BRD-K33127281-001-05-6,0.625,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::2.5::HTS002,BRD-K33127281-001-05-6,2.5,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::10::HTS002,BRD-K33127281-001-05-6,10.0,HTS002,PREP014,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33379087-001-07-5::0.00061034::HTS002,BRD-K33379087-001-07-5,0.00061034,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.0024414::HTS002,BRD-K33379087-001-07-5,0.0024414,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.00976562::HTS002,BRD-K33379087-001-07-5,0.00976562,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.0390625::HTS002,BRD-K33379087-001-07-5,0.0390625,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.15625::HTS002,BRD-K33379087-001-07-5,0.15625,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::0.625::HTS002,BRD-K33379087-001-07-5,0.625,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::2.5::HTS002,BRD-K33379087-001-07-5,2.5,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33379087-001-07-5::10::HTS002,BRD-K33379087-001-07-5,10.0,HTS002,PREP045,tivantinib,tyrosine kinase inhibitor,MET,NA,NA,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23,Phase 3
BRD-K33588785-001-01-9::0.000610352::HTS002,BRD-K33588785-001-01-9,0.000610352,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::0.00244141::HTS002,BRD-K33588785-001-01-9,0.00244141,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::0.00976562::HTS002,BRD-K33588785-001-01-9,0.00976562,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::0.0390625::HTS002,BRD-K33588785-001-01-9,0.0390625,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::0.15625::HTS002,BRD-K33588785-001-01-9,0.15625,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::0.625::HTS002,BRD-K33588785-001-01-9,0.625,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::2.5::HTS002,BRD-K33588785-001-01-9,2.5,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33588785-001-01-9::10::HTS002,BRD-K33588785-001-01-9,10.0,HTS002,PREP039,obidoxime,cholinesterase reactivator,ACHE,"critical care, neurology/psychiatry","poison antidote, nerve gas poisoning",O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1,Launched
BRD-K33610132-001-02-9::0.00061034::HTS002,BRD-K33610132-001-02-9,0.00061034,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.0024414::HTS002,BRD-K33610132-001-02-9,0.0024414,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.00976562::HTS002,BRD-K33610132-001-02-9,0.00976562,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.0390625::HTS002,BRD-K33610132-001-02-9,0.0390625,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.15625::HTS002,BRD-K33610132-001-02-9,0.15625,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::0.625::HTS002,BRD-K33610132-001-02-9,0.625,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::2.5::HTS002,BRD-K33610132-001-02-9,2.5,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33610132-001-02-9::10::HTS002,BRD-K33610132-001-02-9,10.0,HTS002,PREP042,rociletinib,EGFR inhibitor,EGFR,NA,NA,COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O,Phase 3
BRD-K33622447-066-01-9::0.00061034::HTS002,BRD-K33622447-066-01-9,0.00061034,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.0024414::HTS002,BRD-K33622447-066-01-9,0.0024414,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.00976562::HTS002,BRD-K33622447-066-01-9,0.00976562,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.0390625::HTS002,BRD-K33622447-066-01-9,0.0390625,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.15625::HTS002,BRD-K33622447-066-01-9,0.15625,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::0.625::HTS002,BRD-K33622447-066-01-9,0.625,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::2.5::HTS002,BRD-K33622447-066-01-9,2.5,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33622447-066-01-9::10::HTS002,BRD-K33622447-066-01-9,10.0,HTS002,PREP033,abemaciclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1,Launched
BRD-K33720171-001-01-0::0.00061034::HTS002,BRD-K33720171-001-01-0,0.00061034,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::0.0024414::HTS002,BRD-K33720171-001-01-0,0.0024414,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::0.00976562::HTS002,BRD-K33720171-001-01-0,0.00976562,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::0.0390625::HTS002,BRD-K33720171-001-01-0,0.0390625,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::0.15625::HTS002,BRD-K33720171-001-01-0,0.15625,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::0.625::HTS002,BRD-K33720171-001-01-0,0.625,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::2.5::HTS002,BRD-K33720171-001-01-0,2.5,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33720171-001-01-0::10::HTS002,BRD-K33720171-001-01-0,10.0,HTS002,PREP033,difluprednate,glucocorticoid receptor agonist,NR3C1,ophthalmology,endogenous uveitis,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,Launched
BRD-K33743361-003-02-6::0.00061034::HTS002,BRD-K33743361-003-02-6,0.00061034,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::0.0024414::HTS002,BRD-K33743361-003-02-6,0.0024414,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::0.00976562::HTS002,BRD-K33743361-003-02-6,0.00976562,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::0.0390625::HTS002,BRD-K33743361-003-02-6,0.0390625,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::0.15625::HTS002,BRD-K33743361-003-02-6,0.15625,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::0.625::HTS002,BRD-K33743361-003-02-6,0.625,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::2.5::HTS002,BRD-K33743361-003-02-6,2.5,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33743361-003-02-6::10::HTS002,BRD-K33743361-003-02-6,10.0,HTS002,PREP040,ML133,potassium channel blocker,NA,NA,NA,COc1ccc(CNCc2cccc3ccccc23)cc1,Preclinical
BRD-K33813875-003-01-8::0.00061034::HTS002,BRD-K33813875-003-01-8,0.00061034,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::0.0024414::HTS002,BRD-K33813875-003-01-8,0.0024414,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::0.00976562::HTS002,BRD-K33813875-003-01-8,0.00976562,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::0.0390625::HTS002,BRD-K33813875-003-01-8,0.0390625,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::0.15625::HTS002,BRD-K33813875-003-01-8,0.15625,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::0.625::HTS002,BRD-K33813875-003-01-8,0.625,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::2.5::HTS002,BRD-K33813875-003-01-8,2.5,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33813875-003-01-8::10::HTS002,BRD-K33813875-003-01-8,10.0,HTS002,PREP034,valnemulin,bacterial 50S ribosomal subunit inhibitor,NA,"infectious disease, gastroenterology","dysentry, colitis, pneumonia",CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3,Launched
BRD-K33818169-003-04-6::0.00061034::HTS002,BRD-K33818169-003-04-6,0.00061034,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::0.0024414::HTS002,BRD-K33818169-003-04-6,0.0024414,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::0.00976562::HTS002,BRD-K33818169-003-04-6,0.00976562,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::0.0390625::HTS002,BRD-K33818169-003-04-6,0.0390625,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::0.15625::HTS002,BRD-K33818169-003-04-6,0.15625,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::0.625::HTS002,BRD-K33818169-003-04-6,0.625,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::2.5::HTS002,BRD-K33818169-003-04-6,2.5,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33818169-003-04-6::10::HTS002,BRD-K33818169-003-04-6,10.0,HTS002,PREP033,GW-3965,LXR agonist,"NR1H2, NR1H3",NA,NA,"OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",Preclinical
BRD-K33882852-003-02-8::0.00061034::HTS002,BRD-K33882852-003-02-8,0.00061034,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::0.0024414::HTS002,BRD-K33882852-003-02-8,0.0024414,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::0.00976562::HTS002,BRD-K33882852-003-02-8,0.00976562,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::0.0390625::HTS002,BRD-K33882852-003-02-8,0.0390625,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::0.15625::HTS002,BRD-K33882852-003-02-8,0.15625,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::0.625::HTS002,BRD-K33882852-003-02-8,0.625,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::2.5::HTS002,BRD-K33882852-003-02-8,2.5,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K33882852-003-02-8::10::HTS002,BRD-K33882852-003-02-8,10.0,HTS002,PREP038,ZK-93423,benzodiazepine receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2",NA,NA,"CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",Phase 3
BRD-K34022604-001-06-6::0.00061034::HTS002,BRD-K34022604-001-06-6,0.00061034,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::0.0024414::HTS002,BRD-K34022604-001-06-6,0.0024414,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::0.00976562::HTS002,BRD-K34022604-001-06-6,0.00976562,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::0.0390625::HTS002,BRD-K34022604-001-06-6,0.0390625,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::0.15625::HTS002,BRD-K34022604-001-06-6,0.15625,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::0.625::HTS002,BRD-K34022604-001-06-6,0.625,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::2.5::HTS002,BRD-K34022604-001-06-6,2.5,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34022604-001-06-6::10::HTS002,BRD-K34022604-001-06-6,10.0,HTS002,PREP017,clofarabine,ribonucleotide reductase inhibitor,"POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,acute lymphoblastic leukemia (ALL),"Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",Launched
BRD-K34073885-001-09-3::0.000621179::HTS002,BRD-K34073885-001-09-3,0.000621179,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::0.00248472::HTS002,BRD-K34073885-001-09-3,0.00248472,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::0.00993887::HTS002,BRD-K34073885-001-09-3,0.00993887,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::0.0397555::HTS002,BRD-K34073885-001-09-3,0.0397555,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::0.159022::HTS002,BRD-K34073885-001-09-3,0.159022,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::0.636087::HTS002,BRD-K34073885-001-09-3,0.636087,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::2.54435::HTS002,BRD-K34073885-001-09-3,2.54435,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34073885-001-09-3::10.1774::HTS002,BRD-K34073885-001-09-3,10.1774,HTS002,PREP026,tanshinone-i,AP inhibitor,IFNG,NA,NA,"Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",Phase 2
BRD-K34157611-001-16-0::0.00061034::HTS002,BRD-K34157611-001-16-0,0.00061034,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::0.0024414::HTS002,BRD-K34157611-001-16-0,0.0024414,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::0.00976562::HTS002,BRD-K34157611-001-16-0,0.00976562,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::0.0390625::HTS002,BRD-K34157611-001-16-0,0.0390625,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::0.15625::HTS002,BRD-K34157611-001-16-0,0.15625,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::0.625::HTS002,BRD-K34157611-001-16-0,0.625,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::2.5::HTS002,BRD-K34157611-001-16-0,2.5,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34157611-001-16-0::10::HTS002,BRD-K34157611-001-16-0,10.0,HTS002,PREP016,cimetidine,histamine receptor antagonist,"HRH2, SLC29A4, SLC47A1, SLC47A2","gastroenterology, hematologic malignancy, endocrinology","duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma","CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N, CN\C(NCCSCc1nc[nH]c1C)=N/C#N",Launched
BRD-K34332569-001-01-3::0.00061034::HTS002,BRD-K34332569-001-01-3,0.00061034,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.0024414::HTS002,BRD-K34332569-001-01-3,0.0024414,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.00976562::HTS002,BRD-K34332569-001-01-3,0.00976562,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.0390625::HTS002,BRD-K34332569-001-01-3,0.0390625,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.15625::HTS002,BRD-K34332569-001-01-3,0.15625,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.625::HTS002,BRD-K34332569-001-01-3,0.625,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::2.5::HTS002,BRD-K34332569-001-01-3,2.5,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::10::HTS002,BRD-K34332569-001-01-3,10.0,HTS002,PREP029,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34411947-001-12-5::0.00061034::HTS002,BRD-K34411947-001-12-5,0.00061034,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::0.0024414::HTS002,BRD-K34411947-001-12-5,0.0024414,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::0.00976562::HTS002,BRD-K34411947-001-12-5,0.00976562,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::0.0390625::HTS002,BRD-K34411947-001-12-5,0.0390625,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::0.15625::HTS002,BRD-K34411947-001-12-5,0.15625,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::0.625::HTS002,BRD-K34411947-001-12-5,0.625,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::2.5::HTS002,BRD-K34411947-001-12-5,2.5,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34411947-001-12-5::10::HTS002,BRD-K34411947-001-12-5,10.0,HTS002,PREP022,streptozotocin,DNA alkylating agent,SLC2A2,oncology,pancreatic cancer,"CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K34533029-001-08-5::0.00061034::HTS002,BRD-K34533029-001-08-5,0.00061034,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::0.0024414::HTS002,BRD-K34533029-001-08-5,0.0024414,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::0.00976562::HTS002,BRD-K34533029-001-08-5,0.00976562,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::0.0390625::HTS002,BRD-K34533029-001-08-5,0.0390625,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::0.15625::HTS002,BRD-K34533029-001-08-5,0.15625,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::0.625::HTS002,BRD-K34533029-001-08-5,0.625,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::2.5::HTS002,BRD-K34533029-001-08-5,2.5,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34533029-001-08-5::10::HTS002,BRD-K34533029-001-08-5,10.0,HTS002,PREP043,tyrphostin-AG-494,EGFR inhibitor,EGFR,NA,NA,Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1,Preclinical
BRD-K34851558-001-02-3::0.00061034::HTS002,BRD-K34851558-001-02-3,0.00061034,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::0.0024414::HTS002,BRD-K34851558-001-02-3,0.0024414,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::0.00976562::HTS002,BRD-K34851558-001-02-3,0.00976562,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::0.0390625::HTS002,BRD-K34851558-001-02-3,0.0390625,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::0.15625::HTS002,BRD-K34851558-001-02-3,0.15625,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::0.625::HTS002,BRD-K34851558-001-02-3,0.625,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::2.5::HTS002,BRD-K34851558-001-02-3,2.5,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K34851558-001-02-3::10::HTS002,BRD-K34851558-001-02-3,10.0,HTS002,PREP033,parthenolide-(-),NFkB pathway inhibitor,HDAC1,NA,NA,C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,Preclinical
BRD-K35189033-001-26-1::0.00061034::HTS002,BRD-K35189033-001-26-1,0.00061034,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::0.0024414::HTS002,BRD-K35189033-001-26-1,0.0024414,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::0.00976562::HTS002,BRD-K35189033-001-26-1,0.00976562,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::0.0390625::HTS002,BRD-K35189033-001-26-1,0.0390625,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::0.15625::HTS002,BRD-K35189033-001-26-1,0.15625,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::0.625::HTS002,BRD-K35189033-001-26-1,0.625,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::2.5::HTS002,BRD-K35189033-001-26-1,2.5,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35189033-001-26-1::10::HTS002,BRD-K35189033-001-26-1,10.0,HTS002,PREP023,levonorgestrel,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","AR, ESR1, PGR, SRD5A1",endocrinology,contraceptive,"CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K35245662-001-01-2::0.00061034::HTS002,BRD-K35245662-001-01-2,0.00061034,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::0.0024414::HTS002,BRD-K35245662-001-01-2,0.0024414,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::0.00976562::HTS002,BRD-K35245662-001-01-2,0.00976562,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::0.0390625::HTS002,BRD-K35245662-001-01-2,0.0390625,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::0.15625::HTS002,BRD-K35245662-001-01-2,0.15625,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::0.625::HTS002,BRD-K35245662-001-01-2,0.625,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::2.5::HTS002,BRD-K35245662-001-01-2,2.5,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35245662-001-01-2::10::HTS002,BRD-K35245662-001-01-2,10.0,HTS002,PREP020,ciclesonide,glucocorticoid receptor agonist,"NR3C1, SERPINA6",allergy,allergic rhinitis,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,Launched
BRD-K35329391-334-01-7::0.00061034::HTS002,BRD-K35329391-334-01-7,0.00061034,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::0.0024414::HTS002,BRD-K35329391-334-01-7,0.0024414,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::0.00976562::HTS002,BRD-K35329391-334-01-7,0.00976562,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::0.0390625::HTS002,BRD-K35329391-334-01-7,0.0390625,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::0.15625::HTS002,BRD-K35329391-334-01-7,0.15625,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::0.625::HTS002,BRD-K35329391-334-01-7,0.625,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::2.5::HTS002,BRD-K35329391-334-01-7,2.5,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35329391-334-01-7::10::HTS002,BRD-K35329391-334-01-7,10.0,HTS002,PREP014,GZD824,Bcr-Abl kinase inhibitor,"ABL1, BCR",NA,NA,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1,Preclinical
BRD-K35520305-001-17-7::0.00061034::HTS002,BRD-K35520305-001-17-7,0.00061034,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::0.0024414::HTS002,BRD-K35520305-001-17-7,0.0024414,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::0.00976562::HTS002,BRD-K35520305-001-17-7,0.00976562,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::0.0390625::HTS002,BRD-K35520305-001-17-7,0.0390625,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::0.15625::HTS002,BRD-K35520305-001-17-7,0.15625,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::0.625::HTS002,BRD-K35520305-001-17-7,0.625,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::2.5::HTS002,BRD-K35520305-001-17-7,2.5,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35520305-001-17-7::10::HTS002,BRD-K35520305-001-17-7,10.0,HTS002,PREP023,dacarbazine,DNA alkylating agent,"PGD, POLA2","oncology, hematologic malignancy","melanoma, Hodgkin's lymphoma","CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O",Launched
BRD-K35629949-001-02-0::0.00061034::HTS002,BRD-K35629949-001-02-0,0.00061034,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::0.0024414::HTS002,BRD-K35629949-001-02-0,0.0024414,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::0.00976562::HTS002,BRD-K35629949-001-02-0,0.00976562,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::0.0390625::HTS002,BRD-K35629949-001-02-0,0.0390625,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::0.15625::HTS002,BRD-K35629949-001-02-0,0.15625,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::0.625::HTS002,BRD-K35629949-001-02-0,0.625,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::2.5::HTS002,BRD-K35629949-001-02-0,2.5,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35629949-001-02-0::10::HTS002,BRD-K35629949-001-02-0,10.0,HTS002,PREP038,SR-27897,CCK receptor antagonist,CCKAR,NA,NA,"OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",Phase 2
BRD-K35687421-001-02-5::0.00061034::HTS002,BRD-K35687421-001-02-5,0.00061034,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::0.0024414::HTS002,BRD-K35687421-001-02-5,0.0024414,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::0.00976562::HTS002,BRD-K35687421-001-02-5,0.00976562,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::0.0390625::HTS002,BRD-K35687421-001-02-5,0.0390625,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::0.15625::HTS002,BRD-K35687421-001-02-5,0.15625,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::0.625::HTS002,BRD-K35687421-001-02-5,0.625,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::2.5::HTS002,BRD-K35687421-001-02-5,2.5,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35687421-001-02-5::10::HTS002,BRD-K35687421-001-02-5,10.0,HTS002,PREP017,gimeracil,dihydropyrimidine dehydrogenase inhibitor,DPYD,oncology,gastric adenocarcinoma,"Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl",Launched
BRD-K35952844-236-01-6::0.000610352::HTS002,BRD-K35952844-236-01-6,0.000610352,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::0.00244141::HTS002,BRD-K35952844-236-01-6,0.00244141,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::0.00976562::HTS002,BRD-K35952844-236-01-6,0.00976562,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::0.0390625::HTS002,BRD-K35952844-236-01-6,0.0390625,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::0.15625::HTS002,BRD-K35952844-236-01-6,0.15625,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::0.625::HTS002,BRD-K35952844-236-01-6,0.625,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::2.5::HTS002,BRD-K35952844-236-01-6,2.5,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35952844-236-01-6::10::HTS002,BRD-K35952844-236-01-6,10.0,HTS002,PREP020,sodium-glucoheptonate,NA,NA,NA,NA,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O,Launched
BRD-K35960502-001-20-0::0.00061034::HTS002,BRD-K35960502-001-20-0,0.00061034,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::0.0024414::HTS002,BRD-K35960502-001-20-0,0.0024414,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::0.00976562::HTS002,BRD-K35960502-001-20-0,0.00976562,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::0.0390625::HTS002,BRD-K35960502-001-20-0,0.0390625,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::0.15625::HTS002,BRD-K35960502-001-20-0,0.15625,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::0.625::HTS002,BRD-K35960502-001-20-0,0.625,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::2.5::HTS002,BRD-K35960502-001-20-0,2.5,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K35960502-001-20-0::10::HTS002,BRD-K35960502-001-20-0,10.0,HTS002,PREP030,niclosamide,"DNA replication inhibitor, STAT inhibitor",STAT3,infectious disease,tapeworm,"Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O",Launched
BRD-K36021395-300-02-4::0.00061034::HTS002,BRD-K36021395-300-02-4,0.00061034,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::0.0024414::HTS002,BRD-K36021395-300-02-4,0.0024414,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::0.00976562::HTS002,BRD-K36021395-300-02-4,0.00976562,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::0.0390625::HTS002,BRD-K36021395-300-02-4,0.0390625,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::0.15625::HTS002,BRD-K36021395-300-02-4,0.15625,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::0.625::HTS002,BRD-K36021395-300-02-4,0.625,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::2.5::HTS002,BRD-K36021395-300-02-4,2.5,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36021395-300-02-4::10::HTS002,BRD-K36021395-300-02-4,10.0,HTS002,PREP037,ABT-702,adenosine kinase inhibitor,ADK,NA,NA,"Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",Preclinical
BRD-K36055864-001-19-2::0.00061034::HTS002,BRD-K36055864-001-19-2,0.00061034,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::0.0024414::HTS002,BRD-K36055864-001-19-2,0.0024414,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::0.00976562::HTS002,BRD-K36055864-001-19-2,0.00976562,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::0.0390625::HTS002,BRD-K36055864-001-19-2,0.0390625,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::0.15625::HTS002,BRD-K36055864-001-19-2,0.15625,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::0.625::HTS002,BRD-K36055864-001-19-2,0.625,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::2.5::HTS002,BRD-K36055864-001-19-2,2.5,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36055864-001-19-2::10::HTS002,BRD-K36055864-001-19-2,10.0,HTS002,PREP014,cycloheximide,protein synthesis inhibitor,RPL3,NA,NA,"C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",Preclinical
BRD-K36198571-001-02-0::0.00061034::HTS002,BRD-K36198571-001-02-0,0.00061034,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::0.0024414::HTS002,BRD-K36198571-001-02-0,0.0024414,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::0.00976562::HTS002,BRD-K36198571-001-02-0,0.00976562,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::0.0390625::HTS002,BRD-K36198571-001-02-0,0.0390625,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::0.15625::HTS002,BRD-K36198571-001-02-0,0.15625,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::0.625::HTS002,BRD-K36198571-001-02-0,0.625,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::2.5::HTS002,BRD-K36198571-001-02-0,2.5,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36198571-001-02-0::10::HTS002,BRD-K36198571-001-02-0,10.0,HTS002,PREP033,WAY-170523,metalloproteinase inhibitor,MMP13,NA,NA,"Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",Preclinical
BRD-K36222532-001-01-8::0.00061034::HTS002,BRD-K36222532-001-01-8,0.00061034,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::0.0024414::HTS002,BRD-K36222532-001-01-8,0.0024414,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::0.00976562::HTS002,BRD-K36222532-001-01-8,0.00976562,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::0.0390625::HTS002,BRD-K36222532-001-01-8,0.0390625,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::0.15625::HTS002,BRD-K36222532-001-01-8,0.15625,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::0.625::HTS002,BRD-K36222532-001-01-8,0.625,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::2.5::HTS002,BRD-K36222532-001-01-8,2.5,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36222532-001-01-8::10::HTS002,BRD-K36222532-001-01-8,10.0,HTS002,PREP033,broxaldine,NA,NA,NA,NA,Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1,Preclinical
BRD-K36234266-001-09-8::0.00061034::HTS002,BRD-K36234266-001-09-8,0.00061034,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::0.0024414::HTS002,BRD-K36234266-001-09-8,0.0024414,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::0.00976562::HTS002,BRD-K36234266-001-09-8,0.00976562,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::0.0390625::HTS002,BRD-K36234266-001-09-8,0.0390625,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::0.15625::HTS002,BRD-K36234266-001-09-8,0.15625,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::0.625::HTS002,BRD-K36234266-001-09-8,0.625,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::2.5::HTS002,BRD-K36234266-001-09-8,2.5,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36234266-001-09-8::10::HTS002,BRD-K36234266-001-09-8,10.0,HTS002,PREP048,carmustine,"DNA alkylating agent, DNA inhibitor",GSR,"hematologic malignancy, oncology","non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma",[O-][N+]N(CCCl)C(=O)NCCCl,Launched
BRD-K36269323-300-02-6::0.000610352::HTS002,BRD-K36269323-300-02-6,0.000610352,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::0.00244141::HTS002,BRD-K36269323-300-02-6,0.00244141,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::0.00976562::HTS002,BRD-K36269323-300-02-6,0.00976562,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::0.0390625::HTS002,BRD-K36269323-300-02-6,0.0390625,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::0.15625::HTS002,BRD-K36269323-300-02-6,0.15625,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::0.625::HTS002,BRD-K36269323-300-02-6,0.625,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::2.5::HTS002,BRD-K36269323-300-02-6,2.5,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36269323-300-02-6::10::HTS002,BRD-K36269323-300-02-6,10.0,HTS002,PREP026,asymmetrical-dimethylarginine,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,CN(C)C(=N)NCCC[C@H](N)C(O)=O,Phase 1
BRD-K36363294-001-04-2::0.00061034::HTS002,BRD-K36363294-001-04-2,0.00061034,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::0.0024414::HTS002,BRD-K36363294-001-04-2,0.0024414,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::0.00976562::HTS002,BRD-K36363294-001-04-2,0.00976562,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::0.0390625::HTS002,BRD-K36363294-001-04-2,0.0390625,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::0.15625::HTS002,BRD-K36363294-001-04-2,0.15625,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::0.625::HTS002,BRD-K36363294-001-04-2,0.625,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::2.5::HTS002,BRD-K36363294-001-04-2,2.5,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36363294-001-04-2::10::HTS002,BRD-K36363294-001-04-2,10.0,HTS002,PREP033,I-BET151,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",Preclinical
BRD-K36386086-001-01-1::0.00061034::HTS002,BRD-K36386086-001-01-1,0.00061034,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::0.0024414::HTS002,BRD-K36386086-001-01-1,0.0024414,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::0.00976562::HTS002,BRD-K36386086-001-01-1,0.00976562,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::0.0390625::HTS002,BRD-K36386086-001-01-1,0.0390625,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::0.15625::HTS002,BRD-K36386086-001-01-1,0.15625,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::0.625::HTS002,BRD-K36386086-001-01-1,0.625,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::2.5::HTS002,BRD-K36386086-001-01-1,2.5,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36386086-001-01-1::10::HTS002,BRD-K36386086-001-01-1,10.0,HTS002,PREP022,dolutegravir,HIV integrase inhibitor,"CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1",infectious disease,human immunodeficiency virus (HIV-1),C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,Launched
BRD-K36467523-001-02-8::0.00061034::HTS002,BRD-K36467523-001-02-8,0.00061034,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::0.0024414::HTS002,BRD-K36467523-001-02-8,0.0024414,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::0.00976562::HTS002,BRD-K36467523-001-02-8,0.00976562,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::0.0390625::HTS002,BRD-K36467523-001-02-8,0.0390625,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::0.15625::HTS002,BRD-K36467523-001-02-8,0.15625,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::0.625::HTS002,BRD-K36467523-001-02-8,0.625,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::2.5::HTS002,BRD-K36467523-001-02-8,2.5,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36467523-001-02-8::10::HTS002,BRD-K36467523-001-02-8,10.0,HTS002,PREP045,bindarit,NFkB pathway inhibitor,"CCL2, CCL7, CCL8",NA,NA,CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O,Phase 2
BRD-K36529613-001-02-6::0.00061034::HTS002,BRD-K36529613-001-02-6,0.00061034,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::0.0024414::HTS002,BRD-K36529613-001-02-6,0.0024414,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::0.00976562::HTS002,BRD-K36529613-001-02-6,0.00976562,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::0.0390625::HTS002,BRD-K36529613-001-02-6,0.0390625,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::0.15625::HTS002,BRD-K36529613-001-02-6,0.15625,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::0.625::HTS002,BRD-K36529613-001-02-6,0.625,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::2.5::HTS002,BRD-K36529613-001-02-6,2.5,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36529613-001-02-6::10::HTS002,BRD-K36529613-001-02-6,10.0,HTS002,PREP045,PU-H71,HSP inhibitor,HSP90AA1,NA,NA,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,Phase 1
BRD-K36627727-001-05-4::0.00061034::HTS002,BRD-K36627727-001-05-4,0.00061034,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.0024414::HTS002,BRD-K36627727-001-05-4,0.0024414,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.00976562::HTS002,BRD-K36627727-001-05-4,0.00976562,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.0390625::HTS002,BRD-K36627727-001-05-4,0.0390625,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.15625::HTS002,BRD-K36627727-001-05-4,0.15625,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::0.625::HTS002,BRD-K36627727-001-05-4,0.625,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::2.5::HTS002,BRD-K36627727-001-05-4,2.5,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36627727-001-05-4::10::HTS002,BRD-K36627727-001-05-4,10.0,HTS002,PREP016,tamibarotene,retinoid receptor agonist,"RARA, RARB",hematologic malignancy,acute promyelocytic leukemia (APL),CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,Launched
BRD-K36711084-001-02-0::0.00061034::HTS002,BRD-K36711084-001-02-0,0.00061034,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::0.0024414::HTS002,BRD-K36711084-001-02-0,0.0024414,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::0.00976562::HTS002,BRD-K36711084-001-02-0,0.00976562,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::0.0390625::HTS002,BRD-K36711084-001-02-0,0.0390625,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::0.15625::HTS002,BRD-K36711084-001-02-0,0.15625,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::0.625::HTS002,BRD-K36711084-001-02-0,0.625,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::2.5::HTS002,BRD-K36711084-001-02-0,2.5,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36711084-001-02-0::10::HTS002,BRD-K36711084-001-02-0,10.0,HTS002,PREP017,cyromazine,NA,NA,NA,NA,"Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1",Launched
BRD-K36739687-001-03-0::0.00061034::HTS002,BRD-K36739687-001-03-0,0.00061034,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::0.0024414::HTS002,BRD-K36739687-001-03-0,0.0024414,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::0.00976562::HTS002,BRD-K36739687-001-03-0,0.00976562,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::0.0390625::HTS002,BRD-K36739687-001-03-0,0.0390625,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::0.15625::HTS002,BRD-K36739687-001-03-0,0.15625,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::0.625::HTS002,BRD-K36739687-001-03-0,0.625,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::2.5::HTS002,BRD-K36739687-001-03-0,2.5,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36739687-001-03-0::10::HTS002,BRD-K36739687-001-03-0,10.0,HTS002,PREP042,stemregenin-1,aryl hydrocarbon receptor antagonist,AHR,NA,NA,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,Preclinical
BRD-K36740062-001-06-6::0.00061034::HTS002,BRD-K36740062-001-06-6,0.00061034,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::0.0024414::HTS002,BRD-K36740062-001-06-6,0.0024414,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::0.00976562::HTS002,BRD-K36740062-001-06-6,0.00976562,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::0.0390625::HTS002,BRD-K36740062-001-06-6,0.0390625,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::0.15625::HTS002,BRD-K36740062-001-06-6,0.15625,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::0.625::HTS002,BRD-K36740062-001-06-6,0.625,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::2.5::HTS002,BRD-K36740062-001-06-6,2.5,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36740062-001-06-6::10::HTS002,BRD-K36740062-001-06-6,10.0,HTS002,PREP046,GSK1070916,Aurora kinase inhibitor,"AURKA, AURKB, AURKC, CYP2D6, CYP3A4",NA,NA,CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1,Phase 1
BRD-K36788280-001-01-2::0.00061034::HTS002,BRD-K36788280-001-01-2,0.00061034,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.0024414::HTS002,BRD-K36788280-001-01-2,0.0024414,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.00976562::HTS002,BRD-K36788280-001-01-2,0.00976562,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.0390625::HTS002,BRD-K36788280-001-01-2,0.0390625,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.15625::HTS002,BRD-K36788280-001-01-2,0.15625,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::0.625::HTS002,BRD-K36788280-001-01-2,0.625,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::2.5::HTS002,BRD-K36788280-001-01-2,2.5,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36788280-001-01-2::10::HTS002,BRD-K36788280-001-01-2,10.0,HTS002,PREP045,ribociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1",Launched
BRD-K36889451-001-01-1::0.000610352::HTS002,BRD-K36889451-001-01-1,0.000610352,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::0.00244141::HTS002,BRD-K36889451-001-01-1,0.00244141,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::0.00976562::HTS002,BRD-K36889451-001-01-1,0.00976562,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::0.0390625::HTS002,BRD-K36889451-001-01-1,0.0390625,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::0.15625::HTS002,BRD-K36889451-001-01-1,0.15625,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::0.625::HTS002,BRD-K36889451-001-01-1,0.625,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::2.5::HTS002,BRD-K36889451-001-01-1,2.5,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K36889451-001-01-1::10::HTS002,BRD-K36889451-001-01-1,10.0,HTS002,PREP042,tetramethylthiuram-monosulfide,NA,NA,NA,NA,CN(C)C(=S)SC(=S)N(C)C,Preclinical
BRD-K37069697-001-01-3::0.000610352::HTS002,BRD-K37069697-001-01-3,0.000610352,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::0.00244141::HTS002,BRD-K37069697-001-01-3,0.00244141,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::0.00976562::HTS002,BRD-K37069697-001-01-3,0.00976562,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::0.0390625::HTS002,BRD-K37069697-001-01-3,0.0390625,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::0.15625::HTS002,BRD-K37069697-001-01-3,0.15625,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::0.625::HTS002,BRD-K37069697-001-01-3,0.625,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::2.5::HTS002,BRD-K37069697-001-01-3,2.5,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37069697-001-01-3::10::HTS002,BRD-K37069697-001-01-3,10.0,HTS002,PREP025,fexinidazole,NA,NA,NA,NA,CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1,Phase 2/Phase 3
BRD-K37237504-001-02-7::0.00061034::HTS002,BRD-K37237504-001-02-7,0.00061034,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::0.0024414::HTS002,BRD-K37237504-001-02-7,0.0024414,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::0.00976562::HTS002,BRD-K37237504-001-02-7,0.00976562,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::0.0390625::HTS002,BRD-K37237504-001-02-7,0.0390625,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::0.15625::HTS002,BRD-K37237504-001-02-7,0.15625,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::0.625::HTS002,BRD-K37237504-001-02-7,0.625,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::2.5::HTS002,BRD-K37237504-001-02-7,2.5,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37237504-001-02-7::10::HTS002,BRD-K37237504-001-02-7,10.0,HTS002,PREP046,CEP-33779,JAK inhibitor,JAK2,NA,NA,"CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",Preclinical
BRD-K37249724-001-25-7::0.00061034::HTS002,BRD-K37249724-001-25-7,0.00061034,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::0.0024414::HTS002,BRD-K37249724-001-25-7,0.0024414,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::0.00976562::HTS002,BRD-K37249724-001-25-7,0.00976562,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::0.0390625::HTS002,BRD-K37249724-001-25-7,0.0390625,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::0.15625::HTS002,BRD-K37249724-001-25-7,0.15625,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::0.625::HTS002,BRD-K37249724-001-25-7,0.625,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::2.5::HTS002,BRD-K37249724-001-25-7,2.5,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37249724-001-25-7::10::HTS002,BRD-K37249724-001-25-7,10.0,HTS002,PREP015,astemizole,histamine receptor antagonist,"HRH1, KCNH1, KCNH2",NA,NA,"COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",Withdrawn
BRD-K37270826-001-27-6::0.000649269::HTS002,BRD-K37270826-001-27-6,0.000649269,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::0.00259708::HTS002,BRD-K37270826-001-27-6,0.00259708,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::0.0103883::HTS002,BRD-K37270826-001-27-6,0.0103883,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::0.0415532::HTS002,BRD-K37270826-001-27-6,0.0415532,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::0.166213::HTS002,BRD-K37270826-001-27-6,0.166213,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::0.664852::HTS002,BRD-K37270826-001-27-6,0.664852,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::2.65941::HTS002,BRD-K37270826-001-27-6,2.65941,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37270826-001-27-6::10.6376::HTS002,BRD-K37270826-001-27-6,10.6376,HTS002,PREP031,mifepristone,"glucocorticoid receptor antagonist, progesterone receptor antagonist","AR, NR1I2, NR3C1, PGR",endocrinology,"hyperglycemia, diabetes mellitus","CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C",Launched
BRD-K37312348-001-15-0::0.00061034::HTS002,BRD-K37312348-001-15-0,0.00061034,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::0.0024414::HTS002,BRD-K37312348-001-15-0,0.0024414,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::0.00976562::HTS002,BRD-K37312348-001-15-0,0.00976562,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::0.0390625::HTS002,BRD-K37312348-001-15-0,0.0390625,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::0.15625::HTS002,BRD-K37312348-001-15-0,0.15625,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::0.625::HTS002,BRD-K37312348-001-15-0,0.625,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::2.5::HTS002,BRD-K37312348-001-15-0,2.5,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37312348-001-15-0::10::HTS002,BRD-K37312348-001-15-0,10.0,HTS002,PREP047,kenpaullone,"CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B",NA,NA,"Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",Preclinical
BRD-K37379014-001-01-2::0.00061034::HTS002,BRD-K37379014-001-01-2,0.00061034,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::0.0024414::HTS002,BRD-K37379014-001-01-2,0.0024414,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::0.00976562::HTS002,BRD-K37379014-001-01-2,0.00976562,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::0.0390625::HTS002,BRD-K37379014-001-01-2,0.0390625,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::0.15625::HTS002,BRD-K37379014-001-01-2,0.15625,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::0.625::HTS002,BRD-K37379014-001-01-2,0.625,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::2.5::HTS002,BRD-K37379014-001-01-2,2.5,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37379014-001-01-2::10::HTS002,BRD-K37379014-001-01-2,10.0,HTS002,PREP026,filanesib,"kinesin inhibitor, kinesin-like spindle protein inhibitor",KIF11,NA,NA,"CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F",Phase 3
BRD-K37561857-001-15-5::0.00061034::HTS002,BRD-K37561857-001-15-5,0.00061034,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::0.0024414::HTS002,BRD-K37561857-001-15-5,0.0024414,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::0.00976562::HTS002,BRD-K37561857-001-15-5,0.00976562,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::0.0390625::HTS002,BRD-K37561857-001-15-5,0.0390625,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::0.15625::HTS002,BRD-K37561857-001-15-5,0.15625,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::0.625::HTS002,BRD-K37561857-001-15-5,0.625,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::2.5::HTS002,BRD-K37561857-001-15-5,2.5,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37561857-001-15-5::10::HTS002,BRD-K37561857-001-15-5,10.0,HTS002,PREP045,zardaverine,phosphodiesterase inhibitor,PDE4D,NA,NA,"COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",Phase 2
BRD-K37590257-001-02-8::0.00061034::HTS002,BRD-K37590257-001-02-8,0.00061034,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::0.0024414::HTS002,BRD-K37590257-001-02-8,0.0024414,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::0.00976562::HTS002,BRD-K37590257-001-02-8,0.00976562,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::0.0390625::HTS002,BRD-K37590257-001-02-8,0.0390625,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::0.15625::HTS002,BRD-K37590257-001-02-8,0.15625,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::0.625::HTS002,BRD-K37590257-001-02-8,0.625,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::2.5::HTS002,BRD-K37590257-001-02-8,2.5,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37590257-001-02-8::10::HTS002,BRD-K37590257-001-02-8,10.0,HTS002,PREP024,GSK256066,phosphodiesterase inhibitor,PDE4A,NA,NA,COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1,Phase 2
BRD-K37618799-001-03-0::0.00061034::HTS002,BRD-K37618799-001-03-0,0.00061034,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.0024414::HTS002,BRD-K37618799-001-03-0,0.0024414,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.00976562::HTS002,BRD-K37618799-001-03-0,0.00976562,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.0390625::HTS002,BRD-K37618799-001-03-0,0.0390625,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.15625::HTS002,BRD-K37618799-001-03-0,0.15625,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.625::HTS002,BRD-K37618799-001-03-0,0.625,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::2.5::HTS002,BRD-K37618799-001-03-0,2.5,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::10::HTS002,BRD-K37618799-001-03-0,10.0,HTS002,PREP025,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37687095-001-06-9::0.00061034::HTS002,BRD-K37687095-001-06-9,0.00061034,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::0.0024414::HTS002,BRD-K37687095-001-06-9,0.0024414,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::0.00976562::HTS002,BRD-K37687095-001-06-9,0.00976562,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::0.0390625::HTS002,BRD-K37687095-001-06-9,0.0390625,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::0.15625::HTS002,BRD-K37687095-001-06-9,0.15625,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::0.625::HTS002,BRD-K37687095-001-06-9,0.625,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::2.5::HTS002,BRD-K37687095-001-06-9,2.5,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37687095-001-06-9::10::HTS002,BRD-K37687095-001-06-9,10.0,HTS002,PREP039,AZD8330,MEK inhibitor,NA,NA,NA,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",Phase 1
BRD-K37720887-001-07-8::0.00061034::HTS002,BRD-K37720887-001-07-8,0.00061034,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::0.0024414::HTS002,BRD-K37720887-001-07-8,0.0024414,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::0.00976562::HTS002,BRD-K37720887-001-07-8,0.00976562,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::0.0390625::HTS002,BRD-K37720887-001-07-8,0.0390625,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::0.15625::HTS002,BRD-K37720887-001-07-8,0.15625,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::0.625::HTS002,BRD-K37720887-001-07-8,0.625,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::2.5::HTS002,BRD-K37720887-001-07-8,2.5,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37720887-001-07-8::10::HTS002,BRD-K37720887-001-07-8,10.0,HTS002,PREP024,SB-525334,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C",Preclinical
BRD-K37723606-001-01-5::0.00061034::HTS002,BRD-K37723606-001-01-5,0.00061034,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::0.0024414::HTS002,BRD-K37723606-001-01-5,0.0024414,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::0.00976562::HTS002,BRD-K37723606-001-01-5,0.00976562,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::0.0390625::HTS002,BRD-K37723606-001-01-5,0.0390625,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::0.15625::HTS002,BRD-K37723606-001-01-5,0.15625,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::0.625::HTS002,BRD-K37723606-001-01-5,0.625,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::2.5::HTS002,BRD-K37723606-001-01-5,2.5,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37723606-001-01-5::10::HTS002,BRD-K37723606-001-01-5,10.0,HTS002,PREP033,dioscin,apoptosis stimulant,CXCR3,NA,NA,C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1,Preclinical
BRD-K37764012-001-04-1::0.00061034::HTS002,BRD-K37764012-001-04-1,0.00061034,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::0.0024414::HTS002,BRD-K37764012-001-04-1,0.0024414,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::0.00976562::HTS002,BRD-K37764012-001-04-1,0.00976562,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::0.0390625::HTS002,BRD-K37764012-001-04-1,0.0390625,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::0.15625::HTS002,BRD-K37764012-001-04-1,0.15625,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::0.625::HTS002,BRD-K37764012-001-04-1,0.625,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::2.5::HTS002,BRD-K37764012-001-04-1,2.5,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37764012-001-04-1::10::HTS002,BRD-K37764012-001-04-1,10.0,HTS002,PREP027,PF-03758309,p21 activated kinase inhibitor,PAK4,NA,NA,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,Phase 1
BRD-K37793595-003-01-7::0.00061034::HTS002,BRD-K37793595-003-01-7,0.00061034,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::0.0024414::HTS002,BRD-K37793595-003-01-7,0.0024414,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::0.00976562::HTS002,BRD-K37793595-003-01-7,0.00976562,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::0.0390625::HTS002,BRD-K37793595-003-01-7,0.0390625,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::0.15625::HTS002,BRD-K37793595-003-01-7,0.15625,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::0.625::HTS002,BRD-K37793595-003-01-7,0.625,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::2.5::HTS002,BRD-K37793595-003-01-7,2.5,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37793595-003-01-7::10::HTS002,BRD-K37793595-003-01-7,10.0,HTS002,PREP031,afobazole,anxiolytic,NA,neurology/psychiatry,anxiety,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,Launched
BRD-K37865504-001-04-1::0.00061034::HTS002,BRD-K37865504-001-04-1,0.00061034,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::0.0024414::HTS002,BRD-K37865504-001-04-1,0.0024414,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::0.00976562::HTS002,BRD-K37865504-001-04-1,0.00976562,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::0.0390625::HTS002,BRD-K37865504-001-04-1,0.0390625,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::0.15625::HTS002,BRD-K37865504-001-04-1,0.15625,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::0.625::HTS002,BRD-K37865504-001-04-1,0.625,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::2.5::HTS002,BRD-K37865504-001-04-1,2.5,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37865504-001-04-1::10::HTS002,BRD-K37865504-001-04-1,10.0,HTS002,PREP037,LY2183240,"FAAH inhibitor, FAAH reuptake inhibitor",FAAH,NA,NA,"CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",Preclinical
BRD-K37890730-001-15-1::0.00061034::HTS002,BRD-K37890730-001-15-1,0.00061034,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::0.0024414::HTS002,BRD-K37890730-001-15-1,0.0024414,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::0.00976562::HTS002,BRD-K37890730-001-15-1,0.00976562,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::0.0390625::HTS002,BRD-K37890730-001-15-1,0.0390625,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::0.15625::HTS002,BRD-K37890730-001-15-1,0.15625,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::0.625::HTS002,BRD-K37890730-001-15-1,0.625,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::2.5::HTS002,BRD-K37890730-001-15-1,2.5,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K37890730-001-15-1::10::HTS002,BRD-K37890730-001-15-1,10.0,HTS002,PREP038,camptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",Phase 3
BRD-K38003476-001-09-1::0.00061034::HTS002,BRD-K38003476-001-09-1,0.00061034,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::0.0024414::HTS002,BRD-K38003476-001-09-1,0.0024414,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::0.00976562::HTS002,BRD-K38003476-001-09-1,0.00976562,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::0.0390625::HTS002,BRD-K38003476-001-09-1,0.0390625,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::0.15625::HTS002,BRD-K38003476-001-09-1,0.15625,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::0.625::HTS002,BRD-K38003476-001-09-1,0.625,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::2.5::HTS002,BRD-K38003476-001-09-1,2.5,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38003476-001-09-1::10::HTS002,BRD-K38003476-001-09-1,10.0,HTS002,PREP023,clocortolone-pivalate,steroid,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,Launched
BRD-K38183498-001-02-0::0.00061034::HTS002,BRD-K38183498-001-02-0,0.00061034,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::0.0024414::HTS002,BRD-K38183498-001-02-0,0.0024414,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::0.00976562::HTS002,BRD-K38183498-001-02-0,0.00976562,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::0.0390625::HTS002,BRD-K38183498-001-02-0,0.0390625,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::0.15625::HTS002,BRD-K38183498-001-02-0,0.15625,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::0.625::HTS002,BRD-K38183498-001-02-0,0.625,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::2.5::HTS002,BRD-K38183498-001-02-0,2.5,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38183498-001-02-0::10::HTS002,BRD-K38183498-001-02-0,10.0,HTS002,PREP016,clonazepam,GABA benzodiazepine site receptor agonist,"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO",neurology/psychiatry,"seizures, panic disorders",[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,Launched
BRD-K38197229-001-29-9::0.00061034::HTS002,BRD-K38197229-001-29-9,0.00061034,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::0.0024414::HTS002,BRD-K38197229-001-29-9,0.0024414,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::0.00976562::HTS002,BRD-K38197229-001-29-9,0.00976562,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::0.0390625::HTS002,BRD-K38197229-001-29-9,0.0390625,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::0.15625::HTS002,BRD-K38197229-001-29-9,0.15625,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::0.625::HTS002,BRD-K38197229-001-29-9,0.625,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::2.5::HTS002,BRD-K38197229-001-29-9,2.5,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38197229-001-29-9::10::HTS002,BRD-K38197229-001-29-9,10.0,HTS002,PREP022,bumetanide,solute carrier family member inhibitor,"CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5",cardiology,"edema, congestive heart failure","CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O",Launched
BRD-K38287497-001-01-2::0.00061034::HTS002,BRD-K38287497-001-01-2,0.00061034,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::0.0024414::HTS002,BRD-K38287497-001-01-2,0.0024414,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::0.00976562::HTS002,BRD-K38287497-001-01-2,0.00976562,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::0.0390625::HTS002,BRD-K38287497-001-01-2,0.0390625,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::0.15625::HTS002,BRD-K38287497-001-01-2,0.15625,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::0.625::HTS002,BRD-K38287497-001-01-2,0.625,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::2.5::HTS002,BRD-K38287497-001-01-2,2.5,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38287497-001-01-2::10::HTS002,BRD-K38287497-001-01-2,10.0,HTS002,PREP026,narlaprevir,HCV inhibitor,NA,NA,NA,CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1,Phase 2/Phase 3
BRD-K38305202-001-17-4::0.00061034::HTS002,BRD-K38305202-001-17-4,0.00061034,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::0.0024414::HTS002,BRD-K38305202-001-17-4,0.0024414,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::0.00976562::HTS002,BRD-K38305202-001-17-4,0.00976562,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::0.0390625::HTS002,BRD-K38305202-001-17-4,0.0390625,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::0.15625::HTS002,BRD-K38305202-001-17-4,0.15625,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::0.625::HTS002,BRD-K38305202-001-17-4,0.625,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::2.5::HTS002,BRD-K38305202-001-17-4,2.5,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38305202-001-17-4::10::HTS002,BRD-K38305202-001-17-4,10.0,HTS002,PREP035,domperidone,dopamine receptor antagonist,"DRD2, DRD3",infectious disease,fescue toxicosis,"Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1",Launched
BRD-K38332599-001-01-3::0.00061034::HTS002,BRD-K38332599-001-01-3,0.00061034,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.0024414::HTS002,BRD-K38332599-001-01-3,0.0024414,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.00976562::HTS002,BRD-K38332599-001-01-3,0.00976562,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.0390625::HTS002,BRD-K38332599-001-01-3,0.0390625,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.15625::HTS002,BRD-K38332599-001-01-3,0.15625,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::0.625::HTS002,BRD-K38332599-001-01-3,0.625,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::2.5::HTS002,BRD-K38332599-001-01-3,2.5,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38332599-001-01-3::10::HTS002,BRD-K38332599-001-01-3,10.0,HTS002,PREP027,uprosertib,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1,Phase 2
BRD-K38350380-001-01-8::0.00061034::HTS002,BRD-K38350380-001-01-8,0.00061034,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::0.0024414::HTS002,BRD-K38350380-001-01-8,0.0024414,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::0.00976562::HTS002,BRD-K38350380-001-01-8,0.00976562,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::0.0390625::HTS002,BRD-K38350380-001-01-8,0.0390625,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::0.15625::HTS002,BRD-K38350380-001-01-8,0.15625,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::0.625::HTS002,BRD-K38350380-001-01-8,0.625,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::2.5::HTS002,BRD-K38350380-001-01-8,2.5,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38350380-001-01-8::10::HTS002,BRD-K38350380-001-01-8,10.0,HTS002,PREP045,FK-3311,cyclooxygenase inhibitor,PTGS2,NA,NA,CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1,Phase 2
BRD-K38458514-001-01-8::0.000610352::HTS002,BRD-K38458514-001-01-8,0.000610352,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::0.00244141::HTS002,BRD-K38458514-001-01-8,0.00244141,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::0.00976562::HTS002,BRD-K38458514-001-01-8,0.00976562,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::0.0390625::HTS002,BRD-K38458514-001-01-8,0.0390625,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::0.15625::HTS002,BRD-K38458514-001-01-8,0.15625,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::0.625::HTS002,BRD-K38458514-001-01-8,0.625,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::2.5::HTS002,BRD-K38458514-001-01-8,2.5,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38458514-001-01-8::10::HTS002,BRD-K38458514-001-01-8,10.0,HTS002,PREP030,diazooxonorleucine,glutamate receptor antagonist,NA,NA,NA,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,Phase 2
BRD-K38548312-001-01-0::0.00061034::HTS002,BRD-K38548312-001-01-0,0.00061034,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::0.0024414::HTS002,BRD-K38548312-001-01-0,0.0024414,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::0.00976562::HTS002,BRD-K38548312-001-01-0,0.00976562,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::0.0390625::HTS002,BRD-K38548312-001-01-0,0.0390625,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::0.15625::HTS002,BRD-K38548312-001-01-0,0.15625,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::0.625::HTS002,BRD-K38548312-001-01-0,0.625,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::2.5::HTS002,BRD-K38548312-001-01-0,2.5,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38548312-001-01-0::10::HTS002,BRD-K38548312-001-01-0,10.0,HTS002,PREP040,VER-49009,HSP inhibitor,HSP90AA1,NA,NA,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,Preclinical
BRD-K38852836-001-02-1::0.00061034::HTS002,BRD-K38852836-001-02-1,0.00061034,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.0024414::HTS002,BRD-K38852836-001-02-1,0.0024414,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.00976562::HTS002,BRD-K38852836-001-02-1,0.00976562,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.0390625::HTS002,BRD-K38852836-001-02-1,0.0390625,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.15625::HTS002,BRD-K38852836-001-02-1,0.15625,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::0.625::HTS002,BRD-K38852836-001-02-1,0.625,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::2.5::HTS002,BRD-K38852836-001-02-1,2.5,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38852836-001-02-1::10::HTS002,BRD-K38852836-001-02-1,10.0,HTS002,PREP018,ganetespib,HSP inhibitor,HSP90AA1,NA,NA,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O,Phase 3
BRD-K38860038-001-01-2::0.00061034::HTS002,BRD-K38860038-001-01-2,0.00061034,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::0.0024414::HTS002,BRD-K38860038-001-01-2,0.0024414,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::0.00976562::HTS002,BRD-K38860038-001-01-2,0.00976562,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::0.0390625::HTS002,BRD-K38860038-001-01-2,0.0390625,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::0.15625::HTS002,BRD-K38860038-001-01-2,0.15625,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::0.625::HTS002,BRD-K38860038-001-01-2,0.625,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::2.5::HTS002,BRD-K38860038-001-01-2,2.5,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38860038-001-01-2::10::HTS002,BRD-K38860038-001-01-2,10.0,HTS002,PREP041,JK-184,hedgehog pathway inhibitor,NA,NA,NA,"CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",Preclinical
BRD-K38868394-001-01-3::0.00061034::HTS002,BRD-K38868394-001-01-3,0.00061034,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::0.0024414::HTS002,BRD-K38868394-001-01-3,0.0024414,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::0.00976562::HTS002,BRD-K38868394-001-01-3,0.00976562,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::0.0390625::HTS002,BRD-K38868394-001-01-3,0.0390625,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::0.15625::HTS002,BRD-K38868394-001-01-3,0.15625,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::0.625::HTS002,BRD-K38868394-001-01-3,0.625,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::2.5::HTS002,BRD-K38868394-001-01-3,2.5,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38868394-001-01-3::10::HTS002,BRD-K38868394-001-01-3,10.0,HTS002,PREP044,MK-0773,androgen receptor modulator,AR,NA,NA,CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O,Phase 2
BRD-K38904395-001-02-3::0.00061034::HTS002,BRD-K38904395-001-02-3,0.00061034,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::0.0024414::HTS002,BRD-K38904395-001-02-3,0.0024414,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::0.00976562::HTS002,BRD-K38904395-001-02-3,0.00976562,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::0.0390625::HTS002,BRD-K38904395-001-02-3,0.0390625,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::0.15625::HTS002,BRD-K38904395-001-02-3,0.15625,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::0.625::HTS002,BRD-K38904395-001-02-3,0.625,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::2.5::HTS002,BRD-K38904395-001-02-3,2.5,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K38904395-001-02-3::10::HTS002,BRD-K38904395-001-02-3,10.0,HTS002,PREP042,SAR131675,VEGFR inhibitor,FLT4,NA,NA,CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC,Preclinical
BRD-K39160765-003-02-9::0.00061034::HTS002,BRD-K39160765-003-02-9,0.00061034,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::0.0024414::HTS002,BRD-K39160765-003-02-9,0.0024414,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::0.00976562::HTS002,BRD-K39160765-003-02-9,0.00976562,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::0.0390625::HTS002,BRD-K39160765-003-02-9,0.0390625,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::0.15625::HTS002,BRD-K39160765-003-02-9,0.15625,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::0.625::HTS002,BRD-K39160765-003-02-9,0.625,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::2.5::HTS002,BRD-K39160765-003-02-9,2.5,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39160765-003-02-9::10::HTS002,BRD-K39160765-003-02-9,10.0,HTS002,PREP040,4-chlorophenylguanidine,urokinase inhibitor,PLAUR,NA,NA,NC(=N)Nc1ccc(Cl)cc1,Preclinical
BRD-K39171998-001-01-1::0.00061034::HTS002,BRD-K39171998-001-01-1,0.00061034,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::0.0024414::HTS002,BRD-K39171998-001-01-1,0.0024414,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::0.00976562::HTS002,BRD-K39171998-001-01-1,0.00976562,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::0.0390625::HTS002,BRD-K39171998-001-01-1,0.0390625,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::0.15625::HTS002,BRD-K39171998-001-01-1,0.15625,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::0.625::HTS002,BRD-K39171998-001-01-1,0.625,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::2.5::HTS002,BRD-K39171998-001-01-1,2.5,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39171998-001-01-1::10::HTS002,BRD-K39171998-001-01-1,10.0,HTS002,PREP041,STF-118804,NAMPT inhibitor,NAMPT,NA,NA,"Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",Preclinical
BRD-K39252998-003-01-5::0.00061034::HTS002,BRD-K39252998-003-01-5,0.00061034,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::0.0024414::HTS002,BRD-K39252998-003-01-5,0.0024414,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::0.00976562::HTS002,BRD-K39252998-003-01-5,0.00976562,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::0.0390625::HTS002,BRD-K39252998-003-01-5,0.0390625,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::0.15625::HTS002,BRD-K39252998-003-01-5,0.15625,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::0.625::HTS002,BRD-K39252998-003-01-5,0.625,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::2.5::HTS002,BRD-K39252998-003-01-5,2.5,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39252998-003-01-5::10::HTS002,BRD-K39252998-003-01-5,10.0,HTS002,PREP034,atipamezole,adrenergic receptor antagonist,NA,neurology/psychiatry,reverse sedative,"CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1",Launched
BRD-K39381259-001-01-0::0.00061034::HTS002,BRD-K39381259-001-01-0,0.00061034,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::0.0024414::HTS002,BRD-K39381259-001-01-0,0.0024414,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::0.00976562::HTS002,BRD-K39381259-001-01-0,0.00976562,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::0.0390625::HTS002,BRD-K39381259-001-01-0,0.0390625,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::0.15625::HTS002,BRD-K39381259-001-01-0,0.15625,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::0.625::HTS002,BRD-K39381259-001-01-0,0.625,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::2.5::HTS002,BRD-K39381259-001-01-0,2.5,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39381259-001-01-0::10::HTS002,BRD-K39381259-001-01-0,10.0,HTS002,PREP043,DMH1,ALK tyrosine kinase receptor inhibitor,ACVR1,NA,NA,"CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",Preclinical
BRD-K39467894-001-06-7::0.000610352::HTS002,BRD-K39467894-001-06-7,0.000610352,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::0.00244141::HTS002,BRD-K39467894-001-06-7,0.00244141,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::0.00976562::HTS002,BRD-K39467894-001-06-7,0.00976562,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::0.0390625::HTS002,BRD-K39467894-001-06-7,0.0390625,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::0.15625::HTS002,BRD-K39467894-001-06-7,0.15625,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::0.625::HTS002,BRD-K39467894-001-06-7,0.625,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::2.5::HTS002,BRD-K39467894-001-06-7,2.5,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39467894-001-06-7::10::HTS002,BRD-K39467894-001-06-7,10.0,HTS002,PREP035,nithiamide,bacterial DNA inhibitor,NA,NA,NA,"CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",Preclinical
BRD-K39558284-001-01-2::0.00061034::HTS002,BRD-K39558284-001-01-2,0.00061034,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::0.0024414::HTS002,BRD-K39558284-001-01-2,0.0024414,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::0.00976562::HTS002,BRD-K39558284-001-01-2,0.00976562,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::0.0390625::HTS002,BRD-K39558284-001-01-2,0.0390625,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::0.15625::HTS002,BRD-K39558284-001-01-2,0.15625,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::0.625::HTS002,BRD-K39558284-001-01-2,0.625,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::2.5::HTS002,BRD-K39558284-001-01-2,2.5,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39558284-001-01-2::10::HTS002,BRD-K39558284-001-01-2,10.0,HTS002,PREP033,SDZ-WAG-994,adenosine receptor agonist,ADORA1,NA,NA,"CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",Phase 2
BRD-K39624409-003-02-6::0.00061034::HTS002,BRD-K39624409-003-02-6,0.00061034,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::0.0024414::HTS002,BRD-K39624409-003-02-6,0.0024414,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::0.00976562::HTS002,BRD-K39624409-003-02-6,0.00976562,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::0.0390625::HTS002,BRD-K39624409-003-02-6,0.0390625,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::0.15625::HTS002,BRD-K39624409-003-02-6,0.15625,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::0.625::HTS002,BRD-K39624409-003-02-6,0.625,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::2.5::HTS002,BRD-K39624409-003-02-6,2.5,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39624409-003-02-6::10::HTS002,BRD-K39624409-003-02-6,10.0,HTS002,PREP026,ADL5859,opioid receptor agonist,OPRD1,NA,NA,"CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12",Phase 2
BRD-K39841531-001-02-1::0.00061034::HTS002,BRD-K39841531-001-02-1,0.00061034,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::0.0024414::HTS002,BRD-K39841531-001-02-1,0.0024414,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::0.00976562::HTS002,BRD-K39841531-001-02-1,0.00976562,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::0.0390625::HTS002,BRD-K39841531-001-02-1,0.0390625,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::0.15625::HTS002,BRD-K39841531-001-02-1,0.15625,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::0.625::HTS002,BRD-K39841531-001-02-1,0.625,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::2.5::HTS002,BRD-K39841531-001-02-1,2.5,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39841531-001-02-1::10::HTS002,BRD-K39841531-001-02-1,10.0,HTS002,PREP043,TG-101209,JAK inhibitor,"JAK2, JAK3",NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1,Preclinical
BRD-K39974922-001-04-3::0.00061034::HTS002,BRD-K39974922-001-04-3,0.00061034,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.0024414::HTS002,BRD-K39974922-001-04-3,0.0024414,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.00976562::HTS002,BRD-K39974922-001-04-3,0.00976562,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.0390625::HTS002,BRD-K39974922-001-04-3,0.0390625,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.15625::HTS002,BRD-K39974922-001-04-3,0.15625,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::0.625::HTS002,BRD-K39974922-001-04-3,0.625,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::2.5::HTS002,BRD-K39974922-001-04-3,2.5,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39974922-001-04-3::10::HTS002,BRD-K39974922-001-04-3,10.0,HTS002,PREP034,lenvatinib,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT4, KDR",oncology,thyroid cancer,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,Launched
BRD-K39987650-001-24-1::0.00061034::HTS002,BRD-K39987650-001-24-1,0.00061034,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::0.0024414::HTS002,BRD-K39987650-001-24-1,0.0024414,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::0.00976562::HTS002,BRD-K39987650-001-24-1,0.00976562,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::0.0390625::HTS002,BRD-K39987650-001-24-1,0.0390625,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::0.15625::HTS002,BRD-K39987650-001-24-1,0.15625,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::0.625::HTS002,BRD-K39987650-001-24-1,0.625,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::2.5::HTS002,BRD-K39987650-001-24-1,2.5,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K39987650-001-24-1::10::HTS002,BRD-K39987650-001-24-1,10.0,HTS002,PREP029,bisacodyl,laxative,NA,gastroenterology,constipation,"CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1",Launched
BRD-K40109029-001-02-9::0.00061034::HTS002,BRD-K40109029-001-02-9,0.00061034,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::0.0024414::HTS002,BRD-K40109029-001-02-9,0.0024414,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::0.00976562::HTS002,BRD-K40109029-001-02-9,0.00976562,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::0.0390625::HTS002,BRD-K40109029-001-02-9,0.0390625,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::0.15625::HTS002,BRD-K40109029-001-02-9,0.15625,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::0.625::HTS002,BRD-K40109029-001-02-9,0.625,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::2.5::HTS002,BRD-K40109029-001-02-9,2.5,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40109029-001-02-9::10::HTS002,BRD-K40109029-001-02-9,10.0,HTS002,PREP040,SB-505124,ALK tyrosine kinase receptor inhibitor,TGFBR1,NA,NA,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C,Preclinical
BRD-K40175214-001-11-6::0.00061034::HTS002,BRD-K40175214-001-11-6,0.00061034,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::0.0024414::HTS002,BRD-K40175214-001-11-6,0.0024414,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::0.00976562::HTS002,BRD-K40175214-001-11-6,0.00976562,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::0.0390625::HTS002,BRD-K40175214-001-11-6,0.0390625,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::0.15625::HTS002,BRD-K40175214-001-11-6,0.15625,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::0.625::HTS002,BRD-K40175214-001-11-6,0.625,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::2.5::HTS002,BRD-K40175214-001-11-6,2.5,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40175214-001-11-6::10::HTS002,BRD-K40175214-001-11-6,10.0,HTS002,PREP040,torin-1,mTOR inhibitor,MTOR,NA,NA,"CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",Preclinical
BRD-K40255344-001-17-6::0.00061034::HTS002,BRD-K40255344-001-17-6,0.00061034,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::0.0024414::HTS002,BRD-K40255344-001-17-6,0.0024414,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::0.00976562::HTS002,BRD-K40255344-001-17-6,0.00976562,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::0.0390625::HTS002,BRD-K40255344-001-17-6,0.0390625,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::0.15625::HTS002,BRD-K40255344-001-17-6,0.15625,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::0.625::HTS002,BRD-K40255344-001-17-6,0.625,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::2.5::HTS002,BRD-K40255344-001-17-6,2.5,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40255344-001-17-6::10::HTS002,BRD-K40255344-001-17-6,10.0,HTS002,PREP040,tyrphostin-A9,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",NA,NA,NA,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,Preclinical
BRD-K40308497-001-01-2::0.000619363::HTS002,BRD-K40308497-001-01-2,0.000619363,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::0.00247745::HTS002,BRD-K40308497-001-01-2,0.00247745,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::0.0099098::HTS002,BRD-K40308497-001-01-2,0.0099098,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::0.0396392::HTS002,BRD-K40308497-001-01-2,0.0396392,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::0.158557::HTS002,BRD-K40308497-001-01-2,0.158557,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::0.634227::HTS002,BRD-K40308497-001-01-2,0.634227,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::2.53691::HTS002,BRD-K40308497-001-01-2,2.53691,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40308497-001-01-2::10.1476::HTS002,BRD-K40308497-001-01-2,10.1476,HTS002,PREP029,crizotinib-(S),MTH1 inhibitor,NUDT1,NA,NA,"C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Preclinical
BRD-K40331046-305-01-5::0.00061034::HTS002,BRD-K40331046-305-01-5,0.00061034,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::0.0024414::HTS002,BRD-K40331046-305-01-5,0.0024414,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::0.00976562::HTS002,BRD-K40331046-305-01-5,0.00976562,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::0.0390625::HTS002,BRD-K40331046-305-01-5,0.0390625,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::0.15625::HTS002,BRD-K40331046-305-01-5,0.15625,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::0.625::HTS002,BRD-K40331046-305-01-5,0.625,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::2.5::HTS002,BRD-K40331046-305-01-5,2.5,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40331046-305-01-5::10::HTS002,BRD-K40331046-305-01-5,10.0,HTS002,PREP037,CR8-(R),CDK inhibitor,CCNA2,NA,NA,"CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",Preclinical
BRD-K40438880-305-06-6::0.00061034::HTS002,BRD-K40438880-305-06-6,0.00061034,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::0.0024414::HTS002,BRD-K40438880-305-06-6,0.0024414,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::0.00976562::HTS002,BRD-K40438880-305-06-6,0.00976562,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::0.0390625::HTS002,BRD-K40438880-305-06-6,0.0390625,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::0.15625::HTS002,BRD-K40438880-305-06-6,0.15625,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::0.625::HTS002,BRD-K40438880-305-06-6,0.625,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::2.5::HTS002,BRD-K40438880-305-06-6,2.5,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40438880-305-06-6::10::HTS002,BRD-K40438880-305-06-6,10.0,HTS002,PREP047,spermidine,glutamate receptor modulator,"KCNJ4, TXNRD1",NA,NA,NCCCCNCCCN,Preclinical
BRD-K40496271-396-01-1::0.000572268::HTS002,BRD-K40496271-396-01-1,0.000572268,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::0.00228907::HTS002,BRD-K40496271-396-01-1,0.00228907,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::0.00915629::HTS002,BRD-K40496271-396-01-1,0.00915629,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::0.0366252::HTS002,BRD-K40496271-396-01-1,0.0366252,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::0.146501::HTS002,BRD-K40496271-396-01-1,0.146501,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::0.586003::HTS002,BRD-K40496271-396-01-1,0.586003,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::2.34401::HTS002,BRD-K40496271-396-01-1,2.34401,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40496271-396-01-1::9.37604::HTS002,BRD-K40496271-396-01-1,9.37604,HTS002,PREP035,eltrombopag,thrombopoietin receptor agonist,MPL,"hematology, infectious disease","anemia, hepatitis C, thrombocytopenia","CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1",Launched
BRD-K40718343-001-02-6::0.00061034::HTS002,BRD-K40718343-001-02-6,0.00061034,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::0.0024414::HTS002,BRD-K40718343-001-02-6,0.0024414,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::0.00976562::HTS002,BRD-K40718343-001-02-6,0.00976562,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::0.0390625::HTS002,BRD-K40718343-001-02-6,0.0390625,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::0.15625::HTS002,BRD-K40718343-001-02-6,0.15625,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::0.625::HTS002,BRD-K40718343-001-02-6,0.625,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::2.5::HTS002,BRD-K40718343-001-02-6,2.5,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40718343-001-02-6::10::HTS002,BRD-K40718343-001-02-6,10.0,HTS002,PREP032,AEE788,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR",NA,NA,"CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",Phase 1/Phase 2
BRD-K40797222-001-01-8::0.00061034::HTS002,BRD-K40797222-001-01-8,0.00061034,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::0.0024414::HTS002,BRD-K40797222-001-01-8,0.0024414,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::0.00976562::HTS002,BRD-K40797222-001-01-8,0.00976562,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::0.0390625::HTS002,BRD-K40797222-001-01-8,0.0390625,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::0.15625::HTS002,BRD-K40797222-001-01-8,0.15625,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::0.625::HTS002,BRD-K40797222-001-01-8,0.625,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::2.5::HTS002,BRD-K40797222-001-01-8,2.5,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40797222-001-01-8::10::HTS002,BRD-K40797222-001-01-8,10.0,HTS002,PREP019,SC-12267,dihydroorotate dehydrogenase inhibitor,IL17A,NA,NA,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,Phase 2
BRD-K40992116-001-09-7::0.00061034::HTS002,BRD-K40992116-001-09-7,0.00061034,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::0.0024414::HTS002,BRD-K40992116-001-09-7,0.0024414,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::0.00976562::HTS002,BRD-K40992116-001-09-7,0.00976562,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::0.0390625::HTS002,BRD-K40992116-001-09-7,0.0390625,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::0.15625::HTS002,BRD-K40992116-001-09-7,0.15625,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::0.625::HTS002,BRD-K40992116-001-09-7,0.625,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::2.5::HTS002,BRD-K40992116-001-09-7,2.5,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K40992116-001-09-7::10::HTS002,BRD-K40992116-001-09-7,10.0,HTS002,PREP020,parachlorophenol,antiinfective drug,NA,NA,NA,Oc1ccc(Cl)cc1,Launched
BRD-K41104902-001-01-3::0.00061034::HTS002,BRD-K41104902-001-01-3,0.00061034,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::0.0024414::HTS002,BRD-K41104902-001-01-3,0.0024414,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::0.00976562::HTS002,BRD-K41104902-001-01-3,0.00976562,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::0.0390625::HTS002,BRD-K41104902-001-01-3,0.0390625,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::0.15625::HTS002,BRD-K41104902-001-01-3,0.15625,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::0.625::HTS002,BRD-K41104902-001-01-3,0.625,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::2.5::HTS002,BRD-K41104902-001-01-3,2.5,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41104902-001-01-3::10::HTS002,BRD-K41104902-001-01-3,10.0,HTS002,PREP046,GSK2656157,PERK inhibitor,NA,NA,NA,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,Preclinical
BRD-K41213548-001-02-0::0.00061034::HTS002,BRD-K41213548-001-02-0,0.00061034,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::0.0024414::HTS002,BRD-K41213548-001-02-0,0.0024414,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::0.00976562::HTS002,BRD-K41213548-001-02-0,0.00976562,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::0.0390625::HTS002,BRD-K41213548-001-02-0,0.0390625,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::0.15625::HTS002,BRD-K41213548-001-02-0,0.15625,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::0.625::HTS002,BRD-K41213548-001-02-0,0.625,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::2.5::HTS002,BRD-K41213548-001-02-0,2.5,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41213548-001-02-0::10::HTS002,BRD-K41213548-001-02-0,10.0,HTS002,PREP039,KW-2478,HSP inhibitor,NA,NA,NA,CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC,Phase 1/Phase 2
BRD-K41278234-001-03-0::0.00061034::HTS002,BRD-K41278234-001-03-0,0.00061034,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::0.0024414::HTS002,BRD-K41278234-001-03-0,0.0024414,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::0.00976562::HTS002,BRD-K41278234-001-03-0,0.00976562,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::0.0390625::HTS002,BRD-K41278234-001-03-0,0.0390625,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::0.15625::HTS002,BRD-K41278234-001-03-0,0.15625,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::0.625::HTS002,BRD-K41278234-001-03-0,0.625,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::2.5::HTS002,BRD-K41278234-001-03-0,2.5,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41278234-001-03-0::10::HTS002,BRD-K41278234-001-03-0,10.0,HTS002,PREP024,CUDC-101,EGFR inhibitor,"EGFR, ERBB2",NA,NA,COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO,Phase 1
BRD-K41312087-001-02-7::0.00061034::HTS002,BRD-K41312087-001-02-7,0.00061034,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::0.0024414::HTS002,BRD-K41312087-001-02-7,0.0024414,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::0.00976562::HTS002,BRD-K41312087-001-02-7,0.00976562,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::0.0390625::HTS002,BRD-K41312087-001-02-7,0.0390625,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::0.15625::HTS002,BRD-K41312087-001-02-7,0.15625,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::0.625::HTS002,BRD-K41312087-001-02-7,0.625,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::2.5::HTS002,BRD-K41312087-001-02-7,2.5,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41312087-001-02-7::10::HTS002,BRD-K41312087-001-02-7,10.0,HTS002,PREP037,GW-441756,growth factor receptor inhibitor,NTRK1,NA,NA,"Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",Preclinical
BRD-K41337261-001-03-0::0.00061034::HTS002,BRD-K41337261-001-03-0,0.00061034,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::0.0024414::HTS002,BRD-K41337261-001-03-0,0.0024414,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::0.00976562::HTS002,BRD-K41337261-001-03-0,0.00976562,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::0.0390625::HTS002,BRD-K41337261-001-03-0,0.0390625,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::0.15625::HTS002,BRD-K41337261-001-03-0,0.15625,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::0.625::HTS002,BRD-K41337261-001-03-0,0.625,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::2.5::HTS002,BRD-K41337261-001-03-0,2.5,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41337261-001-03-0::10::HTS002,BRD-K41337261-001-03-0,10.0,HTS002,PREP037,ZM-306416,"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",Preclinical
BRD-K41599323-001-02-3::0.00061034::HTS002,BRD-K41599323-001-02-3,0.00061034,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::0.0024414::HTS002,BRD-K41599323-001-02-3,0.0024414,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::0.00976562::HTS002,BRD-K41599323-001-02-3,0.00976562,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::0.0390625::HTS002,BRD-K41599323-001-02-3,0.0390625,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::0.15625::HTS002,BRD-K41599323-001-02-3,0.15625,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::0.625::HTS002,BRD-K41599323-001-02-3,0.625,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::2.5::HTS002,BRD-K41599323-001-02-3,2.5,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-K41599323-001-02-3::10::HTS002,BRD-K41599323-001-02-3,10.0,HTS002,PREP027,lonafarnib,farnesyltransferase inhibitor,"FNTA, HRAS, KRAS, NRAS",NA,NA,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1,Phase 3
BRD-A92439610-001-05-7::0.00061034::HTS002,BRD-A92439610-001-05-7,0.00061034,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::0.0024414::HTS002,BRD-A92439610-001-05-7,0.0024414,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::0.00976562::HTS002,BRD-A92439610-001-05-7,0.00976562,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::0.0390625::HTS002,BRD-A92439610-001-05-7,0.0390625,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::0.15625::HTS002,BRD-A92439610-001-05-7,0.15625,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::0.625::HTS002,BRD-A92439610-001-05-7,0.625,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::2.5::HTS002,BRD-A92439610-001-05-7,2.5,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-A92439610-001-05-7::10::HTS002,BRD-A92439610-001-05-7,10.0,HTS002,PREP022,triamcinolone-acetonide,"glucocorticoid receptor agonist, immunosuppressant",NR3C1,dermatology,corticosteroid-responsive dermatoses,"CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO",Launched
BRD-K41783120-001-02-8::0.00061034::HTS002,BRD-K41783120-001-02-8,0.00061034,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.0024414::HTS002,BRD-K41783120-001-02-8,0.0024414,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.00976562::HTS002,BRD-K41783120-001-02-8,0.00976562,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.0390625::HTS002,BRD-K41783120-001-02-8,0.0390625,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.15625::HTS002,BRD-K41783120-001-02-8,0.15625,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.625::HTS002,BRD-K41783120-001-02-8,0.625,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::2.5::HTS002,BRD-K41783120-001-02-8,2.5,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::10::HTS002,BRD-K41783120-001-02-8,10.0,HTS002,PREP038,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41859756-001-06-8::0.00061034::HTS002,BRD-K41859756-001-06-8,0.00061034,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.0024414::HTS002,BRD-K41859756-001-06-8,0.0024414,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.00976562::HTS002,BRD-K41859756-001-06-8,0.00976562,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.0390625::HTS002,BRD-K41859756-001-06-8,0.0390625,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.15625::HTS002,BRD-K41859756-001-06-8,0.15625,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::0.625::HTS002,BRD-K41859756-001-06-8,0.625,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::2.5::HTS002,BRD-K41859756-001-06-8,2.5,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41859756-001-06-8::10::HTS002,BRD-K41859756-001-06-8,10.0,HTS002,PREP045,NVP-AUY922,HSP inhibitor,"HSP90AA1, HSP90AB1",NA,NA,"CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",Phase 2
BRD-K41876534-001-13-7::0.00061034::HTS002,BRD-K41876534-001-13-7,0.00061034,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::0.0024414::HTS002,BRD-K41876534-001-13-7,0.0024414,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::0.00976562::HTS002,BRD-K41876534-001-13-7,0.00976562,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::0.0390625::HTS002,BRD-K41876534-001-13-7,0.0390625,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::0.15625::HTS002,BRD-K41876534-001-13-7,0.15625,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::0.625::HTS002,BRD-K41876534-001-13-7,0.625,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::2.5::HTS002,BRD-K41876534-001-13-7,2.5,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K41876534-001-13-7::10::HTS002,BRD-K41876534-001-13-7,10.0,HTS002,PREP033,tioxolone,carbonic anhydrase inhibitor,CA2,NA,NA,"Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",Preclinical
BRD-K42191735-001-05-3::0.00061034::HTS002,BRD-K42191735-001-05-3,0.00061034,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::0.0024414::HTS002,BRD-K42191735-001-05-3,0.0024414,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::0.00976562::HTS002,BRD-K42191735-001-05-3,0.00976562,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::0.0390625::HTS002,BRD-K42191735-001-05-3,0.0390625,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::0.15625::HTS002,BRD-K42191735-001-05-3,0.15625,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::0.625::HTS002,BRD-K42191735-001-05-3,0.625,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::2.5::HTS002,BRD-K42191735-001-05-3,2.5,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42191735-001-05-3::10::HTS002,BRD-K42191735-001-05-3,10.0,HTS002,PREP046,buparlisib,PI3K inhibitor,"PIK3CA, PIK3CG",NA,NA,"Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",Phase 3
BRD-K42205652-001-02-7::0.00061034::HTS002,BRD-K42205652-001-02-7,0.00061034,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::0.0024414::HTS002,BRD-K42205652-001-02-7,0.0024414,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::0.00976562::HTS002,BRD-K42205652-001-02-7,0.00976562,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::0.0390625::HTS002,BRD-K42205652-001-02-7,0.0390625,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::0.15625::HTS002,BRD-K42205652-001-02-7,0.15625,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::0.625::HTS002,BRD-K42205652-001-02-7,0.625,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::2.5::HTS002,BRD-K42205652-001-02-7,2.5,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42205652-001-02-7::10::HTS002,BRD-K42205652-001-02-7,10.0,HTS002,PREP042,"MNS-(3,4-Methylenedioxy-nitrostyrene)","src inhibitor, syk inhibitor","SRC, SYK",NA,NA,"[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",Preclinical
BRD-K42436189-001-01-2::0.00061034::HTS002,BRD-K42436189-001-01-2,0.00061034,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::0.0024414::HTS002,BRD-K42436189-001-01-2,0.0024414,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::0.00976562::HTS002,BRD-K42436189-001-01-2,0.00976562,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::0.0390625::HTS002,BRD-K42436189-001-01-2,0.0390625,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::0.15625::HTS002,BRD-K42436189-001-01-2,0.15625,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::0.625::HTS002,BRD-K42436189-001-01-2,0.625,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::2.5::HTS002,BRD-K42436189-001-01-2,2.5,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42436189-001-01-2::10::HTS002,BRD-K42436189-001-01-2,10.0,HTS002,PREP041,AZ20,ATR kinase inhibitor,"ATR, MTOR",NA,NA,"C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",Preclinical
BRD-K42495768-001-01-7::0.00061034::HTS002,BRD-K42495768-001-01-7,0.00061034,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.0024414::HTS002,BRD-K42495768-001-01-7,0.0024414,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.00976562::HTS002,BRD-K42495768-001-01-7,0.00976562,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.0390625::HTS002,BRD-K42495768-001-01-7,0.0390625,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.15625::HTS002,BRD-K42495768-001-01-7,0.15625,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::0.625::HTS002,BRD-K42495768-001-01-7,0.625,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::2.5::HTS002,BRD-K42495768-001-01-7,2.5,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42495768-001-01-7::10::HTS002,BRD-K42495768-001-01-7,10.0,HTS002,PREP045,tasisulam,apoptosis stimulant,NA,NA,NA,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,Phase 3
BRD-K42497885-001-01-1::0.00061034::HTS002,BRD-K42497885-001-01-1,0.00061034,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::0.0024414::HTS002,BRD-K42497885-001-01-1,0.0024414,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::0.00976562::HTS002,BRD-K42497885-001-01-1,0.00976562,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::0.0390625::HTS002,BRD-K42497885-001-01-1,0.0390625,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::0.15625::HTS002,BRD-K42497885-001-01-1,0.15625,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::0.625::HTS002,BRD-K42497885-001-01-1,0.625,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::2.5::HTS002,BRD-K42497885-001-01-1,2.5,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42497885-001-01-1::10::HTS002,BRD-K42497885-001-01-1,10.0,HTS002,PREP045,satraplatin,DNA alkylating agent,NA,NA,NA,"NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",Phase 3
BRD-K42756753-001-01-9::0.00061034::HTS002,BRD-K42756753-001-01-9,0.00061034,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::0.0024414::HTS002,BRD-K42756753-001-01-9,0.0024414,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::0.00976562::HTS002,BRD-K42756753-001-01-9,0.00976562,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::0.0390625::HTS002,BRD-K42756753-001-01-9,0.0390625,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::0.15625::HTS002,BRD-K42756753-001-01-9,0.15625,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::0.625::HTS002,BRD-K42756753-001-01-9,0.625,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::2.5::HTS002,BRD-K42756753-001-01-9,2.5,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42756753-001-01-9::10::HTS002,BRD-K42756753-001-01-9,10.0,HTS002,PREP033,epiandrosterone,steroid,G6PD,NA,NA,C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Preclinical
BRD-K42805893-001-04-9::0.00061034::HTS002,BRD-K42805893-001-04-9,0.00061034,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.0024414::HTS002,BRD-K42805893-001-04-9,0.0024414,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.00976562::HTS002,BRD-K42805893-001-04-9,0.00976562,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.0390625::HTS002,BRD-K42805893-001-04-9,0.0390625,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.15625::HTS002,BRD-K42805893-001-04-9,0.15625,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::0.625::HTS002,BRD-K42805893-001-04-9,0.625,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::2.5::HTS002,BRD-K42805893-001-04-9,2.5,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42805893-001-04-9::10::HTS002,BRD-K42805893-001-04-9,10.0,HTS002,PREP033,osimertinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12,Launched
BRD-K42828737-044-09-0::0.00061034::HTS002,BRD-K42828737-044-09-0,0.00061034,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::0.0024414::HTS002,BRD-K42828737-044-09-0,0.0024414,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::0.00976562::HTS002,BRD-K42828737-044-09-0,0.00976562,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::0.0390625::HTS002,BRD-K42828737-044-09-0,0.0390625,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::0.15625::HTS002,BRD-K42828737-044-09-0,0.15625,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::0.625::HTS002,BRD-K42828737-044-09-0,0.625,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::2.5::HTS002,BRD-K42828737-044-09-0,2.5,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42828737-044-09-0::10::HTS002,BRD-K42828737-044-09-0,10.0,HTS002,PREP029,sunitinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET",oncology,"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C",Launched
BRD-K42898655-001-01-8::0.00061034::HTS002,BRD-K42898655-001-01-8,0.00061034,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.0024414::HTS002,BRD-K42898655-001-01-8,0.0024414,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.00976562::HTS002,BRD-K42898655-001-01-8,0.00976562,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.0390625::HTS002,BRD-K42898655-001-01-8,0.0390625,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.15625::HTS002,BRD-K42898655-001-01-8,0.15625,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::0.625::HTS002,BRD-K42898655-001-01-8,0.625,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::2.5::HTS002,BRD-K42898655-001-01-8,2.5,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42898655-001-01-8::10::HTS002,BRD-K42898655-001-01-8,10.0,HTS002,PREP030,temsirolimus,mTOR inhibitor,MTOR,oncology,renal cell carcinoma (RCC),CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,Launched
BRD-K42938903-332-01-1::0.00061034::HTS002,BRD-K42938903-332-01-1,0.00061034,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::0.0024414::HTS002,BRD-K42938903-332-01-1,0.0024414,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::0.00976562::HTS002,BRD-K42938903-332-01-1,0.00976562,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::0.0390625::HTS002,BRD-K42938903-332-01-1,0.0390625,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::0.15625::HTS002,BRD-K42938903-332-01-1,0.15625,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::0.625::HTS002,BRD-K42938903-332-01-1,0.625,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::2.5::HTS002,BRD-K42938903-332-01-1,2.5,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42938903-332-01-1::10::HTS002,BRD-K42938903-332-01-1,10.0,HTS002,PREP020,acetophenazine,dopamine receptor antagonist,"DRD1, DRD2",neurology/psychiatry,psychosis,CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1,Launched
BRD-K42973005-001-04-0::0.00061034::HTS002,BRD-K42973005-001-04-0,0.00061034,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::0.0024414::HTS002,BRD-K42973005-001-04-0,0.0024414,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::0.00976562::HTS002,BRD-K42973005-001-04-0,0.00976562,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::0.0390625::HTS002,BRD-K42973005-001-04-0,0.0390625,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::0.15625::HTS002,BRD-K42973005-001-04-0,0.15625,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::0.625::HTS002,BRD-K42973005-001-04-0,0.625,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::2.5::HTS002,BRD-K42973005-001-04-0,2.5,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42973005-001-04-0::10::HTS002,BRD-K42973005-001-04-0,10.0,HTS002,PREP036,CHIR-98014,glycogen synthase kinase inhibitor,"GSK3A, GSK3B",NA,NA,Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O,Preclinical
BRD-K42981054-001-01-9::0.00061034::HTS002,BRD-K42981054-001-01-9,0.00061034,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::0.0024414::HTS002,BRD-K42981054-001-01-9,0.0024414,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::0.00976562::HTS002,BRD-K42981054-001-01-9,0.00976562,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::0.0390625::HTS002,BRD-K42981054-001-01-9,0.0390625,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::0.15625::HTS002,BRD-K42981054-001-01-9,0.15625,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::0.625::HTS002,BRD-K42981054-001-01-9,0.625,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::2.5::HTS002,BRD-K42981054-001-01-9,2.5,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K42981054-001-01-9::10::HTS002,BRD-K42981054-001-01-9,10.0,HTS002,PREP044,mibampator,glutamate receptor modulator,GRIA1,NA,NA,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,Phase 2
BRD-K43002771-034-01-6::0.00061034::HTS002,BRD-K43002771-034-01-6,0.00061034,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::0.0024414::HTS002,BRD-K43002771-034-01-6,0.0024414,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::0.00976562::HTS002,BRD-K43002771-034-01-6,0.00976562,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::0.0390625::HTS002,BRD-K43002771-034-01-6,0.0390625,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::0.15625::HTS002,BRD-K43002771-034-01-6,0.15625,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::0.625::HTS002,BRD-K43002771-034-01-6,0.625,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::2.5::HTS002,BRD-K43002771-034-01-6,2.5,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43002771-034-01-6::10::HTS002,BRD-K43002771-034-01-6,10.0,HTS002,PREP044,SR-33805,calcium channel blocker,NA,NA,NA,"COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",Phase 1
BRD-K43187018-001-03-3::0.000616335::HTS002,BRD-K43187018-001-03-3,0.000616335,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::0.00246534::HTS002,BRD-K43187018-001-03-3,0.00246534,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::0.00986136::HTS002,BRD-K43187018-001-03-3,0.00986136,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::0.0394454::HTS002,BRD-K43187018-001-03-3,0.0394454,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::0.157782::HTS002,BRD-K43187018-001-03-3,0.157782,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::0.631127::HTS002,BRD-K43187018-001-03-3,0.631127,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::2.52451::HTS002,BRD-K43187018-001-03-3,2.52451,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43187018-001-03-3::10.098::HTS002,BRD-K43187018-001-03-3,10.098,HTS002,PREP032,GDC-0349,Pim kinase inhibitor,PIK3CA,NA,NA,"CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",Phase 1
BRD-K43236057-001-07-1::0.000634712::HTS002,BRD-K43236057-001-07-1,0.000634712,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::0.00253885::HTS002,BRD-K43236057-001-07-1,0.00253885,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::0.0101554::HTS002,BRD-K43236057-001-07-1,0.0101554,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::0.0406216::HTS002,BRD-K43236057-001-07-1,0.0406216,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::0.162486::HTS002,BRD-K43236057-001-07-1,0.162486,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::0.649945::HTS002,BRD-K43236057-001-07-1,0.649945,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::2.59978::HTS002,BRD-K43236057-001-07-1,2.59978,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43236057-001-07-1::10.3991::HTS002,BRD-K43236057-001-07-1,10.3991,HTS002,PREP034,polydatin,ICAM1 expression inhibitor,ICAM1,NA,NA,"OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",Phase 2
BRD-K43389698-001-09-9::0.000586357::HTS002,BRD-K43389698-001-09-9,0.000586357,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::0.00234543::HTS002,BRD-K43389698-001-09-9,0.00234543,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::0.00938171::HTS002,BRD-K43389698-001-09-9,0.00938171,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::0.0375268::HTS002,BRD-K43389698-001-09-9,0.0375268,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::0.150107::HTS002,BRD-K43389698-001-09-9,0.150107,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::0.600429::HTS002,BRD-K43389698-001-09-9,0.600429,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::2.40172::HTS002,BRD-K43389698-001-09-9,2.40172,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43389698-001-09-9::9.60687::HTS002,BRD-K43389698-001-09-9,9.60687,HTS002,PREP019,BMS-387032,"CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9",NA,NA,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",Phase 1
BRD-K43449605-001-01-0::0.00061034::HTS002,BRD-K43449605-001-01-0,0.00061034,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::0.0024414::HTS002,BRD-K43449605-001-01-0,0.0024414,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::0.00976562::HTS002,BRD-K43449605-001-01-0,0.00976562,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::0.0390625::HTS002,BRD-K43449605-001-01-0,0.0390625,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::0.15625::HTS002,BRD-K43449605-001-01-0,0.15625,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::0.625::HTS002,BRD-K43449605-001-01-0,0.625,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::2.5::HTS002,BRD-K43449605-001-01-0,2.5,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43449605-001-01-0::10::HTS002,BRD-K43449605-001-01-0,10.0,HTS002,PREP043,oncrasin-1,apoptosis stimulant,NA,NA,NA,Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1,Preclinical
BRD-K43457670-001-27-8::0.00061034::HTS002,BRD-K43457670-001-27-8,0.00061034,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::0.0024414::HTS002,BRD-K43457670-001-27-8,0.0024414,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::0.00976562::HTS002,BRD-K43457670-001-27-8,0.00976562,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::0.0390625::HTS002,BRD-K43457670-001-27-8,0.0390625,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::0.15625::HTS002,BRD-K43457670-001-27-8,0.15625,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::0.625::HTS002,BRD-K43457670-001-27-8,0.625,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::2.5::HTS002,BRD-K43457670-001-27-8,2.5,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43457670-001-27-8::10::HTS002,BRD-K43457670-001-27-8,10.0,HTS002,PREP034,acetazolamide,carbonic anhydrase inhibitor,"AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7",ophthalmology,glaucoma,CC(=O)Nc1nnc(s1)S(N)(=O)=O,Launched
BRD-K43471985-001-03-0::0.000656761::HTS002,BRD-K43471985-001-03-0,0.000656761,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::0.00262704::HTS002,BRD-K43471985-001-03-0,0.00262704,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::0.0105082::HTS002,BRD-K43471985-001-03-0,0.0105082,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::0.0420327::HTS002,BRD-K43471985-001-03-0,0.0420327,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::0.168131::HTS002,BRD-K43471985-001-03-0,0.168131,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::0.672524::HTS002,BRD-K43471985-001-03-0,0.672524,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::2.69009::HTS002,BRD-K43471985-001-03-0,2.69009,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43471985-001-03-0::10.7604::HTS002,BRD-K43471985-001-03-0,10.7604,HTS002,PREP044,OTX015,bromodomain inhibitor,"BRD2, BRD3, BRD4",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1",Phase 1/Phase 2
BRD-K43578482-001-01-4::0.00061034::HTS002,BRD-K43578482-001-01-4,0.00061034,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::0.0024414::HTS002,BRD-K43578482-001-01-4,0.0024414,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::0.00976562::HTS002,BRD-K43578482-001-01-4,0.00976562,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::0.0390625::HTS002,BRD-K43578482-001-01-4,0.0390625,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::0.15625::HTS002,BRD-K43578482-001-01-4,0.15625,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::0.625::HTS002,BRD-K43578482-001-01-4,0.625,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::2.5::HTS002,BRD-K43578482-001-01-4,2.5,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43578482-001-01-4::10::HTS002,BRD-K43578482-001-01-4,10.0,HTS002,PREP025,defactinib,focal adhesion kinase inhibitor,PTK2,NA,NA,"CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",Phase 2
BRD-K43621685-001-02-5::0.00061034::HTS002,BRD-K43621685-001-02-5,0.00061034,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::0.0024414::HTS002,BRD-K43621685-001-02-5,0.0024414,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::0.00976562::HTS002,BRD-K43621685-001-02-5,0.00976562,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::0.0390625::HTS002,BRD-K43621685-001-02-5,0.0390625,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::0.15625::HTS002,BRD-K43621685-001-02-5,0.15625,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::0.625::HTS002,BRD-K43621685-001-02-5,0.625,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::2.5::HTS002,BRD-K43621685-001-02-5,2.5,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43621685-001-02-5::10::HTS002,BRD-K43621685-001-02-5,10.0,HTS002,PREP033,CP-673451,PDGFR tyrosine kinase receptor inhibitor,"KIT, PDGFRA, PDGFRB",NA,NA,"COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",Preclinical
BRD-K43644456-001-04-0::0.000580647::HTS002,BRD-K43644456-001-04-0,0.000580647,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::0.00232259::HTS002,BRD-K43644456-001-04-0,0.00232259,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::0.00929035::HTS002,BRD-K43644456-001-04-0,0.00929035,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::0.0371614::HTS002,BRD-K43644456-001-04-0,0.0371614,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::0.148646::HTS002,BRD-K43644456-001-04-0,0.148646,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::0.594582::HTS002,BRD-K43644456-001-04-0,0.594582,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::2.37833::HTS002,BRD-K43644456-001-04-0,2.37833,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43644456-001-04-0::9.51332::HTS002,BRD-K43644456-001-04-0,9.51332,HTS002,PREP040,WP1130,deubiquitinase inhibitor,"JAK2, UCHL5, USP14, USP9X",NA,NA,"CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",Preclinical
BRD-K43860855-065-11-9::0.000610352::HTS002,BRD-K43860855-065-11-9,0.000610352,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::0.00244141::HTS002,BRD-K43860855-065-11-9,0.00244141,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::0.00976562::HTS002,BRD-K43860855-065-11-9,0.00976562,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::0.0390625::HTS002,BRD-K43860855-065-11-9,0.0390625,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::0.15625::HTS002,BRD-K43860855-065-11-9,0.15625,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::0.625::HTS002,BRD-K43860855-065-11-9,0.625,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::2.5::HTS002,BRD-K43860855-065-11-9,2.5,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43860855-065-11-9::10::HTS002,BRD-K43860855-065-11-9,10.0,HTS002,PREP022,iobenguane,antineoplastic agent,NA,"oncology, cardiology, endocrinology","neuroblastoma, congestive heart failure, pheochromocytoma","NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1",Launched
BRD-K43905307-001-01-2::0.00061034::HTS002,BRD-K43905307-001-01-2,0.00061034,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::0.0024414::HTS002,BRD-K43905307-001-01-2,0.0024414,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::0.00976562::HTS002,BRD-K43905307-001-01-2,0.00976562,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::0.0390625::HTS002,BRD-K43905307-001-01-2,0.0390625,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::0.15625::HTS002,BRD-K43905307-001-01-2,0.15625,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::0.625::HTS002,BRD-K43905307-001-01-2,0.625,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::2.5::HTS002,BRD-K43905307-001-01-2,2.5,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K43905307-001-01-2::10::HTS002,BRD-K43905307-001-01-2,10.0,HTS002,PREP041,"L-798,106",prostanoid receptor antagonist,PTGER3,NA,NA,"COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",Preclinical
BRD-K44067360-001-30-3::0.00061034::HTS002,BRD-K44067360-001-30-3,0.00061034,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::0.0024414::HTS002,BRD-K44067360-001-30-3,0.0024414,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::0.00976562::HTS002,BRD-K44067360-001-30-3,0.00976562,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::0.0390625::HTS002,BRD-K44067360-001-30-3,0.0390625,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::0.15625::HTS002,BRD-K44067360-001-30-3,0.15625,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::0.625::HTS002,BRD-K44067360-001-30-3,0.625,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::2.5::HTS002,BRD-K44067360-001-30-3,2.5,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44067360-001-30-3::10::HTS002,BRD-K44067360-001-30-3,10.0,HTS002,PREP014,flufenamic-acid,chloride channel blocker,"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5",NA,NA,"OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",Preclinical
BRD-K44084986-300-08-4::0.00061034::HTS002,BRD-K44084986-300-08-4,0.00061034,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::0.0024414::HTS002,BRD-K44084986-300-08-4,0.0024414,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::0.00976562::HTS002,BRD-K44084986-300-08-4,0.00976562,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::0.0390625::HTS002,BRD-K44084986-300-08-4,0.0390625,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::0.15625::HTS002,BRD-K44084986-300-08-4,0.15625,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::0.625::HTS002,BRD-K44084986-300-08-4,0.625,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::2.5::HTS002,BRD-K44084986-300-08-4,2.5,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44084986-300-08-4::10::HTS002,BRD-K44084986-300-08-4,10.0,HTS002,PREP044,Y-27632,rho associated kinase inhibitor,"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2",NA,NA,"C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",Preclinical
BRD-K44227013-001-06-4::0.00061034::HTS002,BRD-K44227013-001-06-4,0.00061034,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.0024414::HTS002,BRD-K44227013-001-06-4,0.0024414,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.00976562::HTS002,BRD-K44227013-001-06-4,0.00976562,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.0390625::HTS002,BRD-K44227013-001-06-4,0.0390625,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.15625::HTS002,BRD-K44227013-001-06-4,0.15625,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::0.625::HTS002,BRD-K44227013-001-06-4,0.625,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::2.5::HTS002,BRD-K44227013-001-06-4,2.5,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44227013-001-06-4::10::HTS002,BRD-K44227013-001-06-4,10.0,HTS002,PREP031,ponatinib,"Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1",Launched
BRD-K44408410-001-17-6::0.00061034::HTS002,BRD-K44408410-001-17-6,0.00061034,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.0024414::HTS002,BRD-K44408410-001-17-6,0.0024414,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.00976562::HTS002,BRD-K44408410-001-17-6,0.00976562,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.0390625::HTS002,BRD-K44408410-001-17-6,0.0390625,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.15625::HTS002,BRD-K44408410-001-17-6,0.15625,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::0.625::HTS002,BRD-K44408410-001-17-6,0.625,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::2.5::HTS002,BRD-K44408410-001-17-6,2.5,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44408410-001-17-6::10::HTS002,BRD-K44408410-001-17-6,10.0,HTS002,PREP018,2-methoxyestradiol,hypoxia inducible factor inhibitor,"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB",NA,NA,"COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",Phase 2
BRD-K44590731-001-01-7::0.000610352::HTS002,BRD-K44590731-001-01-7,0.000610352,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::0.00244141::HTS002,BRD-K44590731-001-01-7,0.00244141,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::0.00976562::HTS002,BRD-K44590731-001-01-7,0.00976562,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::0.0390625::HTS002,BRD-K44590731-001-01-7,0.0390625,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::0.15625::HTS002,BRD-K44590731-001-01-7,0.15625,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::0.625::HTS002,BRD-K44590731-001-01-7,0.625,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::2.5::HTS002,BRD-K44590731-001-01-7,2.5,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44590731-001-01-7::10::HTS002,BRD-K44590731-001-01-7,10.0,HTS002,PREP044,TU-2100,NA,NA,NA,NA,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,Phase 2
BRD-K44665581-001-01-8::0.00061034::HTS002,BRD-K44665581-001-01-8,0.00061034,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::0.0024414::HTS002,BRD-K44665581-001-01-8,0.0024414,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::0.00976562::HTS002,BRD-K44665581-001-01-8,0.00976562,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::0.0390625::HTS002,BRD-K44665581-001-01-8,0.0390625,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::0.15625::HTS002,BRD-K44665581-001-01-8,0.15625,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::0.625::HTS002,BRD-K44665581-001-01-8,0.625,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::2.5::HTS002,BRD-K44665581-001-01-8,2.5,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44665581-001-01-8::10::HTS002,BRD-K44665581-001-01-8,10.0,HTS002,PREP015,bromosporine,bromodomain inhibitor,NA,NA,NA,"CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",Preclinical
BRD-K44827188-001-06-0::0.00061034::HTS002,BRD-K44827188-001-06-0,0.00061034,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.0024414::HTS002,BRD-K44827188-001-06-0,0.0024414,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.00976562::HTS002,BRD-K44827188-001-06-0,0.00976562,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.0390625::HTS002,BRD-K44827188-001-06-0,0.0390625,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.15625::HTS002,BRD-K44827188-001-06-0,0.15625,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::0.625::HTS002,BRD-K44827188-001-06-0,0.625,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::2.5::HTS002,BRD-K44827188-001-06-0,2.5,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44827188-001-06-0::10::HTS002,BRD-K44827188-001-06-0,10.0,HTS002,PREP029,vismodegib,"hedgehog pathway inhibitor, smoothened receptor antagonist",SMO,oncology,basal cell carcinoma (BCC),Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O,Launched
BRD-K44844162-001-01-6::0.00061034::HTS002,BRD-K44844162-001-01-6,0.00061034,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::0.0024414::HTS002,BRD-K44844162-001-01-6,0.0024414,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::0.00976562::HTS002,BRD-K44844162-001-01-6,0.00976562,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::0.0390625::HTS002,BRD-K44844162-001-01-6,0.0390625,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::0.15625::HTS002,BRD-K44844162-001-01-6,0.15625,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::0.625::HTS002,BRD-K44844162-001-01-6,0.625,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::2.5::HTS002,BRD-K44844162-001-01-6,2.5,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44844162-001-01-6::10::HTS002,BRD-K44844162-001-01-6,10.0,HTS002,PREP032,taselisib,PI3K inhibitor,PIK3CA,NA,NA,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,Phase 3
BRD-K44993696-001-12-3::0.00061034::HTS002,BRD-K44993696-001-12-3,0.00061034,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::0.0024414::HTS002,BRD-K44993696-001-12-3,0.0024414,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::0.00976562::HTS002,BRD-K44993696-001-12-3,0.00976562,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::0.0390625::HTS002,BRD-K44993696-001-12-3,0.0390625,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::0.15625::HTS002,BRD-K44993696-001-12-3,0.15625,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::0.625::HTS002,BRD-K44993696-001-12-3,0.625,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::2.5::HTS002,BRD-K44993696-001-12-3,2.5,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K44993696-001-12-3::10::HTS002,BRD-K44993696-001-12-3,10.0,HTS002,PREP042,atenolol-(-),adrenergic receptor antagonist,NA,NA,NA,"CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1",Phase 2
BRD-K45033733-001-12-2::0.00061034::HTS002,BRD-K45033733-001-12-2,0.00061034,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::0.0024414::HTS002,BRD-K45033733-001-12-2,0.0024414,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::0.00976562::HTS002,BRD-K45033733-001-12-2,0.00976562,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::0.0390625::HTS002,BRD-K45033733-001-12-2,0.0390625,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::0.15625::HTS002,BRD-K45033733-001-12-2,0.15625,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::0.625::HTS002,BRD-K45033733-001-12-2,0.625,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::2.5::HTS002,BRD-K45033733-001-12-2,2.5,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45033733-001-12-2::10::HTS002,BRD-K45033733-001-12-2,10.0,HTS002,PREP022,famciclovir,DNA polymerase inhibitor,NA,"dental, infectious disease","cold sore, genitial herpes, shingles","CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O",Launched
BRD-K45252063-001-13-6::0.00061034::HTS002,BRD-K45252063-001-13-6,0.00061034,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::0.0024414::HTS002,BRD-K45252063-001-13-6,0.0024414,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::0.00976562::HTS002,BRD-K45252063-001-13-6,0.00976562,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::0.0390625::HTS002,BRD-K45252063-001-13-6,0.0390625,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::0.15625::HTS002,BRD-K45252063-001-13-6,0.15625,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::0.625::HTS002,BRD-K45252063-001-13-6,0.625,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::2.5::HTS002,BRD-K45252063-001-13-6,2.5,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45252063-001-13-6::10::HTS002,BRD-K45252063-001-13-6,10.0,HTS002,PREP022,clofibrate,PPAR receptor agonist,"LPL, PPARA","endocrinology, cardiology","hyperlipidemia, cholesterol","CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1",Launched
BRD-K45293975-001-02-0::0.000610352::HTS002,BRD-K45293975-001-02-0,0.000610352,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::0.00244141::HTS002,BRD-K45293975-001-02-0,0.00244141,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::0.00976562::HTS002,BRD-K45293975-001-02-0,0.00976562,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::0.0390625::HTS002,BRD-K45293975-001-02-0,0.0390625,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::0.15625::HTS002,BRD-K45293975-001-02-0,0.15625,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::0.625::HTS002,BRD-K45293975-001-02-0,0.625,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::2.5::HTS002,BRD-K45293975-001-02-0,2.5,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45293975-001-02-0::10::HTS002,BRD-K45293975-001-02-0,10.0,HTS002,PREP044,7-hydroxystaurosporine,"CDK inhibitor, CHK inhibitor, PKC inhibitor","CHEK1, MARK3, PDPK1",NA,NA,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13,Phase 2
BRD-K45401373-001-20-9::0.000610733::HTS002,BRD-K45401373-001-20-9,0.000610733,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::0.00244293::HTS002,BRD-K45401373-001-20-9,0.00244293,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::0.00977173::HTS002,BRD-K45401373-001-20-9,0.00977173,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::0.0390869::HTS002,BRD-K45401373-001-20-9,0.0390869,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::0.156348::HTS002,BRD-K45401373-001-20-9,0.156348,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::0.625391::HTS002,BRD-K45401373-001-20-9,0.625391,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::2.50156::HTS002,BRD-K45401373-001-20-9,2.50156,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45401373-001-20-9::10.0063::HTS002,BRD-K45401373-001-20-9,10.0063,HTS002,PREP044,betulinic-acid,"apoptosis stimulant, NFkB pathway inhibitor",GPBAR1,NA,NA,"CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",Phase 1/Phase 2
BRD-K45446451-001-05-0::0.00061034::HTS002,BRD-K45446451-001-05-0,0.00061034,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::0.0024414::HTS002,BRD-K45446451-001-05-0,0.0024414,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::0.00976562::HTS002,BRD-K45446451-001-05-0,0.00976562,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::0.0390625::HTS002,BRD-K45446451-001-05-0,0.0390625,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::0.15625::HTS002,BRD-K45446451-001-05-0,0.15625,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::0.625::HTS002,BRD-K45446451-001-05-0,0.625,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::2.5::HTS002,BRD-K45446451-001-05-0,2.5,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45446451-001-05-0::10::HTS002,BRD-K45446451-001-05-0,10.0,HTS002,PREP040,JZL-184,monoacylglucerol lipase inhibitor,MGLL,NA,NA,"OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",Preclinical
BRD-K45462423-001-03-7::0.00061034::HTS002,BRD-K45462423-001-03-7,0.00061034,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::0.0024414::HTS002,BRD-K45462423-001-03-7,0.0024414,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::0.00976562::HTS002,BRD-K45462423-001-03-7,0.00976562,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::0.0390625::HTS002,BRD-K45462423-001-03-7,0.0390625,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::0.15625::HTS002,BRD-K45462423-001-03-7,0.15625,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::0.625::HTS002,BRD-K45462423-001-03-7,0.625,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::2.5::HTS002,BRD-K45462423-001-03-7,2.5,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45462423-001-03-7::10::HTS002,BRD-K45462423-001-03-7,10.0,HTS002,PREP036,VU0361737,glutamate receptor positive allosteric modulator,GRM4,NA,NA,"COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",Preclinical
BRD-K45528773-001-07-2::0.000632783::HTS002,BRD-K45528773-001-07-2,0.000632783,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::0.00253113::HTS002,BRD-K45528773-001-07-2,0.00253113,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::0.0101245::HTS002,BRD-K45528773-001-07-2,0.0101245,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::0.0404981::HTS002,BRD-K45528773-001-07-2,0.0404981,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::0.161993::HTS002,BRD-K45528773-001-07-2,0.161993,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::0.64797::HTS002,BRD-K45528773-001-07-2,0.64797,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::2.59188::HTS002,BRD-K45528773-001-07-2,2.59188,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45528773-001-07-2::10.3675::HTS002,BRD-K45528773-001-07-2,10.3675,HTS002,PREP040,M-344,HDAC inhibitor,NA,NA,NA,"CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",Preclinical
BRD-K45551181-001-02-1::0.000608034::HTS002,BRD-K45551181-001-02-1,0.000608034,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::0.00243214::HTS002,BRD-K45551181-001-02-1,0.00243214,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::0.00972855::HTS002,BRD-K45551181-001-02-1,0.00972855,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::0.0389142::HTS002,BRD-K45551181-001-02-1,0.0389142,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::0.155657::HTS002,BRD-K45551181-001-02-1,0.155657,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::0.622627::HTS002,BRD-K45551181-001-02-1,0.622627,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::2.49051::HTS002,BRD-K45551181-001-02-1,2.49051,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45551181-001-02-1::9.96203::HTS002,BRD-K45551181-001-02-1,9.96203,HTS002,PREP042,MPI-0479605,mitotic kinase inhibitor,TTK,NA,NA,"Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",Preclinical
BRD-K45662124-050-01-5::0.00061034::HTS002,BRD-K45662124-050-01-5,0.00061034,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::0.0024414::HTS002,BRD-K45662124-050-01-5,0.0024414,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::0.00976562::HTS002,BRD-K45662124-050-01-5,0.00976562,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::0.0390625::HTS002,BRD-K45662124-050-01-5,0.0390625,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::0.15625::HTS002,BRD-K45662124-050-01-5,0.15625,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::0.625::HTS002,BRD-K45662124-050-01-5,0.625,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::2.5::HTS002,BRD-K45662124-050-01-5,2.5,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45662124-050-01-5::10::HTS002,BRD-K45662124-050-01-5,10.0,HTS002,PREP041,3'-fluorobenzylspiperone,dopamine receptor ligand,DRD2,NA,NA,"Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",Preclinical
BRD-K45724504-001-01-6::0.000333156::HTS002,BRD-K45724504-001-01-6,0.000333156,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::0.00133263::HTS002,BRD-K45724504-001-01-6,0.00133263,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::0.0053305::HTS002,BRD-K45724504-001-01-6,0.0053305,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::0.021322::HTS002,BRD-K45724504-001-01-6,0.021322,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::0.085288::HTS002,BRD-K45724504-001-01-6,0.085288,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::0.341152::HTS002,BRD-K45724504-001-01-6,0.341152,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::1.36461::HTS002,BRD-K45724504-001-01-6,1.36461,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45724504-001-01-6::5.45843::HTS002,BRD-K45724504-001-01-6,5.45843,HTS002,PREP019,anguidine,protein synthesis inhibitor,SLC5A1,NA,NA,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,Phase 2
BRD-K45875383-001-01-2::0.00061034::HTS002,BRD-K45875383-001-01-2,0.00061034,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::0.0024414::HTS002,BRD-K45875383-001-01-2,0.0024414,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::0.00976562::HTS002,BRD-K45875383-001-01-2,0.00976562,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::0.0390625::HTS002,BRD-K45875383-001-01-2,0.0390625,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::0.15625::HTS002,BRD-K45875383-001-01-2,0.15625,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::0.625::HTS002,BRD-K45875383-001-01-2,0.625,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::2.5::HTS002,BRD-K45875383-001-01-2,2.5,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K45875383-001-01-2::10::HTS002,BRD-K45875383-001-01-2,10.0,HTS002,PREP046,XBD173,benzodiazepine receptor ligand,TSPO,NA,NA,"CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",Phase 2
BRD-K46386702-001-02-1::0.00061034::HTS002,BRD-K46386702-001-02-1,0.00061034,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.0024414::HTS002,BRD-K46386702-001-02-1,0.0024414,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.00976562::HTS002,BRD-K46386702-001-02-1,0.00976562,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.0390625::HTS002,BRD-K46386702-001-02-1,0.0390625,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.15625::HTS002,BRD-K46386702-001-02-1,0.15625,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::0.625::HTS002,BRD-K46386702-001-02-1,0.625,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::2.5::HTS002,BRD-K46386702-001-02-1,2.5,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46386702-001-02-1::10::HTS002,BRD-K46386702-001-02-1,10.0,HTS002,PREP019,ARRY-334543,EGFR inhibitor,ERBB2,NA,NA,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,Phase 2
BRD-K46392623-001-02-5::0.00061034::HTS002,BRD-K46392623-001-02-5,0.00061034,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::0.0024414::HTS002,BRD-K46392623-001-02-5,0.0024414,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::0.00976562::HTS002,BRD-K46392623-001-02-5,0.00976562,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::0.0390625::HTS002,BRD-K46392623-001-02-5,0.0390625,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::0.15625::HTS002,BRD-K46392623-001-02-5,0.15625,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::0.625::HTS002,BRD-K46392623-001-02-5,0.625,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::2.5::HTS002,BRD-K46392623-001-02-5,2.5,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46392623-001-02-5::10::HTS002,BRD-K46392623-001-02-5,10.0,HTS002,PREP040,TG-100713,PI3K inhibitor,NA,NA,NA,Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1,Preclinical
BRD-K46585355-001-14-3::0.00061034::HTS002,BRD-K46585355-001-14-3,0.00061034,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::0.0024414::HTS002,BRD-K46585355-001-14-3,0.0024414,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::0.00976562::HTS002,BRD-K46585355-001-14-3,0.00976562,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::0.0390625::HTS002,BRD-K46585355-001-14-3,0.0390625,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::0.15625::HTS002,BRD-K46585355-001-14-3,0.15625,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::0.625::HTS002,BRD-K46585355-001-14-3,0.625,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::2.5::HTS002,BRD-K46585355-001-14-3,2.5,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46585355-001-14-3::10::HTS002,BRD-K46585355-001-14-3,10.0,HTS002,PREP036,acetylsalicylsalicylic-acid,cyclooxygenase inhibitor,NA,NA,NA,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O,Preclinical
BRD-K46690591-001-01-2::0.000610352::HTS002,BRD-K46690591-001-01-2,0.000610352,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::0.00244141::HTS002,BRD-K46690591-001-01-2,0.00244141,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::0.00976562::HTS002,BRD-K46690591-001-01-2,0.00976562,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::0.0390625::HTS002,BRD-K46690591-001-01-2,0.0390625,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::0.15625::HTS002,BRD-K46690591-001-01-2,0.15625,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::0.625::HTS002,BRD-K46690591-001-01-2,0.625,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::2.5::HTS002,BRD-K46690591-001-01-2,2.5,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46690591-001-01-2::10::HTS002,BRD-K46690591-001-01-2,10.0,HTS002,PREP025,KP-1212,NA,NA,NA,NA,NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 2
BRD-K46937689-001-15-0::0.00061034::HTS002,BRD-K46937689-001-15-0,0.00061034,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::0.0024414::HTS002,BRD-K46937689-001-15-0,0.0024414,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::0.00976562::HTS002,BRD-K46937689-001-15-0,0.00976562,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::0.0390625::HTS002,BRD-K46937689-001-15-0,0.0390625,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::0.15625::HTS002,BRD-K46937689-001-15-0,0.15625,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::0.625::HTS002,BRD-K46937689-001-15-0,0.625,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::2.5::HTS002,BRD-K46937689-001-15-0,2.5,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K46937689-001-15-0::10::HTS002,BRD-K46937689-001-15-0,10.0,HTS002,PREP021,phenazone,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,"Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C",Launched
BRD-K47000838-001-01-6::0.000254521::HTS002,BRD-K47000838-001-01-6,0.000254521,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::0.00101808::HTS002,BRD-K47000838-001-01-6,0.00101808,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::0.00407234::HTS002,BRD-K47000838-001-01-6,0.00407234,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::0.0162894::HTS002,BRD-K47000838-001-01-6,0.0162894,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::0.0651574::HTS002,BRD-K47000838-001-01-6,0.0651574,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::0.26063::HTS002,BRD-K47000838-001-01-6,0.26063,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::1.04252::HTS002,BRD-K47000838-001-01-6,1.04252,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47000838-001-01-6::4.17007::HTS002,BRD-K47000838-001-01-6,4.17007,HTS002,PREP039,cytochalasin-b,microtubule inhibitor,ACTB,NA,NA,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,Phase 2
BRD-K47049295-300-01-5::0.00061034::HTS002,BRD-K47049295-300-01-5,0.00061034,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::0.0024414::HTS002,BRD-K47049295-300-01-5,0.0024414,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::0.00976562::HTS002,BRD-K47049295-300-01-5,0.00976562,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::0.0390625::HTS002,BRD-K47049295-300-01-5,0.0390625,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::0.15625::HTS002,BRD-K47049295-300-01-5,0.15625,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::0.625::HTS002,BRD-K47049295-300-01-5,0.625,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::2.5::HTS002,BRD-K47049295-300-01-5,2.5,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47049295-300-01-5::10::HTS002,BRD-K47049295-300-01-5,10.0,HTS002,PREP036,BAN-ORL-24,nociceptin/orphanin FQ receptor antagonist,OPRL1,NA,NA,"O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",Preclinical
BRD-K47079459-004-04-6::0.00061034::HTS002,BRD-K47079459-004-04-6,0.00061034,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::0.0024414::HTS002,BRD-K47079459-004-04-6,0.0024414,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::0.00976562::HTS002,BRD-K47079459-004-04-6,0.00976562,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::0.0390625::HTS002,BRD-K47079459-004-04-6,0.0390625,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::0.15625::HTS002,BRD-K47079459-004-04-6,0.15625,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::0.625::HTS002,BRD-K47079459-004-04-6,0.625,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::2.5::HTS002,BRD-K47079459-004-04-6,2.5,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47079459-004-04-6::10::HTS002,BRD-K47079459-004-04-6,10.0,HTS002,PREP031,cetrimonium,NA,NA,dermatology,cosmetic,"CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C",Launched
BRD-K47114202-001-14-6::0.000629748::HTS002,BRD-K47114202-001-14-6,0.000629748,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::0.00251899::HTS002,BRD-K47114202-001-14-6,0.00251899,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::0.010076::HTS002,BRD-K47114202-001-14-6,0.010076,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::0.0403039::HTS002,BRD-K47114202-001-14-6,0.0403039,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::0.161215::HTS002,BRD-K47114202-001-14-6,0.161215,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::0.644862::HTS002,BRD-K47114202-001-14-6,0.644862,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::2.57945::HTS002,BRD-K47114202-001-14-6,2.57945,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47114202-001-14-6::10.3178::HTS002,BRD-K47114202-001-14-6,10.3178,HTS002,PREP031,chlorogenic-acid,antioxidant,SLC37A4,"neurology/psychiatry, pulmonary, allergy","headache, chest congestion, allergic rhinitis","O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O",Launched
BRD-K47150025-001-05-3::0.00061034::HTS002,BRD-K47150025-001-05-3,0.00061034,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::0.0024414::HTS002,BRD-K47150025-001-05-3,0.0024414,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::0.00976562::HTS002,BRD-K47150025-001-05-3,0.00976562,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::0.0390625::HTS002,BRD-K47150025-001-05-3,0.0390625,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::0.15625::HTS002,BRD-K47150025-001-05-3,0.15625,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::0.625::HTS002,BRD-K47150025-001-05-3,0.625,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::2.5::HTS002,BRD-K47150025-001-05-3,2.5,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K47150025-001-05-3::10::HTS002,BRD-K47150025-001-05-3,10.0,HTS002,PREP015,KI-8751,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",Preclinical
BRD-K13049116-001-05-7::0.00061034::HTS002,BRD-K13049116-001-05-7,0.00061034,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::0.0024414::HTS002,BRD-K13049116-001-05-7,0.0024414,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::0.00976562::HTS002,BRD-K13049116-001-05-7,0.00976562,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::0.0390625::HTS002,BRD-K13049116-001-05-7,0.0390625,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::0.15625::HTS002,BRD-K13049116-001-05-7,0.15625,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::0.625::HTS002,BRD-K13049116-001-05-7,0.625,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::2.5::HTS002,BRD-K13049116-001-05-7,2.5,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K13049116-001-05-7::10::HTS002,BRD-K13049116-001-05-7,10.0,HTS002,PREP027,BMS-754807,IGF-1 inhibitor,"AKT1, IGF1R",NA,NA,"C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",Phase 2
BRD-K47337578-034-02-5::0.00061034::HTS002,BRD-K47337578-034-02-5,0.00061034,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::0.0024414::HTS002,BRD-K47337578-034-02-5,0.0024414,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::0.00976562::HTS002,BRD-K47337578-034-02-5,0.00976562,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::0.0390625::HTS002,BRD-K47337578-034-02-5,0.0390625,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::0.15625::HTS002,BRD-K47337578-034-02-5,0.15625,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::0.625::HTS002,BRD-K47337578-034-02-5,0.625,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::2.5::HTS002,BRD-K47337578-034-02-5,2.5,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47337578-034-02-5::10::HTS002,BRD-K47337578-034-02-5,10.0,HTS002,PREP043,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,serotonin receptor antagonist,HTR2A,NA,NA,"Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",Preclinical
BRD-K47557313-001-02-7::0.00061034::HTS002,BRD-K47557313-001-02-7,0.00061034,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::0.0024414::HTS002,BRD-K47557313-001-02-7,0.0024414,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::0.00976562::HTS002,BRD-K47557313-001-02-7,0.00976562,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::0.0390625::HTS002,BRD-K47557313-001-02-7,0.0390625,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::0.15625::HTS002,BRD-K47557313-001-02-7,0.15625,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::0.625::HTS002,BRD-K47557313-001-02-7,0.625,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::2.5::HTS002,BRD-K47557313-001-02-7,2.5,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47557313-001-02-7::10::HTS002,BRD-K47557313-001-02-7,10.0,HTS002,PREP033,LY2109761,TGF beta receptor inhibitor,"TGFBR1, TGFBR2",NA,NA,C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1,Preclinical
BRD-K47598052-001-15-8::0.00061034::HTS002,BRD-K47598052-001-15-8,0.00061034,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::0.0024414::HTS002,BRD-K47598052-001-15-8,0.0024414,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::0.00976562::HTS002,BRD-K47598052-001-15-8,0.00976562,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::0.0390625::HTS002,BRD-K47598052-001-15-8,0.0390625,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::0.15625::HTS002,BRD-K47598052-001-15-8,0.15625,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::0.625::HTS002,BRD-K47598052-001-15-8,0.625,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::2.5::HTS002,BRD-K47598052-001-15-8,2.5,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47598052-001-15-8::10::HTS002,BRD-K47598052-001-15-8,10.0,HTS002,PREP041,PP-1,src inhibitor,"HCK, RET",NA,NA,"Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",Preclinical
BRD-K47869605-001-32-0::0.00061034::HTS002,BRD-K47869605-001-32-0,0.00061034,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::0.0024414::HTS002,BRD-K47869605-001-32-0,0.0024414,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::0.00976562::HTS002,BRD-K47869605-001-32-0,0.00976562,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::0.0390625::HTS002,BRD-K47869605-001-32-0,0.0390625,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::0.15625::HTS002,BRD-K47869605-001-32-0,0.15625,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::0.625::HTS002,BRD-K47869605-001-32-0,0.625,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::2.5::HTS002,BRD-K47869605-001-32-0,2.5,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47869605-001-32-0::10::HTS002,BRD-K47869605-001-32-0,10.0,HTS002,PREP035,podophyllotoxin,"microtubule inhibitor, tubulin polymerization inhibitor","IGF1R, TOP2A, TUBA4A, TUBB",infectious disease,genital warts,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,Launched
BRD-K47878171-086-06-0::0.00061034::HTS002,BRD-K47878171-086-06-0,0.00061034,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::0.0024414::HTS002,BRD-K47878171-086-06-0,0.0024414,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::0.00976562::HTS002,BRD-K47878171-086-06-0,0.00976562,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::0.0390625::HTS002,BRD-K47878171-086-06-0,0.0390625,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::0.15625::HTS002,BRD-K47878171-086-06-0,0.15625,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::0.625::HTS002,BRD-K47878171-086-06-0,0.625,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::2.5::HTS002,BRD-K47878171-086-06-0,2.5,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47878171-086-06-0::10::HTS002,BRD-K47878171-086-06-0,10.0,HTS002,PREP029,bephenium-hydroxynaphthoate,anthelmintic agent,NA,infectious disease,ascariasis,"C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1",Launched
BRD-K47976015-001-01-2::0.00061034::HTS002,BRD-K47976015-001-01-2,0.00061034,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::0.0024414::HTS002,BRD-K47976015-001-01-2,0.0024414,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::0.00976562::HTS002,BRD-K47976015-001-01-2,0.00976562,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::0.0390625::HTS002,BRD-K47976015-001-01-2,0.0390625,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::0.15625::HTS002,BRD-K47976015-001-01-2,0.15625,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::0.625::HTS002,BRD-K47976015-001-01-2,0.625,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::2.5::HTS002,BRD-K47976015-001-01-2,2.5,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47976015-001-01-2::10::HTS002,BRD-K47976015-001-01-2,10.0,HTS002,PREP038,balapiravir,RNA polymerase inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-],Phase 2
BRD-K47978074-001-02-4::0.00061034::HTS002,BRD-K47978074-001-02-4,0.00061034,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::0.0024414::HTS002,BRD-K47978074-001-02-4,0.0024414,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::0.00976562::HTS002,BRD-K47978074-001-02-4,0.00976562,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::0.0390625::HTS002,BRD-K47978074-001-02-4,0.0390625,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::0.15625::HTS002,BRD-K47978074-001-02-4,0.15625,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::0.625::HTS002,BRD-K47978074-001-02-4,0.625,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::2.5::HTS002,BRD-K47978074-001-02-4,2.5,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K47978074-001-02-4::10::HTS002,BRD-K47978074-001-02-4,10.0,HTS002,PREP017,trometamol,NA,"AMD1, CANT1, DCN, NEIL1, VEGFA",NA,NA,"NC(CO)(CO)CO, NC(CO)(CO)CO",Launched
BRD-K48141473-001-01-7::0.00061034::HTS002,BRD-K48141473-001-01-7,0.00061034,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::0.0024414::HTS002,BRD-K48141473-001-01-7,0.0024414,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::0.00976562::HTS002,BRD-K48141473-001-01-7,0.00976562,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::0.0390625::HTS002,BRD-K48141473-001-01-7,0.0390625,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::0.15625::HTS002,BRD-K48141473-001-01-7,0.15625,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::0.625::HTS002,BRD-K48141473-001-01-7,0.625,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::2.5::HTS002,BRD-K48141473-001-01-7,2.5,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48141473-001-01-7::10::HTS002,BRD-K48141473-001-01-7,10.0,HTS002,PREP047,cebranopadol,opioid receptor agonist,"OPRL1, OPRM1",NA,NA,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,Phase 3
BRD-K48195801-001-01-6::0.000610352::HTS002,BRD-K48195801-001-01-6,0.000610352,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::0.00244141::HTS002,BRD-K48195801-001-01-6,0.00244141,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::0.00976562::HTS002,BRD-K48195801-001-01-6,0.00976562,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::0.0390625::HTS002,BRD-K48195801-001-01-6,0.0390625,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::0.15625::HTS002,BRD-K48195801-001-01-6,0.15625,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::0.625::HTS002,BRD-K48195801-001-01-6,0.625,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::2.5::HTS002,BRD-K48195801-001-01-6,2.5,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48195801-001-01-6::10::HTS002,BRD-K48195801-001-01-6,10.0,HTS002,PREP038,tecastemizole,histamine receptor antagonist,KCNH2,NA,NA,Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1,Phase 3
BRD-K48443249-001-01-0::0.00061034::HTS002,BRD-K48443249-001-01-0,0.00061034,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::0.0024414::HTS002,BRD-K48443249-001-01-0,0.0024414,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::0.00976562::HTS002,BRD-K48443249-001-01-0,0.00976562,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::0.0390625::HTS002,BRD-K48443249-001-01-0,0.0390625,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::0.15625::HTS002,BRD-K48443249-001-01-0,0.15625,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::0.625::HTS002,BRD-K48443249-001-01-0,0.625,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::2.5::HTS002,BRD-K48443249-001-01-0,2.5,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48443249-001-01-0::10::HTS002,BRD-K48443249-001-01-0,10.0,HTS002,PREP036,CNX-774,Bruton's tyrosine kinase (BTK) inhibitor,BTK,NA,NA,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,Preclinical
BRD-K48488978-001-05-3::0.00061034::HTS002,BRD-K48488978-001-05-3,0.00061034,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::0.0024414::HTS002,BRD-K48488978-001-05-3,0.0024414,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::0.00976562::HTS002,BRD-K48488978-001-05-3,0.00976562,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::0.0390625::HTS002,BRD-K48488978-001-05-3,0.0390625,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::0.15625::HTS002,BRD-K48488978-001-05-3,0.15625,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::0.625::HTS002,BRD-K48488978-001-05-3,0.625,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::2.5::HTS002,BRD-K48488978-001-05-3,2.5,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48488978-001-05-3::10::HTS002,BRD-K48488978-001-05-3,10.0,HTS002,PREP036,YM-201636,PI3K inhibitor,NA,NA,NA,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,Preclinical
BRD-K48578705-001-17-6::0.000610352::HTS002,BRD-K48578705-001-17-6,0.000610352,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::0.00244141::HTS002,BRD-K48578705-001-17-6,0.00244141,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::0.00976562::HTS002,BRD-K48578705-001-17-6,0.00976562,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::0.0390625::HTS002,BRD-K48578705-001-17-6,0.0390625,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::0.15625::HTS002,BRD-K48578705-001-17-6,0.15625,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::0.625::HTS002,BRD-K48578705-001-17-6,0.625,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::2.5::HTS002,BRD-K48578705-001-17-6,2.5,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48578705-001-17-6::10::HTS002,BRD-K48578705-001-17-6,10.0,HTS002,PREP033,methyldopa,adrenergic receptor agonist,"ADRA2A, ADRA2B, ADRA2C, DDC",cardiology,hypertension,"C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O",Launched
BRD-K48684885-001-04-2::0.00061034::HTS002,BRD-K48684885-001-04-2,0.00061034,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::0.0024414::HTS002,BRD-K48684885-001-04-2,0.0024414,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::0.00976562::HTS002,BRD-K48684885-001-04-2,0.00976562,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::0.0390625::HTS002,BRD-K48684885-001-04-2,0.0390625,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::0.15625::HTS002,BRD-K48684885-001-04-2,0.15625,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::0.625::HTS002,BRD-K48684885-001-04-2,0.625,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::2.5::HTS002,BRD-K48684885-001-04-2,2.5,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48684885-001-04-2::10::HTS002,BRD-K48684885-001-04-2,10.0,HTS002,PREP037,BAY-11-7085,NFkB pathway inhibitor,NFKBIA,NA,NA,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,Preclinical
BRD-K48826825-001-01-8::0.00061034::HTS002,BRD-K48826825-001-01-8,0.00061034,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::0.0024414::HTS002,BRD-K48826825-001-01-8,0.0024414,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::0.00976562::HTS002,BRD-K48826825-001-01-8,0.00976562,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::0.0390625::HTS002,BRD-K48826825-001-01-8,0.0390625,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::0.15625::HTS002,BRD-K48826825-001-01-8,0.15625,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::0.625::HTS002,BRD-K48826825-001-01-8,0.625,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::2.5::HTS002,BRD-K48826825-001-01-8,2.5,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48826825-001-01-8::10::HTS002,BRD-K48826825-001-01-8,10.0,HTS002,PREP033,S26948,PPAR receptor agonist,PPARG,NA,NA,"COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",Preclinical
BRD-K48988407-001-01-2::0.000610352::HTS002,BRD-K48988407-001-01-2,0.000610352,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::0.00244141::HTS002,BRD-K48988407-001-01-2,0.00244141,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::0.00976562::HTS002,BRD-K48988407-001-01-2,0.00976562,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::0.0390625::HTS002,BRD-K48988407-001-01-2,0.0390625,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::0.15625::HTS002,BRD-K48988407-001-01-2,0.15625,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::0.625::HTS002,BRD-K48988407-001-01-2,0.625,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::2.5::HTS002,BRD-K48988407-001-01-2,2.5,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K48988407-001-01-2::10::HTS002,BRD-K48988407-001-01-2,10.0,HTS002,PREP047,cytochlor,NA,NA,NA,NA,Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1,Phase 1
BRD-K49027941-001-01-1::0.00061034::HTS002,BRD-K49027941-001-01-1,0.00061034,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::0.0024414::HTS002,BRD-K49027941-001-01-1,0.0024414,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::0.00976562::HTS002,BRD-K49027941-001-01-1,0.00976562,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::0.0390625::HTS002,BRD-K49027941-001-01-1,0.0390625,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::0.15625::HTS002,BRD-K49027941-001-01-1,0.15625,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::0.625::HTS002,BRD-K49027941-001-01-1,0.625,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::2.5::HTS002,BRD-K49027941-001-01-1,2.5,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K49027941-001-01-1::10::HTS002,BRD-K49027941-001-01-1,10.0,HTS002,PREP041,PSB-1115,adenosine receptor antagonist,"ADORA1, ADORA2B, ADORA3",NA,NA,"CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",Preclinical
BRD-K44009692-001-02-3::0.00061034::HTS002,BRD-K44009692-001-02-3,0.00061034,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::0.0024414::HTS002,BRD-K44009692-001-02-3,0.0024414,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::0.00976562::HTS002,BRD-K44009692-001-02-3,0.00976562,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::0.0390625::HTS002,BRD-K44009692-001-02-3,0.0390625,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::0.15625::HTS002,BRD-K44009692-001-02-3,0.15625,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::0.625::HTS002,BRD-K44009692-001-02-3,0.625,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::2.5::HTS002,BRD-K44009692-001-02-3,2.5,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K44009692-001-02-3::10::HTS002,BRD-K44009692-001-02-3,10.0,HTS002,PREP046,hyodeoxycholic-acid,atherosclerosis formation inhibitor,NA,NA,NA,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Phase 1
BRD-K49049886-001-08-7::0.00061034::HTS002,BRD-K49049886-001-08-7,0.00061034,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.0024414::HTS002,BRD-K49049886-001-08-7,0.0024414,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.00976562::HTS002,BRD-K49049886-001-08-7,0.00976562,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.0390625::HTS002,BRD-K49049886-001-08-7,0.0390625,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.15625::HTS002,BRD-K49049886-001-08-7,0.15625,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.625::HTS002,BRD-K49049886-001-08-7,0.625,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::2.5::HTS002,BRD-K49049886-001-08-7,2.5,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::10::HTS002,BRD-K49049886-001-08-7,10.0,HTS002,PREP036,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49071277-001-04-7::0.00061034::HTS002,BRD-K49071277-001-04-7,0.00061034,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::0.0024414::HTS002,BRD-K49071277-001-04-7,0.0024414,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::0.00976562::HTS002,BRD-K49071277-001-04-7,0.00976562,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::0.0390625::HTS002,BRD-K49071277-001-04-7,0.0390625,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::0.15625::HTS002,BRD-K49071277-001-04-7,0.15625,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::0.625::HTS002,BRD-K49071277-001-04-7,0.625,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::2.5::HTS002,BRD-K49071277-001-04-7,2.5,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49071277-001-04-7::10::HTS002,BRD-K49071277-001-04-7,10.0,HTS002,PREP041,securinine,"GABA receptor antagonist, TP53 activator",GABRA1,NA,NA,O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,Preclinical
BRD-K49075727-001-08-5::0.00061034::HTS002,BRD-K49075727-001-08-5,0.00061034,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::0.0024414::HTS002,BRD-K49075727-001-08-5,0.0024414,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::0.00976562::HTS002,BRD-K49075727-001-08-5,0.00976562,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::0.0390625::HTS002,BRD-K49075727-001-08-5,0.0390625,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::0.15625::HTS002,BRD-K49075727-001-08-5,0.15625,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::0.625::HTS002,BRD-K49075727-001-08-5,0.625,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::2.5::HTS002,BRD-K49075727-001-08-5,2.5,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49075727-001-08-5::10::HTS002,BRD-K49075727-001-08-5,10.0,HTS002,PREP032,nintedanib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",pulmonary,idiopathic pulmonary fibrosis (IPF),"COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1",Launched
BRD-K49111258-003-29-7::0.00061034::HTS002,BRD-K49111258-003-29-7,0.00061034,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::0.0024414::HTS002,BRD-K49111258-003-29-7,0.0024414,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::0.00976562::HTS002,BRD-K49111258-003-29-7,0.00976562,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::0.0390625::HTS002,BRD-K49111258-003-29-7,0.0390625,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::0.15625::HTS002,BRD-K49111258-003-29-7,0.15625,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::0.625::HTS002,BRD-K49111258-003-29-7,0.625,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::2.5::HTS002,BRD-K49111258-003-29-7,2.5,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K49111258-003-29-7::10::HTS002,BRD-K49111258-003-29-7,10.0,HTS002,PREP031,prazosin,adrenergic receptor antagonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7",cardiology,hypertension,"COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1",Launched
BRD-K12251893-065-04-7::0.00061034::HTS002,BRD-K12251893-065-04-7,0.00061034,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::0.0024414::HTS002,BRD-K12251893-065-04-7,0.0024414,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::0.00976562::HTS002,BRD-K12251893-065-04-7,0.00976562,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::0.0390625::HTS002,BRD-K12251893-065-04-7,0.0390625,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::0.15625::HTS002,BRD-K12251893-065-04-7,0.15625,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::0.625::HTS002,BRD-K12251893-065-04-7,0.625,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::2.5::HTS002,BRD-K12251893-065-04-7,2.5,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K12251893-065-04-7::10::HTS002,BRD-K12251893-065-04-7,10.0,HTS002,PREP038,vincristine,tubulin polymerization inhibitor,"TUBA4A, TUBB",hematologic malignancy,acute lymphoblastic leukemia (ALL),"CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K49294207-300-03-8::0.00061034::HTS002,BRD-K49294207-300-03-8,0.00061034,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::0.0024414::HTS002,BRD-K49294207-300-03-8,0.0024414,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::0.00976562::HTS002,BRD-K49294207-300-03-8,0.00976562,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::0.0390625::HTS002,BRD-K49294207-300-03-8,0.0390625,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::0.15625::HTS002,BRD-K49294207-300-03-8,0.15625,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::0.625::HTS002,BRD-K49294207-300-03-8,0.625,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::2.5::HTS002,BRD-K49294207-300-03-8,2.5,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49294207-300-03-8::10::HTS002,BRD-K49294207-300-03-8,10.0,HTS002,PREP037,BIBU-1361,EGFR inhibitor,EGFR,NA,NA,"CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Preclinical
BRD-K49313711-001-05-4::0.00061034::HTS002,BRD-K49313711-001-05-4,0.00061034,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::0.0024414::HTS002,BRD-K49313711-001-05-4,0.0024414,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::0.00976562::HTS002,BRD-K49313711-001-05-4,0.00976562,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::0.0390625::HTS002,BRD-K49313711-001-05-4,0.0390625,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::0.15625::HTS002,BRD-K49313711-001-05-4,0.15625,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::0.625::HTS002,BRD-K49313711-001-05-4,0.625,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::2.5::HTS002,BRD-K49313711-001-05-4,2.5,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49313711-001-05-4::10::HTS002,BRD-K49313711-001-05-4,10.0,HTS002,PREP043,ribitol,NA,NA,NA,NA,OC[C@H](O)[C@H](O)[C@H](O)CO,Preclinical
BRD-K49328571-001-15-0::0.00061034::HTS002,BRD-K49328571-001-15-0,0.00061034,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.0024414::HTS002,BRD-K49328571-001-15-0,0.0024414,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.00976562::HTS002,BRD-K49328571-001-15-0,0.00976562,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.0390625::HTS002,BRD-K49328571-001-15-0,0.0390625,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.15625::HTS002,BRD-K49328571-001-15-0,0.15625,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::0.625::HTS002,BRD-K49328571-001-15-0,0.625,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::2.5::HTS002,BRD-K49328571-001-15-0,2.5,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49328571-001-15-0::10::HTS002,BRD-K49328571-001-15-0,10.0,HTS002,PREP022,dasatinib,"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1",hematologic malignancy,"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1",Launched
BRD-K49350383-001-13-7::0.00061034::HTS002,BRD-K49350383-001-13-7,0.00061034,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::0.0024414::HTS002,BRD-K49350383-001-13-7,0.0024414,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::0.00976562::HTS002,BRD-K49350383-001-13-7,0.00976562,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::0.0390625::HTS002,BRD-K49350383-001-13-7,0.0390625,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::0.15625::HTS002,BRD-K49350383-001-13-7,0.15625,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::0.625::HTS002,BRD-K49350383-001-13-7,0.625,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::2.5::HTS002,BRD-K49350383-001-13-7,2.5,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49350383-001-13-7::10::HTS002,BRD-K49350383-001-13-7,10.0,HTS002,PREP028,thioguanine,purine antagonist,"IMPDH1, IMPDH2",hematologic malignancy,acute myeloid leukemia (AML),"Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1",Launched
BRD-K49371609-003-03-8::0.00061034::HTS002,BRD-K49371609-003-03-8,0.00061034,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::0.0024414::HTS002,BRD-K49371609-003-03-8,0.0024414,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::0.00976562::HTS002,BRD-K49371609-003-03-8,0.00976562,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::0.0390625::HTS002,BRD-K49371609-003-03-8,0.0390625,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::0.15625::HTS002,BRD-K49371609-003-03-8,0.15625,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::0.625::HTS002,BRD-K49371609-003-03-8,0.625,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::2.5::HTS002,BRD-K49371609-003-03-8,2.5,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49371609-003-03-8::10::HTS002,BRD-K49371609-003-03-8,10.0,HTS002,PREP036,PIK-75,"DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,Preclinical
BRD-K49456274-001-01-9::0.00061034::HTS002,BRD-K49456274-001-01-9,0.00061034,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::0.0024414::HTS002,BRD-K49456274-001-01-9,0.0024414,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::0.00976562::HTS002,BRD-K49456274-001-01-9,0.00976562,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::0.0390625::HTS002,BRD-K49456274-001-01-9,0.0390625,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::0.15625::HTS002,BRD-K49456274-001-01-9,0.15625,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::0.625::HTS002,BRD-K49456274-001-01-9,0.625,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::2.5::HTS002,BRD-K49456274-001-01-9,2.5,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49456274-001-01-9::10::HTS002,BRD-K49456274-001-01-9,10.0,HTS002,PREP039,pilaralisib,PI3K inhibitor,NA,NA,NA,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,Phase 2
BRD-K49555808-001-03-9::0.00061034::HTS002,BRD-K49555808-001-03-9,0.00061034,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::0.0024414::HTS002,BRD-K49555808-001-03-9,0.0024414,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::0.00976562::HTS002,BRD-K49555808-001-03-9,0.00976562,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::0.0390625::HTS002,BRD-K49555808-001-03-9,0.0390625,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::0.15625::HTS002,BRD-K49555808-001-03-9,0.15625,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::0.625::HTS002,BRD-K49555808-001-03-9,0.625,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::2.5::HTS002,BRD-K49555808-001-03-9,2.5,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49555808-001-03-9::10::HTS002,BRD-K49555808-001-03-9,10.0,HTS002,PREP024,BMS-707035,HIV integrase inhibitor,NA,NA,NA,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,Phase 2
BRD-K49669041-001-08-4::0.00061034::HTS002,BRD-K49669041-001-08-4,0.00061034,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::0.0024414::HTS002,BRD-K49669041-001-08-4,0.0024414,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::0.00976562::HTS002,BRD-K49669041-001-08-4,0.00976562,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::0.0390625::HTS002,BRD-K49669041-001-08-4,0.0390625,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::0.15625::HTS002,BRD-K49669041-001-08-4,0.15625,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::0.625::HTS002,BRD-K49669041-001-08-4,0.625,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::2.5::HTS002,BRD-K49669041-001-08-4,2.5,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49669041-001-08-4::10::HTS002,BRD-K49669041-001-08-4,10.0,HTS002,PREP043,BX-912,pyruvate dehydrogenase kinase inhibitor,"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1",NA,NA,Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1,Preclinical
BRD-K49759007-001-11-9::0.00061034::HTS002,BRD-K49759007-001-11-9,0.00061034,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::0.0024414::HTS002,BRD-K49759007-001-11-9,0.0024414,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::0.00976562::HTS002,BRD-K49759007-001-11-9,0.00976562,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::0.0390625::HTS002,BRD-K49759007-001-11-9,0.0390625,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::0.15625::HTS002,BRD-K49759007-001-11-9,0.15625,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::0.625::HTS002,BRD-K49759007-001-11-9,0.625,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::2.5::HTS002,BRD-K49759007-001-11-9,2.5,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49759007-001-11-9::10::HTS002,BRD-K49759007-001-11-9,10.0,HTS002,PREP014,4-hydroxy-phenazone,NA,NA,NA,NA,Cc1c(O)c(=O)n(-c2ccccc2)n1C,Preclinical
BRD-K49840922-001-05-1::0.000610352::HTS002,BRD-K49840922-001-05-1,0.000610352,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::0.00244141::HTS002,BRD-K49840922-001-05-1,0.00244141,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::0.00976562::HTS002,BRD-K49840922-001-05-1,0.00976562,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::0.0390625::HTS002,BRD-K49840922-001-05-1,0.0390625,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::0.15625::HTS002,BRD-K49840922-001-05-1,0.15625,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::0.625::HTS002,BRD-K49840922-001-05-1,0.625,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::2.5::HTS002,BRD-K49840922-001-05-1,2.5,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49840922-001-05-1::10::HTS002,BRD-K49840922-001-05-1,10.0,HTS002,PREP023,etofylline-clofibrate,platelet aggregation inhibitor,PPARA,NA,NA,Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O,Launched
BRD-K49865102-001-08-4::0.00061034::HTS002,BRD-K49865102-001-08-4,0.00061034,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::0.0024414::HTS002,BRD-K49865102-001-08-4,0.0024414,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::0.00976562::HTS002,BRD-K49865102-001-08-4,0.00976562,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::0.0390625::HTS002,BRD-K49865102-001-08-4,0.0390625,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::0.15625::HTS002,BRD-K49865102-001-08-4,0.15625,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::0.625::HTS002,BRD-K49865102-001-08-4,0.625,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::2.5::HTS002,BRD-K49865102-001-08-4,2.5,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49865102-001-08-4::10::HTS002,BRD-K49865102-001-08-4,10.0,HTS002,PREP033,PD-0325901,MEK inhibitor,MAP2K1,NA,NA,OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,Phase 2
BRD-K49954789-001-02-9::0.00061034::HTS002,BRD-K49954789-001-02-9,0.00061034,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::0.0024414::HTS002,BRD-K49954789-001-02-9,0.0024414,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::0.00976562::HTS002,BRD-K49954789-001-02-9,0.00976562,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::0.0390625::HTS002,BRD-K49954789-001-02-9,0.0390625,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::0.15625::HTS002,BRD-K49954789-001-02-9,0.15625,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::0.625::HTS002,BRD-K49954789-001-02-9,0.625,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::2.5::HTS002,BRD-K49954789-001-02-9,2.5,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K49954789-001-02-9::10::HTS002,BRD-K49954789-001-02-9,10.0,HTS002,PREP034,mesna,antioxidant,NA,urology,hemorrhagic cystitis,"OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS",Launched
BRD-K50000283-001-04-4::0.00061034::HTS002,BRD-K50000283-001-04-4,0.00061034,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::0.0024414::HTS002,BRD-K50000283-001-04-4,0.0024414,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::0.00976562::HTS002,BRD-K50000283-001-04-4,0.00976562,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::0.0390625::HTS002,BRD-K50000283-001-04-4,0.0390625,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::0.15625::HTS002,BRD-K50000283-001-04-4,0.15625,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::0.625::HTS002,BRD-K50000283-001-04-4,0.625,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::2.5::HTS002,BRD-K50000283-001-04-4,2.5,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50000283-001-04-4::10::HTS002,BRD-K50000283-001-04-4,10.0,HTS002,PREP040,PHA-767491,CDC inhibitor,"CDK1, RPS6KB1",NA,NA,"O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",Preclinical
BRD-K50018155-003-02-1::0.00061034::HTS002,BRD-K50018155-003-02-1,0.00061034,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::0.0024414::HTS002,BRD-K50018155-003-02-1,0.0024414,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::0.00976562::HTS002,BRD-K50018155-003-02-1,0.00976562,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::0.0390625::HTS002,BRD-K50018155-003-02-1,0.0390625,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::0.15625::HTS002,BRD-K50018155-003-02-1,0.15625,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::0.625::HTS002,BRD-K50018155-003-02-1,0.625,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::2.5::HTS002,BRD-K50018155-003-02-1,2.5,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50018155-003-02-1::10::HTS002,BRD-K50018155-003-02-1,10.0,HTS002,PREP044,RS-67506,serotonin receptor partial agonist,HTR4,NA,NA,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,Preclinical
BRD-K50140147-001-10-1::0.00061034::HTS002,BRD-K50140147-001-10-1,0.00061034,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::0.0024414::HTS002,BRD-K50140147-001-10-1,0.0024414,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::0.00976562::HTS002,BRD-K50140147-001-10-1,0.00976562,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::0.0390625::HTS002,BRD-K50140147-001-10-1,0.0390625,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::0.15625::HTS002,BRD-K50140147-001-10-1,0.15625,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::0.625::HTS002,BRD-K50140147-001-10-1,0.625,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::2.5::HTS002,BRD-K50140147-001-10-1,2.5,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50140147-001-10-1::10::HTS002,BRD-K50140147-001-10-1,10.0,HTS002,PREP042,NVP-TAE684,ALK tyrosine kinase receptor inhibitor,"ALK, INSR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1,Preclinical
BRD-K50168500-001-07-9::0.00061034::HTS002,BRD-K50168500-001-07-9,0.00061034,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.0024414::HTS002,BRD-K50168500-001-07-9,0.0024414,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.00976562::HTS002,BRD-K50168500-001-07-9,0.00976562,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.0390625::HTS002,BRD-K50168500-001-07-9,0.0390625,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.15625::HTS002,BRD-K50168500-001-07-9,0.15625,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::0.625::HTS002,BRD-K50168500-001-07-9,0.625,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::2.5::HTS002,BRD-K50168500-001-07-9,2.5,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50168500-001-07-9::10::HTS002,BRD-K50168500-001-07-9,10.0,HTS002,PREP019,canertinib,EGFR inhibitor,"AKT1, EGFR, ERBB2, ERBB4",NA,NA,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,Phase 3
BRD-K50388907-001-30-4::0.00061034::HTS002,BRD-K50388907-001-30-4,0.00061034,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::0.0024414::HTS002,BRD-K50388907-001-30-4,0.0024414,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::0.00976562::HTS002,BRD-K50388907-001-30-4,0.00976562,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::0.0390625::HTS002,BRD-K50388907-001-30-4,0.0390625,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::0.15625::HTS002,BRD-K50388907-001-30-4,0.15625,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::0.625::HTS002,BRD-K50388907-001-30-4,0.625,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::2.5::HTS002,BRD-K50388907-001-30-4,2.5,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50388907-001-30-4::10::HTS002,BRD-K50388907-001-30-4,10.0,HTS002,PREP031,fenofibrate,PPAR receptor agonist,"MMP25, PPARA",endocrinology,"hypercholesterolemia, hypertriglyceridemia","CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1",Launched
BRD-K50590187-001-19-9::0.00061034::HTS002,BRD-K50590187-001-19-9,0.00061034,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::0.0024414::HTS002,BRD-K50590187-001-19-9,0.0024414,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::0.00976562::HTS002,BRD-K50590187-001-19-9,0.00976562,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::0.0390625::HTS002,BRD-K50590187-001-19-9,0.0390625,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::0.15625::HTS002,BRD-K50590187-001-19-9,0.15625,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::0.625::HTS002,BRD-K50590187-001-19-9,0.625,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::2.5::HTS002,BRD-K50590187-001-19-9,2.5,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50590187-001-19-9::10::HTS002,BRD-K50590187-001-19-9,10.0,HTS002,PREP023,capsaicin,TRPV agonist,"CFTR, TRPV1","neurology/psychiatry, rheumatology","muscle pain, rheumatoid arthritis","COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O",Launched
BRD-K50677762-001-01-5::0.00061034::HTS002,BRD-K50677762-001-01-5,0.00061034,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.0024414::HTS002,BRD-K50677762-001-01-5,0.0024414,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.00976562::HTS002,BRD-K50677762-001-01-5,0.00976562,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.0390625::HTS002,BRD-K50677762-001-01-5,0.0390625,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.15625::HTS002,BRD-K50677762-001-01-5,0.15625,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.625::HTS002,BRD-K50677762-001-01-5,0.625,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::2.5::HTS002,BRD-K50677762-001-01-5,2.5,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::10::HTS002,BRD-K50677762-001-01-5,10.0,HTS002,PREP031,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50850824-237-04-8::0.000610352::HTS002,BRD-K50850824-237-04-8,0.000610352,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::0.00244141::HTS002,BRD-K50850824-237-04-8,0.00244141,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::0.00976562::HTS002,BRD-K50850824-237-04-8,0.00976562,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::0.0390625::HTS002,BRD-K50850824-237-04-8,0.0390625,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::0.15625::HTS002,BRD-K50850824-237-04-8,0.15625,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::0.625::HTS002,BRD-K50850824-237-04-8,0.625,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::2.5::HTS002,BRD-K50850824-237-04-8,2.5,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K50850824-237-04-8::10::HTS002,BRD-K50850824-237-04-8,10.0,HTS002,PREP039,acesulfame-potassium,NA,NA,NA,NA,"CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1",Phase 3
BRD-K51040301-001-02-1::0.00061034::HTS002,BRD-K51040301-001-02-1,0.00061034,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::0.0024414::HTS002,BRD-K51040301-001-02-1,0.0024414,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::0.00976562::HTS002,BRD-K51040301-001-02-1,0.00976562,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::0.0390625::HTS002,BRD-K51040301-001-02-1,0.0390625,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::0.15625::HTS002,BRD-K51040301-001-02-1,0.15625,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::0.625::HTS002,BRD-K51040301-001-02-1,0.625,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::2.5::HTS002,BRD-K51040301-001-02-1,2.5,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51040301-001-02-1::10::HTS002,BRD-K51040301-001-02-1,10.0,HTS002,PREP030,cobicistat,cytochrome P450 inhibitor,"CYP3A4, CYP3A43, CYP3A5, CYP3A7",infectious disease,human immunodeficiency virus (HIV-1),CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,Launched
BRD-K51143828-003-03-1::0.00061034::HTS002,BRD-K51143828-003-03-1,0.00061034,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::0.0024414::HTS002,BRD-K51143828-003-03-1,0.0024414,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::0.00976562::HTS002,BRD-K51143828-003-03-1,0.00976562,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::0.0390625::HTS002,BRD-K51143828-003-03-1,0.0390625,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::0.15625::HTS002,BRD-K51143828-003-03-1,0.15625,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::0.625::HTS002,BRD-K51143828-003-03-1,0.625,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::2.5::HTS002,BRD-K51143828-003-03-1,2.5,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51143828-003-03-1::10::HTS002,BRD-K51143828-003-03-1,10.0,HTS002,PREP033,lurasidone,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7",neurology/psychiatry,schizophrenia,O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12,Launched
BRD-K51199656-003-01-4::0.000610352::HTS002,BRD-K51199656-003-01-4,0.000610352,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::0.00244141::HTS002,BRD-K51199656-003-01-4,0.00244141,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::0.00976562::HTS002,BRD-K51199656-003-01-4,0.00976562,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::0.0390625::HTS002,BRD-K51199656-003-01-4,0.0390625,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::0.15625::HTS002,BRD-K51199656-003-01-4,0.15625,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::0.625::HTS002,BRD-K51199656-003-01-4,0.625,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::2.5::HTS002,BRD-K51199656-003-01-4,2.5,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51199656-003-01-4::10::HTS002,BRD-K51199656-003-01-4,10.0,HTS002,PREP023,fluoromethylcholine,NA,NA,NA,NA,C[N+](C)(CF)CCO,Launched
BRD-K51313569-003-03-3::0.00061034::HTS002,BRD-K51313569-003-03-3,0.00061034,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::0.0024414::HTS002,BRD-K51313569-003-03-3,0.0024414,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::0.00976562::HTS002,BRD-K51313569-003-03-3,0.00976562,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::0.0390625::HTS002,BRD-K51313569-003-03-3,0.0390625,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::0.15625::HTS002,BRD-K51313569-003-03-3,0.15625,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::0.625::HTS002,BRD-K51313569-003-03-3,0.625,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::2.5::HTS002,BRD-K51313569-003-03-3,2.5,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51313569-003-03-3::10::HTS002,BRD-K51313569-003-03-3,10.0,HTS002,PREP021,palbociclib,CDK inhibitor,"CDK4, CDK6",oncology,breast cancer,"CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O",Launched
BRD-K51318897-001-15-3::0.00061034::HTS002,BRD-K51318897-001-15-3,0.00061034,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::0.0024414::HTS002,BRD-K51318897-001-15-3,0.0024414,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::0.00976562::HTS002,BRD-K51318897-001-15-3,0.00976562,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::0.0390625::HTS002,BRD-K51318897-001-15-3,0.0390625,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::0.15625::HTS002,BRD-K51318897-001-15-3,0.15625,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::0.625::HTS002,BRD-K51318897-001-15-3,0.625,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::2.5::HTS002,BRD-K51318897-001-15-3,2.5,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51318897-001-15-3::10::HTS002,BRD-K51318897-001-15-3,10.0,HTS002,PREP021,fenbendazole,tubulin polymerization inhibitor,TUBB,infectious disease,"gastrointestinal parasites, gastrointestinal roundworms","COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1",Launched
BRD-K51324732-001-01-0::0.000610352::HTS002,BRD-K51324732-001-01-0,0.000610352,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::0.00244141::HTS002,BRD-K51324732-001-01-0,0.00244141,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::0.00976562::HTS002,BRD-K51324732-001-01-0,0.00976562,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::0.0390625::HTS002,BRD-K51324732-001-01-0,0.0390625,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::0.15625::HTS002,BRD-K51324732-001-01-0,0.15625,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::0.625::HTS002,BRD-K51324732-001-01-0,0.625,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::2.5::HTS002,BRD-K51324732-001-01-0,2.5,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51324732-001-01-0::10::HTS002,BRD-K51324732-001-01-0,10.0,HTS002,PREP018,meglitinide,potassium channel blocker,CCR2,NA,NA,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O,Phase 2
BRD-K51350053-048-16-5::0.00061034::HTS002,BRD-K51350053-048-16-5,0.00061034,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::0.0024414::HTS002,BRD-K51350053-048-16-5,0.0024414,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::0.00976562::HTS002,BRD-K51350053-048-16-5,0.00976562,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::0.0390625::HTS002,BRD-K51350053-048-16-5,0.0390625,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::0.15625::HTS002,BRD-K51350053-048-16-5,0.15625,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::0.625::HTS002,BRD-K51350053-048-16-5,0.625,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::2.5::HTS002,BRD-K51350053-048-16-5,2.5,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51350053-048-16-5::10::HTS002,BRD-K51350053-048-16-5,10.0,HTS002,PREP030,toremifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)",ESR1,oncology,breast cancer,"CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1",Launched
BRD-K51471001-303-04-7::0.00061034::HTS002,BRD-K51471001-303-04-7,0.00061034,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::0.0024414::HTS002,BRD-K51471001-303-04-7,0.0024414,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::0.00976562::HTS002,BRD-K51471001-303-04-7,0.00976562,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::0.0390625::HTS002,BRD-K51471001-303-04-7,0.0390625,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::0.15625::HTS002,BRD-K51471001-303-04-7,0.15625,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::0.625::HTS002,BRD-K51471001-303-04-7,0.625,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::2.5::HTS002,BRD-K51471001-303-04-7,2.5,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51471001-303-04-7::10::HTS002,BRD-K51471001-303-04-7,10.0,HTS002,PREP015,demecarium,acetylcholinesterase inhibitor,"ACHE, BCHE",ophthalmology,"intraocular pressure, glaucoma",CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,Launched
BRD-K51474575-001-10-4::0.00061034::HTS002,BRD-K51474575-001-10-4,0.00061034,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::0.0024414::HTS002,BRD-K51474575-001-10-4,0.0024414,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::0.00976562::HTS002,BRD-K51474575-001-10-4,0.00976562,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::0.0390625::HTS002,BRD-K51474575-001-10-4,0.0390625,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::0.15625::HTS002,BRD-K51474575-001-10-4,0.15625,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::0.625::HTS002,BRD-K51474575-001-10-4,0.625,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::2.5::HTS002,BRD-K51474575-001-10-4,2.5,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51474575-001-10-4::10::HTS002,BRD-K51474575-001-10-4,10.0,HTS002,PREP024,taurine,antioxidant,NA,neurology/psychiatry,"anxiety, irritability, sleeplessness","NCCS(O)(=O)=O, NCCS(O)(=O)=O",Launched
BRD-K51544265-001-04-2::0.00061034::HTS002,BRD-K51544265-001-04-2,0.00061034,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::0.0024414::HTS002,BRD-K51544265-001-04-2,0.0024414,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::0.00976562::HTS002,BRD-K51544265-001-04-2,0.00976562,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::0.0390625::HTS002,BRD-K51544265-001-04-2,0.0390625,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::0.15625::HTS002,BRD-K51544265-001-04-2,0.15625,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::0.625::HTS002,BRD-K51544265-001-04-2,0.625,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::2.5::HTS002,BRD-K51544265-001-04-2,2.5,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51544265-001-04-2::10::HTS002,BRD-K51544265-001-04-2,10.0,HTS002,PREP016,cabozantinib,"RET tyrosine kinase inhibitor, VEGFR inhibitor","KDR, MET",oncology,medullary thyroid cancer (MTC),"COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC",Launched
BRD-K51575138-001-13-2::0.00061034::HTS002,BRD-K51575138-001-13-2,0.00061034,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::0.0024414::HTS002,BRD-K51575138-001-13-2,0.0024414,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::0.00976562::HTS002,BRD-K51575138-001-13-2,0.00976562,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::0.0390625::HTS002,BRD-K51575138-001-13-2,0.0390625,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::0.15625::HTS002,BRD-K51575138-001-13-2,0.15625,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::0.625::HTS002,BRD-K51575138-001-13-2,0.625,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::2.5::HTS002,BRD-K51575138-001-13-2,2.5,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51575138-001-13-2::10::HTS002,BRD-K51575138-001-13-2,10.0,HTS002,PREP043,TPCA-1,IKK inhibitor,IKBKB,NA,NA,"NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",Preclinical
BRD-K51662849-001-08-8::0.000637854::HTS002,BRD-K51662849-001-08-8,0.000637854,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::0.00255142::HTS002,BRD-K51662849-001-08-8,0.00255142,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::0.0102057::HTS002,BRD-K51662849-001-08-8,0.0102057,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::0.0408227::HTS002,BRD-K51662849-001-08-8,0.0408227,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::0.163291::HTS002,BRD-K51662849-001-08-8,0.163291,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::0.653163::HTS002,BRD-K51662849-001-08-8,0.653163,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::2.61265::HTS002,BRD-K51662849-001-08-8,2.61265,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51662849-001-08-8::10.4506::HTS002,BRD-K51662849-001-08-8,10.4506,HTS002,PREP019,ilomastat,matrix metalloprotease inhibitor,"ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9",NA,NA,"CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",Phase 3
BRD-K51747290-001-13-1::0.00061034::HTS002,BRD-K51747290-001-13-1,0.00061034,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::0.0024414::HTS002,BRD-K51747290-001-13-1,0.0024414,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::0.00976562::HTS002,BRD-K51747290-001-13-1,0.00976562,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::0.0390625::HTS002,BRD-K51747290-001-13-1,0.0390625,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::0.15625::HTS002,BRD-K51747290-001-13-1,0.15625,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::0.625::HTS002,BRD-K51747290-001-13-1,0.625,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::2.5::HTS002,BRD-K51747290-001-13-1,2.5,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51747290-001-13-1::10::HTS002,BRD-K51747290-001-13-1,10.0,HTS002,PREP017,hydroxyurea,ribonucleotide reductase inhibitor,"RRM1, RRM2, RRM2B","hematologic malignancy, oncology","chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)","NC(=O)NO, NC(=O)NO, NC(=O)NO",Launched
BRD-K51791723-003-01-7::0.00061034::HTS002,BRD-K51791723-003-01-7,0.00061034,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.0024414::HTS002,BRD-K51791723-003-01-7,0.0024414,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.00976562::HTS002,BRD-K51791723-003-01-7,0.00976562,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.0390625::HTS002,BRD-K51791723-003-01-7,0.0390625,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.15625::HTS002,BRD-K51791723-003-01-7,0.15625,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::0.625::HTS002,BRD-K51791723-003-01-7,0.625,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::2.5::HTS002,BRD-K51791723-003-01-7,2.5,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51791723-003-01-7::10::HTS002,BRD-K51791723-003-01-7,10.0,HTS002,PREP018,P276-00,CDK inhibitor,"CDK1, CDK4, CDK9",NA,NA,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,Phase 2
BRD-K51911221-001-01-2::0.00061034::HTS002,BRD-K51911221-001-01-2,0.00061034,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::0.0024414::HTS002,BRD-K51911221-001-01-2,0.0024414,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::0.00976562::HTS002,BRD-K51911221-001-01-2,0.00976562,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::0.0390625::HTS002,BRD-K51911221-001-01-2,0.0390625,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::0.15625::HTS002,BRD-K51911221-001-01-2,0.15625,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::0.625::HTS002,BRD-K51911221-001-01-2,0.625,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::2.5::HTS002,BRD-K51911221-001-01-2,2.5,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51911221-001-01-2::10::HTS002,BRD-K51911221-001-01-2,10.0,HTS002,PREP047,nemorubicin,topoisomerase inhibitor,"TOP1, TOP2A",NA,NA,CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O,Phase 2
BRD-K51967704-001-03-6::0.00061034::HTS002,BRD-K51967704-001-03-6,0.00061034,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.0024414::HTS002,BRD-K51967704-001-03-6,0.0024414,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.00976562::HTS002,BRD-K51967704-001-03-6,0.00976562,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.0390625::HTS002,BRD-K51967704-001-03-6,0.0390625,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.15625::HTS002,BRD-K51967704-001-03-6,0.15625,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::0.625::HTS002,BRD-K51967704-001-03-6,0.625,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::2.5::HTS002,BRD-K51967704-001-03-6,2.5,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K51967704-001-03-6::10::HTS002,BRD-K51967704-001-03-6,10.0,HTS002,PREP019,BIIB021,HSP inhibitor,HSP90AA1,NA,NA,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",Phase 2
BRD-K52020312-001-26-8::0.00061034::HTS002,BRD-K52020312-001-26-8,0.00061034,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::0.0024414::HTS002,BRD-K52020312-001-26-8,0.0024414,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::0.00976562::HTS002,BRD-K52020312-001-26-8,0.00976562,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::0.0390625::HTS002,BRD-K52020312-001-26-8,0.0390625,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::0.15625::HTS002,BRD-K52020312-001-26-8,0.15625,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::0.625::HTS002,BRD-K52020312-001-26-8,0.625,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::2.5::HTS002,BRD-K52020312-001-26-8,2.5,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52020312-001-26-8::10::HTS002,BRD-K52020312-001-26-8,10.0,HTS002,PREP031,metronidazole,DNA inhibitor,"CYP2C9, CYP3A4",dermatology,rosacea,"Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O",Launched
BRD-K52075715-001-06-7::0.00061034::HTS002,BRD-K52075715-001-06-7,0.00061034,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::0.0024414::HTS002,BRD-K52075715-001-06-7,0.0024414,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::0.00976562::HTS002,BRD-K52075715-001-06-7,0.00976562,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::0.0390625::HTS002,BRD-K52075715-001-06-7,0.0390625,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::0.15625::HTS002,BRD-K52075715-001-06-7,0.15625,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::0.625::HTS002,BRD-K52075715-001-06-7,0.625,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::2.5::HTS002,BRD-K52075715-001-06-7,2.5,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52075715-001-06-7::10::HTS002,BRD-K52075715-001-06-7,10.0,HTS002,PREP035,oxibendazole,tubulin polymerization inhibitor,"TUBB, TUBB4B",infectious disease,strongyles,"CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1",Launched
BRD-K52172416-001-11-4::0.00061034::HTS002,BRD-K52172416-001-11-4,0.00061034,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::0.0024414::HTS002,BRD-K52172416-001-11-4,0.0024414,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::0.00976562::HTS002,BRD-K52172416-001-11-4,0.00976562,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::0.0390625::HTS002,BRD-K52172416-001-11-4,0.0390625,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::0.15625::HTS002,BRD-K52172416-001-11-4,0.15625,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::0.625::HTS002,BRD-K52172416-001-11-4,0.625,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::2.5::HTS002,BRD-K52172416-001-11-4,2.5,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52172416-001-11-4::10::HTS002,BRD-K52172416-001-11-4,10.0,HTS002,PREP024,anastrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N",Launched
BRD-K52233191-001-02-4::0.00061034::HTS002,BRD-K52233191-001-02-4,0.00061034,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::0.0024414::HTS002,BRD-K52233191-001-02-4,0.0024414,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::0.00976562::HTS002,BRD-K52233191-001-02-4,0.00976562,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::0.0390625::HTS002,BRD-K52233191-001-02-4,0.0390625,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::0.15625::HTS002,BRD-K52233191-001-02-4,0.15625,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::0.625::HTS002,BRD-K52233191-001-02-4,0.625,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::2.5::HTS002,BRD-K52233191-001-02-4,2.5,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52233191-001-02-4::10::HTS002,BRD-K52233191-001-02-4,10.0,HTS002,PREP024,R547,CDK inhibitor,"CDK1, CDK2, CDK4, CDK7",NA,NA,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,Phase 1
BRD-K52256627-300-06-6::0.00061034::HTS002,BRD-K52256627-300-06-6,0.00061034,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::0.0024414::HTS002,BRD-K52256627-300-06-6,0.0024414,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::0.00976562::HTS002,BRD-K52256627-300-06-6,0.00976562,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::0.0390625::HTS002,BRD-K52256627-300-06-6,0.0390625,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::0.15625::HTS002,BRD-K52256627-300-06-6,0.15625,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::0.625::HTS002,BRD-K52256627-300-06-6,0.625,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::2.5::HTS002,BRD-K52256627-300-06-6,2.5,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52256627-300-06-6::10::HTS002,BRD-K52256627-300-06-6,10.0,HTS002,PREP020,chlorhexidine,membrane integrity inhibitor,NA,"dermatology, infectious disease, dental","cosmetic, skin infections, gingivitis",Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,Launched
BRD-K52313696-001-12-3::0.00061034::HTS002,BRD-K52313696-001-12-3,0.00061034,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.0024414::HTS002,BRD-K52313696-001-12-3,0.0024414,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.00976562::HTS002,BRD-K52313696-001-12-3,0.00976562,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.0390625::HTS002,BRD-K52313696-001-12-3,0.0390625,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.15625::HTS002,BRD-K52313696-001-12-3,0.15625,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::0.625::HTS002,BRD-K52313696-001-12-3,0.625,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::2.5::HTS002,BRD-K52313696-001-12-3,2.5,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-K52313696-001-12-3::10::HTS002,BRD-K52313696-001-12-3,10.0,HTS002,PREP024,tacedinaline,HDAC inhibitor,HDAC1,NA,NA,"CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",Phase 3
BRD-A81541225-001-06-8::0.00061034::HTS002,BRD-A81541225-001-06-8,0.00061034,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::0.0024414::HTS002,BRD-A81541225-001-06-8,0.0024414,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::0.00976562::HTS002,BRD-A81541225-001-06-8,0.00976562,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::0.0390625::HTS002,BRD-A81541225-001-06-8,0.0390625,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::0.15625::HTS002,BRD-A81541225-001-06-8,0.15625,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::0.625::HTS002,BRD-A81541225-001-06-8,0.625,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::2.5::HTS002,BRD-A81541225-001-06-8,2.5,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-A81541225-001-06-8::10::HTS002,BRD-A81541225-001-06-8,10.0,HTS002,PREP043,oligomycin-a,"ATP synthase inhibitor, ATPase inhibitor",ATP5A1,NA,NA,CCC1CCC2OC3(CC[C@@H](C)C(C[C@H](C)O)O3)[C@H](C)C(OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C\1)[C@H]2C,Preclinical
BRD-K27771035-001-02-5::0.00061034::HTS002,BRD-K27771035-001-02-5,0.00061034,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::0.0024414::HTS002,BRD-K27771035-001-02-5,0.0024414,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::0.00976562::HTS002,BRD-K27771035-001-02-5,0.00976562,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::0.0390625::HTS002,BRD-K27771035-001-02-5,0.0390625,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::0.15625::HTS002,BRD-K27771035-001-02-5,0.15625,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::0.625::HTS002,BRD-K27771035-001-02-5,0.625,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::2.5::HTS002,BRD-K27771035-001-02-5,2.5,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K27771035-001-02-5::10::HTS002,BRD-K27771035-001-02-5,10.0,HTS002,PREP039,clindamycin-phosphate,protein synthesis inhibitor,NA,obstetrics/gynecology,bacterial vaginosis,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O,Launched
BRD-K52662033-003-21-2::0.00061034::HTS002,BRD-K52662033-003-21-2,0.00061034,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::0.0024414::HTS002,BRD-K52662033-003-21-2,0.0024414,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::0.00976562::HTS002,BRD-K52662033-003-21-2,0.00976562,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::0.0390625::HTS002,BRD-K52662033-003-21-2,0.0390625,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::0.15625::HTS002,BRD-K52662033-003-21-2,0.15625,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::0.625::HTS002,BRD-K52662033-003-21-2,0.625,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::2.5::HTS002,BRD-K52662033-003-21-2,2.5,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52662033-003-21-2::10::HTS002,BRD-K52662033-003-21-2,10.0,HTS002,PREP031,lidocaine,histamine receptor agonist,"EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","neurology/psychiatry, dermatology, hematology","itching, eczema, hemorrhage","CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C",Launched
BRD-K52751261-001-06-1::0.00061034::HTS002,BRD-K52751261-001-06-1,0.00061034,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::0.0024414::HTS002,BRD-K52751261-001-06-1,0.0024414,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::0.00976562::HTS002,BRD-K52751261-001-06-1,0.00976562,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::0.0390625::HTS002,BRD-K52751261-001-06-1,0.0390625,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::0.15625::HTS002,BRD-K52751261-001-06-1,0.15625,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::0.625::HTS002,BRD-K52751261-001-06-1,0.625,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::2.5::HTS002,BRD-K52751261-001-06-1,2.5,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52751261-001-06-1::10::HTS002,BRD-K52751261-001-06-1,10.0,HTS002,PREP019,TAK-715,p38 MAPK inhibitor,MAPK14,NA,NA,"CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",Phase 2
BRD-K52756523-001-24-7::0.00061034::HTS002,BRD-K52756523-001-24-7,0.00061034,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::0.0024414::HTS002,BRD-K52756523-001-24-7,0.0024414,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::0.00976562::HTS002,BRD-K52756523-001-24-7,0.00976562,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::0.0390625::HTS002,BRD-K52756523-001-24-7,0.0390625,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::0.15625::HTS002,BRD-K52756523-001-24-7,0.15625,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::0.625::HTS002,BRD-K52756523-001-24-7,0.625,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::2.5::HTS002,BRD-K52756523-001-24-7,2.5,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52756523-001-24-7::10::HTS002,BRD-K52756523-001-24-7,10.0,HTS002,PREP035,dirithromycin,bacterial 50S ribosomal subunit inhibitor,NA,pulmonary,bronchitis,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",Launched
BRD-K52762805-001-01-2::0.00061034::HTS002,BRD-K52762805-001-01-2,0.00061034,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::0.0024414::HTS002,BRD-K52762805-001-01-2,0.0024414,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::0.00976562::HTS002,BRD-K52762805-001-01-2,0.00976562,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::0.0390625::HTS002,BRD-K52762805-001-01-2,0.0390625,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::0.15625::HTS002,BRD-K52762805-001-01-2,0.15625,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::0.625::HTS002,BRD-K52762805-001-01-2,0.625,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::2.5::HTS002,BRD-K52762805-001-01-2,2.5,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52762805-001-01-2::10::HTS002,BRD-K52762805-001-01-2,10.0,HTS002,PREP025,epothilone-d,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 2
BRD-K52911425-001-09-8::0.00061034::HTS002,BRD-K52911425-001-09-8,0.00061034,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::0.0024414::HTS002,BRD-K52911425-001-09-8,0.0024414,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::0.00976562::HTS002,BRD-K52911425-001-09-8,0.00976562,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::0.0390625::HTS002,BRD-K52911425-001-09-8,0.0390625,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::0.15625::HTS002,BRD-K52911425-001-09-8,0.15625,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::0.625::HTS002,BRD-K52911425-001-09-8,0.625,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::2.5::HTS002,BRD-K52911425-001-09-8,2.5,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K52911425-001-09-8::10::HTS002,BRD-K52911425-001-09-8,10.0,HTS002,PREP018,GDC-0941,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,Phase 2
BRD-K53097745-001-01-5::0.00061034::HTS002,BRD-K53097745-001-01-5,0.00061034,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::0.0024414::HTS002,BRD-K53097745-001-01-5,0.0024414,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::0.00976562::HTS002,BRD-K53097745-001-01-5,0.00976562,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::0.0390625::HTS002,BRD-K53097745-001-01-5,0.0390625,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::0.15625::HTS002,BRD-K53097745-001-01-5,0.15625,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::0.625::HTS002,BRD-K53097745-001-01-5,0.625,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::2.5::HTS002,BRD-K53097745-001-01-5,2.5,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53097745-001-01-5::10::HTS002,BRD-K53097745-001-01-5,10.0,HTS002,PREP019,pterostilbene,"cyclooxygenase inhibitor, PPAR receptor agonist",PTGS2,NA,NA,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,Phase 2/Phase 3
BRD-K53123955-001-10-5::0.00061034::HTS002,BRD-K53123955-001-10-5,0.00061034,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::0.0024414::HTS002,BRD-K53123955-001-10-5,0.0024414,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::0.00976562::HTS002,BRD-K53123955-001-10-5,0.00976562,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::0.0390625::HTS002,BRD-K53123955-001-10-5,0.0390625,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::0.15625::HTS002,BRD-K53123955-001-10-5,0.15625,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::0.625::HTS002,BRD-K53123955-001-10-5,0.625,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::2.5::HTS002,BRD-K53123955-001-10-5,2.5,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53123955-001-10-5::10::HTS002,BRD-K53123955-001-10-5,10.0,HTS002,PREP014,niridazole,phosphofructokinase inhibitor,NA,infectious disease,schistosomiasis,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,Launched
BRD-K53414658-001-08-2::0.00061034::HTS002,BRD-K53414658-001-08-2,0.00061034,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.0024414::HTS002,BRD-K53414658-001-08-2,0.0024414,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.00976562::HTS002,BRD-K53414658-001-08-2,0.00976562,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.0390625::HTS002,BRD-K53414658-001-08-2,0.0390625,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.15625::HTS002,BRD-K53414658-001-08-2,0.15625,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::0.625::HTS002,BRD-K53414658-001-08-2,0.625,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::2.5::HTS002,BRD-K53414658-001-08-2,2.5,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53414658-001-08-2::10::HTS002,BRD-K53414658-001-08-2,10.0,HTS002,PREP033,tivozanib,VEGFR inhibitor,"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,Phase 3
BRD-K53417444-003-03-1::0.00061034::HTS002,BRD-K53417444-003-03-1,0.00061034,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::0.0024414::HTS002,BRD-K53417444-003-03-1,0.0024414,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::0.00976562::HTS002,BRD-K53417444-003-03-1,0.00976562,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::0.0390625::HTS002,BRD-K53417444-003-03-1,0.0390625,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::0.15625::HTS002,BRD-K53417444-003-03-1,0.15625,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::0.625::HTS002,BRD-K53417444-003-03-1,0.625,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::2.5::HTS002,BRD-K53417444-003-03-1,2.5,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53417444-003-03-1::10::HTS002,BRD-K53417444-003-03-1,10.0,HTS002,PREP039,OTS167,maternal embryonic leucine zipper kinase inhibitor,MELK,NA,NA,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,Phase 1
BRD-K53523901-001-04-4::0.00061034::HTS002,BRD-K53523901-001-04-4,0.00061034,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::0.0024414::HTS002,BRD-K53523901-001-04-4,0.0024414,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::0.00976562::HTS002,BRD-K53523901-001-04-4,0.00976562,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::0.0390625::HTS002,BRD-K53523901-001-04-4,0.0390625,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::0.15625::HTS002,BRD-K53523901-001-04-4,0.15625,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::0.625::HTS002,BRD-K53523901-001-04-4,0.625,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::2.5::HTS002,BRD-K53523901-001-04-4,2.5,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53523901-001-04-4::10::HTS002,BRD-K53523901-001-04-4,10.0,HTS002,PREP037,arctigenin,MEK inhibitor,"CHUK, MAP2K1",NA,NA,"COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O, COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O",Preclinical
BRD-K53561341-001-07-5::0.00061034::HTS002,BRD-K53561341-001-07-5,0.00061034,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::0.0024414::HTS002,BRD-K53561341-001-07-5,0.0024414,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::0.00976562::HTS002,BRD-K53561341-001-07-5,0.00976562,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::0.0390625::HTS002,BRD-K53561341-001-07-5,0.0390625,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::0.15625::HTS002,BRD-K53561341-001-07-5,0.15625,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::0.625::HTS002,BRD-K53561341-001-07-5,0.625,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::2.5::HTS002,BRD-K53561341-001-07-5,2.5,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53561341-001-07-5::10::HTS002,BRD-K53561341-001-07-5,10.0,HTS002,PREP047,aurora-a-inhibitor-i,Aurora kinase inhibitor,AURKA,NA,NA,"CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",Preclinical
BRD-K53581288-001-02-9::0.00061034::HTS002,BRD-K53581288-001-02-9,0.00061034,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::0.0024414::HTS002,BRD-K53581288-001-02-9,0.0024414,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::0.00976562::HTS002,BRD-K53581288-001-02-9,0.00976562,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::0.0390625::HTS002,BRD-K53581288-001-02-9,0.0390625,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::0.15625::HTS002,BRD-K53581288-001-02-9,0.15625,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::0.625::HTS002,BRD-K53581288-001-02-9,0.625,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::2.5::HTS002,BRD-K53581288-001-02-9,2.5,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53581288-001-02-9::10::HTS002,BRD-K53581288-001-02-9,10.0,HTS002,PREP033,baricitinib,JAK inhibitor,"JAK1, JAK2",NA,NA,CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,Phase 3
BRD-K53665955-001-03-0::0.00061034::HTS002,BRD-K53665955-001-03-0,0.00061034,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::0.0024414::HTS002,BRD-K53665955-001-03-0,0.0024414,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::0.00976562::HTS002,BRD-K53665955-001-03-0,0.00976562,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::0.0390625::HTS002,BRD-K53665955-001-03-0,0.0390625,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::0.15625::HTS002,BRD-K53665955-001-03-0,0.15625,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::0.625::HTS002,BRD-K53665955-001-03-0,0.625,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::2.5::HTS002,BRD-K53665955-001-03-0,2.5,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53665955-001-03-0::10::HTS002,BRD-K53665955-001-03-0,10.0,HTS002,PREP027,MK-5108,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,Phase 1
BRD-K53720352-001-03-2::0.00061034::HTS002,BRD-K53720352-001-03-2,0.00061034,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::0.0024414::HTS002,BRD-K53720352-001-03-2,0.0024414,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::0.00976562::HTS002,BRD-K53720352-001-03-2,0.00976562,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::0.0390625::HTS002,BRD-K53720352-001-03-2,0.0390625,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::0.15625::HTS002,BRD-K53720352-001-03-2,0.15625,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::0.625::HTS002,BRD-K53720352-001-03-2,0.625,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::2.5::HTS002,BRD-K53720352-001-03-2,2.5,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53720352-001-03-2::10::HTS002,BRD-K53720352-001-03-2,10.0,HTS002,PREP045,cinalukast,leukotriene receptor antagonist,CYSLTR1,NA,NA,"CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",Phase 2
BRD-K53734668-003-02-0::0.000648796::HTS002,BRD-K53734668-003-02-0,0.000648796,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::0.00259518::HTS002,BRD-K53734668-003-02-0,0.00259518,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::0.0103807::HTS002,BRD-K53734668-003-02-0,0.0103807,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::0.0415229::HTS002,BRD-K53734668-003-02-0,0.0415229,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::0.166092::HTS002,BRD-K53734668-003-02-0,0.166092,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::0.664367::HTS002,BRD-K53734668-003-02-0,0.664367,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::2.65747::HTS002,BRD-K53734668-003-02-0,2.65747,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53734668-003-02-0::10.6299::HTS002,BRD-K53734668-003-02-0,10.6299,HTS002,PREP030,PRT062607,syk inhibitor,"FGR, MAP3K9, SYK",NA,NA,"N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",Phase 2
BRD-K53972329-001-07-0::0.00061034::HTS002,BRD-K53972329-001-07-0,0.00061034,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.0024414::HTS002,BRD-K53972329-001-07-0,0.0024414,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.00976562::HTS002,BRD-K53972329-001-07-0,0.00976562,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.0390625::HTS002,BRD-K53972329-001-07-0,0.0390625,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.15625::HTS002,BRD-K53972329-001-07-0,0.15625,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::0.625::HTS002,BRD-K53972329-001-07-0,0.625,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::2.5::HTS002,BRD-K53972329-001-07-0,2.5,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K53972329-001-07-0::10::HTS002,BRD-K53972329-001-07-0,10.0,HTS002,PREP021,ruxolitinib,JAK inhibitor,"JAK1, JAK2, JAK3, TYK2","hematologic malignancy, hematology","myelofibrosis, polycythemia vera",N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12,Launched
BRD-K54094468-003-11-1::0.00061034::HTS002,BRD-K54094468-003-11-1,0.00061034,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::0.0024414::HTS002,BRD-K54094468-003-11-1,0.0024414,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::0.00976562::HTS002,BRD-K54094468-003-11-1,0.00976562,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::0.0390625::HTS002,BRD-K54094468-003-11-1,0.0390625,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::0.15625::HTS002,BRD-K54094468-003-11-1,0.15625,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::0.625::HTS002,BRD-K54094468-003-11-1,0.625,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::2.5::HTS002,BRD-K54094468-003-11-1,2.5,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54094468-003-11-1::10::HTS002,BRD-K54094468-003-11-1,10.0,HTS002,PREP022,remoxipride,dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR2A, SIGMAR1",NA,NA,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Withdrawn
BRD-K54095730-001-03-1::0.00061034::HTS002,BRD-K54095730-001-03-1,0.00061034,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::0.0024414::HTS002,BRD-K54095730-001-03-1,0.0024414,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::0.00976562::HTS002,BRD-K54095730-001-03-1,0.00976562,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::0.0390625::HTS002,BRD-K54095730-001-03-1,0.0390625,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::0.15625::HTS002,BRD-K54095730-001-03-1,0.15625,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::0.625::HTS002,BRD-K54095730-001-03-1,0.625,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::2.5::HTS002,BRD-K54095730-001-03-1,2.5,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54095730-001-03-1::10::HTS002,BRD-K54095730-001-03-1,10.0,HTS002,PREP037,CMPD-1,p38 MAPK inhibitor,"GNRHR, MAPK14",NA,NA,"Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",Preclinical
BRD-K54247840-004-01-3::0.000610352::HTS002,BRD-K54247840-004-01-3,0.000610352,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::0.00244141::HTS002,BRD-K54247840-004-01-3,0.00244141,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::0.00976562::HTS002,BRD-K54247840-004-01-3,0.00976562,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::0.0390625::HTS002,BRD-K54247840-004-01-3,0.0390625,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::0.15625::HTS002,BRD-K54247840-004-01-3,0.15625,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::0.625::HTS002,BRD-K54247840-004-01-3,0.625,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::2.5::HTS002,BRD-K54247840-004-01-3,2.5,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54247840-004-01-3::10::HTS002,BRD-K54247840-004-01-3,10.0,HTS002,PREP028,halofuginone,collagenase inhibitor,"COL1A1, MMP2",rheumatology,scleroderma,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,Launched
BRD-K54256913-001-08-7::0.00061034::HTS002,BRD-K54256913-001-08-7,0.00061034,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.0024414::HTS002,BRD-K54256913-001-08-7,0.0024414,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.00976562::HTS002,BRD-K54256913-001-08-7,0.00976562,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.0390625::HTS002,BRD-K54256913-001-08-7,0.0390625,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.15625::HTS002,BRD-K54256913-001-08-7,0.15625,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::0.625::HTS002,BRD-K54256913-001-08-7,0.625,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::2.5::HTS002,BRD-K54256913-001-08-7,2.5,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54256913-001-08-7::10::HTS002,BRD-K54256913-001-08-7,10.0,HTS002,PREP019,MK-1775,WEE1 kinase inhibitor,WEE1,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1,Phase 2
BRD-K54262262-001-09-0::0.00061034::HTS002,BRD-K54262262-001-09-0,0.00061034,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::0.0024414::HTS002,BRD-K54262262-001-09-0,0.0024414,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::0.00976562::HTS002,BRD-K54262262-001-09-0,0.00976562,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::0.0390625::HTS002,BRD-K54262262-001-09-0,0.0390625,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::0.15625::HTS002,BRD-K54262262-001-09-0,0.15625,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::0.625::HTS002,BRD-K54262262-001-09-0,0.625,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::2.5::HTS002,BRD-K54262262-001-09-0,2.5,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54262262-001-09-0::10::HTS002,BRD-K54262262-001-09-0,10.0,HTS002,PREP023,monobenzone,melanin inhibitor,TYR,dermatology,skin depigmentation,"Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1",Launched
BRD-K54314721-001-10-2::0.00061034::HTS002,BRD-K54314721-001-10-2,0.00061034,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::0.0024414::HTS002,BRD-K54314721-001-10-2,0.0024414,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::0.00976562::HTS002,BRD-K54314721-001-10-2,0.00976562,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::0.0390625::HTS002,BRD-K54314721-001-10-2,0.0390625,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::0.15625::HTS002,BRD-K54314721-001-10-2,0.15625,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::0.625::HTS002,BRD-K54314721-001-10-2,0.625,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::2.5::HTS002,BRD-K54314721-001-10-2,2.5,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54314721-001-10-2::10::HTS002,BRD-K54314721-001-10-2,10.0,HTS002,PREP034,zolmitriptan,serotonin receptor agonist,"HTR1A, HTR1B, HTR1D, HTR1E, HTR1F",neurology/psychiatry,migraine headache,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12",Launched
BRD-K54395039-001-01-7::0.00061034::HTS002,BRD-K54395039-001-01-7,0.00061034,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::0.0024414::HTS002,BRD-K54395039-001-01-7,0.0024414,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::0.00976562::HTS002,BRD-K54395039-001-01-7,0.00976562,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::0.0390625::HTS002,BRD-K54395039-001-01-7,0.0390625,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::0.15625::HTS002,BRD-K54395039-001-01-7,0.15625,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::0.625::HTS002,BRD-K54395039-001-01-7,0.625,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::2.5::HTS002,BRD-K54395039-001-01-7,2.5,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54395039-001-01-7::10::HTS002,BRD-K54395039-001-01-7,10.0,HTS002,PREP046,PR-619,DUB inhibitor,NA,NA,NA,"Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",Preclinical
BRD-K54606188-001-13-1::0.00061034::HTS002,BRD-K54606188-001-13-1,0.00061034,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::0.0024414::HTS002,BRD-K54606188-001-13-1,0.0024414,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::0.00976562::HTS002,BRD-K54606188-001-13-1,0.00976562,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::0.0390625::HTS002,BRD-K54606188-001-13-1,0.0390625,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::0.15625::HTS002,BRD-K54606188-001-13-1,0.15625,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::0.625::HTS002,BRD-K54606188-001-13-1,0.625,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::2.5::HTS002,BRD-K54606188-001-13-1,2.5,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54606188-001-13-1::10::HTS002,BRD-K54606188-001-13-1,10.0,HTS002,PREP043,JQ1-(+),bromodomain inhibitor,"BRD4, BRDT",NA,NA,"Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1",Preclinical
BRD-K54838207-001-03-8::0.000610352::HTS002,BRD-K54838207-001-03-8,0.000610352,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::0.00244141::HTS002,BRD-K54838207-001-03-8,0.00244141,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::0.00976562::HTS002,BRD-K54838207-001-03-8,0.00976562,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::0.0390625::HTS002,BRD-K54838207-001-03-8,0.0390625,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::0.15625::HTS002,BRD-K54838207-001-03-8,0.15625,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::0.625::HTS002,BRD-K54838207-001-03-8,0.625,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::2.5::HTS002,BRD-K54838207-001-03-8,2.5,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54838207-001-03-8::10::HTS002,BRD-K54838207-001-03-8,10.0,HTS002,PREP034,fudosteine,mucolytic agent,NA,pulmonary,chest congestion,"N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O",Launched
BRD-K54847683-001-04-0::0.000610352::HTS002,BRD-K54847683-001-04-0,0.000610352,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::0.00244141::HTS002,BRD-K54847683-001-04-0,0.00244141,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::0.00976562::HTS002,BRD-K54847683-001-04-0,0.00976562,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::0.0390625::HTS002,BRD-K54847683-001-04-0,0.0390625,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::0.15625::HTS002,BRD-K54847683-001-04-0,0.15625,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::0.625::HTS002,BRD-K54847683-001-04-0,0.625,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::2.5::HTS002,BRD-K54847683-001-04-0,2.5,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54847683-001-04-0::10::HTS002,BRD-K54847683-001-04-0,10.0,HTS002,PREP034,equol,estrogen receptor agonist,"ESR1, ESR2",NA,NA,"Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1",Launched
BRD-K54997624-001-06-0::0.00061034::HTS002,BRD-K54997624-001-06-0,0.00061034,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.0024414::HTS002,BRD-K54997624-001-06-0,0.0024414,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.00976562::HTS002,BRD-K54997624-001-06-0,0.00976562,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.0390625::HTS002,BRD-K54997624-001-06-0,0.0390625,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.15625::HTS002,BRD-K54997624-001-06-0,0.15625,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::0.625::HTS002,BRD-K54997624-001-06-0,0.625,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::2.5::HTS002,BRD-K54997624-001-06-0,2.5,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K54997624-001-06-0::10::HTS002,BRD-K54997624-001-06-0,10.0,HTS002,PREP025,alpelisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,Phase 3
BRD-K03406345-001-27-8::0.00061034::HTS002,BRD-K03406345-001-27-8,0.00061034,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::0.0024414::HTS002,BRD-K03406345-001-27-8,0.0024414,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::0.00976562::HTS002,BRD-K03406345-001-27-8,0.00976562,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::0.0390625::HTS002,BRD-K03406345-001-27-8,0.0390625,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::0.15625::HTS002,BRD-K03406345-001-27-8,0.15625,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::0.625::HTS002,BRD-K03406345-001-27-8,0.625,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::2.5::HTS002,BRD-K03406345-001-27-8,2.5,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K03406345-001-27-8::10::HTS002,BRD-K03406345-001-27-8,10.0,HTS002,PREP030,azacitidine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1",Launched
BRD-K55187425-236-05-2::0.00061034::HTS002,BRD-K55187425-236-05-2,0.00061034,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.0024414::HTS002,BRD-K55187425-236-05-2,0.0024414,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.00976562::HTS002,BRD-K55187425-236-05-2,0.00976562,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.0390625::HTS002,BRD-K55187425-236-05-2,0.0390625,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.15625::HTS002,BRD-K55187425-236-05-2,0.15625,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::0.625::HTS002,BRD-K55187425-236-05-2,0.625,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::2.5::HTS002,BRD-K55187425-236-05-2,2.5,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55187425-236-05-2::10::HTS002,BRD-K55187425-236-05-2,10.0,HTS002,PREP044,rigosertib,"cell cycle inhibitor, PLK inhibitor",PLK1,NA,NA,"COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",Phase 3
BRD-K55305701-001-01-2::0.00061034::HTS002,BRD-K55305701-001-01-2,0.00061034,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::0.0024414::HTS002,BRD-K55305701-001-01-2,0.0024414,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::0.00976562::HTS002,BRD-K55305701-001-01-2,0.00976562,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::0.0390625::HTS002,BRD-K55305701-001-01-2,0.0390625,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::0.15625::HTS002,BRD-K55305701-001-01-2,0.15625,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::0.625::HTS002,BRD-K55305701-001-01-2,0.625,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::2.5::HTS002,BRD-K55305701-001-01-2,2.5,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55305701-001-01-2::10::HTS002,BRD-K55305701-001-01-2,10.0,HTS002,PREP041,SC-144,P glycoprotein inhibitor,NA,NA,NA,"Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",Preclinical
BRD-K55462201-001-07-3::0.00061034::HTS002,BRD-K55462201-001-07-3,0.00061034,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::0.0024414::HTS002,BRD-K55462201-001-07-3,0.0024414,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::0.00976562::HTS002,BRD-K55462201-001-07-3,0.00976562,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::0.0390625::HTS002,BRD-K55462201-001-07-3,0.0390625,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::0.15625::HTS002,BRD-K55462201-001-07-3,0.15625,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::0.625::HTS002,BRD-K55462201-001-07-3,0.625,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::2.5::HTS002,BRD-K55462201-001-07-3,2.5,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55462201-001-07-3::10::HTS002,BRD-K55462201-001-07-3,10.0,HTS002,PREP025,AM-404,"cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1",NA,NA,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1,Preclinical
BRD-K55703048-001-07-7::0.000610352::HTS002,BRD-K55703048-001-07-7,0.000610352,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::0.00244141::HTS002,BRD-K55703048-001-07-7,0.00244141,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::0.00976562::HTS002,BRD-K55703048-001-07-7,0.00976562,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::0.0390625::HTS002,BRD-K55703048-001-07-7,0.0390625,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::0.15625::HTS002,BRD-K55703048-001-07-7,0.15625,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::0.625::HTS002,BRD-K55703048-001-07-7,0.625,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::2.5::HTS002,BRD-K55703048-001-07-7,2.5,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55703048-001-07-7::10::HTS002,BRD-K55703048-001-07-7,10.0,HTS002,PREP025,latrepirdine,glutamate receptor antagonist,"HRH1, HTR6",NA,NA,"CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",Phase 3
BRD-K55966568-001-05-4::0.00061034::HTS002,BRD-K55966568-001-05-4,0.00061034,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::0.0024414::HTS002,BRD-K55966568-001-05-4,0.0024414,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::0.00976562::HTS002,BRD-K55966568-001-05-4,0.00976562,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::0.0390625::HTS002,BRD-K55966568-001-05-4,0.0390625,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::0.15625::HTS002,BRD-K55966568-001-05-4,0.15625,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::0.625::HTS002,BRD-K55966568-001-05-4,0.625,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::2.5::HTS002,BRD-K55966568-001-05-4,2.5,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K55966568-001-05-4::10::HTS002,BRD-K55966568-001-05-4,10.0,HTS002,PREP019,orantinib,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB",NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",Phase 3
BRD-K56032964-001-02-1::0.00061034::HTS002,BRD-K56032964-001-02-1,0.00061034,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::0.0024414::HTS002,BRD-K56032964-001-02-1,0.0024414,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::0.00976562::HTS002,BRD-K56032964-001-02-1,0.00976562,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::0.0390625::HTS002,BRD-K56032964-001-02-1,0.0390625,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::0.15625::HTS002,BRD-K56032964-001-02-1,0.15625,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::0.625::HTS002,BRD-K56032964-001-02-1,0.625,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::2.5::HTS002,BRD-K56032964-001-02-1,2.5,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K56032964-001-02-1::10::HTS002,BRD-K56032964-001-02-1,10.0,HTS002,PREP026,AP26113,ALK tyrosine kinase receptor inhibitor,"ALK, EGFR",NA,NA,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C,Phase 2
BRD-K01507359-001-22-9::0.000610352::HTS002,BRD-K01507359-001-22-9,0.000610352,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::0.00244141::HTS002,BRD-K01507359-001-22-9,0.00244141,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::0.00976562::HTS002,BRD-K01507359-001-22-9,0.00976562,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::0.0390625::HTS002,BRD-K01507359-001-22-9,0.0390625,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::0.15625::HTS002,BRD-K01507359-001-22-9,0.15625,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::0.625::HTS002,BRD-K01507359-001-22-9,0.625,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::2.5::HTS002,BRD-K01507359-001-22-9,2.5,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K01507359-001-22-9::10::HTS002,BRD-K01507359-001-22-9,10.0,HTS002,PREP030,rifampin,RNA polymerase inhibitor,"NR1I2, SLCO1A2, SLCO1B1, SLCO1B3",infectious disease,"tuberculosis, meningitis","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C",Launched
BRD-K56277358-001-07-5::0.00061034::HTS002,BRD-K56277358-001-07-5,0.00061034,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::0.0024414::HTS002,BRD-K56277358-001-07-5,0.0024414,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::0.00976562::HTS002,BRD-K56277358-001-07-5,0.00976562,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::0.0390625::HTS002,BRD-K56277358-001-07-5,0.0390625,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::0.15625::HTS002,BRD-K56277358-001-07-5,0.15625,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::0.625::HTS002,BRD-K56277358-001-07-5,0.625,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::2.5::HTS002,BRD-K56277358-001-07-5,2.5,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56277358-001-07-5::10::HTS002,BRD-K56277358-001-07-5,10.0,HTS002,PREP040,MGCD-265,VEGFR inhibitor,"AXL, MET",NA,NA,Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1,Preclinical
BRD-K56291712-001-01-0::0.00061034::HTS002,BRD-K56291712-001-01-0,0.00061034,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::0.0024414::HTS002,BRD-K56291712-001-01-0,0.0024414,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::0.00976562::HTS002,BRD-K56291712-001-01-0,0.00976562,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::0.0390625::HTS002,BRD-K56291712-001-01-0,0.0390625,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::0.15625::HTS002,BRD-K56291712-001-01-0,0.15625,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::0.625::HTS002,BRD-K56291712-001-01-0,0.625,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::2.5::HTS002,BRD-K56291712-001-01-0,2.5,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56291712-001-01-0::10::HTS002,BRD-K56291712-001-01-0,10.0,HTS002,PREP038,voxtalisib,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA",NA,NA,CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O,Phase 2
BRD-K56301217-001-07-4::0.00061034::HTS002,BRD-K56301217-001-07-4,0.00061034,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::0.0024414::HTS002,BRD-K56301217-001-07-4,0.0024414,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::0.00976562::HTS002,BRD-K56301217-001-07-4,0.00976562,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::0.0390625::HTS002,BRD-K56301217-001-07-4,0.0390625,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::0.15625::HTS002,BRD-K56301217-001-07-4,0.15625,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::0.625::HTS002,BRD-K56301217-001-07-4,0.625,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::2.5::HTS002,BRD-K56301217-001-07-4,2.5,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56301217-001-07-4::10::HTS002,BRD-K56301217-001-07-4,10.0,HTS002,PREP039,ABT-737,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",Phase 1/Phase 2
BRD-K56334280-001-05-1::0.00061034::HTS002,BRD-K56334280-001-05-1,0.00061034,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::0.0024414::HTS002,BRD-K56334280-001-05-1,0.0024414,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::0.00976562::HTS002,BRD-K56334280-001-05-1,0.00976562,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::0.0390625::HTS002,BRD-K56334280-001-05-1,0.0390625,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::0.15625::HTS002,BRD-K56334280-001-05-1,0.15625,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::0.625::HTS002,BRD-K56334280-001-05-1,0.625,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::2.5::HTS002,BRD-K56334280-001-05-1,2.5,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56334280-001-05-1::10::HTS002,BRD-K56334280-001-05-1,10.0,HTS002,PREP038,amonafide,topoisomerase inhibitor,"TOP2A, TOP2B",NA,NA,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,Phase 3
BRD-K56343971-001-10-6::0.00061034::HTS002,BRD-K56343971-001-10-6,0.00061034,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::0.0024414::HTS002,BRD-K56343971-001-10-6,0.0024414,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::0.00976562::HTS002,BRD-K56343971-001-10-6,0.00976562,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::0.0390625::HTS002,BRD-K56343971-001-10-6,0.0390625,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::0.15625::HTS002,BRD-K56343971-001-10-6,0.15625,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::0.625::HTS002,BRD-K56343971-001-10-6,0.625,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::2.5::HTS002,BRD-K56343971-001-10-6,2.5,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56343971-001-10-6::10::HTS002,BRD-K56343971-001-10-6,10.0,HTS002,PREP022,vemurafenib,RAF inhibitor,"BRAF, RAF1",oncology,melanoma,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F",Launched
BRD-K56405753-001-02-4::0.00061034::HTS002,BRD-K56405753-001-02-4,0.00061034,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::0.0024414::HTS002,BRD-K56405753-001-02-4,0.0024414,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::0.00976562::HTS002,BRD-K56405753-001-02-4,0.00976562,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::0.0390625::HTS002,BRD-K56405753-001-02-4,0.0390625,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::0.15625::HTS002,BRD-K56405753-001-02-4,0.15625,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::0.625::HTS002,BRD-K56405753-001-02-4,0.625,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::2.5::HTS002,BRD-K56405753-001-02-4,2.5,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56405753-001-02-4::10::HTS002,BRD-K56405753-001-02-4,10.0,HTS002,PREP038,MK-2461,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB",NA,NA,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1,Phase 1/Phase 2
BRD-K56483981-342-06-4::0.00061034::HTS002,BRD-K56483981-342-06-4,0.00061034,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::0.0024414::HTS002,BRD-K56483981-342-06-4,0.0024414,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::0.00976562::HTS002,BRD-K56483981-342-06-4,0.00976562,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::0.0390625::HTS002,BRD-K56483981-342-06-4,0.0390625,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::0.15625::HTS002,BRD-K56483981-342-06-4,0.15625,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::0.625::HTS002,BRD-K56483981-342-06-4,0.625,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::2.5::HTS002,BRD-K56483981-342-06-4,2.5,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56483981-342-06-4::10::HTS002,BRD-K56483981-342-06-4,10.0,HTS002,PREP047,chicago-sky-blue-6b,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",MIF,NA,NA,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,Preclinical
BRD-K56614220-001-19-0::0.00061034::HTS002,BRD-K56614220-001-19-0,0.00061034,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::0.0024414::HTS002,BRD-K56614220-001-19-0,0.0024414,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::0.00976562::HTS002,BRD-K56614220-001-19-0,0.00976562,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::0.0390625::HTS002,BRD-K56614220-001-19-0,0.0390625,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::0.15625::HTS002,BRD-K56614220-001-19-0,0.15625,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::0.625::HTS002,BRD-K56614220-001-19-0,0.625,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::2.5::HTS002,BRD-K56614220-001-19-0,2.5,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56614220-001-19-0::10::HTS002,BRD-K56614220-001-19-0,10.0,HTS002,PREP016,clofazimine,GK0582 inhibitor,NA,infectious disease,leprosy,"CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1",Launched
BRD-K56707426-001-02-0::0.00061034::HTS002,BRD-K56707426-001-02-0,0.00061034,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::0.0024414::HTS002,BRD-K56707426-001-02-0,0.0024414,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::0.00976562::HTS002,BRD-K56707426-001-02-0,0.00976562,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::0.0390625::HTS002,BRD-K56707426-001-02-0,0.0390625,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::0.15625::HTS002,BRD-K56707426-001-02-0,0.15625,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::0.625::HTS002,BRD-K56707426-001-02-0,0.625,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::2.5::HTS002,BRD-K56707426-001-02-0,2.5,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56707426-001-02-0::10::HTS002,BRD-K56707426-001-02-0,10.0,HTS002,PREP025,nitarsone,NA,NA,dermatology,blackhead disease,"O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O",Launched
BRD-K56751279-300-01-4::0.00061034::HTS002,BRD-K56751279-300-01-4,0.00061034,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::0.0024414::HTS002,BRD-K56751279-300-01-4,0.0024414,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::0.00976562::HTS002,BRD-K56751279-300-01-4,0.00976562,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::0.0390625::HTS002,BRD-K56751279-300-01-4,0.0390625,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::0.15625::HTS002,BRD-K56751279-300-01-4,0.15625,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::0.625::HTS002,BRD-K56751279-300-01-4,0.625,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::2.5::HTS002,BRD-K56751279-300-01-4,2.5,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K56751279-300-01-4::10::HTS002,BRD-K56751279-300-01-4,10.0,HTS002,PREP026,Y-39983,rho associated kinase inhibitor,"ROCK1, ROCK2",NA,NA,C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12,Phase 2
BRD-K04548931-003-16-5::0.00061034::HTS002,BRD-K04548931-003-16-5,0.00061034,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::0.0024414::HTS002,BRD-K04548931-003-16-5,0.0024414,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::0.00976562::HTS002,BRD-K04548931-003-16-5,0.00976562,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::0.0390625::HTS002,BRD-K04548931-003-16-5,0.0390625,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::0.15625::HTS002,BRD-K04548931-003-16-5,0.15625,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::0.625::HTS002,BRD-K04548931-003-16-5,0.625,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::2.5::HTS002,BRD-K04548931-003-16-5,2.5,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K04548931-003-16-5::10::HTS002,BRD-K04548931-003-16-5,10.0,HTS002,PREP023,epirubicin,topoisomerase inhibitor,"CHD1, TOP2A",oncology,breast cancer,"COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K56851771-001-06-8::0.00061034::HTS002,BRD-K56851771-001-06-8,0.00061034,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::0.0024414::HTS002,BRD-K56851771-001-06-8,0.0024414,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::0.00976562::HTS002,BRD-K56851771-001-06-8,0.00976562,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::0.0390625::HTS002,BRD-K56851771-001-06-8,0.0390625,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::0.15625::HTS002,BRD-K56851771-001-06-8,0.15625,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::0.625::HTS002,BRD-K56851771-001-06-8,0.625,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::2.5::HTS002,BRD-K56851771-001-06-8,2.5,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56851771-001-06-8::10::HTS002,BRD-K56851771-001-06-8,10.0,HTS002,PREP022,enzalutamide,androgen receptor antagonist,AR,oncology,prostate cancer,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F,Launched
BRD-K56908511-001-01-2::0.00061034::HTS002,BRD-K56908511-001-01-2,0.00061034,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::0.0024414::HTS002,BRD-K56908511-001-01-2,0.0024414,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::0.00976562::HTS002,BRD-K56908511-001-01-2,0.00976562,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::0.0390625::HTS002,BRD-K56908511-001-01-2,0.0390625,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::0.15625::HTS002,BRD-K56908511-001-01-2,0.15625,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::0.625::HTS002,BRD-K56908511-001-01-2,0.625,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::2.5::HTS002,BRD-K56908511-001-01-2,2.5,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56908511-001-01-2::10::HTS002,BRD-K56908511-001-01-2,10.0,HTS002,PREP048,fluroxene,local anesthetic,NA,NA,NA,"FC(F)(F)COC=C, FC(F)(F)COC=C",Preclinical
BRD-K56957086-001-06-3::0.00061034::HTS002,BRD-K56957086-001-06-3,0.00061034,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::0.0024414::HTS002,BRD-K56957086-001-06-3,0.0024414,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::0.00976562::HTS002,BRD-K56957086-001-06-3,0.00976562,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::0.0390625::HTS002,BRD-K56957086-001-06-3,0.0390625,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::0.15625::HTS002,BRD-K56957086-001-06-3,0.15625,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::0.625::HTS002,BRD-K56957086-001-06-3,0.625,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::2.5::HTS002,BRD-K56957086-001-06-3,2.5,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K56957086-001-06-3::10::HTS002,BRD-K56957086-001-06-3,10.0,HTS002,PREP045,dacinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",Phase 1
BRD-K57080016-001-15-9::0.00061034::HTS002,BRD-K57080016-001-15-9,0.00061034,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.0024414::HTS002,BRD-K57080016-001-15-9,0.0024414,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.00976562::HTS002,BRD-K57080016-001-15-9,0.00976562,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.0390625::HTS002,BRD-K57080016-001-15-9,0.0390625,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.15625::HTS002,BRD-K57080016-001-15-9,0.15625,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::0.625::HTS002,BRD-K57080016-001-15-9,0.625,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::2.5::HTS002,BRD-K57080016-001-15-9,2.5,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57080016-001-15-9::10::HTS002,BRD-K57080016-001-15-9,10.0,HTS002,PREP038,selumetinib,MEK inhibitor,MAP2K1,NA,NA,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",Phase 3
BRD-K57136142-001-02-4::0.00061034::HTS002,BRD-K57136142-001-02-4,0.00061034,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::0.0024414::HTS002,BRD-K57136142-001-02-4,0.0024414,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::0.00976562::HTS002,BRD-K57136142-001-02-4,0.00976562,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::0.0390625::HTS002,BRD-K57136142-001-02-4,0.0390625,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::0.15625::HTS002,BRD-K57136142-001-02-4,0.15625,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::0.625::HTS002,BRD-K57136142-001-02-4,0.625,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::2.5::HTS002,BRD-K57136142-001-02-4,2.5,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57136142-001-02-4::10::HTS002,BRD-K57136142-001-02-4,10.0,HTS002,PREP036,CCT129202,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1",Preclinical
BRD-K57169635-001-04-5::0.00061034::HTS002,BRD-K57169635-001-04-5,0.00061034,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.0024414::HTS002,BRD-K57169635-001-04-5,0.0024414,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.00976562::HTS002,BRD-K57169635-001-04-5,0.00976562,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.0390625::HTS002,BRD-K57169635-001-04-5,0.0390625,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.15625::HTS002,BRD-K57169635-001-04-5,0.15625,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::0.625::HTS002,BRD-K57169635-001-04-5,0.625,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::2.5::HTS002,BRD-K57169635-001-04-5,2.5,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57169635-001-04-5::10::HTS002,BRD-K57169635-001-04-5,10.0,HTS002,PREP039,dacomitinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1,Phase 3
BRD-K57284066-001-01-6::0.00061034::HTS002,BRD-K57284066-001-01-6,0.00061034,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::0.0024414::HTS002,BRD-K57284066-001-01-6,0.0024414,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::0.00976562::HTS002,BRD-K57284066-001-01-6,0.00976562,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::0.0390625::HTS002,BRD-K57284066-001-01-6,0.0390625,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::0.15625::HTS002,BRD-K57284066-001-01-6,0.15625,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::0.625::HTS002,BRD-K57284066-001-01-6,0.625,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::2.5::HTS002,BRD-K57284066-001-01-6,2.5,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57284066-001-01-6::10::HTS002,BRD-K57284066-001-01-6,10.0,HTS002,PREP040,Ro-9187,HCV inhibitor,NA,NA,NA,Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1,Preclinical
BRD-K57927309-001-01-7::0.00061034::HTS002,BRD-K57927309-001-01-7,0.00061034,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::0.0024414::HTS002,BRD-K57927309-001-01-7,0.0024414,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::0.00976562::HTS002,BRD-K57927309-001-01-7,0.00976562,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::0.0390625::HTS002,BRD-K57927309-001-01-7,0.0390625,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::0.15625::HTS002,BRD-K57927309-001-01-7,0.15625,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::0.625::HTS002,BRD-K57927309-001-01-7,0.625,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::2.5::HTS002,BRD-K57927309-001-01-7,2.5,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K57927309-001-01-7::10::HTS002,BRD-K57927309-001-01-7,10.0,HTS002,PREP018,BW-180C,opioid receptor agonist,"OPRD1, OPRM1",NA,NA,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O,Phase 2
BRD-K58122457-001-02-2::0.00061034::HTS002,BRD-K58122457-001-02-2,0.00061034,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::0.0024414::HTS002,BRD-K58122457-001-02-2,0.0024414,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::0.00976562::HTS002,BRD-K58122457-001-02-2,0.00976562,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::0.0390625::HTS002,BRD-K58122457-001-02-2,0.0390625,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::0.15625::HTS002,BRD-K58122457-001-02-2,0.15625,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::0.625::HTS002,BRD-K58122457-001-02-2,0.625,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::2.5::HTS002,BRD-K58122457-001-02-2,2.5,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58122457-001-02-2::10::HTS002,BRD-K58122457-001-02-2,10.0,HTS002,PREP024,hesperadin,Aurora kinase inhibitor,AURKB,NA,NA,"CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1",Preclinical
BRD-K58299615-001-03-5::0.00061034::HTS002,BRD-K58299615-001-03-5,0.00061034,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::0.0024414::HTS002,BRD-K58299615-001-03-5,0.0024414,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::0.00976562::HTS002,BRD-K58299615-001-03-5,0.00976562,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::0.0390625::HTS002,BRD-K58299615-001-03-5,0.0390625,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::0.15625::HTS002,BRD-K58299615-001-03-5,0.15625,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::0.625::HTS002,BRD-K58299615-001-03-5,0.625,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::2.5::HTS002,BRD-K58299615-001-03-5,2.5,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58299615-001-03-5::10::HTS002,BRD-K58299615-001-03-5,10.0,HTS002,PREP037,Ro-90-7501,NA,APP,NA,NA,"Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",Preclinical
BRD-K58435339-001-03-0::0.00061034::HTS002,BRD-K58435339-001-03-0,0.00061034,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.0024414::HTS002,BRD-K58435339-001-03-0,0.0024414,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.00976562::HTS002,BRD-K58435339-001-03-0,0.00976562,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.0390625::HTS002,BRD-K58435339-001-03-0,0.0390625,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.15625::HTS002,BRD-K58435339-001-03-0,0.15625,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::0.625::HTS002,BRD-K58435339-001-03-0,0.625,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::2.5::HTS002,BRD-K58435339-001-03-0,2.5,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58435339-001-03-0::10::HTS002,BRD-K58435339-001-03-0,10.0,HTS002,PREP027,AT13387,HSP antagonist,HSP90AA1,NA,NA,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",Phase 2
BRD-K58466253-003-14-0::0.00061034::HTS002,BRD-K58466253-003-14-0,0.00061034,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::0.0024414::HTS002,BRD-K58466253-003-14-0,0.0024414,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::0.00976562::HTS002,BRD-K58466253-003-14-0,0.00976562,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::0.0390625::HTS002,BRD-K58466253-003-14-0,0.0390625,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::0.15625::HTS002,BRD-K58466253-003-14-0,0.15625,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::0.625::HTS002,BRD-K58466253-003-14-0,0.625,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::2.5::HTS002,BRD-K58466253-003-14-0,2.5,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58466253-003-14-0::10::HTS002,BRD-K58466253-003-14-0,10.0,HTS002,PREP032,palmatine-chloride,dopamine synthesis inhibitor,CYP3A4,NA,NA,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,Preclinical
BRD-K58550667-001-08-7::0.00061034::HTS002,BRD-K58550667-001-08-7,0.00061034,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.0024414::HTS002,BRD-K58550667-001-08-7,0.0024414,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.00976562::HTS002,BRD-K58550667-001-08-7,0.00976562,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.0390625::HTS002,BRD-K58550667-001-08-7,0.0390625,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.15625::HTS002,BRD-K58550667-001-08-7,0.15625,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::0.625::HTS002,BRD-K58550667-001-08-7,0.625,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::2.5::HTS002,BRD-K58550667-001-08-7,2.5,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K58550667-001-08-7::10::HTS002,BRD-K58550667-001-08-7,10.0,HTS002,PREP027,FK-866,niacinamide phosphoribosyltransferase inhibitor,NAMPT,NA,NA,O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1,Phase 2
BRD-K55044200-001-15-3::0.00061034::HTS002,BRD-K55044200-001-15-3,0.00061034,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::0.0024414::HTS002,BRD-K55044200-001-15-3,0.0024414,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::0.00976562::HTS002,BRD-K55044200-001-15-3,0.00976562,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::0.0390625::HTS002,BRD-K55044200-001-15-3,0.0390625,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::0.15625::HTS002,BRD-K55044200-001-15-3,0.15625,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::0.625::HTS002,BRD-K55044200-001-15-3,0.625,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::2.5::HTS002,BRD-K55044200-001-15-3,2.5,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K55044200-001-15-3::10::HTS002,BRD-K55044200-001-15-3,10.0,HTS002,PREP034,amoxicillin,penicillin binding protein inhibitor,"CYP2C19, SLC15A1, SLC15A2, SLC22A6","infectious disease, gastroenterology","skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O",Launched
BRD-K58770988-001-01-8::0.00061034::HTS002,BRD-K58770988-001-01-8,0.00061034,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::0.0024414::HTS002,BRD-K58770988-001-01-8,0.0024414,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::0.00976562::HTS002,BRD-K58770988-001-01-8,0.00976562,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::0.0390625::HTS002,BRD-K58770988-001-01-8,0.0390625,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::0.15625::HTS002,BRD-K58770988-001-01-8,0.15625,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::0.625::HTS002,BRD-K58770988-001-01-8,0.625,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::2.5::HTS002,BRD-K58770988-001-01-8,2.5,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58770988-001-01-8::10::HTS002,BRD-K58770988-001-01-8,10.0,HTS002,PREP015,NMS-E973,HSP inhibitor,NA,NA,NA,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,Preclinical
BRD-K58772419-001-07-0::0.00061034::HTS002,BRD-K58772419-001-07-0,0.00061034,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::0.0024414::HTS002,BRD-K58772419-001-07-0,0.0024414,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::0.00976562::HTS002,BRD-K58772419-001-07-0,0.00976562,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::0.0390625::HTS002,BRD-K58772419-001-07-0,0.0390625,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::0.15625::HTS002,BRD-K58772419-001-07-0,0.15625,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::0.625::HTS002,BRD-K58772419-001-07-0,0.625,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::2.5::HTS002,BRD-K58772419-001-07-0,2.5,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K58772419-001-07-0::10::HTS002,BRD-K58772419-001-07-0,10.0,HTS002,PREP039,AZD6482,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,"C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",Phase 1
BRD-K59058747-001-18-3::0.00061034::HTS002,BRD-K59058747-001-18-3,0.00061034,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::0.0024414::HTS002,BRD-K59058747-001-18-3,0.0024414,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::0.00976562::HTS002,BRD-K59058747-001-18-3,0.00976562,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::0.0390625::HTS002,BRD-K59058747-001-18-3,0.0390625,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::0.15625::HTS002,BRD-K59058747-001-18-3,0.15625,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::0.625::HTS002,BRD-K59058747-001-18-3,0.625,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::2.5::HTS002,BRD-K59058747-001-18-3,2.5,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59058747-001-18-3::10::HTS002,BRD-K59058747-001-18-3,10.0,HTS002,PREP048,acetylcysteine,mucolytic agent,"ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11",gastroenterology,"acetaminophen overdose, hepatic injury","CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O",Launched
BRD-K59146805-001-03-7::0.00061034::HTS002,BRD-K59146805-001-03-7,0.00061034,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::0.0024414::HTS002,BRD-K59146805-001-03-7,0.0024414,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::0.00976562::HTS002,BRD-K59146805-001-03-7,0.00976562,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::0.0390625::HTS002,BRD-K59146805-001-03-7,0.0390625,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::0.15625::HTS002,BRD-K59146805-001-03-7,0.15625,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::0.625::HTS002,BRD-K59146805-001-03-7,0.625,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::2.5::HTS002,BRD-K59146805-001-03-7,2.5,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59146805-001-03-7::10::HTS002,BRD-K59146805-001-03-7,10.0,HTS002,PREP015,AZ3146,monopolar spindle 1 kinase inhibitor,NA,NA,NA,"COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",Preclinical
BRD-K59197931-001-04-5::0.00061034::HTS002,BRD-K59197931-001-04-5,0.00061034,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::0.0024414::HTS002,BRD-K59197931-001-04-5,0.0024414,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::0.00976562::HTS002,BRD-K59197931-001-04-5,0.00976562,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::0.0390625::HTS002,BRD-K59197931-001-04-5,0.0390625,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::0.15625::HTS002,BRD-K59197931-001-04-5,0.15625,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::0.625::HTS002,BRD-K59197931-001-04-5,0.625,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::2.5::HTS002,BRD-K59197931-001-04-5,2.5,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59197931-001-04-5::10::HTS002,BRD-K59197931-001-04-5,10.0,HTS002,PREP022,naproxen,cyclooxygenase inhibitor,"PTGS1, PTGS2","neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology","pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever","COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O",Launched
BRD-K59317601-001-05-5::0.00061034::HTS002,BRD-K59317601-001-05-5,0.00061034,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.0024414::HTS002,BRD-K59317601-001-05-5,0.0024414,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.00976562::HTS002,BRD-K59317601-001-05-5,0.00976562,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.0390625::HTS002,BRD-K59317601-001-05-5,0.0390625,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.15625::HTS002,BRD-K59317601-001-05-5,0.15625,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::0.625::HTS002,BRD-K59317601-001-05-5,0.625,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::2.5::HTS002,BRD-K59317601-001-05-5,2.5,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59317601-001-05-5::10::HTS002,BRD-K59317601-001-05-5,10.0,HTS002,PREP025,MLN0128,mTOR inhibitor,"MTOR, PIK3CA, PIK3CD, PIK3CG",NA,NA,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,Phase 2
BRD-K59325863-001-02-8::0.00061034::HTS002,BRD-K59325863-001-02-8,0.00061034,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::0.0024414::HTS002,BRD-K59325863-001-02-8,0.0024414,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::0.00976562::HTS002,BRD-K59325863-001-02-8,0.00976562,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::0.0390625::HTS002,BRD-K59325863-001-02-8,0.0390625,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::0.15625::HTS002,BRD-K59325863-001-02-8,0.15625,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::0.625::HTS002,BRD-K59325863-001-02-8,0.625,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::2.5::HTS002,BRD-K59325863-001-02-8,2.5,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59325863-001-02-8::10::HTS002,BRD-K59325863-001-02-8,10.0,HTS002,PREP027,delanzomib,proteasome inhibitor,"CMA1, CTSG, CYP3A4, ELANE",NA,NA,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",Phase 1/Phase 2
BRD-K59369769-001-20-3::0.00061034::HTS002,BRD-K59369769-001-20-3,0.00061034,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::0.0024414::HTS002,BRD-K59369769-001-20-3,0.0024414,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::0.00976562::HTS002,BRD-K59369769-001-20-3,0.00976562,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::0.0390625::HTS002,BRD-K59369769-001-20-3,0.0390625,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::0.15625::HTS002,BRD-K59369769-001-20-3,0.15625,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::0.625::HTS002,BRD-K59369769-001-20-3,0.625,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::2.5::HTS002,BRD-K59369769-001-20-3,2.5,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59369769-001-20-3::10::HTS002,BRD-K59369769-001-20-3,10.0,HTS002,PREP039,tozasertib,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK",NA,NA,"CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",Phase 2
BRD-K59436580-001-01-7::0.00061034::HTS002,BRD-K59436580-001-01-7,0.00061034,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::0.0024414::HTS002,BRD-K59436580-001-01-7,0.0024414,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::0.00976562::HTS002,BRD-K59436580-001-01-7,0.00976562,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::0.0390625::HTS002,BRD-K59436580-001-01-7,0.0390625,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::0.15625::HTS002,BRD-K59436580-001-01-7,0.15625,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::0.625::HTS002,BRD-K59436580-001-01-7,0.625,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::2.5::HTS002,BRD-K59436580-001-01-7,2.5,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59436580-001-01-7::10::HTS002,BRD-K59436580-001-01-7,10.0,HTS002,PREP015,tedizolid,bacterial 50S ribosomal subunit inhibitor,NA,infectious disease,skin infections,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,Launched
BRD-K59522102-001-14-6::0.00061034::HTS002,BRD-K59522102-001-14-6,0.00061034,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::0.0024414::HTS002,BRD-K59522102-001-14-6,0.0024414,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::0.00976562::HTS002,BRD-K59522102-001-14-6,0.00976562,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::0.0390625::HTS002,BRD-K59522102-001-14-6,0.0390625,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::0.15625::HTS002,BRD-K59522102-001-14-6,0.15625,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::0.625::HTS002,BRD-K59522102-001-14-6,0.625,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::2.5::HTS002,BRD-K59522102-001-14-6,2.5,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K59522102-001-14-6::10::HTS002,BRD-K59522102-001-14-6,10.0,HTS002,PREP039,piperine,monoamine oxidase inhibitor,"MAOA, MAOB, TRPV1",NA,NA,"O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",Phase 1
BRD-K41141507-001-16-2::0.00061034::HTS002,BRD-K41141507-001-16-2,0.00061034,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::0.0024414::HTS002,BRD-K41141507-001-16-2,0.0024414,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::0.00976562::HTS002,BRD-K41141507-001-16-2,0.00976562,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::0.0390625::HTS002,BRD-K41141507-001-16-2,0.0390625,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::0.15625::HTS002,BRD-K41141507-001-16-2,0.15625,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::0.625::HTS002,BRD-K41141507-001-16-2,0.625,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::2.5::HTS002,BRD-K41141507-001-16-2,2.5,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K41141507-001-16-2::10::HTS002,BRD-K41141507-001-16-2,10.0,HTS002,PREP022,cyproterone-acetate,androgen receptor antagonist,"ADORA1, AR",oncology,prostate cancer,"CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O",Launched
BRD-K59574735-001-11-8::0.00061034::HTS002,BRD-K59574735-001-11-8,0.00061034,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::0.0024414::HTS002,BRD-K59574735-001-11-8,0.0024414,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::0.00976562::HTS002,BRD-K59574735-001-11-8,0.00976562,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::0.0390625::HTS002,BRD-K59574735-001-11-8,0.0390625,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::0.15625::HTS002,BRD-K59574735-001-11-8,0.15625,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::0.625::HTS002,BRD-K59574735-001-11-8,0.625,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::2.5::HTS002,BRD-K59574735-001-11-8,2.5,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59574735-001-11-8::10::HTS002,BRD-K59574735-001-11-8,10.0,HTS002,PREP023,ubenimex,leukotriene synthesis inhibitor,"LTA4H, RNPEP",hematologic malignancy,acute myeloid leukemia (AML),"CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O",Launched
BRD-K59632282-052-03-1::0.00061034::HTS002,BRD-K59632282-052-03-1,0.00061034,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::0.0024414::HTS002,BRD-K59632282-052-03-1,0.0024414,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::0.00976562::HTS002,BRD-K59632282-052-03-1,0.00976562,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::0.0390625::HTS002,BRD-K59632282-052-03-1,0.0390625,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::0.15625::HTS002,BRD-K59632282-052-03-1,0.15625,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::0.625::HTS002,BRD-K59632282-052-03-1,0.625,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::2.5::HTS002,BRD-K59632282-052-03-1,2.5,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59632282-052-03-1::10::HTS002,BRD-K59632282-052-03-1,10.0,HTS002,PREP015,quinidine,sodium channel blocker,"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","infectious disease, cardiology","malaria, atrial fibrillation (AF), ventricular arrhythmias",COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,Launched
BRD-K59647213-001-10-5::0.00061034::HTS002,BRD-K59647213-001-10-5,0.00061034,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::0.0024414::HTS002,BRD-K59647213-001-10-5,0.0024414,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::0.00976562::HTS002,BRD-K59647213-001-10-5,0.00976562,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::0.0390625::HTS002,BRD-K59647213-001-10-5,0.0390625,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::0.15625::HTS002,BRD-K59647213-001-10-5,0.15625,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::0.625::HTS002,BRD-K59647213-001-10-5,0.625,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::2.5::HTS002,BRD-K59647213-001-10-5,2.5,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59647213-001-10-5::10::HTS002,BRD-K59647213-001-10-5,10.0,HTS002,PREP020,levocarnitine,NA,NA,endocrinology,carnitine deficiency,"C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O",Launched
BRD-K59831625-001-01-6::0.00061034::HTS002,BRD-K59831625-001-01-6,0.00061034,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::0.0024414::HTS002,BRD-K59831625-001-01-6,0.0024414,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::0.00976562::HTS002,BRD-K59831625-001-01-6,0.00976562,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::0.0390625::HTS002,BRD-K59831625-001-01-6,0.0390625,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::0.15625::HTS002,BRD-K59831625-001-01-6,0.15625,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::0.625::HTS002,BRD-K59831625-001-01-6,0.625,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::2.5::HTS002,BRD-K59831625-001-01-6,2.5,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59831625-001-01-6::10::HTS002,BRD-K59831625-001-01-6,10.0,HTS002,PREP040,LDN-212854,bone morphogenic protein inhibitor,"ABL1, ACVR1, RIPK2",NA,NA,"C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",Preclinical
BRD-K59929863-001-01-9::0.000610352::HTS002,BRD-K59929863-001-01-9,0.000610352,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::0.00244141::HTS002,BRD-K59929863-001-01-9,0.00244141,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::0.00976562::HTS002,BRD-K59929863-001-01-9,0.00976562,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::0.0390625::HTS002,BRD-K59929863-001-01-9,0.0390625,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::0.15625::HTS002,BRD-K59929863-001-01-9,0.15625,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::0.625::HTS002,BRD-K59929863-001-01-9,0.625,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::2.5::HTS002,BRD-K59929863-001-01-9,2.5,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59929863-001-01-9::10::HTS002,BRD-K59929863-001-01-9,10.0,HTS002,PREP038,CB-10-277,DNA synthesis inhibitor,NA,NA,NA,CN(C)\N=N\c1ccc(cc1)C(O)=O,Phase 1
BRD-K59983611-001-21-9::0.00061034::HTS002,BRD-K59983611-001-21-9,0.00061034,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::0.0024414::HTS002,BRD-K59983611-001-21-9,0.0024414,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::0.00976562::HTS002,BRD-K59983611-001-21-9,0.00976562,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::0.0390625::HTS002,BRD-K59983611-001-21-9,0.0390625,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::0.15625::HTS002,BRD-K59983611-001-21-9,0.15625,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::0.625::HTS002,BRD-K59983611-001-21-9,0.625,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::2.5::HTS002,BRD-K59983611-001-21-9,2.5,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K59983611-001-21-9::10::HTS002,BRD-K59983611-001-21-9,10.0,HTS002,PREP044,sulfabenzamide,bacterial antifolate,NA,NA,NA,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,Launched
BRD-K60025295-003-06-6::0.00061034::HTS002,BRD-K60025295-003-06-6,0.00061034,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::0.0024414::HTS002,BRD-K60025295-003-06-6,0.0024414,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::0.00976562::HTS002,BRD-K60025295-003-06-6,0.00976562,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::0.0390625::HTS002,BRD-K60025295-003-06-6,0.0390625,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::0.15625::HTS002,BRD-K60025295-003-06-6,0.15625,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::0.625::HTS002,BRD-K60025295-003-06-6,0.625,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::2.5::HTS002,BRD-K60025295-003-06-6,2.5,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60025295-003-06-6::10::HTS002,BRD-K60025295-003-06-6,10.0,HTS002,PREP038,crystal-violet,other antibiotic,NA,NA,NA,"CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C",Launched
BRD-K60160658-003-11-2::0.00061034::HTS002,BRD-K60160658-003-11-2,0.00061034,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::0.0024414::HTS002,BRD-K60160658-003-11-2,0.0024414,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::0.00976562::HTS002,BRD-K60160658-003-11-2,0.00976562,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::0.0390625::HTS002,BRD-K60160658-003-11-2,0.0390625,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::0.15625::HTS002,BRD-K60160658-003-11-2,0.15625,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::0.625::HTS002,BRD-K60160658-003-11-2,0.625,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::2.5::HTS002,BRD-K60160658-003-11-2,2.5,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60160658-003-11-2::10::HTS002,BRD-K60160658-003-11-2,10.0,HTS002,PREP022,tiagabine,GABA uptake inhibitor,SLC6A1,neurology/psychiatry,seizures,"Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C",Launched
BRD-K60184833-001-05-6::0.00061034::HTS002,BRD-K60184833-001-05-6,0.00061034,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::0.0024414::HTS002,BRD-K60184833-001-05-6,0.0024414,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::0.00976562::HTS002,BRD-K60184833-001-05-6,0.00976562,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::0.0390625::HTS002,BRD-K60184833-001-05-6,0.0390625,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::0.15625::HTS002,BRD-K60184833-001-05-6,0.15625,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::0.625::HTS002,BRD-K60184833-001-05-6,0.625,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::2.5::HTS002,BRD-K60184833-001-05-6,2.5,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60184833-001-05-6::10::HTS002,BRD-K60184833-001-05-6,10.0,HTS002,PREP043,tyrphostin-AG-99,tyrosine kinase inhibitor,EGFR,NA,NA,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,Preclinical
BRD-K60230970-001-17-5::0.000586438::HTS002,BRD-K60230970-001-17-5,0.000586438,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::0.00234575::HTS002,BRD-K60230970-001-17-5,0.00234575,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::0.009383::HTS002,BRD-K60230970-001-17-5,0.009383,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::0.037532::HTS002,BRD-K60230970-001-17-5,0.037532,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::0.150128::HTS002,BRD-K60230970-001-17-5,0.150128,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::0.600512::HTS002,BRD-K60230970-001-17-5,0.600512,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::2.40205::HTS002,BRD-K60230970-001-17-5,2.40205,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60230970-001-17-5::9.6082::HTS002,BRD-K60230970-001-17-5,9.6082,HTS002,PREP041,MG-132,proteasome inhibitor,PSMB1,NA,NA,"CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",Preclinical
BRD-K60237333-001-27-1::0.00061034::HTS002,BRD-K60237333-001-27-1,0.00061034,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::0.0024414::HTS002,BRD-K60237333-001-27-1,0.0024414,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::0.00976562::HTS002,BRD-K60237333-001-27-1,0.00976562,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::0.0390625::HTS002,BRD-K60237333-001-27-1,0.0390625,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::0.15625::HTS002,BRD-K60237333-001-27-1,0.15625,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::0.625::HTS002,BRD-K60237333-001-27-1,0.625,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::2.5::HTS002,BRD-K60237333-001-27-1,2.5,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60237333-001-27-1::10::HTS002,BRD-K60237333-001-27-1,10.0,HTS002,PREP022,niacin,"NAD precursor, vitamin B","DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT",endocrinology,hypertriglyceridemia,"OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1",Launched
BRD-K60341624-001-02-2::0.00061034::HTS002,BRD-K60341624-001-02-2,0.00061034,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::0.0024414::HTS002,BRD-K60341624-001-02-2,0.0024414,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::0.00976562::HTS002,BRD-K60341624-001-02-2,0.00976562,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::0.0390625::HTS002,BRD-K60341624-001-02-2,0.0390625,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::0.15625::HTS002,BRD-K60341624-001-02-2,0.15625,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::0.625::HTS002,BRD-K60341624-001-02-2,0.625,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::2.5::HTS002,BRD-K60341624-001-02-2,2.5,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60341624-001-02-2::10::HTS002,BRD-K60341624-001-02-2,10.0,HTS002,PREP019,GSK1292263,glucose dependent insulinotropic receptor agonist,GRPR,NA,NA,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,Phase 2
BRD-K60348325-065-09-9::0.000610352::HTS002,BRD-K60348325-065-09-9,0.000610352,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::0.00244141::HTS002,BRD-K60348325-065-09-9,0.00244141,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::0.00976562::HTS002,BRD-K60348325-065-09-9,0.00976562,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::0.0390625::HTS002,BRD-K60348325-065-09-9,0.0390625,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::0.15625::HTS002,BRD-K60348325-065-09-9,0.15625,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::0.625::HTS002,BRD-K60348325-065-09-9,0.625,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::2.5::HTS002,BRD-K60348325-065-09-9,2.5,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60348325-065-09-9::10::HTS002,BRD-K60348325-065-09-9,10.0,HTS002,PREP028,brilliant-green,NA,NA,NA,NA,CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC,Launched
BRD-K60443845-001-08-6::0.00061034::HTS002,BRD-K60443845-001-08-6,0.00061034,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::0.0024414::HTS002,BRD-K60443845-001-08-6,0.0024414,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::0.00976562::HTS002,BRD-K60443845-001-08-6,0.00976562,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::0.0390625::HTS002,BRD-K60443845-001-08-6,0.0390625,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::0.15625::HTS002,BRD-K60443845-001-08-6,0.15625,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::0.625::HTS002,BRD-K60443845-001-08-6,0.625,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::2.5::HTS002,BRD-K60443845-001-08-6,2.5,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60443845-001-08-6::10::HTS002,BRD-K60443845-001-08-6,10.0,HTS002,PREP048,chlormidazole,fungal lanosterol demethylase inhibitor,NA,infectious disease,fungal infection,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,Launched
BRD-K60446698-001-01-2::0.00061034::HTS002,BRD-K60446698-001-01-2,0.00061034,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::0.0024414::HTS002,BRD-K60446698-001-01-2,0.0024414,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::0.00976562::HTS002,BRD-K60446698-001-01-2,0.00976562,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::0.0390625::HTS002,BRD-K60446698-001-01-2,0.0390625,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::0.15625::HTS002,BRD-K60446698-001-01-2,0.15625,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::0.625::HTS002,BRD-K60446698-001-01-2,0.625,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::2.5::HTS002,BRD-K60446698-001-01-2,2.5,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60446698-001-01-2::10::HTS002,BRD-K60446698-001-01-2,10.0,HTS002,PREP014,ONX-0914,proteasome inhibitor,NA,NA,NA,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1,Preclinical
BRD-K60585088-001-01-5::0.00061034::HTS002,BRD-K60585088-001-01-5,0.00061034,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::0.0024414::HTS002,BRD-K60585088-001-01-5,0.0024414,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::0.00976562::HTS002,BRD-K60585088-001-01-5,0.00976562,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::0.0390625::HTS002,BRD-K60585088-001-01-5,0.0390625,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::0.15625::HTS002,BRD-K60585088-001-01-5,0.15625,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::0.625::HTS002,BRD-K60585088-001-01-5,0.625,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::2.5::HTS002,BRD-K60585088-001-01-5,2.5,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60585088-001-01-5::10::HTS002,BRD-K60585088-001-01-5,10.0,HTS002,PREP022,paricalcitol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperthyroidism",C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1,Launched
BRD-K60866521-001-07-1::0.00061034::HTS002,BRD-K60866521-001-07-1,0.00061034,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.0024414::HTS002,BRD-K60866521-001-07-1,0.0024414,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.00976562::HTS002,BRD-K60866521-001-07-1,0.00976562,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.0390625::HTS002,BRD-K60866521-001-07-1,0.0390625,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.15625::HTS002,BRD-K60866521-001-07-1,0.15625,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::0.625::HTS002,BRD-K60866521-001-07-1,0.625,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::2.5::HTS002,BRD-K60866521-001-07-1,2.5,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60866521-001-07-1::10::HTS002,BRD-K60866521-001-07-1,10.0,HTS002,PREP022,idelalisib,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",hematologic malignancy,chronic lymphocytic leukemia (CLL),CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,Launched
BRD-K60997853-001-02-3::0.00061034::HTS002,BRD-K60997853-001-02-3,0.00061034,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.0024414::HTS002,BRD-K60997853-001-02-3,0.0024414,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.00976562::HTS002,BRD-K60997853-001-02-3,0.00976562,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.0390625::HTS002,BRD-K60997853-001-02-3,0.0390625,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.15625::HTS002,BRD-K60997853-001-02-3,0.15625,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::0.625::HTS002,BRD-K60997853-001-02-3,0.625,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::2.5::HTS002,BRD-K60997853-001-02-3,2.5,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K60997853-001-02-3::10::HTS002,BRD-K60997853-001-02-3,10.0,HTS002,PREP026,PHA-848125,"CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1",NA,NA,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,Phase 2
BRD-K61036791-001-01-6::0.000610352::HTS002,BRD-K61036791-001-01-6,0.000610352,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::0.00244141::HTS002,BRD-K61036791-001-01-6,0.00244141,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::0.00976562::HTS002,BRD-K61036791-001-01-6,0.00976562,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::0.0390625::HTS002,BRD-K61036791-001-01-6,0.0390625,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::0.15625::HTS002,BRD-K61036791-001-01-6,0.15625,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::0.625::HTS002,BRD-K61036791-001-01-6,0.625,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::2.5::HTS002,BRD-K61036791-001-01-6,2.5,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61036791-001-01-6::10::HTS002,BRD-K61036791-001-01-6,10.0,HTS002,PREP027,rucinol,tyrosinase inhibitor,TYR,NA,NA,CCCCc1ccc(O)cc1O,Phase 1
BRD-K61097567-001-08-5::0.00061034::HTS002,BRD-K61097567-001-08-5,0.00061034,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::0.0024414::HTS002,BRD-K61097567-001-08-5,0.0024414,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::0.00976562::HTS002,BRD-K61097567-001-08-5,0.00976562,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::0.0390625::HTS002,BRD-K61097567-001-08-5,0.0390625,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::0.15625::HTS002,BRD-K61097567-001-08-5,0.15625,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::0.625::HTS002,BRD-K61097567-001-08-5,0.625,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::2.5::HTS002,BRD-K61097567-001-08-5,2.5,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61097567-001-08-5::10::HTS002,BRD-K61097567-001-08-5,10.0,HTS002,PREP042,SB-218795,tachykinin antagonist,TACR3,NA,NA,"COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",Preclinical
BRD-K61195623-001-01-4::0.000610352::HTS002,BRD-K61195623-001-01-4,0.000610352,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::0.00244141::HTS002,BRD-K61195623-001-01-4,0.00244141,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::0.00976562::HTS002,BRD-K61195623-001-01-4,0.00976562,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::0.0390625::HTS002,BRD-K61195623-001-01-4,0.0390625,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::0.15625::HTS002,BRD-K61195623-001-01-4,0.15625,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::0.625::HTS002,BRD-K61195623-001-01-4,0.625,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::2.5::HTS002,BRD-K61195623-001-01-4,2.5,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61195623-001-01-4::10::HTS002,BRD-K61195623-001-01-4,10.0,HTS002,PREP038,combretastatin-A-4,tubulin polymerization inhibitor,NA,NA,NA,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,Phase 2
BRD-K61228301-001-01-2::0.00061034::HTS002,BRD-K61228301-001-01-2,0.00061034,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::0.0024414::HTS002,BRD-K61228301-001-01-2,0.0024414,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::0.00976562::HTS002,BRD-K61228301-001-01-2,0.00976562,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::0.0390625::HTS002,BRD-K61228301-001-01-2,0.0390625,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::0.15625::HTS002,BRD-K61228301-001-01-2,0.15625,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::0.625::HTS002,BRD-K61228301-001-01-2,0.625,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::2.5::HTS002,BRD-K61228301-001-01-2,2.5,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61228301-001-01-2::10::HTS002,BRD-K61228301-001-01-2,10.0,HTS002,PREP037,SGI-1027,DNA methyltransferase inhibitor,"DNMT1, DNMT3A, DNMT3B",NA,NA,Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1,Preclinical
BRD-K61250484-001-02-3::0.00061034::HTS002,BRD-K61250484-001-02-3,0.00061034,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::0.0024414::HTS002,BRD-K61250484-001-02-3,0.0024414,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::0.00976562::HTS002,BRD-K61250484-001-02-3,0.00976562,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::0.0390625::HTS002,BRD-K61250484-001-02-3,0.0390625,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::0.15625::HTS002,BRD-K61250484-001-02-3,0.15625,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::0.625::HTS002,BRD-K61250484-001-02-3,0.625,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::2.5::HTS002,BRD-K61250484-001-02-3,2.5,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61250484-001-02-3::10::HTS002,BRD-K61250484-001-02-3,10.0,HTS002,PREP044,FPH1-(BRD-6125),hepatocyte function enhancer,NA,NA,NA,Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O,Preclinical
BRD-K61295575-001-03-6::0.00061034::HTS002,BRD-K61295575-001-03-6,0.00061034,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::0.0024414::HTS002,BRD-K61295575-001-03-6,0.0024414,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::0.00976562::HTS002,BRD-K61295575-001-03-6,0.00976562,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::0.0390625::HTS002,BRD-K61295575-001-03-6,0.0390625,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::0.15625::HTS002,BRD-K61295575-001-03-6,0.15625,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::0.625::HTS002,BRD-K61295575-001-03-6,0.625,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::2.5::HTS002,BRD-K61295575-001-03-6,2.5,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61295575-001-03-6::10::HTS002,BRD-K61295575-001-03-6,10.0,HTS002,PREP040,blebbistatin-(-),ATPase inhibitor,NA,NA,NA,Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1,Preclinical
BRD-K61314889-001-04-4::0.00061034::HTS002,BRD-K61314889-001-04-4,0.00061034,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::0.0024414::HTS002,BRD-K61314889-001-04-4,0.0024414,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::0.00976562::HTS002,BRD-K61314889-001-04-4,0.00976562,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::0.0390625::HTS002,BRD-K61314889-001-04-4,0.0390625,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::0.15625::HTS002,BRD-K61314889-001-04-4,0.15625,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::0.625::HTS002,BRD-K61314889-001-04-4,0.625,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::2.5::HTS002,BRD-K61314889-001-04-4,2.5,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61314889-001-04-4::10::HTS002,BRD-K61314889-001-04-4,10.0,HTS002,PREP043,endo-IWR-1,PARP inhibitor,"TNKS, TNKS2",NA,NA,"O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O",Preclinical
BRD-K61323504-001-04-0::0.00061034::HTS002,BRD-K61323504-001-04-0,0.00061034,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::0.0024414::HTS002,BRD-K61323504-001-04-0,0.0024414,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::0.00976562::HTS002,BRD-K61323504-001-04-0,0.00976562,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::0.0390625::HTS002,BRD-K61323504-001-04-0,0.0390625,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::0.15625::HTS002,BRD-K61323504-001-04-0,0.15625,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::0.625::HTS002,BRD-K61323504-001-04-0,0.625,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::2.5::HTS002,BRD-K61323504-001-04-0,2.5,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61323504-001-04-0::10::HTS002,BRD-K61323504-001-04-0,10.0,HTS002,PREP044,SB-225002,CC chemokine receptor antagonist,CXCR2,NA,NA,"Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",Preclinical
BRD-K61397605-001-03-4::0.00061034::HTS002,BRD-K61397605-001-03-4,0.00061034,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::0.0024414::HTS002,BRD-K61397605-001-03-4,0.0024414,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::0.00976562::HTS002,BRD-K61397605-001-03-4,0.00976562,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::0.0390625::HTS002,BRD-K61397605-001-03-4,0.0390625,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::0.15625::HTS002,BRD-K61397605-001-03-4,0.15625,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::0.625::HTS002,BRD-K61397605-001-03-4,0.625,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::2.5::HTS002,BRD-K61397605-001-03-4,2.5,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61397605-001-03-4::10::HTS002,BRD-K61397605-001-03-4,10.0,HTS002,PREP014,romidepsin,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Launched
BRD-K61443650-236-13-1::0.00061034::HTS002,BRD-K61443650-236-13-1,0.00061034,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::0.0024414::HTS002,BRD-K61443650-236-13-1,0.0024414,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::0.00976562::HTS002,BRD-K61443650-236-13-1,0.00976562,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::0.0390625::HTS002,BRD-K61443650-236-13-1,0.0390625,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::0.15625::HTS002,BRD-K61443650-236-13-1,0.15625,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::0.625::HTS002,BRD-K61443650-236-13-1,0.625,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::2.5::HTS002,BRD-K61443650-236-13-1,2.5,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61443650-236-13-1::10::HTS002,BRD-K61443650-236-13-1,10.0,HTS002,PREP030,thiomersal,other antibiotic,OXCT1,NA,NA,CC[Hg]Sc1ccccc1C(O)=O,Launched
BRD-K61536336-001-01-7::0.00061034::HTS002,BRD-K61536336-001-01-7,0.00061034,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::0.0024414::HTS002,BRD-K61536336-001-01-7,0.0024414,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::0.00976562::HTS002,BRD-K61536336-001-01-7,0.00976562,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::0.0390625::HTS002,BRD-K61536336-001-01-7,0.0390625,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::0.15625::HTS002,BRD-K61536336-001-01-7,0.15625,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::0.625::HTS002,BRD-K61536336-001-01-7,0.625,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::2.5::HTS002,BRD-K61536336-001-01-7,2.5,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61536336-001-01-7::10::HTS002,BRD-K61536336-001-01-7,10.0,HTS002,PREP032,SB-366791,TRPV antagonist,TRPV1,NA,NA,"COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",Preclinical
BRD-K61567297-001-01-9::0.00061034::HTS002,BRD-K61567297-001-01-9,0.00061034,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::0.0024414::HTS002,BRD-K61567297-001-01-9,0.0024414,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::0.00976562::HTS002,BRD-K61567297-001-01-9,0.00976562,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::0.0390625::HTS002,BRD-K61567297-001-01-9,0.0390625,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::0.15625::HTS002,BRD-K61567297-001-01-9,0.15625,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::0.625::HTS002,BRD-K61567297-001-01-9,0.625,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::2.5::HTS002,BRD-K61567297-001-01-9,2.5,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61567297-001-01-9::10::HTS002,BRD-K61567297-001-01-9,10.0,HTS002,PREP039,resatorvid,toll-like receptor antagonist,TLR4,NA,NA,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl",Phase 3
BRD-K61642990-001-01-0::0.00061034::HTS002,BRD-K61642990-001-01-0,0.00061034,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::0.0024414::HTS002,BRD-K61642990-001-01-0,0.0024414,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::0.00976562::HTS002,BRD-K61642990-001-01-0,0.00976562,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::0.0390625::HTS002,BRD-K61642990-001-01-0,0.0390625,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::0.15625::HTS002,BRD-K61642990-001-01-0,0.15625,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::0.625::HTS002,BRD-K61642990-001-01-0,0.625,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::2.5::HTS002,BRD-K61642990-001-01-0,2.5,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61642990-001-01-0::10::HTS002,BRD-K61642990-001-01-0,10.0,HTS002,PREP037,FERb-033,EGFR inhibitor,ERBB2,NA,NA,"O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O, O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O",Preclinical
BRD-K61688984-001-02-9::0.00061034::HTS002,BRD-K61688984-001-02-9,0.00061034,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::0.0024414::HTS002,BRD-K61688984-001-02-9,0.0024414,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::0.00976562::HTS002,BRD-K61688984-001-02-9,0.00976562,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::0.0390625::HTS002,BRD-K61688984-001-02-9,0.0390625,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::0.15625::HTS002,BRD-K61688984-001-02-9,0.15625,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::0.625::HTS002,BRD-K61688984-001-02-9,0.625,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::2.5::HTS002,BRD-K61688984-001-02-9,2.5,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61688984-001-02-9::10::HTS002,BRD-K61688984-001-02-9,10.0,HTS002,PREP014,RGFP966,HDAC inhibitor,HDAC3,NA,NA,Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1,Preclinical
BRD-K61717546-001-05-0::0.000604122::HTS002,BRD-K61717546-001-05-0,0.000604122,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::0.00241649::HTS002,BRD-K61717546-001-05-0,0.00241649,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::0.00966594::HTS002,BRD-K61717546-001-05-0,0.00966594,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::0.0386638::HTS002,BRD-K61717546-001-05-0,0.0386638,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::0.154655::HTS002,BRD-K61717546-001-05-0,0.154655,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::0.61862::HTS002,BRD-K61717546-001-05-0,0.61862,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::2.47448::HTS002,BRD-K61717546-001-05-0,2.47448,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61717546-001-05-0::9.89793::HTS002,BRD-K61717546-001-05-0,9.89793,HTS002,PREP035,fleroxacin,topoisomerase inhibitor,NA,"infectious disease, gastroenterology","gonorrhea, enteritis, diarrhea, respiratory tract infections","CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O",Launched
BRD-K61734568-003-02-1::0.00061034::HTS002,BRD-K61734568-003-02-1,0.00061034,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::0.0024414::HTS002,BRD-K61734568-003-02-1,0.0024414,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::0.00976562::HTS002,BRD-K61734568-003-02-1,0.00976562,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::0.0390625::HTS002,BRD-K61734568-003-02-1,0.0390625,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::0.15625::HTS002,BRD-K61734568-003-02-1,0.15625,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::0.625::HTS002,BRD-K61734568-003-02-1,0.625,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::2.5::HTS002,BRD-K61734568-003-02-1,2.5,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61734568-003-02-1::10::HTS002,BRD-K61734568-003-02-1,10.0,HTS002,PREP036,"2,3-DCPE",Bcl-XL downregulator,BCL2L1,NA,NA,OCCNCCCOc1cccc(Cl)c1Cl,Preclinical
BRD-K61936403-001-01-7::0.00061034::HTS002,BRD-K61936403-001-01-7,0.00061034,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::0.0024414::HTS002,BRD-K61936403-001-01-7,0.0024414,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::0.00976562::HTS002,BRD-K61936403-001-01-7,0.00976562,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::0.0390625::HTS002,BRD-K61936403-001-01-7,0.0390625,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::0.15625::HTS002,BRD-K61936403-001-01-7,0.15625,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::0.625::HTS002,BRD-K61936403-001-01-7,0.625,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::2.5::HTS002,BRD-K61936403-001-01-7,2.5,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K61936403-001-01-7::10::HTS002,BRD-K61936403-001-01-7,10.0,HTS002,PREP041,AS-1949490,SHIP2 phosphatase inhibitor,INPP5D,NA,NA,"C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",Preclinical
BRD-K62196610-001-01-6::0.00061034::HTS002,BRD-K62196610-001-01-6,0.00061034,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.0024414::HTS002,BRD-K62196610-001-01-6,0.0024414,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.00976562::HTS002,BRD-K62196610-001-01-6,0.00976562,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.0390625::HTS002,BRD-K62196610-001-01-6,0.0390625,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.15625::HTS002,BRD-K62196610-001-01-6,0.15625,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::0.625::HTS002,BRD-K62196610-001-01-6,0.625,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::2.5::HTS002,BRD-K62196610-001-01-6,2.5,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62196610-001-01-6::10::HTS002,BRD-K62196610-001-01-6,10.0,HTS002,PREP024,AVN-944,inosine monophosphate dehydrogenase inhibitor,"IMPDH1, IMPDH2",NA,NA,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,Phase 2
BRD-K62200014-003-10-5::0.00061034::HTS002,BRD-K62200014-003-10-5,0.00061034,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.0024414::HTS002,BRD-K62200014-003-10-5,0.0024414,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.00976562::HTS002,BRD-K62200014-003-10-5,0.00976562,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.0390625::HTS002,BRD-K62200014-003-10-5,0.0390625,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.15625::HTS002,BRD-K62200014-003-10-5,0.15625,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::0.625::HTS002,BRD-K62200014-003-10-5,0.625,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::2.5::HTS002,BRD-K62200014-003-10-5,2.5,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62200014-003-10-5::10::HTS002,BRD-K62200014-003-10-5,10.0,HTS002,PREP028,anagrelide,phosphodiesterase inhibitor,PDE3A,"hematology, hematologic malignancy","thrombocythemia, myeloproliferative neoplasms","Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl",Launched
BRD-K62310379-001-10-5::0.00061034::HTS002,BRD-K62310379-001-10-5,0.00061034,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::0.0024414::HTS002,BRD-K62310379-001-10-5,0.0024414,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::0.00976562::HTS002,BRD-K62310379-001-10-5,0.00976562,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::0.0390625::HTS002,BRD-K62310379-001-10-5,0.0390625,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::0.15625::HTS002,BRD-K62310379-001-10-5,0.15625,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::0.625::HTS002,BRD-K62310379-001-10-5,0.625,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::2.5::HTS002,BRD-K62310379-001-10-5,2.5,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62310379-001-10-5::10::HTS002,BRD-K62310379-001-10-5,10.0,HTS002,PREP022,fluticasone-propionate,glucocorticoid receptor agonist,"NR3C1, NR3C2, PGR, PLA2G4A",dermatology,corticosteroid-responsive dermatoses,"CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF",Launched
BRD-K62391742-001-03-0::0.00061034::HTS002,BRD-K62391742-001-03-0,0.00061034,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::0.0024414::HTS002,BRD-K62391742-001-03-0,0.0024414,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::0.00976562::HTS002,BRD-K62391742-001-03-0,0.00976562,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::0.0390625::HTS002,BRD-K62391742-001-03-0,0.0390625,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::0.15625::HTS002,BRD-K62391742-001-03-0,0.15625,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::0.625::HTS002,BRD-K62391742-001-03-0,0.625,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::2.5::HTS002,BRD-K62391742-001-03-0,2.5,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62391742-001-03-0::10::HTS002,BRD-K62391742-001-03-0,10.0,HTS002,PREP045,venetoclax,BCL inhibitor,BCL2,hematologic malignancy,chronic lymphocytic leukemia (CLL),"CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1",Launched
BRD-K62398570-300-01-2::0.000610352::HTS002,BRD-K62398570-300-01-2,0.000610352,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::0.00244141::HTS002,BRD-K62398570-300-01-2,0.00244141,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::0.00976562::HTS002,BRD-K62398570-300-01-2,0.00976562,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::0.0390625::HTS002,BRD-K62398570-300-01-2,0.0390625,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::0.15625::HTS002,BRD-K62398570-300-01-2,0.15625,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::0.625::HTS002,BRD-K62398570-300-01-2,0.625,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::2.5::HTS002,BRD-K62398570-300-01-2,2.5,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62398570-300-01-2::10::HTS002,BRD-K62398570-300-01-2,10.0,HTS002,PREP019,lerisetron,serotonin receptor antagonist,HTR3A,NA,NA,C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1,Phase 3
BRD-K62607865-001-09-7::0.000640562::HTS002,BRD-K62607865-001-09-7,0.000640562,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::0.00256225::HTS002,BRD-K62607865-001-09-7,0.00256225,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::0.010249::HTS002,BRD-K62607865-001-09-7,0.010249,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::0.040996::HTS002,BRD-K62607865-001-09-7,0.040996,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::0.163984::HTS002,BRD-K62607865-001-09-7,0.163984,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::0.655936::HTS002,BRD-K62607865-001-09-7,0.655936,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::2.62374::HTS002,BRD-K62607865-001-09-7,2.62374,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62607865-001-09-7::10.495::HTS002,BRD-K62607865-001-09-7,10.495,HTS002,PREP031,aztreonam,bacterial cell wall synthesis inhibitor,NA,infectious disease,"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O",Launched
BRD-K62627508-001-01-5::0.00061034::HTS002,BRD-K62627508-001-01-5,0.00061034,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.0024414::HTS002,BRD-K62627508-001-01-5,0.0024414,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.00976562::HTS002,BRD-K62627508-001-01-5,0.00976562,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.0390625::HTS002,BRD-K62627508-001-01-5,0.0390625,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.15625::HTS002,BRD-K62627508-001-01-5,0.15625,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::0.625::HTS002,BRD-K62627508-001-01-5,0.625,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::2.5::HTS002,BRD-K62627508-001-01-5,2.5,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62627508-001-01-5::10::HTS002,BRD-K62627508-001-01-5,10.0,HTS002,PREP045,idasanutlin,MDM inhibitor,"MDM2, TP53",NA,NA,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,Phase 3
BRD-K62696033-001-01-4::0.00061034::HTS002,BRD-K62696033-001-01-4,0.00061034,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::0.0024414::HTS002,BRD-K62696033-001-01-4,0.0024414,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::0.00976562::HTS002,BRD-K62696033-001-01-4,0.00976562,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::0.0390625::HTS002,BRD-K62696033-001-01-4,0.0390625,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::0.15625::HTS002,BRD-K62696033-001-01-4,0.15625,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::0.625::HTS002,BRD-K62696033-001-01-4,0.625,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::2.5::HTS002,BRD-K62696033-001-01-4,2.5,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62696033-001-01-4::10::HTS002,BRD-K62696033-001-01-4,10.0,HTS002,PREP036,G-1,G protein-coupled receptor agonist,GPER1,NA,NA,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,Preclinical
BRD-K62762455-001-01-3::0.00061034::HTS002,BRD-K62762455-001-01-3,0.00061034,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::0.0024414::HTS002,BRD-K62762455-001-01-3,0.0024414,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::0.00976562::HTS002,BRD-K62762455-001-01-3,0.00976562,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::0.0390625::HTS002,BRD-K62762455-001-01-3,0.0390625,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::0.15625::HTS002,BRD-K62762455-001-01-3,0.15625,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::0.625::HTS002,BRD-K62762455-001-01-3,0.625,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::2.5::HTS002,BRD-K62762455-001-01-3,2.5,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62762455-001-01-3::10::HTS002,BRD-K62762455-001-01-3,10.0,HTS002,PREP025,RU-58841,androgen receptor antagonist,AR,NA,NA,CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F,Phase 2
BRD-K62779383-001-05-5::0.000580092::HTS002,BRD-K62779383-001-05-5,0.000580092,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::0.00232037::HTS002,BRD-K62779383-001-05-5,0.00232037,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::0.00928147::HTS002,BRD-K62779383-001-05-5,0.00928147,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::0.0371259::HTS002,BRD-K62779383-001-05-5,0.0371259,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::0.148504::HTS002,BRD-K62779383-001-05-5,0.148504,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::0.594014::HTS002,BRD-K62779383-001-05-5,0.594014,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::2.37606::HTS002,BRD-K62779383-001-05-5,2.37606,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62779383-001-05-5::9.50423::HTS002,BRD-K62779383-001-05-5,9.50423,HTS002,PREP035,cholecalciferol,NA,VDR,endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C",Launched
BRD-K62810658-001-12-2::0.00061034::HTS002,BRD-K62810658-001-12-2,0.00061034,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::0.0024414::HTS002,BRD-K62810658-001-12-2,0.0024414,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::0.00976562::HTS002,BRD-K62810658-001-12-2,0.00976562,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::0.0390625::HTS002,BRD-K62810658-001-12-2,0.0390625,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::0.15625::HTS002,BRD-K62810658-001-12-2,0.15625,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::0.625::HTS002,BRD-K62810658-001-12-2,0.625,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::2.5::HTS002,BRD-K62810658-001-12-2,2.5,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62810658-001-12-2::10::HTS002,BRD-K62810658-001-12-2,10.0,HTS002,PREP024,PD-98059,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N",Preclinical
BRD-K62814476-001-03-3::0.00061034::HTS002,BRD-K62814476-001-03-3,0.00061034,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::0.0024414::HTS002,BRD-K62814476-001-03-3,0.0024414,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::0.00976562::HTS002,BRD-K62814476-001-03-3,0.00976562,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::0.0390625::HTS002,BRD-K62814476-001-03-3,0.0390625,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::0.15625::HTS002,BRD-K62814476-001-03-3,0.15625,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::0.625::HTS002,BRD-K62814476-001-03-3,0.625,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::2.5::HTS002,BRD-K62814476-001-03-3,2.5,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62814476-001-03-3::10::HTS002,BRD-K62814476-001-03-3,10.0,HTS002,PREP032,BMS-265246,CDK inhibitor,"CDK1, CDK2",NA,NA,"CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F",Preclinical
BRD-K62965247-001-04-9::0.00061034::HTS002,BRD-K62965247-001-04-9,0.00061034,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::0.0024414::HTS002,BRD-K62965247-001-04-9,0.0024414,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::0.00976562::HTS002,BRD-K62965247-001-04-9,0.00976562,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::0.0390625::HTS002,BRD-K62965247-001-04-9,0.0390625,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::0.15625::HTS002,BRD-K62965247-001-04-9,0.15625,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::0.625::HTS002,BRD-K62965247-001-04-9,0.625,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::2.5::HTS002,BRD-K62965247-001-04-9,2.5,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K62965247-001-04-9::10::HTS002,BRD-K62965247-001-04-9,10.0,HTS002,PREP018,tipifarnib,farnesyltransferase inhibitor,"FNTA, FNTB",NA,NA,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1,Phase 3
BRD-K63068307-001-08-9::0.00061034::HTS002,BRD-K63068307-001-08-9,0.00061034,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::0.0024414::HTS002,BRD-K63068307-001-08-9,0.0024414,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::0.00976562::HTS002,BRD-K63068307-001-08-9,0.00976562,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::0.0390625::HTS002,BRD-K63068307-001-08-9,0.0390625,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::0.15625::HTS002,BRD-K63068307-001-08-9,0.15625,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::0.625::HTS002,BRD-K63068307-001-08-9,0.625,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::2.5::HTS002,BRD-K63068307-001-08-9,2.5,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63068307-001-08-9::10::HTS002,BRD-K63068307-001-08-9,10.0,HTS002,PREP047,ZSTK-474,PI3K inhibitor,"PIK3CB, PIK3CD, PIK3CG",NA,NA,FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,Phase 1/Phase 2
BRD-K63123526-001-01-2::0.000610352::HTS002,BRD-K63123526-001-01-2,0.000610352,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::0.00244141::HTS002,BRD-K63123526-001-01-2,0.00244141,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::0.00976562::HTS002,BRD-K63123526-001-01-2,0.00976562,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::0.0390625::HTS002,BRD-K63123526-001-01-2,0.0390625,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::0.15625::HTS002,BRD-K63123526-001-01-2,0.15625,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::0.625::HTS002,BRD-K63123526-001-01-2,0.625,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::2.5::HTS002,BRD-K63123526-001-01-2,2.5,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K63123526-001-01-2::10::HTS002,BRD-K63123526-001-01-2,10.0,HTS002,PREP038,S-methylcysteine,NA,"CTSD, MGMT",NA,NA,"CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",Phase 1
BRD-K69650333-003-14-0::0.00061034::HTS002,BRD-K69650333-003-14-0,0.00061034,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::0.0024414::HTS002,BRD-K69650333-003-14-0,0.0024414,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::0.00976562::HTS002,BRD-K69650333-003-14-0,0.00976562,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::0.0390625::HTS002,BRD-K69650333-003-14-0,0.0390625,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::0.15625::HTS002,BRD-K69650333-003-14-0,0.15625,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::0.625::HTS002,BRD-K69650333-003-14-0,0.625,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::2.5::HTS002,BRD-K69650333-003-14-0,2.5,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K69650333-003-14-0::10::HTS002,BRD-K69650333-003-14-0,10.0,HTS002,PREP021,idarubicin,topoisomerase inhibitor,TOP2A,hematologic malignancy,acute myeloid leukemia (AML),"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O",Launched
BRD-K63126190-003-01-6::0.00061034::HTS002,BRD-K63126190-003-01-6,0.00061034,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::0.0024414::HTS002,BRD-K63126190-003-01-6,0.0024414,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::0.00976562::HTS002,BRD-K63126190-003-01-6,0.00976562,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::0.0390625::HTS002,BRD-K63126190-003-01-6,0.0390625,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::0.15625::HTS002,BRD-K63126190-003-01-6,0.15625,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::0.625::HTS002,BRD-K63126190-003-01-6,0.625,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::2.5::HTS002,BRD-K63126190-003-01-6,2.5,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K63126190-003-01-6::10::HTS002,BRD-K63126190-003-01-6,10.0,HTS002,PREP021,epinephrine,"adrenergic receptor agonist, neurotransmitter","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF","cardiology, allergy, pulmonary","cardiac arrest, anaphylactic shock, asthma","CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K26531771-001-02-2::0.000574227::HTS002,BRD-K26531771-001-02-2,0.000574227,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::0.00229691::HTS002,BRD-K26531771-001-02-2,0.00229691,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::0.00918764::HTS002,BRD-K26531771-001-02-2,0.00918764,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::0.0367505::HTS002,BRD-K26531771-001-02-2,0.0367505,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::0.147002::HTS002,BRD-K26531771-001-02-2,0.147002,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::0.588009::HTS002,BRD-K26531771-001-02-2,0.588009,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::2.35203::HTS002,BRD-K26531771-001-02-2,2.35203,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K26531771-001-02-2::9.40814::HTS002,BRD-K26531771-001-02-2,9.40814,HTS002,PREP015,EPZ-5676,histone lysine methyltransferase inhibitor,DOT1L,NA,NA,"CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1",Phase 1
BRD-K63504947-001-15-4::0.00061034::HTS002,BRD-K63504947-001-15-4,0.00061034,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::0.0024414::HTS002,BRD-K63504947-001-15-4,0.0024414,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::0.00976562::HTS002,BRD-K63504947-001-15-4,0.00976562,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::0.0390625::HTS002,BRD-K63504947-001-15-4,0.0390625,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::0.15625::HTS002,BRD-K63504947-001-15-4,0.15625,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::0.625::HTS002,BRD-K63504947-001-15-4,0.625,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::2.5::HTS002,BRD-K63504947-001-15-4,2.5,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63504947-001-15-4::10::HTS002,BRD-K63504947-001-15-4,10.0,HTS002,PREP024,semaxanib,VEGFR inhibitor,"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET",NA,NA,"Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",Phase 3
BRD-K63712959-001-01-8::0.00061034::HTS002,BRD-K63712959-001-01-8,0.00061034,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.0024414::HTS002,BRD-K63712959-001-01-8,0.0024414,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.00976562::HTS002,BRD-K63712959-001-01-8,0.00976562,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.0390625::HTS002,BRD-K63712959-001-01-8,0.0390625,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.15625::HTS002,BRD-K63712959-001-01-8,0.15625,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::0.625::HTS002,BRD-K63712959-001-01-8,0.625,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::2.5::HTS002,BRD-K63712959-001-01-8,2.5,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63712959-001-01-8::10::HTS002,BRD-K63712959-001-01-8,10.0,HTS002,PREP030,temoporfin,radical formation stimulant,NA,oncology,head and neck squamous cell carcinoma (HNSCC),Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2,Launched
BRD-K63736853-001-04-8::0.00061034::HTS002,BRD-K63736853-001-04-8,0.00061034,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::0.0024414::HTS002,BRD-K63736853-001-04-8,0.0024414,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::0.00976562::HTS002,BRD-K63736853-001-04-8,0.00976562,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::0.0390625::HTS002,BRD-K63736853-001-04-8,0.0390625,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::0.15625::HTS002,BRD-K63736853-001-04-8,0.15625,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::0.625::HTS002,BRD-K63736853-001-04-8,0.625,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::2.5::HTS002,BRD-K63736853-001-04-8,2.5,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63736853-001-04-8::10::HTS002,BRD-K63736853-001-04-8,10.0,HTS002,PREP048,acipimox,cholesterol inhibitor,HCAR2,endocrinology,hyperlipidemia,"Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O",Launched
BRD-K63750851-001-20-7::0.00061034::HTS002,BRD-K63750851-001-20-7,0.00061034,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::0.0024414::HTS002,BRD-K63750851-001-20-7,0.0024414,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::0.00976562::HTS002,BRD-K63750851-001-20-7,0.00976562,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::0.0390625::HTS002,BRD-K63750851-001-20-7,0.0390625,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::0.15625::HTS002,BRD-K63750851-001-20-7,0.15625,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::0.625::HTS002,BRD-K63750851-001-20-7,0.625,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::2.5::HTS002,BRD-K63750851-001-20-7,2.5,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63750851-001-20-7::10::HTS002,BRD-K63750851-001-20-7,10.0,HTS002,PREP023,mycophenolic-acid,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O",Launched
BRD-K63784565-001-06-2::0.00061239::HTS002,BRD-K63784565-001-06-2,0.00061239,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::0.00244956::HTS002,BRD-K63784565-001-06-2,0.00244956,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::0.00979824::HTS002,BRD-K63784565-001-06-2,0.00979824,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::0.039193::HTS002,BRD-K63784565-001-06-2,0.039193,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::0.156772::HTS002,BRD-K63784565-001-06-2,0.156772,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::0.627088::HTS002,BRD-K63784565-001-06-2,0.627088,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::2.50835::HTS002,BRD-K63784565-001-06-2,2.50835,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63784565-001-06-2::10.0334::HTS002,BRD-K63784565-001-06-2,10.0334,HTS002,PREP041,10-hydroxycamptothecin,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",Preclinical
BRD-K63828191-003-32-1::0.00061034::HTS002,BRD-K63828191-003-32-1,0.00061034,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::0.0024414::HTS002,BRD-K63828191-003-32-1,0.0024414,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::0.00976562::HTS002,BRD-K63828191-003-32-1,0.00976562,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::0.0390625::HTS002,BRD-K63828191-003-32-1,0.0390625,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::0.15625::HTS002,BRD-K63828191-003-32-1,0.15625,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::0.625::HTS002,BRD-K63828191-003-32-1,0.625,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::2.5::HTS002,BRD-K63828191-003-32-1,2.5,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63828191-003-32-1::10::HTS002,BRD-K63828191-003-32-1,10.0,HTS002,PREP023,raloxifene,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","ESR1, ESR2","orthopedics, oncology","osteoporosis, breast cancer","Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1",Launched
BRD-K63923597-001-10-0::0.00061034::HTS002,BRD-K63923597-001-10-0,0.00061034,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::0.0024414::HTS002,BRD-K63923597-001-10-0,0.0024414,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::0.00976562::HTS002,BRD-K63923597-001-10-0,0.00976562,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::0.0390625::HTS002,BRD-K63923597-001-10-0,0.0390625,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::0.15625::HTS002,BRD-K63923597-001-10-0,0.15625,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::0.625::HTS002,BRD-K63923597-001-10-0,0.625,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::2.5::HTS002,BRD-K63923597-001-10-0,2.5,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63923597-001-10-0::10::HTS002,BRD-K63923597-001-10-0,10.0,HTS002,PREP026,barasertib-HQPA,Aurora kinase inhibitor,AURKB,NA,NA,"CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1",Phase 2/Phase 3
BRD-K63932022-001-01-5::0.00061034::HTS002,BRD-K63932022-001-01-5,0.00061034,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::0.0024414::HTS002,BRD-K63932022-001-01-5,0.0024414,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::0.00976562::HTS002,BRD-K63932022-001-01-5,0.00976562,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::0.0390625::HTS002,BRD-K63932022-001-01-5,0.0390625,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::0.15625::HTS002,BRD-K63932022-001-01-5,0.15625,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::0.625::HTS002,BRD-K63932022-001-01-5,0.625,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::2.5::HTS002,BRD-K63932022-001-01-5,2.5,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K63932022-001-01-5::10::HTS002,BRD-K63932022-001-01-5,10.0,HTS002,PREP042,2'-MeCCPA,adenosine receptor agonist,ADORA1,NA,NA,"C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",Preclinical
BRD-K64052750-001-17-5::0.00061034::HTS002,BRD-K64052750-001-17-5,0.00061034,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::0.0024414::HTS002,BRD-K64052750-001-17-5,0.0024414,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::0.00976562::HTS002,BRD-K64052750-001-17-5,0.00976562,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::0.0390625::HTS002,BRD-K64052750-001-17-5,0.0390625,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::0.15625::HTS002,BRD-K64052750-001-17-5,0.15625,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::0.625::HTS002,BRD-K64052750-001-17-5,0.625,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::2.5::HTS002,BRD-K64052750-001-17-5,2.5,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K64052750-001-17-5::10::HTS002,BRD-K64052750-001-17-5,10.0,HTS002,PREP022,gefitinib,EGFR inhibitor,EGFR,oncology,non-small cell lung cancer (NSCLC),"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1",Launched
BRD-K50853363-001-02-3::0.00061034::HTS002,BRD-K50853363-001-02-3,0.00061034,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::0.0024414::HTS002,BRD-K50853363-001-02-3,0.0024414,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::0.00976562::HTS002,BRD-K50853363-001-02-3,0.00976562,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::0.0390625::HTS002,BRD-K50853363-001-02-3,0.0390625,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::0.15625::HTS002,BRD-K50853363-001-02-3,0.15625,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::0.625::HTS002,BRD-K50853363-001-02-3,0.625,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::2.5::HTS002,BRD-K50853363-001-02-3,2.5,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K50853363-001-02-3::10::HTS002,BRD-K50853363-001-02-3,10.0,HTS002,PREP045,dienogest,progesterone receptor agonist,PGR,"endocrinology, obstetrics/gynecology","contraceptive, endometriosis",C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Launched
BRD-K64538373-001-01-4::0.00061034::HTS002,BRD-K64538373-001-01-4,0.00061034,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::0.0024414::HTS002,BRD-K64538373-001-01-4,0.0024414,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::0.00976562::HTS002,BRD-K64538373-001-01-4,0.00976562,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::0.0390625::HTS002,BRD-K64538373-001-01-4,0.0390625,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::0.15625::HTS002,BRD-K64538373-001-01-4,0.15625,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::0.625::HTS002,BRD-K64538373-001-01-4,0.625,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::2.5::HTS002,BRD-K64538373-001-01-4,2.5,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K64538373-001-01-4::10::HTS002,BRD-K64538373-001-01-4,10.0,HTS002,PREP018,Ro-4987655,MEK inhibitor,MAP2K1,NA,NA,OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,Phase 1
BRD-K55675242-001-03-0::0.00061034::HTS002,BRD-K55675242-001-03-0,0.00061034,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::0.0024414::HTS002,BRD-K55675242-001-03-0,0.0024414,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::0.00976562::HTS002,BRD-K55675242-001-03-0,0.00976562,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::0.0390625::HTS002,BRD-K55675242-001-03-0,0.0390625,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::0.15625::HTS002,BRD-K55675242-001-03-0,0.15625,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::0.625::HTS002,BRD-K55675242-001-03-0,0.625,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::2.5::HTS002,BRD-K55675242-001-03-0,2.5,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K55675242-001-03-0::10::HTS002,BRD-K55675242-001-03-0,10.0,HTS002,PREP038,torcetrapib,cholesteryl ester transfer protein inhibitor,CETP,NA,NA,"CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",Phase 3
BRD-K64785675-001-04-0::0.00061034::HTS002,BRD-K64785675-001-04-0,0.00061034,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::0.0024414::HTS002,BRD-K64785675-001-04-0,0.0024414,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::0.00976562::HTS002,BRD-K64785675-001-04-0,0.00976562,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::0.0390625::HTS002,BRD-K64785675-001-04-0,0.0390625,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::0.15625::HTS002,BRD-K64785675-001-04-0,0.15625,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::0.625::HTS002,BRD-K64785675-001-04-0,0.625,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::2.5::HTS002,BRD-K64785675-001-04-0,2.5,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64785675-001-04-0::10::HTS002,BRD-K64785675-001-04-0,10.0,HTS002,PREP039,TG100-115,PI3K inhibitor,"PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,Phase 1/Phase 2
BRD-K64800655-001-07-4::0.00061034::HTS002,BRD-K64800655-001-07-4,0.00061034,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::0.0024414::HTS002,BRD-K64800655-001-07-4,0.0024414,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::0.00976562::HTS002,BRD-K64800655-001-07-4,0.00976562,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::0.0390625::HTS002,BRD-K64800655-001-07-4,0.0390625,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::0.15625::HTS002,BRD-K64800655-001-07-4,0.15625,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::0.625::HTS002,BRD-K64800655-001-07-4,0.625,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::2.5::HTS002,BRD-K64800655-001-07-4,2.5,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64800655-001-07-4::10::HTS002,BRD-K64800655-001-07-4,10.0,HTS002,PREP038,PHA-793887,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9",NA,NA,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",Phase 1
BRD-K64866502-001-03-9::0.00061034::HTS002,BRD-K64866502-001-03-9,0.00061034,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::0.0024414::HTS002,BRD-K64866502-001-03-9,0.0024414,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::0.00976562::HTS002,BRD-K64866502-001-03-9,0.00976562,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::0.0390625::HTS002,BRD-K64866502-001-03-9,0.0390625,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::0.15625::HTS002,BRD-K64866502-001-03-9,0.15625,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::0.625::HTS002,BRD-K64866502-001-03-9,0.625,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::2.5::HTS002,BRD-K64866502-001-03-9,2.5,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64866502-001-03-9::10::HTS002,BRD-K64866502-001-03-9,10.0,HTS002,PREP026,CYC116,Aurora kinase inhibitor,"AURKA, AURKB, KDR",NA,NA,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 1
BRD-K64881305-001-03-7::0.00061034::HTS002,BRD-K64881305-001-03-7,0.00061034,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.0024414::HTS002,BRD-K64881305-001-03-7,0.0024414,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.00976562::HTS002,BRD-K64881305-001-03-7,0.00976562,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.0390625::HTS002,BRD-K64881305-001-03-7,0.0390625,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.15625::HTS002,BRD-K64881305-001-03-7,0.15625,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::0.625::HTS002,BRD-K64881305-001-03-7,0.625,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::2.5::HTS002,BRD-K64881305-001-03-7,2.5,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64881305-001-03-7::10::HTS002,BRD-K64881305-001-03-7,10.0,HTS002,PREP045,ispinesib,kinesin inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",Phase 2
BRD-K64888243-001-03-7::0.00061034::HTS002,BRD-K64888243-001-03-7,0.00061034,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::0.0024414::HTS002,BRD-K64888243-001-03-7,0.0024414,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::0.00976562::HTS002,BRD-K64888243-001-03-7,0.00976562,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::0.0390625::HTS002,BRD-K64888243-001-03-7,0.0390625,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::0.15625::HTS002,BRD-K64888243-001-03-7,0.15625,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::0.625::HTS002,BRD-K64888243-001-03-7,0.625,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::2.5::HTS002,BRD-K64888243-001-03-7,2.5,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64888243-001-03-7::10::HTS002,BRD-K64888243-001-03-7,10.0,HTS002,PREP014,AZ960,JAK inhibitor,JAK2,NA,NA,"C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c1ccc(F)cc1",Preclinical
BRD-K64890080-001-13-8::0.00061034::HTS002,BRD-K64890080-001-13-8,0.00061034,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::0.0024414::HTS002,BRD-K64890080-001-13-8,0.0024414,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::0.00976562::HTS002,BRD-K64890080-001-13-8,0.00976562,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::0.0390625::HTS002,BRD-K64890080-001-13-8,0.0390625,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::0.15625::HTS002,BRD-K64890080-001-13-8,0.15625,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::0.625::HTS002,BRD-K64890080-001-13-8,0.625,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::2.5::HTS002,BRD-K64890080-001-13-8,2.5,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64890080-001-13-8::10::HTS002,BRD-K64890080-001-13-8,10.0,HTS002,PREP033,BI-2536,PLK inhibitor,"BRD4, PLK1, PLK2, PLK3",NA,NA,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,Phase 2
BRD-K64925568-001-01-8::0.00061034::HTS002,BRD-K64925568-001-01-8,0.00061034,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::0.0024414::HTS002,BRD-K64925568-001-01-8,0.0024414,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::0.00976562::HTS002,BRD-K64925568-001-01-8,0.00976562,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::0.0390625::HTS002,BRD-K64925568-001-01-8,0.0390625,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::0.15625::HTS002,BRD-K64925568-001-01-8,0.15625,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::0.625::HTS002,BRD-K64925568-001-01-8,0.625,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::2.5::HTS002,BRD-K64925568-001-01-8,2.5,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K64925568-001-01-8::10::HTS002,BRD-K64925568-001-01-8,10.0,HTS002,PREP019,AMG-232,MDM inhibitor,MDM2,NA,NA,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1,Phase 1/Phase 2
BRD-K65377893-001-07-4::0.000630323::HTS002,BRD-K65377893-001-07-4,0.000630323,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::0.00252129::HTS002,BRD-K65377893-001-07-4,0.00252129,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::0.0100852::HTS002,BRD-K65377893-001-07-4,0.0100852,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::0.0403407::HTS002,BRD-K65377893-001-07-4,0.0403407,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::0.161363::HTS002,BRD-K65377893-001-07-4,0.161363,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::0.645451::HTS002,BRD-K65377893-001-07-4,0.645451,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::2.5818::HTS002,BRD-K65377893-001-07-4,2.5818,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65377893-001-07-4::10.3272::HTS002,BRD-K65377893-001-07-4,10.3272,HTS002,PREP028,7-aminocephalosporanic-acid,beta lactamase inhibitor,NA,NA,NA,"CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O",Preclinical
BRD-K65678996-001-05-5::0.00061034::HTS002,BRD-K65678996-001-05-5,0.00061034,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::0.0024414::HTS002,BRD-K65678996-001-05-5,0.0024414,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::0.00976562::HTS002,BRD-K65678996-001-05-5,0.00976562,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::0.0390625::HTS002,BRD-K65678996-001-05-5,0.0390625,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::0.15625::HTS002,BRD-K65678996-001-05-5,0.15625,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::0.625::HTS002,BRD-K65678996-001-05-5,0.625,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::2.5::HTS002,BRD-K65678996-001-05-5,2.5,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65678996-001-05-5::10::HTS002,BRD-K65678996-001-05-5,10.0,HTS002,PREP032,nefiracetam,"acetylcholine receptor agonist, benzodiazepine receptor agonist",CHRM1,NA,NA,"Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",Phase 3
BRD-K65781196-001-03-0::0.00061034::HTS002,BRD-K65781196-001-03-0,0.00061034,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::0.0024414::HTS002,BRD-K65781196-001-03-0,0.0024414,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::0.00976562::HTS002,BRD-K65781196-001-03-0,0.00976562,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::0.0390625::HTS002,BRD-K65781196-001-03-0,0.0390625,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::0.15625::HTS002,BRD-K65781196-001-03-0,0.15625,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::0.625::HTS002,BRD-K65781196-001-03-0,0.625,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::2.5::HTS002,BRD-K65781196-001-03-0,2.5,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65781196-001-03-0::10::HTS002,BRD-K65781196-001-03-0,10.0,HTS002,PREP029,avanafil,phosphodiesterase inhibitor,PDE5A,urology,erectile dysfunction,"COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl",Launched
BRD-K65814004-003-02-9::0.00061034::HTS002,BRD-K65814004-003-02-9,0.00061034,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::0.0024414::HTS002,BRD-K65814004-003-02-9,0.0024414,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::0.00976562::HTS002,BRD-K65814004-003-02-9,0.00976562,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::0.0390625::HTS002,BRD-K65814004-003-02-9,0.0390625,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::0.15625::HTS002,BRD-K65814004-003-02-9,0.15625,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::0.625::HTS002,BRD-K65814004-003-02-9,0.625,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::2.5::HTS002,BRD-K65814004-003-02-9,2.5,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65814004-003-02-9::10::HTS002,BRD-K65814004-003-02-9,10.0,HTS002,PREP042,diphenyleneiodonium,nitric oxide synthase inhibitor,"NOS2, NOS3",NA,NA,[I+]1c2ccccc2-c2ccccc12,Preclinical
BRD-K65877271-001-01-8::0.00061034::HTS002,BRD-K65877271-001-01-8,0.00061034,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::0.0024414::HTS002,BRD-K65877271-001-01-8,0.0024414,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::0.00976562::HTS002,BRD-K65877271-001-01-8,0.00976562,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::0.0390625::HTS002,BRD-K65877271-001-01-8,0.0390625,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::0.15625::HTS002,BRD-K65877271-001-01-8,0.15625,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::0.625::HTS002,BRD-K65877271-001-01-8,0.625,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::2.5::HTS002,BRD-K65877271-001-01-8,2.5,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65877271-001-01-8::10::HTS002,BRD-K65877271-001-01-8,10.0,HTS002,PREP034,halobetasol-propionate,glucocorticoid receptor agonist,"NR3C1, PLA2G1B",dermatology,corticosteroid-responsive dermatoses,CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl,Launched
BRD-K65924316-001-03-1::0.00061034::HTS002,BRD-K65924316-001-03-1,0.00061034,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::0.0024414::HTS002,BRD-K65924316-001-03-1,0.0024414,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::0.00976562::HTS002,BRD-K65924316-001-03-1,0.00976562,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::0.0390625::HTS002,BRD-K65924316-001-03-1,0.0390625,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::0.15625::HTS002,BRD-K65924316-001-03-1,0.15625,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::0.625::HTS002,BRD-K65924316-001-03-1,0.625,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::2.5::HTS002,BRD-K65924316-001-03-1,2.5,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65924316-001-03-1::10::HTS002,BRD-K65924316-001-03-1,10.0,HTS002,PREP024,serdemetan,MDM inhibitor,MDM2,NA,NA,"C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",Phase 1
BRD-K65928735-001-04-3::0.00061034::HTS002,BRD-K65928735-001-04-3,0.00061034,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::0.0024414::HTS002,BRD-K65928735-001-04-3,0.0024414,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::0.00976562::HTS002,BRD-K65928735-001-04-3,0.00976562,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::0.0390625::HTS002,BRD-K65928735-001-04-3,0.0390625,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::0.15625::HTS002,BRD-K65928735-001-04-3,0.15625,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::0.625::HTS002,BRD-K65928735-001-04-3,0.625,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::2.5::HTS002,BRD-K65928735-001-04-3,2.5,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K65928735-001-04-3::10::HTS002,BRD-K65928735-001-04-3,10.0,HTS002,PREP038,AZD1480,JAK inhibitor,"JAK1, JAK2, JAK3",NA,NA,"C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1",Phase 1
BRD-K66030860-001-03-6::0.00061034::HTS002,BRD-K66030860-001-03-6,0.00061034,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::0.0024414::HTS002,BRD-K66030860-001-03-6,0.0024414,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::0.00976562::HTS002,BRD-K66030860-001-03-6,0.00976562,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::0.0390625::HTS002,BRD-K66030860-001-03-6,0.0390625,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::0.15625::HTS002,BRD-K66030860-001-03-6,0.15625,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::0.625::HTS002,BRD-K66030860-001-03-6,0.625,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::2.5::HTS002,BRD-K66030860-001-03-6,2.5,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66030860-001-03-6::10::HTS002,BRD-K66030860-001-03-6,10.0,HTS002,PREP032,salidroside,beta amyloid protein neurotoxicity inhibitor,APP,NA,NA,"OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",Preclinical
BRD-K66094457-001-01-5::0.000610352::HTS002,BRD-K66094457-001-01-5,0.000610352,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::0.00244141::HTS002,BRD-K66094457-001-01-5,0.00244141,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::0.00976562::HTS002,BRD-K66094457-001-01-5,0.00976562,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::0.0390625::HTS002,BRD-K66094457-001-01-5,0.0390625,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::0.15625::HTS002,BRD-K66094457-001-01-5,0.15625,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::0.625::HTS002,BRD-K66094457-001-01-5,0.625,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::2.5::HTS002,BRD-K66094457-001-01-5,2.5,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66094457-001-01-5::10::HTS002,BRD-K66094457-001-01-5,10.0,HTS002,PREP035,CPP,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D",NA,NA,"OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)C1CN(CCCP(O)(O)=O)CCN1",Phase 2
BRD-K66097663-001-01-8::0.00061034::HTS002,BRD-K66097663-001-01-8,0.00061034,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::0.0024414::HTS002,BRD-K66097663-001-01-8,0.0024414,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::0.00976562::HTS002,BRD-K66097663-001-01-8,0.00976562,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::0.0390625::HTS002,BRD-K66097663-001-01-8,0.0390625,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::0.15625::HTS002,BRD-K66097663-001-01-8,0.15625,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::0.625::HTS002,BRD-K66097663-001-01-8,0.625,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::2.5::HTS002,BRD-K66097663-001-01-8,2.5,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66097663-001-01-8::10::HTS002,BRD-K66097663-001-01-8,10.0,HTS002,PREP045,TMC-353121,RSV fusion inhibitor,NA,NA,NA,Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1,Phase 2
BRD-K66175015-001-09-0::0.00061034::HTS002,BRD-K66175015-001-09-0,0.00061034,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::0.0024414::HTS002,BRD-K66175015-001-09-0,0.0024414,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::0.00976562::HTS002,BRD-K66175015-001-09-0,0.00976562,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::0.0390625::HTS002,BRD-K66175015-001-09-0,0.0390625,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::0.15625::HTS002,BRD-K66175015-001-09-0,0.15625,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::0.625::HTS002,BRD-K66175015-001-09-0,0.625,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::2.5::HTS002,BRD-K66175015-001-09-0,2.5,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66175015-001-09-0::10::HTS002,BRD-K66175015-001-09-0,10.0,HTS002,PREP021,afatinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",oncology,non-small cell lung cancer (NSCLC),"CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1",Launched
BRD-K66241279-001-01-8::0.00061034::HTS002,BRD-K66241279-001-01-8,0.00061034,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::0.0024414::HTS002,BRD-K66241279-001-01-8,0.0024414,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::0.00976562::HTS002,BRD-K66241279-001-01-8,0.00976562,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::0.0390625::HTS002,BRD-K66241279-001-01-8,0.0390625,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::0.15625::HTS002,BRD-K66241279-001-01-8,0.15625,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::0.625::HTS002,BRD-K66241279-001-01-8,0.625,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::2.5::HTS002,BRD-K66241279-001-01-8,2.5,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66241279-001-01-8::10::HTS002,BRD-K66241279-001-01-8,10.0,HTS002,PREP019,cinromide,NA,NA,NA,NA,CCNC(=O)\C=C\c1cccc(Br)c1,Phase 3
BRD-K66296774-236-11-3::0.000642003::HTS002,BRD-K66296774-236-11-3,0.000642003,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::0.00256801::HTS002,BRD-K66296774-236-11-3,0.00256801,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::0.0102721::HTS002,BRD-K66296774-236-11-3,0.0102721,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::0.0410882::HTS002,BRD-K66296774-236-11-3,0.0410882,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::0.164353::HTS002,BRD-K66296774-236-11-3,0.164353,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::0.657411::HTS002,BRD-K66296774-236-11-3,0.657411,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::2.62965::HTS002,BRD-K66296774-236-11-3,2.62965,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66296774-236-11-3::10.5186::HTS002,BRD-K66296774-236-11-3,10.5186,HTS002,PREP031,fluvastatin,HMGCR inhibitor,HMGCR,"endocrinology, cardiology","hypercholesterolemia, congenital heart defects","CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12",Launched
BRD-K66527818-001-02-6::0.00061034::HTS002,BRD-K66527818-001-02-6,0.00061034,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::0.0024414::HTS002,BRD-K66527818-001-02-6,0.0024414,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::0.00976562::HTS002,BRD-K66527818-001-02-6,0.00976562,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::0.0390625::HTS002,BRD-K66527818-001-02-6,0.0390625,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::0.15625::HTS002,BRD-K66527818-001-02-6,0.15625,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::0.625::HTS002,BRD-K66527818-001-02-6,0.625,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::2.5::HTS002,BRD-K66527818-001-02-6,2.5,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66527818-001-02-6::10::HTS002,BRD-K66527818-001-02-6,10.0,HTS002,PREP040,VU0364770,glutamate receptor positive allosteric modulator,GRM4,NA,NA,Clc1cccc(NC(=O)c2ccccn2)c1,Preclinical
BRD-K66715657-050-01-0::0.00061034::HTS002,BRD-K66715657-050-01-0,0.00061034,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::0.0024414::HTS002,BRD-K66715657-050-01-0,0.0024414,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::0.00976562::HTS002,BRD-K66715657-050-01-0,0.00976562,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::0.0390625::HTS002,BRD-K66715657-050-01-0,0.0390625,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::0.15625::HTS002,BRD-K66715657-050-01-0,0.15625,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::0.625::HTS002,BRD-K66715657-050-01-0,0.625,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::2.5::HTS002,BRD-K66715657-050-01-0,2.5,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66715657-050-01-0::10::HTS002,BRD-K66715657-050-01-0,10.0,HTS002,PREP015,UH-232-(+),dopamine receptor antagonist,"DRD2, DRD3, DRD4, HTR1A",NA,NA,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,Preclinical
BRD-K66788707-001-14-3::0.00061034::HTS002,BRD-K66788707-001-14-3,0.00061034,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::0.0024414::HTS002,BRD-K66788707-001-14-3,0.0024414,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::0.00976562::HTS002,BRD-K66788707-001-14-3,0.00976562,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::0.0390625::HTS002,BRD-K66788707-001-14-3,0.0390625,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::0.15625::HTS002,BRD-K66788707-001-14-3,0.15625,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::0.625::HTS002,BRD-K66788707-001-14-3,0.625,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::2.5::HTS002,BRD-K66788707-001-14-3,2.5,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66788707-001-14-3::10::HTS002,BRD-K66788707-001-14-3,10.0,HTS002,PREP028,fludarabine,ribonucleotide reductase inhibitor,"ADA, RRM1, RRM2",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K66808046-065-03-7::0.00061034::HTS002,BRD-K66808046-065-03-7,0.00061034,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.0024414::HTS002,BRD-K66808046-065-03-7,0.0024414,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.00976562::HTS002,BRD-K66808046-065-03-7,0.00976562,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.0390625::HTS002,BRD-K66808046-065-03-7,0.0390625,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.15625::HTS002,BRD-K66808046-065-03-7,0.15625,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.625::HTS002,BRD-K66808046-065-03-7,0.625,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::2.5::HTS002,BRD-K66808046-065-03-7,2.5,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::10::HTS002,BRD-K66808046-065-03-7,10.0,HTS002,PREP021,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66911501-003-01-2::0.00061034::HTS002,BRD-K66911501-003-01-2,0.00061034,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::0.0024414::HTS002,BRD-K66911501-003-01-2,0.0024414,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::0.00976562::HTS002,BRD-K66911501-003-01-2,0.00976562,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::0.0390625::HTS002,BRD-K66911501-003-01-2,0.0390625,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::0.15625::HTS002,BRD-K66911501-003-01-2,0.15625,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::0.625::HTS002,BRD-K66911501-003-01-2,0.625,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::2.5::HTS002,BRD-K66911501-003-01-2,2.5,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66911501-003-01-2::10::HTS002,BRD-K66911501-003-01-2,10.0,HTS002,PREP018,MK-3207,calcitonin antagonist,CALCA,NA,NA,Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31,Phase 2
BRD-K66956375-001-11-3::0.00061034::HTS002,BRD-K66956375-001-11-3,0.00061034,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::0.0024414::HTS002,BRD-K66956375-001-11-3,0.0024414,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::0.00976562::HTS002,BRD-K66956375-001-11-3,0.00976562,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::0.0390625::HTS002,BRD-K66956375-001-11-3,0.0390625,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::0.15625::HTS002,BRD-K66956375-001-11-3,0.15625,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::0.625::HTS002,BRD-K66956375-001-11-3,0.625,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::2.5::HTS002,BRD-K66956375-001-11-3,2.5,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K66956375-001-11-3::10::HTS002,BRD-K66956375-001-11-3,10.0,HTS002,PREP015,oleoylethanolamide,"cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA",NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCO,Preclinical
BRD-K67043667-001-26-4::0.00061034::HTS002,BRD-K67043667-001-26-4,0.00061034,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::0.0024414::HTS002,BRD-K67043667-001-26-4,0.0024414,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::0.00976562::HTS002,BRD-K67043667-001-26-4,0.00976562,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::0.0390625::HTS002,BRD-K67043667-001-26-4,0.0390625,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::0.15625::HTS002,BRD-K67043667-001-26-4,0.15625,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::0.625::HTS002,BRD-K67043667-001-26-4,0.625,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::2.5::HTS002,BRD-K67043667-001-26-4,2.5,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67043667-001-26-4::10::HTS002,BRD-K67043667-001-26-4,10.0,HTS002,PREP022,altretamine,DNA synthesis inhibitor,NA,oncology,ovarian cancer,"CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C",Launched
BRD-K67173685-001-06-9::0.000582967::HTS002,BRD-K67173685-001-06-9,0.000582967,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::0.00233187::HTS002,BRD-K67173685-001-06-9,0.00233187,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::0.00932747::HTS002,BRD-K67173685-001-06-9,0.00932747,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::0.0373099::HTS002,BRD-K67173685-001-06-9,0.0373099,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::0.14924::HTS002,BRD-K67173685-001-06-9,0.14924,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::0.596958::HTS002,BRD-K67173685-001-06-9,0.596958,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::2.38783::HTS002,BRD-K67173685-001-06-9,2.38783,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67173685-001-06-9::9.55133::HTS002,BRD-K67173685-001-06-9,9.55133,HTS002,PREP044,4E1RCat,protein synthesis inhibitor,"EIF4E, EIF4G1",NA,NA,"OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O",Preclinical
BRD-K67261995-001-11-7::0.00061034::HTS002,BRD-K67261995-001-11-7,0.00061034,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::0.0024414::HTS002,BRD-K67261995-001-11-7,0.0024414,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::0.00976562::HTS002,BRD-K67261995-001-11-7,0.00976562,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::0.0390625::HTS002,BRD-K67261995-001-11-7,0.0390625,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::0.15625::HTS002,BRD-K67261995-001-11-7,0.15625,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::0.625::HTS002,BRD-K67261995-001-11-7,0.625,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::2.5::HTS002,BRD-K67261995-001-11-7,2.5,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67261995-001-11-7::10::HTS002,BRD-K67261995-001-11-7,10.0,HTS002,PREP028,iodipamide,radiopaque medium,ALB,radiology,contrast agent,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,Launched
BRD-K67298865-001-09-0::0.00061034::HTS002,BRD-K67298865-001-09-0,0.00061034,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::0.0024414::HTS002,BRD-K67298865-001-09-0,0.0024414,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::0.00976562::HTS002,BRD-K67298865-001-09-0,0.00976562,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::0.0390625::HTS002,BRD-K67298865-001-09-0,0.0390625,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::0.15625::HTS002,BRD-K67298865-001-09-0,0.15625,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::0.625::HTS002,BRD-K67298865-001-09-0,0.625,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::2.5::HTS002,BRD-K67298865-001-09-0,2.5,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67298865-001-09-0::10::HTS002,BRD-K67298865-001-09-0,10.0,HTS002,PREP040,SB-431542,TGF beta receptor inhibitor,"ACVR1C, TGFBR1",NA,NA,"NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",Preclinical
BRD-K67537649-001-04-5::0.00061034::HTS002,BRD-K67537649-001-04-5,0.00061034,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::0.0024414::HTS002,BRD-K67537649-001-04-5,0.0024414,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::0.00976562::HTS002,BRD-K67537649-001-04-5,0.00976562,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::0.0390625::HTS002,BRD-K67537649-001-04-5,0.0390625,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::0.15625::HTS002,BRD-K67537649-001-04-5,0.15625,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::0.625::HTS002,BRD-K67537649-001-04-5,0.625,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::2.5::HTS002,BRD-K67537649-001-04-5,2.5,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67537649-001-04-5::10::HTS002,BRD-K67537649-001-04-5,10.0,HTS002,PREP041,PQ-401,IGF-1 inhibitor,IGF1R,NA,NA,"COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",Preclinical
BRD-K67566344-001-07-5::0.00061034::HTS002,BRD-K67566344-001-07-5,0.00061034,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::0.0024414::HTS002,BRD-K67566344-001-07-5,0.0024414,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::0.00976562::HTS002,BRD-K67566344-001-07-5,0.00976562,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::0.0390625::HTS002,BRD-K67566344-001-07-5,0.0390625,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::0.15625::HTS002,BRD-K67566344-001-07-5,0.15625,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::0.625::HTS002,BRD-K67566344-001-07-5,0.625,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::2.5::HTS002,BRD-K67566344-001-07-5,2.5,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67566344-001-07-5::10::HTS002,BRD-K67566344-001-07-5,10.0,HTS002,PREP037,ku-0063794,mTOR inhibitor,MTOR,NA,NA,"COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",Preclinical
BRD-K67578145-001-09-7::0.000581718::HTS002,BRD-K67578145-001-09-7,0.000581718,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::0.00232687::HTS002,BRD-K67578145-001-09-7,0.00232687,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::0.00930748::HTS002,BRD-K67578145-001-09-7,0.00930748,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::0.0372299::HTS002,BRD-K67578145-001-09-7,0.0372299,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::0.14892::HTS002,BRD-K67578145-001-09-7,0.14892,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::0.595679::HTS002,BRD-K67578145-001-09-7,0.595679,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::2.38272::HTS002,BRD-K67578145-001-09-7,2.38272,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67578145-001-09-7::9.53086::HTS002,BRD-K67578145-001-09-7,9.53086,HTS002,PREP042,GDC-0879,RAF inhibitor,BRAF,NA,NA,"OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1",Preclinical
BRD-K67772619-001-05-1::0.00061034::HTS002,BRD-K67772619-001-05-1,0.00061034,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::0.0024414::HTS002,BRD-K67772619-001-05-1,0.0024414,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::0.00976562::HTS002,BRD-K67772619-001-05-1,0.00976562,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::0.0390625::HTS002,BRD-K67772619-001-05-1,0.0390625,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::0.15625::HTS002,BRD-K67772619-001-05-1,0.15625,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::0.625::HTS002,BRD-K67772619-001-05-1,0.625,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::2.5::HTS002,BRD-K67772619-001-05-1,2.5,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67772619-001-05-1::10::HTS002,BRD-K67772619-001-05-1,10.0,HTS002,PREP033,rheochrysidin,protein tyrosine kinase inhibitor,PTPN1,NA,NA,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,Preclinical
BRD-K67844266-003-01-9::0.00061034::HTS002,BRD-K67844266-003-01-9,0.00061034,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.0024414::HTS002,BRD-K67844266-003-01-9,0.0024414,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.00976562::HTS002,BRD-K67844266-003-01-9,0.00976562,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.0390625::HTS002,BRD-K67844266-003-01-9,0.0390625,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.15625::HTS002,BRD-K67844266-003-01-9,0.15625,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::0.625::HTS002,BRD-K67844266-003-01-9,0.625,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::2.5::HTS002,BRD-K67844266-003-01-9,2.5,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67844266-003-01-9::10::HTS002,BRD-K67844266-003-01-9,10.0,HTS002,PREP027,pevonedistat,nedd activating enzyme inhibitor,"NAE1, UBA3",NA,NA,NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12,Phase 2
BRD-K67868012-001-07-6::0.00061034::HTS002,BRD-K67868012-001-07-6,0.00061034,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::0.0024414::HTS002,BRD-K67868012-001-07-6,0.0024414,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::0.00976562::HTS002,BRD-K67868012-001-07-6,0.00976562,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::0.0390625::HTS002,BRD-K67868012-001-07-6,0.0390625,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::0.15625::HTS002,BRD-K67868012-001-07-6,0.15625,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::0.625::HTS002,BRD-K67868012-001-07-6,0.625,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::2.5::HTS002,BRD-K67868012-001-07-6,2.5,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67868012-001-07-6::10::HTS002,BRD-K67868012-001-07-6,10.0,HTS002,PREP040,PI-103,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC",NA,NA,"Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",Preclinical
BRD-K67977190-066-02-3::0.00061034::HTS002,BRD-K67977190-066-02-3,0.00061034,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::0.0024414::HTS002,BRD-K67977190-066-02-3,0.0024414,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::0.00976562::HTS002,BRD-K67977190-066-02-3,0.00976562,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::0.0390625::HTS002,BRD-K67977190-066-02-3,0.0390625,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::0.15625::HTS002,BRD-K67977190-066-02-3,0.15625,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::0.625::HTS002,BRD-K67977190-066-02-3,0.625,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::2.5::HTS002,BRD-K67977190-066-02-3,2.5,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K67977190-066-02-3::10::HTS002,BRD-K67977190-066-02-3,10.0,HTS002,PREP017,eprosartan,angiotensin receptor antagonist,AGTR1,cardiology,hypertension,"CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O",Launched
BRD-K68065987-300-09-1::0.00061034::HTS002,BRD-K68065987-300-09-1,0.00061034,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.0024414::HTS002,BRD-K68065987-300-09-1,0.0024414,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.00976562::HTS002,BRD-K68065987-300-09-1,0.00976562,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.0390625::HTS002,BRD-K68065987-300-09-1,0.0390625,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.15625::HTS002,BRD-K68065987-300-09-1,0.15625,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.625::HTS002,BRD-K68065987-300-09-1,0.625,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::2.5::HTS002,BRD-K68065987-300-09-1,2.5,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::10::HTS002,BRD-K68065987-300-09-1,10.0,HTS002,PREP024,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68095457-001-10-1::0.00061034::HTS002,BRD-K68095457-001-10-1,0.00061034,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::0.0024414::HTS002,BRD-K68095457-001-10-1,0.0024414,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::0.00976562::HTS002,BRD-K68095457-001-10-1,0.00976562,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::0.0390625::HTS002,BRD-K68095457-001-10-1,0.0390625,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::0.15625::HTS002,BRD-K68095457-001-10-1,0.15625,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::0.625::HTS002,BRD-K68095457-001-10-1,0.625,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::2.5::HTS002,BRD-K68095457-001-10-1,2.5,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68095457-001-10-1::10::HTS002,BRD-K68095457-001-10-1,10.0,HTS002,PREP017,palmitoylethanolamide,cannabinoid receptor agonist,"CNR2, GPR119, GPR55",NA,NA,"CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO",Launched
BRD-K68103045-001-02-9::0.00061034::HTS002,BRD-K68103045-001-02-9,0.00061034,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::0.0024414::HTS002,BRD-K68103045-001-02-9,0.0024414,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::0.00976562::HTS002,BRD-K68103045-001-02-9,0.00976562,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::0.0390625::HTS002,BRD-K68103045-001-02-9,0.0390625,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::0.15625::HTS002,BRD-K68103045-001-02-9,0.15625,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::0.625::HTS002,BRD-K68103045-001-02-9,0.625,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::2.5::HTS002,BRD-K68103045-001-02-9,2.5,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68103045-001-02-9::10::HTS002,BRD-K68103045-001-02-9,10.0,HTS002,PREP027,CGS-20625,"benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6",NA,NA,"COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O, COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O",Phase 1
BRD-K68164687-001-01-6::0.00061034::HTS002,BRD-K68164687-001-01-6,0.00061034,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::0.0024414::HTS002,BRD-K68164687-001-01-6,0.0024414,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::0.00976562::HTS002,BRD-K68164687-001-01-6,0.00976562,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::0.0390625::HTS002,BRD-K68164687-001-01-6,0.0390625,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::0.15625::HTS002,BRD-K68164687-001-01-6,0.15625,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::0.625::HTS002,BRD-K68164687-001-01-6,0.625,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::2.5::HTS002,BRD-K68164687-001-01-6,2.5,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68164687-001-01-6::10::HTS002,BRD-K68164687-001-01-6,10.0,HTS002,PREP027,epothilone-b,"microtubule stabilizing agent, tubulin polymerization inhibitor","TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B",NA,NA,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Phase 3
BRD-K68174511-001-06-6::0.00061034::HTS002,BRD-K68174511-001-06-6,0.00061034,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::0.0024414::HTS002,BRD-K68174511-001-06-6,0.0024414,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::0.00976562::HTS002,BRD-K68174511-001-06-6,0.00976562,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::0.0390625::HTS002,BRD-K68174511-001-06-6,0.0390625,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::0.15625::HTS002,BRD-K68174511-001-06-6,0.15625,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::0.625::HTS002,BRD-K68174511-001-06-6,0.625,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::2.5::HTS002,BRD-K68174511-001-06-6,2.5,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68174511-001-06-6::10::HTS002,BRD-K68174511-001-06-6,10.0,HTS002,PREP041,torin-2,mTOR inhibitor,MTOR,NA,NA,"Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",Preclinical
BRD-K68202742-001-16-5::0.000643289::HTS002,BRD-K68202742-001-16-5,0.000643289,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::0.00257315::HTS002,BRD-K68202742-001-16-5,0.00257315,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::0.0102926::HTS002,BRD-K68202742-001-16-5,0.0102926,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::0.0411705::HTS002,BRD-K68202742-001-16-5,0.0411705,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::0.164682::HTS002,BRD-K68202742-001-16-5,0.164682,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::0.658728::HTS002,BRD-K68202742-001-16-5,0.658728,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::2.63491::HTS002,BRD-K68202742-001-16-5,2.63491,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68202742-001-16-5::10.5396::HTS002,BRD-K68202742-001-16-5,10.5396,HTS002,PREP042,trichostatin-a,HDAC inhibitor,"HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9",NA,NA,"C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",Preclinical
BRD-K68336408-001-10-9::0.00061034::HTS002,BRD-K68336408-001-10-9,0.00061034,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::0.0024414::HTS002,BRD-K68336408-001-10-9,0.0024414,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::0.00976562::HTS002,BRD-K68336408-001-10-9,0.00976562,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::0.0390625::HTS002,BRD-K68336408-001-10-9,0.0390625,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::0.15625::HTS002,BRD-K68336408-001-10-9,0.15625,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::0.625::HTS002,BRD-K68336408-001-10-9,0.625,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::2.5::HTS002,BRD-K68336408-001-10-9,2.5,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68336408-001-10-9::10::HTS002,BRD-K68336408-001-10-9,10.0,HTS002,PREP043,tyrphostin-AG-1478,EGFR inhibitor,"EGFR, MAPK14",NA,NA,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,Preclinical
BRD-K68346641-001-01-4::0.00061034::HTS002,BRD-K68346641-001-01-4,0.00061034,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::0.0024414::HTS002,BRD-K68346641-001-01-4,0.0024414,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::0.00976562::HTS002,BRD-K68346641-001-01-4,0.00976562,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::0.0390625::HTS002,BRD-K68346641-001-01-4,0.0390625,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::0.15625::HTS002,BRD-K68346641-001-01-4,0.15625,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::0.625::HTS002,BRD-K68346641-001-01-4,0.625,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::2.5::HTS002,BRD-K68346641-001-01-4,2.5,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68346641-001-01-4::10::HTS002,BRD-K68346641-001-01-4,10.0,HTS002,PREP021,amsacrine,topoisomerase inhibitor,"KCNH2, TOP2A",hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)","COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12",Launched
BRD-K68392338-003-02-0::0.00061034::HTS002,BRD-K68392338-003-02-0,0.00061034,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::0.0024414::HTS002,BRD-K68392338-003-02-0,0.0024414,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::0.00976562::HTS002,BRD-K68392338-003-02-0,0.00976562,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::0.0390625::HTS002,BRD-K68392338-003-02-0,0.0390625,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::0.15625::HTS002,BRD-K68392338-003-02-0,0.15625,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::0.625::HTS002,BRD-K68392338-003-02-0,0.625,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::2.5::HTS002,BRD-K68392338-003-02-0,2.5,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68392338-003-02-0::10::HTS002,BRD-K68392338-003-02-0,10.0,HTS002,PREP027,ZK-93426,benzodiazepine receptor antagonist,"GABRA1, GABRA2, GABRA3, GABRA5",NA,NA,"CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",Phase 1
BRD-K68395654-001-03-1::0.00061034::HTS002,BRD-K68395654-001-03-1,0.00061034,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::0.0024414::HTS002,BRD-K68395654-001-03-1,0.0024414,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::0.00976562::HTS002,BRD-K68395654-001-03-1,0.00976562,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::0.0390625::HTS002,BRD-K68395654-001-03-1,0.0390625,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::0.15625::HTS002,BRD-K68395654-001-03-1,0.15625,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::0.625::HTS002,BRD-K68395654-001-03-1,0.625,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::2.5::HTS002,BRD-K68395654-001-03-1,2.5,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68395654-001-03-1::10::HTS002,BRD-K68395654-001-03-1,10.0,HTS002,PREP040,EVP4593,NFkB pathway inhibitor,NA,NA,NA,"Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",Preclinical
BRD-K68408467-065-01-8::0.00061034::HTS002,BRD-K68408467-065-01-8,0.00061034,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::0.0024414::HTS002,BRD-K68408467-065-01-8,0.0024414,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::0.00976562::HTS002,BRD-K68408467-065-01-8,0.00976562,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::0.0390625::HTS002,BRD-K68408467-065-01-8,0.0390625,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::0.15625::HTS002,BRD-K68408467-065-01-8,0.15625,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::0.625::HTS002,BRD-K68408467-065-01-8,0.625,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::2.5::HTS002,BRD-K68408467-065-01-8,2.5,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68408467-065-01-8::10::HTS002,BRD-K68408467-065-01-8,10.0,HTS002,PREP044,proflavine-hemisulfate,topical anesthetic,F2,NA,NA,Nc1ccc2cc3ccc(N)cc3nc2c1,Phase 2
BRD-K68488863-001-04-9::0.00061034::HTS002,BRD-K68488863-001-04-9,0.00061034,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::0.0024414::HTS002,BRD-K68488863-001-04-9,0.0024414,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::0.00976562::HTS002,BRD-K68488863-001-04-9,0.00976562,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::0.0390625::HTS002,BRD-K68488863-001-04-9,0.0390625,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::0.15625::HTS002,BRD-K68488863-001-04-9,0.15625,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::0.625::HTS002,BRD-K68488863-001-04-9,0.625,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::2.5::HTS002,BRD-K68488863-001-04-9,2.5,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68488863-001-04-9::10::HTS002,BRD-K68488863-001-04-9,10.0,HTS002,PREP026,ENMD-2076,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC",NA,NA,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,Phase 2
BRD-K68502831-001-01-2::0.00061034::HTS002,BRD-K68502831-001-01-2,0.00061034,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::0.0024414::HTS002,BRD-K68502831-001-01-2,0.0024414,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::0.00976562::HTS002,BRD-K68502831-001-01-2,0.00976562,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::0.0390625::HTS002,BRD-K68502831-001-01-2,0.0390625,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::0.15625::HTS002,BRD-K68502831-001-01-2,0.15625,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::0.625::HTS002,BRD-K68502831-001-01-2,0.625,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::2.5::HTS002,BRD-K68502831-001-01-2,2.5,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68502831-001-01-2::10::HTS002,BRD-K68502831-001-01-2,10.0,HTS002,PREP048,dianhydrogalactitol,DNA alkylating agent,NA,NA,NA,O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1,Phase 1
BRD-K68507560-003-24-6::0.00061034::HTS002,BRD-K68507560-003-24-6,0.00061034,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::0.0024414::HTS002,BRD-K68507560-003-24-6,0.0024414,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::0.00976562::HTS002,BRD-K68507560-003-24-6,0.00976562,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::0.0390625::HTS002,BRD-K68507560-003-24-6,0.0390625,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::0.15625::HTS002,BRD-K68507560-003-24-6,0.15625,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::0.625::HTS002,BRD-K68507560-003-24-6,0.625,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::2.5::HTS002,BRD-K68507560-003-24-6,2.5,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68507560-003-24-6::10::HTS002,BRD-K68507560-003-24-6,10.0,HTS002,PREP028,dicycloverine,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3",gastroenterology,irritable bowel syndrome,"CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1",Launched
BRD-K68532323-003-02-8::0.00061034::HTS002,BRD-K68532323-003-02-8,0.00061034,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::0.0024414::HTS002,BRD-K68532323-003-02-8,0.0024414,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::0.00976562::HTS002,BRD-K68532323-003-02-8,0.00976562,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::0.0390625::HTS002,BRD-K68532323-003-02-8,0.0390625,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::0.15625::HTS002,BRD-K68532323-003-02-8,0.15625,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::0.625::HTS002,BRD-K68532323-003-02-8,0.625,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::2.5::HTS002,BRD-K68532323-003-02-8,2.5,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68532323-003-02-8::10::HTS002,BRD-K68532323-003-02-8,10.0,HTS002,PREP018,SB-743921,kinesin-like spindle protein inhibitor,KIF11,NA,NA,"CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",Phase 1/Phase 2
BRD-K68552125-001-05-3::0.000494753::HTS002,BRD-K68552125-001-05-3,0.000494753,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::0.00197901::HTS002,BRD-K68552125-001-05-3,0.00197901,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::0.00791604::HTS002,BRD-K68552125-001-05-3,0.00791604,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::0.0316642::HTS002,BRD-K68552125-001-05-3,0.0316642,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::0.126657::HTS002,BRD-K68552125-001-05-3,0.126657,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::0.506627::HTS002,BRD-K68552125-001-05-3,0.506627,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::2.02651::HTS002,BRD-K68552125-001-05-3,2.02651,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68552125-001-05-3::8.10603::HTS002,BRD-K68552125-001-05-3,8.10603,HTS002,PREP026,12-O-tetradecanoylphorbol-13-acetate,PKC activator,"KCNT2, TRPV4",NA,NA,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,Phase 2
BRD-K68567222-001-01-2::0.00061034::HTS002,BRD-K68567222-001-01-2,0.00061034,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::0.0024414::HTS002,BRD-K68567222-001-01-2,0.0024414,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::0.00976562::HTS002,BRD-K68567222-001-01-2,0.00976562,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::0.0390625::HTS002,BRD-K68567222-001-01-2,0.0390625,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::0.15625::HTS002,BRD-K68567222-001-01-2,0.15625,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::0.625::HTS002,BRD-K68567222-001-01-2,0.625,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::2.5::HTS002,BRD-K68567222-001-01-2,2.5,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68567222-001-01-2::10::HTS002,BRD-K68567222-001-01-2,10.0,HTS002,PREP043,BVT-948,tyrosine phosphatase inhibitor,"PTPN1, PTPN11, PTPN2",NA,NA,"CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21, CC1(C)C2C(=NC1=O)c1ccccc1C(=O)C2=O",Preclinical
BRD-K68633617-003-02-9::0.00061034::HTS002,BRD-K68633617-003-02-9,0.00061034,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::0.0024414::HTS002,BRD-K68633617-003-02-9,0.0024414,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::0.00976562::HTS002,BRD-K68633617-003-02-9,0.00976562,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::0.0390625::HTS002,BRD-K68633617-003-02-9,0.0390625,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::0.15625::HTS002,BRD-K68633617-003-02-9,0.15625,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::0.625::HTS002,BRD-K68633617-003-02-9,0.625,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::2.5::HTS002,BRD-K68633617-003-02-9,2.5,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68633617-003-02-9::10::HTS002,BRD-K68633617-003-02-9,10.0,HTS002,PREP024,ACDPP,glutamate receptor antagonist,GRM5,NA,NA,CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1,Preclinical
BRD-K68693535-001-03-4::0.000610352::HTS002,BRD-K68693535-001-03-4,0.000610352,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::0.00244141::HTS002,BRD-K68693535-001-03-4,0.00244141,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::0.00976562::HTS002,BRD-K68693535-001-03-4,0.00976562,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::0.0390625::HTS002,BRD-K68693535-001-03-4,0.0390625,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::0.15625::HTS002,BRD-K68693535-001-03-4,0.15625,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::0.625::HTS002,BRD-K68693535-001-03-4,0.625,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::2.5::HTS002,BRD-K68693535-001-03-4,2.5,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68693535-001-03-4::10::HTS002,BRD-K68693535-001-03-4,10.0,HTS002,PREP023,lidamidine,adrenergic receptor agonist,NA,gastroenterology,diarrhea,CNC(=N)NC(=O)Nc1c(C)cccc1C,Launched
BRD-K68747584-001-02-0::0.00061034::HTS002,BRD-K68747584-001-02-0,0.00061034,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::0.0024414::HTS002,BRD-K68747584-001-02-0,0.0024414,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::0.00976562::HTS002,BRD-K68747584-001-02-0,0.00976562,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::0.0390625::HTS002,BRD-K68747584-001-02-0,0.0390625,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::0.15625::HTS002,BRD-K68747584-001-02-0,0.15625,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::0.625::HTS002,BRD-K68747584-001-02-0,0.625,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::2.5::HTS002,BRD-K68747584-001-02-0,2.5,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68747584-001-02-0::10::HTS002,BRD-K68747584-001-02-0,10.0,HTS002,PREP026,PF-03814735,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",Phase 1
BRD-K68870568-066-01-5::0.00061034::HTS002,BRD-K68870568-066-01-5,0.00061034,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::0.0024414::HTS002,BRD-K68870568-066-01-5,0.0024414,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::0.00976562::HTS002,BRD-K68870568-066-01-5,0.00976562,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::0.0390625::HTS002,BRD-K68870568-066-01-5,0.0390625,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::0.15625::HTS002,BRD-K68870568-066-01-5,0.15625,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::0.625::HTS002,BRD-K68870568-066-01-5,0.625,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::2.5::HTS002,BRD-K68870568-066-01-5,2.5,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68870568-066-01-5::10::HTS002,BRD-K68870568-066-01-5,10.0,HTS002,PREP018,flumatinib,Bcr-Abl kinase inhibitor,"ABL1, PDGFRB",NA,NA,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,Phase 3
BRD-K68938568-001-01-7::0.00061034::HTS002,BRD-K68938568-001-01-7,0.00061034,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::0.0024414::HTS002,BRD-K68938568-001-01-7,0.0024414,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::0.00976562::HTS002,BRD-K68938568-001-01-7,0.00976562,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::0.0390625::HTS002,BRD-K68938568-001-01-7,0.0390625,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::0.15625::HTS002,BRD-K68938568-001-01-7,0.15625,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::0.625::HTS002,BRD-K68938568-001-01-7,0.625,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::2.5::HTS002,BRD-K68938568-001-01-7,2.5,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68938568-001-01-7::10::HTS002,BRD-K68938568-001-01-7,10.0,HTS002,PREP026,GDC-0152,XIAP inhibitor,"BIRC2, BIRC3, BIRC7, XIAP",NA,NA,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1,Phase 1
BRD-K68997413-001-05-1::0.00061034::HTS002,BRD-K68997413-001-05-1,0.00061034,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::0.0024414::HTS002,BRD-K68997413-001-05-1,0.0024414,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::0.00976562::HTS002,BRD-K68997413-001-05-1,0.00976562,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::0.0390625::HTS002,BRD-K68997413-001-05-1,0.0390625,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::0.15625::HTS002,BRD-K68997413-001-05-1,0.15625,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::0.625::HTS002,BRD-K68997413-001-05-1,0.625,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::2.5::HTS002,BRD-K68997413-001-05-1,2.5,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K68997413-001-05-1::10::HTS002,BRD-K68997413-001-05-1,10.0,HTS002,PREP014,PF-3845,FAAH inhibitor,FAAH,NA,NA,"FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",Preclinical
BRD-K69001009-001-02-8::0.00061034::HTS002,BRD-K69001009-001-02-8,0.00061034,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.0024414::HTS002,BRD-K69001009-001-02-8,0.0024414,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.00976562::HTS002,BRD-K69001009-001-02-8,0.00976562,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.0390625::HTS002,BRD-K69001009-001-02-8,0.0390625,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.15625::HTS002,BRD-K69001009-001-02-8,0.15625,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::0.625::HTS002,BRD-K69001009-001-02-8,0.625,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::2.5::HTS002,BRD-K69001009-001-02-8,2.5,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69001009-001-02-8::10::HTS002,BRD-K69001009-001-02-8,10.0,HTS002,PREP025,golvatinib,VEGFR inhibitor,"KDR, MET",NA,NA,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1,Phase 2
BRD-K69116396-001-04-1::0.00061034::HTS002,BRD-K69116396-001-04-1,0.00061034,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::0.0024414::HTS002,BRD-K69116396-001-04-1,0.0024414,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::0.00976562::HTS002,BRD-K69116396-001-04-1,0.00976562,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::0.0390625::HTS002,BRD-K69116396-001-04-1,0.0390625,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::0.15625::HTS002,BRD-K69116396-001-04-1,0.15625,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::0.625::HTS002,BRD-K69116396-001-04-1,0.625,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::2.5::HTS002,BRD-K69116396-001-04-1,2.5,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69116396-001-04-1::10::HTS002,BRD-K69116396-001-04-1,10.0,HTS002,PREP016,sertindole,"dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2",NA,NA,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,Withdrawn
BRD-K69172251-001-08-9::0.00061034::HTS002,BRD-K69172251-001-08-9,0.00061034,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::0.0024414::HTS002,BRD-K69172251-001-08-9,0.0024414,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::0.00976562::HTS002,BRD-K69172251-001-08-9,0.00976562,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::0.0390625::HTS002,BRD-K69172251-001-08-9,0.0390625,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::0.15625::HTS002,BRD-K69172251-001-08-9,0.15625,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::0.625::HTS002,BRD-K69172251-001-08-9,0.625,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::2.5::HTS002,BRD-K69172251-001-08-9,2.5,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69172251-001-08-9::10::HTS002,BRD-K69172251-001-08-9,10.0,HTS002,PREP048,cisplatin,"DNA alkylating agent, DNA synthesis inhibitor",XIAP,oncology,"testicular carcinoma, ovarian cancer, bladder cancer","N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl",Launched
BRD-K69195780-004-08-4::0.00061034::HTS002,BRD-K69195780-004-08-4,0.00061034,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::0.0024414::HTS002,BRD-K69195780-004-08-4,0.0024414,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::0.00976562::HTS002,BRD-K69195780-004-08-4,0.00976562,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::0.0390625::HTS002,BRD-K69195780-004-08-4,0.0390625,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::0.15625::HTS002,BRD-K69195780-004-08-4,0.15625,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::0.625::HTS002,BRD-K69195780-004-08-4,0.625,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::2.5::HTS002,BRD-K69195780-004-08-4,2.5,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69195780-004-08-4::10::HTS002,BRD-K69195780-004-08-4,10.0,HTS002,PREP047,NAN-190,serotonin receptor agonist,"ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F",NA,NA,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,Preclinical
BRD-K69280563-001-01-8::0.00061034::HTS002,BRD-K69280563-001-01-8,0.00061034,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::0.0024414::HTS002,BRD-K69280563-001-01-8,0.0024414,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::0.00976562::HTS002,BRD-K69280563-001-01-8,0.00976562,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::0.0390625::HTS002,BRD-K69280563-001-01-8,0.0390625,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::0.15625::HTS002,BRD-K69280563-001-01-8,0.15625,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::0.625::HTS002,BRD-K69280563-001-01-8,0.625,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::2.5::HTS002,BRD-K69280563-001-01-8,2.5,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69280563-001-01-8::10::HTS002,BRD-K69280563-001-01-8,10.0,HTS002,PREP017,vinorelbine,tubulin polymerization inhibitor,"TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8",oncology,non-small cell lung cancer (NSCLC),"CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K69726342-238-02-4::0.00061034::HTS002,BRD-K69726342-238-02-4,0.00061034,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::0.0024414::HTS002,BRD-K69726342-238-02-4,0.0024414,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::0.00976562::HTS002,BRD-K69726342-238-02-4,0.00976562,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::0.0390625::HTS002,BRD-K69726342-238-02-4,0.0390625,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::0.15625::HTS002,BRD-K69726342-238-02-4,0.15625,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::0.625::HTS002,BRD-K69726342-238-02-4,0.625,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::2.5::HTS002,BRD-K69726342-238-02-4,2.5,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726342-238-02-4::10::HTS002,BRD-K69726342-238-02-4,10.0,HTS002,PREP016,atorvastatin,HMGCR inhibitor,"AHR, DPP4, HMGCR","neurology/psychiatry, cardiology","stroke, heart attack","CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1",Launched
BRD-K69726595-001-01-2::0.00061034::HTS002,BRD-K69726595-001-01-2,0.00061034,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::0.0024414::HTS002,BRD-K69726595-001-01-2,0.0024414,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::0.00976562::HTS002,BRD-K69726595-001-01-2,0.00976562,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::0.0390625::HTS002,BRD-K69726595-001-01-2,0.0390625,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::0.15625::HTS002,BRD-K69726595-001-01-2,0.15625,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::0.625::HTS002,BRD-K69726595-001-01-2,0.625,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::2.5::HTS002,BRD-K69726595-001-01-2,2.5,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69726595-001-01-2::10::HTS002,BRD-K69726595-001-01-2,10.0,HTS002,PREP026,mericitabine,HCV inhibitor,NA,NA,NA,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,Phase 2
BRD-K69776681-001-03-8::0.00061034::HTS002,BRD-K69776681-001-03-8,0.00061034,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.0024414::HTS002,BRD-K69776681-001-03-8,0.0024414,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.00976562::HTS002,BRD-K69776681-001-03-8,0.00976562,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.0390625::HTS002,BRD-K69776681-001-03-8,0.0390625,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.15625::HTS002,BRD-K69776681-001-03-8,0.15625,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::0.625::HTS002,BRD-K69776681-001-03-8,0.625,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::2.5::HTS002,BRD-K69776681-001-03-8,2.5,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69776681-001-03-8::10::HTS002,BRD-K69776681-001-03-8,10.0,HTS002,PREP026,volasertib,PLK inhibitor,PLK1,NA,NA,"CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",Phase 3
BRD-K69932463-001-10-6::0.00061034::HTS002,BRD-K69932463-001-10-6,0.00061034,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::0.0024414::HTS002,BRD-K69932463-001-10-6,0.0024414,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::0.00976562::HTS002,BRD-K69932463-001-10-6,0.00976562,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::0.0390625::HTS002,BRD-K69932463-001-10-6,0.0390625,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::0.15625::HTS002,BRD-K69932463-001-10-6,0.15625,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::0.625::HTS002,BRD-K69932463-001-10-6,0.625,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::2.5::HTS002,BRD-K69932463-001-10-6,2.5,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K69932463-001-10-6::10::HTS002,BRD-K69932463-001-10-6,10.0,HTS002,PREP026,AZD8055,mTOR inhibitor,MTOR,NA,NA,COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 1
BRD-K70159787-001-01-1::0.00061034::HTS002,BRD-K70159787-001-01-1,0.00061034,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::0.0024414::HTS002,BRD-K70159787-001-01-1,0.0024414,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::0.00976562::HTS002,BRD-K70159787-001-01-1,0.00976562,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::0.0390625::HTS002,BRD-K70159787-001-01-1,0.0390625,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::0.15625::HTS002,BRD-K70159787-001-01-1,0.15625,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::0.625::HTS002,BRD-K70159787-001-01-1,0.625,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::2.5::HTS002,BRD-K70159787-001-01-1,2.5,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70159787-001-01-1::10::HTS002,BRD-K70159787-001-01-1,10.0,HTS002,PREP041,SMI-4a,Pim kinase inhibitor,PIM1,NA,NA,FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O,Preclinical
BRD-K70163715-300-05-7::0.000590328::HTS002,BRD-K70163715-300-05-7,0.000590328,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::0.00236131::HTS002,BRD-K70163715-300-05-7,0.00236131,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::0.00944525::HTS002,BRD-K70163715-300-05-7,0.00944525,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::0.037781::HTS002,BRD-K70163715-300-05-7,0.037781,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::0.151124::HTS002,BRD-K70163715-300-05-7,0.151124,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::0.604496::HTS002,BRD-K70163715-300-05-7,0.604496,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::2.41798::HTS002,BRD-K70163715-300-05-7,2.41798,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70163715-300-05-7::9.67193::HTS002,BRD-K70163715-300-05-7,9.67193,HTS002,PREP027,vatalanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB",NA,NA,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",Phase 3
BRD-K70177501-003-01-4::0.00061034::HTS002,BRD-K70177501-003-01-4,0.00061034,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::0.0024414::HTS002,BRD-K70177501-003-01-4,0.0024414,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::0.00976562::HTS002,BRD-K70177501-003-01-4,0.00976562,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::0.0390625::HTS002,BRD-K70177501-003-01-4,0.0390625,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::0.15625::HTS002,BRD-K70177501-003-01-4,0.15625,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::0.625::HTS002,BRD-K70177501-003-01-4,0.625,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::2.5::HTS002,BRD-K70177501-003-01-4,2.5,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70177501-003-01-4::10::HTS002,BRD-K70177501-003-01-4,10.0,HTS002,PREP043,INH1,Hec1 inhibitor,NDC80,NA,NA,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,Preclinical
BRD-K70246307-001-04-1::0.00061034::HTS002,BRD-K70246307-001-04-1,0.00061034,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::0.0024414::HTS002,BRD-K70246307-001-04-1,0.0024414,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::0.00976562::HTS002,BRD-K70246307-001-04-1,0.00976562,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::0.0390625::HTS002,BRD-K70246307-001-04-1,0.0390625,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::0.15625::HTS002,BRD-K70246307-001-04-1,0.15625,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::0.625::HTS002,BRD-K70246307-001-04-1,0.625,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::2.5::HTS002,BRD-K70246307-001-04-1,2.5,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70246307-001-04-1::10::HTS002,BRD-K70246307-001-04-1,10.0,HTS002,PREP017,riboflavin,vitamin B2,"BLVRB, RFK",gastroenterology,jaundice,"Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C",Launched
BRD-K70301465-001-02-6::0.00061034::HTS002,BRD-K70301465-001-02-6,0.00061034,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::0.0024414::HTS002,BRD-K70301465-001-02-6,0.0024414,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::0.00976562::HTS002,BRD-K70301465-001-02-6,0.00976562,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::0.0390625::HTS002,BRD-K70301465-001-02-6,0.0390625,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::0.15625::HTS002,BRD-K70301465-001-02-6,0.15625,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::0.625::HTS002,BRD-K70301465-001-02-6,0.625,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::2.5::HTS002,BRD-K70301465-001-02-6,2.5,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K70301465-001-02-6::10::HTS002,BRD-K70301465-001-02-6,10.0,HTS002,PREP017,ibrutinib,Bruton's tyrosine kinase (BTK) inhibitor,"BLK, BMX, BTK",hematologic malignancy,"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C",Launched
BRD-K31086665-005-04-6::0.00061034::HTS002,BRD-K31086665-005-04-6,0.00061034,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::0.0024414::HTS002,BRD-K31086665-005-04-6,0.0024414,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::0.00976562::HTS002,BRD-K31086665-005-04-6,0.00976562,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::0.0390625::HTS002,BRD-K31086665-005-04-6,0.0390625,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::0.15625::HTS002,BRD-K31086665-005-04-6,0.15625,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::0.625::HTS002,BRD-K31086665-005-04-6,0.625,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::2.5::HTS002,BRD-K31086665-005-04-6,2.5,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K31086665-005-04-6::10::HTS002,BRD-K31086665-005-04-6,10.0,HTS002,PREP037,NH125,eukaryotic translation elongation factor 2 inhibitor,NA,NA,NA,"CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",Preclinical
BRD-K70358946-001-15-7::0.00061034::HTS002,BRD-K70358946-001-15-7,0.00061034,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::0.0024414::HTS002,BRD-K70358946-001-15-7,0.0024414,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::0.00976562::HTS002,BRD-K70358946-001-15-7,0.00976562,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::0.0390625::HTS002,BRD-K70358946-001-15-7,0.0390625,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::0.15625::HTS002,BRD-K70358946-001-15-7,0.15625,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::0.625::HTS002,BRD-K70358946-001-15-7,0.625,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::2.5::HTS002,BRD-K70358946-001-15-7,2.5,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70358946-001-15-7::10::HTS002,BRD-K70358946-001-15-7,10.0,HTS002,PREP023,aripiprazole,"serotonin receptor agonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7",neurology/psychiatry,"depression, schizophrenia, bipolar disorder","Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl",Launched
BRD-K70401845-003-09-6::0.00061034::HTS002,BRD-K70401845-003-09-6,0.00061034,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::0.0024414::HTS002,BRD-K70401845-003-09-6,0.0024414,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::0.00976562::HTS002,BRD-K70401845-003-09-6,0.00976562,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::0.0390625::HTS002,BRD-K70401845-003-09-6,0.0390625,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::0.15625::HTS002,BRD-K70401845-003-09-6,0.15625,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::0.625::HTS002,BRD-K70401845-003-09-6,0.625,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::2.5::HTS002,BRD-K70401845-003-09-6,2.5,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70401845-003-09-6::10::HTS002,BRD-K70401845-003-09-6,10.0,HTS002,PREP016,erlotinib,EGFR inhibitor,"EGFR, NR1I2",oncology,"non-small cell lung cancer (NSCLC), pancreatic cancer","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC",Launched
BRD-K70402238-001-02-8::0.00061034::HTS002,BRD-K70402238-001-02-8,0.00061034,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::0.0024414::HTS002,BRD-K70402238-001-02-8,0.0024414,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::0.00976562::HTS002,BRD-K70402238-001-02-8,0.00976562,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::0.0390625::HTS002,BRD-K70402238-001-02-8,0.0390625,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::0.15625::HTS002,BRD-K70402238-001-02-8,0.15625,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::0.625::HTS002,BRD-K70402238-001-02-8,0.625,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::2.5::HTS002,BRD-K70402238-001-02-8,2.5,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70402238-001-02-8::10::HTS002,BRD-K70402238-001-02-8,10.0,HTS002,PREP042,nexturastat-a,HDAC inhibitor,"HDAC1, HDAC6",NA,NA,CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1,Preclinical
BRD-K70463136-001-01-5::0.00061034::HTS002,BRD-K70463136-001-01-5,0.00061034,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::0.0024414::HTS002,BRD-K70463136-001-01-5,0.0024414,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::0.00976562::HTS002,BRD-K70463136-001-01-5,0.00976562,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::0.0390625::HTS002,BRD-K70463136-001-01-5,0.0390625,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::0.15625::HTS002,BRD-K70463136-001-01-5,0.15625,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::0.625::HTS002,BRD-K70463136-001-01-5,0.625,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::2.5::HTS002,BRD-K70463136-001-01-5,2.5,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70463136-001-01-5::10::HTS002,BRD-K70463136-001-01-5,10.0,HTS002,PREP019,BAY-87-2243,hypoxia inducible factor inhibitor,HIF1A,NA,NA,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1,Phase 1
BRD-K70505054-003-12-4::0.00061034::HTS002,BRD-K70505054-003-12-4,0.00061034,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::0.0024414::HTS002,BRD-K70505054-003-12-4,0.0024414,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::0.00976562::HTS002,BRD-K70505054-003-12-4,0.00976562,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::0.0390625::HTS002,BRD-K70505054-003-12-4,0.0390625,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::0.15625::HTS002,BRD-K70505054-003-12-4,0.15625,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::0.625::HTS002,BRD-K70505054-003-12-4,0.625,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::2.5::HTS002,BRD-K70505054-003-12-4,2.5,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70505054-003-12-4::10::HTS002,BRD-K70505054-003-12-4,10.0,HTS002,PREP023,ranitidine,histamine receptor antagonist,HRH2,gastroenterology,heartburn,"CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O",Launched
BRD-K70511574-001-06-9::0.00061034::HTS002,BRD-K70511574-001-06-9,0.00061034,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::0.0024414::HTS002,BRD-K70511574-001-06-9,0.0024414,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::0.00976562::HTS002,BRD-K70511574-001-06-9,0.00976562,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::0.0390625::HTS002,BRD-K70511574-001-06-9,0.0390625,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::0.15625::HTS002,BRD-K70511574-001-06-9,0.15625,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::0.625::HTS002,BRD-K70511574-001-06-9,0.625,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::2.5::HTS002,BRD-K70511574-001-06-9,2.5,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70511574-001-06-9::10::HTS002,BRD-K70511574-001-06-9,10.0,HTS002,PREP027,HMN-214,PLK inhibitor,PLK1,NA,NA,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,Phase 1
BRD-K70821460-300-02-4::0.00061034::HTS002,BRD-K70821460-300-02-4,0.00061034,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::0.0024414::HTS002,BRD-K70821460-300-02-4,0.0024414,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::0.00976562::HTS002,BRD-K70821460-300-02-4,0.00976562,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::0.0390625::HTS002,BRD-K70821460-300-02-4,0.0390625,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::0.15625::HTS002,BRD-K70821460-300-02-4,0.15625,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::0.625::HTS002,BRD-K70821460-300-02-4,0.625,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::2.5::HTS002,BRD-K70821460-300-02-4,2.5,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70821460-300-02-4::10::HTS002,BRD-K70821460-300-02-4,10.0,HTS002,PREP042,4-methylhistamine,histamine receptor agonist,HRH4,NA,NA,Cc1nc[nH]c1CCN,Preclinical
BRD-K70914287-300-02-8::0.00061034::HTS002,BRD-K70914287-300-02-8,0.00061034,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::0.0024414::HTS002,BRD-K70914287-300-02-8,0.0024414,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::0.00976562::HTS002,BRD-K70914287-300-02-8,0.00976562,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::0.0390625::HTS002,BRD-K70914287-300-02-8,0.0390625,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::0.15625::HTS002,BRD-K70914287-300-02-8,0.15625,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::0.625::HTS002,BRD-K70914287-300-02-8,0.625,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::2.5::HTS002,BRD-K70914287-300-02-8,2.5,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K70914287-300-02-8::10::HTS002,BRD-K70914287-300-02-8,10.0,HTS002,PREP019,BIBX-1382,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",Phase 1
BRD-K71035033-001-07-1::0.00061034::HTS002,BRD-K71035033-001-07-1,0.00061034,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::0.0024414::HTS002,BRD-K71035033-001-07-1,0.0024414,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::0.00976562::HTS002,BRD-K71035033-001-07-1,0.00976562,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::0.0390625::HTS002,BRD-K71035033-001-07-1,0.0390625,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::0.15625::HTS002,BRD-K71035033-001-07-1,0.15625,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::0.625::HTS002,BRD-K71035033-001-07-1,0.625,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::2.5::HTS002,BRD-K71035033-001-07-1,2.5,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71035033-001-07-1::10::HTS002,BRD-K71035033-001-07-1,10.0,HTS002,PREP014,masitinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","FGFR3, KIT, PDGFRA, PDGFRB",dermatology,mastocytoma,"CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1",Launched
BRD-K71075609-003-01-0::0.00061034::HTS002,BRD-K71075609-003-01-0,0.00061034,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::0.0024414::HTS002,BRD-K71075609-003-01-0,0.0024414,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::0.00976562::HTS002,BRD-K71075609-003-01-0,0.00976562,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::0.0390625::HTS002,BRD-K71075609-003-01-0,0.0390625,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::0.15625::HTS002,BRD-K71075609-003-01-0,0.15625,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::0.625::HTS002,BRD-K71075609-003-01-0,0.625,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::2.5::HTS002,BRD-K71075609-003-01-0,2.5,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71075609-003-01-0::10::HTS002,BRD-K71075609-003-01-0,10.0,HTS002,PREP022,dorzolamide,carbonic anhydrase inhibitor,"CA1, CA12, CA14, CA2, CA4, CA7",ophthalmology,"intraocular pressure, glaucoma",CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,Launched
BRD-K71106091-001-06-1::0.00061034::HTS002,BRD-K71106091-001-06-1,0.00061034,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::0.0024414::HTS002,BRD-K71106091-001-06-1,0.0024414,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::0.00976562::HTS002,BRD-K71106091-001-06-1,0.00976562,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::0.0390625::HTS002,BRD-K71106091-001-06-1,0.0390625,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::0.15625::HTS002,BRD-K71106091-001-06-1,0.15625,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::0.625::HTS002,BRD-K71106091-001-06-1,0.625,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::2.5::HTS002,BRD-K71106091-001-06-1,2.5,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71106091-001-06-1::10::HTS002,BRD-K71106091-001-06-1,10.0,HTS002,PREP016,fludarabine-phosphate,ribonucleotide reductase inhibitor,"DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B",hematologic malignancy,chronic lymphocytic leukemia (CLL),"Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O",Launched
BRD-K71164191-001-01-0::0.000610352::HTS002,BRD-K71164191-001-01-0,0.000610352,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::0.00244141::HTS002,BRD-K71164191-001-01-0,0.00244141,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::0.00976562::HTS002,BRD-K71164191-001-01-0,0.00976562,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::0.0390625::HTS002,BRD-K71164191-001-01-0,0.0390625,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::0.15625::HTS002,BRD-K71164191-001-01-0,0.15625,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::0.625::HTS002,BRD-K71164191-001-01-0,0.625,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::2.5::HTS002,BRD-K71164191-001-01-0,2.5,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71164191-001-01-0::10::HTS002,BRD-K71164191-001-01-0,10.0,HTS002,PREP027,KD-023,ACAT inhibitor,"ACACA, ACACB",NA,NA,CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O,Phase 2
BRD-K71221037-001-01-6::0.00061034::HTS002,BRD-K71221037-001-01-6,0.00061034,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::0.0024414::HTS002,BRD-K71221037-001-01-6,0.0024414,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::0.00976562::HTS002,BRD-K71221037-001-01-6,0.00976562,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::0.0390625::HTS002,BRD-K71221037-001-01-6,0.0390625,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::0.15625::HTS002,BRD-K71221037-001-01-6,0.15625,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::0.625::HTS002,BRD-K71221037-001-01-6,0.625,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::2.5::HTS002,BRD-K71221037-001-01-6,2.5,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71221037-001-01-6::10::HTS002,BRD-K71221037-001-01-6,10.0,HTS002,PREP027,birinapant,XIAP inhibitor,"BIRC2, XIAP",NA,NA,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",Phase 2
BRD-K71281111-001-04-3::0.00061034::HTS002,BRD-K71281111-001-04-3,0.00061034,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::0.0024414::HTS002,BRD-K71281111-001-04-3,0.0024414,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::0.00976562::HTS002,BRD-K71281111-001-04-3,0.00976562,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::0.0390625::HTS002,BRD-K71281111-001-04-3,0.0390625,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::0.15625::HTS002,BRD-K71281111-001-04-3,0.15625,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::0.625::HTS002,BRD-K71281111-001-04-3,0.625,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::2.5::HTS002,BRD-K71281111-001-04-3,2.5,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71281111-001-04-3::10::HTS002,BRD-K71281111-001-04-3,10.0,HTS002,PREP018,SNX-2112,HSP inhibitor,NA,NA,NA,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1,Phase 1
BRD-K71467466-001-02-3::0.00061034::HTS002,BRD-K71467466-001-02-3,0.00061034,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::0.0024414::HTS002,BRD-K71467466-001-02-3,0.0024414,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::0.00976562::HTS002,BRD-K71467466-001-02-3,0.00976562,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::0.0390625::HTS002,BRD-K71467466-001-02-3,0.0390625,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::0.15625::HTS002,BRD-K71467466-001-02-3,0.15625,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::0.625::HTS002,BRD-K71467466-001-02-3,0.625,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::2.5::HTS002,BRD-K71467466-001-02-3,2.5,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71467466-001-02-3::10::HTS002,BRD-K71467466-001-02-3,10.0,HTS002,PREP047,KPT-185,exportin antagonist,XPO1,NA,NA,COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1,Preclinical
BRD-K71480163-001-01-4::0.00061034::HTS002,BRD-K71480163-001-01-4,0.00061034,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.0024414::HTS002,BRD-K71480163-001-01-4,0.0024414,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.00976562::HTS002,BRD-K71480163-001-01-4,0.00976562,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.0390625::HTS002,BRD-K71480163-001-01-4,0.0390625,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.15625::HTS002,BRD-K71480163-001-01-4,0.15625,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.625::HTS002,BRD-K71480163-001-01-4,0.625,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::2.5::HTS002,BRD-K71480163-001-01-4,2.5,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::10::HTS002,BRD-K71480163-001-01-4,10.0,HTS002,PREP018,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71512533-066-02-8::0.00061034::HTS002,BRD-K71512533-066-02-8,0.00061034,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::0.0024414::HTS002,BRD-K71512533-066-02-8,0.0024414,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::0.00976562::HTS002,BRD-K71512533-066-02-8,0.00976562,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::0.0390625::HTS002,BRD-K71512533-066-02-8,0.0390625,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::0.15625::HTS002,BRD-K71512533-066-02-8,0.15625,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::0.625::HTS002,BRD-K71512533-066-02-8,0.625,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::2.5::HTS002,BRD-K71512533-066-02-8,2.5,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71512533-066-02-8::10::HTS002,BRD-K71512533-066-02-8,10.0,HTS002,PREP026,SNS-314,Aurora kinase inhibitor,"AURKA, AURKB, AURKC",NA,NA,"Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",Phase 1
BRD-K71822263-001-03-2::0.00061034::HTS002,BRD-K71822263-001-03-2,0.00061034,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::0.0024414::HTS002,BRD-K71822263-001-03-2,0.0024414,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::0.00976562::HTS002,BRD-K71822263-001-03-2,0.00976562,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::0.0390625::HTS002,BRD-K71822263-001-03-2,0.0390625,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::0.15625::HTS002,BRD-K71822263-001-03-2,0.15625,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::0.625::HTS002,BRD-K71822263-001-03-2,0.625,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::2.5::HTS002,BRD-K71822263-001-03-2,2.5,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K71822263-001-03-2::10::HTS002,BRD-K71822263-001-03-2,10.0,HTS002,PREP022,D-Serine,glutamate receptor agonist,"GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3",NA,NA,N[C@H](CO)C(O)=O,Launched
BRD-K72093121-001-16-3::0.00061034::HTS002,BRD-K72093121-001-16-3,0.00061034,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::0.0024414::HTS002,BRD-K72093121-001-16-3,0.0024414,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::0.00976562::HTS002,BRD-K72093121-001-16-3,0.00976562,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::0.0390625::HTS002,BRD-K72093121-001-16-3,0.0390625,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::0.15625::HTS002,BRD-K72093121-001-16-3,0.15625,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::0.625::HTS002,BRD-K72093121-001-16-3,0.625,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::2.5::HTS002,BRD-K72093121-001-16-3,2.5,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72093121-001-16-3::10::HTS002,BRD-K72093121-001-16-3,10.0,HTS002,PREP016,vidarabine,antiviral,ADA,infectious disease,"virus herpes simplex (HSV), varicella-zoster virus (VZV)","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O",Launched
BRD-K72167406-001-02-1::0.000610352::HTS002,BRD-K72167406-001-02-1,0.000610352,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::0.00244141::HTS002,BRD-K72167406-001-02-1,0.00244141,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::0.00976562::HTS002,BRD-K72167406-001-02-1,0.00976562,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::0.0390625::HTS002,BRD-K72167406-001-02-1,0.0390625,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::0.15625::HTS002,BRD-K72167406-001-02-1,0.15625,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::0.625::HTS002,BRD-K72167406-001-02-1,0.625,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::2.5::HTS002,BRD-K72167406-001-02-1,2.5,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72167406-001-02-1::10::HTS002,BRD-K72167406-001-02-1,10.0,HTS002,PREP030,cefditoren-pivoxil,bacterial cell wall synthesis inhibitor,NA,"infectious disease, pulmonary, otolaryngology","pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis","CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1",Launched
BRD-K72231366-001-02-3::0.00061034::HTS002,BRD-K72231366-001-02-3,0.00061034,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::0.0024414::HTS002,BRD-K72231366-001-02-3,0.0024414,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::0.00976562::HTS002,BRD-K72231366-001-02-3,0.00976562,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::0.0390625::HTS002,BRD-K72231366-001-02-3,0.0390625,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::0.15625::HTS002,BRD-K72231366-001-02-3,0.15625,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::0.625::HTS002,BRD-K72231366-001-02-3,0.625,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::2.5::HTS002,BRD-K72231366-001-02-3,2.5,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72231366-001-02-3::10::HTS002,BRD-K72231366-001-02-3,10.0,HTS002,PREP015,TAME,NA,NA,NA,NA,COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1,Preclinical
BRD-K72327355-001-14-7::0.00061034::HTS002,BRD-K72327355-001-14-7,0.00061034,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::0.0024414::HTS002,BRD-K72327355-001-14-7,0.0024414,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::0.00976562::HTS002,BRD-K72327355-001-14-7,0.00976562,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::0.0390625::HTS002,BRD-K72327355-001-14-7,0.0390625,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::0.15625::HTS002,BRD-K72327355-001-14-7,0.15625,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::0.625::HTS002,BRD-K72327355-001-14-7,0.625,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::2.5::HTS002,BRD-K72327355-001-14-7,2.5,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72327355-001-14-7::10::HTS002,BRD-K72327355-001-14-7,10.0,HTS002,PREP036,baicalein,lipoxygenase inhibitor,"ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH",NA,NA,"Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1",Preclinical
BRD-K72414522-001-06-7::0.00061034::HTS002,BRD-K72414522-001-06-7,0.00061034,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::0.0024414::HTS002,BRD-K72414522-001-06-7,0.0024414,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::0.00976562::HTS002,BRD-K72414522-001-06-7,0.00976562,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::0.0390625::HTS002,BRD-K72414522-001-06-7,0.0390625,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::0.15625::HTS002,BRD-K72414522-001-06-7,0.15625,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::0.625::HTS002,BRD-K72414522-001-06-7,0.625,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::2.5::HTS002,BRD-K72414522-001-06-7,2.5,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72414522-001-06-7::10::HTS002,BRD-K72414522-001-06-7,10.0,HTS002,PREP026,AZD5438,CDK inhibitor,KCNH2,NA,NA,"CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",Phase 1
BRD-K72420232-001-12-3::0.00061034::HTS002,BRD-K72420232-001-12-3,0.00061034,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::0.0024414::HTS002,BRD-K72420232-001-12-3,0.0024414,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::0.00976562::HTS002,BRD-K72420232-001-12-3,0.00976562,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::0.0390625::HTS002,BRD-K72420232-001-12-3,0.0390625,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::0.15625::HTS002,BRD-K72420232-001-12-3,0.15625,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::0.625::HTS002,BRD-K72420232-001-12-3,0.625,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::2.5::HTS002,BRD-K72420232-001-12-3,2.5,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72420232-001-12-3::10::HTS002,BRD-K72420232-001-12-3,10.0,HTS002,PREP036,WZ-4002,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",Preclinical
BRD-K72703948-001-10-1::0.00061034::HTS002,BRD-K72703948-001-10-1,0.00061034,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::0.0024414::HTS002,BRD-K72703948-001-10-1,0.0024414,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::0.00976562::HTS002,BRD-K72703948-001-10-1,0.00976562,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::0.0390625::HTS002,BRD-K72703948-001-10-1,0.0390625,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::0.15625::HTS002,BRD-K72703948-001-10-1,0.15625,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::0.625::HTS002,BRD-K72703948-001-10-1,0.625,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::2.5::HTS002,BRD-K72703948-001-10-1,2.5,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72703948-001-10-1::10::HTS002,BRD-K72703948-001-10-1,10.0,HTS002,PREP037,ZM-447439,Aurora kinase inhibitor,"AURKA, AURKB",NA,NA,"COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",Preclinical
BRD-K72723676-003-17-8::0.00061034::HTS002,BRD-K72723676-003-17-8,0.00061034,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::0.0024414::HTS002,BRD-K72723676-003-17-8,0.0024414,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::0.00976562::HTS002,BRD-K72723676-003-17-8,0.00976562,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::0.0390625::HTS002,BRD-K72723676-003-17-8,0.0390625,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::0.15625::HTS002,BRD-K72723676-003-17-8,0.15625,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::0.625::HTS002,BRD-K72723676-003-17-8,0.625,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::2.5::HTS002,BRD-K72723676-003-17-8,2.5,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72723676-003-17-8::10::HTS002,BRD-K72723676-003-17-8,10.0,HTS002,PREP022,benzethonium,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1",Launched
BRD-K72726508-001-02-1::0.00061034::HTS002,BRD-K72726508-001-02-1,0.00061034,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::0.0024414::HTS002,BRD-K72726508-001-02-1,0.0024414,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::0.00976562::HTS002,BRD-K72726508-001-02-1,0.00976562,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::0.0390625::HTS002,BRD-K72726508-001-02-1,0.0390625,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::0.15625::HTS002,BRD-K72726508-001-02-1,0.15625,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::0.625::HTS002,BRD-K72726508-001-02-1,0.625,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::2.5::HTS002,BRD-K72726508-001-02-1,2.5,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72726508-001-02-1::10::HTS002,BRD-K72726508-001-02-1,10.0,HTS002,PREP043,arcyriaflavin-a,CDK inhibitor,"CCND1, CDK4",NA,NA,"O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",Preclinical
BRD-K72815923-034-01-2::0.00061034::HTS002,BRD-K72815923-034-01-2,0.00061034,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::0.0024414::HTS002,BRD-K72815923-034-01-2,0.0024414,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::0.00976562::HTS002,BRD-K72815923-034-01-2,0.00976562,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::0.0390625::HTS002,BRD-K72815923-034-01-2,0.0390625,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::0.15625::HTS002,BRD-K72815923-034-01-2,0.15625,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::0.625::HTS002,BRD-K72815923-034-01-2,0.625,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::2.5::HTS002,BRD-K72815923-034-01-2,2.5,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72815923-034-01-2::10::HTS002,BRD-K72815923-034-01-2,10.0,HTS002,PREP047,xanomeline,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7",NA,NA,"CCCCCCOc1nsnc1C1=CCCN(C)C1, CCCCCCOc1nsnc1C1=CCCN(C)C1",Phase 3
BRD-K72827473-001-01-0::0.00061034::HTS002,BRD-K72827473-001-01-0,0.00061034,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::0.0024414::HTS002,BRD-K72827473-001-01-0,0.0024414,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::0.00976562::HTS002,BRD-K72827473-001-01-0,0.00976562,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::0.0390625::HTS002,BRD-K72827473-001-01-0,0.0390625,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::0.15625::HTS002,BRD-K72827473-001-01-0,0.15625,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::0.625::HTS002,BRD-K72827473-001-01-0,0.625,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::2.5::HTS002,BRD-K72827473-001-01-0,2.5,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72827473-001-01-0::10::HTS002,BRD-K72827473-001-01-0,10.0,HTS002,PREP019,CEP-37440,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl,Phase 1
BRD-K72951360-001-01-4::0.00061034::HTS002,BRD-K72951360-001-01-4,0.00061034,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::0.0024414::HTS002,BRD-K72951360-001-01-4,0.0024414,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::0.00976562::HTS002,BRD-K72951360-001-01-4,0.00976562,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::0.0390625::HTS002,BRD-K72951360-001-01-4,0.0390625,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::0.15625::HTS002,BRD-K72951360-001-01-4,0.15625,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::0.625::HTS002,BRD-K72951360-001-01-4,0.625,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::2.5::HTS002,BRD-K72951360-001-01-4,2.5,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K72951360-001-01-4::10::HTS002,BRD-K72951360-001-01-4,10.0,HTS002,PREP014,valrubicin,"DNA inhibitor, topoisomerase inhibitor",TOP2A,oncology,bladder cancer,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,Launched
BRD-K73073971-001-01-7::0.00061034::HTS002,BRD-K73073971-001-01-7,0.00061034,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::0.0024414::HTS002,BRD-K73073971-001-01-7,0.0024414,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::0.00976562::HTS002,BRD-K73073971-001-01-7,0.00976562,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::0.0390625::HTS002,BRD-K73073971-001-01-7,0.0390625,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::0.15625::HTS002,BRD-K73073971-001-01-7,0.15625,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::0.625::HTS002,BRD-K73073971-001-01-7,0.625,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::2.5::HTS002,BRD-K73073971-001-01-7,2.5,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K73073971-001-01-7::10::HTS002,BRD-K73073971-001-01-7,10.0,HTS002,PREP042,ZLN005,NA,NA,NA,NA,CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1,Preclinical
BRD-K47832606-001-30-1::0.00061034::HTS002,BRD-K47832606-001-30-1,0.00061034,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::0.0024414::HTS002,BRD-K47832606-001-30-1,0.0024414,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::0.00976562::HTS002,BRD-K47832606-001-30-1,0.00976562,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::0.0390625::HTS002,BRD-K47832606-001-30-1,0.0390625,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::0.15625::HTS002,BRD-K47832606-001-30-1,0.15625,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::0.625::HTS002,BRD-K47832606-001-30-1,0.625,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::2.5::HTS002,BRD-K47832606-001-30-1,2.5,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K47832606-001-30-1::10::HTS002,BRD-K47832606-001-30-1,10.0,HTS002,PREP014,floxuridine,DNA synthesis inhibitor,TYMS,oncology,colorectal cancer,"OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K73197500-001-02-2::0.00061034::HTS002,BRD-K73197500-001-02-2,0.00061034,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::0.0024414::HTS002,BRD-K73197500-001-02-2,0.0024414,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::0.00976562::HTS002,BRD-K73197500-001-02-2,0.00976562,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::0.0390625::HTS002,BRD-K73197500-001-02-2,0.0390625,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::0.15625::HTS002,BRD-K73197500-001-02-2,0.15625,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::0.625::HTS002,BRD-K73197500-001-02-2,0.625,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::2.5::HTS002,BRD-K73197500-001-02-2,2.5,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73197500-001-02-2::10::HTS002,BRD-K73197500-001-02-2,10.0,HTS002,PREP044,SNX-5422,HSP inhibitor,HSP90AA1,NA,NA,"CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1",Phase 1/Phase 2
BRD-K73237276-001-01-0::0.00061034::HTS002,BRD-K73237276-001-01-0,0.00061034,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::0.0024414::HTS002,BRD-K73237276-001-01-0,0.0024414,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::0.00976562::HTS002,BRD-K73237276-001-01-0,0.00976562,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::0.0390625::HTS002,BRD-K73237276-001-01-0,0.0390625,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::0.15625::HTS002,BRD-K73237276-001-01-0,0.15625,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::0.625::HTS002,BRD-K73237276-001-01-0,0.625,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::2.5::HTS002,BRD-K73237276-001-01-0,2.5,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73237276-001-01-0::10::HTS002,BRD-K73237276-001-01-0,10.0,HTS002,PREP016,tacalcitol,vitamin D receptor agonist,VDR,dermatology,"psoriasis, chapped lips",CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,Launched
BRD-K73293050-001-03-1::0.00061034::HTS002,BRD-K73293050-001-03-1,0.00061034,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::0.0024414::HTS002,BRD-K73293050-001-03-1,0.0024414,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::0.00976562::HTS002,BRD-K73293050-001-03-1,0.00976562,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::0.0390625::HTS002,BRD-K73293050-001-03-1,0.0390625,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::0.15625::HTS002,BRD-K73293050-001-03-1,0.15625,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::0.625::HTS002,BRD-K73293050-001-03-1,0.625,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::2.5::HTS002,BRD-K73293050-001-03-1,2.5,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73293050-001-03-1::10::HTS002,BRD-K73293050-001-03-1,10.0,HTS002,PREP042,WZ-3146,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K73303757-001-21-6::0.00061034::HTS002,BRD-K73303757-001-21-6,0.00061034,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::0.0024414::HTS002,BRD-K73303757-001-21-6,0.0024414,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::0.00976562::HTS002,BRD-K73303757-001-21-6,0.00976562,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::0.0390625::HTS002,BRD-K73303757-001-21-6,0.0390625,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::0.15625::HTS002,BRD-K73303757-001-21-6,0.15625,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::0.625::HTS002,BRD-K73303757-001-21-6,0.625,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::2.5::HTS002,BRD-K73303757-001-21-6,2.5,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73303757-001-21-6::10::HTS002,BRD-K73303757-001-21-6,10.0,HTS002,PREP032,4-methylgenistein,protein tyrosine kinase inhibitor,"CYP19A1, ESRRA, ESRRB, ESRRG, FASN",NA,NA,COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,Preclinical
BRD-K73309154-003-02-8::0.00061034::HTS002,BRD-K73309154-003-02-8,0.00061034,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::0.0024414::HTS002,BRD-K73309154-003-02-8,0.0024414,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::0.00976562::HTS002,BRD-K73309154-003-02-8,0.00976562,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::0.0390625::HTS002,BRD-K73309154-003-02-8,0.0390625,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::0.15625::HTS002,BRD-K73309154-003-02-8,0.15625,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::0.625::HTS002,BRD-K73309154-003-02-8,0.625,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::2.5::HTS002,BRD-K73309154-003-02-8,2.5,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73309154-003-02-8::10::HTS002,BRD-K73309154-003-02-8,10.0,HTS002,PREP047,OSI-420,EGFR inhibitor,EGFR,NA,NA,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO,Preclinical
BRD-K73319509-001-08-0::0.00061034::HTS002,BRD-K73319509-001-08-0,0.00061034,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::0.0024414::HTS002,BRD-K73319509-001-08-0,0.0024414,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::0.00976562::HTS002,BRD-K73319509-001-08-0,0.00976562,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::0.0390625::HTS002,BRD-K73319509-001-08-0,0.0390625,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::0.15625::HTS002,BRD-K73319509-001-08-0,0.15625,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::0.625::HTS002,BRD-K73319509-001-08-0,0.625,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::2.5::HTS002,BRD-K73319509-001-08-0,2.5,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73319509-001-08-0::10::HTS002,BRD-K73319509-001-08-0,10.0,HTS002,PREP027,PF-04217903,c-Met inhibitor,MET,NA,NA,OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1,Phase 1
BRD-K73391359-003-10-2::0.00061034::HTS002,BRD-K73391359-003-10-2,0.00061034,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::0.0024414::HTS002,BRD-K73391359-003-10-2,0.0024414,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::0.00976562::HTS002,BRD-K73391359-003-10-2,0.00976562,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::0.0390625::HTS002,BRD-K73391359-003-10-2,0.0390625,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::0.15625::HTS002,BRD-K73391359-003-10-2,0.15625,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::0.625::HTS002,BRD-K73391359-003-10-2,0.625,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::2.5::HTS002,BRD-K73391359-003-10-2,2.5,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73391359-003-10-2::10::HTS002,BRD-K73391359-003-10-2,10.0,HTS002,PREP025,dimethisoquin,local anesthetic,NA,neurology/psychiatry,local anesthetic,CCCCc1cc2ccccc2c(OCCN(C)C)n1,Launched
BRD-K73425385-065-04-8::0.00061034::HTS002,BRD-K73425385-065-04-8,0.00061034,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::0.0024414::HTS002,BRD-K73425385-065-04-8,0.0024414,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::0.00976562::HTS002,BRD-K73425385-065-04-8,0.00976562,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::0.0390625::HTS002,BRD-K73425385-065-04-8,0.0390625,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::0.15625::HTS002,BRD-K73425385-065-04-8,0.15625,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::0.625::HTS002,BRD-K73425385-065-04-8,0.625,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::2.5::HTS002,BRD-K73425385-065-04-8,2.5,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73425385-065-04-8::10::HTS002,BRD-K73425385-065-04-8,10.0,HTS002,PREP031,bekanamycin,bacterial 30S ribosomal subunit inhibitor,NA,infectious disease,gram-negative bacterial infections,"NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O",Launched
BRD-K73589491-001-11-2::0.00061034::HTS002,BRD-K73589491-001-11-2,0.00061034,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::0.0024414::HTS002,BRD-K73589491-001-11-2,0.0024414,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::0.00976562::HTS002,BRD-K73589491-001-11-2,0.00976562,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::0.0390625::HTS002,BRD-K73589491-001-11-2,0.0390625,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::0.15625::HTS002,BRD-K73589491-001-11-2,0.15625,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::0.625::HTS002,BRD-K73589491-001-11-2,0.625,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::2.5::HTS002,BRD-K73589491-001-11-2,2.5,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K73589491-001-11-2::10::HTS002,BRD-K73589491-001-11-2,10.0,HTS002,PREP016,nizatidine,histamine receptor antagonist,HRH2,gastroenterology,"duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)","CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O",Launched
BRD-K74501079-001-18-1::0.00061034::HTS002,BRD-K74501079-001-18-1,0.00061034,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::0.0024414::HTS002,BRD-K74501079-001-18-1,0.0024414,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::0.00976562::HTS002,BRD-K74501079-001-18-1,0.00976562,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::0.0390625::HTS002,BRD-K74501079-001-18-1,0.0390625,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::0.15625::HTS002,BRD-K74501079-001-18-1,0.15625,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::0.625::HTS002,BRD-K74501079-001-18-1,0.625,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::2.5::HTS002,BRD-K74501079-001-18-1,2.5,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K74501079-001-18-1::10::HTS002,BRD-K74501079-001-18-1,10.0,HTS002,PREP028,azithromycin,bacterial 50S ribosomal subunit inhibitor,MLNR,infectious disease,"pelvic inflammatory disease, pneumonia","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O",Launched
BRD-K73838513-003-05-5::0.00061034::HTS002,BRD-K73838513-003-05-5,0.00061034,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.0024414::HTS002,BRD-K73838513-003-05-5,0.0024414,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.00976562::HTS002,BRD-K73838513-003-05-5,0.00976562,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.0390625::HTS002,BRD-K73838513-003-05-5,0.0390625,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.15625::HTS002,BRD-K73838513-003-05-5,0.15625,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::0.625::HTS002,BRD-K73838513-003-05-5,0.625,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::2.5::HTS002,BRD-K73838513-003-05-5,2.5,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73838513-003-05-5::10::HTS002,BRD-K73838513-003-05-5,10.0,HTS002,PREP020,cinacalcet,calcium channel activator,CASR,"endocrinology, nephrology, oncology","hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia",C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,Launched
BRD-K73982490-001-02-9::0.00061034::HTS002,BRD-K73982490-001-02-9,0.00061034,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::0.0024414::HTS002,BRD-K73982490-001-02-9,0.0024414,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::0.00976562::HTS002,BRD-K73982490-001-02-9,0.00976562,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::0.0390625::HTS002,BRD-K73982490-001-02-9,0.0390625,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::0.15625::HTS002,BRD-K73982490-001-02-9,0.15625,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::0.625::HTS002,BRD-K73982490-001-02-9,0.625,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::2.5::HTS002,BRD-K73982490-001-02-9,2.5,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K73982490-001-02-9::10::HTS002,BRD-K73982490-001-02-9,10.0,HTS002,PREP046,BI-78D3,JNK inhibitor,MAPK8,NA,NA,"Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1",Preclinical
BRD-K74057757-001-01-9::0.000610352::HTS002,BRD-K74057757-001-01-9,0.000610352,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::0.00244141::HTS002,BRD-K74057757-001-01-9,0.00244141,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::0.00976562::HTS002,BRD-K74057757-001-01-9,0.00976562,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::0.0390625::HTS002,BRD-K74057757-001-01-9,0.0390625,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::0.15625::HTS002,BRD-K74057757-001-01-9,0.15625,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::0.625::HTS002,BRD-K74057757-001-01-9,0.625,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::2.5::HTS002,BRD-K74057757-001-01-9,2.5,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74057757-001-01-9::10::HTS002,BRD-K74057757-001-01-9,10.0,HTS002,PREP019,indibulin,tubulin polymerization inhibitor,NA,NA,NA,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,Phase 1/Phase 2
BRD-K74141488-003-11-2::0.00061034::HTS002,BRD-K74141488-003-11-2,0.00061034,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::0.0024414::HTS002,BRD-K74141488-003-11-2,0.0024414,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::0.00976562::HTS002,BRD-K74141488-003-11-2,0.00976562,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::0.0390625::HTS002,BRD-K74141488-003-11-2,0.0390625,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::0.15625::HTS002,BRD-K74141488-003-11-2,0.15625,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::0.625::HTS002,BRD-K74141488-003-11-2,0.625,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::2.5::HTS002,BRD-K74141488-003-11-2,2.5,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74141488-003-11-2::10::HTS002,BRD-K74141488-003-11-2,10.0,HTS002,PREP031,naftifine,fungal squalene epoxidase inhibitor,SQLE,infectious disease,"tinea pedis, tinea cruris, tinea corporis","CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12",Launched
BRD-K74193284-001-04-8::0.00061034::HTS002,BRD-K74193284-001-04-8,0.00061034,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::0.0024414::HTS002,BRD-K74193284-001-04-8,0.0024414,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::0.00976562::HTS002,BRD-K74193284-001-04-8,0.00976562,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::0.0390625::HTS002,BRD-K74193284-001-04-8,0.0390625,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::0.15625::HTS002,BRD-K74193284-001-04-8,0.15625,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::0.625::HTS002,BRD-K74193284-001-04-8,0.625,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::2.5::HTS002,BRD-K74193284-001-04-8,2.5,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74193284-001-04-8::10::HTS002,BRD-K74193284-001-04-8,10.0,HTS002,PREP048,phenylmercuric-acetate,other antifungal,NA,NA,NA,CC(=O)O[Hg]c1ccccc1,Preclinical
BRD-K74227499-001-01-1::0.000610352::HTS002,BRD-K74227499-001-01-1,0.000610352,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::0.00244141::HTS002,BRD-K74227499-001-01-1,0.00244141,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::0.00976562::HTS002,BRD-K74227499-001-01-1,0.00976562,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::0.0390625::HTS002,BRD-K74227499-001-01-1,0.0390625,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::0.15625::HTS002,BRD-K74227499-001-01-1,0.15625,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::0.625::HTS002,BRD-K74227499-001-01-1,0.625,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::2.5::HTS002,BRD-K74227499-001-01-1,2.5,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74227499-001-01-1::10::HTS002,BRD-K74227499-001-01-1,10.0,HTS002,PREP032,se-methylselenocysteine,NA,NA,NA,NA,"C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",Phase 2
BRD-K74305673-001-06-2::0.00061034::HTS002,BRD-K74305673-001-06-2,0.00061034,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::0.0024414::HTS002,BRD-K74305673-001-06-2,0.0024414,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::0.00976562::HTS002,BRD-K74305673-001-06-2,0.00976562,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::0.0390625::HTS002,BRD-K74305673-001-06-2,0.0390625,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::0.15625::HTS002,BRD-K74305673-001-06-2,0.15625,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::0.625::HTS002,BRD-K74305673-001-06-2,0.625,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::2.5::HTS002,BRD-K74305673-001-06-2,2.5,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74305673-001-06-2::10::HTS002,BRD-K74305673-001-06-2,10.0,HTS002,PREP039,IKK-2-inhibitor-V,"IKK inhibitor, NFkB pathway inhibitor",IKBKB,NA,NA,"Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",Phase 1
BRD-K74514084-001-03-9::0.00061034::HTS002,BRD-K74514084-001-03-9,0.00061034,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::0.0024414::HTS002,BRD-K74514084-001-03-9,0.0024414,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::0.00976562::HTS002,BRD-K74514084-001-03-9,0.00976562,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::0.0390625::HTS002,BRD-K74514084-001-03-9,0.0390625,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::0.15625::HTS002,BRD-K74514084-001-03-9,0.15625,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::0.625::HTS002,BRD-K74514084-001-03-9,0.625,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::2.5::HTS002,BRD-K74514084-001-03-9,2.5,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74514084-001-03-9::10::HTS002,BRD-K74514084-001-03-9,10.0,HTS002,PREP034,pazopanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3",oncology,"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1",Launched
BRD-K74763371-002-04-0::0.00061034::HTS002,BRD-K74763371-002-04-0,0.00061034,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::0.0024414::HTS002,BRD-K74763371-002-04-0,0.0024414,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::0.00976562::HTS002,BRD-K74763371-002-04-0,0.00976562,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::0.0390625::HTS002,BRD-K74763371-002-04-0,0.0390625,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::0.15625::HTS002,BRD-K74763371-002-04-0,0.15625,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::0.625::HTS002,BRD-K74763371-002-04-0,0.625,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::2.5::HTS002,BRD-K74763371-002-04-0,2.5,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K74763371-002-04-0::10::HTS002,BRD-K74763371-002-04-0,10.0,HTS002,PREP029,bosentan,endothelin receptor antagonist,"EDNRA, EDNRB",pulmonary,pulmonary arterial hypertension (PAH),COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1,Launched
BRD-K75009076-001-02-1::0.000593018::HTS002,BRD-K75009076-001-02-1,0.000593018,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.00237207::HTS002,BRD-K75009076-001-02-1,0.00237207,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.00948828::HTS002,BRD-K75009076-001-02-1,0.00948828,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.0379531::HTS002,BRD-K75009076-001-02-1,0.0379531,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.151812::HTS002,BRD-K75009076-001-02-1,0.151812,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::0.60725::HTS002,BRD-K75009076-001-02-1,0.60725,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::2.429::HTS002,BRD-K75009076-001-02-1,2.429,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75009076-001-02-1::9.716::HTS002,BRD-K75009076-001-02-1,9.716,HTS002,PREP019,SCH-900776,CHK inhibitor,"CDK2, CHEK1",NA,NA,"Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",Phase 2
BRD-K75037734-003-13-9::0.00061034::HTS002,BRD-K75037734-003-13-9,0.00061034,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::0.0024414::HTS002,BRD-K75037734-003-13-9,0.0024414,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::0.00976562::HTS002,BRD-K75037734-003-13-9,0.00976562,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::0.0390625::HTS002,BRD-K75037734-003-13-9,0.0390625,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::0.15625::HTS002,BRD-K75037734-003-13-9,0.15625,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::0.625::HTS002,BRD-K75037734-003-13-9,0.625,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::2.5::HTS002,BRD-K75037734-003-13-9,2.5,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75037734-003-13-9::10::HTS002,BRD-K75037734-003-13-9,10.0,HTS002,PREP023,carbachol,cholinergic receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2",ophthalmology,intraocular pressure,"C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O",Launched
BRD-K75295174-001-05-0::0.00061034::HTS002,BRD-K75295174-001-05-0,0.00061034,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::0.0024414::HTS002,BRD-K75295174-001-05-0,0.0024414,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::0.00976562::HTS002,BRD-K75295174-001-05-0,0.00976562,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::0.0390625::HTS002,BRD-K75295174-001-05-0,0.0390625,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::0.15625::HTS002,BRD-K75295174-001-05-0,0.15625,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::0.625::HTS002,BRD-K75295174-001-05-0,0.625,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::2.5::HTS002,BRD-K75295174-001-05-0,2.5,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75295174-001-05-0::10::HTS002,BRD-K75295174-001-05-0,10.0,HTS002,PREP038,alisertib,Aurora kinase inhibitor,AURKA,NA,NA,COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O,Phase 3
BRD-K75352575-001-01-3::0.00061034::HTS002,BRD-K75352575-001-01-3,0.00061034,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::0.0024414::HTS002,BRD-K75352575-001-01-3,0.0024414,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::0.00976562::HTS002,BRD-K75352575-001-01-3,0.00976562,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::0.0390625::HTS002,BRD-K75352575-001-01-3,0.0390625,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::0.15625::HTS002,BRD-K75352575-001-01-3,0.15625,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::0.625::HTS002,BRD-K75352575-001-01-3,0.625,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::2.5::HTS002,BRD-K75352575-001-01-3,2.5,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75352575-001-01-3::10::HTS002,BRD-K75352575-001-01-3,10.0,HTS002,PREP036,KPT-276,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1,Preclinical
BRD-K75466013-001-14-4::0.00061034::HTS002,BRD-K75466013-001-14-4,0.00061034,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::0.0024414::HTS002,BRD-K75466013-001-14-4,0.0024414,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::0.00976562::HTS002,BRD-K75466013-001-14-4,0.00976562,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::0.0390625::HTS002,BRD-K75466013-001-14-4,0.0390625,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::0.15625::HTS002,BRD-K75466013-001-14-4,0.15625,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::0.625::HTS002,BRD-K75466013-001-14-4,0.625,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::2.5::HTS002,BRD-K75466013-001-14-4,2.5,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75466013-001-14-4::10::HTS002,BRD-K75466013-001-14-4,10.0,HTS002,PREP023,benzocaine,sodium channel blocker,SCN10A,infectious disease,first-aid antiseptic,"CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1",Launched
BRD-K75478907-001-02-3::0.00061034::HTS002,BRD-K75478907-001-02-3,0.00061034,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::0.0024414::HTS002,BRD-K75478907-001-02-3,0.0024414,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::0.00976562::HTS002,BRD-K75478907-001-02-3,0.00976562,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::0.0390625::HTS002,BRD-K75478907-001-02-3,0.0390625,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::0.15625::HTS002,BRD-K75478907-001-02-3,0.15625,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::0.625::HTS002,BRD-K75478907-001-02-3,0.625,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::2.5::HTS002,BRD-K75478907-001-02-3,2.5,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75478907-001-02-3::10::HTS002,BRD-K75478907-001-02-3,10.0,HTS002,PREP036,GS-39783,GABA receptor modulator,GABBR1,NA,NA,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,Preclinical
BRD-K75649340-001-13-1::0.00061034::HTS002,BRD-K75649340-001-13-1,0.00061034,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::0.0024414::HTS002,BRD-K75649340-001-13-1,0.0024414,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::0.00976562::HTS002,BRD-K75649340-001-13-1,0.00976562,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::0.0390625::HTS002,BRD-K75649340-001-13-1,0.0390625,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::0.15625::HTS002,BRD-K75649340-001-13-1,0.15625,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::0.625::HTS002,BRD-K75649340-001-13-1,0.625,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::2.5::HTS002,BRD-K75649340-001-13-1,2.5,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75649340-001-13-1::10::HTS002,BRD-K75649340-001-13-1,10.0,HTS002,PREP019,tioguanine,purine antagonist,NA,NA,NA,Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Phase 2
BRD-K75911534-001-01-6::0.00061034::HTS002,BRD-K75911534-001-01-6,0.00061034,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::0.0024414::HTS002,BRD-K75911534-001-01-6,0.0024414,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::0.00976562::HTS002,BRD-K75911534-001-01-6,0.00976562,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::0.0390625::HTS002,BRD-K75911534-001-01-6,0.0390625,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::0.15625::HTS002,BRD-K75911534-001-01-6,0.15625,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::0.625::HTS002,BRD-K75911534-001-01-6,0.625,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::2.5::HTS002,BRD-K75911534-001-01-6,2.5,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75911534-001-01-6::10::HTS002,BRD-K75911534-001-01-6,10.0,HTS002,PREP039,SU014813,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,Phase 2
BRD-K75958547-238-01-0::0.00061034::HTS002,BRD-K75958547-238-01-0,0.00061034,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::0.0024414::HTS002,BRD-K75958547-238-01-0,0.0024414,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::0.00976562::HTS002,BRD-K75958547-238-01-0,0.00976562,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::0.0390625::HTS002,BRD-K75958547-238-01-0,0.0390625,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::0.15625::HTS002,BRD-K75958547-238-01-0,0.15625,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::0.625::HTS002,BRD-K75958547-238-01-0,0.625,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::2.5::HTS002,BRD-K75958547-238-01-0,2.5,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K75958547-238-01-0::10::HTS002,BRD-K75958547-238-01-0,10.0,HTS002,PREP023,pitavastatin,HMGCR inhibitor,HMGCR,endocrinology,hyperlipidemia,"O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O",Launched
BRD-K76011241-001-01-8::0.00061034::HTS002,BRD-K76011241-001-01-8,0.00061034,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::0.0024414::HTS002,BRD-K76011241-001-01-8,0.0024414,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::0.00976562::HTS002,BRD-K76011241-001-01-8,0.00976562,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::0.0390625::HTS002,BRD-K76011241-001-01-8,0.0390625,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::0.15625::HTS002,BRD-K76011241-001-01-8,0.15625,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::0.625::HTS002,BRD-K76011241-001-01-8,0.625,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::2.5::HTS002,BRD-K76011241-001-01-8,2.5,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76011241-001-01-8::10::HTS002,BRD-K76011241-001-01-8,10.0,HTS002,PREP016,oseltamivir-phosphate,neuraminidase inhibitor,"CES1, NEU1, NEU2",infectious disease,influenza A virus infection,"CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1",Launched
BRD-K76037122-001-02-5::0.00061034::HTS002,BRD-K76037122-001-02-5,0.00061034,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::0.0024414::HTS002,BRD-K76037122-001-02-5,0.0024414,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::0.00976562::HTS002,BRD-K76037122-001-02-5,0.00976562,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::0.0390625::HTS002,BRD-K76037122-001-02-5,0.0390625,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::0.15625::HTS002,BRD-K76037122-001-02-5,0.15625,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::0.625::HTS002,BRD-K76037122-001-02-5,0.625,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::2.5::HTS002,BRD-K76037122-001-02-5,2.5,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76037122-001-02-5::10::HTS002,BRD-K76037122-001-02-5,10.0,HTS002,PREP030,guanidine,HSP inhibitor,"ALDH2, DLG4, GAMT, RNASE1",neurology/psychiatry,Lambert-Eaton myasthenic syndrome (LEMS),"NC(N)=N, NC(N)=N",Launched
BRD-K76064317-001-07-3::0.00061034::HTS002,BRD-K76064317-001-07-3,0.00061034,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::0.0024414::HTS002,BRD-K76064317-001-07-3,0.0024414,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::0.00976562::HTS002,BRD-K76064317-001-07-3,0.00976562,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::0.0390625::HTS002,BRD-K76064317-001-07-3,0.0390625,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::0.15625::HTS002,BRD-K76064317-001-07-3,0.15625,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::0.625::HTS002,BRD-K76064317-001-07-3,0.625,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::2.5::HTS002,BRD-K76064317-001-07-3,2.5,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76064317-001-07-3::10::HTS002,BRD-K76064317-001-07-3,10.0,HTS002,PREP040,tyrphostin-AG-1296,FLT3 inhibitor,FLT3,NA,NA,"COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",Preclinical
BRD-K76180386-001-01-6::0.00061034::HTS002,BRD-K76180386-001-01-6,0.00061034,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::0.0024414::HTS002,BRD-K76180386-001-01-6,0.0024414,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::0.00976562::HTS002,BRD-K76180386-001-01-6,0.00976562,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::0.0390625::HTS002,BRD-K76180386-001-01-6,0.0390625,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::0.15625::HTS002,BRD-K76180386-001-01-6,0.15625,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::0.625::HTS002,BRD-K76180386-001-01-6,0.625,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::2.5::HTS002,BRD-K76180386-001-01-6,2.5,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K76180386-001-01-6::10::HTS002,BRD-K76180386-001-01-6,10.0,HTS002,PREP036,JIB04,histone lysine demethylase inhibitor,KDM4E,NA,NA,"Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",Preclinical
BRD-K64381438-001-03-8::0.00061034::HTS002,BRD-K64381438-001-03-8,0.00061034,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::0.0024414::HTS002,BRD-K64381438-001-03-8,0.0024414,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::0.00976562::HTS002,BRD-K64381438-001-03-8,0.00976562,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::0.0390625::HTS002,BRD-K64381438-001-03-8,0.0390625,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::0.15625::HTS002,BRD-K64381438-001-03-8,0.15625,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::0.625::HTS002,BRD-K64381438-001-03-8,0.625,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::2.5::HTS002,BRD-K64381438-001-03-8,2.5,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K64381438-001-03-8::10::HTS002,BRD-K64381438-001-03-8,10.0,HTS002,PREP023,ulipristal,progesterone receptor antagonist,PGR,endocrinology,contraceptive,"CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12",Launched
BRD-K76210423-001-01-6::0.00061034::HTS002,BRD-K76210423-001-01-6,0.00061034,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.0024414::HTS002,BRD-K76210423-001-01-6,0.0024414,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.00976562::HTS002,BRD-K76210423-001-01-6,0.00976562,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.0390625::HTS002,BRD-K76210423-001-01-6,0.0390625,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.15625::HTS002,BRD-K76210423-001-01-6,0.15625,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::0.625::HTS002,BRD-K76210423-001-01-6,0.625,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::2.5::HTS002,BRD-K76210423-001-01-6,2.5,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76210423-001-01-6::10::HTS002,BRD-K76210423-001-01-6,10.0,HTS002,PREP039,resiquimod,toll-like receptor agonist,"TLR7, TLR8",NA,NA,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",Phase 3
BRD-K76239644-001-01-8::0.00061034::HTS002,BRD-K76239644-001-01-8,0.00061034,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::0.0024414::HTS002,BRD-K76239644-001-01-8,0.0024414,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::0.00976562::HTS002,BRD-K76239644-001-01-8,0.00976562,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::0.0390625::HTS002,BRD-K76239644-001-01-8,0.0390625,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::0.15625::HTS002,BRD-K76239644-001-01-8,0.15625,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::0.625::HTS002,BRD-K76239644-001-01-8,0.625,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::2.5::HTS002,BRD-K76239644-001-01-8,2.5,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76239644-001-01-8::10::HTS002,BRD-K76239644-001-01-8,10.0,HTS002,PREP018,BMS-690514,"EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR",NA,NA,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",Phase 2
BRD-K76406695-001-02-9::0.00061034::HTS002,BRD-K76406695-001-02-9,0.00061034,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::0.0024414::HTS002,BRD-K76406695-001-02-9,0.0024414,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::0.00976562::HTS002,BRD-K76406695-001-02-9,0.00976562,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::0.0390625::HTS002,BRD-K76406695-001-02-9,0.0390625,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::0.15625::HTS002,BRD-K76406695-001-02-9,0.15625,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::0.625::HTS002,BRD-K76406695-001-02-9,0.625,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::2.5::HTS002,BRD-K76406695-001-02-9,2.5,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76406695-001-02-9::10::HTS002,BRD-K76406695-001-02-9,10.0,HTS002,PREP043,CCT128930,AKT inhibitor,"PKIA, PRKACA",NA,NA,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,Preclinical
BRD-K76674262-001-03-3::0.00061034::HTS002,BRD-K76674262-001-03-3,0.00061034,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.0024414::HTS002,BRD-K76674262-001-03-3,0.0024414,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.00976562::HTS002,BRD-K76674262-001-03-3,0.00976562,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.0390625::HTS002,BRD-K76674262-001-03-3,0.0390625,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.15625::HTS002,BRD-K76674262-001-03-3,0.15625,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::0.625::HTS002,BRD-K76674262-001-03-3,0.625,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::2.5::HTS002,BRD-K76674262-001-03-3,2.5,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76674262-001-03-3::10::HTS002,BRD-K76674262-001-03-3,10.0,HTS002,PREP029,homoharringtonine,protein synthesis inhibitor,RPL3,hematologic malignancy,chronic myeloid leukemia (CML),COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Launched
BRD-K76703230-004-04-1::0.00061034::HTS002,BRD-K76703230-004-04-1,0.00061034,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::0.0024414::HTS002,BRD-K76703230-004-04-1,0.0024414,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::0.00976562::HTS002,BRD-K76703230-004-04-1,0.00976562,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::0.0390625::HTS002,BRD-K76703230-004-04-1,0.0390625,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::0.15625::HTS002,BRD-K76703230-004-04-1,0.15625,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::0.625::HTS002,BRD-K76703230-004-04-1,0.625,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::2.5::HTS002,BRD-K76703230-004-04-1,2.5,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76703230-004-04-1::10::HTS002,BRD-K76703230-004-04-1,10.0,HTS002,PREP027,YM-155,survivin inhibitor,BIRC5,NA,NA,"COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C",Phase 2
BRD-K76840893-003-02-5::0.00061034::HTS002,BRD-K76840893-003-02-5,0.00061034,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::0.0024414::HTS002,BRD-K76840893-003-02-5,0.0024414,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::0.00976562::HTS002,BRD-K76840893-003-02-5,0.00976562,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::0.0390625::HTS002,BRD-K76840893-003-02-5,0.0390625,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::0.15625::HTS002,BRD-K76840893-003-02-5,0.15625,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::0.625::HTS002,BRD-K76840893-003-02-5,0.625,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::2.5::HTS002,BRD-K76840893-003-02-5,2.5,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76840893-003-02-5::10::HTS002,BRD-K76840893-003-02-5,10.0,HTS002,PREP040,RS-17053,adrenergic receptor antagonist,"ADRA1A, ADRA1D",NA,NA,"CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",Preclinical
BRD-K76908866-001-07-6::0.00061034::HTS002,BRD-K76908866-001-07-6,0.00061034,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.0024414::HTS002,BRD-K76908866-001-07-6,0.0024414,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.00976562::HTS002,BRD-K76908866-001-07-6,0.00976562,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.0390625::HTS002,BRD-K76908866-001-07-6,0.0390625,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.15625::HTS002,BRD-K76908866-001-07-6,0.15625,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::0.625::HTS002,BRD-K76908866-001-07-6,0.625,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::2.5::HTS002,BRD-K76908866-001-07-6,2.5,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76908866-001-07-6::10::HTS002,BRD-K76908866-001-07-6,10.0,HTS002,PREP027,CP-724714,"EGFR inhibitor, protein tyrosine kinase inhibitor",ERBB2,NA,NA,COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,Phase 2
BRD-K76973696-001-12-6::0.000491751::HTS002,BRD-K76973696-001-12-6,0.000491751,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::0.001967::HTS002,BRD-K76973696-001-12-6,0.001967,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::0.00786801::HTS002,BRD-K76973696-001-12-6,0.00786801,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::0.031472::HTS002,BRD-K76973696-001-12-6,0.031472,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::0.125888::HTS002,BRD-K76973696-001-12-6,0.125888,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::0.503553::HTS002,BRD-K76973696-001-12-6,0.503553,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::2.01421::HTS002,BRD-K76973696-001-12-6,2.01421,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K76973696-001-12-6::8.05684::HTS002,BRD-K76973696-001-12-6,8.05684,HTS002,PREP043,tryptanthrin,cyclooxygenase inhibitor,IDO1,NA,NA,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,Preclinical
BRD-K77008974-001-03-2::0.00061034::HTS002,BRD-K77008974-001-03-2,0.00061034,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::0.0024414::HTS002,BRD-K77008974-001-03-2,0.0024414,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::0.00976562::HTS002,BRD-K77008974-001-03-2,0.00976562,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::0.0390625::HTS002,BRD-K77008974-001-03-2,0.0390625,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::0.15625::HTS002,BRD-K77008974-001-03-2,0.15625,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::0.625::HTS002,BRD-K77008974-001-03-2,0.625,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::2.5::HTS002,BRD-K77008974-001-03-2,2.5,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77008974-001-03-2::10::HTS002,BRD-K77008974-001-03-2,10.0,HTS002,PREP037,WYE-354,mTOR inhibitor,MTOR,NA,NA,COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,Preclinical
BRD-K77245796-003-01-6::0.00061034::HTS002,BRD-K77245796-003-01-6,0.00061034,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::0.0024414::HTS002,BRD-K77245796-003-01-6,0.0024414,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::0.00976562::HTS002,BRD-K77245796-003-01-6,0.00976562,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::0.0390625::HTS002,BRD-K77245796-003-01-6,0.0390625,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::0.15625::HTS002,BRD-K77245796-003-01-6,0.15625,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::0.625::HTS002,BRD-K77245796-003-01-6,0.625,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::2.5::HTS002,BRD-K77245796-003-01-6,2.5,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77245796-003-01-6::10::HTS002,BRD-K77245796-003-01-6,10.0,HTS002,PREP042,gamma-aminobutyric-acid,benzodiazepine receptor agonist,"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1",NA,NA,NCCCC(O)=O,Preclinical
BRD-K77554836-001-11-6::0.000628195::HTS002,BRD-K77554836-001-11-6,0.000628195,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::0.00251278::HTS002,BRD-K77554836-001-11-6,0.00251278,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::0.0100511::HTS002,BRD-K77554836-001-11-6,0.0100511,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::0.0402045::HTS002,BRD-K77554836-001-11-6,0.0402045,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::0.160818::HTS002,BRD-K77554836-001-11-6,0.160818,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::0.643271::HTS002,BRD-K77554836-001-11-6,0.643271,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::2.57309::HTS002,BRD-K77554836-001-11-6,2.57309,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77554836-001-11-6::10.2923::HTS002,BRD-K77554836-001-11-6,10.2923,HTS002,PREP035,triamcinolone,glucocorticoid receptor agonist,"NR3C1, SERPINA6",dermatology,corticosteroid-responsive dermatoses,"C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO",Launched
BRD-K77625799-001-07-7::0.00061034::HTS002,BRD-K77625799-001-07-7,0.00061034,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.0024414::HTS002,BRD-K77625799-001-07-7,0.0024414,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.00976562::HTS002,BRD-K77625799-001-07-7,0.00976562,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.0390625::HTS002,BRD-K77625799-001-07-7,0.0390625,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.15625::HTS002,BRD-K77625799-001-07-7,0.15625,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::0.625::HTS002,BRD-K77625799-001-07-7,0.625,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::2.5::HTS002,BRD-K77625799-001-07-7,2.5,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77625799-001-07-7::10::HTS002,BRD-K77625799-001-07-7,10.0,HTS002,PREP029,vandetanib,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA",oncology,medullary thyroid cancer (MTC),COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,Launched
BRD-K77634909-001-03-5::0.00061034::HTS002,BRD-K77634909-001-03-5,0.00061034,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::0.0024414::HTS002,BRD-K77634909-001-03-5,0.0024414,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::0.00976562::HTS002,BRD-K77634909-001-03-5,0.00976562,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::0.0390625::HTS002,BRD-K77634909-001-03-5,0.0390625,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::0.15625::HTS002,BRD-K77634909-001-03-5,0.15625,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::0.625::HTS002,BRD-K77634909-001-03-5,0.625,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::2.5::HTS002,BRD-K77634909-001-03-5,2.5,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77634909-001-03-5::10::HTS002,BRD-K77634909-001-03-5,10.0,HTS002,PREP032,AEG3482,HSP inducer,NA,NA,NA,"NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",Preclinical
BRD-K77638923-001-02-0::0.00061034::HTS002,BRD-K77638923-001-02-0,0.00061034,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::0.0024414::HTS002,BRD-K77638923-001-02-0,0.0024414,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::0.00976562::HTS002,BRD-K77638923-001-02-0,0.00976562,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::0.0390625::HTS002,BRD-K77638923-001-02-0,0.0390625,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::0.15625::HTS002,BRD-K77638923-001-02-0,0.15625,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::0.625::HTS002,BRD-K77638923-001-02-0,0.625,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::2.5::HTS002,BRD-K77638923-001-02-0,2.5,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77638923-001-02-0::10::HTS002,BRD-K77638923-001-02-0,10.0,HTS002,PREP033,CUDC-907,PI3K inhibitor,"HDAC2, PIK3R1",NA,NA,COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1,Phase 2
BRD-K77677632-003-02-6::0.00061034::HTS002,BRD-K77677632-003-02-6,0.00061034,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::0.0024414::HTS002,BRD-K77677632-003-02-6,0.0024414,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::0.00976562::HTS002,BRD-K77677632-003-02-6,0.00976562,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::0.0390625::HTS002,BRD-K77677632-003-02-6,0.0390625,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::0.15625::HTS002,BRD-K77677632-003-02-6,0.15625,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::0.625::HTS002,BRD-K77677632-003-02-6,0.625,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::2.5::HTS002,BRD-K77677632-003-02-6,2.5,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77677632-003-02-6::10::HTS002,BRD-K77677632-003-02-6,10.0,HTS002,PREP047,SB-200646,serotonin receptor antagonist,"HTR2B, HTR2C",NA,NA,"Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",Preclinical
BRD-K77685957-300-09-1::0.00061034::HTS002,BRD-K77685957-300-09-1,0.00061034,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::0.0024414::HTS002,BRD-K77685957-300-09-1,0.0024414,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::0.00976562::HTS002,BRD-K77685957-300-09-1,0.00976562,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::0.0390625::HTS002,BRD-K77685957-300-09-1,0.0390625,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::0.15625::HTS002,BRD-K77685957-300-09-1,0.15625,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::0.625::HTS002,BRD-K77685957-300-09-1,0.625,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::2.5::HTS002,BRD-K77685957-300-09-1,2.5,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77685957-300-09-1::10::HTS002,BRD-K77685957-300-09-1,10.0,HTS002,PREP034,dequalinium,PKC inhibitor,"KCNN1, KCNN3",NA,NA,"Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12",Launched
BRD-K77791657-003-01-7::0.000651132::HTS002,BRD-K77791657-003-01-7,0.000651132,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::0.00260453::HTS002,BRD-K77791657-003-01-7,0.00260453,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::0.0104181::HTS002,BRD-K77791657-003-01-7,0.0104181,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::0.0416724::HTS002,BRD-K77791657-003-01-7,0.0416724,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::0.16669::HTS002,BRD-K77791657-003-01-7,0.16669,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::0.666759::HTS002,BRD-K77791657-003-01-7,0.666759,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::2.66704::HTS002,BRD-K77791657-003-01-7,2.66704,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77791657-003-01-7::10.6681::HTS002,BRD-K77791657-003-01-7,10.6681,HTS002,PREP031,3-deazaneplanocin-A,histone lysine methyltransferase inhibitor,EZH2,NA,NA,"Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O",Preclinical
BRD-K77908580-001-09-6::0.00061034::HTS002,BRD-K77908580-001-09-6,0.00061034,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::0.0024414::HTS002,BRD-K77908580-001-09-6,0.0024414,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::0.00976562::HTS002,BRD-K77908580-001-09-6,0.00976562,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::0.0390625::HTS002,BRD-K77908580-001-09-6,0.0390625,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::0.15625::HTS002,BRD-K77908580-001-09-6,0.15625,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::0.625::HTS002,BRD-K77908580-001-09-6,0.625,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::2.5::HTS002,BRD-K77908580-001-09-6,2.5,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77908580-001-09-6::10::HTS002,BRD-K77908580-001-09-6,10.0,HTS002,PREP027,entinostat,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC9",NA,NA,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",Phase 3
BRD-K77943374-001-02-8::0.00061034::HTS002,BRD-K77943374-001-02-8,0.00061034,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::0.0024414::HTS002,BRD-K77943374-001-02-8,0.0024414,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::0.00976562::HTS002,BRD-K77943374-001-02-8,0.00976562,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::0.0390625::HTS002,BRD-K77943374-001-02-8,0.0390625,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::0.15625::HTS002,BRD-K77943374-001-02-8,0.15625,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::0.625::HTS002,BRD-K77943374-001-02-8,0.625,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::2.5::HTS002,BRD-K77943374-001-02-8,2.5,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77943374-001-02-8::10::HTS002,BRD-K77943374-001-02-8,10.0,HTS002,PREP043,NVP-BVU972,MET inhibitor,MET,NA,NA,Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1,Preclinical
BRD-K77987382-001-13-2::0.00061034::HTS002,BRD-K77987382-001-13-2,0.00061034,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::0.0024414::HTS002,BRD-K77987382-001-13-2,0.0024414,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::0.00976562::HTS002,BRD-K77987382-001-13-2,0.00976562,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::0.0390625::HTS002,BRD-K77987382-001-13-2,0.0390625,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::0.15625::HTS002,BRD-K77987382-001-13-2,0.15625,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::0.625::HTS002,BRD-K77987382-001-13-2,0.625,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::2.5::HTS002,BRD-K77987382-001-13-2,2.5,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K77987382-001-13-2::10::HTS002,BRD-K77987382-001-13-2,10.0,HTS002,PREP023,mebendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"pinworm, whipworm, hookworm, ascariasis",COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,Launched
BRD-K78055238-001-01-8::0.00061034::HTS002,BRD-K78055238-001-01-8,0.00061034,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::0.0024414::HTS002,BRD-K78055238-001-01-8,0.0024414,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::0.00976562::HTS002,BRD-K78055238-001-01-8,0.00976562,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::0.0390625::HTS002,BRD-K78055238-001-01-8,0.0390625,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::0.15625::HTS002,BRD-K78055238-001-01-8,0.15625,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::0.625::HTS002,BRD-K78055238-001-01-8,0.625,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::2.5::HTS002,BRD-K78055238-001-01-8,2.5,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78055238-001-01-8::10::HTS002,BRD-K78055238-001-01-8,10.0,HTS002,PREP039,LY2090314,glycogen synthase kinase inhibitor,GSK3B,NA,NA,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,Phase 2
BRD-K78086729-001-02-7::0.00061034::HTS002,BRD-K78086729-001-02-7,0.00061034,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::0.0024414::HTS002,BRD-K78086729-001-02-7,0.0024414,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::0.00976562::HTS002,BRD-K78086729-001-02-7,0.00976562,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::0.0390625::HTS002,BRD-K78086729-001-02-7,0.0390625,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::0.15625::HTS002,BRD-K78086729-001-02-7,0.15625,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::0.625::HTS002,BRD-K78086729-001-02-7,0.625,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::2.5::HTS002,BRD-K78086729-001-02-7,2.5,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78086729-001-02-7::10::HTS002,BRD-K78086729-001-02-7,10.0,HTS002,PREP041,GW-788388,ALK tyrosine kinase receptor inhibitor,"LCK, MAPK14, TGFBR1",NA,NA,"O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",Preclinical
BRD-K78096648-001-05-7::0.000610352::HTS002,BRD-K78096648-001-05-7,0.000610352,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::0.00244141::HTS002,BRD-K78096648-001-05-7,0.00244141,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::0.00976562::HTS002,BRD-K78096648-001-05-7,0.00976562,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::0.0390625::HTS002,BRD-K78096648-001-05-7,0.0390625,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::0.15625::HTS002,BRD-K78096648-001-05-7,0.15625,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::0.625::HTS002,BRD-K78096648-001-05-7,0.625,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::2.5::HTS002,BRD-K78096648-001-05-7,2.5,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78096648-001-05-7::10::HTS002,BRD-K78096648-001-05-7,10.0,HTS002,PREP039,oxiperomide,dopamine receptor antagonist,NA,NA,NA,Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1,Phase 2
BRD-K78126613-001-28-5::0.00061034::HTS002,BRD-K78126613-001-28-5,0.00061034,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::0.0024414::HTS002,BRD-K78126613-001-28-5,0.0024414,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::0.00976562::HTS002,BRD-K78126613-001-28-5,0.00976562,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::0.0390625::HTS002,BRD-K78126613-001-28-5,0.0390625,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::0.15625::HTS002,BRD-K78126613-001-28-5,0.15625,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::0.625::HTS002,BRD-K78126613-001-28-5,0.625,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::2.5::HTS002,BRD-K78126613-001-28-5,2.5,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78126613-001-28-5::10::HTS002,BRD-K78126613-001-28-5,10.0,HTS002,PREP028,menadione,"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","gastroenterology, neurology/psychiatry, dermatology, rheumatology","ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O",Launched
BRD-K78177893-001-02-4::0.00061034::HTS002,BRD-K78177893-001-02-4,0.00061034,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::0.0024414::HTS002,BRD-K78177893-001-02-4,0.0024414,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::0.00976562::HTS002,BRD-K78177893-001-02-4,0.00976562,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::0.0390625::HTS002,BRD-K78177893-001-02-4,0.0390625,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::0.15625::HTS002,BRD-K78177893-001-02-4,0.15625,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::0.625::HTS002,BRD-K78177893-001-02-4,0.625,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::2.5::HTS002,BRD-K78177893-001-02-4,2.5,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78177893-001-02-4::10::HTS002,BRD-K78177893-001-02-4,10.0,HTS002,PREP042,A-674563,AKT inhibitor,"AKT1, PKIA, PRKACA",NA,NA,Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1,Preclinical
BRD-K78318619-001-02-7::0.00061034::HTS002,BRD-K78318619-001-02-7,0.00061034,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::0.0024414::HTS002,BRD-K78318619-001-02-7,0.0024414,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::0.00976562::HTS002,BRD-K78318619-001-02-7,0.00976562,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::0.0390625::HTS002,BRD-K78318619-001-02-7,0.0390625,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::0.15625::HTS002,BRD-K78318619-001-02-7,0.15625,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::0.625::HTS002,BRD-K78318619-001-02-7,0.625,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::2.5::HTS002,BRD-K78318619-001-02-7,2.5,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78318619-001-02-7::10::HTS002,BRD-K78318619-001-02-7,10.0,HTS002,PREP041,PF-4981517,cytochrome P450 inhibitor,CYP3A4,NA,NA,Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12,Preclinical
BRD-K78431006-001-10-2::0.00061034::HTS002,BRD-K78431006-001-10-2,0.00061034,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::0.0024414::HTS002,BRD-K78431006-001-10-2,0.0024414,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::0.00976562::HTS002,BRD-K78431006-001-10-2,0.00976562,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::0.0390625::HTS002,BRD-K78431006-001-10-2,0.0390625,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::0.15625::HTS002,BRD-K78431006-001-10-2,0.15625,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::0.625::HTS002,BRD-K78431006-001-10-2,0.625,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::2.5::HTS002,BRD-K78431006-001-10-2,2.5,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78431006-001-10-2::10::HTS002,BRD-K78431006-001-10-2,10.0,HTS002,PREP030,crizotinib,ALK tyrosine kinase receptor inhibitor,"ALK, MET",oncology,non-small cell lung cancer (NSCLC),"C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",Launched
BRD-K78496197-001-03-9::0.00061034::HTS002,BRD-K78496197-001-03-9,0.00061034,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::0.0024414::HTS002,BRD-K78496197-001-03-9,0.0024414,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::0.00976562::HTS002,BRD-K78496197-001-03-9,0.00976562,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::0.0390625::HTS002,BRD-K78496197-001-03-9,0.0390625,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::0.15625::HTS002,BRD-K78496197-001-03-9,0.15625,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::0.625::HTS002,BRD-K78496197-001-03-9,0.625,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::2.5::HTS002,BRD-K78496197-001-03-9,2.5,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78496197-001-03-9::10::HTS002,BRD-K78496197-001-03-9,10.0,HTS002,PREP025,SCS,NA,NA,NA,NA,"Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",Preclinical
BRD-K78567475-001-01-4::0.00061034::HTS002,BRD-K78567475-001-01-4,0.00061034,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::0.0024414::HTS002,BRD-K78567475-001-01-4,0.0024414,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::0.00976562::HTS002,BRD-K78567475-001-01-4,0.00976562,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::0.0390625::HTS002,BRD-K78567475-001-01-4,0.0390625,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::0.15625::HTS002,BRD-K78567475-001-01-4,0.15625,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::0.625::HTS002,BRD-K78567475-001-01-4,0.625,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::2.5::HTS002,BRD-K78567475-001-01-4,2.5,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78567475-001-01-4::10::HTS002,BRD-K78567475-001-01-4,10.0,HTS002,PREP039,dolastatin-10,tubulin polymerization inhibitor,TUBB,NA,NA,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,Phase 2
BRD-K78659596-001-03-9::0.00061034::HTS002,BRD-K78659596-001-03-9,0.00061034,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::0.0024414::HTS002,BRD-K78659596-001-03-9,0.0024414,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::0.00976562::HTS002,BRD-K78659596-001-03-9,0.00976562,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::0.0390625::HTS002,BRD-K78659596-001-03-9,0.0390625,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::0.15625::HTS002,BRD-K78659596-001-03-9,0.15625,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::0.625::HTS002,BRD-K78659596-001-03-9,0.625,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::2.5::HTS002,BRD-K78659596-001-03-9,2.5,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78659596-001-03-9::10::HTS002,BRD-K78659596-001-03-9,10.0,HTS002,PREP038,ixazomib,proteasome inhibitor,NA,hematologic malignancy,multiple myeloma,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,Launched
BRD-K78789465-001-01-6::0.000610352::HTS002,BRD-K78789465-001-01-6,0.000610352,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::0.00244141::HTS002,BRD-K78789465-001-01-6,0.00244141,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::0.00976562::HTS002,BRD-K78789465-001-01-6,0.00976562,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::0.0390625::HTS002,BRD-K78789465-001-01-6,0.0390625,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::0.15625::HTS002,BRD-K78789465-001-01-6,0.15625,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::0.625::HTS002,BRD-K78789465-001-01-6,0.625,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::2.5::HTS002,BRD-K78789465-001-01-6,2.5,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78789465-001-01-6::10::HTS002,BRD-K78789465-001-01-6,10.0,HTS002,PREP021,pentagastrin,CCK receptor agonist,CCKBR,gastroenterology,"anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic","CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",Launched
BRD-K78815826-001-14-6::0.00061034::HTS002,BRD-K78815826-001-14-6,0.00061034,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::0.0024414::HTS002,BRD-K78815826-001-14-6,0.0024414,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::0.00976562::HTS002,BRD-K78815826-001-14-6,0.00976562,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::0.0390625::HTS002,BRD-K78815826-001-14-6,0.0390625,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::0.15625::HTS002,BRD-K78815826-001-14-6,0.15625,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::0.625::HTS002,BRD-K78815826-001-14-6,0.625,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::2.5::HTS002,BRD-K78815826-001-14-6,2.5,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78815826-001-14-6::10::HTS002,BRD-K78815826-001-14-6,10.0,HTS002,PREP017,suxibuzone,cyclooxygenase inhibitor,NA,"rheumatology, neurology/psychiatry","joint pain, muscle pain","CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",Launched
BRD-K78960041-001-05-7::0.000626856::HTS002,BRD-K78960041-001-05-7,0.000626856,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::0.00250743::HTS002,BRD-K78960041-001-05-7,0.00250743,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::0.0100297::HTS002,BRD-K78960041-001-05-7,0.0100297,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::0.0401188::HTS002,BRD-K78960041-001-05-7,0.0401188,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::0.160475::HTS002,BRD-K78960041-001-05-7,0.160475,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::0.641901::HTS002,BRD-K78960041-001-05-7,0.641901,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::2.5676::HTS002,BRD-K78960041-001-05-7,2.5676,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K78960041-001-05-7::10.2704::HTS002,BRD-K78960041-001-05-7,10.2704,HTS002,PREP048,oxaliplatin,DNA inhibitor,NA,oncology,colorectal cancer,"O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O",Launched
BRD-K79131256-001-17-9::0.00061034::HTS002,BRD-K79131256-001-17-9,0.00061034,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::0.0024414::HTS002,BRD-K79131256-001-17-9,0.0024414,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::0.00976562::HTS002,BRD-K79131256-001-17-9,0.00976562,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::0.0390625::HTS002,BRD-K79131256-001-17-9,0.0390625,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::0.15625::HTS002,BRD-K79131256-001-17-9,0.15625,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::0.625::HTS002,BRD-K79131256-001-17-9,0.625,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::2.5::HTS002,BRD-K79131256-001-17-9,2.5,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79131256-001-17-9::10::HTS002,BRD-K79131256-001-17-9,10.0,HTS002,PREP029,albendazole,tubulin polymerization inhibitor,"TUBA1A, TUBB, TUBB4B",infectious disease,"cystic hydatid disease, parenchymal neurocysticercosis","CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1",Launched
BRD-K79145628-001-05-5::0.00061034::HTS002,BRD-K79145628-001-05-5,0.00061034,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::0.0024414::HTS002,BRD-K79145628-001-05-5,0.0024414,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::0.00976562::HTS002,BRD-K79145628-001-05-5,0.00976562,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::0.0390625::HTS002,BRD-K79145628-001-05-5,0.0390625,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::0.15625::HTS002,BRD-K79145628-001-05-5,0.15625,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::0.625::HTS002,BRD-K79145628-001-05-5,0.625,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::2.5::HTS002,BRD-K79145628-001-05-5,2.5,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79145628-001-05-5::10::HTS002,BRD-K79145628-001-05-5,10.0,HTS002,PREP031,nimorazole,bacterial DNA inhibitor,NA,oncology,head and neck squamous cell carcinoma (HNSCC),[O-][N+](=O)c1cncn1CCN1CCOCC1,Launched
BRD-K79239947-001-06-8::0.00061034::HTS002,BRD-K79239947-001-06-8,0.00061034,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::0.0024414::HTS002,BRD-K79239947-001-06-8,0.0024414,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::0.00976562::HTS002,BRD-K79239947-001-06-8,0.00976562,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::0.0390625::HTS002,BRD-K79239947-001-06-8,0.0390625,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::0.15625::HTS002,BRD-K79239947-001-06-8,0.15625,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::0.625::HTS002,BRD-K79239947-001-06-8,0.625,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::2.5::HTS002,BRD-K79239947-001-06-8,2.5,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79239947-001-06-8::10::HTS002,BRD-K79239947-001-06-8,10.0,HTS002,PREP032,PF-573228,focal adhesion kinase inhibitor,"CDK1, CDK2, CDK7, GSK3B, IKBKB",NA,NA,"CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",Preclinical
BRD-K79254416-001-22-6::0.00061034::HTS002,BRD-K79254416-001-22-6,0.00061034,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::0.0024414::HTS002,BRD-K79254416-001-22-6,0.0024414,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::0.00976562::HTS002,BRD-K79254416-001-22-6,0.00976562,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::0.0390625::HTS002,BRD-K79254416-001-22-6,0.0390625,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::0.15625::HTS002,BRD-K79254416-001-22-6,0.15625,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::0.625::HTS002,BRD-K79254416-001-22-6,0.625,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::2.5::HTS002,BRD-K79254416-001-22-6,2.5,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79254416-001-22-6::10::HTS002,BRD-K79254416-001-22-6,10.0,HTS002,PREP022,decitabine,DNA methyltransferase inhibitor,"DNMT1, DNMT3A","hematologic malignancy, hematology","myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",Launched
BRD-K79259477-001-04-9::0.00061034::HTS002,BRD-K79259477-001-04-9,0.00061034,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::0.0024414::HTS002,BRD-K79259477-001-04-9,0.0024414,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::0.00976562::HTS002,BRD-K79259477-001-04-9,0.00976562,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::0.0390625::HTS002,BRD-K79259477-001-04-9,0.0390625,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::0.15625::HTS002,BRD-K79259477-001-04-9,0.15625,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::0.625::HTS002,BRD-K79259477-001-04-9,0.625,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::2.5::HTS002,BRD-K79259477-001-04-9,2.5,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79259477-001-04-9::10::HTS002,BRD-K79259477-001-04-9,10.0,HTS002,PREP036,NVP-BHG712,ephrin inhibitor,EPHB4,NA,NA,Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F,Preclinical
BRD-K79315489-001-07-8::0.00061034::HTS002,BRD-K79315489-001-07-8,0.00061034,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::0.0024414::HTS002,BRD-K79315489-001-07-8,0.0024414,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::0.00976562::HTS002,BRD-K79315489-001-07-8,0.00976562,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::0.0390625::HTS002,BRD-K79315489-001-07-8,0.0390625,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::0.15625::HTS002,BRD-K79315489-001-07-8,0.15625,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::0.625::HTS002,BRD-K79315489-001-07-8,0.625,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::2.5::HTS002,BRD-K79315489-001-07-8,2.5,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79315489-001-07-8::10::HTS002,BRD-K79315489-001-07-8,10.0,HTS002,PREP048,erythritol,NA,NA,NA,NA,"OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO",Launched
BRD-K79555887-001-01-0::0.00061034::HTS002,BRD-K79555887-001-01-0,0.00061034,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::0.0024414::HTS002,BRD-K79555887-001-01-0,0.0024414,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::0.00976562::HTS002,BRD-K79555887-001-01-0,0.00976562,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::0.0390625::HTS002,BRD-K79555887-001-01-0,0.0390625,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::0.15625::HTS002,BRD-K79555887-001-01-0,0.15625,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::0.625::HTS002,BRD-K79555887-001-01-0,0.625,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::2.5::HTS002,BRD-K79555887-001-01-0,2.5,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79555887-001-01-0::10::HTS002,BRD-K79555887-001-01-0,10.0,HTS002,PREP041,RI-1,NA,RAD51,NA,NA,ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1,Preclinical
BRD-K79584249-001-01-3::0.00061034::HTS002,BRD-K79584249-001-01-3,0.00061034,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::0.0024414::HTS002,BRD-K79584249-001-01-3,0.0024414,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::0.00976562::HTS002,BRD-K79584249-001-01-3,0.00976562,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::0.0390625::HTS002,BRD-K79584249-001-01-3,0.0390625,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::0.15625::HTS002,BRD-K79584249-001-01-3,0.15625,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::0.625::HTS002,BRD-K79584249-001-01-3,0.625,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::2.5::HTS002,BRD-K79584249-001-01-3,2.5,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79584249-001-01-3::10::HTS002,BRD-K79584249-001-01-3,10.0,HTS002,PREP038,CGM097,MDM inhibitor,MDM2,NA,NA,"COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",Phase 1
BRD-K79612754-001-19-1::0.000639845::HTS002,BRD-K79612754-001-19-1,0.000639845,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::0.00255938::HTS002,BRD-K79612754-001-19-1,0.00255938,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::0.0102375::HTS002,BRD-K79612754-001-19-1,0.0102375,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::0.0409501::HTS002,BRD-K79612754-001-19-1,0.0409501,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::0.1638::HTS002,BRD-K79612754-001-19-1,0.1638,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::0.655201::HTS002,BRD-K79612754-001-19-1,0.655201,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::2.62081::HTS002,BRD-K79612754-001-19-1,2.62081,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79612754-001-19-1::10.4832::HTS002,BRD-K79612754-001-19-1,10.4832,HTS002,PREP034,inosine,neurotrophic agent,"PARP1, PNP",NA,NA,"OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12",Launched
BRD-K79633074-001-01-8::0.000610352::HTS002,BRD-K79633074-001-01-8,0.000610352,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::0.00244141::HTS002,BRD-K79633074-001-01-8,0.00244141,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::0.00976562::HTS002,BRD-K79633074-001-01-8,0.00976562,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::0.0390625::HTS002,BRD-K79633074-001-01-8,0.0390625,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::0.15625::HTS002,BRD-K79633074-001-01-8,0.15625,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::0.625::HTS002,BRD-K79633074-001-01-8,0.625,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::2.5::HTS002,BRD-K79633074-001-01-8,2.5,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79633074-001-01-8::10::HTS002,BRD-K79633074-001-01-8,10.0,HTS002,PREP046,xilobam,NA,NA,NA,NA,CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C,Phase 1
BRD-K79684402-300-02-8::0.00061034::HTS002,BRD-K79684402-300-02-8,0.00061034,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::0.0024414::HTS002,BRD-K79684402-300-02-8,0.0024414,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::0.00976562::HTS002,BRD-K79684402-300-02-8,0.00976562,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::0.0390625::HTS002,BRD-K79684402-300-02-8,0.0390625,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::0.15625::HTS002,BRD-K79684402-300-02-8,0.15625,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::0.625::HTS002,BRD-K79684402-300-02-8,0.625,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::2.5::HTS002,BRD-K79684402-300-02-8,2.5,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79684402-300-02-8::10::HTS002,BRD-K79684402-300-02-8,10.0,HTS002,PREP037,Ro-10-5824,dopamine receptor agonist,DRD4,NA,NA,"Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1",Preclinical
BRD-K79930101-300-03-7::0.00061034::HTS002,BRD-K79930101-300-03-7,0.00061034,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::0.0024414::HTS002,BRD-K79930101-300-03-7,0.0024414,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::0.00976562::HTS002,BRD-K79930101-300-03-7,0.00976562,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::0.0390625::HTS002,BRD-K79930101-300-03-7,0.0390625,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::0.15625::HTS002,BRD-K79930101-300-03-7,0.15625,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::0.625::HTS002,BRD-K79930101-300-03-7,0.625,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::2.5::HTS002,BRD-K79930101-300-03-7,2.5,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K79930101-300-03-7::10::HTS002,BRD-K79930101-300-03-7,10.0,HTS002,PREP043,GW-583340,EGFR inhibitor,"EGFR, ERBB2",NA,NA,"CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",Preclinical
BRD-K80060353-303-03-9::0.000601051::HTS002,BRD-K80060353-303-03-9,0.000601051,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::0.0024042::HTS002,BRD-K80060353-303-03-9,0.0024042,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::0.00961681::HTS002,BRD-K80060353-303-03-9,0.00961681,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::0.0384672::HTS002,BRD-K80060353-303-03-9,0.0384672,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::0.153869::HTS002,BRD-K80060353-303-03-9,0.153869,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::0.615476::HTS002,BRD-K80060353-303-03-9,0.615476,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::2.4619::HTS002,BRD-K80060353-303-03-9,2.4619,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80060353-303-03-9::9.84761::HTS002,BRD-K80060353-303-03-9,9.84761,HTS002,PREP036,IEM1754,glutamate receptor antagonist,GRIA1,NA,NA,"NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",Preclinical
BRD-K80129304-001-08-1::0.00061034::HTS002,BRD-K80129304-001-08-1,0.00061034,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::0.0024414::HTS002,BRD-K80129304-001-08-1,0.0024414,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::0.00976562::HTS002,BRD-K80129304-001-08-1,0.00976562,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::0.0390625::HTS002,BRD-K80129304-001-08-1,0.0390625,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::0.15625::HTS002,BRD-K80129304-001-08-1,0.15625,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::0.625::HTS002,BRD-K80129304-001-08-1,0.625,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::2.5::HTS002,BRD-K80129304-001-08-1,2.5,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80129304-001-08-1::10::HTS002,BRD-K80129304-001-08-1,10.0,HTS002,PREP033,uracil,NA,"DPYD, UCKL1",NA,NA,"Oc1ccnc(O)n1, Oc1ccnc(O)n1",Launched
BRD-K80343549-001-02-6::0.00061034::HTS002,BRD-K80343549-001-02-6,0.00061034,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::0.0024414::HTS002,BRD-K80343549-001-02-6,0.0024414,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::0.00976562::HTS002,BRD-K80343549-001-02-6,0.00976562,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::0.0390625::HTS002,BRD-K80343549-001-02-6,0.0390625,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::0.15625::HTS002,BRD-K80343549-001-02-6,0.15625,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::0.625::HTS002,BRD-K80343549-001-02-6,0.625,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::2.5::HTS002,BRD-K80343549-001-02-6,2.5,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80343549-001-02-6::10::HTS002,BRD-K80343549-001-02-6,10.0,HTS002,PREP045,TAK-285,EGFR inhibitor,ERBB2,NA,NA,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12,Phase 1
BRD-K80431395-001-07-3::0.000607267::HTS002,BRD-K80431395-001-07-3,0.000607267,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::0.00242907::HTS002,BRD-K80431395-001-07-3,0.00242907,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::0.00971627::HTS002,BRD-K80431395-001-07-3,0.00971627,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::0.0388651::HTS002,BRD-K80431395-001-07-3,0.0388651,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::0.15546::HTS002,BRD-K80431395-001-07-3,0.15546,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::0.621842::HTS002,BRD-K80431395-001-07-3,0.621842,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::2.48737::HTS002,BRD-K80431395-001-07-3,2.48737,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80431395-001-07-3::9.94946::HTS002,BRD-K80431395-001-07-3,9.94946,HTS002,PREP030,triciribine,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,"Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",Phase 1/Phase 2
BRD-K80480517-001-02-4::0.00061034::HTS002,BRD-K80480517-001-02-4,0.00061034,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::0.0024414::HTS002,BRD-K80480517-001-02-4,0.0024414,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::0.00976562::HTS002,BRD-K80480517-001-02-4,0.00976562,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::0.0390625::HTS002,BRD-K80480517-001-02-4,0.0390625,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::0.15625::HTS002,BRD-K80480517-001-02-4,0.15625,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::0.625::HTS002,BRD-K80480517-001-02-4,0.625,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::2.5::HTS002,BRD-K80480517-001-02-4,2.5,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80480517-001-02-4::10::HTS002,BRD-K80480517-001-02-4,10.0,HTS002,PREP040,repsox,TGF beta receptor inhibitor,TGFBR1,NA,NA,"Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",Preclinical
BRD-K80608265-001-01-6::0.000610352::HTS002,BRD-K80608265-001-01-6,0.000610352,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::0.00244141::HTS002,BRD-K80608265-001-01-6,0.00244141,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::0.00976562::HTS002,BRD-K80608265-001-01-6,0.00976562,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::0.0390625::HTS002,BRD-K80608265-001-01-6,0.0390625,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::0.15625::HTS002,BRD-K80608265-001-01-6,0.15625,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::0.625::HTS002,BRD-K80608265-001-01-6,0.625,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::2.5::HTS002,BRD-K80608265-001-01-6,2.5,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80608265-001-01-6::10::HTS002,BRD-K80608265-001-01-6,10.0,HTS002,PREP039,erteberel,estrogen receptor agonist,"ESR1, ESR2",NA,NA,Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12,Phase 2
BRD-K80700417-001-04-2::0.00061034::HTS002,BRD-K80700417-001-04-2,0.00061034,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::0.0024414::HTS002,BRD-K80700417-001-04-2,0.0024414,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::0.00976562::HTS002,BRD-K80700417-001-04-2,0.00976562,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::0.0390625::HTS002,BRD-K80700417-001-04-2,0.0390625,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::0.15625::HTS002,BRD-K80700417-001-04-2,0.15625,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::0.625::HTS002,BRD-K80700417-001-04-2,0.625,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::2.5::HTS002,BRD-K80700417-001-04-2,2.5,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80700417-001-04-2::10::HTS002,BRD-K80700417-001-04-2,10.0,HTS002,PREP026,SGI-1776,Pim kinase inhibitor,"FLT3, PIM1, PIM2, PIM3",NA,NA,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,Phase 1
BRD-K80725821-300-02-9::0.00061034::HTS002,BRD-K80725821-300-02-9,0.00061034,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::0.0024414::HTS002,BRD-K80725821-300-02-9,0.0024414,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::0.00976562::HTS002,BRD-K80725821-300-02-9,0.00976562,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::0.0390625::HTS002,BRD-K80725821-300-02-9,0.0390625,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::0.15625::HTS002,BRD-K80725821-300-02-9,0.15625,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::0.625::HTS002,BRD-K80725821-300-02-9,0.625,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::2.5::HTS002,BRD-K80725821-300-02-9,2.5,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K80725821-300-02-9::10::HTS002,BRD-K80725821-300-02-9,10.0,HTS002,PREP041,RS-16566,serotonin receptor antagonist,NA,NA,NA,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,Preclinical
BRD-K81016934-001-02-0::0.00061034::HTS002,BRD-K81016934-001-02-0,0.00061034,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.0024414::HTS002,BRD-K81016934-001-02-0,0.0024414,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.00976562::HTS002,BRD-K81016934-001-02-0,0.00976562,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.0390625::HTS002,BRD-K81016934-001-02-0,0.0390625,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.15625::HTS002,BRD-K81016934-001-02-0,0.15625,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::0.625::HTS002,BRD-K81016934-001-02-0,0.625,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::2.5::HTS002,BRD-K81016934-001-02-0,2.5,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K81016934-001-02-0::10::HTS002,BRD-K81016934-001-02-0,10.0,HTS002,PREP032,INC-280,c-Met inhibitor,MET,NA,NA,CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1,Phase 2
BRD-K67536197-003-11-4::0.00061034::HTS002,BRD-K67536197-003-11-4,0.00061034,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::0.0024414::HTS002,BRD-K67536197-003-11-4,0.0024414,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::0.00976562::HTS002,BRD-K67536197-003-11-4,0.00976562,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::0.0390625::HTS002,BRD-K67536197-003-11-4,0.0390625,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::0.15625::HTS002,BRD-K67536197-003-11-4,0.15625,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::0.625::HTS002,BRD-K67536197-003-11-4,0.625,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::2.5::HTS002,BRD-K67536197-003-11-4,2.5,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K67536197-003-11-4::10::HTS002,BRD-K67536197-003-11-4,10.0,HTS002,PREP041,cyclocytidine,"DNA synthesis inhibitor, RNA synthesis inhibitor",NA,NA,NA,"OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",Preclinical
BRD-K81074237-001-02-3::0.00061034::HTS002,BRD-K81074237-001-02-3,0.00061034,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::0.0024414::HTS002,BRD-K81074237-001-02-3,0.0024414,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::0.00976562::HTS002,BRD-K81074237-001-02-3,0.00976562,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::0.0390625::HTS002,BRD-K81074237-001-02-3,0.0390625,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::0.15625::HTS002,BRD-K81074237-001-02-3,0.15625,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::0.625::HTS002,BRD-K81074237-001-02-3,0.625,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::2.5::HTS002,BRD-K81074237-001-02-3,2.5,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81074237-001-02-3::10::HTS002,BRD-K81074237-001-02-3,10.0,HTS002,PREP034,azilsartan,angiotensin receptor antagonist,"AGTR1, AGTR2",cardiology,hypertension,"CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1",Launched
BRD-K81197548-003-01-4::0.00061034::HTS002,BRD-K81197548-003-01-4,0.00061034,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::0.0024414::HTS002,BRD-K81197548-003-01-4,0.0024414,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::0.00976562::HTS002,BRD-K81197548-003-01-4,0.00976562,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::0.0390625::HTS002,BRD-K81197548-003-01-4,0.0390625,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::0.15625::HTS002,BRD-K81197548-003-01-4,0.15625,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::0.625::HTS002,BRD-K81197548-003-01-4,0.625,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::2.5::HTS002,BRD-K81197548-003-01-4,2.5,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81197548-003-01-4::10::HTS002,BRD-K81197548-003-01-4,10.0,HTS002,PREP043,NSC-632839,ubiquitin specific protease inhibitor,"SENP2, USP1, USP2, USP7",NA,NA,"Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1, Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1",Preclinical
BRD-K81225797-001-02-3::0.00061034::HTS002,BRD-K81225797-001-02-3,0.00061034,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::0.0024414::HTS002,BRD-K81225797-001-02-3,0.0024414,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::0.00976562::HTS002,BRD-K81225797-001-02-3,0.00976562,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::0.0390625::HTS002,BRD-K81225797-001-02-3,0.0390625,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::0.15625::HTS002,BRD-K81225797-001-02-3,0.15625,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::0.625::HTS002,BRD-K81225797-001-02-3,0.625,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::2.5::HTS002,BRD-K81225797-001-02-3,2.5,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K81225797-001-02-3::10::HTS002,BRD-K81225797-001-02-3,10.0,HTS002,PREP042,SCH-58261,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,"Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",Preclinical
BRD-K39484304-001-16-5::0.00061034::HTS002,BRD-K39484304-001-16-5,0.00061034,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::0.0024414::HTS002,BRD-K39484304-001-16-5,0.0024414,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::0.00976562::HTS002,BRD-K39484304-001-16-5,0.00976562,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::0.0390625::HTS002,BRD-K39484304-001-16-5,0.0390625,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::0.15625::HTS002,BRD-K39484304-001-16-5,0.15625,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::0.625::HTS002,BRD-K39484304-001-16-5,0.625,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::2.5::HTS002,BRD-K39484304-001-16-5,2.5,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K39484304-001-16-5::10::HTS002,BRD-K39484304-001-16-5,10.0,HTS002,PREP018,triptolide,RNA polymerase inhibitor,RELA,NA,NA,"CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O",Phase 3
BRD-K81330143-001-04-8::0.000581683::HTS002,BRD-K81330143-001-04-8,0.000581683,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::0.00232673::HTS002,BRD-K81330143-001-04-8,0.00232673,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::0.00930692::HTS002,BRD-K81330143-001-04-8,0.00930692,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::0.0372277::HTS002,BRD-K81330143-001-04-8,0.0372277,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::0.148911::HTS002,BRD-K81330143-001-04-8,0.148911,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::0.595643::HTS002,BRD-K81330143-001-04-8,0.595643,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::2.38257::HTS002,BRD-K81330143-001-04-8,2.38257,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81330143-001-04-8::9.53029::HTS002,BRD-K81330143-001-04-8,9.53029,HTS002,PREP047,tideglusib,glycogen synthase kinase inhibitor,GSK3B,NA,NA,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",Phase 2
BRD-K81332461-001-01-4::0.00061034::HTS002,BRD-K81332461-001-01-4,0.00061034,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::0.0024414::HTS002,BRD-K81332461-001-01-4,0.0024414,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::0.00976562::HTS002,BRD-K81332461-001-01-4,0.00976562,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::0.0390625::HTS002,BRD-K81332461-001-01-4,0.0390625,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::0.15625::HTS002,BRD-K81332461-001-01-4,0.15625,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::0.625::HTS002,BRD-K81332461-001-01-4,0.625,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::2.5::HTS002,BRD-K81332461-001-01-4,2.5,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81332461-001-01-4::10::HTS002,BRD-K81332461-001-01-4,10.0,HTS002,PREP033,maxacalcitol,vitamin D receptor agonist,VDR,endocrinology,hyperparathyroidism,[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H],Launched
BRD-K81418486-001-47-5::0.000610352::HTS002,BRD-K81418486-001-47-5,0.000610352,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::0.00244141::HTS002,BRD-K81418486-001-47-5,0.00244141,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::0.00976562::HTS002,BRD-K81418486-001-47-5,0.00976562,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::0.0390625::HTS002,BRD-K81418486-001-47-5,0.0390625,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::0.15625::HTS002,BRD-K81418486-001-47-5,0.15625,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::0.625::HTS002,BRD-K81418486-001-47-5,0.625,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::2.5::HTS002,BRD-K81418486-001-47-5,2.5,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81418486-001-47-5::10::HTS002,BRD-K81418486-001-47-5,10.0,HTS002,PREP048,vorinostat,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),"ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1",Launched
BRD-K81458380-001-04-9::0.00061034::HTS002,BRD-K81458380-001-04-9,0.00061034,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::0.0024414::HTS002,BRD-K81458380-001-04-9,0.0024414,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::0.00976562::HTS002,BRD-K81458380-001-04-9,0.00976562,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::0.0390625::HTS002,BRD-K81458380-001-04-9,0.0390625,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::0.15625::HTS002,BRD-K81458380-001-04-9,0.15625,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::0.625::HTS002,BRD-K81458380-001-04-9,0.625,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::2.5::HTS002,BRD-K81458380-001-04-9,2.5,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81458380-001-04-9::10::HTS002,BRD-K81458380-001-04-9,10.0,HTS002,PREP024,CX-4945,casein kinase inhibitor,"CSNK2A1, CSNK2A2, DAPK3, HIPK3",NA,NA,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,Phase 1/Phase 2
BRD-K81473043-001-14-6::0.000610352::HTS002,BRD-K81473043-001-14-6,0.000610352,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::0.00244141::HTS002,BRD-K81473043-001-14-6,0.00244141,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::0.00976562::HTS002,BRD-K81473043-001-14-6,0.00976562,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::0.0390625::HTS002,BRD-K81473043-001-14-6,0.0390625,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::0.15625::HTS002,BRD-K81473043-001-14-6,0.15625,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::0.625::HTS002,BRD-K81473043-001-14-6,0.625,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::2.5::HTS002,BRD-K81473043-001-14-6,2.5,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81473043-001-14-6::10::HTS002,BRD-K81473043-001-14-6,10.0,HTS002,PREP035,tanespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 3
BRD-K81528515-001-13-8::0.00061034::HTS002,BRD-K81528515-001-13-8,0.00061034,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::0.0024414::HTS002,BRD-K81528515-001-13-8,0.0024414,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::0.00976562::HTS002,BRD-K81528515-001-13-8,0.00976562,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::0.0390625::HTS002,BRD-K81528515-001-13-8,0.0390625,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::0.15625::HTS002,BRD-K81528515-001-13-8,0.15625,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::0.625::HTS002,BRD-K81528515-001-13-8,0.625,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::2.5::HTS002,BRD-K81528515-001-13-8,2.5,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81528515-001-13-8::10::HTS002,BRD-K81528515-001-13-8,10.0,HTS002,PREP035,nilotinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","ABL1, KIT",hematologic malignancy,chronic myeloid leukemia (CML),Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,Launched
BRD-K81548480-001-01-2::0.00061034::HTS002,BRD-K81548480-001-01-2,0.00061034,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::0.0024414::HTS002,BRD-K81548480-001-01-2,0.0024414,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::0.00976562::HTS002,BRD-K81548480-001-01-2,0.00976562,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::0.0390625::HTS002,BRD-K81548480-001-01-2,0.0390625,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::0.15625::HTS002,BRD-K81548480-001-01-2,0.15625,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::0.625::HTS002,BRD-K81548480-001-01-2,0.625,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::2.5::HTS002,BRD-K81548480-001-01-2,2.5,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81548480-001-01-2::10::HTS002,BRD-K81548480-001-01-2,10.0,HTS002,PREP043,AC-264613,PAR agonist,F2RL1,NA,NA,"C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",Preclinical
BRD-K81613478-001-01-8::0.00061034::HTS002,BRD-K81613478-001-01-8,0.00061034,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::0.0024414::HTS002,BRD-K81613478-001-01-8,0.0024414,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::0.00976562::HTS002,BRD-K81613478-001-01-8,0.00976562,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::0.0390625::HTS002,BRD-K81613478-001-01-8,0.0390625,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::0.15625::HTS002,BRD-K81613478-001-01-8,0.15625,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::0.625::HTS002,BRD-K81613478-001-01-8,0.625,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::2.5::HTS002,BRD-K81613478-001-01-8,2.5,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81613478-001-01-8::10::HTS002,BRD-K81613478-001-01-8,10.0,HTS002,PREP045,gastrodin,NA,NA,NA,NA,OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O,Phase 2
BRD-K81645907-001-01-1::0.00061034::HTS002,BRD-K81645907-001-01-1,0.00061034,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::0.0024414::HTS002,BRD-K81645907-001-01-1,0.0024414,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::0.00976562::HTS002,BRD-K81645907-001-01-1,0.00976562,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::0.0390625::HTS002,BRD-K81645907-001-01-1,0.0390625,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::0.15625::HTS002,BRD-K81645907-001-01-1,0.15625,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::0.625::HTS002,BRD-K81645907-001-01-1,0.625,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::2.5::HTS002,BRD-K81645907-001-01-1,2.5,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81645907-001-01-1::10::HTS002,BRD-K81645907-001-01-1,10.0,HTS002,PREP048,captamine,NA,NA,NA,NA,CN(C)CCS,Preclinical
BRD-K81694556-003-01-9::0.00061034::HTS002,BRD-K81694556-003-01-9,0.00061034,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::0.0024414::HTS002,BRD-K81694556-003-01-9,0.0024414,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::0.00976562::HTS002,BRD-K81694556-003-01-9,0.00976562,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::0.0390625::HTS002,BRD-K81694556-003-01-9,0.0390625,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::0.15625::HTS002,BRD-K81694556-003-01-9,0.15625,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::0.625::HTS002,BRD-K81694556-003-01-9,0.625,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::2.5::HTS002,BRD-K81694556-003-01-9,2.5,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81694556-003-01-9::10::HTS002,BRD-K81694556-003-01-9,10.0,HTS002,PREP025,VTP-27999,renin inhibitor,REN,NA,NA,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,Phase 1
BRD-K81728688-001-04-4::0.00061034::HTS002,BRD-K81728688-001-04-4,0.00061034,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::0.0024414::HTS002,BRD-K81728688-001-04-4,0.0024414,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::0.00976562::HTS002,BRD-K81728688-001-04-4,0.00976562,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::0.0390625::HTS002,BRD-K81728688-001-04-4,0.0390625,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::0.15625::HTS002,BRD-K81728688-001-04-4,0.15625,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::0.625::HTS002,BRD-K81728688-001-04-4,0.625,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::2.5::HTS002,BRD-K81728688-001-04-4,2.5,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81728688-001-04-4::10::HTS002,BRD-K81728688-001-04-4,10.0,HTS002,PREP043,WZ8040,EGFR inhibitor,EGFR,NA,NA,CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1,Preclinical
BRD-K81801188-001-02-8::0.00061034::HTS002,BRD-K81801188-001-02-8,0.00061034,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::0.0024414::HTS002,BRD-K81801188-001-02-8,0.0024414,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::0.00976562::HTS002,BRD-K81801188-001-02-8,0.00976562,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::0.0390625::HTS002,BRD-K81801188-001-02-8,0.0390625,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::0.15625::HTS002,BRD-K81801188-001-02-8,0.15625,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::0.625::HTS002,BRD-K81801188-001-02-8,0.625,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::2.5::HTS002,BRD-K81801188-001-02-8,2.5,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81801188-001-02-8::10::HTS002,BRD-K81801188-001-02-8,10.0,HTS002,PREP040,PP-121,protein tyrosine kinase inhibitor,"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC",NA,NA,"C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12",Preclinical
BRD-K81916719-001-13-9::0.00061034::HTS002,BRD-K81916719-001-13-9,0.00061034,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::0.0024414::HTS002,BRD-K81916719-001-13-9,0.0024414,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::0.00976562::HTS002,BRD-K81916719-001-13-9,0.00976562,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::0.0390625::HTS002,BRD-K81916719-001-13-9,0.0390625,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::0.15625::HTS002,BRD-K81916719-001-13-9,0.15625,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::0.625::HTS002,BRD-K81916719-001-13-9,0.625,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::2.5::HTS002,BRD-K81916719-001-13-9,2.5,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K81916719-001-13-9::10::HTS002,BRD-K81916719-001-13-9,10.0,HTS002,PREP035,triclabendazole,microtubule inhibitor,DNMT1,infectious disease,tapeworm,"CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1",Launched
BRD-K82091397-001-03-0::0.00061034::HTS002,BRD-K82091397-001-03-0,0.00061034,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::0.0024414::HTS002,BRD-K82091397-001-03-0,0.0024414,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::0.00976562::HTS002,BRD-K82091397-001-03-0,0.00976562,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::0.0390625::HTS002,BRD-K82091397-001-03-0,0.0390625,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::0.15625::HTS002,BRD-K82091397-001-03-0,0.15625,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::0.625::HTS002,BRD-K82091397-001-03-0,0.625,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::2.5::HTS002,BRD-K82091397-001-03-0,2.5,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82091397-001-03-0::10::HTS002,BRD-K82091397-001-03-0,10.0,HTS002,PREP043,SB-239063,p38 MAPK inhibitor,"MAPK11, MAPK14, PTGS2",NA,NA,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,Preclinical
BRD-K82122102-323-01-1::0.00061034::HTS002,BRD-K82122102-323-01-1,0.00061034,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::0.0024414::HTS002,BRD-K82122102-323-01-1,0.0024414,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::0.00976562::HTS002,BRD-K82122102-323-01-1,0.00976562,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::0.0390625::HTS002,BRD-K82122102-323-01-1,0.0390625,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::0.15625::HTS002,BRD-K82122102-323-01-1,0.15625,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::0.625::HTS002,BRD-K82122102-323-01-1,0.625,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::2.5::HTS002,BRD-K82122102-323-01-1,2.5,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82122102-323-01-1::10::HTS002,BRD-K82122102-323-01-1,10.0,HTS002,PREP034,amfenac,cyclooxygenase inhibitor,"PTGS1, PTGS2",neurology/psychiatry,pain relief,Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1,Launched
BRD-K82135108-001-04-3::0.00061034::HTS002,BRD-K82135108-001-04-3,0.00061034,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.0024414::HTS002,BRD-K82135108-001-04-3,0.0024414,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.00976562::HTS002,BRD-K82135108-001-04-3,0.00976562,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.0390625::HTS002,BRD-K82135108-001-04-3,0.0390625,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.15625::HTS002,BRD-K82135108-001-04-3,0.15625,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::0.625::HTS002,BRD-K82135108-001-04-3,0.625,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::2.5::HTS002,BRD-K82135108-001-04-3,2.5,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82135108-001-04-3::10::HTS002,BRD-K82135108-001-04-3,10.0,HTS002,PREP019,elesclomol,oxidative stress inducer,HSPA1A,NA,NA,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,Phase 3
BRD-K82181219-001-04-3::0.00061034::HTS002,BRD-K82181219-001-04-3,0.00061034,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::0.0024414::HTS002,BRD-K82181219-001-04-3,0.0024414,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::0.00976562::HTS002,BRD-K82181219-001-04-3,0.00976562,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::0.0390625::HTS002,BRD-K82181219-001-04-3,0.0390625,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::0.15625::HTS002,BRD-K82181219-001-04-3,0.15625,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::0.625::HTS002,BRD-K82181219-001-04-3,0.625,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::2.5::HTS002,BRD-K82181219-001-04-3,2.5,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82181219-001-04-3::10::HTS002,BRD-K82181219-001-04-3,10.0,HTS002,PREP022,pyritinol,NA,NA,"rheumatology, neurology/psychiatry","rheumatoid arthritis, senile dementia",Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O,Launched
BRD-K82244583-001-01-3::0.00061034::HTS002,BRD-K82244583-001-01-3,0.00061034,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::0.0024414::HTS002,BRD-K82244583-001-01-3,0.0024414,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::0.00976562::HTS002,BRD-K82244583-001-01-3,0.00976562,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::0.0390625::HTS002,BRD-K82244583-001-01-3,0.0390625,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::0.15625::HTS002,BRD-K82244583-001-01-3,0.15625,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::0.625::HTS002,BRD-K82244583-001-01-3,0.625,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::2.5::HTS002,BRD-K82244583-001-01-3,2.5,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82244583-001-01-3::10::HTS002,BRD-K82244583-001-01-3,10.0,HTS002,PREP046,MEK162,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,Phase 3
BRD-K82746043-001-15-1::0.00061034::HTS002,BRD-K82746043-001-15-1,0.00061034,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::0.0024414::HTS002,BRD-K82746043-001-15-1,0.0024414,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::0.00976562::HTS002,BRD-K82746043-001-15-1,0.00976562,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::0.0390625::HTS002,BRD-K82746043-001-15-1,0.0390625,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::0.15625::HTS002,BRD-K82746043-001-15-1,0.15625,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::0.625::HTS002,BRD-K82746043-001-15-1,0.625,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::2.5::HTS002,BRD-K82746043-001-15-1,2.5,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82746043-001-15-1::10::HTS002,BRD-K82746043-001-15-1,10.0,HTS002,PREP026,navitoclax,BCL inhibitor,"BCL2, BCL2L1, BCL2L2",NA,NA,"CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1",Phase 2
BRD-K82818427-001-02-2::0.000583959::HTS002,BRD-K82818427-001-02-2,0.000583959,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::0.00233583::HTS002,BRD-K82818427-001-02-2,0.00233583,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::0.00934334::HTS002,BRD-K82818427-001-02-2,0.00934334,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::0.0373733::HTS002,BRD-K82818427-001-02-2,0.0373733,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::0.149493::HTS002,BRD-K82818427-001-02-2,0.149493,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::0.597974::HTS002,BRD-K82818427-001-02-2,0.597974,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::2.39189::HTS002,BRD-K82818427-001-02-2,2.39189,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82818427-001-02-2::9.56758::HTS002,BRD-K82818427-001-02-2,9.56758,HTS002,PREP030,batimastat,matrix metalloprotease inhibitor,"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8",NA,NA,"CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",Phase 3
BRD-K82823804-001-04-1::0.00061034::HTS002,BRD-K82823804-001-04-1,0.00061034,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::0.0024414::HTS002,BRD-K82823804-001-04-1,0.0024414,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::0.00976562::HTS002,BRD-K82823804-001-04-1,0.00976562,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::0.0390625::HTS002,BRD-K82823804-001-04-1,0.0390625,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::0.15625::HTS002,BRD-K82823804-001-04-1,0.15625,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::0.625::HTS002,BRD-K82823804-001-04-1,0.625,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::2.5::HTS002,BRD-K82823804-001-04-1,2.5,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82823804-001-04-1::10::HTS002,BRD-K82823804-001-04-1,10.0,HTS002,PREP046,PD-407824,PKC inhibitor,WEE1,NA,NA,"Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",Preclinical
BRD-K82846253-001-15-4::0.00061034::HTS002,BRD-K82846253-001-15-4,0.00061034,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::0.0024414::HTS002,BRD-K82846253-001-15-4,0.0024414,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::0.00976562::HTS002,BRD-K82846253-001-15-4,0.00976562,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::0.0390625::HTS002,BRD-K82846253-001-15-4,0.0390625,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::0.15625::HTS002,BRD-K82846253-001-15-4,0.15625,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::0.625::HTS002,BRD-K82846253-001-15-4,0.625,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::2.5::HTS002,BRD-K82846253-001-15-4,2.5,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82846253-001-15-4::10::HTS002,BRD-K82846253-001-15-4,10.0,HTS002,PREP032,repaglinide,insulin secretagogue,"ABCC8, KCNJ11, PPARG",endocrinology,diabetes mellitus,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O",Launched
BRD-K82850175-001-01-1::0.00061034::HTS002,BRD-K82850175-001-01-1,0.00061034,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::0.0024414::HTS002,BRD-K82850175-001-01-1,0.0024414,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::0.00976562::HTS002,BRD-K82850175-001-01-1,0.00976562,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::0.0390625::HTS002,BRD-K82850175-001-01-1,0.0390625,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::0.15625::HTS002,BRD-K82850175-001-01-1,0.15625,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::0.625::HTS002,BRD-K82850175-001-01-1,0.625,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::2.5::HTS002,BRD-K82850175-001-01-1,2.5,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82850175-001-01-1::10::HTS002,BRD-K82850175-001-01-1,10.0,HTS002,PREP046,navarixin,CC chemokine receptor antagonist,"CXCR1, CXCR2",NA,NA,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,Phase 2
BRD-K82861010-001-02-5::0.00061034::HTS002,BRD-K82861010-001-02-5,0.00061034,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::0.0024414::HTS002,BRD-K82861010-001-02-5,0.0024414,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::0.00976562::HTS002,BRD-K82861010-001-02-5,0.00976562,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::0.0390625::HTS002,BRD-K82861010-001-02-5,0.0390625,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::0.15625::HTS002,BRD-K82861010-001-02-5,0.15625,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::0.625::HTS002,BRD-K82861010-001-02-5,0.625,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::2.5::HTS002,BRD-K82861010-001-02-5,2.5,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82861010-001-02-5::10::HTS002,BRD-K82861010-001-02-5,10.0,HTS002,PREP021,daclatasvir,HCV inhibitor,NA,infectious disease,hepatitis C,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,Launched
BRD-K82928847-001-04-7::0.00061034::HTS002,BRD-K82928847-001-04-7,0.00061034,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::0.0024414::HTS002,BRD-K82928847-001-04-7,0.0024414,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::0.00976562::HTS002,BRD-K82928847-001-04-7,0.00976562,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::0.0390625::HTS002,BRD-K82928847-001-04-7,0.0390625,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::0.15625::HTS002,BRD-K82928847-001-04-7,0.15625,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::0.625::HTS002,BRD-K82928847-001-04-7,0.625,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::2.5::HTS002,BRD-K82928847-001-04-7,2.5,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928847-001-04-7::10::HTS002,BRD-K82928847-001-04-7,10.0,HTS002,PREP030,ACY-1215,HDAC inhibitor,"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8",NA,NA,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,Phase 1/Phase 2
BRD-K82928892-001-02-5::0.000600467::HTS002,BRD-K82928892-001-02-5,0.000600467,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::0.00240187::HTS002,BRD-K82928892-001-02-5,0.00240187,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::0.00960747::HTS002,BRD-K82928892-001-02-5,0.00960747,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::0.0384299::HTS002,BRD-K82928892-001-02-5,0.0384299,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::0.153719::HTS002,BRD-K82928892-001-02-5,0.153719,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::0.614878::HTS002,BRD-K82928892-001-02-5,0.614878,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::2.45951::HTS002,BRD-K82928892-001-02-5,2.45951,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K82928892-001-02-5::9.83805::HTS002,BRD-K82928892-001-02-5,9.83805,HTS002,PREP020,doxercalciferol,vitamin D receptor agonist,VDR,"nephrology, endocrinology","chronic kidney disease (CKD), hyperparathyroidism","CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K83003151-057-02-4::0.000573114::HTS002,BRD-K83003151-057-02-4,0.000573114,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::0.00229246::HTS002,BRD-K83003151-057-02-4,0.00229246,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::0.00916982::HTS002,BRD-K83003151-057-02-4,0.00916982,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::0.0366793::HTS002,BRD-K83003151-057-02-4,0.0366793,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::0.146717::HTS002,BRD-K83003151-057-02-4,0.146717,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::0.586869::HTS002,BRD-K83003151-057-02-4,0.586869,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::2.34747::HTS002,BRD-K83003151-057-02-4,2.34747,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83003151-057-02-4::9.3899::HTS002,BRD-K83003151-057-02-4,9.3899,HTS002,PREP020,alogliptin,dipeptidyl peptidase inhibitor,DPP4,endocrinology,diabetes mellitus,"Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O",Launched
BRD-K83022601-001-01-0::0.000610352::HTS002,BRD-K83022601-001-01-0,0.000610352,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::0.00244141::HTS002,BRD-K83022601-001-01-0,0.00244141,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::0.00976562::HTS002,BRD-K83022601-001-01-0,0.00976562,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::0.0390625::HTS002,BRD-K83022601-001-01-0,0.0390625,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::0.15625::HTS002,BRD-K83022601-001-01-0,0.15625,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::0.625::HTS002,BRD-K83022601-001-01-0,0.625,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::2.5::HTS002,BRD-K83022601-001-01-0,2.5,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K83022601-001-01-0::10::HTS002,BRD-K83022601-001-01-0,10.0,HTS002,PREP033,CI-844,NA,NA,NA,NA,O(c1ccccc1)c1cccnc1,Phase 2
BRD-K58262659-001-09-7::0.00061034::HTS002,BRD-K58262659-001-09-7,0.00061034,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::0.0024414::HTS002,BRD-K58262659-001-09-7,0.0024414,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::0.00976562::HTS002,BRD-K58262659-001-09-7,0.00976562,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::0.0390625::HTS002,BRD-K58262659-001-09-7,0.0390625,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::0.15625::HTS002,BRD-K58262659-001-09-7,0.15625,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::0.625::HTS002,BRD-K58262659-001-09-7,0.625,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::2.5::HTS002,BRD-K58262659-001-09-7,2.5,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K58262659-001-09-7::10::HTS002,BRD-K58262659-001-09-7,10.0,HTS002,PREP035,doxifluridine,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O",Launched
BRD-K83257731-003-23-5::0.00061034::HTS002,BRD-K83257731-003-23-5,0.00061034,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::0.0024414::HTS002,BRD-K83257731-003-23-5,0.0024414,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::0.00976562::HTS002,BRD-K83257731-003-23-5,0.00976562,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::0.0390625::HTS002,BRD-K83257731-003-23-5,0.0390625,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::0.15625::HTS002,BRD-K83257731-003-23-5,0.15625,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::0.625::HTS002,BRD-K83257731-003-23-5,0.625,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::2.5::HTS002,BRD-K83257731-003-23-5,2.5,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83257731-003-23-5::10::HTS002,BRD-K83257731-003-23-5,10.0,HTS002,PREP022,chloropyramine,histamine receptor antagonist,HRH1,"cardiology, ophthalmology, allergy, pulmonary","edema, conjunctivitis, allergic rhinitis, asthma",CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1,Launched
BRD-K83508485-001-02-7::0.00061034::HTS002,BRD-K83508485-001-02-7,0.00061034,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::0.0024414::HTS002,BRD-K83508485-001-02-7,0.0024414,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::0.00976562::HTS002,BRD-K83508485-001-02-7,0.00976562,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::0.0390625::HTS002,BRD-K83508485-001-02-7,0.0390625,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::0.15625::HTS002,BRD-K83508485-001-02-7,0.15625,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::0.625::HTS002,BRD-K83508485-001-02-7,0.625,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::2.5::HTS002,BRD-K83508485-001-02-7,2.5,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83508485-001-02-7::10::HTS002,BRD-K83508485-001-02-7,10.0,HTS002,PREP018,FK-888,tachykinin antagonist,"TACR1, TACR2",NA,NA,"CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",Phase 2
BRD-K83607951-001-02-2::0.00061034::HTS002,BRD-K83607951-001-02-2,0.00061034,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::0.0024414::HTS002,BRD-K83607951-001-02-2,0.0024414,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::0.00976562::HTS002,BRD-K83607951-001-02-2,0.00976562,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::0.0390625::HTS002,BRD-K83607951-001-02-2,0.0390625,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::0.15625::HTS002,BRD-K83607951-001-02-2,0.15625,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::0.625::HTS002,BRD-K83607951-001-02-2,0.625,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::2.5::HTS002,BRD-K83607951-001-02-2,2.5,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83607951-001-02-2::10::HTS002,BRD-K83607951-001-02-2,10.0,HTS002,PREP036,skepinone-l,p38 MAPK inhibitor,MAPK14,NA,NA,OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1,Preclinical
BRD-K83699324-001-01-1::0.00061034::HTS002,BRD-K83699324-001-01-1,0.00061034,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::0.0024414::HTS002,BRD-K83699324-001-01-1,0.0024414,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::0.00976562::HTS002,BRD-K83699324-001-01-1,0.00976562,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::0.0390625::HTS002,BRD-K83699324-001-01-1,0.0390625,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::0.15625::HTS002,BRD-K83699324-001-01-1,0.15625,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::0.625::HTS002,BRD-K83699324-001-01-1,0.625,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::2.5::HTS002,BRD-K83699324-001-01-1,2.5,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83699324-001-01-1::10::HTS002,BRD-K83699324-001-01-1,10.0,HTS002,PREP025,NMS-1286937,PLK inhibitor,"FLT3, PLK1, PLK2, PLK3",NA,NA,CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1,Phase 1
BRD-K83834509-001-01-1::0.00061034::HTS002,BRD-K83834509-001-01-1,0.00061034,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::0.0024414::HTS002,BRD-K83834509-001-01-1,0.0024414,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::0.00976562::HTS002,BRD-K83834509-001-01-1,0.00976562,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::0.0390625::HTS002,BRD-K83834509-001-01-1,0.0390625,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::0.15625::HTS002,BRD-K83834509-001-01-1,0.15625,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::0.625::HTS002,BRD-K83834509-001-01-1,0.625,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::2.5::HTS002,BRD-K83834509-001-01-1,2.5,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83834509-001-01-1::10::HTS002,BRD-K83834509-001-01-1,10.0,HTS002,PREP041,PTC-209,BMI-1 inhibitor,NA,NA,NA,"COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",Preclinical
BRD-K83837640-001-04-8::0.00061034::HTS002,BRD-K83837640-001-04-8,0.00061034,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::0.0024414::HTS002,BRD-K83837640-001-04-8,0.0024414,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::0.00976562::HTS002,BRD-K83837640-001-04-8,0.00976562,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::0.0390625::HTS002,BRD-K83837640-001-04-8,0.0390625,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::0.15625::HTS002,BRD-K83837640-001-04-8,0.15625,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::0.625::HTS002,BRD-K83837640-001-04-8,0.625,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::2.5::HTS002,BRD-K83837640-001-04-8,2.5,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83837640-001-04-8::10::HTS002,BRD-K83837640-001-04-8,10.0,HTS002,PREP025,JNJ-26481585,HDAC inhibitor,"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2",NA,NA,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,Phase 2
BRD-K83963101-001-06-9::0.00061034::HTS002,BRD-K83963101-001-06-9,0.00061034,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::0.0024414::HTS002,BRD-K83963101-001-06-9,0.0024414,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::0.00976562::HTS002,BRD-K83963101-001-06-9,0.00976562,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::0.0390625::HTS002,BRD-K83963101-001-06-9,0.0390625,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::0.15625::HTS002,BRD-K83963101-001-06-9,0.15625,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::0.625::HTS002,BRD-K83963101-001-06-9,0.625,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::2.5::HTS002,BRD-K83963101-001-06-9,2.5,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83963101-001-06-9::10::HTS002,BRD-K83963101-001-06-9,10.0,HTS002,PREP025,MLN-8054,Aurora kinase inhibitor,AURKA,NA,NA,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,Phase 1
BRD-K83988098-003-03-4::0.000610352::HTS002,BRD-K83988098-003-03-4,0.000610352,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::0.00244141::HTS002,BRD-K83988098-003-03-4,0.00244141,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::0.00976562::HTS002,BRD-K83988098-003-03-4,0.00976562,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::0.0390625::HTS002,BRD-K83988098-003-03-4,0.0390625,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::0.15625::HTS002,BRD-K83988098-003-03-4,0.15625,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::0.625::HTS002,BRD-K83988098-003-03-4,0.625,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::2.5::HTS002,BRD-K83988098-003-03-4,2.5,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K83988098-003-03-4::10::HTS002,BRD-K83988098-003-03-4,10.0,HTS002,PREP031,alvespimycin,HSP inhibitor,HSP90AA1,NA,NA,"CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O",Phase 2
BRD-K84011460-051-01-7::0.000610352::HTS002,BRD-K84011460-051-01-7,0.000610352,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::0.00244141::HTS002,BRD-K84011460-051-01-7,0.00244141,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::0.00976562::HTS002,BRD-K84011460-051-01-7,0.00976562,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::0.0390625::HTS002,BRD-K84011460-051-01-7,0.0390625,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::0.15625::HTS002,BRD-K84011460-051-01-7,0.15625,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::0.625::HTS002,BRD-K84011460-051-01-7,0.625,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::2.5::HTS002,BRD-K84011460-051-01-7,2.5,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84011460-051-01-7::10::HTS002,BRD-K84011460-051-01-7,10.0,HTS002,PREP034,nizofenone,ion channel antagonist,NA,neurology/psychiatry,stroke,CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O,Launched
BRD-K84091759-001-07-1::0.00061034::HTS002,BRD-K84091759-001-07-1,0.00061034,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::0.0024414::HTS002,BRD-K84091759-001-07-1,0.0024414,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::0.00976562::HTS002,BRD-K84091759-001-07-1,0.00976562,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::0.0390625::HTS002,BRD-K84091759-001-07-1,0.0390625,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::0.15625::HTS002,BRD-K84091759-001-07-1,0.15625,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::0.625::HTS002,BRD-K84091759-001-07-1,0.625,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::2.5::HTS002,BRD-K84091759-001-07-1,2.5,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84091759-001-07-1::10::HTS002,BRD-K84091759-001-07-1,10.0,HTS002,PREP020,candesartan,angiotensin receptor antagonist,AGTR1,cardiology,"hypertension, congestive heart failure","CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1",Launched
BRD-K84163249-001-01-9::0.00061034::HTS002,BRD-K84163249-001-01-9,0.00061034,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::0.0024414::HTS002,BRD-K84163249-001-01-9,0.0024414,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::0.00976562::HTS002,BRD-K84163249-001-01-9,0.00976562,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::0.0390625::HTS002,BRD-K84163249-001-01-9,0.0390625,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::0.15625::HTS002,BRD-K84163249-001-01-9,0.15625,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::0.625::HTS002,BRD-K84163249-001-01-9,0.625,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::2.5::HTS002,BRD-K84163249-001-01-9,2.5,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84163249-001-01-9::10::HTS002,BRD-K84163249-001-01-9,10.0,HTS002,PREP046,ercalcitriol,vitamin D receptor agonist,VDR,NA,NA,"C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Phase 1
BRD-K84466663-001-05-4::0.00061034::HTS002,BRD-K84466663-001-05-4,0.00061034,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::0.0024414::HTS002,BRD-K84466663-001-05-4,0.0024414,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::0.00976562::HTS002,BRD-K84466663-001-05-4,0.00976562,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::0.0390625::HTS002,BRD-K84466663-001-05-4,0.0390625,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::0.15625::HTS002,BRD-K84466663-001-05-4,0.15625,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::0.625::HTS002,BRD-K84466663-001-05-4,0.625,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::2.5::HTS002,BRD-K84466663-001-05-4,2.5,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84466663-001-05-4::10::HTS002,BRD-K84466663-001-05-4,10.0,HTS002,PREP017,nelarabine,"DNA synthesis inhibitor, T cell inhibitor",POLA1,hematologic malignancy,"acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)",COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,Launched
BRD-K84564571-001-02-4::0.00061034::HTS002,BRD-K84564571-001-02-4,0.00061034,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::0.0024414::HTS002,BRD-K84564571-001-02-4,0.0024414,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::0.00976562::HTS002,BRD-K84564571-001-02-4,0.00976562,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::0.0390625::HTS002,BRD-K84564571-001-02-4,0.0390625,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::0.15625::HTS002,BRD-K84564571-001-02-4,0.15625,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::0.625::HTS002,BRD-K84564571-001-02-4,0.625,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::2.5::HTS002,BRD-K84564571-001-02-4,2.5,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84564571-001-02-4::10::HTS002,BRD-K84564571-001-02-4,10.0,HTS002,PREP045,telatinib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",KDR,NA,NA,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,Phase 2
BRD-K84663978-003-02-9::0.00061034::HTS002,BRD-K84663978-003-02-9,0.00061034,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::0.0024414::HTS002,BRD-K84663978-003-02-9,0.0024414,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::0.00976562::HTS002,BRD-K84663978-003-02-9,0.00976562,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::0.0390625::HTS002,BRD-K84663978-003-02-9,0.0390625,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::0.15625::HTS002,BRD-K84663978-003-02-9,0.15625,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::0.625::HTS002,BRD-K84663978-003-02-9,0.625,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::2.5::HTS002,BRD-K84663978-003-02-9,2.5,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84663978-003-02-9::10::HTS002,BRD-K84663978-003-02-9,10.0,HTS002,PREP036,trequinsin,phosphodiesterase inhibitor,PDE5A,NA,NA,"COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",Phase 1
BRD-K84683831-001-01-0::0.00061034::HTS002,BRD-K84683831-001-01-0,0.00061034,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::0.0024414::HTS002,BRD-K84683831-001-01-0,0.0024414,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::0.00976562::HTS002,BRD-K84683831-001-01-0,0.00976562,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::0.0390625::HTS002,BRD-K84683831-001-01-0,0.0390625,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::0.15625::HTS002,BRD-K84683831-001-01-0,0.15625,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::0.625::HTS002,BRD-K84683831-001-01-0,0.625,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::2.5::HTS002,BRD-K84683831-001-01-0,2.5,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84683831-001-01-0::10::HTS002,BRD-K84683831-001-01-0,10.0,HTS002,PREP024,radezolid,"bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor",NA,NA,NA,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1,Phase 2
BRD-K84783599-001-01-0::0.00061034::HTS002,BRD-K84783599-001-01-0,0.00061034,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::0.0024414::HTS002,BRD-K84783599-001-01-0,0.0024414,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::0.00976562::HTS002,BRD-K84783599-001-01-0,0.00976562,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::0.0390625::HTS002,BRD-K84783599-001-01-0,0.0390625,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::0.15625::HTS002,BRD-K84783599-001-01-0,0.15625,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::0.625::HTS002,BRD-K84783599-001-01-0,0.625,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::2.5::HTS002,BRD-K84783599-001-01-0,2.5,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84783599-001-01-0::10::HTS002,BRD-K84783599-001-01-0,10.0,HTS002,PREP020,riociguat,guanylate cyclase stimulant,"GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3",cardiology,hypertension,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,Launched
BRD-K84798689-236-02-9::0.000610352::HTS002,BRD-K84798689-236-02-9,0.000610352,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::0.00244141::HTS002,BRD-K84798689-236-02-9,0.00244141,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::0.00976562::HTS002,BRD-K84798689-236-02-9,0.00976562,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::0.0390625::HTS002,BRD-K84798689-236-02-9,0.0390625,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::0.15625::HTS002,BRD-K84798689-236-02-9,0.15625,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::0.625::HTS002,BRD-K84798689-236-02-9,0.625,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::2.5::HTS002,BRD-K84798689-236-02-9,2.5,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84798689-236-02-9::10::HTS002,BRD-K84798689-236-02-9,10.0,HTS002,PREP032,sodium-tanshinone-ii-a-sulfonate,potassium channel activator,NA,NA,NA,Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O,Phase 2
BRD-K84810405-003-01-1::0.00061034::HTS002,BRD-K84810405-003-01-1,0.00061034,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::0.0024414::HTS002,BRD-K84810405-003-01-1,0.0024414,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::0.00976562::HTS002,BRD-K84810405-003-01-1,0.00976562,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::0.0390625::HTS002,BRD-K84810405-003-01-1,0.0390625,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::0.15625::HTS002,BRD-K84810405-003-01-1,0.15625,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::0.625::HTS002,BRD-K84810405-003-01-1,0.625,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::2.5::HTS002,BRD-K84810405-003-01-1,2.5,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84810405-003-01-1::10::HTS002,BRD-K84810405-003-01-1,10.0,HTS002,PREP033,almorexant,orexin receptor antagonist,"HCRTR1, HCRTR2",NA,NA,CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1,Phase 3
BRD-K84892605-001-01-1::0.00061034::HTS002,BRD-K84892605-001-01-1,0.00061034,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::0.0024414::HTS002,BRD-K84892605-001-01-1,0.0024414,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::0.00976562::HTS002,BRD-K84892605-001-01-1,0.00976562,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::0.0390625::HTS002,BRD-K84892605-001-01-1,0.0390625,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::0.15625::HTS002,BRD-K84892605-001-01-1,0.15625,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::0.625::HTS002,BRD-K84892605-001-01-1,0.625,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::2.5::HTS002,BRD-K84892605-001-01-1,2.5,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84892605-001-01-1::10::HTS002,BRD-K84892605-001-01-1,10.0,HTS002,PREP032,IOWH032,CFTR channel antagonist,CFTR,NA,NA,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,Phase 2
BRD-K84937637-001-09-9::0.000610352::HTS002,BRD-K84937637-001-09-9,0.000610352,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::0.00244141::HTS002,BRD-K84937637-001-09-9,0.00244141,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::0.00976562::HTS002,BRD-K84937637-001-09-9,0.00976562,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::0.0390625::HTS002,BRD-K84937637-001-09-9,0.0390625,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::0.15625::HTS002,BRD-K84937637-001-09-9,0.15625,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::0.625::HTS002,BRD-K84937637-001-09-9,0.625,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::2.5::HTS002,BRD-K84937637-001-09-9,2.5,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K84937637-001-09-9::10::HTS002,BRD-K84937637-001-09-9,10.0,HTS002,PREP031,sirolimus,mTOR inhibitor,"FGF2, FKBP1A, MTOR","transplant, pulmonary","organ rejection, lymphangioleiomyomatosis","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O",Launched
BRD-K85014146-001-02-5::0.00061034::HTS002,BRD-K85014146-001-02-5,0.00061034,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::0.0024414::HTS002,BRD-K85014146-001-02-5,0.0024414,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::0.00976562::HTS002,BRD-K85014146-001-02-5,0.00976562,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::0.0390625::HTS002,BRD-K85014146-001-02-5,0.0390625,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::0.15625::HTS002,BRD-K85014146-001-02-5,0.15625,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::0.625::HTS002,BRD-K85014146-001-02-5,0.625,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::2.5::HTS002,BRD-K85014146-001-02-5,2.5,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85014146-001-02-5::10::HTS002,BRD-K85014146-001-02-5,10.0,HTS002,PREP045,AZD2461,PARP inhibitor,NA,NA,NA,COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F,Phase 1
BRD-K85090592-008-22-7::0.00061034::HTS002,BRD-K85090592-008-22-7,0.00061034,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::0.0024414::HTS002,BRD-K85090592-008-22-7,0.0024414,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::0.00976562::HTS002,BRD-K85090592-008-22-7,0.00976562,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::0.0390625::HTS002,BRD-K85090592-008-22-7,0.0390625,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::0.15625::HTS002,BRD-K85090592-008-22-7,0.15625,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::0.625::HTS002,BRD-K85090592-008-22-7,0.625,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::2.5::HTS002,BRD-K85090592-008-22-7,2.5,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85090592-008-22-7::10::HTS002,BRD-K85090592-008-22-7,10.0,HTS002,PREP021,pilocarpine,acetylcholine receptor agonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","ophthalmology, cardiology","glaucoma, hypertension","CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O",Launched
BRD-K85140930-001-12-7::0.000610352::HTS002,BRD-K85140930-001-12-7,0.000610352,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::0.00244141::HTS002,BRD-K85140930-001-12-7,0.00244141,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::0.00976562::HTS002,BRD-K85140930-001-12-7,0.00976562,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::0.0390625::HTS002,BRD-K85140930-001-12-7,0.0390625,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::0.15625::HTS002,BRD-K85140930-001-12-7,0.15625,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::0.625::HTS002,BRD-K85140930-001-12-7,0.625,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::2.5::HTS002,BRD-K85140930-001-12-7,2.5,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85140930-001-12-7::10::HTS002,BRD-K85140930-001-12-7,10.0,HTS002,PREP044,aphidicolin,RNA synthesis inhibitor,NA,NA,NA,C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO,Phase 1
BRD-K85146014-314-05-4::0.00061034::HTS002,BRD-K85146014-314-05-4,0.00061034,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::0.0024414::HTS002,BRD-K85146014-314-05-4,0.0024414,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::0.00976562::HTS002,BRD-K85146014-314-05-4,0.00976562,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::0.0390625::HTS002,BRD-K85146014-314-05-4,0.0390625,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::0.15625::HTS002,BRD-K85146014-314-05-4,0.15625,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::0.625::HTS002,BRD-K85146014-314-05-4,0.625,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::2.5::HTS002,BRD-K85146014-314-05-4,2.5,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85146014-314-05-4::10::HTS002,BRD-K85146014-314-05-4,10.0,HTS002,PREP048,foscarnet,DNA polymerase inhibitor,NA,infectious disease,"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O",Launched
BRD-K85307935-236-09-5::0.00061034::HTS002,BRD-K85307935-236-09-5,0.00061034,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::0.0024414::HTS002,BRD-K85307935-236-09-5,0.0024414,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::0.00976562::HTS002,BRD-K85307935-236-09-5,0.00976562,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::0.0390625::HTS002,BRD-K85307935-236-09-5,0.0390625,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::0.15625::HTS002,BRD-K85307935-236-09-5,0.15625,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::0.625::HTS002,BRD-K85307935-236-09-5,0.625,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::2.5::HTS002,BRD-K85307935-236-09-5,2.5,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85307935-236-09-5::10::HTS002,BRD-K85307935-236-09-5,10.0,HTS002,PREP048,novobiocin,bacterial DNA gyrase inhibitor,NA,obstetrics/gynecology,mastitis,"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C",Launched
BRD-K85333151-003-13-4::0.00061034::HTS002,BRD-K85333151-003-13-4,0.00061034,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::0.0024414::HTS002,BRD-K85333151-003-13-4,0.0024414,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::0.00976562::HTS002,BRD-K85333151-003-13-4,0.00976562,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::0.0390625::HTS002,BRD-K85333151-003-13-4,0.0390625,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::0.15625::HTS002,BRD-K85333151-003-13-4,0.15625,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::0.625::HTS002,BRD-K85333151-003-13-4,0.625,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::2.5::HTS002,BRD-K85333151-003-13-4,2.5,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85333151-003-13-4::10::HTS002,BRD-K85333151-003-13-4,10.0,HTS002,PREP021,ramifenazone,cyclooxygenase inhibitor,NA,"neurology/psychiatry, endocrinology","pain relief, fever","CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O",Launched
BRD-K85402309-001-06-6::0.00061034::HTS002,BRD-K85402309-001-06-6,0.00061034,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::0.0024414::HTS002,BRD-K85402309-001-06-6,0.0024414,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::0.00976562::HTS002,BRD-K85402309-001-06-6,0.00976562,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::0.0390625::HTS002,BRD-K85402309-001-06-6,0.0390625,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::0.15625::HTS002,BRD-K85402309-001-06-6,0.15625,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::0.625::HTS002,BRD-K85402309-001-06-6,0.625,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::2.5::HTS002,BRD-K85402309-001-06-6,2.5,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85402309-001-06-6::10::HTS002,BRD-K85402309-001-06-6,10.0,HTS002,PREP044,dovitinib,"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB",NA,NA,"CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",Phase 3
BRD-K85406984-001-01-0::0.00061034::HTS002,BRD-K85406984-001-01-0,0.00061034,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::0.0024414::HTS002,BRD-K85406984-001-01-0,0.0024414,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::0.00976562::HTS002,BRD-K85406984-001-01-0,0.00976562,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::0.0390625::HTS002,BRD-K85406984-001-01-0,0.0390625,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::0.15625::HTS002,BRD-K85406984-001-01-0,0.15625,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::0.625::HTS002,BRD-K85406984-001-01-0,0.625,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::2.5::HTS002,BRD-K85406984-001-01-0,2.5,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85406984-001-01-0::10::HTS002,BRD-K85406984-001-01-0,10.0,HTS002,PREP024,sobetirome,thyroid hormone receptor agonist,"THRA, THRB",NA,NA,"CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",Phase 1
BRD-K85554912-001-06-3::0.000610352::HTS002,BRD-K85554912-001-06-3,0.000610352,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::0.00244141::HTS002,BRD-K85554912-001-06-3,0.00244141,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::0.00976562::HTS002,BRD-K85554912-001-06-3,0.00976562,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::0.0390625::HTS002,BRD-K85554912-001-06-3,0.0390625,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::0.15625::HTS002,BRD-K85554912-001-06-3,0.15625,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::0.625::HTS002,BRD-K85554912-001-06-3,0.625,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::2.5::HTS002,BRD-K85554912-001-06-3,2.5,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85554912-001-06-3::10::HTS002,BRD-K85554912-001-06-3,10.0,HTS002,PREP030,ivermectin,benzodiazepine receptor agonist,"CHRNA7, GABRB3, GLRA3, P2RX7",infectious disease,"gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies","CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2",Launched
BRD-K85606544-001-09-1::0.00061034::HTS002,BRD-K85606544-001-09-1,0.00061034,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.0024414::HTS002,BRD-K85606544-001-09-1,0.0024414,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.00976562::HTS002,BRD-K85606544-001-09-1,0.00976562,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.0390625::HTS002,BRD-K85606544-001-09-1,0.0390625,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.15625::HTS002,BRD-K85606544-001-09-1,0.15625,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::0.625::HTS002,BRD-K85606544-001-09-1,0.625,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::2.5::HTS002,BRD-K85606544-001-09-1,2.5,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85606544-001-09-1::10::HTS002,BRD-K85606544-001-09-1,10.0,HTS002,PREP047,neratinib,EGFR inhibitor,"EGFR, ERBB2, KDR",NA,NA,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,Phase 3
BRD-K85751432-001-03-3::0.00061034::HTS002,BRD-K85751432-001-03-3,0.00061034,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::0.0024414::HTS002,BRD-K85751432-001-03-3,0.0024414,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::0.00976562::HTS002,BRD-K85751432-001-03-3,0.00976562,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::0.0390625::HTS002,BRD-K85751432-001-03-3,0.0390625,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::0.15625::HTS002,BRD-K85751432-001-03-3,0.15625,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::0.625::HTS002,BRD-K85751432-001-03-3,0.625,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::2.5::HTS002,BRD-K85751432-001-03-3,2.5,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85751432-001-03-3::10::HTS002,BRD-K85751432-001-03-3,10.0,HTS002,PREP025,refametinib,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,Phase 2
BRD-K85849709-001-01-5::0.00061034::HTS002,BRD-K85849709-001-01-5,0.00061034,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::0.0024414::HTS002,BRD-K85849709-001-01-5,0.0024414,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::0.00976562::HTS002,BRD-K85849709-001-01-5,0.00976562,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::0.0390625::HTS002,BRD-K85849709-001-01-5,0.0390625,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::0.15625::HTS002,BRD-K85849709-001-01-5,0.15625,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::0.625::HTS002,BRD-K85849709-001-01-5,0.625,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::2.5::HTS002,BRD-K85849709-001-01-5,2.5,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85849709-001-01-5::10::HTS002,BRD-K85849709-001-01-5,10.0,HTS002,PREP047,AZD2858,glycogen synthase kinase inhibitor,GSK3B,NA,NA,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,Preclinical
BRD-K85872723-001-15-9::0.00061034::HTS002,BRD-K85872723-001-15-9,0.00061034,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::0.0024414::HTS002,BRD-K85872723-001-15-9,0.0024414,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::0.00976562::HTS002,BRD-K85872723-001-15-9,0.00976562,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::0.0390625::HTS002,BRD-K85872723-001-15-9,0.0390625,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::0.15625::HTS002,BRD-K85872723-001-15-9,0.15625,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::0.625::HTS002,BRD-K85872723-001-15-9,0.625,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::2.5::HTS002,BRD-K85872723-001-15-9,2.5,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85872723-001-15-9::10::HTS002,BRD-K85872723-001-15-9,10.0,HTS002,PREP042,kynurenic-acid,glutamate receptor antagonist,"GPR35, GRIN1, GRIN2A, GRIN2B",NA,NA,"OC(=O)c1cc(O)c2ccccc2n1, OC(=O)c1cc(O)c2ccccc2n1",Preclinical
BRD-K85920262-001-02-1::0.00061034::HTS002,BRD-K85920262-001-02-1,0.00061034,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::0.0024414::HTS002,BRD-K85920262-001-02-1,0.0024414,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::0.00976562::HTS002,BRD-K85920262-001-02-1,0.00976562,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::0.0390625::HTS002,BRD-K85920262-001-02-1,0.0390625,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::0.15625::HTS002,BRD-K85920262-001-02-1,0.15625,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::0.625::HTS002,BRD-K85920262-001-02-1,0.625,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::2.5::HTS002,BRD-K85920262-001-02-1,2.5,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K85920262-001-02-1::10::HTS002,BRD-K85920262-001-02-1,10.0,HTS002,PREP043,WAY-600,mTOR inhibitor,MTOR,NA,NA,C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1,Preclinical
BRD-K86003836-001-10-5::0.00061034::HTS002,BRD-K86003836-001-10-5,0.00061034,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::0.0024414::HTS002,BRD-K86003836-001-10-5,0.0024414,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::0.00976562::HTS002,BRD-K86003836-001-10-5,0.00976562,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::0.0390625::HTS002,BRD-K86003836-001-10-5,0.0390625,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::0.15625::HTS002,BRD-K86003836-001-10-5,0.15625,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::0.625::HTS002,BRD-K86003836-001-10-5,0.625,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::2.5::HTS002,BRD-K86003836-001-10-5,2.5,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86003836-001-10-5::10::HTS002,BRD-K86003836-001-10-5,10.0,HTS002,PREP039,flubendazole,tubulin polymerization inhibitor,TUBB,infectious disease,gastrointestinal parasites,"COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1",Launched
BRD-K86118762-001-01-8::0.00061034::HTS002,BRD-K86118762-001-01-8,0.00061034,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.0024414::HTS002,BRD-K86118762-001-01-8,0.0024414,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.00976562::HTS002,BRD-K86118762-001-01-8,0.00976562,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.0390625::HTS002,BRD-K86118762-001-01-8,0.0390625,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.15625::HTS002,BRD-K86118762-001-01-8,0.15625,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::0.625::HTS002,BRD-K86118762-001-01-8,0.625,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::2.5::HTS002,BRD-K86118762-001-01-8,2.5,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86118762-001-01-8::10::HTS002,BRD-K86118762-001-01-8,10.0,HTS002,PREP044,linsitinib,IGF-1 inhibitor,"IGF1R, INSR, INSRR",NA,NA,"C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12",Phase 3
BRD-K86204871-001-16-2::0.00061034::HTS002,BRD-K86204871-001-16-2,0.00061034,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::0.0024414::HTS002,BRD-K86204871-001-16-2,0.0024414,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::0.00976562::HTS002,BRD-K86204871-001-16-2,0.00976562,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::0.0390625::HTS002,BRD-K86204871-001-16-2,0.0390625,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::0.15625::HTS002,BRD-K86204871-001-16-2,0.15625,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::0.625::HTS002,BRD-K86204871-001-16-2,0.625,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::2.5::HTS002,BRD-K86204871-001-16-2,2.5,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86204871-001-16-2::10::HTS002,BRD-K86204871-001-16-2,10.0,HTS002,PREP020,terconazole,sterol demethylase inhibitor,NA,infectious disease,vulvovaginal candidiasis,"CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1",Launched
BRD-K86525559-001-07-8::0.00061565::HTS002,BRD-K86525559-001-07-8,0.00061565,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::0.0024626::HTS002,BRD-K86525559-001-07-8,0.0024626,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::0.0098504::HTS002,BRD-K86525559-001-07-8,0.0098504,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::0.0394016::HTS002,BRD-K86525559-001-07-8,0.0394016,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::0.157606::HTS002,BRD-K86525559-001-07-8,0.157606,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::0.630426::HTS002,BRD-K86525559-001-07-8,0.630426,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::2.5217::HTS002,BRD-K86525559-001-07-8,2.5217,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86525559-001-07-8::10.0868::HTS002,BRD-K86525559-001-07-8,10.0868,HTS002,PREP018,AZD7762,CHK inhibitor,"CHEK1, CHEK2",NA,NA,"NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",Phase 1
BRD-K86687746-001-01-3::0.000610352::HTS002,BRD-K86687746-001-01-3,0.000610352,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::0.00244141::HTS002,BRD-K86687746-001-01-3,0.00244141,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::0.00976562::HTS002,BRD-K86687746-001-01-3,0.00976562,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::0.0390625::HTS002,BRD-K86687746-001-01-3,0.0390625,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::0.15625::HTS002,BRD-K86687746-001-01-3,0.15625,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::0.625::HTS002,BRD-K86687746-001-01-3,0.625,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::2.5::HTS002,BRD-K86687746-001-01-3,2.5,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86687746-001-01-3::10::HTS002,BRD-K86687746-001-01-3,10.0,HTS002,PREP044,R306465,HDAC inhibitor,NA,NA,NA,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,Phase 1
BRD-K86727142-001-12-4::0.00061034::HTS002,BRD-K86727142-001-12-4,0.00061034,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::0.0024414::HTS002,BRD-K86727142-001-12-4,0.0024414,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::0.00976562::HTS002,BRD-K86727142-001-12-4,0.00976562,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::0.0390625::HTS002,BRD-K86727142-001-12-4,0.0390625,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::0.15625::HTS002,BRD-K86727142-001-12-4,0.15625,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::0.625::HTS002,BRD-K86727142-001-12-4,0.625,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::2.5::HTS002,BRD-K86727142-001-12-4,2.5,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86727142-001-12-4::10::HTS002,BRD-K86727142-001-12-4,10.0,HTS002,PREP024,embelin,"HCV inhibitor, XIAP inhibitor",XIAP,NA,NA,"CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O",Preclinical
BRD-K86797399-001-05-1::0.000622424::HTS002,BRD-K86797399-001-05-1,0.000622424,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::0.0024897::HTS002,BRD-K86797399-001-05-1,0.0024897,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::0.00995879::HTS002,BRD-K86797399-001-05-1,0.00995879,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::0.0398351::HTS002,BRD-K86797399-001-05-1,0.0398351,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::0.159341::HTS002,BRD-K86797399-001-05-1,0.159341,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::0.637362::HTS002,BRD-K86797399-001-05-1,0.637362,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::2.54945::HTS002,BRD-K86797399-001-05-1,2.54945,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86797399-001-05-1::10.1978::HTS002,BRD-K86797399-001-05-1,10.1978,HTS002,PREP027,SB-939,HDAC inhibitor,"HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9",NA,NA,"CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO",Phase 2
BRD-K86816506-001-01-8::0.00061034::HTS002,BRD-K86816506-001-01-8,0.00061034,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::0.0024414::HTS002,BRD-K86816506-001-01-8,0.0024414,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::0.00976562::HTS002,BRD-K86816506-001-01-8,0.00976562,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::0.0390625::HTS002,BRD-K86816506-001-01-8,0.0390625,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::0.15625::HTS002,BRD-K86816506-001-01-8,0.15625,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::0.625::HTS002,BRD-K86816506-001-01-8,0.625,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::2.5::HTS002,BRD-K86816506-001-01-8,2.5,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86816506-001-01-8::10::HTS002,BRD-K86816506-001-01-8,10.0,HTS002,PREP039,PF-04457845,FAAH inhibitor,FAAH,NA,NA,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,Phase 2
BRD-K86887724-001-10-6::0.000631667::HTS002,BRD-K86887724-001-10-6,0.000631667,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::0.00252667::HTS002,BRD-K86887724-001-10-6,0.00252667,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::0.0101067::HTS002,BRD-K86887724-001-10-6,0.0101067,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::0.0404267::HTS002,BRD-K86887724-001-10-6,0.0404267,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::0.161707::HTS002,BRD-K86887724-001-10-6,0.161707,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::0.646827::HTS002,BRD-K86887724-001-10-6,0.646827,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::2.58731::HTS002,BRD-K86887724-001-10-6,2.58731,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86887724-001-10-6::10.3492::HTS002,BRD-K86887724-001-10-6,10.3492,HTS002,PREP035,dofetilide,potassium channel blocker,"KCNH1, KCNH2, KCNJ12, KCNK2",NA,NA,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",Withdrawn
BRD-K86930074-001-05-0::0.00061034::HTS002,BRD-K86930074-001-05-0,0.00061034,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::0.0024414::HTS002,BRD-K86930074-001-05-0,0.0024414,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::0.00976562::HTS002,BRD-K86930074-001-05-0,0.00976562,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::0.0390625::HTS002,BRD-K86930074-001-05-0,0.0390625,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::0.15625::HTS002,BRD-K86930074-001-05-0,0.15625,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::0.625::HTS002,BRD-K86930074-001-05-0,0.625,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::2.5::HTS002,BRD-K86930074-001-05-0,2.5,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86930074-001-05-0::10::HTS002,BRD-K86930074-001-05-0,10.0,HTS002,PREP039,cediranib,"KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB",NA,NA,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,Phase 3
BRD-K86972824-001-01-4::0.00061034::HTS002,BRD-K86972824-001-01-4,0.00061034,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.0024414::HTS002,BRD-K86972824-001-01-4,0.0024414,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.00976562::HTS002,BRD-K86972824-001-01-4,0.00976562,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.0390625::HTS002,BRD-K86972824-001-01-4,0.0390625,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.15625::HTS002,BRD-K86972824-001-01-4,0.15625,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::0.625::HTS002,BRD-K86972824-001-01-4,0.625,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::2.5::HTS002,BRD-K86972824-001-01-4,2.5,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K86972824-001-01-4::10::HTS002,BRD-K86972824-001-01-4,10.0,HTS002,PREP038,oltipraz,"nuclear factor erythroid derived, like (NRF2) activator",ANG,NA,NA,"Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",Phase 3
BRD-K87024524-065-17-7::0.00061034::HTS002,BRD-K87024524-065-17-7,0.00061034,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::0.0024414::HTS002,BRD-K87024524-065-17-7,0.0024414,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::0.00976562::HTS002,BRD-K87024524-065-17-7,0.00976562,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::0.0390625::HTS002,BRD-K87024524-065-17-7,0.0390625,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::0.15625::HTS002,BRD-K87024524-065-17-7,0.15625,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::0.625::HTS002,BRD-K87024524-065-17-7,0.625,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::2.5::HTS002,BRD-K87024524-065-17-7,2.5,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K87024524-065-17-7::10::HTS002,BRD-K87024524-065-17-7,10.0,HTS002,PREP020,phenelzine,monoamine oxidase inhibitor,"ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4",neurology/psychiatry,depression,"NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1",Launched
BRD-K71823332-001-03-7::0.00061034::HTS002,BRD-K71823332-001-03-7,0.00061034,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::0.0024414::HTS002,BRD-K71823332-001-03-7,0.0024414,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::0.00976562::HTS002,BRD-K71823332-001-03-7,0.00976562,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::0.0390625::HTS002,BRD-K71823332-001-03-7,0.0390625,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::0.15625::HTS002,BRD-K71823332-001-03-7,0.15625,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::0.625::HTS002,BRD-K71823332-001-03-7,0.625,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::2.5::HTS002,BRD-K71823332-001-03-7,2.5,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K71823332-001-03-7::10::HTS002,BRD-K71823332-001-03-7,10.0,HTS002,PREP036,epothilone-a,microtubule stabilizing agent,NA,NA,NA,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,Preclinical
BRD-K87036601-001-01-6::0.000610352::HTS002,BRD-K87036601-001-01-6,0.000610352,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::0.00244141::HTS002,BRD-K87036601-001-01-6,0.00244141,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::0.00976562::HTS002,BRD-K87036601-001-01-6,0.00976562,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::0.0390625::HTS002,BRD-K87036601-001-01-6,0.0390625,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::0.15625::HTS002,BRD-K87036601-001-01-6,0.15625,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::0.625::HTS002,BRD-K87036601-001-01-6,0.625,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::2.5::HTS002,BRD-K87036601-001-01-6,2.5,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87036601-001-01-6::10::HTS002,BRD-K87036601-001-01-6,10.0,HTS002,PREP032,azodicarbonamide,DNA synthesis inhibitor,NA,NA,NA,"NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",Phase 2
BRD-K87112191-001-04-5::0.00061034::HTS002,BRD-K87112191-001-04-5,0.00061034,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::0.0024414::HTS002,BRD-K87112191-001-04-5,0.0024414,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::0.00976562::HTS002,BRD-K87112191-001-04-5,0.00976562,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::0.0390625::HTS002,BRD-K87112191-001-04-5,0.0390625,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::0.15625::HTS002,BRD-K87112191-001-04-5,0.15625,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::0.625::HTS002,BRD-K87112191-001-04-5,0.625,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::2.5::HTS002,BRD-K87112191-001-04-5,2.5,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87112191-001-04-5::10::HTS002,BRD-K87112191-001-04-5,10.0,HTS002,PREP015,PP242,mTOR inhibitor,"MTOR, PASK",NA,NA,"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",Preclinical
BRD-K87124298-001-03-4::0.00061034::HTS002,BRD-K87124298-001-03-4,0.00061034,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::0.0024414::HTS002,BRD-K87124298-001-03-4,0.0024414,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::0.00976562::HTS002,BRD-K87124298-001-03-4,0.00976562,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::0.0390625::HTS002,BRD-K87124298-001-03-4,0.0390625,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::0.15625::HTS002,BRD-K87124298-001-03-4,0.15625,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::0.625::HTS002,BRD-K87124298-001-03-4,0.625,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::2.5::HTS002,BRD-K87124298-001-03-4,2.5,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87124298-001-03-4::10::HTS002,BRD-K87124298-001-03-4,10.0,HTS002,PREP039,OSI-027,mTOR inhibitor,MTOR,NA,NA,"COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12",Phase 1
BRD-K87349682-347-03-8::0.000576702::HTS002,BRD-K87349682-347-03-8,0.000576702,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::0.00230681::HTS002,BRD-K87349682-347-03-8,0.00230681,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::0.00922723::HTS002,BRD-K87349682-347-03-8,0.00922723,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::0.0369089::HTS002,BRD-K87349682-347-03-8,0.0369089,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::0.147636::HTS002,BRD-K87349682-347-03-8,0.147636,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::0.590543::HTS002,BRD-K87349682-347-03-8,0.590543,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::2.36217::HTS002,BRD-K87349682-347-03-8,2.36217,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87349682-347-03-8::9.44868::HTS002,BRD-K87349682-347-03-8,9.44868,HTS002,PREP030,norepinephrine,adrenergic receptor agonist,"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","cardiology, allergy, neurology/psychiatry","hypertension, urticaria, headache, seasonal affective disorder","NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1",Launched
BRD-K87510569-001-02-8::0.00061034::HTS002,BRD-K87510569-001-02-8,0.00061034,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::0.0024414::HTS002,BRD-K87510569-001-02-8,0.0024414,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::0.00976562::HTS002,BRD-K87510569-001-02-8,0.00976562,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::0.0390625::HTS002,BRD-K87510569-001-02-8,0.0390625,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::0.15625::HTS002,BRD-K87510569-001-02-8,0.15625,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::0.625::HTS002,BRD-K87510569-001-02-8,0.625,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::2.5::HTS002,BRD-K87510569-001-02-8,2.5,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87510569-001-02-8::10::HTS002,BRD-K87510569-001-02-8,10.0,HTS002,PREP040,RS-504393,CC chemokine receptor antagonist,"CCL2, CCR2",NA,NA,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,Preclinical
BRD-K87512222-019-01-7::0.00061034::HTS002,BRD-K87512222-019-01-7,0.00061034,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::0.0024414::HTS002,BRD-K87512222-019-01-7,0.0024414,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::0.00976562::HTS002,BRD-K87512222-019-01-7,0.00976562,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::0.0390625::HTS002,BRD-K87512222-019-01-7,0.0390625,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::0.15625::HTS002,BRD-K87512222-019-01-7,0.15625,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::0.625::HTS002,BRD-K87512222-019-01-7,0.625,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::2.5::HTS002,BRD-K87512222-019-01-7,2.5,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87512222-019-01-7::10::HTS002,BRD-K87512222-019-01-7,10.0,HTS002,PREP044,taltobulin,tubulin polymerization inhibitor,NA,NA,NA,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,Phase 1
BRD-K87696786-003-04-4::0.00061034::HTS002,BRD-K87696786-003-04-4,0.00061034,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::0.0024414::HTS002,BRD-K87696786-003-04-4,0.0024414,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::0.00976562::HTS002,BRD-K87696786-003-04-4,0.00976562,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::0.0390625::HTS002,BRD-K87696786-003-04-4,0.0390625,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::0.15625::HTS002,BRD-K87696786-003-04-4,0.15625,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::0.625::HTS002,BRD-K87696786-003-04-4,0.625,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::2.5::HTS002,BRD-K87696786-003-04-4,2.5,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87696786-003-04-4::10::HTS002,BRD-K87696786-003-04-4,10.0,HTS002,PREP036,LY456236,glutamate receptor antagonist,GRM1,NA,NA,"COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",Preclinical
BRD-K87700323-003-05-1::0.00061034::HTS002,BRD-K87700323-003-05-1,0.00061034,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::0.0024414::HTS002,BRD-K87700323-003-05-1,0.0024414,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::0.00976562::HTS002,BRD-K87700323-003-05-1,0.00976562,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::0.0390625::HTS002,BRD-K87700323-003-05-1,0.0390625,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::0.15625::HTS002,BRD-K87700323-003-05-1,0.15625,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::0.625::HTS002,BRD-K87700323-003-05-1,0.625,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::2.5::HTS002,BRD-K87700323-003-05-1,2.5,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87700323-003-05-1::10::HTS002,BRD-K87700323-003-05-1,10.0,HTS002,PREP045,cetylpyridinium,NA,NA,dental,"gingivitis, mouth inflammation","CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1",Launched
BRD-K87737963-001-06-0::0.00061034::HTS002,BRD-K87737963-001-06-0,0.00061034,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.0024414::HTS002,BRD-K87737963-001-06-0,0.0024414,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.00976562::HTS002,BRD-K87737963-001-06-0,0.00976562,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.0390625::HTS002,BRD-K87737963-001-06-0,0.0390625,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.15625::HTS002,BRD-K87737963-001-06-0,0.15625,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::0.625::HTS002,BRD-K87737963-001-06-0,0.625,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::2.5::HTS002,BRD-K87737963-001-06-0,2.5,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87737963-001-06-0::10::HTS002,BRD-K87737963-001-06-0,10.0,HTS002,PREP024,cyt387,NA,"JAK1, JAK2, JAK3",NA,NA,"O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",Phase 3
BRD-K87774949-001-03-9::0.00061034::HTS002,BRD-K87774949-001-03-9,0.00061034,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::0.0024414::HTS002,BRD-K87774949-001-03-9,0.0024414,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::0.00976562::HTS002,BRD-K87774949-001-03-9,0.00976562,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::0.0390625::HTS002,BRD-K87774949-001-03-9,0.0390625,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::0.15625::HTS002,BRD-K87774949-001-03-9,0.15625,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::0.625::HTS002,BRD-K87774949-001-03-9,0.625,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::2.5::HTS002,BRD-K87774949-001-03-9,2.5,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87774949-001-03-9::10::HTS002,BRD-K87774949-001-03-9,10.0,HTS002,PREP022,istradefylline,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",neurology/psychiatry,"Parkinson's Disease, dyskinesia","CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O",Launched
BRD-K87782578-001-01-4::0.00061034::HTS002,BRD-K87782578-001-01-4,0.00061034,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.0024414::HTS002,BRD-K87782578-001-01-4,0.0024414,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.00976562::HTS002,BRD-K87782578-001-01-4,0.00976562,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.0390625::HTS002,BRD-K87782578-001-01-4,0.0390625,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.15625::HTS002,BRD-K87782578-001-01-4,0.15625,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::0.625::HTS002,BRD-K87782578-001-01-4,0.625,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::2.5::HTS002,BRD-K87782578-001-01-4,2.5,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87782578-001-01-4::10::HTS002,BRD-K87782578-001-01-4,10.0,HTS002,PREP025,AVL-292,Bruton's tyrosine kinase (BTK) inhibitor,"BTK, YES1",NA,NA,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,Phase 2
BRD-K87827419-001-16-8::0.000610352::HTS002,BRD-K87827419-001-16-8,0.000610352,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::0.00244141::HTS002,BRD-K87827419-001-16-8,0.00244141,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::0.00976562::HTS002,BRD-K87827419-001-16-8,0.00976562,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::0.0390625::HTS002,BRD-K87827419-001-16-8,0.0390625,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::0.15625::HTS002,BRD-K87827419-001-16-8,0.15625,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::0.625::HTS002,BRD-K87827419-001-16-8,0.625,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::2.5::HTS002,BRD-K87827419-001-16-8,2.5,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87827419-001-16-8::10::HTS002,BRD-K87827419-001-16-8,10.0,HTS002,PREP017,melphalan,"DNA alkylating agent, DNA inhibitor",NA,hematologic malignancy,multiple myeloma,"N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O",Launched
BRD-K87909389-003-03-4::0.00061034::HTS002,BRD-K87909389-003-03-4,0.00061034,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.0024414::HTS002,BRD-K87909389-003-03-4,0.0024414,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.00976562::HTS002,BRD-K87909389-003-03-4,0.00976562,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.0390625::HTS002,BRD-K87909389-003-03-4,0.0390625,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.15625::HTS002,BRD-K87909389-003-03-4,0.15625,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::0.625::HTS002,BRD-K87909389-003-03-4,0.625,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::2.5::HTS002,BRD-K87909389-003-03-4,2.5,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87909389-003-03-4::10::HTS002,BRD-K87909389-003-03-4,10.0,HTS002,PREP027,alvocidib,CDK inhibitor,"CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM",NA,NA,"CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",Phase 2
BRD-K87990216-001-10-2::0.00061034::HTS002,BRD-K87990216-001-10-2,0.00061034,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::0.0024414::HTS002,BRD-K87990216-001-10-2,0.0024414,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::0.00976562::HTS002,BRD-K87990216-001-10-2,0.00976562,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::0.0390625::HTS002,BRD-K87990216-001-10-2,0.0390625,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::0.15625::HTS002,BRD-K87990216-001-10-2,0.15625,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::0.625::HTS002,BRD-K87990216-001-10-2,0.625,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::2.5::HTS002,BRD-K87990216-001-10-2,2.5,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K87990216-001-10-2::10::HTS002,BRD-K87990216-001-10-2,10.0,HTS002,PREP030,piretanide,glucocorticoid receptor agonist,"SLC12A1, SLC12A2",cardiology,"hypertension, edema",NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,Launched
BRD-K88172511-003-20-3::0.000590494::HTS002,BRD-K88172511-003-20-3,0.000590494,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::0.00236198::HTS002,BRD-K88172511-003-20-3,0.00236198,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::0.0094479::HTS002,BRD-K88172511-003-20-3,0.0094479,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::0.0377916::HTS002,BRD-K88172511-003-20-3,0.0377916,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::0.151166::HTS002,BRD-K88172511-003-20-3,0.151166,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::0.604666::HTS002,BRD-K88172511-003-20-3,0.604666,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::2.41866::HTS002,BRD-K88172511-003-20-3,2.41866,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88172511-003-20-3::9.67465::HTS002,BRD-K88172511-003-20-3,9.67465,HTS002,PREP016,naltrexone,opioid receptor antagonist,"OPRD1, OPRK1, OPRM1, SIGMAR1",neurology/psychiatry,abstinence from alcohol,"Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O",Launched
BRD-K88429204-001-35-1::0.00061034::HTS002,BRD-K88429204-001-35-1,0.00061034,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::0.0024414::HTS002,BRD-K88429204-001-35-1,0.0024414,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::0.00976562::HTS002,BRD-K88429204-001-35-1,0.00976562,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::0.0390625::HTS002,BRD-K88429204-001-35-1,0.0390625,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::0.15625::HTS002,BRD-K88429204-001-35-1,0.15625,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::0.625::HTS002,BRD-K88429204-001-35-1,0.625,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::2.5::HTS002,BRD-K88429204-001-35-1,2.5,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88429204-001-35-1::10::HTS002,BRD-K88429204-001-35-1,10.0,HTS002,PREP017,pyrimethamine,dihydrofolate reductase inhibitor,"DHFR, SLC47A1",infectious disease,malaria,"CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1",Launched
BRD-K88506063-001-01-8::0.00061034::HTS002,BRD-K88506063-001-01-8,0.00061034,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::0.0024414::HTS002,BRD-K88506063-001-01-8,0.0024414,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::0.00976562::HTS002,BRD-K88506063-001-01-8,0.00976562,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::0.0390625::HTS002,BRD-K88506063-001-01-8,0.0390625,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::0.15625::HTS002,BRD-K88506063-001-01-8,0.15625,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::0.625::HTS002,BRD-K88506063-001-01-8,0.625,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::2.5::HTS002,BRD-K88506063-001-01-8,2.5,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88506063-001-01-8::10::HTS002,BRD-K88506063-001-01-8,10.0,HTS002,PREP027,KD025,rho associated kinase inhibitor,ROCK2,NA,NA,CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1,Phase 2
BRD-K88510285-001-11-1::0.00061034::HTS002,BRD-K88510285-001-11-1,0.00061034,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::0.0024414::HTS002,BRD-K88510285-001-11-1,0.0024414,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::0.00976562::HTS002,BRD-K88510285-001-11-1,0.00976562,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::0.0390625::HTS002,BRD-K88510285-001-11-1,0.0390625,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::0.15625::HTS002,BRD-K88510285-001-11-1,0.15625,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::0.625::HTS002,BRD-K88510285-001-11-1,0.625,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::2.5::HTS002,BRD-K88510285-001-11-1,2.5,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88510285-001-11-1::10::HTS002,BRD-K88510285-001-11-1,10.0,HTS002,PREP015,bortezomib,"NFkB pathway inhibitor, proteasome inhibitor","PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA",hematologic malignancy,"multiple myeloma, mantle cell lymphoma (MCL)","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O",Launched
BRD-K88568253-011-19-9::0.00061034::HTS002,BRD-K88568253-011-19-9,0.00061034,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::0.0024414::HTS002,BRD-K88568253-011-19-9,0.0024414,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::0.00976562::HTS002,BRD-K88568253-011-19-9,0.00976562,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::0.0390625::HTS002,BRD-K88568253-011-19-9,0.0390625,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::0.15625::HTS002,BRD-K88568253-011-19-9,0.15625,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::0.625::HTS002,BRD-K88568253-011-19-9,0.625,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::2.5::HTS002,BRD-K88568253-011-19-9,2.5,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88568253-011-19-9::10::HTS002,BRD-K88568253-011-19-9,10.0,HTS002,PREP021,iproniazid,monoamine oxidase inhibitor,"MAOA, MAOB",NA,NA,CC(C)NNC(=O)c1ccncc1,Withdrawn
BRD-K88625236-001-04-2::0.00061034::HTS002,BRD-K88625236-001-04-2,0.00061034,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::0.0024414::HTS002,BRD-K88625236-001-04-2,0.0024414,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::0.00976562::HTS002,BRD-K88625236-001-04-2,0.00976562,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::0.0390625::HTS002,BRD-K88625236-001-04-2,0.0390625,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::0.15625::HTS002,BRD-K88625236-001-04-2,0.15625,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::0.625::HTS002,BRD-K88625236-001-04-2,0.625,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::2.5::HTS002,BRD-K88625236-001-04-2,2.5,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88625236-001-04-2::10::HTS002,BRD-K88625236-001-04-2,10.0,HTS002,PREP035,nonoxynol-9,membrane integrity inhibitor,NA,endocrinology,contraceptive,"CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1",Launched
BRD-K88677950-001-03-9::0.00061034::HTS002,BRD-K88677950-001-03-9,0.00061034,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::0.0024414::HTS002,BRD-K88677950-001-03-9,0.0024414,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::0.00976562::HTS002,BRD-K88677950-001-03-9,0.00976562,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::0.0390625::HTS002,BRD-K88677950-001-03-9,0.0390625,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::0.15625::HTS002,BRD-K88677950-001-03-9,0.15625,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::0.625::HTS002,BRD-K88677950-001-03-9,0.625,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::2.5::HTS002,BRD-K88677950-001-03-9,2.5,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88677950-001-03-9::10::HTS002,BRD-K88677950-001-03-9,10.0,HTS002,PREP043,PD-198306,"MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2",NA,NA,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,Preclinical
BRD-K88789588-001-14-9::0.00061034::HTS002,BRD-K88789588-001-14-9,0.00061034,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::0.0024414::HTS002,BRD-K88789588-001-14-9,0.0024414,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::0.00976562::HTS002,BRD-K88789588-001-14-9,0.00976562,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::0.0390625::HTS002,BRD-K88789588-001-14-9,0.0390625,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::0.15625::HTS002,BRD-K88789588-001-14-9,0.15625,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::0.625::HTS002,BRD-K88789588-001-14-9,0.625,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::2.5::HTS002,BRD-K88789588-001-14-9,2.5,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K88789588-001-14-9::10::HTS002,BRD-K88789588-001-14-9,10.0,HTS002,PREP031,letrozole,aromatase inhibitor,CYP19A1,oncology,breast cancer,"N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1",Launched
BRD-K89014967-001-04-3::0.00061034::HTS002,BRD-K89014967-001-04-3,0.00061034,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.0024414::HTS002,BRD-K89014967-001-04-3,0.0024414,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.00976562::HTS002,BRD-K89014967-001-04-3,0.00976562,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.0390625::HTS002,BRD-K89014967-001-04-3,0.0390625,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.15625::HTS002,BRD-K89014967-001-04-3,0.15625,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::0.625::HTS002,BRD-K89014967-001-04-3,0.625,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::2.5::HTS002,BRD-K89014967-001-04-3,2.5,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89014967-001-04-3::10::HTS002,BRD-K89014967-001-04-3,10.0,HTS002,PREP046,AS-703026,MEK inhibitor,"MAP2K1, MAP2K2",NA,NA,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,Phase 2
BRD-K89015388-001-01-7::0.00061034::HTS002,BRD-K89015388-001-01-7,0.00061034,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::0.0024414::HTS002,BRD-K89015388-001-01-7,0.0024414,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::0.00976562::HTS002,BRD-K89015388-001-01-7,0.00976562,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::0.0390625::HTS002,BRD-K89015388-001-01-7,0.0390625,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::0.15625::HTS002,BRD-K89015388-001-01-7,0.15625,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::0.625::HTS002,BRD-K89015388-001-01-7,0.625,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::2.5::HTS002,BRD-K89015388-001-01-7,2.5,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89015388-001-01-7::10::HTS002,BRD-K89015388-001-01-7,10.0,HTS002,PREP046,GSK923295,centromere associated protein inhibitor,CENPE,NA,NA,CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1,Phase 1
BRD-K89053832-001-01-0::0.000610352::HTS002,BRD-K89053832-001-01-0,0.000610352,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::0.00244141::HTS002,BRD-K89053832-001-01-0,0.00244141,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::0.00976562::HTS002,BRD-K89053832-001-01-0,0.00976562,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::0.0390625::HTS002,BRD-K89053832-001-01-0,0.0390625,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::0.15625::HTS002,BRD-K89053832-001-01-0,0.15625,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::0.625::HTS002,BRD-K89053832-001-01-0,0.625,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::2.5::HTS002,BRD-K89053832-001-01-0,2.5,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89053832-001-01-0::10::HTS002,BRD-K89053832-001-01-0,10.0,HTS002,PREP038,VLX600,ubiquitin C-terminal hydrolase inhibitor,USP14,NA,NA,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,Phase 1
BRD-K89162000-001-06-4::0.00061034::HTS002,BRD-K89162000-001-06-4,0.00061034,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::0.0024414::HTS002,BRD-K89162000-001-06-4,0.0024414,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::0.00976562::HTS002,BRD-K89162000-001-06-4,0.00976562,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::0.0390625::HTS002,BRD-K89162000-001-06-4,0.0390625,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::0.15625::HTS002,BRD-K89162000-001-06-4,0.15625,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::0.625::HTS002,BRD-K89162000-001-06-4,0.625,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::2.5::HTS002,BRD-K89162000-001-06-4,2.5,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89162000-001-06-4::10::HTS002,BRD-K89162000-001-06-4,10.0,HTS002,PREP026,tandutinib,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB",NA,NA,"COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",Phase 2
BRD-K89299012-001-06-0::0.00061034::HTS002,BRD-K89299012-001-06-0,0.00061034,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::0.0024414::HTS002,BRD-K89299012-001-06-0,0.0024414,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::0.00976562::HTS002,BRD-K89299012-001-06-0,0.00976562,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::0.0390625::HTS002,BRD-K89299012-001-06-0,0.0390625,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::0.15625::HTS002,BRD-K89299012-001-06-0,0.15625,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::0.625::HTS002,BRD-K89299012-001-06-0,0.625,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::2.5::HTS002,BRD-K89299012-001-06-0,2.5,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89299012-001-06-0::10::HTS002,BRD-K89299012-001-06-0,10.0,HTS002,PREP046,DCEBIO,potassium channel activator,"KCNN2, KCNN3, KCNN4",NA,NA,"CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12",Preclinical
BRD-K89391146-001-08-0::0.00061034::HTS002,BRD-K89391146-001-08-0,0.00061034,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::0.0024414::HTS002,BRD-K89391146-001-08-0,0.0024414,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::0.00976562::HTS002,BRD-K89391146-001-08-0,0.00976562,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::0.0390625::HTS002,BRD-K89391146-001-08-0,0.0390625,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::0.15625::HTS002,BRD-K89391146-001-08-0,0.15625,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::0.625::HTS002,BRD-K89391146-001-08-0,0.625,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::2.5::HTS002,BRD-K89391146-001-08-0,2.5,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89391146-001-08-0::10::HTS002,BRD-K89391146-001-08-0,10.0,HTS002,PREP032,RG108,DNA methyltransferase inhibitor,"DNMT1, DNMT3B",NA,NA,"OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",Preclinical
BRD-K89561498-001-01-7::0.00061034::HTS002,BRD-K89561498-001-01-7,0.00061034,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::0.0024414::HTS002,BRD-K89561498-001-01-7,0.0024414,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::0.00976562::HTS002,BRD-K89561498-001-01-7,0.00976562,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::0.0390625::HTS002,BRD-K89561498-001-01-7,0.0390625,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::0.15625::HTS002,BRD-K89561498-001-01-7,0.15625,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::0.625::HTS002,BRD-K89561498-001-01-7,0.625,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::2.5::HTS002,BRD-K89561498-001-01-7,2.5,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89561498-001-01-7::10::HTS002,BRD-K89561498-001-01-7,10.0,HTS002,PREP030,SN-38,topoisomerase inhibitor,TOP1,oncology,colorectal cancer,"CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12",Launched
BRD-K89704198-001-12-3::0.00061034::HTS002,BRD-K89704198-001-12-3,0.00061034,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::0.0024414::HTS002,BRD-K89704198-001-12-3,0.0024414,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::0.00976562::HTS002,BRD-K89704198-001-12-3,0.00976562,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::0.0390625::HTS002,BRD-K89704198-001-12-3,0.0390625,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::0.15625::HTS002,BRD-K89704198-001-12-3,0.15625,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::0.625::HTS002,BRD-K89704198-001-12-3,0.625,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::2.5::HTS002,BRD-K89704198-001-12-3,2.5,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89704198-001-12-3::10::HTS002,BRD-K89704198-001-12-3,10.0,HTS002,PREP031,vincamine,adrenergic receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4",NA,NA,CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC,Withdrawn
BRD-K89714990-001-01-5::0.00061034::HTS002,BRD-K89714990-001-01-5,0.00061034,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.0024414::HTS002,BRD-K89714990-001-01-5,0.0024414,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.00976562::HTS002,BRD-K89714990-001-01-5,0.00976562,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.0390625::HTS002,BRD-K89714990-001-01-5,0.0390625,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.15625::HTS002,BRD-K89714990-001-01-5,0.15625,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.625::HTS002,BRD-K89714990-001-01-5,0.625,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::2.5::HTS002,BRD-K89714990-001-01-5,2.5,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::10::HTS002,BRD-K89714990-001-01-5,10.0,HTS002,PREP016,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89839824-001-05-3::0.00061034::HTS002,BRD-K89839824-001-05-3,0.00061034,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::0.0024414::HTS002,BRD-K89839824-001-05-3,0.0024414,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::0.00976562::HTS002,BRD-K89839824-001-05-3,0.00976562,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::0.0390625::HTS002,BRD-K89839824-001-05-3,0.0390625,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::0.15625::HTS002,BRD-K89839824-001-05-3,0.15625,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::0.625::HTS002,BRD-K89839824-001-05-3,0.625,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::2.5::HTS002,BRD-K89839824-001-05-3,2.5,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K89839824-001-05-3::10::HTS002,BRD-K89839824-001-05-3,10.0,HTS002,PREP031,raltitrexed,thymidylate synthase inhibitor,"FPGS, TYMS",oncology,mesothelioma,"CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O",Launched
BRD-K90027121-003-01-7::0.00061034::HTS002,BRD-K90027121-003-01-7,0.00061034,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::0.0024414::HTS002,BRD-K90027121-003-01-7,0.0024414,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::0.00976562::HTS002,BRD-K90027121-003-01-7,0.00976562,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::0.0390625::HTS002,BRD-K90027121-003-01-7,0.0390625,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::0.15625::HTS002,BRD-K90027121-003-01-7,0.15625,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::0.625::HTS002,BRD-K90027121-003-01-7,0.625,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::2.5::HTS002,BRD-K90027121-003-01-7,2.5,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027121-003-01-7::10::HTS002,BRD-K90027121-003-01-7,10.0,HTS002,PREP014,amprolium,thiamine uptake blocker,NA,infectious disease,coccidiosis,"CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1",Launched
BRD-K90027355-001-13-3::0.000594809::HTS002,BRD-K90027355-001-13-3,0.000594809,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::0.00237924::HTS002,BRD-K90027355-001-13-3,0.00237924,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::0.00951694::HTS002,BRD-K90027355-001-13-3,0.00951694,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::0.0380678::HTS002,BRD-K90027355-001-13-3,0.0380678,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::0.152271::HTS002,BRD-K90027355-001-13-3,0.152271,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::0.609084::HTS002,BRD-K90027355-001-13-3,0.609084,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::2.43634::HTS002,BRD-K90027355-001-13-3,2.43634,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90027355-001-13-3::9.74535::HTS002,BRD-K90027355-001-13-3,9.74535,HTS002,PREP028,spironolactone,mineralocorticoid receptor antagonist,"AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG","endocrinology, cardiology, gastroenterology, rheumatology","hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia","CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12",Launched
BRD-K90374350-001-09-2::0.00061034::HTS002,BRD-K90374350-001-09-2,0.00061034,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::0.0024414::HTS002,BRD-K90374350-001-09-2,0.0024414,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::0.00976562::HTS002,BRD-K90374350-001-09-2,0.00976562,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::0.0390625::HTS002,BRD-K90374350-001-09-2,0.0390625,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::0.15625::HTS002,BRD-K90374350-001-09-2,0.15625,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::0.625::HTS002,BRD-K90374350-001-09-2,0.625,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::2.5::HTS002,BRD-K90374350-001-09-2,2.5,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90374350-001-09-2::10::HTS002,BRD-K90374350-001-09-2,10.0,HTS002,PREP016,chlorquinaldol,other antibiotic,NA,infectious disease,fungal infection,"Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",Launched
BRD-K90382497-001-10-7::0.00061034::HTS002,BRD-K90382497-001-10-7,0.00061034,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::0.0024414::HTS002,BRD-K90382497-001-10-7,0.0024414,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::0.00976562::HTS002,BRD-K90382497-001-10-7,0.00976562,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::0.0390625::HTS002,BRD-K90382497-001-10-7,0.0390625,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::0.15625::HTS002,BRD-K90382497-001-10-7,0.15625,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::0.625::HTS002,BRD-K90382497-001-10-7,0.625,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::2.5::HTS002,BRD-K90382497-001-10-7,2.5,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90382497-001-10-7::10::HTS002,BRD-K90382497-001-10-7,10.0,HTS002,PREP033,GW-843682X,PLK inhibitor,"PLK1, PLK3",NA,NA,"COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",Preclinical
BRD-K90497590-001-04-2::0.00061034::HTS002,BRD-K90497590-001-04-2,0.00061034,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::0.0024414::HTS002,BRD-K90497590-001-04-2,0.0024414,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::0.00976562::HTS002,BRD-K90497590-001-04-2,0.00976562,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::0.0390625::HTS002,BRD-K90497590-001-04-2,0.0390625,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::0.15625::HTS002,BRD-K90497590-001-04-2,0.15625,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::0.625::HTS002,BRD-K90497590-001-04-2,0.625,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::2.5::HTS002,BRD-K90497590-001-04-2,2.5,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90497590-001-04-2::10::HTS002,BRD-K90497590-001-04-2,10.0,HTS002,PREP046,AR-12,phosphoinositide dependent kinase inhibitor,PDPK1,NA,NA,"NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",Phase 1
BRD-K90574421-001-03-5::0.00061034::HTS002,BRD-K90574421-001-03-5,0.00061034,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::0.0024414::HTS002,BRD-K90574421-001-03-5,0.0024414,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::0.00976562::HTS002,BRD-K90574421-001-03-5,0.00976562,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::0.0390625::HTS002,BRD-K90574421-001-03-5,0.0390625,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::0.15625::HTS002,BRD-K90574421-001-03-5,0.15625,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::0.625::HTS002,BRD-K90574421-001-03-5,0.625,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::2.5::HTS002,BRD-K90574421-001-03-5,2.5,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90574421-001-03-5::10::HTS002,BRD-K90574421-001-03-5,10.0,HTS002,PREP044,ipsapirone,serotonin receptor agonist,HTR1A,NA,NA,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,Phase 3
BRD-K90647725-001-07-3::0.000610733::HTS002,BRD-K90647725-001-07-3,0.000610733,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::0.00244293::HTS002,BRD-K90647725-001-07-3,0.00244293,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::0.00977173::HTS002,BRD-K90647725-001-07-3,0.00977173,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::0.0390869::HTS002,BRD-K90647725-001-07-3,0.0390869,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::0.156348::HTS002,BRD-K90647725-001-07-3,0.156348,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::0.625391::HTS002,BRD-K90647725-001-07-3,0.625391,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::2.50156::HTS002,BRD-K90647725-001-07-3,2.50156,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90647725-001-07-3::10.0063::HTS002,BRD-K90647725-001-07-3,10.0063,HTS002,PREP048,oleanolic-acid,G protein-coupled receptor agonist,GPBAR1,NA,NA,"CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O",Preclinical
BRD-K90947825-001-02-7::0.00061034::HTS002,BRD-K90947825-001-02-7,0.00061034,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::0.0024414::HTS002,BRD-K90947825-001-02-7,0.0024414,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::0.00976562::HTS002,BRD-K90947825-001-02-7,0.00976562,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::0.0390625::HTS002,BRD-K90947825-001-02-7,0.0390625,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::0.15625::HTS002,BRD-K90947825-001-02-7,0.15625,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::0.625::HTS002,BRD-K90947825-001-02-7,0.625,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::2.5::HTS002,BRD-K90947825-001-02-7,2.5,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90947825-001-02-7::10::HTS002,BRD-K90947825-001-02-7,10.0,HTS002,PREP048,carboplatin,"DNA alkylating agent, DNA inhibitor",NA,oncology,ovarian cancer,"N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1",Launched
BRD-K90948141-001-01-4::0.00061034::HTS002,BRD-K90948141-001-01-4,0.00061034,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::0.0024414::HTS002,BRD-K90948141-001-01-4,0.0024414,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::0.00976562::HTS002,BRD-K90948141-001-01-4,0.00976562,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::0.0390625::HTS002,BRD-K90948141-001-01-4,0.0390625,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::0.15625::HTS002,BRD-K90948141-001-01-4,0.15625,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::0.625::HTS002,BRD-K90948141-001-01-4,0.625,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::2.5::HTS002,BRD-K90948141-001-01-4,2.5,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K90948141-001-01-4::10::HTS002,BRD-K90948141-001-01-4,10.0,HTS002,PREP039,indiplon,benzodiazepine receptor agonist,GABRA1,NA,NA,"CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",Phase 3
BRD-K91370081-001-25-1::0.00061034::HTS002,BRD-K91370081-001-25-1,0.00061034,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::0.0024414::HTS002,BRD-K91370081-001-25-1,0.0024414,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::0.00976562::HTS002,BRD-K91370081-001-25-1,0.00976562,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::0.0390625::HTS002,BRD-K91370081-001-25-1,0.0390625,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::0.15625::HTS002,BRD-K91370081-001-25-1,0.15625,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::0.625::HTS002,BRD-K91370081-001-25-1,0.625,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::2.5::HTS002,BRD-K91370081-001-25-1,2.5,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91370081-001-25-1::10::HTS002,BRD-K91370081-001-25-1,10.0,HTS002,PREP040,anisomycin,DNA synthesis inhibitor,"NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1",NA,NA,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,Preclinical
BRD-K91601245-001-12-0::0.00061034::HTS002,BRD-K91601245-001-12-0,0.00061034,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::0.0024414::HTS002,BRD-K91601245-001-12-0,0.0024414,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::0.00976562::HTS002,BRD-K91601245-001-12-0,0.00976562,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::0.0390625::HTS002,BRD-K91601245-001-12-0,0.0390625,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::0.15625::HTS002,BRD-K91601245-001-12-0,0.15625,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::0.625::HTS002,BRD-K91601245-001-12-0,0.625,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::2.5::HTS002,BRD-K91601245-001-12-0,2.5,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91601245-001-12-0::10::HTS002,BRD-K91601245-001-12-0,10.0,HTS002,PREP017,mercaptopurine,"immunosuppressant, protein synthesis inhibitor, purine antagonist","HPRT1, IMPDH1, IMPDH2, PPAT",hematologic malignancy,acute lymphoblastic leukemia (ALL),"S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12",Launched
BRD-K91614056-001-02-2::0.00061034::HTS002,BRD-K91614056-001-02-2,0.00061034,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::0.0024414::HTS002,BRD-K91614056-001-02-2,0.0024414,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::0.00976562::HTS002,BRD-K91614056-001-02-2,0.00976562,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::0.0390625::HTS002,BRD-K91614056-001-02-2,0.0390625,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::0.15625::HTS002,BRD-K91614056-001-02-2,0.15625,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::0.625::HTS002,BRD-K91614056-001-02-2,0.625,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::2.5::HTS002,BRD-K91614056-001-02-2,2.5,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91614056-001-02-2::10::HTS002,BRD-K91614056-001-02-2,10.0,HTS002,PREP048,trans-4-Hydroxycrotonic-acid,gamma hydroxybutyric acid ligand,NA,NA,NA,OC\C=C\C(O)=O,Preclinical
BRD-K91623615-001-05-0::0.000600752::HTS002,BRD-K91623615-001-05-0,0.000600752,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::0.00240301::HTS002,BRD-K91623615-001-05-0,0.00240301,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::0.00961203::HTS002,BRD-K91623615-001-05-0,0.00961203,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::0.0384481::HTS002,BRD-K91623615-001-05-0,0.0384481,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::0.153792::HTS002,BRD-K91623615-001-05-0,0.153792,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::0.61517::HTS002,BRD-K91623615-001-05-0,0.61517,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::2.46068::HTS002,BRD-K91623615-001-05-0,2.46068,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91623615-001-05-0::9.84272::HTS002,BRD-K91623615-001-05-0,9.84272,HTS002,PREP019,ABT-751,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",Phase 2
BRD-K91701654-001-03-1::0.000651216::HTS002,BRD-K91701654-001-03-1,0.000651216,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::0.00260487::HTS002,BRD-K91701654-001-03-1,0.00260487,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::0.0104195::HTS002,BRD-K91701654-001-03-1,0.0104195,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::0.0416778::HTS002,BRD-K91701654-001-03-1,0.0416778,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::0.166711::HTS002,BRD-K91701654-001-03-1,0.166711,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::0.666846::HTS002,BRD-K91701654-001-03-1,0.666846,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::2.66738::HTS002,BRD-K91701654-001-03-1,2.66738,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91701654-001-03-1::10.6695::HTS002,BRD-K91701654-001-03-1,10.6695,HTS002,PREP048,U-0126,MEK inhibitor,"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1",NA,NA,"N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N",Preclinical
BRD-K91825936-001-01-2::0.00061034::HTS002,BRD-K91825936-001-01-2,0.00061034,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::0.0024414::HTS002,BRD-K91825936-001-01-2,0.0024414,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::0.00976562::HTS002,BRD-K91825936-001-01-2,0.00976562,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::0.0390625::HTS002,BRD-K91825936-001-01-2,0.0390625,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::0.15625::HTS002,BRD-K91825936-001-01-2,0.15625,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::0.625::HTS002,BRD-K91825936-001-01-2,0.625,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::2.5::HTS002,BRD-K91825936-001-01-2,2.5,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K91825936-001-01-2::10::HTS002,BRD-K91825936-001-01-2,10.0,HTS002,PREP031,ZK811752,CC chemokine receptor antagonist,CCR1,NA,NA,"C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",Phase 2
BRD-K92000912-001-12-6::0.00061034::HTS002,BRD-K92000912-001-12-6,0.00061034,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::0.0024414::HTS002,BRD-K92000912-001-12-6,0.0024414,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::0.00976562::HTS002,BRD-K92000912-001-12-6,0.00976562,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::0.0390625::HTS002,BRD-K92000912-001-12-6,0.0390625,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::0.15625::HTS002,BRD-K92000912-001-12-6,0.15625,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::0.625::HTS002,BRD-K92000912-001-12-6,0.625,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::2.5::HTS002,BRD-K92000912-001-12-6,2.5,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92000912-001-12-6::10::HTS002,BRD-K92000912-001-12-6,10.0,HTS002,PREP037,AM-251,cannabinoid receptor antagonist,"CNR1, GPR18, GPR55",NA,NA,"Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",Preclinical
BRD-K92049597-001-20-8::0.00061034::HTS002,BRD-K92049597-001-20-8,0.00061034,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::0.0024414::HTS002,BRD-K92049597-001-20-8,0.0024414,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::0.00976562::HTS002,BRD-K92049597-001-20-8,0.00976562,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::0.0390625::HTS002,BRD-K92049597-001-20-8,0.0390625,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::0.15625::HTS002,BRD-K92049597-001-20-8,0.15625,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::0.625::HTS002,BRD-K92049597-001-20-8,0.625,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::2.5::HTS002,BRD-K92049597-001-20-8,2.5,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92049597-001-20-8::10::HTS002,BRD-K92049597-001-20-8,10.0,HTS002,PREP016,triamterene,sodium channel blocker,"SCNN1A, SCNN1B, SCNN1D, SCNN1G","endocrinology, cardiology","hypokalemia, hypertension, edema","Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1",Launched
BRD-K92093830-003-30-8::0.00061034::HTS002,BRD-K92093830-003-30-8,0.00061034,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::0.0024414::HTS002,BRD-K92093830-003-30-8,0.0024414,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::0.00976562::HTS002,BRD-K92093830-003-30-8,0.00976562,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::0.0390625::HTS002,BRD-K92093830-003-30-8,0.0390625,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::0.15625::HTS002,BRD-K92093830-003-30-8,0.15625,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::0.625::HTS002,BRD-K92093830-003-30-8,0.625,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::2.5::HTS002,BRD-K92093830-003-30-8,2.5,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92093830-003-30-8::10::HTS002,BRD-K92093830-003-30-8,10.0,HTS002,PREP015,doxorubicin,topoisomerase inhibitor,TOP2A,"hematologic malignancy, oncology","acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO",Launched
BRD-K92150287-066-01-2::0.00061034::HTS002,BRD-K92150287-066-01-2,0.00061034,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::0.0024414::HTS002,BRD-K92150287-066-01-2,0.0024414,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::0.00976562::HTS002,BRD-K92150287-066-01-2,0.00976562,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::0.0390625::HTS002,BRD-K92150287-066-01-2,0.0390625,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::0.15625::HTS002,BRD-K92150287-066-01-2,0.15625,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::0.625::HTS002,BRD-K92150287-066-01-2,0.625,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::2.5::HTS002,BRD-K92150287-066-01-2,2.5,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92150287-066-01-2::10::HTS002,BRD-K92150287-066-01-2,10.0,HTS002,PREP026,exatecan-mesylate,topoisomerase inhibitor,TOP1,NA,NA,"CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",Phase 3
BRD-K92213669-001-01-3::0.00061034::HTS002,BRD-K92213669-001-01-3,0.00061034,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::0.0024414::HTS002,BRD-K92213669-001-01-3,0.0024414,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::0.00976562::HTS002,BRD-K92213669-001-01-3,0.00976562,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::0.0390625::HTS002,BRD-K92213669-001-01-3,0.0390625,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::0.15625::HTS002,BRD-K92213669-001-01-3,0.15625,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::0.625::HTS002,BRD-K92213669-001-01-3,0.625,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::2.5::HTS002,BRD-K92213669-001-01-3,2.5,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92213669-001-01-3::10::HTS002,BRD-K92213669-001-01-3,10.0,HTS002,PREP029,lomitapide,microsomal trigylceride transfer protein inhibitor,MTTP,endocrinology,hypercholesterolemia,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,Launched
BRD-K92241597-001-06-0::0.00061034::HTS002,BRD-K92241597-001-06-0,0.00061034,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.0024414::HTS002,BRD-K92241597-001-06-0,0.0024414,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.00976562::HTS002,BRD-K92241597-001-06-0,0.00976562,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.0390625::HTS002,BRD-K92241597-001-06-0,0.0390625,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.15625::HTS002,BRD-K92241597-001-06-0,0.15625,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.625::HTS002,BRD-K92241597-001-06-0,0.625,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::2.5::HTS002,BRD-K92241597-001-06-0,2.5,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::10::HTS002,BRD-K92241597-001-06-0,10.0,HTS002,PREP018,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92428153-001-04-4::0.00061034::HTS002,BRD-K92428153-001-04-4,0.00061034,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::0.0024414::HTS002,BRD-K92428153-001-04-4,0.0024414,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::0.00976562::HTS002,BRD-K92428153-001-04-4,0.00976562,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::0.0390625::HTS002,BRD-K92428153-001-04-4,0.0390625,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::0.15625::HTS002,BRD-K92428153-001-04-4,0.15625,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::0.625::HTS002,BRD-K92428153-001-04-4,0.625,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::2.5::HTS002,BRD-K92428153-001-04-4,2.5,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428153-001-04-4::10::HTS002,BRD-K92428153-001-04-4,10.0,HTS002,PREP022,mycophenolate-mofetil,"dehydrogenase inhibitor, inositol monophosphatase inhibitor","IMPDH1, IMPDH2",transplant,organ rejection,"COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1",Launched
BRD-K92428232-001-10-6::0.00061034::HTS002,BRD-K92428232-001-10-6,0.00061034,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::0.0024414::HTS002,BRD-K92428232-001-10-6,0.0024414,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::0.00976562::HTS002,BRD-K92428232-001-10-6,0.00976562,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::0.0390625::HTS002,BRD-K92428232-001-10-6,0.0390625,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::0.15625::HTS002,BRD-K92428232-001-10-6,0.15625,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::0.625::HTS002,BRD-K92428232-001-10-6,0.625,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::2.5::HTS002,BRD-K92428232-001-10-6,2.5,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92428232-001-10-6::10::HTS002,BRD-K92428232-001-10-6,10.0,HTS002,PREP038,GSK461364,PLK inhibitor,PLK1,NA,NA,C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F,Phase 1
BRD-K92441787-001-04-1::0.00061034::HTS002,BRD-K92441787-001-04-1,0.00061034,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.0024414::HTS002,BRD-K92441787-001-04-1,0.0024414,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.00976562::HTS002,BRD-K92441787-001-04-1,0.00976562,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.0390625::HTS002,BRD-K92441787-001-04-1,0.0390625,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.15625::HTS002,BRD-K92441787-001-04-1,0.15625,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::0.625::HTS002,BRD-K92441787-001-04-1,0.625,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::2.5::HTS002,BRD-K92441787-001-04-1,2.5,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K92441787-001-04-1::10::HTS002,BRD-K92441787-001-04-1,10.0,HTS002,PREP031,bexarotene,retinoid receptor agonist,"RXRA, RXRB, RXRG",hematologic malignancy,cutaneous T-cell lymphoma (CTCL),Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C,Launched
BRD-K49522529-001-02-9::0.000618468::HTS002,BRD-K49522529-001-02-9,0.000618468,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::0.00247387::HTS002,BRD-K49522529-001-02-9,0.00247387,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::0.00989549::HTS002,BRD-K49522529-001-02-9,0.00989549,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::0.039582::HTS002,BRD-K49522529-001-02-9,0.039582,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::0.158328::HTS002,BRD-K49522529-001-02-9,0.158328,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::0.633311::HTS002,BRD-K49522529-001-02-9,0.633311,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::2.53325::HTS002,BRD-K49522529-001-02-9,2.53325,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K49522529-001-02-9::10.133::HTS002,BRD-K49522529-001-02-9,10.133,HTS002,PREP034,alfacalcidol,vitamin D receptor agonist,"CYP27B1, VDR",endocrinology,vitamin D deficiency,"CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C",Launched
BRD-K92657060-001-05-7::0.00061034::HTS002,BRD-K92657060-001-05-7,0.00061034,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::0.0024414::HTS002,BRD-K92657060-001-05-7,0.0024414,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::0.00976562::HTS002,BRD-K92657060-001-05-7,0.00976562,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::0.0390625::HTS002,BRD-K92657060-001-05-7,0.0390625,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::0.15625::HTS002,BRD-K92657060-001-05-7,0.15625,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::0.625::HTS002,BRD-K92657060-001-05-7,0.625,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::2.5::HTS002,BRD-K92657060-001-05-7,2.5,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92657060-001-05-7::10::HTS002,BRD-K92657060-001-05-7,10.0,HTS002,PREP030,zaleplon,benzodiazepine receptor agonist,"GABRA1, GABRB1, GABRG2, TSPO",neurology/psychiatry,insomnia,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,Launched
BRD-K92723993-001-06-7::0.00061034::HTS002,BRD-K92723993-001-06-7,0.00061034,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::0.0024414::HTS002,BRD-K92723993-001-06-7,0.0024414,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::0.00976562::HTS002,BRD-K92723993-001-06-7,0.00976562,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::0.0390625::HTS002,BRD-K92723993-001-06-7,0.0390625,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::0.15625::HTS002,BRD-K92723993-001-06-7,0.15625,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::0.625::HTS002,BRD-K92723993-001-06-7,0.625,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::2.5::HTS002,BRD-K92723993-001-06-7,2.5,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92723993-001-06-7::10::HTS002,BRD-K92723993-001-06-7,10.0,HTS002,PREP031,imatinib,"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","hematologic malignancy, oncology","chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",Launched
BRD-K92968657-001-01-6::0.00061034::HTS002,BRD-K92968657-001-01-6,0.00061034,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::0.0024414::HTS002,BRD-K92968657-001-01-6,0.0024414,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::0.00976562::HTS002,BRD-K92968657-001-01-6,0.00976562,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::0.0390625::HTS002,BRD-K92968657-001-01-6,0.0390625,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::0.15625::HTS002,BRD-K92968657-001-01-6,0.15625,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::0.625::HTS002,BRD-K92968657-001-01-6,0.625,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::2.5::HTS002,BRD-K92968657-001-01-6,2.5,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92968657-001-01-6::10::HTS002,BRD-K92968657-001-01-6,10.0,HTS002,PREP018,tirapazamine,DNA inhibitor,NA,NA,NA,"Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",Phase 3
BRD-K92991072-001-04-9::0.00061034::HTS002,BRD-K92991072-001-04-9,0.00061034,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::0.0024414::HTS002,BRD-K92991072-001-04-9,0.0024414,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::0.00976562::HTS002,BRD-K92991072-001-04-9,0.00976562,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::0.0390625::HTS002,BRD-K92991072-001-04-9,0.0390625,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::0.15625::HTS002,BRD-K92991072-001-04-9,0.15625,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::0.625::HTS002,BRD-K92991072-001-04-9,0.625,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::2.5::HTS002,BRD-K92991072-001-04-9,2.5,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K92991072-001-04-9::10::HTS002,BRD-K92991072-001-04-9,10.0,HTS002,PREP032,PAC-1,caspase activator,CASP3,NA,NA,"Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",Phase 1
BRD-K93034159-001-25-8::0.00061034::HTS002,BRD-K93034159-001-25-8,0.00061034,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::0.0024414::HTS002,BRD-K93034159-001-25-8,0.0024414,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::0.00976562::HTS002,BRD-K93034159-001-25-8,0.00976562,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::0.0390625::HTS002,BRD-K93034159-001-25-8,0.0390625,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::0.15625::HTS002,BRD-K93034159-001-25-8,0.15625,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::0.625::HTS002,BRD-K93034159-001-25-8,0.625,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::2.5::HTS002,BRD-K93034159-001-25-8,2.5,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93034159-001-25-8::10::HTS002,BRD-K93034159-001-25-8,10.0,HTS002,PREP023,cladribine,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor","ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B",hematologic malignancy,hairy cell leukemia,Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1,Launched
BRD-K93123848-001-04-1::0.00061034::HTS002,BRD-K93123848-001-04-1,0.00061034,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::0.0024414::HTS002,BRD-K93123848-001-04-1,0.0024414,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::0.00976562::HTS002,BRD-K93123848-001-04-1,0.00976562,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::0.0390625::HTS002,BRD-K93123848-001-04-1,0.0390625,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::0.15625::HTS002,BRD-K93123848-001-04-1,0.15625,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::0.625::HTS002,BRD-K93123848-001-04-1,0.625,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::2.5::HTS002,BRD-K93123848-001-04-1,2.5,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93123848-001-04-1::10::HTS002,BRD-K93123848-001-04-1,10.0,HTS002,PREP045,RAF265,"RAF inhibitor, VEGFR inhibitor",BRAF,NA,NA,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,Phase 2
BRD-K93441486-067-12-8::0.00061034::HTS002,BRD-K93441486-067-12-8,0.00061034,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::0.0024414::HTS002,BRD-K93441486-067-12-8,0.0024414,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::0.00976562::HTS002,BRD-K93441486-067-12-8,0.00976562,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::0.0390625::HTS002,BRD-K93441486-067-12-8,0.0390625,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::0.15625::HTS002,BRD-K93441486-067-12-8,0.15625,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::0.625::HTS002,BRD-K93441486-067-12-8,0.625,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::2.5::HTS002,BRD-K93441486-067-12-8,2.5,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93441486-067-12-8::10::HTS002,BRD-K93441486-067-12-8,10.0,HTS002,PREP030,diphemanil,acetylcholine receptor antagonist,CHRM3,neurology/psychiatry,spasms,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,Launched
BRD-K93754473-048-20-2::0.00061034::HTS002,BRD-K93754473-048-20-2,0.00061034,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::0.0024414::HTS002,BRD-K93754473-048-20-2,0.0024414,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::0.00976562::HTS002,BRD-K93754473-048-20-2,0.00976562,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::0.0390625::HTS002,BRD-K93754473-048-20-2,0.0390625,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::0.15625::HTS002,BRD-K93754473-048-20-2,0.15625,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::0.625::HTS002,BRD-K93754473-048-20-2,0.625,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::2.5::HTS002,BRD-K93754473-048-20-2,2.5,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93754473-048-20-2::10::HTS002,BRD-K93754473-048-20-2,10.0,HTS002,PREP034,tamoxifen,"estrogen receptor antagonist, selective estrogen receptor modulator (SERM)","EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ",oncology,breast cancer,"CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1",Launched
BRD-K93779381-001-01-9::0.00061034::HTS002,BRD-K93779381-001-01-9,0.00061034,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::0.0024414::HTS002,BRD-K93779381-001-01-9,0.0024414,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::0.00976562::HTS002,BRD-K93779381-001-01-9,0.00976562,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::0.0390625::HTS002,BRD-K93779381-001-01-9,0.0390625,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::0.15625::HTS002,BRD-K93779381-001-01-9,0.15625,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::0.625::HTS002,BRD-K93779381-001-01-9,0.625,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::2.5::HTS002,BRD-K93779381-001-01-9,2.5,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93779381-001-01-9::10::HTS002,BRD-K93779381-001-01-9,10.0,HTS002,PREP035,ingenol-mebutate,PKC activator,"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG",dermatology,actinic keratosis (AK),C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C,Launched
BRD-K93869735-001-01-1::0.00061034::HTS002,BRD-K93869735-001-01-1,0.00061034,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::0.0024414::HTS002,BRD-K93869735-001-01-1,0.0024414,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::0.00976562::HTS002,BRD-K93869735-001-01-1,0.00976562,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::0.0390625::HTS002,BRD-K93869735-001-01-1,0.0390625,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::0.15625::HTS002,BRD-K93869735-001-01-1,0.15625,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::0.625::HTS002,BRD-K93869735-001-01-1,0.625,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::2.5::HTS002,BRD-K93869735-001-01-1,2.5,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93869735-001-01-1::10::HTS002,BRD-K93869735-001-01-1,10.0,HTS002,PREP028,taltirelin,thyrotropin releasing hormone receptor agonist,TRHR,neurology/psychiatry,spinocerebellar ataxia,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O,Launched
BRD-K93918653-001-08-9::0.00061034::HTS002,BRD-K93918653-001-08-9,0.00061034,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::0.0024414::HTS002,BRD-K93918653-001-08-9,0.0024414,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::0.00976562::HTS002,BRD-K93918653-001-08-9,0.00976562,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::0.0390625::HTS002,BRD-K93918653-001-08-9,0.0390625,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::0.15625::HTS002,BRD-K93918653-001-08-9,0.15625,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::0.625::HTS002,BRD-K93918653-001-08-9,0.625,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::2.5::HTS002,BRD-K93918653-001-08-9,2.5,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K93918653-001-08-9::10::HTS002,BRD-K93918653-001-08-9,10.0,HTS002,PREP027,quizartinib,FLT3 inhibitor,"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET",NA,NA,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,Phase 3
BRD-K94176593-001-09-4::0.00061034::HTS002,BRD-K94176593-001-09-4,0.00061034,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::0.0024414::HTS002,BRD-K94176593-001-09-4,0.0024414,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::0.00976562::HTS002,BRD-K94176593-001-09-4,0.00976562,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::0.0390625::HTS002,BRD-K94176593-001-09-4,0.0390625,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::0.15625::HTS002,BRD-K94176593-001-09-4,0.15625,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::0.625::HTS002,BRD-K94176593-001-09-4,0.625,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::2.5::HTS002,BRD-K94176593-001-09-4,2.5,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K94176593-001-09-4::10::HTS002,BRD-K94176593-001-09-4,10.0,HTS002,PREP043,TWS-119,glycogen synthase kinase inhibitor,"GSK3B, JUN, MYC",NA,NA,"Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",Preclinical
BRD-K96006502-001-02-6::0.00061034::HTS002,BRD-K96006502-001-02-6,0.00061034,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::0.0024414::HTS002,BRD-K96006502-001-02-6,0.0024414,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::0.00976562::HTS002,BRD-K96006502-001-02-6,0.00976562,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::0.0390625::HTS002,BRD-K96006502-001-02-6,0.0390625,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::0.15625::HTS002,BRD-K96006502-001-02-6,0.15625,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::0.625::HTS002,BRD-K96006502-001-02-6,0.625,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::2.5::HTS002,BRD-K96006502-001-02-6,2.5,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K96006502-001-02-6::10::HTS002,BRD-K96006502-001-02-6,10.0,HTS002,PREP029,deflazacort,glucocorticoid receptor agonist,NR3C1,rheumatology,joint inflammation,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,Launched
BRD-K60369935-001-18-3::0.00061034::HTS002,BRD-K60369935-001-18-3,0.00061034,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::0.0024414::HTS002,BRD-K60369935-001-18-3,0.0024414,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::0.00976562::HTS002,BRD-K60369935-001-18-3,0.00976562,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::0.0390625::HTS002,BRD-K60369935-001-18-3,0.0390625,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::0.15625::HTS002,BRD-K60369935-001-18-3,0.15625,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::0.625::HTS002,BRD-K60369935-001-18-3,0.625,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::2.5::HTS002,BRD-K60369935-001-18-3,2.5,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K60369935-001-18-3::10::HTS002,BRD-K60369935-001-18-3,10.0,HTS002,PREP035,ribavirin,antiviral,"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2",infectious disease,hepatitis C,"NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",Launched
BRD-K94420399-001-01-9::0.00061034::HTS002,BRD-K94420399-001-01-9,0.00061034,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::0.0024414::HTS002,BRD-K94420399-001-01-9,0.0024414,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::0.00976562::HTS002,BRD-K94420399-001-01-9,0.00976562,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::0.0390625::HTS002,BRD-K94420399-001-01-9,0.0390625,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::0.15625::HTS002,BRD-K94420399-001-01-9,0.15625,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::0.625::HTS002,BRD-K94420399-001-01-9,0.625,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::2.5::HTS002,BRD-K94420399-001-01-9,2.5,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94420399-001-01-9::10::HTS002,BRD-K94420399-001-01-9,10.0,HTS002,PREP019,PF-04136309,CC chemokine receptor antagonist,NA,NA,NA,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,Phase 2
BRD-K94441233-001-13-0::0.000634502::HTS002,BRD-K94441233-001-13-0,0.000634502,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::0.00253801::HTS002,BRD-K94441233-001-13-0,0.00253801,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::0.010152::HTS002,BRD-K94441233-001-13-0,0.010152,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::0.0406081::HTS002,BRD-K94441233-001-13-0,0.0406081,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::0.162432::HTS002,BRD-K94441233-001-13-0,0.162432,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::0.64973::HTS002,BRD-K94441233-001-13-0,0.64973,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::2.59892::HTS002,BRD-K94441233-001-13-0,2.59892,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94441233-001-13-0::10.3957::HTS002,BRD-K94441233-001-13-0,10.3957,HTS002,PREP034,mevastatin,HMGCR inhibitor,HMGCR,NA,NA,"CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12",Preclinical
BRD-K94455792-001-01-8::0.00061034::HTS002,BRD-K94455792-001-01-8,0.00061034,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::0.0024414::HTS002,BRD-K94455792-001-01-8,0.0024414,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::0.00976562::HTS002,BRD-K94455792-001-01-8,0.00976562,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::0.0390625::HTS002,BRD-K94455792-001-01-8,0.0390625,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::0.15625::HTS002,BRD-K94455792-001-01-8,0.15625,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::0.625::HTS002,BRD-K94455792-001-01-8,0.625,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::2.5::HTS002,BRD-K94455792-001-01-8,2.5,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94455792-001-01-8::10::HTS002,BRD-K94455792-001-01-8,10.0,HTS002,PREP033,ICG-001,beta-catenin inhibitor,CTNNB1,NA,NA,Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1,Preclinical
BRD-K94485812-001-02-9::0.00062313::HTS002,BRD-K94485812-001-02-9,0.00062313,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::0.00249252::HTS002,BRD-K94485812-001-02-9,0.00249252,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::0.00997008::HTS002,BRD-K94485812-001-02-9,0.00997008,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::0.0398803::HTS002,BRD-K94485812-001-02-9,0.0398803,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::0.159521::HTS002,BRD-K94485812-001-02-9,0.159521,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::0.638085::HTS002,BRD-K94485812-001-02-9,0.638085,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::2.55234::HTS002,BRD-K94485812-001-02-9,2.55234,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94485812-001-02-9::10.2094::HTS002,BRD-K94485812-001-02-9,10.2094,HTS002,PREP014,LDN-57444,ubiquitin C-terminal hydrolase inhibitor,NA,NA,NA,"CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",Preclinical
BRD-K94559059-091-01-6::0.00061034::HTS002,BRD-K94559059-091-01-6,0.00061034,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::0.0024414::HTS002,BRD-K94559059-091-01-6,0.0024414,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::0.00976562::HTS002,BRD-K94559059-091-01-6,0.00976562,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::0.0390625::HTS002,BRD-K94559059-091-01-6,0.0390625,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::0.15625::HTS002,BRD-K94559059-091-01-6,0.15625,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::0.625::HTS002,BRD-K94559059-091-01-6,0.625,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::2.5::HTS002,BRD-K94559059-091-01-6,2.5,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94559059-091-01-6::10::HTS002,BRD-K94559059-091-01-6,10.0,HTS002,PREP024,telotristat-ethyl,tryptophan hydroxylase inhibitor,TPH1,gastroenterology,diarrhea,"CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1",Launched
BRD-K94720315-001-10-4::0.00061034::HTS002,BRD-K94720315-001-10-4,0.00061034,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::0.0024414::HTS002,BRD-K94720315-001-10-4,0.0024414,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::0.00976562::HTS002,BRD-K94720315-001-10-4,0.00976562,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::0.0390625::HTS002,BRD-K94720315-001-10-4,0.0390625,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::0.15625::HTS002,BRD-K94720315-001-10-4,0.15625,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::0.625::HTS002,BRD-K94720315-001-10-4,0.625,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::2.5::HTS002,BRD-K94720315-001-10-4,2.5,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K94720315-001-10-4::10::HTS002,BRD-K94720315-001-10-4,10.0,HTS002,PREP029,chromocarb,antispasmodic,NA,NA,NA,"OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1",Launched
BRD-K95142244-001-01-5::0.00061034::HTS002,BRD-K95142244-001-01-5,0.00061034,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.0024414::HTS002,BRD-K95142244-001-01-5,0.0024414,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.00976562::HTS002,BRD-K95142244-001-01-5,0.00976562,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.0390625::HTS002,BRD-K95142244-001-01-5,0.0390625,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.15625::HTS002,BRD-K95142244-001-01-5,0.15625,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.625::HTS002,BRD-K95142244-001-01-5,0.625,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::2.5::HTS002,BRD-K95142244-001-01-5,2.5,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::10::HTS002,BRD-K95142244-001-01-5,10.0,HTS002,PREP030,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95292280-001-01-3::0.00061034::HTS002,BRD-K95292280-001-01-3,0.00061034,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::0.0024414::HTS002,BRD-K95292280-001-01-3,0.0024414,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::0.00976562::HTS002,BRD-K95292280-001-01-3,0.00976562,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::0.0390625::HTS002,BRD-K95292280-001-01-3,0.0390625,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::0.15625::HTS002,BRD-K95292280-001-01-3,0.15625,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::0.625::HTS002,BRD-K95292280-001-01-3,0.625,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::2.5::HTS002,BRD-K95292280-001-01-3,2.5,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95292280-001-01-3::10::HTS002,BRD-K95292280-001-01-3,10.0,HTS002,PREP042,SB-657510,urotensin receptor antagonist,UTS2R,NA,NA,"COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",Preclinical
BRD-K95435023-001-08-5::0.000610352::HTS002,BRD-K95435023-001-08-5,0.000610352,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::0.00244141::HTS002,BRD-K95435023-001-08-5,0.00244141,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::0.00976562::HTS002,BRD-K95435023-001-08-5,0.00976562,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::0.0390625::HTS002,BRD-K95435023-001-08-5,0.0390625,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::0.15625::HTS002,BRD-K95435023-001-08-5,0.15625,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::0.625::HTS002,BRD-K95435023-001-08-5,0.625,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::2.5::HTS002,BRD-K95435023-001-08-5,2.5,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95435023-001-08-5::10::HTS002,BRD-K95435023-001-08-5,10.0,HTS002,PREP042,PHA-665752,c-Met inhibitor,MET,NA,NA,"Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",Preclinical
BRD-K95523387-001-09-6::0.00061034::HTS002,BRD-K95523387-001-09-6,0.00061034,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::0.0024414::HTS002,BRD-K95523387-001-09-6,0.0024414,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::0.00976562::HTS002,BRD-K95523387-001-09-6,0.00976562,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::0.0390625::HTS002,BRD-K95523387-001-09-6,0.0390625,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::0.15625::HTS002,BRD-K95523387-001-09-6,0.15625,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::0.625::HTS002,BRD-K95523387-001-09-6,0.625,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::2.5::HTS002,BRD-K95523387-001-09-6,2.5,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95523387-001-09-6::10::HTS002,BRD-K95523387-001-09-6,10.0,HTS002,PREP044,OLDA,TRPV agonist,GPR119,NA,NA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,Preclinical
BRD-K95573441-001-01-2::0.00061034::HTS002,BRD-K95573441-001-01-2,0.00061034,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::0.0024414::HTS002,BRD-K95573441-001-01-2,0.0024414,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::0.00976562::HTS002,BRD-K95573441-001-01-2,0.00976562,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::0.0390625::HTS002,BRD-K95573441-001-01-2,0.0390625,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::0.15625::HTS002,BRD-K95573441-001-01-2,0.15625,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::0.625::HTS002,BRD-K95573441-001-01-2,0.625,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::2.5::HTS002,BRD-K95573441-001-01-2,2.5,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95573441-001-01-2::10::HTS002,BRD-K95573441-001-01-2,10.0,HTS002,PREP025,PFK-015,phosphofructokinase inhibitor,PFKFB3,NA,NA,"O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",Phase 1
BRD-K95581532-001-01-5::0.00061034::HTS002,BRD-K95581532-001-01-5,0.00061034,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::0.0024414::HTS002,BRD-K95581532-001-01-5,0.0024414,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::0.00976562::HTS002,BRD-K95581532-001-01-5,0.00976562,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::0.0390625::HTS002,BRD-K95581532-001-01-5,0.0390625,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::0.15625::HTS002,BRD-K95581532-001-01-5,0.15625,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::0.625::HTS002,BRD-K95581532-001-01-5,0.625,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::2.5::HTS002,BRD-K95581532-001-01-5,2.5,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95581532-001-01-5::10::HTS002,BRD-K95581532-001-01-5,10.0,HTS002,PREP036,RN-1734,TRPV antagonist,TRPV4,NA,NA,"CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",Preclinical
BRD-K95763993-001-19-3::0.00061034::HTS002,BRD-K95763993-001-19-3,0.00061034,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::0.0024414::HTS002,BRD-K95763993-001-19-3,0.0024414,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::0.00976562::HTS002,BRD-K95763993-001-19-3,0.00976562,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::0.0390625::HTS002,BRD-K95763993-001-19-3,0.0390625,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::0.15625::HTS002,BRD-K95763993-001-19-3,0.15625,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::0.625::HTS002,BRD-K95763993-001-19-3,0.625,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::2.5::HTS002,BRD-K95763993-001-19-3,2.5,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95763993-001-19-3::10::HTS002,BRD-K95763993-001-19-3,10.0,HTS002,PREP030,trapidil,PDGFR tyrosine kinase receptor inhibitor,PDGFRA,cardiology,coronary artery disease (CAD),CCN(CC)c1cc(C)nc2ncnn12,Launched
BRD-K95773607-004-03-8::0.00061034::HTS002,BRD-K95773607-004-03-8,0.00061034,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::0.0024414::HTS002,BRD-K95773607-004-03-8,0.0024414,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::0.00976562::HTS002,BRD-K95773607-004-03-8,0.00976562,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::0.0390625::HTS002,BRD-K95773607-004-03-8,0.0390625,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::0.15625::HTS002,BRD-K95773607-004-03-8,0.15625,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::0.625::HTS002,BRD-K95773607-004-03-8,0.625,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::2.5::HTS002,BRD-K95773607-004-03-8,2.5,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95773607-004-03-8::10::HTS002,BRD-K95773607-004-03-8,10.0,HTS002,PREP034,darifenacin,acetylcholine receptor antagonist,"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5",urology,urinary incontinence,"NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1",Launched
BRD-K95785345-300-14-8::0.00061034::HTS002,BRD-K95785345-300-14-8,0.00061034,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::0.0024414::HTS002,BRD-K95785345-300-14-8,0.0024414,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::0.00976562::HTS002,BRD-K95785345-300-14-8,0.00976562,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::0.0390625::HTS002,BRD-K95785345-300-14-8,0.0390625,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::0.15625::HTS002,BRD-K95785345-300-14-8,0.15625,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::0.625::HTS002,BRD-K95785345-300-14-8,0.625,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::2.5::HTS002,BRD-K95785345-300-14-8,2.5,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785345-300-14-8::10::HTS002,BRD-K95785345-300-14-8,10.0,HTS002,PREP034,thiamine,vitamin B,"SLC19A2, SLC19A3, TPK1",metabolism,thiamine deficiency,"Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N",Launched
BRD-K95785537-001-23-1::0.00061034::HTS002,BRD-K95785537-001-23-1,0.00061034,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::0.0024414::HTS002,BRD-K95785537-001-23-1,0.0024414,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::0.00976562::HTS002,BRD-K95785537-001-23-1,0.00976562,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::0.0390625::HTS002,BRD-K95785537-001-23-1,0.0390625,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::0.15625::HTS002,BRD-K95785537-001-23-1,0.15625,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::0.625::HTS002,BRD-K95785537-001-23-1,0.625,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::2.5::HTS002,BRD-K95785537-001-23-1,2.5,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95785537-001-23-1::10::HTS002,BRD-K95785537-001-23-1,10.0,HTS002,PREP042,PP-2,src inhibitor,"ABL1, LCK, LYN, RIPK2, SRC",NA,NA,"CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",Preclinical
BRD-K95926480-003-03-6::0.00061034::HTS002,BRD-K95926480-003-03-6,0.00061034,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::0.0024414::HTS002,BRD-K95926480-003-03-6,0.0024414,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::0.00976562::HTS002,BRD-K95926480-003-03-6,0.00976562,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::0.0390625::HTS002,BRD-K95926480-003-03-6,0.0390625,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::0.15625::HTS002,BRD-K95926480-003-03-6,0.15625,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::0.625::HTS002,BRD-K95926480-003-03-6,0.625,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::2.5::HTS002,BRD-K95926480-003-03-6,2.5,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K95926480-003-03-6::10::HTS002,BRD-K95926480-003-03-6,10.0,HTS002,PREP036,SRT1720,SIRT activator,SIRT1,NA,NA,O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1,Preclinical
BRD-K96104201-001-01-5::0.00061034::HTS002,BRD-K96104201-001-01-5,0.00061034,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::0.0024414::HTS002,BRD-K96104201-001-01-5,0.0024414,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::0.00976562::HTS002,BRD-K96104201-001-01-5,0.00976562,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::0.0390625::HTS002,BRD-K96104201-001-01-5,0.0390625,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::0.15625::HTS002,BRD-K96104201-001-01-5,0.15625,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::0.625::HTS002,BRD-K96104201-001-01-5,0.625,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::2.5::HTS002,BRD-K96104201-001-01-5,2.5,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96104201-001-01-5::10::HTS002,BRD-K96104201-001-01-5,10.0,HTS002,PREP032,azalomycin-b,bacterial 50S ribosomal subunit inhibitor,NA,NA,NA,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,Preclinical
BRD-K96123349-236-02-8::0.000610352::HTS002,BRD-K96123349-236-02-8,0.000610352,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.00244141::HTS002,BRD-K96123349-236-02-8,0.00244141,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.00976562::HTS002,BRD-K96123349-236-02-8,0.00976562,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.0390625::HTS002,BRD-K96123349-236-02-8,0.0390625,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.15625::HTS002,BRD-K96123349-236-02-8,0.15625,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::0.625::HTS002,BRD-K96123349-236-02-8,0.625,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::2.5::HTS002,BRD-K96123349-236-02-8,2.5,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96123349-236-02-8::10::HTS002,BRD-K96123349-236-02-8,10.0,HTS002,PREP018,brequinar,dihydroorotate dehydrogenase inhibitor,DHODH,NA,NA,Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F,Phase 2
BRD-K96153583-001-05-1::0.000614725::HTS002,BRD-K96153583-001-05-1,0.000614725,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::0.0024589::HTS002,BRD-K96153583-001-05-1,0.0024589,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::0.0098356::HTS002,BRD-K96153583-001-05-1,0.0098356,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::0.0393424::HTS002,BRD-K96153583-001-05-1,0.0393424,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::0.15737::HTS002,BRD-K96153583-001-05-1,0.15737,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::0.629478::HTS002,BRD-K96153583-001-05-1,0.629478,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::2.51791::HTS002,BRD-K96153583-001-05-1,2.51791,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96153583-001-05-1::10.0717::HTS002,BRD-K96153583-001-05-1,10.0717,HTS002,PREP034,cidofovir,DNA polymerase inhibitor,NA,infectious disease,"acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis","Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1",Launched
BRD-K96159438-001-06-3::0.00061034::HTS002,BRD-K96159438-001-06-3,0.00061034,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::0.0024414::HTS002,BRD-K96159438-001-06-3,0.0024414,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::0.00976562::HTS002,BRD-K96159438-001-06-3,0.00976562,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::0.0390625::HTS002,BRD-K96159438-001-06-3,0.0390625,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::0.15625::HTS002,BRD-K96159438-001-06-3,0.15625,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::0.625::HTS002,BRD-K96159438-001-06-3,0.625,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::2.5::HTS002,BRD-K96159438-001-06-3,2.5,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96159438-001-06-3::10::HTS002,BRD-K96159438-001-06-3,10.0,HTS002,PREP022,adefovir-dipivoxil,DNA polymerase inhibitor,NA,infectious disease,hepatitis B,"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C",Launched
BRD-K96188950-001-16-9::0.00061034::HTS002,BRD-K96188950-001-16-9,0.00061034,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::0.0024414::HTS002,BRD-K96188950-001-16-9,0.0024414,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::0.00976562::HTS002,BRD-K96188950-001-16-9,0.00976562,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::0.0390625::HTS002,BRD-K96188950-001-16-9,0.0390625,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::0.15625::HTS002,BRD-K96188950-001-16-9,0.15625,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::0.625::HTS002,BRD-K96188950-001-16-9,0.625,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::2.5::HTS002,BRD-K96188950-001-16-9,2.5,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96188950-001-16-9::10::HTS002,BRD-K96188950-001-16-9,10.0,HTS002,PREP047,caffeic-acid-phenethyl-ester,HIV integrase inhibitor,RELA,NA,NA,"Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",Preclinical
BRD-K96233303-001-01-9::0.00061034::HTS002,BRD-K96233303-001-01-9,0.00061034,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::0.0024414::HTS002,BRD-K96233303-001-01-9,0.0024414,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::0.00976562::HTS002,BRD-K96233303-001-01-9,0.00976562,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::0.0390625::HTS002,BRD-K96233303-001-01-9,0.0390625,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::0.15625::HTS002,BRD-K96233303-001-01-9,0.15625,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::0.625::HTS002,BRD-K96233303-001-01-9,0.625,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::2.5::HTS002,BRD-K96233303-001-01-9,2.5,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96233303-001-01-9::10::HTS002,BRD-K96233303-001-01-9,10.0,HTS002,PREP037,TMS,NA,NA,NA,NA,"COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",Preclinical
BRD-K96253961-046-03-1::0.00061034::HTS002,BRD-K96253961-046-03-1,0.00061034,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::0.0024414::HTS002,BRD-K96253961-046-03-1,0.0024414,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::0.00976562::HTS002,BRD-K96253961-046-03-1,0.00976562,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::0.0390625::HTS002,BRD-K96253961-046-03-1,0.0390625,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::0.15625::HTS002,BRD-K96253961-046-03-1,0.15625,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::0.625::HTS002,BRD-K96253961-046-03-1,0.625,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::2.5::HTS002,BRD-K96253961-046-03-1,2.5,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96253961-046-03-1::10::HTS002,BRD-K96253961-046-03-1,10.0,HTS002,PREP034,metaraminol,adrenergic receptor agonist,ADRA1A,cardiology,hypotension,"C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1",Launched
BRD-K96259238-001-01-4::0.00061034::HTS002,BRD-K96259238-001-01-4,0.00061034,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::0.0024414::HTS002,BRD-K96259238-001-01-4,0.0024414,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::0.00976562::HTS002,BRD-K96259238-001-01-4,0.00976562,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::0.0390625::HTS002,BRD-K96259238-001-01-4,0.0390625,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::0.15625::HTS002,BRD-K96259238-001-01-4,0.15625,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::0.625::HTS002,BRD-K96259238-001-01-4,0.625,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::2.5::HTS002,BRD-K96259238-001-01-4,2.5,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96259238-001-01-4::10::HTS002,BRD-K96259238-001-01-4,10.0,HTS002,PREP042,Y-320,interleukin inhibitor,IL17A,NA,NA,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,Preclinical
BRD-K96358241-001-01-9::0.00022963::HTS002,BRD-K96358241-001-01-9,0.00022963,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::0.000918522::HTS002,BRD-K96358241-001-01-9,0.000918522,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::0.00367409::HTS002,BRD-K96358241-001-01-9,0.00367409,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::0.0146963::HTS002,BRD-K96358241-001-01-9,0.0146963,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::0.0587854::HTS002,BRD-K96358241-001-01-9,0.0587854,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::0.235142::HTS002,BRD-K96358241-001-01-9,0.235142,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::0.940566::HTS002,BRD-K96358241-001-01-9,0.940566,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96358241-001-01-9::3.76226::HTS002,BRD-K96358241-001-01-9,3.76226,HTS002,PREP019,harringtonine,protein synthesis inhibitor,NA,NA,NA,COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,Phase 3
BRD-K96424892-001-02-9::0.00061034::HTS002,BRD-K96424892-001-02-9,0.00061034,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::0.0024414::HTS002,BRD-K96424892-001-02-9,0.0024414,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::0.00976562::HTS002,BRD-K96424892-001-02-9,0.00976562,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::0.0390625::HTS002,BRD-K96424892-001-02-9,0.0390625,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::0.15625::HTS002,BRD-K96424892-001-02-9,0.15625,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::0.625::HTS002,BRD-K96424892-001-02-9,0.625,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::2.5::HTS002,BRD-K96424892-001-02-9,2.5,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96424892-001-02-9::10::HTS002,BRD-K96424892-001-02-9,10.0,HTS002,PREP023,chloramphenicol-palmitate,protein synthesis inhibitor,NA,"infectious disease, endocrinology","meningitis, fever, cholera",CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,Launched
BRD-K96631475-001-02-4::0.000593329::HTS002,BRD-K96631475-001-02-4,0.000593329,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::0.00237332::HTS002,BRD-K96631475-001-02-4,0.00237332,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::0.00949327::HTS002,BRD-K96631475-001-02-4,0.00949327,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::0.0379731::HTS002,BRD-K96631475-001-02-4,0.0379731,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::0.151892::HTS002,BRD-K96631475-001-02-4,0.151892,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::0.607569::HTS002,BRD-K96631475-001-02-4,0.607569,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::2.43028::HTS002,BRD-K96631475-001-02-4,2.43028,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K96631475-001-02-4::9.72111::HTS002,BRD-K96631475-001-02-4,9.72111,HTS002,PREP031,10-deacetylbaccatin,antitumor agent,NA,NA,NA,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C",Preclinical
BRD-K97010173-001-04-1::0.00061034::HTS002,BRD-K97010173-001-04-1,0.00061034,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::0.0024414::HTS002,BRD-K97010173-001-04-1,0.0024414,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::0.00976562::HTS002,BRD-K97010173-001-04-1,0.00976562,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::0.0390625::HTS002,BRD-K97010173-001-04-1,0.0390625,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::0.15625::HTS002,BRD-K97010173-001-04-1,0.15625,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::0.625::HTS002,BRD-K97010173-001-04-1,0.625,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::2.5::HTS002,BRD-K97010173-001-04-1,2.5,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97010173-001-04-1::10::HTS002,BRD-K97010173-001-04-1,10.0,HTS002,PREP035,deferasirox,chelating agent,CYP3A4,hematology,"transfusional hemosiderosis, thalassemia, iron overload",OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O,Launched
BRD-K97101532-001-02-8::0.00061034::HTS002,BRD-K97101532-001-02-8,0.00061034,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::0.0024414::HTS002,BRD-K97101532-001-02-8,0.0024414,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::0.00976562::HTS002,BRD-K97101532-001-02-8,0.00976562,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::0.0390625::HTS002,BRD-K97101532-001-02-8,0.0390625,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::0.15625::HTS002,BRD-K97101532-001-02-8,0.15625,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::0.625::HTS002,BRD-K97101532-001-02-8,0.625,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::2.5::HTS002,BRD-K97101532-001-02-8,2.5,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97101532-001-02-8::10::HTS002,BRD-K97101532-001-02-8,10.0,HTS002,PREP018,tezacaftor,CFTR channel agonist,NA,pulmonary,cystic fibrosis,CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO,Launched
BRD-K97365803-001-02-1::0.00061034::HTS002,BRD-K97365803-001-02-1,0.00061034,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::0.0024414::HTS002,BRD-K97365803-001-02-1,0.0024414,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::0.00976562::HTS002,BRD-K97365803-001-02-1,0.00976562,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::0.0390625::HTS002,BRD-K97365803-001-02-1,0.0390625,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::0.15625::HTS002,BRD-K97365803-001-02-1,0.15625,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::0.625::HTS002,BRD-K97365803-001-02-1,0.625,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::2.5::HTS002,BRD-K97365803-001-02-1,2.5,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97365803-001-02-1::10::HTS002,BRD-K97365803-001-02-1,10.0,HTS002,PREP014,PI-828,PI3K inhibitor,NA,NA,NA,"Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",Preclinical
BRD-K97440753-066-18-1::0.00061034::HTS002,BRD-K97440753-066-18-1,0.00061034,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::0.0024414::HTS002,BRD-K97440753-066-18-1,0.0024414,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::0.00976562::HTS002,BRD-K97440753-066-18-1,0.00976562,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::0.0390625::HTS002,BRD-K97440753-066-18-1,0.0390625,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::0.15625::HTS002,BRD-K97440753-066-18-1,0.15625,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::0.625::HTS002,BRD-K97440753-066-18-1,0.625,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::2.5::HTS002,BRD-K97440753-066-18-1,2.5,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97440753-066-18-1::10::HTS002,BRD-K97440753-066-18-1,10.0,HTS002,PREP034,dihydroergocristine,"adrenergic receptor antagonist, prolactin inhibitor","ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7",NA,NA,"CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O",Launched
BRD-K97464279-001-03-5::0.00061034::HTS002,BRD-K97464279-001-03-5,0.00061034,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::0.0024414::HTS002,BRD-K97464279-001-03-5,0.0024414,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::0.00976562::HTS002,BRD-K97464279-001-03-5,0.00976562,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::0.0390625::HTS002,BRD-K97464279-001-03-5,0.0390625,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::0.15625::HTS002,BRD-K97464279-001-03-5,0.15625,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::0.625::HTS002,BRD-K97464279-001-03-5,0.625,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::2.5::HTS002,BRD-K97464279-001-03-5,2.5,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97464279-001-03-5::10::HTS002,BRD-K97464279-001-03-5,10.0,HTS002,PREP045,diaveridine,dihydrofolate reductase inhibitor,NA,NA,NA,COc1ccc(Cc2cnc(N)nc2N)cc1OC,Launched
BRD-K97472745-001-01-8::0.00061034::HTS002,BRD-K97472745-001-01-8,0.00061034,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::0.0024414::HTS002,BRD-K97472745-001-01-8,0.0024414,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::0.00976562::HTS002,BRD-K97472745-001-01-8,0.00976562,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::0.0390625::HTS002,BRD-K97472745-001-01-8,0.0390625,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::0.15625::HTS002,BRD-K97472745-001-01-8,0.15625,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::0.625::HTS002,BRD-K97472745-001-01-8,0.625,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::2.5::HTS002,BRD-K97472745-001-01-8,2.5,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97472745-001-01-8::10::HTS002,BRD-K97472745-001-01-8,10.0,HTS002,PREP034,gestrinone,progesterone receptor antagonist,"AR, ESR1, PGR",obstetrics/gynecology,endometriosis,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,Launched
BRD-K97714174-001-01-3::0.00061034::HTS002,BRD-K97714174-001-01-3,0.00061034,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::0.0024414::HTS002,BRD-K97714174-001-01-3,0.0024414,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::0.00976562::HTS002,BRD-K97714174-001-01-3,0.00976562,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::0.0390625::HTS002,BRD-K97714174-001-01-3,0.0390625,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::0.15625::HTS002,BRD-K97714174-001-01-3,0.15625,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::0.625::HTS002,BRD-K97714174-001-01-3,0.625,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::2.5::HTS002,BRD-K97714174-001-01-3,2.5,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97714174-001-01-3::10::HTS002,BRD-K97714174-001-01-3,10.0,HTS002,PREP043,P22077,ubiquitin specific protease inhibitor,USP7,NA,NA,"CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",Preclinical
BRD-K97746869-001-27-0::0.00061034::HTS002,BRD-K97746869-001-27-0,0.00061034,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::0.0024414::HTS002,BRD-K97746869-001-27-0,0.0024414,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::0.00976562::HTS002,BRD-K97746869-001-27-0,0.00976562,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::0.0390625::HTS002,BRD-K97746869-001-27-0,0.0390625,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::0.15625::HTS002,BRD-K97746869-001-27-0,0.15625,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::0.625::HTS002,BRD-K97746869-001-27-0,0.625,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::2.5::HTS002,BRD-K97746869-001-27-0,2.5,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97746869-001-27-0::10::HTS002,BRD-K97746869-001-27-0,10.0,HTS002,PREP028,chlorpropamide,ATP channel blocker,"ABCC8, KCNJ10, KCNJ11",endocrinology,diabetes mellitus,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1",Launched
BRD-K97752965-001-16-4::0.000610352::HTS002,BRD-K97752965-001-16-4,0.000610352,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::0.00244141::HTS002,BRD-K97752965-001-16-4,0.00244141,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::0.00976562::HTS002,BRD-K97752965-001-16-4,0.00976562,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::0.0390625::HTS002,BRD-K97752965-001-16-4,0.0390625,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::0.15625::HTS002,BRD-K97752965-001-16-4,0.15625,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::0.625::HTS002,BRD-K97752965-001-16-4,0.625,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::2.5::HTS002,BRD-K97752965-001-16-4,2.5,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97752965-001-16-4::10::HTS002,BRD-K97752965-001-16-4,10.0,HTS002,PREP031,nicorandil,"nitric oxide donor, potassium channel activator",KCNJ11,cardiology,angina pectoris,"[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1",Launched
BRD-K97764662-001-17-3::0.00061034::HTS002,BRD-K97764662-001-17-3,0.00061034,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::0.0024414::HTS002,BRD-K97764662-001-17-3,0.0024414,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::0.00976562::HTS002,BRD-K97764662-001-17-3,0.00976562,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::0.0390625::HTS002,BRD-K97764662-001-17-3,0.0390625,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::0.15625::HTS002,BRD-K97764662-001-17-3,0.15625,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::0.625::HTS002,BRD-K97764662-001-17-3,0.625,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::2.5::HTS002,BRD-K97764662-001-17-3,2.5,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97764662-001-17-3::10::HTS002,BRD-K97764662-001-17-3,10.0,HTS002,PREP042,PD-173074,"FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB",NA,NA,"CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1",Preclinical
BRD-K97799481-001-16-0::0.00061034::HTS002,BRD-K97799481-001-16-0,0.00061034,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::0.0024414::HTS002,BRD-K97799481-001-16-0,0.0024414,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::0.00976562::HTS002,BRD-K97799481-001-16-0,0.00976562,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::0.0390625::HTS002,BRD-K97799481-001-16-0,0.0390625,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::0.15625::HTS002,BRD-K97799481-001-16-0,0.15625,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::0.625::HTS002,BRD-K97799481-001-16-0,0.625,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::2.5::HTS002,BRD-K97799481-001-16-0,2.5,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97799481-001-16-0::10::HTS002,BRD-K97799481-001-16-0,10.0,HTS002,PREP028,theophylline,adenosine receptor antagonist,NA,pulmonary,"asthma, emphysema, bronchitis",Cn1c2nc[nH]c2c(=O)n(C)c1=O,Launched
BRD-K97883416-001-01-4::0.00061034::HTS002,BRD-K97883416-001-01-4,0.00061034,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::0.0024414::HTS002,BRD-K97883416-001-01-4,0.0024414,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::0.00976562::HTS002,BRD-K97883416-001-01-4,0.00976562,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::0.0390625::HTS002,BRD-K97883416-001-01-4,0.0390625,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::0.15625::HTS002,BRD-K97883416-001-01-4,0.15625,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::0.625::HTS002,BRD-K97883416-001-01-4,0.625,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::2.5::HTS002,BRD-K97883416-001-01-4,2.5,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K97883416-001-01-4::10::HTS002,BRD-K97883416-001-01-4,10.0,HTS002,PREP018,BMS-626529,HIV attachment inhibitor,NA,NA,NA,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,Phase 3
BRD-K98157055-001-10-9::0.00061034::HTS002,BRD-K98157055-001-10-9,0.00061034,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::0.0024414::HTS002,BRD-K98157055-001-10-9,0.0024414,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::0.00976562::HTS002,BRD-K98157055-001-10-9,0.00976562,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::0.0390625::HTS002,BRD-K98157055-001-10-9,0.0390625,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::0.15625::HTS002,BRD-K98157055-001-10-9,0.15625,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::0.625::HTS002,BRD-K98157055-001-10-9,0.625,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::2.5::HTS002,BRD-K98157055-001-10-9,2.5,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98157055-001-10-9::10::HTS002,BRD-K98157055-001-10-9,10.0,HTS002,PREP024,SIB-1757,glutamate receptor antagonist,GRM5,NA,NA,Cc1ccc(O)c(N=Nc2ccccc2)n1,Preclinical
BRD-K98203492-003-04-1::0.00061034::HTS002,BRD-K98203492-003-04-1,0.00061034,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::0.0024414::HTS002,BRD-K98203492-003-04-1,0.0024414,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::0.00976562::HTS002,BRD-K98203492-003-04-1,0.00976562,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::0.0390625::HTS002,BRD-K98203492-003-04-1,0.0390625,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::0.15625::HTS002,BRD-K98203492-003-04-1,0.15625,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::0.625::HTS002,BRD-K98203492-003-04-1,0.625,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::2.5::HTS002,BRD-K98203492-003-04-1,2.5,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98203492-003-04-1::10::HTS002,BRD-K98203492-003-04-1,10.0,HTS002,PREP047,GSK-J4,histone lysine demethylase inhibitor,"KDM6A, KDM6B",NA,NA,"CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",Preclinical
BRD-K98384930-003-01-5::0.000610352::HTS002,BRD-K98384930-003-01-5,0.000610352,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::0.00244141::HTS002,BRD-K98384930-003-01-5,0.00244141,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::0.00976562::HTS002,BRD-K98384930-003-01-5,0.00976562,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::0.0390625::HTS002,BRD-K98384930-003-01-5,0.0390625,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::0.15625::HTS002,BRD-K98384930-003-01-5,0.15625,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::0.625::HTS002,BRD-K98384930-003-01-5,0.625,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::2.5::HTS002,BRD-K98384930-003-01-5,2.5,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98384930-003-01-5::10::HTS002,BRD-K98384930-003-01-5,10.0,HTS002,PREP045,finafloxacin,bacterial DNA gyrase inhibitor,NA,"infectious disease, pulmonary","intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis",OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,Launched
BRD-K98521173-001-19-4::0.00061034::HTS002,BRD-K98521173-001-19-4,0.00061034,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::0.0024414::HTS002,BRD-K98521173-001-19-4,0.0024414,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::0.00976562::HTS002,BRD-K98521173-001-19-4,0.00976562,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::0.0390625::HTS002,BRD-K98521173-001-19-4,0.0390625,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::0.15625::HTS002,BRD-K98521173-001-19-4,0.15625,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::0.625::HTS002,BRD-K98521173-001-19-4,0.625,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::2.5::HTS002,BRD-K98521173-001-19-4,2.5,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98521173-001-19-4::10::HTS002,BRD-K98521173-001-19-4,10.0,HTS002,PREP041,desoxycortone,mineralocorticoid receptor agonist,"NR3C1, NR3C2",NA,NA,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,Preclinical
BRD-K98548675-001-05-9::0.00061034::HTS002,BRD-K98548675-001-05-9,0.00061034,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::0.0024414::HTS002,BRD-K98548675-001-05-9,0.0024414,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::0.00976562::HTS002,BRD-K98548675-001-05-9,0.00976562,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::0.0390625::HTS002,BRD-K98548675-001-05-9,0.0390625,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::0.15625::HTS002,BRD-K98548675-001-05-9,0.15625,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::0.625::HTS002,BRD-K98548675-001-05-9,0.625,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::2.5::HTS002,BRD-K98548675-001-05-9,2.5,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98548675-001-05-9::10::HTS002,BRD-K98548675-001-05-9,10.0,HTS002,PREP044,parthenolide,NFkB pathway inhibitor,NA,NA,NA,"C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1",Phase 1
BRD-K98572433-001-02-9::0.00061034::HTS002,BRD-K98572433-001-02-9,0.00061034,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.0024414::HTS002,BRD-K98572433-001-02-9,0.0024414,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.00976562::HTS002,BRD-K98572433-001-02-9,0.00976562,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.0390625::HTS002,BRD-K98572433-001-02-9,0.0390625,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.15625::HTS002,BRD-K98572433-001-02-9,0.15625,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::0.625::HTS002,BRD-K98572433-001-02-9,0.625,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::2.5::HTS002,BRD-K98572433-001-02-9,2.5,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98572433-001-02-9::10::HTS002,BRD-K98572433-001-02-9,10.0,HTS002,PREP039,AZD8931,EGFR inhibitor,"EGFR, ERBB2, ERBB3",NA,NA,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,Phase 2
BRD-K98795921-001-01-7::0.00061034::HTS002,BRD-K98795921-001-01-7,0.00061034,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::0.0024414::HTS002,BRD-K98795921-001-01-7,0.0024414,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::0.00976562::HTS002,BRD-K98795921-001-01-7,0.00976562,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::0.0390625::HTS002,BRD-K98795921-001-01-7,0.0390625,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::0.15625::HTS002,BRD-K98795921-001-01-7,0.15625,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::0.625::HTS002,BRD-K98795921-001-01-7,0.625,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::2.5::HTS002,BRD-K98795921-001-01-7,2.5,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K98795921-001-01-7::10::HTS002,BRD-K98795921-001-01-7,10.0,HTS002,PREP039,SB-2343,"mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG",NA,NA,CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1,Phase 1
BRD-K99023089-001-03-7::0.00061034::HTS002,BRD-K99023089-001-03-7,0.00061034,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::0.0024414::HTS002,BRD-K99023089-001-03-7,0.0024414,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::0.00976562::HTS002,BRD-K99023089-001-03-7,0.00976562,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::0.0390625::HTS002,BRD-K99023089-001-03-7,0.0390625,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::0.15625::HTS002,BRD-K99023089-001-03-7,0.15625,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::0.625::HTS002,BRD-K99023089-001-03-7,0.625,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::2.5::HTS002,BRD-K99023089-001-03-7,2.5,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99023089-001-03-7::10::HTS002,BRD-K99023089-001-03-7,10.0,HTS002,PREP027,AZD5363,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1,Phase 2
BRD-K99107520-001-24-1::0.00061034::HTS002,BRD-K99107520-001-24-1,0.00061034,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.0024414::HTS002,BRD-K99107520-001-24-1,0.0024414,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.00976562::HTS002,BRD-K99107520-001-24-1,0.00976562,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.0390625::HTS002,BRD-K99107520-001-24-1,0.0390625,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.15625::HTS002,BRD-K99107520-001-24-1,0.15625,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.625::HTS002,BRD-K99107520-001-24-1,0.625,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::2.5::HTS002,BRD-K99107520-001-24-1,2.5,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::10::HTS002,BRD-K99107520-001-24-1,10.0,HTS002,PREP030,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99113996-001-02-0::0.00061034::HTS002,BRD-K99113996-001-02-0,0.00061034,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.0024414::HTS002,BRD-K99113996-001-02-0,0.0024414,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.00976562::HTS002,BRD-K99113996-001-02-0,0.00976562,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.0390625::HTS002,BRD-K99113996-001-02-0,0.0390625,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.15625::HTS002,BRD-K99113996-001-02-0,0.15625,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::0.625::HTS002,BRD-K99113996-001-02-0,0.625,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::2.5::HTS002,BRD-K99113996-001-02-0,2.5,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99113996-001-02-0::10::HTS002,BRD-K99113996-001-02-0,10.0,HTS002,PREP019,AZD2014,mTOR inhibitor,MTOR,NA,NA,CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,Phase 2
BRD-K99170882-001-04-3::0.00061034::HTS002,BRD-K99170882-001-04-3,0.00061034,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::0.0024414::HTS002,BRD-K99170882-001-04-3,0.0024414,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::0.00976562::HTS002,BRD-K99170882-001-04-3,0.00976562,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::0.0390625::HTS002,BRD-K99170882-001-04-3,0.0390625,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::0.15625::HTS002,BRD-K99170882-001-04-3,0.15625,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::0.625::HTS002,BRD-K99170882-001-04-3,0.625,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::2.5::HTS002,BRD-K99170882-001-04-3,2.5,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99170882-001-04-3::10::HTS002,BRD-K99170882-001-04-3,10.0,HTS002,PREP014,NSC-319726,p53 activator,NA,NA,NA,"C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1",Preclinical
BRD-K99383816-001-03-5::0.000610352::HTS002,BRD-K99383816-001-03-5,0.000610352,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::0.00244141::HTS002,BRD-K99383816-001-03-5,0.00244141,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::0.00976562::HTS002,BRD-K99383816-001-03-5,0.00976562,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::0.0390625::HTS002,BRD-K99383816-001-03-5,0.0390625,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::0.15625::HTS002,BRD-K99383816-001-03-5,0.15625,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::0.625::HTS002,BRD-K99383816-001-03-5,0.625,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::2.5::HTS002,BRD-K99383816-001-03-5,2.5,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K99383816-001-03-5::10::HTS002,BRD-K99383816-001-03-5,10.0,HTS002,PREP031,ftorafur,thymidylate synthase inhibitor,TYMS,oncology,colorectal cancer,"Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O",Launched
BRD-K49962337-001-02-9::0.00062488::HTS002,BRD-K49962337-001-02-9,0.00062488,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::0.00249952::HTS002,BRD-K49962337-001-02-9,0.00249952,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::0.00999808::HTS002,BRD-K49962337-001-02-9,0.00999808,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::0.0399923::HTS002,BRD-K49962337-001-02-9,0.0399923,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::0.159969::HTS002,BRD-K49962337-001-02-9,0.159969,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::0.639877::HTS002,BRD-K49962337-001-02-9,0.639877,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::2.55951::HTS002,BRD-K49962337-001-02-9,2.55951,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K49962337-001-02-9::10.238::HTS002,BRD-K49962337-001-02-9,10.238,HTS002,PREP028,baicalin,beta glucuronidase inhibitor,PREP,NA,NA,"O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O",Launched
BRD-K99475619-001-01-2::0.00061034::HTS002,BRD-K99475619-001-01-2,0.00061034,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::0.0024414::HTS002,BRD-K99475619-001-01-2,0.0024414,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::0.00976562::HTS002,BRD-K99475619-001-01-2,0.00976562,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::0.0390625::HTS002,BRD-K99475619-001-01-2,0.0390625,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::0.15625::HTS002,BRD-K99475619-001-01-2,0.15625,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::0.625::HTS002,BRD-K99475619-001-01-2,0.625,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::2.5::HTS002,BRD-K99475619-001-01-2,2.5,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99475619-001-01-2::10::HTS002,BRD-K99475619-001-01-2,10.0,HTS002,PREP018,genz-644282,topoisomerase inhibitor,TOP1,NA,NA,CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O,Phase 1
BRD-K99498722-001-02-6::0.00061034::HTS002,BRD-K99498722-001-02-6,0.00061034,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::0.0024414::HTS002,BRD-K99498722-001-02-6,0.0024414,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::0.00976562::HTS002,BRD-K99498722-001-02-6,0.00976562,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::0.0390625::HTS002,BRD-K99498722-001-02-6,0.0390625,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::0.15625::HTS002,BRD-K99498722-001-02-6,0.15625,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::0.625::HTS002,BRD-K99498722-001-02-6,0.625,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::2.5::HTS002,BRD-K99498722-001-02-6,2.5,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99498722-001-02-6::10::HTS002,BRD-K99498722-001-02-6,10.0,HTS002,PREP033,plinabulin,tubulin polymerization inhibitor,NA,NA,NA,"CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",Phase 3
BRD-K99545815-001-06-3::0.00061034::HTS002,BRD-K99545815-001-06-3,0.00061034,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::0.0024414::HTS002,BRD-K99545815-001-06-3,0.0024414,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::0.00976562::HTS002,BRD-K99545815-001-06-3,0.00976562,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::0.0390625::HTS002,BRD-K99545815-001-06-3,0.0390625,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::0.15625::HTS002,BRD-K99545815-001-06-3,0.15625,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::0.625::HTS002,BRD-K99545815-001-06-3,0.625,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::2.5::HTS002,BRD-K99545815-001-06-3,2.5,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K99545815-001-06-3::10::HTS002,BRD-K99545815-001-06-3,10.0,HTS002,PREP018,PF-562271,focal adhesion kinase inhibitor,"PTK2, PTK2B",NA,NA,"CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",Phase 1
BRD-K68904758-001-03-5::0.00061034::HTS002,BRD-K68904758-001-03-5,0.00061034,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::0.0024414::HTS002,BRD-K68904758-001-03-5,0.0024414,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::0.00976562::HTS002,BRD-K68904758-001-03-5,0.00976562,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::0.0390625::HTS002,BRD-K68904758-001-03-5,0.0390625,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::0.15625::HTS002,BRD-K68904758-001-03-5,0.15625,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::0.625::HTS002,BRD-K68904758-001-03-5,0.625,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::2.5::HTS002,BRD-K68904758-001-03-5,2.5,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K68904758-001-03-5::10::HTS002,BRD-K68904758-001-03-5,10.0,HTS002,PREP033,cephalomannine,DNA polymerase inhibitor,NA,NA,NA,"C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1",Preclinical
BRD-K99604664-001-01-1::0.00061034::HTS002,BRD-K99604664-001-01-1,0.00061034,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::0.0024414::HTS002,BRD-K99604664-001-01-1,0.0024414,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::0.00976562::HTS002,BRD-K99604664-001-01-1,0.00976562,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::0.0390625::HTS002,BRD-K99604664-001-01-1,0.0390625,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::0.15625::HTS002,BRD-K99604664-001-01-1,0.15625,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::0.625::HTS002,BRD-K99604664-001-01-1,0.625,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::2.5::HTS002,BRD-K99604664-001-01-1,2.5,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99604664-001-01-1::10::HTS002,BRD-K99604664-001-01-1,10.0,HTS002,PREP018,tanaproget,progesterone receptor agonist,PGR,NA,NA,"Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",Phase 2
BRD-K99749624-001-07-0::0.00061034::HTS002,BRD-K99749624-001-07-0,0.00061034,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.0024414::HTS002,BRD-K99749624-001-07-0,0.0024414,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.00976562::HTS002,BRD-K99749624-001-07-0,0.00976562,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.0390625::HTS002,BRD-K99749624-001-07-0,0.0390625,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.15625::HTS002,BRD-K99749624-001-07-0,0.15625,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::0.625::HTS002,BRD-K99749624-001-07-0,0.625,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::2.5::HTS002,BRD-K99749624-001-07-0,2.5,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99749624-001-07-0::10::HTS002,BRD-K99749624-001-07-0,10.0,HTS002,PREP027,linifanib,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK",NA,NA,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1,Phase 3
BRD-K99792991-001-34-9::0.00061034::HTS002,BRD-K99792991-001-34-9,0.00061034,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::0.0024414::HTS002,BRD-K99792991-001-34-9,0.0024414,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::0.00976562::HTS002,BRD-K99792991-001-34-9,0.00976562,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::0.0390625::HTS002,BRD-K99792991-001-34-9,0.0390625,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::0.15625::HTS002,BRD-K99792991-001-34-9,0.15625,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::0.625::HTS002,BRD-K99792991-001-34-9,0.625,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::2.5::HTS002,BRD-K99792991-001-34-9,2.5,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99792991-001-34-9::10::HTS002,BRD-K99792991-001-34-9,10.0,HTS002,PREP016,hexachlorophene,potassium channel activator,"GLUD1, SDHD",infectious disease,gram-positive bacterial infections,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,Launched
BRD-K99946902-001-07-5::0.00061034::HTS002,BRD-K99946902-001-07-5,0.00061034,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::0.0024414::HTS002,BRD-K99946902-001-07-5,0.0024414,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::0.00976562::HTS002,BRD-K99946902-001-07-5,0.00976562,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::0.0390625::HTS002,BRD-K99946902-001-07-5,0.0390625,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::0.15625::HTS002,BRD-K99946902-001-07-5,0.15625,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::0.625::HTS002,BRD-K99946902-001-07-5,0.625,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::2.5::HTS002,BRD-K99946902-001-07-5,2.5,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99946902-001-07-5::10::HTS002,BRD-K99946902-001-07-5,10.0,HTS002,PREP022,hexylresorcinol,local anesthetic,TYR,infectious disease,"skin infections, first-aid antiseptic",CCCCCCc1ccc(O)cc1O,Launched
BRD-K99964838-001-11-9::0.00061034::HTS002,BRD-K99964838-001-11-9,0.00061034,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::0.0024414::HTS002,BRD-K99964838-001-11-9,0.0024414,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::0.00976562::HTS002,BRD-K99964838-001-11-9,0.00976562,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::0.0390625::HTS002,BRD-K99964838-001-11-9,0.0390625,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::0.15625::HTS002,BRD-K99964838-001-11-9,0.15625,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::0.625::HTS002,BRD-K99964838-001-11-9,0.625,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::2.5::HTS002,BRD-K99964838-001-11-9,2.5,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-K99964838-001-11-9::10::HTS002,BRD-K99964838-001-11-9,10.0,HTS002,PREP017,bosutinib,"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK",hematologic malignancy,chronic myeloid leukemia (CML),"COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl",Launched
BRD-M29182745-001-01-4::0.00061034::HTS002,BRD-M29182745-001-01-4,0.00061034,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::0.0024414::HTS002,BRD-M29182745-001-01-4,0.0024414,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::0.00976562::HTS002,BRD-M29182745-001-01-4,0.00976562,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::0.0390625::HTS002,BRD-M29182745-001-01-4,0.0390625,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::0.15625::HTS002,BRD-M29182745-001-01-4,0.15625,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::0.625::HTS002,BRD-M29182745-001-01-4,0.625,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::2.5::HTS002,BRD-M29182745-001-01-4,2.5,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M29182745-001-01-4::10::HTS002,BRD-M29182745-001-01-4,10.0,HTS002,PREP048,ammonium-lactate,NA,HCAR1,dermatology,"xerosis cutis, ichthyosis vulgaris",N.CC(O)C(O)=O,Launched
BRD-M80207679-001-01-5::0.00061034::HTS002,BRD-M80207679-001-01-5,0.00061034,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::0.0024414::HTS002,BRD-M80207679-001-01-5,0.0024414,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::0.00976562::HTS002,BRD-M80207679-001-01-5,0.00976562,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::0.0390625::HTS002,BRD-M80207679-001-01-5,0.0390625,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::0.15625::HTS002,BRD-M80207679-001-01-5,0.15625,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::0.625::HTS002,BRD-M80207679-001-01-5,0.625,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::2.5::HTS002,BRD-M80207679-001-01-5,2.5,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M80207679-001-01-5::10::HTS002,BRD-M80207679-001-01-5,10.0,HTS002,PREP029,nemonapride,dopamine receptor antagonist,"DRD2, DRD3, DRD4",neurology/psychiatry,schizophrenia,"CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C, CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C",Launched
BRD-M89827113-001-01-5::0.00061034::HTS002,BRD-M89827113-001-01-5,0.00061034,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::0.0024414::HTS002,BRD-M89827113-001-01-5,0.0024414,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::0.00976562::HTS002,BRD-M89827113-001-01-5,0.00976562,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::0.0390625::HTS002,BRD-M89827113-001-01-5,0.0390625,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::0.15625::HTS002,BRD-M89827113-001-01-5,0.15625,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::0.625::HTS002,BRD-M89827113-001-01-5,0.625,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::2.5::HTS002,BRD-M89827113-001-01-5,2.5,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M89827113-001-01-5::10::HTS002,BRD-M89827113-001-01-5,10.0,HTS002,PREP025,cromakalim,NA,KCNJ8,NA,NA,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N,Phase 2
BRD-M97302542-001-03-6::0.00061034::HTS002,BRD-M97302542-001-03-6,0.00061034,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::0.0024414::HTS002,BRD-M97302542-001-03-6,0.0024414,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::0.00976562::HTS002,BRD-M97302542-001-03-6,0.00976562,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::0.0390625::HTS002,BRD-M97302542-001-03-6,0.0390625,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::0.15625::HTS002,BRD-M97302542-001-03-6,0.15625,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::0.625::HTS002,BRD-M97302542-001-03-6,0.625,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::2.5::HTS002,BRD-M97302542-001-03-6,2.5,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-M97302542-001-03-6::10::HTS002,BRD-M97302542-001-03-6,10.0,HTS002,PREP048,dichloroacetate,pyruvate dehydrogenase kinase inhibitor,PDK1,NA,NA,"[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",Phase 3
BRD-K13533483-001-16-2::0.000610351874321::MTS005,BRD-K13533483-001-16-2,0.000610351874321,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::0.00244140583424::MTS005,BRD-K13533483-001-16-2,0.00244140583424,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::0.009765625::MTS005,BRD-K13533483-001-16-2,0.009765625,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::0.0390625::MTS005,BRD-K13533483-001-16-2,0.0390625,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::0.15625::MTS005,BRD-K13533483-001-16-2,0.15625,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::0.625::MTS005,BRD-K13533483-001-16-2,0.625,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::2.5::MTS005,BRD-K13533483-001-16-2,2.5,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K13533483-001-16-2::10::MTS005,BRD-K13533483-001-16-2,10.0,MTS005,PMTS005,cyclosporine,calcineurin inhibitor,"ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3","transplant, rheumatology, dermatology","organ rejection, rheumatoid arthritis, psoriasis","CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C",Launched
BRD-K92073408-001-15-7::0.000610351478725::MTS005,BRD-K92073408-001-15-7,0.000610351478725,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::0.0024414045745::MTS005,BRD-K92073408-001-15-7,0.0024414045745,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::0.009765625::MTS005,BRD-K92073408-001-15-7,0.009765625,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::0.0390625::MTS005,BRD-K92073408-001-15-7,0.0390625,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::0.15625::MTS005,BRD-K92073408-001-15-7,0.15625,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::0.625::MTS005,BRD-K92073408-001-15-7,0.625,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::2.5::MTS005,BRD-K92073408-001-15-7,2.5,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-K92073408-001-15-7::10::MTS005,BRD-K92073408-001-15-7,10.0,MTS005,PMTS005,norethindrone,progesterone receptor agonist,PGR,obstetrics/gynecology,endometriosis,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C",Launched
BRD-A06627858-236-03-0::0.00061035::MTS006,BRD-A06627858-236-03-0,0.00061035,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.002441407::MTS006,BRD-A06627858-236-03-0,0.002441407,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.009765624::MTS006,BRD-A06627858-236-03-0,0.009765624,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.0390625::MTS006,BRD-A06627858-236-03-0,0.0390625,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.156249999::MTS006,BRD-A06627858-236-03-0,0.156249999,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::0.624999999::MTS006,BRD-A06627858-236-03-0,0.624999999,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::2.5::MTS006,BRD-A06627858-236-03-0,2.5,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A06627858-236-03-0::10::MTS006,BRD-A06627858-236-03-0,10.0,MTS006,PMTS010,monensin,bacterial permeability inducer,NA,NA,NA,"CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C",Launched
BRD-A25608658-001-01-1::0.000610351::MTS006,BRD-A25608658-001-01-1,0.000610351,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.002441407::MTS006,BRD-A25608658-001-01-1,0.002441407,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.009765626::MTS006,BRD-A25608658-001-01-1,0.009765626,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.039062499::MTS006,BRD-A25608658-001-01-1,0.039062499,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.156250001::MTS006,BRD-A25608658-001-01-1,0.156250001,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::0.625::MTS006,BRD-A25608658-001-01-1,0.625,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::2.5::MTS006,BRD-A25608658-001-01-1,2.5,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A25608658-001-01-1::10::MTS006,BRD-A25608658-001-01-1,10.0,MTS006,PMTS010,narasin,antiprotozoal agent,NA,infectious disease,coccidiosis,CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O,Launched
BRD-A31095847-001-02-3::0.00061035::MTS006,BRD-A31095847-001-02-3,0.00061035,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.002441406::MTS006,BRD-A31095847-001-02-3,0.002441406,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.009765623::MTS006,BRD-A31095847-001-02-3,0.009765623,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.039062502::MTS006,BRD-A31095847-001-02-3,0.039062502,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.15625::MTS006,BRD-A31095847-001-02-3,0.15625,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::0.624999999::MTS006,BRD-A31095847-001-02-3,0.624999999,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::2.5::MTS006,BRD-A31095847-001-02-3,2.5,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A31095847-001-02-3::10::MTS006,BRD-A31095847-001-02-3,10.0,MTS006,PMTS010,mozavaptan,vasopressin receptor antagonist,"AVPR1A, AVPR1B, AVPR2",endocrinology,hyponatremia,CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12,Launched
BRD-A75975749-001-01-4::0.000610351::MTS006,BRD-A75975749-001-01-4,0.000610351,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::0.002441406::MTS006,BRD-A75975749-001-01-4,0.002441406,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::0.009765624::MTS006,BRD-A75975749-001-01-4,0.009765624,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::0.039062501::MTS006,BRD-A75975749-001-01-4,0.039062501,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::0.156249999::MTS006,BRD-A75975749-001-01-4,0.156249999,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::0.624999999::MTS006,BRD-A75975749-001-01-4,0.624999999,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::2.5::MTS006,BRD-A75975749-001-01-4,2.5,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-A75975749-001-01-4::10::MTS006,BRD-A75975749-001-01-4,10.0,MTS006,PMTS008,bafetinib,"Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN",NA,NA,CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1,Phase 2
BRD-K00634421-001-01-0::0.000610352::MTS006,BRD-K00634421-001-01-0,0.000610352,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::0.002441402::MTS006,BRD-K00634421-001-01-0,0.002441402,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::0.009765626::MTS006,BRD-K00634421-001-01-0,0.009765626,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::0.039062503::MTS006,BRD-K00634421-001-01-0,0.039062503,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::0.156250003::MTS006,BRD-K00634421-001-01-0,0.156250003,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::0.625000002::MTS006,BRD-K00634421-001-01-0,0.625000002,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::2.5::MTS006,BRD-K00634421-001-01-0,2.5,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K00634421-001-01-0::10::MTS006,BRD-K00634421-001-01-0,10.0,MTS006,PMTS008,brivaracetam,voltage-gated sodium channel blocker,SV2A,neurology/psychiatry,seizures,"CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1",Launched
BRD-K02900412-001-11-3::0.000610352::MTS006,BRD-K02900412-001-11-3,0.000610352,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.002441406::MTS006,BRD-K02900412-001-11-3,0.002441406,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.009765625::MTS006,BRD-K02900412-001-11-3,0.009765625,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.039062498::MTS006,BRD-K02900412-001-11-3,0.039062498,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.156249999::MTS006,BRD-K02900412-001-11-3,0.156249999,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::0.624999997::MTS006,BRD-K02900412-001-11-3,0.624999997,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::2.5::MTS006,BRD-K02900412-001-11-3,2.5,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K02900412-001-11-3::10::MTS006,BRD-K02900412-001-11-3,10.0,MTS006,PMTS008,clofoctol,protein synthesis inhibitor,NA,infectious disease,gram-positive bacterial infections,"CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1",Launched
BRD-K03765900-001-01-9::0.000610352::MTS006,BRD-K03765900-001-01-9,0.000610352,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.002441405::MTS006,BRD-K03765900-001-01-9,0.002441405,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.009765626::MTS006,BRD-K03765900-001-01-9,0.009765626,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.039062499::MTS006,BRD-K03765900-001-01-9,0.039062499,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.156249999::MTS006,BRD-K03765900-001-01-9,0.156249999,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::0.624999998::MTS006,BRD-K03765900-001-01-9,0.624999998,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::2.5::MTS006,BRD-K03765900-001-01-9,2.5,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K03765900-001-01-9::10::MTS006,BRD-K03765900-001-01-9,10.0,MTS006,PMTS011,XL-647,"EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR",NA,NA,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1,Phase 3
BRD-K04701033-001-03-9::0.000610352::MTS006,BRD-K04701033-001-03-9,0.000610352,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::0.002441405::MTS006,BRD-K04701033-001-03-9,0.002441405,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::0.009765627::MTS006,BRD-K04701033-001-03-9,0.009765627,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::0.0390625::MTS006,BRD-K04701033-001-03-9,0.0390625,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::0.15625::MTS006,BRD-K04701033-001-03-9,0.15625,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::0.625::MTS006,BRD-K04701033-001-03-9,0.625,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::2.5::MTS006,BRD-K04701033-001-03-9,2.5,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K04701033-001-03-9::10::MTS006,BRD-K04701033-001-03-9,10.0,MTS006,PMTS011,VE-822,ATR kinase inhibitor,"ATM, ATR, MTOR, PIK3CG",NA,NA,"CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",Phase 2
BRD-K11851476-003-01-7::0.000610351::MTS006,BRD-K11851476-003-01-7,0.000610351,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::0.002441409::MTS006,BRD-K11851476-003-01-7,0.002441409,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::0.009765622::MTS006,BRD-K11851476-003-01-7,0.009765622,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::0.039062497::MTS006,BRD-K11851476-003-01-7,0.039062497,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::0.156250001::MTS006,BRD-K11851476-003-01-7,0.156250001,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::0.624999996::MTS006,BRD-K11851476-003-01-7,0.624999996,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::2.5::MTS006,BRD-K11851476-003-01-7,2.5,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K11851476-003-01-7::10::MTS006,BRD-K11851476-003-01-7,10.0,MTS006,PMTS011,pardoprunox,"serotonin receptor agonist, dopamine receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7",NA,NA,CN1CCN(CC1)c1cccc2[nH]c(=O)oc12,Phase 3
BRD-K13060017-001-01-3::0.000610351::MTS006,BRD-K13060017-001-01-3,0.000610351,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::0.002441407::MTS006,BRD-K13060017-001-01-3,0.002441407,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::0.009765625::MTS006,BRD-K13060017-001-01-3,0.009765625,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::0.039062501::MTS006,BRD-K13060017-001-01-3,0.039062501,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::0.15625::MTS006,BRD-K13060017-001-01-3,0.15625,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::0.625000001::MTS006,BRD-K13060017-001-01-3,0.625000001,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::2.5::MTS006,BRD-K13060017-001-01-3,2.5,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K13060017-001-01-3::10::MTS006,BRD-K13060017-001-01-3,10.0,MTS006,PMTS011,UNC0631,histone lysine methyltransferase inhibitor,EHMT2,NA,NA,"COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",Preclinical
BRD-K16180792-001-01-7::0.000610352::MTS006,BRD-K16180792-001-01-7,0.000610352,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::0.002441406::MTS006,BRD-K16180792-001-01-7,0.002441406,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::0.009765625::MTS006,BRD-K16180792-001-01-7,0.009765625,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::0.039062499::MTS006,BRD-K16180792-001-01-7,0.039062499,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::0.15625::MTS006,BRD-K16180792-001-01-7,0.15625,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::0.625000002::MTS006,BRD-K16180792-001-01-7,0.625000002,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::2.5::MTS006,BRD-K16180792-001-01-7,2.5,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16180792-001-01-7::10::MTS006,BRD-K16180792-001-01-7,10.0,MTS006,PMTS008,bis(maltolato)oxovanadium(IV),tyrosine phosphatase inhibitor,PTPN1,NA,NA,Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O,Phase 2
BRD-K16505263-003-02-9::0.000610352::MTS006,BRD-K16505263-003-02-9,0.000610352,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::0.002441407::MTS006,BRD-K16505263-003-02-9,0.002441407,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::0.009765627::MTS006,BRD-K16505263-003-02-9,0.009765627,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::0.039062501::MTS006,BRD-K16505263-003-02-9,0.039062501,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::0.156249998::MTS006,BRD-K16505263-003-02-9,0.156249998,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::0.625::MTS006,BRD-K16505263-003-02-9,0.625,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::2.5::MTS006,BRD-K16505263-003-02-9,2.5,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K16505263-003-02-9::10::MTS006,BRD-K16505263-003-02-9,10.0,MTS006,PMTS008,forodesine,purinergic receptor antagonist,PNP,NA,NA,"OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O",Phase 2
BRD-K17472821-001-01-2::0.000610351::MTS006,BRD-K17472821-001-01-2,0.000610351,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::0.002441408::MTS006,BRD-K17472821-001-01-2,0.002441408,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::0.009765624::MTS006,BRD-K17472821-001-01-2,0.009765624,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::0.039062501::MTS006,BRD-K17472821-001-01-2,0.039062501,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::0.156249998::MTS006,BRD-K17472821-001-01-2,0.156249998,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::0.625::MTS006,BRD-K17472821-001-01-2,0.625,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::2.5::MTS006,BRD-K17472821-001-01-2,2.5,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17472821-001-01-2::10::MTS006,BRD-K17472821-001-01-2,10.0,MTS006,PMTS010,GSK2830371,protein phosphatase inhibitor,PPM1D,NA,NA,"Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",Preclinical
BRD-K17610631-001-03-3::0.000610352::MTS006,BRD-K17610631-001-03-3,0.000610352,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.002441404::MTS006,BRD-K17610631-001-03-3,0.002441404,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.009765627::MTS006,BRD-K17610631-001-03-3,0.009765627,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.039062502::MTS006,BRD-K17610631-001-03-3,0.039062502,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.156250001::MTS006,BRD-K17610631-001-03-3,0.156250001,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::0.625::MTS006,BRD-K17610631-001-03-3,0.625,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::2.5::MTS006,BRD-K17610631-001-03-3,2.5,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K17610631-001-03-3::10::MTS006,BRD-K17610631-001-03-3,10.0,MTS006,PMTS010,indisulam,CDK inhibitor,"CA1, CA12, CA14, CA2, CA6, CA7, CA9",NA,NA,NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12,Phase 2
BRD-K18898553-001-01-1::0.000610353::MTS006,BRD-K18898553-001-01-1,0.000610353,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::0.002441406::MTS006,BRD-K18898553-001-01-1,0.002441406,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::0.009765624::MTS006,BRD-K18898553-001-01-1,0.009765624,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::0.039062501::MTS006,BRD-K18898553-001-01-1,0.039062501,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::0.15625::MTS006,BRD-K18898553-001-01-1,0.15625,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::0.624999999::MTS006,BRD-K18898553-001-01-1,0.624999999,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::2.5::MTS006,BRD-K18898553-001-01-1,2.5,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K18898553-001-01-1::10::MTS006,BRD-K18898553-001-01-1,10.0,MTS006,PMTS011,salvianolic-acid-B,"metalloproteinase inhibitor, EGFR inhibitor",MMP9,NA,NA,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1,Phase 2
BRD-K20463415-300-01-4::0.000610352::MTS006,BRD-K20463415-300-01-4,0.000610352,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::0.002441408::MTS006,BRD-K20463415-300-01-4,0.002441408,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::0.009765623::MTS006,BRD-K20463415-300-01-4,0.009765623,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::0.039062501::MTS006,BRD-K20463415-300-01-4,0.039062501,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::0.156250001::MTS006,BRD-K20463415-300-01-4,0.156250001,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::0.624999998::MTS006,BRD-K20463415-300-01-4,0.624999998,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::2.5::MTS006,BRD-K20463415-300-01-4,2.5,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20463415-300-01-4::10::MTS006,BRD-K20463415-300-01-4,10.0,MTS006,PMTS010,LY2606368,CHK inhibitor,CHEK1,NA,NA,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1",Phase 2
BRD-K20468903-001-01-6::0.000610352::MTS006,BRD-K20468903-001-01-6,0.000610352,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::0.002441409::MTS006,BRD-K20468903-001-01-6,0.002441409,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::0.009765625::MTS006,BRD-K20468903-001-01-6,0.009765625,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::0.039062499::MTS006,BRD-K20468903-001-01-6,0.039062499,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::0.156250001::MTS006,BRD-K20468903-001-01-6,0.156250001,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::0.625000003::MTS006,BRD-K20468903-001-01-6,0.625000003,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::2.5::MTS006,BRD-K20468903-001-01-6,2.5,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K20468903-001-01-6::10::MTS006,BRD-K20468903-001-01-6,10.0,MTS006,PMTS008,BNC105,tubulin polymerization inhibitor,NA,NA,NA,"COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",Phase 2
BRD-K21152241-001-07-3::0.000610352::MTS006,BRD-K21152241-001-07-3,0.000610352,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::0.002441408::MTS006,BRD-K21152241-001-07-3,0.002441408,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::0.009765623::MTS006,BRD-K21152241-001-07-3,0.009765623,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::0.039062501::MTS006,BRD-K21152241-001-07-3,0.039062501,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::0.156250003::MTS006,BRD-K21152241-001-07-3,0.156250003,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::0.624999996::MTS006,BRD-K21152241-001-07-3,0.624999996,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::2.5::MTS006,BRD-K21152241-001-07-3,2.5,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21152241-001-07-3::10::MTS006,BRD-K21152241-001-07-3,10.0,MTS006,PMTS008,enoximone,phosphodiesterase inhibitor,PDE3A,cardiology,congestive heart failure,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,Launched
BRD-K21361524-001-01-1::0.000152588::MTS006,BRD-K21361524-001-01-1,0.000152588,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.00061035::MTS006,BRD-K21361524-001-01-1,0.00061035,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.002441406::MTS006,BRD-K21361524-001-01-1,0.002441406,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.009765625::MTS006,BRD-K21361524-001-01-1,0.009765625,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.039062499::MTS006,BRD-K21361524-001-01-1,0.039062499,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.156249999::MTS006,BRD-K21361524-001-01-1,0.156249999,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::0.625::MTS006,BRD-K21361524-001-01-1,0.625,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K21361524-001-01-1::2.5::MTS006,BRD-K21361524-001-01-1,2.5,MTS006,PMTS010,selinexor,exportin antagonist,XPO1,NA,NA,FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1,Phase 2/Phase 3
BRD-K22064724-001-01-8::0.000610351::MTS006,BRD-K22064724-001-01-8,0.000610351,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.002441405::MTS006,BRD-K22064724-001-01-8,0.002441405,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.009765627::MTS006,BRD-K22064724-001-01-8,0.009765627,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.039062499::MTS006,BRD-K22064724-001-01-8,0.039062499,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.156250004::MTS006,BRD-K22064724-001-01-8,0.156250004,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::0.624999998::MTS006,BRD-K22064724-001-01-8,0.624999998,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::2.5::MTS006,BRD-K22064724-001-01-8,2.5,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22064724-001-01-8::10::MTS006,BRD-K22064724-001-01-8,10.0,MTS006,PMTS010,napabucasin,STAT inhibitor,STAT3,NA,NA,"CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",Phase 3
BRD-K22588750-001-07-0::0.000610354::MTS006,BRD-K22588750-001-07-0,0.000610354,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::0.002441406::MTS006,BRD-K22588750-001-07-0,0.002441406,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::0.009765623::MTS006,BRD-K22588750-001-07-0,0.009765623,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::0.039062498::MTS006,BRD-K22588750-001-07-0,0.039062498,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::0.156250001::MTS006,BRD-K22588750-001-07-0,0.156250001,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::0.624999997::MTS006,BRD-K22588750-001-07-0,0.624999997,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::2.5::MTS006,BRD-K22588750-001-07-0,2.5,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K22588750-001-07-0::10::MTS006,BRD-K22588750-001-07-0,10.0,MTS006,PMTS008,gidazepam,GABA benzodiazepine site receptor agonist,NA,NA,NA,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,Launched
BRD-K25412176-001-01-9::0.000610353::MTS006,BRD-K25412176-001-01-9,0.000610353,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.002441408::MTS006,BRD-K25412176-001-01-9,0.002441408,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.009765625::MTS006,BRD-K25412176-001-01-9,0.009765625,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.039062498::MTS006,BRD-K25412176-001-01-9,0.039062498,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.156249998::MTS006,BRD-K25412176-001-01-9,0.156249998,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::0.624999998::MTS006,BRD-K25412176-001-01-9,0.624999998,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::2.5::MTS006,BRD-K25412176-001-01-9,2.5,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K25412176-001-01-9::10::MTS006,BRD-K25412176-001-01-9,10.0,MTS006,PMTS010,GSK2110183,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1,Phase 2
BRD-K26026438-001-01-0::0.00061035::MTS006,BRD-K26026438-001-01-0,0.00061035,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.002441407::MTS006,BRD-K26026438-001-01-0,0.002441407,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.009765625::MTS006,BRD-K26026438-001-01-0,0.009765625,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.039062501::MTS006,BRD-K26026438-001-01-0,0.039062501,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.156250001::MTS006,BRD-K26026438-001-01-0,0.156250001,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::0.625::MTS006,BRD-K26026438-001-01-0,0.625,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::2.5::MTS006,BRD-K26026438-001-01-0,2.5,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26026438-001-01-0::10::MTS006,BRD-K26026438-001-01-0,10.0,MTS006,PMTS011,tucatinib,EGFR inhibitor,ERBB2,NA,NA,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,Phase 2
BRD-K26530649-001-01-6::0.000610352::MTS006,BRD-K26530649-001-01-6,0.000610352,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::0.002441406::MTS006,BRD-K26530649-001-01-6,0.002441406,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::0.009765624::MTS006,BRD-K26530649-001-01-6,0.009765624,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::0.039062501::MTS006,BRD-K26530649-001-01-6,0.039062501,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::0.156250002::MTS006,BRD-K26530649-001-01-6,0.156250002,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::0.625000003::MTS006,BRD-K26530649-001-01-6,0.625000003,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::2.5::MTS006,BRD-K26530649-001-01-6,2.5,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K26530649-001-01-6::10::MTS006,BRD-K26530649-001-01-6,10.0,MTS006,PMTS008,carboxypyridine-disulfide,NA,NA,NA,NA,OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1,Phase 2
BRD-K28061410-001-06-6::0.000610352::MTS006,BRD-K28061410-001-06-6,0.000610352,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::0.002441409::MTS006,BRD-K28061410-001-06-6,0.002441409,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::0.009765621::MTS006,BRD-K28061410-001-06-6,0.009765621,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::0.0390625::MTS006,BRD-K28061410-001-06-6,0.0390625,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::0.156250001::MTS006,BRD-K28061410-001-06-6,0.156250001,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::0.625000002::MTS006,BRD-K28061410-001-06-6,0.625000002,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::2.5::MTS006,BRD-K28061410-001-06-6,2.5,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28061410-001-06-6::10::MTS006,BRD-K28061410-001-06-6,10.0,MTS006,PMTS008,beta-lapachone,topoisomerase inhibitor,TOP1,NA,NA,"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O",Phase 2
BRD-K28537285-001-01-8::0.000610353::MTS006,BRD-K28537285-001-01-8,0.000610353,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::0.002441406::MTS006,BRD-K28537285-001-01-8,0.002441406,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::0.009765623::MTS006,BRD-K28537285-001-01-8,0.009765623,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::0.039062499::MTS006,BRD-K28537285-001-01-8,0.039062499,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::0.156250002::MTS006,BRD-K28537285-001-01-8,0.156250002,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::0.625000001::MTS006,BRD-K28537285-001-01-8,0.625000001,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::2.5::MTS006,BRD-K28537285-001-01-8,2.5,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K28537285-001-01-8::10::MTS006,BRD-K28537285-001-01-8,10.0,MTS006,PMTS008,chidamide,HDAC inhibitor,"HDAC10, HDAC3",NA,NA,Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1,Launched
BRD-K32744045-001-31-2::0.000610351::MTS006,BRD-K32744045-001-31-2,0.000610351,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.002441406::MTS006,BRD-K32744045-001-31-2,0.002441406,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.009765623::MTS006,BRD-K32744045-001-31-2,0.009765623,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.039062498::MTS006,BRD-K32744045-001-31-2,0.039062498,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.156249997::MTS006,BRD-K32744045-001-31-2,0.156249997,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::0.624999997::MTS006,BRD-K32744045-001-31-2,0.624999997,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::2.5::MTS006,BRD-K32744045-001-31-2,2.5,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K32744045-001-31-2::10::MTS006,BRD-K32744045-001-31-2,10.0,MTS006,PMTS008,disulfiram,"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","ALDH2, DBH",neurology/psychiatry,abstinence from alcohol,"CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC",Launched
BRD-K33127281-001-05-6::0.000610351::MTS006,BRD-K33127281-001-05-6,0.000610351,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.002441408::MTS006,BRD-K33127281-001-05-6,0.002441408,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.009765624::MTS006,BRD-K33127281-001-05-6,0.009765624,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.039062499::MTS006,BRD-K33127281-001-05-6,0.039062499,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.156250001::MTS006,BRD-K33127281-001-05-6,0.156250001,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::0.624999999::MTS006,BRD-K33127281-001-05-6,0.624999999,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::2.5::MTS006,BRD-K33127281-001-05-6,2.5,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K33127281-001-05-6::10::MTS006,BRD-K33127281-001-05-6,10.0,MTS006,PMTS008,adapalene,retinoid receptor agonist,"RARA, RARB, RARG, RXRA, RXRB, RXRG",dermatology,acne vulgaris (AV),"COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O",Launched
BRD-K34251960-036-01-6::0.000610351::MTS006,BRD-K34251960-036-01-6,0.000610351,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::0.002441408::MTS006,BRD-K34251960-036-01-6,0.002441408,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::0.009765627::MTS006,BRD-K34251960-036-01-6,0.009765627,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::0.039062499::MTS006,BRD-K34251960-036-01-6,0.039062499,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::0.156250002::MTS006,BRD-K34251960-036-01-6,0.156250002,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::0.625000003::MTS006,BRD-K34251960-036-01-6,0.625000003,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::2.5::MTS006,BRD-K34251960-036-01-6,2.5,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34251960-036-01-6::10::MTS006,BRD-K34251960-036-01-6,10.0,MTS006,PMTS008,cibenzoline,sodium channel blocker,NA,NA,NA,C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1,Launched
BRD-K34332569-001-01-3::0.000610352::MTS006,BRD-K34332569-001-01-3,0.000610352,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.002441407::MTS006,BRD-K34332569-001-01-3,0.002441407,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.009765623::MTS006,BRD-K34332569-001-01-3,0.009765623,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.039062501::MTS006,BRD-K34332569-001-01-3,0.039062501,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.156250001::MTS006,BRD-K34332569-001-01-3,0.156250001,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::0.624999999::MTS006,BRD-K34332569-001-01-3,0.624999999,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::2.5::MTS006,BRD-K34332569-001-01-3,2.5,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K34332569-001-01-3::10::MTS006,BRD-K34332569-001-01-3,10.0,MTS006,PMTS010,imidapril,angiotensin converting enzyme inhibitor,ACE,cardiology,"hypertension, congestive heart failure",CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O,Launched
BRD-K37618799-001-03-0::0.00061035::MTS006,BRD-K37618799-001-03-0,0.00061035,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.002441408::MTS006,BRD-K37618799-001-03-0,0.002441408,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.009765624::MTS006,BRD-K37618799-001-03-0,0.009765624,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.0390625::MTS006,BRD-K37618799-001-03-0,0.0390625,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.156250002::MTS006,BRD-K37618799-001-03-0,0.156250002,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::0.625000002::MTS006,BRD-K37618799-001-03-0,0.625000002,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::2.5::MTS006,BRD-K37618799-001-03-0,2.5,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K37618799-001-03-0::10::MTS006,BRD-K37618799-001-03-0,10.0,MTS006,PMTS010,MRS-1220,adenosine receptor antagonist,"ADORA2B, ADORA3",NA,NA,"Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",Preclinical
BRD-K38527262-300-01-0::0.000610354::MTS006,BRD-K38527262-300-01-0,0.000610354,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.002441405::MTS006,BRD-K38527262-300-01-0,0.002441405,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.009765623::MTS006,BRD-K38527262-300-01-0,0.009765623,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.039062498::MTS006,BRD-K38527262-300-01-0,0.039062498,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.15625::MTS006,BRD-K38527262-300-01-0,0.15625,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::0.625::MTS006,BRD-K38527262-300-01-0,0.625,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::2.5::MTS006,BRD-K38527262-300-01-0,2.5,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K38527262-300-01-0::10::MTS006,BRD-K38527262-300-01-0,10.0,MTS006,PMTS008,atiprimod,"JAK inhibitor, STAT inhibitor","JAK2, STAT3",NA,NA,CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1,Phase 2
BRD-K41783120-001-02-8::0.000610349::MTS006,BRD-K41783120-001-02-8,0.000610349,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.002441407::MTS006,BRD-K41783120-001-02-8,0.002441407,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.009765627::MTS006,BRD-K41783120-001-02-8,0.009765627,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.039062499::MTS006,BRD-K41783120-001-02-8,0.039062499,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.156249998::MTS006,BRD-K41783120-001-02-8,0.156249998,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::0.625000001::MTS006,BRD-K41783120-001-02-8,0.625000001,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::2.5::MTS006,BRD-K41783120-001-02-8,2.5,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K41783120-001-02-8::10::MTS006,BRD-K41783120-001-02-8,10.0,MTS006,PMTS011,STA-5326,interleukin synthesis inhibitor,IL12A,NA,NA,Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,Phase 2
BRD-K42673188-001-01-1::0.000610352::MTS006,BRD-K42673188-001-01-1,0.000610352,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::0.002441408::MTS006,BRD-K42673188-001-01-1,0.002441408,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::0.009765623::MTS006,BRD-K42673188-001-01-1,0.009765623,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::0.0390625::MTS006,BRD-K42673188-001-01-1,0.0390625,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::0.156249998::MTS006,BRD-K42673188-001-01-1,0.156249998,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::0.625::MTS006,BRD-K42673188-001-01-1,0.625,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::2.5::MTS006,BRD-K42673188-001-01-1,2.5,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K42673188-001-01-1::10::MTS006,BRD-K42673188-001-01-1,10.0,MTS006,PMTS011,verubulin,tubulin polymerization inhibitor,TUBB,NA,NA,"COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",Phase 2
BRD-K46862739-001-14-3::0.000610352::MTS006,BRD-K46862739-001-14-3,0.000610352,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::0.002441405::MTS006,BRD-K46862739-001-14-3,0.002441405,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::0.009765629::MTS006,BRD-K46862739-001-14-3,0.009765629,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::0.039062499::MTS006,BRD-K46862739-001-14-3,0.039062499,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::0.156250003::MTS006,BRD-K46862739-001-14-3,0.156250003,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::0.624999996::MTS006,BRD-K46862739-001-14-3,0.624999996,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::2.5::MTS006,BRD-K46862739-001-14-3,2.5,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K46862739-001-14-3::10::MTS006,BRD-K46862739-001-14-3,10.0,MTS006,PMTS010,metyrapone,cytochrome P450 inhibitor,CYP11B1,nephrology,adrenal diagnostic agent,"CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1",Launched
BRD-K49049886-001-08-7::0.000610352::MTS006,BRD-K49049886-001-08-7,0.000610352,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.002441403::MTS006,BRD-K49049886-001-08-7,0.002441403,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.009765626::MTS006,BRD-K49049886-001-08-7,0.009765626,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.039062498::MTS006,BRD-K49049886-001-08-7,0.039062498,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.156249999::MTS006,BRD-K49049886-001-08-7,0.156249999,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::0.625000004::MTS006,BRD-K49049886-001-08-7,0.625000004,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::2.5::MTS006,BRD-K49049886-001-08-7,2.5,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K49049886-001-08-7::10::MTS006,BRD-K49049886-001-08-7,10.0,MTS006,PMTS008,CGS-15943,adenosine receptor antagonist,"ADORA1, ADORA2A, ADORA2B, ADORA3",NA,NA,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,Preclinical
BRD-K50010139-001-02-3::0.000610353::MTS006,BRD-K50010139-001-02-3,0.000610353,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::0.002441407::MTS006,BRD-K50010139-001-02-3,0.002441407,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::0.009765626::MTS006,BRD-K50010139-001-02-3,0.009765626,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::0.039062498::MTS006,BRD-K50010139-001-02-3,0.039062498,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::0.156250001::MTS006,BRD-K50010139-001-02-3,0.156250001,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::0.625::MTS006,BRD-K50010139-001-02-3,0.625,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::2.5::MTS006,BRD-K50010139-001-02-3,2.5,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50010139-001-02-3::10::MTS006,BRD-K50010139-001-02-3,10.0,MTS006,PMTS011,poziotinib,EGFR inhibitor,"EGFR, ERBB2, ERBB4",NA,NA,"COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",Phase 2
BRD-K50677762-001-01-5::0.000610351::MTS006,BRD-K50677762-001-01-5,0.000610351,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.002441412::MTS006,BRD-K50677762-001-01-5,0.002441412,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.009765623::MTS006,BRD-K50677762-001-01-5,0.009765623,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.039062503::MTS006,BRD-K50677762-001-01-5,0.039062503,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.15625::MTS006,BRD-K50677762-001-01-5,0.15625,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::0.625::MTS006,BRD-K50677762-001-01-5,0.625,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::2.5::MTS006,BRD-K50677762-001-01-5,2.5,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K50677762-001-01-5::10::MTS006,BRD-K50677762-001-01-5,10.0,MTS006,PMTS010,oxiracetam,acetylcholine receptor agonist,NA,NA,NA,NC(=O)CN1C[C@H](O)CC1=O,Launched
BRD-K54955827-001-02-2::0.000610351::MTS006,BRD-K54955827-001-02-2,0.000610351,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.002441406::MTS006,BRD-K54955827-001-02-2,0.002441406,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.009765625::MTS006,BRD-K54955827-001-02-2,0.009765625,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.0390625::MTS006,BRD-K54955827-001-02-2,0.0390625,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.15625::MTS006,BRD-K54955827-001-02-2,0.15625,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::0.625000002::MTS006,BRD-K54955827-001-02-2,0.625000002,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::2.5::MTS006,BRD-K54955827-001-02-2,2.5,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K54955827-001-02-2::10::MTS006,BRD-K54955827-001-02-2,10.0,MTS006,PMTS010,niraparib,PARP inhibitor,PARP1,oncology,primary peritoneal cancer (PPC),"NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1",Launched
BRD-K55696337-003-24-4::0.000610351::MTS006,BRD-K55696337-003-24-4,0.000610351,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::0.002441408::MTS006,BRD-K55696337-003-24-4,0.002441408,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::0.009765625::MTS006,BRD-K55696337-003-24-4,0.009765625,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::0.0390625::MTS006,BRD-K55696337-003-24-4,0.0390625,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::0.156249998::MTS006,BRD-K55696337-003-24-4,0.156249998,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::0.624999998::MTS006,BRD-K55696337-003-24-4,0.624999998,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::2.5::MTS006,BRD-K55696337-003-24-4,2.5,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K55696337-003-24-4::10::MTS006,BRD-K55696337-003-24-4,10.0,MTS006,PMTS011,topotecan,topoisomerase inhibitor,"TOP1, TOP1MT",oncology,"small cell lung cancer, cervical cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O",Launched
BRD-K56981171-001-01-0::0.000610352::MTS006,BRD-K56981171-001-01-0,0.000610352,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::0.002441406::MTS006,BRD-K56981171-001-01-0,0.002441406,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::0.009765626::MTS006,BRD-K56981171-001-01-0,0.009765626,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::0.0390625::MTS006,BRD-K56981171-001-01-0,0.0390625,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::0.156249998::MTS006,BRD-K56981171-001-01-0,0.156249998,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::0.625::MTS006,BRD-K56981171-001-01-0,0.625,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::2.5::MTS006,BRD-K56981171-001-01-0,2.5,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K56981171-001-01-0::10::MTS006,BRD-K56981171-001-01-0,10.0,MTS006,PMTS008,brigatinib,"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","ALK, EGFR",oncology,non-small cell lung cancer (NSCLC),"COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1",Launched
BRD-K58529924-001-01-5::0.000610351::MTS006,BRD-K58529924-001-01-5,0.000610351,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.002441407::MTS006,BRD-K58529924-001-01-5,0.002441407,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.009765624::MTS006,BRD-K58529924-001-01-5,0.009765624,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.0390625::MTS006,BRD-K58529924-001-01-5,0.0390625,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.156249998::MTS006,BRD-K58529924-001-01-5,0.156249998,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::0.624999997::MTS006,BRD-K58529924-001-01-5,0.624999997,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::2.5::MTS006,BRD-K58529924-001-01-5,2.5,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K58529924-001-01-5::10::MTS006,BRD-K58529924-001-01-5,10.0,MTS006,PMTS010,ONC201,"AKT inhibitor, MAP kinase inhibitor",TNFSF10,NA,NA,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,Phase 2
BRD-K59753975-001-02-6::0.000610352::MTS006,BRD-K59753975-001-02-6,0.000610352,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::0.002441406::MTS006,BRD-K59753975-001-02-6,0.002441406,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::0.009765626::MTS006,BRD-K59753975-001-02-6,0.009765626,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::0.0390625::MTS006,BRD-K59753975-001-02-6,0.0390625,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::0.156250001::MTS006,BRD-K59753975-001-02-6,0.156250001,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::0.624999999::MTS006,BRD-K59753975-001-02-6,0.624999999,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::2.5::MTS006,BRD-K59753975-001-02-6,2.5,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59753975-001-02-6::10::MTS006,BRD-K59753975-001-02-6,10.0,MTS006,PMTS011,vindesine,tubulin polymerization inhibitor,"TUBB, TUBB1",oncology,"breast cancer, non-small cell lung cancer (NSCLC), melanoma",CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O,Launched
BRD-K59866480-001-07-3::0.000610354::MTS006,BRD-K59866480-001-07-3,0.000610354,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::0.002441405::MTS006,BRD-K59866480-001-07-3,0.002441405,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::0.009765624::MTS006,BRD-K59866480-001-07-3,0.009765624,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::0.039062502::MTS006,BRD-K59866480-001-07-3,0.039062502,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::0.156250002::MTS006,BRD-K59866480-001-07-3,0.156250002,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::0.625000001::MTS006,BRD-K59866480-001-07-3,0.625000001,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::2.5::MTS006,BRD-K59866480-001-07-3,2.5,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K59866480-001-07-3::10::MTS006,BRD-K59866480-001-07-3,10.0,MTS006,PMTS008,cyclovalone,breast cancer resistance protein inhibitor,ABCG2,gastroenterology,bile stimulation,"COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1",Launched
BRD-K62374002-001-01-5::0.000610353::MTS006,BRD-K62374002-001-01-5,0.000610353,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::0.002441407::MTS006,BRD-K62374002-001-01-5,0.002441407,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::0.009765624::MTS006,BRD-K62374002-001-01-5,0.009765624,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::0.039062501::MTS006,BRD-K62374002-001-01-5,0.039062501,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::0.156249998::MTS006,BRD-K62374002-001-01-5,0.156249998,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::0.625::MTS006,BRD-K62374002-001-01-5,0.625,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::2.5::MTS006,BRD-K62374002-001-01-5,2.5,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K62374002-001-01-5::10::MTS006,BRD-K62374002-001-01-5,10.0,MTS006,PMTS011,PI3K-IN-2,PI3K inhibitor,NA,NA,NA,Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F,Phase 2
BRD-K64120610-001-01-4::0.000610352::MTS006,BRD-K64120610-001-01-4,0.000610352,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::0.002441406::MTS006,BRD-K64120610-001-01-4,0.002441406,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::0.009765626::MTS006,BRD-K64120610-001-01-4,0.009765626,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::0.039062499::MTS006,BRD-K64120610-001-01-4,0.039062499,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::0.15625::MTS006,BRD-K64120610-001-01-4,0.15625,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::0.625000001::MTS006,BRD-K64120610-001-01-4,0.625000001,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::2.5::MTS006,BRD-K64120610-001-01-4,2.5,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K64120610-001-01-4::10::MTS006,BRD-K64120610-001-01-4,10.0,MTS006,PMTS011,vinflunine,microtubule inhibitor,NA,oncology,bladder cancer,"CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC",Launched
BRD-K66808046-065-03-7::0.000610351::MTS006,BRD-K66808046-065-03-7,0.000610351,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.002441407::MTS006,BRD-K66808046-065-03-7,0.002441407,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.009765627::MTS006,BRD-K66808046-065-03-7,0.009765627,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.039062499::MTS006,BRD-K66808046-065-03-7,0.039062499,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.156249996::MTS006,BRD-K66808046-065-03-7,0.156249996,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::0.625::MTS006,BRD-K66808046-065-03-7,0.625,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::2.5::MTS006,BRD-K66808046-065-03-7,2.5,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K66808046-065-03-7::10::MTS006,BRD-K66808046-065-03-7,10.0,MTS006,PMTS011,oxyquinoline,chelating agent,METAP2,dermatology,cosmetic,Oc1cccc2cccnc12,Launched
BRD-K68065987-300-09-1::0.000610351::MTS006,BRD-K68065987-300-09-1,0.000610351,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.002441405::MTS006,BRD-K68065987-300-09-1,0.002441405,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.009765623::MTS006,BRD-K68065987-300-09-1,0.009765623,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.039062501::MTS006,BRD-K68065987-300-09-1,0.039062501,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.156250002::MTS006,BRD-K68065987-300-09-1,0.156250002,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::0.625000002::MTS006,BRD-K68065987-300-09-1,0.625000002,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::2.5::MTS006,BRD-K68065987-300-09-1,2.5,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68065987-300-09-1::10::MTS006,BRD-K68065987-300-09-1,10.0,MTS006,PMTS010,MK-2206,AKT inhibitor,"AKT1, AKT2, AKT3",NA,NA,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,Phase 2
BRD-K68408772-001-05-4::0.00061035::MTS006,BRD-K68408772-001-05-4,0.00061035,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::0.002441408::MTS006,BRD-K68408772-001-05-4,0.002441408,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::0.009765624::MTS006,BRD-K68408772-001-05-4,0.009765624,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::0.039062501::MTS006,BRD-K68408772-001-05-4,0.039062501,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::0.156250002::MTS006,BRD-K68408772-001-05-4,0.156250002,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::0.625::MTS006,BRD-K68408772-001-05-4,0.625,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::2.5::MTS006,BRD-K68408772-001-05-4,2.5,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K68408772-001-05-4::10::MTS006,BRD-K68408772-001-05-4,10.0,MTS006,PMTS008,carboxyamidotriazole,calcium channel blocker,CXCL8,NA,NA,NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N,Phase 3
BRD-K71480163-001-01-4::0.00061035::MTS006,BRD-K71480163-001-01-4,0.00061035,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.002441406::MTS006,BRD-K71480163-001-01-4,0.002441406,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.009765627::MTS006,BRD-K71480163-001-01-4,0.009765627,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.039062498::MTS006,BRD-K71480163-001-01-4,0.039062498,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.156249998::MTS006,BRD-K71480163-001-01-4,0.156249998,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::0.625::MTS006,BRD-K71480163-001-01-4,0.625,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::2.5::MTS006,BRD-K71480163-001-01-4,2.5,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K71480163-001-01-4::10::MTS006,BRD-K71480163-001-01-4,10.0,MTS006,PMTS008,GDC-0068,AKT inhibitor,"AKT1, AKT2, AKT3, PRKG1",NA,NA,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,Phase 2
BRD-K72280606-001-01-2::0.000610351::MTS006,BRD-K72280606-001-01-2,0.000610351,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::0.002441407::MTS006,BRD-K72280606-001-01-2,0.002441407,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::0.009765626::MTS006,BRD-K72280606-001-01-2,0.009765626,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::0.039062498::MTS006,BRD-K72280606-001-01-2,0.039062498,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::0.15625::MTS006,BRD-K72280606-001-01-2,0.15625,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::0.625000001::MTS006,BRD-K72280606-001-01-2,0.625000001,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::2.5::MTS006,BRD-K72280606-001-01-2,2.5,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72280606-001-01-2::10::MTS006,BRD-K72280606-001-01-2,10.0,MTS006,PMTS010,gilteritinib,FLT3 inhibitor,FLT3,NA,NA,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1,Phase 3
BRD-K72533376-001-01-2::0.000610351::MTS006,BRD-K72533376-001-01-2,0.000610351,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::0.002441407::MTS006,BRD-K72533376-001-01-2,0.002441407,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::0.009765624::MTS006,BRD-K72533376-001-01-2,0.009765624,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::0.039062501::MTS006,BRD-K72533376-001-01-2,0.039062501,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::0.15625::MTS006,BRD-K72533376-001-01-2,0.15625,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::0.624999999::MTS006,BRD-K72533376-001-01-2,0.624999999,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::2.5::MTS006,BRD-K72533376-001-01-2,2.5,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K72533376-001-01-2::10::MTS006,BRD-K72533376-001-01-2,10.0,MTS006,PMTS008,etoposide-phosphate,topoisomerase inhibitor,TOP2A,oncology,"testicular carcinoma, small cell lung cancer",COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,Launched
BRD-K73753850-003-01-6::0.000610352::MTS006,BRD-K73753850-003-01-6,0.000610352,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::0.002441406::MTS006,BRD-K73753850-003-01-6,0.002441406,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::0.009765625::MTS006,BRD-K73753850-003-01-6,0.009765625,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::0.039062499::MTS006,BRD-K73753850-003-01-6,0.039062499,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::0.156250002::MTS006,BRD-K73753850-003-01-6,0.156250002,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::0.625::MTS006,BRD-K73753850-003-01-6,0.625,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::2.5::MTS006,BRD-K73753850-003-01-6,2.5,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K73753850-003-01-6::10::MTS006,BRD-K73753850-003-01-6,10.0,MTS006,PMTS010,hexaminolevulinate,NA,NA,radiology,diagnostic agent,CCCCCCOC(=O)CCC(=O)CN,Launched
BRD-K74671368-001-01-8::0.000610352::MTS006,BRD-K74671368-001-01-8,0.000610352,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::0.002441408::MTS006,BRD-K74671368-001-01-8,0.002441408,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::0.009765623::MTS006,BRD-K74671368-001-01-8,0.009765623,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::0.039062501::MTS006,BRD-K74671368-001-01-8,0.039062501,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::0.156250002::MTS006,BRD-K74671368-001-01-8,0.156250002,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::0.625::MTS006,BRD-K74671368-001-01-8,0.625,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::2.5::MTS006,BRD-K74671368-001-01-8,2.5,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K74671368-001-01-8::10::MTS006,BRD-K74671368-001-01-8,10.0,MTS006,PMTS010,idronoxil,XIAP inhibitor,"ENOX2, SPHK1",NA,NA,Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1,Phase 3
BRD-K76719364-001-02-5::0.00061035::MTS006,BRD-K76719364-001-02-5,0.00061035,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::0.002441404::MTS006,BRD-K76719364-001-02-5,0.002441404,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::0.009765627::MTS006,BRD-K76719364-001-02-5,0.009765627,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::0.039062502::MTS006,BRD-K76719364-001-02-5,0.039062502,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::0.156249999::MTS006,BRD-K76719364-001-02-5,0.156249999,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::0.625000001::MTS006,BRD-K76719364-001-02-5,0.625000001,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::2.5::MTS006,BRD-K76719364-001-02-5,2.5,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K76719364-001-02-5::10::MTS006,BRD-K76719364-001-02-5,10.0,MTS006,PMTS010,GS-9973,syk inhibitor,SYK,NA,NA,"C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1",Phase 2
BRD-K79821389-001-03-5::0.000610353::MTS006,BRD-K79821389-001-03-5,0.000610353,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::0.002441406::MTS006,BRD-K79821389-001-03-5,0.002441406,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::0.009765623::MTS006,BRD-K79821389-001-03-5,0.009765623,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::0.039062498::MTS006,BRD-K79821389-001-03-5,0.039062498,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::0.156250003::MTS006,BRD-K79821389-001-03-5,0.156250003,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::0.625::MTS006,BRD-K79821389-001-03-5,0.625,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::2.5::MTS006,BRD-K79821389-001-03-5,2.5,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K79821389-001-03-5::10::MTS006,BRD-K79821389-001-03-5,10.0,MTS006,PMTS011,rubitecan,topoisomerase inhibitor,TOP1,NA,NA,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,Phase 3
BRD-K81405859-300-01-4::0.00061035::MTS006,BRD-K81405859-300-01-4,0.00061035,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::0.002441406::MTS006,BRD-K81405859-300-01-4,0.002441406,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::0.009765625::MTS006,BRD-K81405859-300-01-4,0.009765625,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::0.0390625::MTS006,BRD-K81405859-300-01-4,0.0390625,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::0.15625::MTS006,BRD-K81405859-300-01-4,0.15625,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::0.625000002::MTS006,BRD-K81405859-300-01-4,0.625000002,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::2.5::MTS006,BRD-K81405859-300-01-4,2.5,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K81405859-300-01-4::10::MTS006,BRD-K81405859-300-01-4,10.0,MTS006,PMTS010,JTE-607,cytokine production inhibitor,"IL10, IL1B, IL6, TNF",NA,NA,"CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",Phase 2
BRD-K82967180-001-01-6::0.000610351::MTS006,BRD-K82967180-001-01-6,0.000610351,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::0.002441405::MTS006,BRD-K82967180-001-01-6,0.002441405,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::0.009765623::MTS006,BRD-K82967180-001-01-6,0.009765623,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::0.039062502::MTS006,BRD-K82967180-001-01-6,0.039062502,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::0.156250002::MTS006,BRD-K82967180-001-01-6,0.156250002,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::0.625000001::MTS006,BRD-K82967180-001-01-6,0.625000001,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::2.5::MTS006,BRD-K82967180-001-01-6,2.5,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K82967180-001-01-6::10::MTS006,BRD-K82967180-001-01-6,10.0,MTS006,PMTS010,LY3023414,"PI3K inhibitor, mTOR inhibitor",MTOR,NA,NA,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,Phase 2
BRD-K83029223-001-01-3::0.000610353::MTS006,BRD-K83029223-001-01-3,0.000610353,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.002441406::MTS006,BRD-K83029223-001-01-3,0.002441406,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.009765625::MTS006,BRD-K83029223-001-01-3,0.009765625,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.039062499::MTS006,BRD-K83029223-001-01-3,0.039062499,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.156250001::MTS006,BRD-K83029223-001-01-3,0.156250001,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::0.625000002::MTS006,BRD-K83029223-001-01-3,0.625000002,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::2.5::MTS006,BRD-K83029223-001-01-3,2.5,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K83029223-001-01-3::10::MTS006,BRD-K83029223-001-01-3,10.0,MTS006,PMTS010,litronesib,kinesin-like spindle protein inhibitor,KIF11,NA,NA,CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1,Phase 2
BRD-K84868168-001-01-0::0.000610353::MTS006,BRD-K84868168-001-01-0,0.000610353,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::0.002441408::MTS006,BRD-K84868168-001-01-0,0.002441408,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::0.009765625::MTS006,BRD-K84868168-001-01-0,0.009765625,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::0.039062499::MTS006,BRD-K84868168-001-01-0,0.039062499,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::0.156250001::MTS006,BRD-K84868168-001-01-0,0.156250001,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::0.625000001::MTS006,BRD-K84868168-001-01-0,0.625000001,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::2.5::MTS006,BRD-K84868168-001-01-0,2.5,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K84868168-001-01-0::10::MTS006,BRD-K84868168-001-01-0,10.0,MTS006,PMTS008,erdafitinib,FGFR inhibitor,"FGFR1, FGFR2, FGFR3, FGFR4",NA,NA,COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1,Phase 2
BRD-K88807631-001-01-3::0.000610351::MTS006,BRD-K88807631-001-01-3,0.000610351,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::0.002441407::MTS006,BRD-K88807631-001-01-3,0.002441407,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::0.009765626::MTS006,BRD-K88807631-001-01-3,0.009765626,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::0.039062499::MTS006,BRD-K88807631-001-01-3,0.039062499,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::0.156250002::MTS006,BRD-K88807631-001-01-3,0.156250002,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::0.624999999::MTS006,BRD-K88807631-001-01-3,0.624999999,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::2.5::MTS006,BRD-K88807631-001-01-3,2.5,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K88807631-001-01-3::10::MTS006,BRD-K88807631-001-01-3,10.0,MTS006,PMTS008,elacridar,P glycoprotein inhibitor,ABCB1,NA,NA,"COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",Phase 1
BRD-K89121095-001-01-7::0.000610351::MTS006,BRD-K89121095-001-01-7,0.000610351,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::0.002441405::MTS006,BRD-K89121095-001-01-7,0.002441405,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::0.009765625::MTS006,BRD-K89121095-001-01-7,0.009765625,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::0.039062502::MTS006,BRD-K89121095-001-01-7,0.039062502,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::0.156249999::MTS006,BRD-K89121095-001-01-7,0.156249999,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::0.624999999::MTS006,BRD-K89121095-001-01-7,0.624999999,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::2.5::MTS006,BRD-K89121095-001-01-7,2.5,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89121095-001-01-7::10::MTS006,BRD-K89121095-001-01-7,10.0,MTS006,PMTS011,tedizolid-phosphate,protein synthesis inhibitor,NA,infectious disease,skin infections,"Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O",Launched
BRD-K89490285-001-08-1::0.000610351::MTS006,BRD-K89490285-001-08-1,0.000610351,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::0.002441409::MTS006,BRD-K89490285-001-08-1,0.002441409,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::0.009765624::MTS006,BRD-K89490285-001-08-1,0.009765624,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::0.039062503::MTS006,BRD-K89490285-001-08-1,0.039062503,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::0.156249997::MTS006,BRD-K89490285-001-08-1,0.156249997,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::0.625000003::MTS006,BRD-K89490285-001-08-1,0.625000003,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::2.5::MTS006,BRD-K89490285-001-08-1,2.5,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89490285-001-08-1::10::MTS006,BRD-K89490285-001-08-1,10.0,MTS006,PMTS008,bentazepam,benzodiazepine receptor agonist,NA,neurology/psychiatry,"anxiety, sedative, muscle relaxant",O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1,Launched
BRD-K89714990-001-01-5::0.00061035::MTS006,BRD-K89714990-001-01-5,0.00061035,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.002441406::MTS006,BRD-K89714990-001-01-5,0.002441406,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.009765625::MTS006,BRD-K89714990-001-01-5,0.009765625,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.039062502::MTS006,BRD-K89714990-001-01-5,0.039062502,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.156249997::MTS006,BRD-K89714990-001-01-5,0.156249997,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::0.625::MTS006,BRD-K89714990-001-01-5,0.625,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::2.5::MTS006,BRD-K89714990-001-01-5,2.5,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K89714990-001-01-5::10::MTS006,BRD-K89714990-001-01-5,10.0,MTS006,PMTS011,tepoxalin,"cyclooxygenase inhibitor, lipoxygenase inhibitor",ALOX5,"rheumatology, orthopedics","rheumatoid arthritis, hip dysplasia","COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1",Launched
BRD-K91543828-001-02-0::0.000610351::MTS006,BRD-K91543828-001-02-0,0.000610351,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::0.002441407::MTS006,BRD-K91543828-001-02-0,0.002441407,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::0.009765627::MTS006,BRD-K91543828-001-02-0,0.009765627,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::0.039062501::MTS006,BRD-K91543828-001-02-0,0.039062501,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::0.156249997::MTS006,BRD-K91543828-001-02-0,0.156249997,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::0.625000002::MTS006,BRD-K91543828-001-02-0,0.625000002,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::2.5::MTS006,BRD-K91543828-001-02-0,2.5,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K91543828-001-02-0::10::MTS006,BRD-K91543828-001-02-0,10.0,MTS006,PMTS011,pentostatin,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",ADA,hematologic malignancy,hairy cell leukemia,"OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12",Launched
BRD-K92241597-001-06-0::0.000610353::MTS006,BRD-K92241597-001-06-0,0.000610353,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.002441404::MTS006,BRD-K92241597-001-06-0,0.002441404,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.009765625::MTS006,BRD-K92241597-001-06-0,0.009765625,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.0390625::MTS006,BRD-K92241597-001-06-0,0.0390625,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.156250002::MTS006,BRD-K92241597-001-06-0,0.156250002,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::0.625000001::MTS006,BRD-K92241597-001-06-0,0.625000001,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::2.5::MTS006,BRD-K92241597-001-06-0,2.5,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K92241597-001-06-0::10::MTS006,BRD-K92241597-001-06-0,10.0,MTS006,PMTS011,tosedostat,peptidase inhibitor,"ANPEP, LAP3, NPEPPS",NA,NA,"CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",Phase 2
BRD-K95142244-001-01-5::0.000610352::MTS006,BRD-K95142244-001-01-5,0.000610352,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.002441409::MTS006,BRD-K95142244-001-01-5,0.002441409,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.009765624::MTS006,BRD-K95142244-001-01-5,0.009765624,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.039062503::MTS006,BRD-K95142244-001-01-5,0.039062503,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.15625::MTS006,BRD-K95142244-001-01-5,0.15625,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::0.624999999::MTS006,BRD-K95142244-001-01-5,0.624999999,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::2.5::MTS006,BRD-K95142244-001-01-5,2.5,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K95142244-001-01-5::10::MTS006,BRD-K95142244-001-01-5,10.0,MTS006,PMTS011,talazoparib,PARP inhibitor,PARP2,NA,NA,Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1,Phase 3
BRD-K96344439-002-02-7::0.00061035::MTS006,BRD-K96344439-002-02-7,0.00061035,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::0.002441408::MTS006,BRD-K96344439-002-02-7,0.002441408,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::0.009765627::MTS006,BRD-K96344439-002-02-7,0.009765627,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::0.039062498::MTS006,BRD-K96344439-002-02-7,0.039062498,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::0.156250002::MTS006,BRD-K96344439-002-02-7,0.156250002,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::0.625000001::MTS006,BRD-K96344439-002-02-7,0.625000001,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::2.5::MTS006,BRD-K96344439-002-02-7,2.5,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K96344439-002-02-7::10::MTS006,BRD-K96344439-002-02-7,10.0,MTS006,PMTS011,tofogliflozin,sodium/glucose cotransporter inhibitor,GCK,endocrinology,"diabetes mellitus, diabetes mellitus","CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1",Launched
BRD-K99107520-001-24-1::0.000610351::MTS006,BRD-K99107520-001-24-1,0.000610351,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.002441405::MTS006,BRD-K99107520-001-24-1,0.002441405,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.009765627::MTS006,BRD-K99107520-001-24-1,0.009765627,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.0390625::MTS006,BRD-K99107520-001-24-1,0.0390625,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.156249998::MTS006,BRD-K99107520-001-24-1,0.156249998,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::0.625000002::MTS006,BRD-K99107520-001-24-1,0.625000002,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::2.5::MTS006,BRD-K99107520-001-24-1,2.5,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99107520-001-24-1::10::MTS006,BRD-K99107520-001-24-1,10.0,MTS006,PMTS008,felbamate,glutamate receptor antagonist,"GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B",neurology/psychiatry,epilepsy,"NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1",Launched
BRD-K99616396-001-05-1::0.000610351::MTS006,BRD-K99616396-001-05-1,0.000610351,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.002441408::MTS006,BRD-K99616396-001-05-1,0.002441408,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.009765626::MTS006,BRD-K99616396-001-05-1,0.009765626,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.039062501::MTS006,BRD-K99616396-001-05-1,0.039062501,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.156250002::MTS006,BRD-K99616396-001-05-1,0.156250002,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::0.624999999::MTS006,BRD-K99616396-001-05-1,0.624999999,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::2.5::MTS006,BRD-K99616396-001-05-1,2.5,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99616396-001-05-1::10::MTS006,BRD-K99616396-001-05-1,10.0,MTS006,PMTS010,motesanib,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT",NA,NA,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",Phase 3
BRD-K99879819-001-02-1::0.00061035::MTS006,BRD-K99879819-001-02-1,0.00061035,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::0.002441408::MTS006,BRD-K99879819-001-02-1,0.002441408,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::0.009765623::MTS006,BRD-K99879819-001-02-1,0.009765623,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::0.0390625::MTS006,BRD-K99879819-001-02-1,0.0390625,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::0.156250002::MTS006,BRD-K99879819-001-02-1,0.156250002,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::0.625000002::MTS006,BRD-K99879819-001-02-1,0.625000002,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::2.5::MTS006,BRD-K99879819-001-02-1,2.5,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K99879819-001-02-1::10::MTS006,BRD-K99879819-001-02-1,10.0,MTS006,PMTS010,lorlatinib,ALK tyrosine kinase receptor inhibitor,ALK,NA,NA,"C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N",Phase 2
BRD-K06519765-065-01-6::0.000610352::MTS006,BRD-K06519765-065-01-6,0.000610352,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::0.002441405::MTS006,BRD-K06519765-065-01-6,0.002441405,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::0.009765624::MTS006,BRD-K06519765-065-01-6,0.009765624,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::0.039062501::MTS006,BRD-K06519765-065-01-6,0.039062501,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::0.156249999::MTS006,BRD-K06519765-065-01-6,0.156249999,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::0.625000001::MTS006,BRD-K06519765-065-01-6,0.625000001,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::2.5::MTS006,BRD-K06519765-065-01-6,2.5,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K06519765-065-01-6::10::MTS006,BRD-K06519765-065-01-6,10.0,MTS006,PMTS011,vinblastine,"microtubule inhibitor, tubulin polymerization inhibitor","JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","hematologic malignancy, infectious disease, oncology","Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC",Launched
BRD-K89085489-001-23-2::0.00061035::MTS006,BRD-K89085489-001-23-2,0.00061035,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::0.002441406::MTS006,BRD-K89085489-001-23-2,0.002441406,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::0.009765623::MTS006,BRD-K89085489-001-23-2,0.009765623,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::0.039062498::MTS006,BRD-K89085489-001-23-2,0.039062498,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::0.156249998::MTS006,BRD-K89085489-001-23-2,0.156249998,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::0.625000003::MTS006,BRD-K89085489-001-23-2,0.625000003,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::2.5::MTS006,BRD-K89085489-001-23-2,2.5,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
BRD-K89085489-001-23-2::10::MTS006,BRD-K89085489-001-23-2,10.0,MTS006,PMTS008,fenretinide,"apoptosis stimulant, retinoid receptor agonist",RARA,NA,NA,"CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1",Phase 3
